"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02412306","Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",,"Completed","Has Results","Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia","Drug: Blinatumomab","Phase 1b: Number of Participants With Dose-limiting Toxicities|Phase 2: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Expansion Cohort: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs|Phase 1b Adults: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Phase 1b Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment|Phase 1b and Phase 2: Duration of Response|Phase 1b and Phase 2: Relapse-free Survival|Phase 1b and Phase 2: Overall Survival|Phase 2: Best Overall Response Within 2 Cycles of Treatment|Phase 2: Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission|Phase 2: 100-Day Mortality After Allogeneic HSCT|Phase 1b and Phase 2: Number of Participants With TEAEs|Phase 1b and Phase 2: Serum Blinatumomab Concentration at Steady State|Phase 1b and Phase 2: Systemic Clearance of Blinatumomab|Phase 1b and Phase 2: Terminal Half-life of Blinatumomab|Phase 1b and Phase 2: Volume of Distribution of Blinatumomab|Phase 1b and Phase 2: Number of Participants Who Developed Anti-Blinatumomab Antibodies|Phase 1b and Phase 2: Interleukin-2 Concentration|Phase 1b and Phase 2: Interleukin-6 Concentration|Phase 1b and Phase 2: Interleukin-10 Concentration|Phase 1b and Phase 2: Tumor Necrosis Factor-Alpha (TNFα) Concentration|Phase 1b and Phase 2: Interferon Gamma (IFN-γ) Concentration|Expansion Cohort Adult: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Expansion Cohort Pediatric: Percentage of Participants With M1 Remission Within 2 Cycles of Treatment","Amgen|Amgen Astellas Biopharma K.K.","All","Child, Adult, Older Adult","Phase 1|Phase 2","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130265","June 4, 2015","February 6, 2019","July 4, 2019","April 9, 2015","January 10, 2020","January 10, 2020","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Gunmaken Saiseikai Maebashi Hospital, Maebashi-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saitama-shi, Saitama, Japan|Research Site, Shimotsuke-shi, Tochigi, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02412306/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02412306/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02412306"
2,"NCT01652690","Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice",,"Completed","Has Results","Osteoporosis, Postmenopausal","Biological: Denosumab","Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office|Number of Participants Receiving an Individual Prescription and Injection of Denosumab From the Initial Prescribing Physician Office by Each Individual Injection|Number of Participants Receiving All Prescriptions and Injections of Denosumab|Number of Participants With a Referral by the Prescribing Physician to Other Health Care Providers for Continuation or Follow-up of Care|Types of Health Care Providers Administering an Individual Injection of Denosumab at the Baseline Injection|Types of Health Care Providers Administering Denosumab at the First Post-baseline Injection|Types of Health Care Providers Administering Denosumab at the Second Post-baseline Injection|Types of Health Care Providers Administering Denosumab at the Third Post-baseline Injection|Types of Health Care Providers Administering Denosumab at the Fourth Post-baseline Injection|Number of Denosumab Post-baseline Injections Received by Each Participant|Number of Participants Having Radiologic Bone Assessments|Number of Participants Having Osteoporosis Related Laboratory Examinations|Number of Participants With Adverse Drug Reactions (ADRs) to Denosumab|Number of Participants With Serious ADRs to Denosumab","Amgen|One Amgen Center Drive|THOUSAND OAKS|CA|91320-1799|USA","Female","Child, Adult, Older Adult",,"600","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20110132","June 26, 2012","May 15, 2015","May 15, 2015","July 30, 2012","May 26, 2016","March 6, 2019","Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Ostrava-Trebovice, Czechia|Research Site, Ostrava, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 11, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Trutnov, Czechia|Research Site, Vsetin, Czechia|Research Site, Zlin, Czechia|Osteocentrum Zlin, Zlin, Czechia|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Humenne, Slovakia|Research Site, Kosice-Saca, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lubochna, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT01652690"
3,"NCT04221542","Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer",,"Not yet recruiting","No Results Available","Prostate Cancer","Drug: AMG 509|Drug: Dexamethasone","Incidence of treatment-emergent adverse events|Incidence of treatment-related adverse events|Dose limiting toxicities (DLTs)|Number of participants with changes in vital signs|Number of participants with changes in the electrocardiogram (ECG) records.|Number of participants with changes in the clinical laboratory tests results.|Maximum serum concentration (Cmax) for AMG 509|Minimum serum concentration (Cmin) for AMG 509|Area under the concentration-time curve (AUC) over the dosing interval for AMG 509|Accumulation following multiple dosing for AMG 509|Objective response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications|Prostate specific antigen (PSA) response|Duration of response (DOR) (radiographic and PSA)|Time to progression (radiographic and PSA)|Progression-free survival (PFS) (radiographic and PSA)|1, 2, and 3-year overall survival (OS)|Circulating tumor cells response (CTC0)|Rate of circulating tumor cells CTC conversion|time to symptomatic skeletal events.|alkaline phosphatase (total, bone)|lactate dehydrogenase (LDH)|hemoglobin|urine N-telopeptide|neutrophil-tolymphocyteratio","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180146","January 10, 2020","December 9, 2022","December 9, 2022","January 9, 2020",,"January 9, 2020",,,"https://ClinicalTrials.gov/show/NCT04221542"
4,"NCT04199351","Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity",,"Recruiting","No Results Available","Obesity","Drug: AMG 171|Drug: Placebo","Subject incidence of treatment-emergent adverse events.|Pharmacokinetic parameter - maximum plasma concentration (Cmax)|Pharmacokinetic parameter - time to maximum plasma concentration (Tmax)|Pharmacokinetic parameter - area under the plasma concentration-time curve (AUC)|Incidence of anti-AMG 171 antibody formation","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20180224","December 13, 2019","September 7, 2022","September 7, 2022","December 13, 2019",,"December 24, 2019","Research Site, Anaheim, California, United States|Research Site, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT04199351"
5,"NCT04197453","The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)","cvMOBIUS","Recruiting","No Results Available","ASCVD",,"Incident event rate for the composite of all-cause mortality, non-fatal myocardial infarction (MI), and non-fatal ischemic stroke (IS).|Incident event rate for all-cause mortality|Incident event rate for non-fatal MI|Incident event rate for non-fatal IS|Incident event rate for coronary or peripheral revascularization|Incident event rate for major adverse limb events (MALE) including amputation|Incident event rate for cardiovascular death|Incident event rate for coronary heart disease (CHD) death|Incident event rate for transient ischemic attack (TIA)|Incident event rate for unstable angina (UA)|Longitudinal patterns of lipid control, use of and persistence with lipid lowering therapies (LLT) including statins, ezetimibe, and PCSK9 inhibitors|The strengths and limitations of data harvested directly from electronic health record (EHR) systems as compared with prospectively collected information","Amgen|Duke Clinical Research Institute","All","40 Years to 99 Years   (Adult, Older Adult)",,"8500","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20180059","December 6, 2019","December 18, 2025","December 18, 2025","December 13, 2019",,"January 18, 2020","Research Site, Lake Success, New York, United States|Research Site, McKinney, Texas, United States|Research Site, Cambridge, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04197453"
6,"NCT04191616","Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet","SELECT","Not yet recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Pomalidomide","Number of participants with best minimal residual disease (MRD)|Subject incidence of treatment-emergent adverse event|Number of participants with negative minimal residual disease negative (MRD[-])|Number of participants with Sustained negative MRD|Number of participants with sustained negative MRD|Overall response rate (ORR)|Overall response rate at 12 month landmark|Duration of response|Time to response|Progression-free survival (PFS)|Overall survival (OS)|Best overall confirmed response of complete response (CR) or better","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","85","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180117|2019-001169-34","February 24, 2020","February 24, 2022","March 28, 2025","December 10, 2019",,"December 10, 2019",,,"https://ClinicalTrials.gov/show/NCT04191616"
7,"NCT04185883","AMG 510 Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)",,"Recruiting","No Results Available","Advanced Solid Tumors|Kirsten Rat Sarcoma (KRAS) pG12C Mutation","Drug: AMG 510|Drug: PD1 inhibitor","Number of Participants with Abnormal Laboratory Values|Number of subjects with clinically significant changes in vital signs.|Number of subjects with changes on ECG.|Maximum Plasma concentration (Cmax)|Time to maximum plasma concentration (tmax)|Area under the plasma concentration-time curve (AUC)|Disease control rate|Duration of response|Progression-free survival|Duration of stable disease","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20190135","December 17, 2019","July 7, 2022","December 2, 2024","December 4, 2019",,"January 21, 2020","City of Hope, Duarte, California, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04185883"
8,"NCT04175808","Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Subjects",,"Active, not recruiting","No Results Available","QT Intervals Changes|QTc Intervals Changes","Drug: Omecamtiv Mecarbil (OM)|Drug: Placebo|Drug: Moxifloxacin","Change from baseline in QT interval corrected for heart rate based on the Fridericia correction|PK parameters for Omecamtiv mecarbil following oral administration included but not limited to maximum serum concentration (Cmax)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited to time to maximum plasma concentration (Tmax)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited to if feasible, half-life (t1/2)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited apparent volume of distribution (VZ/F)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited apparent total plasma clearance (CL/F)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited AUC from time 0 to infinity (AUCinf)|PK parameters for Omecamtiv mecarbil following oral administration included but not limited the percentage of AUCinf due to extrapolation (%AUCextrap)|Changes in T-wave morphology|Changes in U-wave presence|Number of Subjects with Changes in laboratory safety tests|Number of Subjects with Changes in Blood pressure|Number of Subjects with Changes in ECGs parameters|Subject incidence of treatment-emergent adverse events (TEAEs)|Number of Subjects with Changes in pulse rate|Number of Subjects with Changes in body temperature","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090231|2018-003157-19","November 14, 2019","March 4, 2020","March 4, 2020","November 25, 2019",,"January 13, 2020","Research Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04175808"
9,"NCT04117958","Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer",,"Recruiting","No Results Available","Gastric and Gastroesophageal Junction Cancer","Drug: AMG 199","Incidence of Dose-limiting toxicities (DLT)|Incidence of Treatment-emergent adverse events (TEAEs)|Incidence of Treatment-related adverse events (TRAEs)|Number of subjects with changes in vital signs|Number of subjects with changes in clinical laboratory tests|Number of subjects with changes in electrocardiogram (ECG)|Maximum serum concentration (Cmax) of AMG 199|Minimum serum concentration (Cmax) of AMG 199|Area under the concentration-time curve (AUC) of AMG 199|Accumulation following multiple dosing of AMG 199|Half-life (t1/2) of AMG 199|Objective response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST.|Duration of response (DOR).|Time to progression (TTP)|Progression-free survival (PFS), 6-month PFS|Progression-free survival (PFS), 1-year PFS|Overall survival (OS), 1-year OS.|Overall survival (OS), 2-year OS","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180290|2019-002708-42","January 20, 2020","February 9, 2024","September 13, 2026","October 7, 2019",,"January 18, 2020","Research Site, Duarte, California, United States",,"https://ClinicalTrials.gov/show/NCT04117958"
10,"NCT04068181","Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)",,"Not yet recruiting","No Results Available","Melanoma","Drug: Talimogene laherparepvec|Drug: Pembrolizumab","Objective Response Rate (Complete Response plus Partial Response by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST v1.1))|Complete Response Rate by investigator assessment using Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Best Overall Response by investigator assessment using Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Durable Response Rate by investigator assessment using Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Duration Of Response by investigator assessment using Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Disease Control Rate by investigator assessment using Response Evaluation Criteria in Solid Tumor (RECIST v1.1) and modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Objective Response Rate by investigator assessment using modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST).|Progression Free Survival by investigator assessment using modified Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 and modified immune-related Response Criteria simulating Response evaluation criteria in Solid Tumors (irRC-RECIST).|Overall Survival|Incidence of treatment-emergent adverse events.|Incidence of treatment related adverse events.|Incidence of abnormal laboratory tests.|Time to subsequent anti-cancer therapy.","Amgen|Merck Sharp & Dohme Corp.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180115|2019-001906-61","January 27, 2020","April 23, 2021","October 24, 2023","August 28, 2019",,"October 21, 2019",,,"https://ClinicalTrials.gov/show/NCT04068181"
11,"NCT04058028","Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)",,"Not yet recruiting","No Results Available","Systemic Lupus Erythematosus (SLE)","Drug: AMG 570|Drug: Placebo for AMG 570","Per cent of patients achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at week 24.|Per cent of patients with an improvement in tender and swollen join count greater than or equal to 50% amongst those with greater than or equal to 6 tender and greater than or equal to 6 swollen joints at baseline|Per cent of patients who achieve a greater than or equal to 50% improvement from baseline in the Cutaneous Lupus Erythematosus Area and Severity Index (CLASI) activity score amongst those with a CLASI score greater than or equal to 10 at baseline.|Subject incidence of Adverse Events|Subject incidence of Serious adverse events|Number of Subjects with significant changes in laboratory values|Number of Subjects with significant changes in vital signs|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score change from baseline|Medical Outcomes Short Form 36 version 2 Questionnaire (SF36v2) score change from baseline|Modified Lupus QoL score and change from baseline|Patient Global Assessment (PtGA) score change from baseline|Serum AMG 570 trough concentrations|AMG 570 terminal elimination half-life, if possible|SRI-4 at week 52 with reduction of OCS to less than or equal to 7.5 mg/day by week 44 and sustained through week 52|Per cent of patients achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at week 52","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170588","January 31, 2020","May 19, 2022","March 31, 2023","August 15, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04058028"
12,"NCT03971071","A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache",,"Recruiting","No Results Available","Migraine Headache","Drug: Erenumab 70 mg|Drug: Erenumab 140mg|Drug: Placebo","Number of participants with absence of Medication Overuse Headache (MOH) at Month 6|Number of participants with change from baseline in mean monthly acute headache medication days (AHMD)|Number of participants with sustained Medication Overuse Headache (MOH) remission|Number of participants with change from baseline in mean monthly average physical impairment domain scores as measured by the MPFID|Number of participants with change from baseline in mean monthly average impact on everyday activities domain scores as measured by the MPFID|Number of participants with change from baseline in mean HIT-6 score","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","687","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170703|2018-003342-16","October 7, 2019","November 16, 2021","May 31, 2022","June 3, 2019",,"January 10, 2020","Research Site, Santa Monica, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Tampa, Florida, United States|Research Site, Overland Park, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Bolivar, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Huntington, West Virginia, United States|Research Site, Sydney, New South Wales, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Nice cedex 1, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Catanzaro, Italy|Research Site, Palermo, Italy|Research Site, Roma, Italy|Research Site, Ksawerow, Poland|Research Site, Legionowo, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Zaragoza, Aragón, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Hull, United Kingdom|Research Site, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03971071"
13,"NCT03969329","A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis",,"Recruiting","No Results Available","Secondary Hyperparathyroidism","Drug: Etelcalcetide","Percent change in intact parathyroid hormone (iPTH) from baseline during the efficacy assessment period (EAP) at weeks 20 to 26|Achievement of a greater than 30% reduction from baseline in mean intact parathyroid hormone (iPTH) during the efficacy assessment period (EAP)|Percent change from baseline in corrected total serum calcium (Ca) and serum phosphorus from baseline during the EAP|Proportion of subjects achieving corrected serum calcium (Ca) levels less than 8.0 mg/dL (2.0 mmol/L) at any time during the study|Proportion of subjects with changes in laboratory parameters, including clinical chemistry|Proportion of subjects with hypocalcemia (corrected serum calcium levels less than 8.4 mg/dL)|Etelcalcetide plasma concentrations before and at the end of dialysis after single and multiple doses|Etelcalcetide PK parameter of maximum-observed concentration (Cmax)|Etelcalcetide pharmacokinetic (PK) parameter of plasma trough concentrations (Cmin)|Subject incidence of all treatment-emergent adverse events","Amgen","All","2 Years to 17 Years   (Child)","Phase 3","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170724","December 20, 2019","June 29, 2022","June 29, 2022","May 31, 2019",,"January 18, 2020","Research Site, Praha 5, Czechia|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Szeged, Hungary|Research Site, Firenze, Italy|Research Site, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03969329"
14,"NCT03937154","Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",,"Not yet recruiting","No Results Available","Chemotherapy-induced Thrombocytopenia","Drug: Romiplostim|Drug: Placebo","Incidence of either a chemotherapy dose delay or reduction|Depth of Platelet Count|Time to First platelet response|the duration-adjusted event rate of ≥ grade 2 bleeding events|Overall survival|Proportion of subjects with at leat 1 incidence of platelet transfusion|proportion of patients achieving platelet count >= 100 x 10 9/L|The subject incidence of adverse events|Number of subjects who develop anti-romiplostim antibodies|Number of subjects who develop anti-TPO antibodies|Number of subjects who experience myelodysplastic syndromes|Number of subjects who experience secondary malignancies","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170770","December 30, 2019","October 28, 2021","September 28, 2022","May 3, 2019",,"December 13, 2019","Research Site, Jonesboro, Arkansas, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Sparta, New Jersey, United States|Research Site, Johnson City, New York, United States|Research Site, Fort Worth, Texas, United States|Research Site, Heraklion - Crete, Greece|Research Site, Thessaloniki, Greece|Research Site, Denizli, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Malatya, Turkey|Research Site, Tekirdag, Turkey",,"https://ClinicalTrials.gov/show/NCT03937154"
15,"NCT03934684","Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Relapsed Refractory Multiple Myeloma","Drug: Drug: Carfilzomib + Dexamethasone|Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone","Number of participants with treatment-emergent adverse events as assessed by CTCAE v4.03|Progression Free Survival|Overall Response Rate|Clinical Benefit Rate|Time to Response|Duration of Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160372","September 16, 2019","April 28, 2022","August 1, 2024","May 2, 2019",,"October 21, 2019","Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT03934684"
16,"NCT03927144","Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients",,"Recruiting","No Results Available","Episodic Migraine","Drug: Erenumab|Drug: Oral Prophylactic","Proportion of subjects who complete initially assigned treatment and achieve at least 50% reduction from baseline in monthly migraine days at Month 12|Proportion of subjects completing the treatment period at Month 12 on the initially assigned treatment|Cumulative average change from baseline on the monthly migraine days during the treatment period for subjects on the initially assigned treatment (Months 1-12)|Proportion of responders (PGI-I score greater than or equal to 5) as measured by PGIC at month 12 for subjects completing the treatment period at Month 12 on initially assigned treatment","Amgen|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMG334A2401|2018-001228-20|CAMG334A2401","May 15, 2019","June 30, 2021","July 15, 2021","April 25, 2019",,"December 18, 2019","Stanford Headache Center, Stanford, California, United States|Yale Center for Clinical Research, New Haven, Connecticut, United States|New England Institute for Neurology and Headache, Stamford, Connecticut, United States|George Washington Hospital, Washington, District of Columbia, United States|University of Miami Headache Division, Miami, Florida, United States|Premier Research Institute, West Palm Beach, Florida, United States|Diamond Headache Clinic, Chicago, Illinois, United States|Robbins Headache Clinic, Riverwoods, Illinois, United States|Medvadis, Watertown, Massachusetts, United States|New England Regional Headache Center, Inc, Worcester, Massachusetts, United States|MHNI, Ann Arbor, Michigan, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|The Headache Center, Ridgeland, Mississippi, United States|Mercy Health Research, Saint Louis, Missouri, United States|Study Metrix Research, Saint Peters, Missouri, United States|Laszlo Mechtler, Amherst, New York, United States|Oklahoma Headache center, Norman, Oklahoma, United States|Jefferson Headache Center, Philadelphia, Pennsylvania, United States|Nashville Neuroscience Group, Nashville, Tennessee, United States|Texas Neurology, Dallas, Texas, United States|Texas Institute for Neurological Disorders, Sherman, Texas, United States|Univ. Klinik fuer Neurologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzigen Schwestern, Linz, Austria|Univ Klinik fuer AKH, Vienna, Austria|AZ Sint Jan, Brugge, Belgium|UZ Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|Jessa Ziekenhuis- Campus Virga Jesse Dienst Gastro-entrologie, Hasselt, Belgium|Centre Hospitalier Regional de la Citadelle, Liege, Belgium|Heilig Hart Ziekenhuis Lier, Lier, Belgium|Neurologicka ambulance Quattromedica, Brno, Czechia|NEUROHK sro, Chocen, Czechia|DADO Medical S R O, Prague, Czechia|Institut neuropsychiatricke pece, Prague, Czechia|Clintrial SRO, Praha 10, Czechia|Thomayerova Nemocnice, Praha 4, Czechia|Terveystalo Ruoholahti, Helsinki, Finland|Laakarikeskus Aava Itakeskus, Helsinki, Finland|Terveystalo Pulssi, Turku, Finland|CHRU de LILLE, LILLE Cedex, France|Hopital Lariboisiere Centre d Urgence des Cephalees, Paris cedex 10, France|Hopital Charles Nicolle Departement de Neurologie, Rouen, France|CH Yves Le Foll, Saint Brieuc, France|CHU St Etienne Hopital Nord Bat A, SAINT ETIENNE cedex 2, France|GP Dept of Neurology, Bochum, Germany|Neurologische Gemeinschaftspraxis Klemt & Bauersachs, Dortmund, Germany|Medamed GmbH Studienambulanz, Leipzig, Germany|Gemeinschaftspraxis für Neurologie Simm, Gillwald, Wiese, Mönchengladbach, Germany|Navy Hospital of Athens ""NNA"" Main Centre, Athens, Greece|Aeginition Hospital of Athens, University of Athens, Athens, Greece|401 Army General Hospital of Athens Main Centre, Athens, Greece|MEDITERRANEO Hospital, Glyfada, Greece|Euromedica General Clinic of Thessaloniki Neurology Dept, Thessaloniki, Greece|Bon Secours Hospital, Cork, Ireland|Beaumont Hospital, Dublin 9, Ireland|Hillel Yaffe MC, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Laniado, Netanya, Israel|Sheba MC, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center Ichilov, Tel Aviv, Israel|A O Perugia Osp S Maria Misericordia Loc S Andrea d Fratte, Perugia, PG, Italy|IRCCS San Raffaele Pisana, Roma, RM, Italy|Ospedali Riuniti Torrette di Ancona, Ancona, Italy|ASST degli Spedali Civili di Brescia Univ degli Studi, Brescia, Italy|Policl.Universit.Campus Bio-Medico Università Campus Bio-Med U.O.C.Area di Oncologia Medica, Roma, Italy|Azienda Ospedaliera Sant'Andrea - Università La Sapienza, Roma, Italy|Zuyderland Medisch Centrum, Geleen, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Canisius Wilhelmina Hospital Dept of Neurology C-70, Nijmegen, Netherlands|Isala Ziekenhuis, Zwolle, Netherlands|Centrum Leczenia Padaczki i Migreny, Krakow, Poland|Centrum Leczenia Padaczki i Migreny, Krakow, Poland|Gabient Lekarski Jacek Rozniecki, Lodz, Poland|OHA MED Sp zo o, Warszawa, Poland|ETG Warszawa, Warszawa, Poland|Wojskowy Instutyt Medyczny CSK MON, Warszawa, Poland|Hospital Garcia de Orta EPE, Almada, Portugal|Hospital da Luz, Lisboa, Portugal|Hospital Santa Maria, Lisboa, Portugal|Hospital Pedro Hispano Matosinhos E P E, Matosinhos, Portugal|Centro Hospitalar do Porto Hospital Geral de Santo Antonio Serviço de Neurologia, Porto, Portugal|Nemocnica sv Michala a s, Bratislava, Slovakia|Nemocnica Komarno s r o, Komarno, Slovakia|Neurologicke oddelenie VNsP Levoca, Levoca, Slovakia|Neurolog odd NsP Liptovsky Mikulas, Liptovsky Mikulas, Slovakia|Neurologicka a algeziologicka ambulancia SANERA s r o, Presov, Slovakia|Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Castilla Y Leon, Spain|Hospital Vall D'Hebron, Barcelona, Cataluña, Spain|Hospital Clinico Universitario Valencia, Valencia, Communidad Valencia, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Galicia, Spain|Hospital Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain|Queen Elizabeth Hospital Pharmacy Dept., Edgbaston, Birmingham, United Kingdom|Basildon and Thurrock University Hospitals, Basildon, Essex, United Kingdom|The John Radcliffe Hospital, Headington, Oxfordshire, United Kingdom|University Hospital of North Midlands NHS Trust, Stoke on Trent, Staffordshire, United Kingdom|Glasgow Clinical Research Facility, Glasgow, United Kingdom|Hull and amp East Yorkshire Hospitals NHS Trust, Hull, United Kingdom|St Thomas Hospital, London, United Kingdom|King's College Hospital London, London, United Kingdom|Royal Victoria Infirmary, Newcastile Upon Tyne, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03927144"
17,"NCT03912337","Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine",,"Recruiting","No Results Available","Migraine","Drug: Placebo|Drug: Erenumab","Sum of monthly changes from baseline in modified Migraine Disability Assessment (MIDAS)|Change from baseline in mean monthly migraine days (MMD)|Change from baseline in mean monthly percent work impairment|Change from baseline in mean physical function|Change from baseline in mean usual activities|Change from baseline in mean social function","Amgen|Novartis","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20180060","December 4, 2019","April 23, 2021","April 23, 2021","April 11, 2019",,"December 20, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Basalt, Colorado, United States|Research Site, East Hartford, Connecticut, United States|Research Site, New London, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Orlando, Florida, United States|Research Site, Chalmette, Louisiana, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Toms River, New Jersey, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Frisco, Texas, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03912337"
18,"NCT03904069","Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML",,"Not yet recruiting","No Results Available","Relapsed/Refractory Acute Myeloid Leukemia","Drug: AMG 553","Dose limiting toxicities (DLTs)|Treatment-emergent adverse events|Treatment-related adverse events|Complete response (CR)|Complete response with partial recovery of peripheral blood counts (CRh)|Complete response with incomplete recovery of peripheral blood counts (CRi)|Morphologic leukemia-free state (MLFS)|Duration of response (DOR)|Progression free survival (PFS)|Overall Survival (OS)|Proportion of subjects with minimal-residual disease (MRD) negative response|The area under the concentration time-curve (AUC) of AMG 553|Peak levels of AMG 553 (maximum concentration or Cmax)","Amgen","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180091","December 15, 2021","May 9, 2029","May 9, 2029","April 4, 2019",,"October 30, 2019","City of Hope National Medical Center, Duarte, California, United States|Stanford University, Palo Alto, California, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03904069"
19,"NCT03872401","Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","VESALIUS-CV","Recruiting","No Results Available","Coronary Heart Disease (CHD)","Drug: Evolocumab|Drug: Placebo","Time to Coronary Heart Disease Death, Myocardial Infarction, or Ischemic Stroke|Time to Coronary Heart Disease Death, Myocardial Infarction, Ischemic Stroke, or Any Ischemia-driven Arterial Sroke|Time to MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization|Time to CHD Death, MI, or Any Ischemia-driven Arterial Revascularization|Time to Cardiovascular Death, MI, or Stroke|Time to Myocardial Infarction|Time to Any Ischemia-driven Arterial Revascularization|Time to CHD Death|Time to Cardiovascular Death|Time to All Cause of Death|Time to Ischemic Stroke","Amgen","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 3","13000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170625|2018-004565-14","June 11, 2019","May 29, 2024","May 29, 2024","March 13, 2019",,"December 27, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, Torrance, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Cumming, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Covington, Kentucky, United States|Research Site, Eunice, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Great Barrington, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Southampton, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Greenwich, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Little River, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Zarate, Buenos Aires, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Juan, Argentina|Research Site, San Luis, Argentina|Research Site, Garran, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Bundaberg, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Leabrook, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Joondalup, Western Australia, Australia|Research Site, Woolloongabba, Australia|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Nepean, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Jerome, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Broumov, Czechia|Research Site, Havirov - Mesto, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Svitavy, Czechia|Research Site, Trinec, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Kobenhavn O, Denmark|Research Site, Kobenhavn S, Denmark|Research Site, Kolding, Denmark|Research Site, Silkeborg, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Bron, France|Research Site, Grenoble, France|Research Site, Le Coudray, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Fulda, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Markleeberg, Germany|Research Site, Papenburg, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Balatonkeresztur, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Catanzaro, Italy|Research Site, Chieti, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, San Donato Milanese, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dirksland, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Meppel, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, The Hague, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zaandam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krosno, Poland|Research Site, Leczna, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Miechow, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Siedlce, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Szczecin, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wegrow, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sait-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Almeria, Andalucía, Spain|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Falun, Sweden|Research Site, Goteborg, Sweden|Research Site, Harnosand, Sweden|Research Site, Jonkoping, Sweden|Research Site, Lidkoping, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Hualien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Barnsley, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Bollington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Burton-on-Trent, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Cleveleys, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Crawley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Kenilworth, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Shipley, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Thetford, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Watford, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Wokingham, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Yeovil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03872401"
20,"NCT03859427","A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","ARROW2","Recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Overall Response Rate (ORR)|1-year Progression free survival|Convenience|Subject incidence of treatment-emergent adverse events|Additional efficacy parameter - Time to Response|Additional efficacy parameter - Duration of Response|Additional efficacy parameter - Time to Progression|1-year Overall Survival|MRD[-]CR rate|MRD[-] rate at 12 months|Physical functioning and role functioning|Treatment satisfaction as measured by the Satisfaction with Therapy (SWT) subscale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180015","May 8, 2019","December 10, 2021","December 10, 2021","March 1, 2019",,"January 18, 2020","Research Site, Fountain Valley, California, United States|Research Site, Plainville, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Albany, New York, United States|Research Site, Denton, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Nantes, France|Research Site, Nice cedex 3, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pierre-Benite, France|Research Site, Poitiers Cedex, France|Research Site, Rennes, France|Research Site, Strasbourg cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Vandoeuvre-lès-Nancy, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Köln, Germany|Research Site, Mainz, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Shibukawa-shi, Gunma, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Osakasayama-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Falun, Sweden|Research Site, Goteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Lulea, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT03859427"
21,"NCT03853109","AMG 404 in Patients With Advanced Solid Tumors.",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: AMG 404","Subject incidence of Dose limiting toxicities (DLTs)|Subject incidence of treatment emergent adverse events|Subject incidence of treatment related adverse events|Subject incidence of changes in vital signs|Subject incidence of clinical laboratory tests|QT interval relationship|Subject incidence of anti-AMG 404 antibodies|Maximum observed concentration (Cmax) of AMG 404|Time of maximum observed concentration (Tmax) of AMG 404|Area under the serum concentration-time curve (AUC) of AMG 404","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","92","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180143","March 5, 2019","June 15, 2022","June 15, 2022","February 25, 2019",,"October 3, 2019","Research Site, Santa Monica, California, United States|Research Site, Denver, Colorado, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Edegem, Belgium|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Wakayama-shi, Wakayama, Japan|Research Site, Warszawa, Poland|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03853109"
22,"NCT03836053","Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma","AMG420","Recruiting","No Results Available","Relapsed and/or Refractory Multiple Myeloma","Drug: AMG 420","Subject incidence of dose-limiting toxicities|Subject incidence of treatment emergent adverse events|Subject incidence of treatment related adverse events|Subject incidence of changes in vital signs|Subject Incidence of Changes in ECGs|Subject incidence of Changes in clinical laboratory tests|Overall Response Rate|Duration of Response|Minimal Residual Disease negativity at the time of CR|Half-life|Time to response|Clearance|Apparent Css|Progression Free Survival (PFS)|Overall Survival|Best Overall Response|Treatment-free Interval","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160370","March 4, 2019","November 26, 2021","October 29, 2025","February 11, 2019",,"January 18, 2020","Research Site, Park Ridge, Illinois, United States|Research Site, New York, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fitzroy, VIC, Victoria, Australia|Research Site, Haine Saint Paul - La Louviere, Belgium|Research Site, Okayama-shi, Okayama, Japan|Research Site, St. Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT03836053"
23,"NCT03836040","Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine","OASIS (EM)","Recruiting","No Results Available","Migraine","Drug: Erenumab Dose 1|Drug: Erenumab Dose 2|Drug: Erenumab Dose 3|Other: Placebo","Change from baseline in monthly migraine days (MMDs)|Change in monthly headache days from baseline|Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline|Change in monthly migraine days (MMDs) from baseline to the average of the first 3 months|Change in monthly migraine days (MMDs) from baseline to the average of the first 6 month|Change in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale)|Change from baseline in migraine-related disability and productivity","Amgen","All","6 Years to 17 Years   (Child)","Phase 3","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150125|2017-002397-39","July 19, 2019","December 17, 2022","December 16, 2023","February 11, 2019",,"January 18, 2020","Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Brussel, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Turku, Finland|Research Site, Essen, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Milano, Italy|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Basel, Switzerland|Research Site, Zollikon, Switzerland|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03836040"
24,"NCT03832998","Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine","OASIS (CM)","Recruiting","No Results Available","Migraine","Drug: Erenumab Dose 1|Drug: Erenumab Dose 2|Drug: Erenumab Dose 3|Other: Placebo","Change from baseline in monthly migraine days (MMDs)|Change in monthly headache days from baseline|Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline|Change in monthly migraine days (MMDs) from baseline to the average of the first 3 months|Change in monthly migraine days (MMDs) from baseline to the average of the first 6 months|Change in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale)|Change from baseline in migraine-related disability and productivity","Amgen","All","6 Years to 17 Years   (Child)","Phase 3","286","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160354|2017-002399-23","September 5, 2019","April 17, 2024","April 16, 2025","February 6, 2019",,"January 18, 2020","Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Brussel, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Turku, Finland|Research Site, Essen, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Milano, Italy|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03832998"
25,"NCT03822078","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women",,"Completed","Has Results","Osteoporosis","Drug: Placebo|Biological: Denosumab","Number of Participants With Adverse Events|Area Under the Serum Concentration Time Curve From Time 0 to Time of Last Quantifiable Serum Concentration (AUC0-t) of Denosumab|Maximum Observed Concentration of Denosumab (Cmax)|Time to Maximum Observed Concentration (Tmax) of Denosumab|Apparent Clearance (CL/F) of Denosumab|Mean Residence Time (MRT) From Time 0 to Time of Last Quantifiable Serum Concentration|Percent Change From Baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (N-Tx/Cr)|Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP)|Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)","Amgen",,"Child, Adult, Older Adult","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20030164","September 30, 2003","December 24, 2004","December 24, 2004","January 30, 2019","July 24, 2019","July 24, 2019",,,"https://ClinicalTrials.gov/show/NCT03822078"
26,"NCT03818607","A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH","DAHLIA","Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: ABP 959|Drug: Eculizumab","Hemolysis as measured by Lactate dehydrogenas (LDH) (Parallel Comparison)|Hemolysis as measured by LDH (Crossover Comparison)|Total hemolytic complement (Total Complement)|Total hemoglobin|Serum-free hemoglobin|Haptoglobin|Bilirubin|Degree of hemoglobinuria|Type III erythrocytes|Crossover comparison of hemolysis as measured by LDH|Lactate dehydrogenase-time profile|Incidence of red blood cell transfusion|Pharmacokinetic area under the curve (AUC) of ABP 959|Pharmacokinetic area under the curve (AUC) of eculizumab","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150168","April 24, 2019","November 30, 2020","June 5, 2021","January 28, 2019",,"December 6, 2019","Research Site, Whittier, California, United States|Research Site, Athens, Georgia, United States|Research Site, Cesson-Sevigne, Bretagne, France|Research Site, Amiens Cedex 1, Picardie, France|Research Site, Poitiers, Poitou-charentes, France|Research Site, Göppingen, Baden-wuerttemberg, Germany|Research Site, Meldola, Forli-cesena, Italy|Research Site, Bologna, Italy|Research Site, Cremona, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Roma, Italy|Research Site, Nijmegen, Gelderland, Netherlands|Research Site, Majadahonda, Madrid, Spain|Research Site, Madrid, Spain|Research Site, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03818607"
27,"NCT03812224","A Controlled Trial of Erenumab in Migraine Prevention",,"Active, not recruiting","No Results Available","Migraine","Drug: Erenumab","Mean Monthly Migraine Days|50% reduction in MMD","Amgen","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 3","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170609","April 12, 2019","March 16, 2020","November 22, 2020","January 23, 2019",,"October 4, 2019","Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kochi-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Iruma-gun, Saitama, Japan|Research Site, Saitama-shi, Saitama, Japan|Research Site, Tokorozawa-shi, Saitama, Japan|Research Site, Shizuoka-shi, Shizuoka, Japan|Research Site, Shimotsuga-gun, Tochigi, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Tottori-shi, Tottori, Japan|Research Site, Yonago-shi, Tottori, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Hofu-shi, Yamaguchi, Japan|Research Site, Yamaguchi-shi, Yamaguchi, Japan|Research Site, Kai-shi, Yamanashi, Japan",,"https://ClinicalTrials.gov/show/NCT03812224"
28,"NCT03809663","A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis","Drug: Tezepelumab|Other: Placebo","Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) (IGA 0/1) and 75% reduction of EASI at Week 16|50% and 90% reduction in EASI|Time at which EASI 50/75/90 is achieved from day 1|SCORAD (Scoring Atopic Dermatitis) at week 16|Pruritus NRS (Numerical Rating Scale) at week 16|Serum trough concentrations of tezepelumab at scheduled visits","Amgen|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170755|2018-001997-52","March 15, 2019","July 3, 2021","July 3, 2021","January 18, 2019",,"December 27, 2019","Research Site, Fountain Valley, California, United States|Research Site, Santa Monica, California, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Springfield, Illinois, United States|Research Site, West Dundee, Illinois, United States|Research Site, New Albany, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Clarkston, Michigan, United States|Research Site, Henderson, Nevada, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Sydney, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Carlton, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Surrey, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brno, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 8, Czechia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Tartu, Estonia|Research Site, Berlin, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Sakura-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Obihiro-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Nishinomiya-shi, Hyogo, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Sakai-shi, Osaka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Takaoka-shi, Toyama, Japan|Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Ventspils, Latvia|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Sevilla, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, Chernivtsi, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Dundee, United Kingdom|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03809663"
29,"NCT03792841","Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC",,"Recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer|Prostate Cancer","Drug: AMG 160|Drug: Pembrolizumab","Number of participants with dose-limiting toxicity|Number of participants with treatment-emergent adverse events|Number of participants with treatment-related adverse events|Number of participants with clinically significant changes in vital signs|Number of participants with clinically significant changes in electrocardiogram (ECG)|Number of participants with clinically significant changes in clinical laboratory tests|Part 1 and Part 2- Subject incidence of changes in pharmacokinetics - maximum serum concentration (Cmax)|Part 1 and 2 -Objective response (OR)|Part 1 and 2 - Prostate-specific antigen (PSA) response|Part 1 and 2 - Duration of response (DOR) (radiographic and PSA)|Part 1 and 2- Change in time to progression (radiographic and PSA)|Part 1 and 2 - 1, 2 and 3-year overall survival (OS)|Part 1 and 2 - Other PCWG3-recommended endpoints - time to symptomatic skeletal events|Part 1 and Part 2- Subject incidence of changes in pharmacokinetics - minimum serum concentration (Cmin)|Part 1 and Part 2- Subject incidence of changes in pharmacokinetics - area under the concentration-time curve (AUC) over the dosing interval|Part 1 and Part 2- Subject incidence of changes in pharmacokinetics - administration including accumulation following multiple dosing|Part 1 and Part 2- Subject incidence of changes in pharmacokinetics - half-life|Part 1 and 2 - Other PCWG3-recommended endpoints - lactate dehydrogenase [LDH]|Part 1 and 2 - Other PCWG3-recommended endpoints - hemoglobin|Part 1 and 2 - Other PCWG3-recommended endpoints - neutrophil-to-lymphocyte ratio|Part 1 and 2 - Other PCWG3-recommended endpoints - urine N-telopeptide|Part 1 and 2 - Other PCWG3-recommended endpoints alkaline phosphatase [total, bone]","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20180101","February 5, 2019","November 6, 2021","November 6, 2021","January 3, 2019",,"January 22, 2020","Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Salzburg, Austria|Research Site, Bruxelles, Belgium|Research Site, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03792841"
30,"NCT03781375","Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis",,"Terminated","Has Results","Juvenile Rheumatoid Arthritis","Drug: Etanercept|Drug: Placebo to Etanerceot|Drug: Methotrexate","Percentage of Participants With a JRA Response at Month 6|Percentage of Participants With a 50% Improvement in JRA DOI at Month 6|Percentage of Participants With a 70% Improvement in JRA DOI at Month 6","Amgen",,"Child, Adult, Older Adult","Phase 3","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20021628|016.0028","August 24, 2000","June 20, 2002","June 24, 2002","December 19, 2018","August 2, 2019","August 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03781375"
31,"NCT03780959","Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)",,"Completed","Has Results","Juvenile Rheumatoid Arthritis","Drug: Etanercept|Drug: Placebo","Percentage of Participants With Disease Flare in Part 2|Time to Flare in Part 2|Number of Participants With Adverse Events","Amgen","All","4 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20021616|016.0016","May 1, 1997","July 8, 1998","July 8, 1998","December 19, 2018","August 2, 2019","August 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03780959"
32,"NCT03776058","Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)",,"Completed","No Results Available","Primary Hyperparathyroidism","Drug: Cinacalcet|Drug: Placebo","Number of Participants with Adverse Events|Number of Participants with Clinically Significant Laboratory Tests, Vital Signs or Electrocardiogram Assessments|Percent Change from Baseline in Serum Calcium|Percent Change from Baseline in Plasma Intact Parathyroid Hormone (iPTH)|Percent Change from Baseline in Bone-specific Alkaline Phosphatase (BALP)|Percent Change from Baseline in 1,25 dihydroxy Vitamin D3|Percent Change from Baseline in Serum Phosphorus|Percent Change from Baseline in N-telopeptide (NTx)|Percent Change from Baseline in Urine Osmolality|Percent Change from Baseline in Calcium/Creatinine Ratio|Percent Change from Baseline in Phosphorus/Creatinine Ratio|Percent Change from Baseline in N-telopeptide/Creatinine Ratio","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00990160","June 15, 2000","December 26, 2000","December 26, 2000","December 14, 2018",,"December 14, 2018",,,"https://ClinicalTrials.gov/show/NCT03776058"
33,"NCT03776032","A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy",,"Completed","No Results Available","Anemia","Drug: Darbepoetin alfa|Drug: Placebo","Percentage of Participants with a Red Blood Cell Transfusion During Weeks 5 to 12|Time to First Red Blood Cell Transfusion During Weeks 5 to 12|Percentage of Participants with a Hemoglobin Response by Week 12|Time to Hemoglobin Response|Percentage of Participants who Achieved a Sustained Hemoglobin Response by Week 12|Time to Sustained Hemoglobin Response|Percentage of Participants who Achieved a Hemoglobin Correction by Week 12|Percentage of Participants who Achieved a Sustained Hemoglobin Correction by Week 12|Time to Hemoglobin Correction|Time to Sustained Hemoglobin Correction|Change from Baseline in Hemoglobin at Week 12|Percentage of Participants who Received a Red Blood Cell Transfusion During Weeks 1 to 4, 5 to 8, and 9 to 12|Number of Standard Units of RBCs Transfused During Weeks 5 to 12|Number of Days with RBC Transfusions During Weeks 5 to 12|Change from Baseline in the Functional Assessment of Cancer Therapy (FACT)-Anemia Subscales at Week 12|Number of Participants with Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00980297","September 14, 1999","November 8, 2000","February 27, 2002","December 14, 2018",,"December 20, 2018",,,"https://ClinicalTrials.gov/show/NCT03776032"
34,"NCT03774771","Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism",,"Completed","No Results Available","Primary Hyperparathyroidism","Drug: Cinacalcet|Drug: Placebo","Number of Participants with Adverse Events in Part 1 and Part 2|Percent Change from Baseline in Serum Calcium Concentration|Area Under the Serum Calcium Concentration-time Curve from 0 to 24 Hours After Dosing (AUC0-24) in Part 1|Area Under the Serum Calcium Concentration-time Curve from 0 to 12 Hours After Dosing (AUC0-12) in Part 2|Minimum Serum Calcium Concentration in Part 1|Minimum Serum Calcium Concentration in Part 2|Cumulative Time When Serum Calcium was Below Baseline During the 24-hour Dosing Interval in Part 1|Cumulative Time When Serum Calcium was Below Baseline During the 12-hour Dosing Interval in Part 2|Cumulative Time Over the Day When Serum Calcium was ≤ 10.3 mg/dL In Part 1|Cumulative Time Over the Day When Serum Calcium was ≤ 10.3 mg/dL In Part 2|Percent Change from Baseline in Plasma Intact parathyroid Hormone (iPTH) Concentration|Area Under the Plasma iPTH Concentration-time Curve from 0 to 24 Hours After Dosing (AUC0-24) in Part 1|Area Under the Plasma iPTH Concentration-time Curve from 0 to 12 Hours After Dosing (AUC0-12) in Part 2|Minimum iPTH Concentration in Part 1|Minimum iPTH Concentration in Part 2|Time of Minimum iPTH Concentration in Part 1|Time of Minimum iPTH Concentration in Part 2|Cumulative Time When iPTH was Below Baseline During the 24-hour Dosing Interval in Part 1|Cumulative Time When iPTH was Below Baseline During the 12-hour Dosing Interval in Part 2|Cumulative Time iPTH was Below 45 pg/mL in Part 1|Cumulative Time iPTH was Below 45 pg/mL in Part 2|Percent Change from Baseline in Serum Calcitonin Concentration|Percentage of Participants with Serum Calcitonin Concentration Less than 10 pg/mL|Percent Change from Baseline in Bone-specific Alkaline Phosphatase (BALP) Concentration|Percentage of Participants with BALP Concentration Within Normal Range|Percent Change from Baseline in Serum N-telopeptide (NTx) Concentration|Percentage of Participants with Serum NTx Concentration Within Normal Range|Percent Change from Baseline in Urinary NTx Concentration|Percentage of Participants with Urinary NTx Concentration Within Normal Range|Percent Change from Baseline in Urinary Calcium/Creatinine Ratio|Percent Change from Baseline in Urinary Calcium Concentration|Percentage of Participants with Urinary Calcium Concentration Within Normal Range|Percent Change from Baseline in 1,25-Dihydroxy Vitamin D|Percentage of Participants with 1,25-Dihydroxy Vitamin D Concentration in the Normal Range|Percent Change from Baseline in Urinary and Serum Phosphorus Concentrations","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00980125","September 29, 1998","December 13, 1999","December 13, 1999","December 13, 2018",,"December 13, 2018",,,"https://ClinicalTrials.gov/show/NCT03774771"
35,"NCT03759392","Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure","METEORIC-HF","Recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction","Drug: Omecamtiv Mecarbil|Drug: Placebo","Change in peak oxygen uptake (VO2) on cardiopulmonary exercise testing from baseline to Week 20|Change in exercise capacity, as measured by the change in total workload during cardiopulmonary exercise testing (CPET) from baseline to Week 20|Change in ventilatory efficiency, as measured by the change in Ventilation (VE)/Carbon dioxide output (VCO2) slope during cardiopulmonary exercise testing (CPET) from baseline to Week 20|Change in the average daily activity units measured over a 2-week period from baseline (Week -2 to Day 1) to Week 18-20","Amgen|Cytokinetics|Servier","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CY 1031|2018-001233-40","April 9, 2019","February 15, 2021","March 15, 2021","November 30, 2018",,"November 26, 2019","Alaska Heart and Vascular Institute, Anchorage, Alaska, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Harbor-UCLA Medical Center, Torrance, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Hartford Hospital-University of Connecticut School of Medicine, Hartford, Connecticut, United States|Holy Cross Hospital - Fort Lauderdale, Fort Lauderdale, Florida, United States|Broward Research Center - Pembroke Pines, Pembroke Pines, Florida, United States|Emory University, Atlanta, Georgia, United States|Saint Vincent Medical Group Inc., Indianapolis, Indiana, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital (MGH) - Cardiac Unit Associates, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Heart & Vascular Institute, Detroit, Michigan, United States|McLaren Health Care Corporation, Petoskey, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Cardiovascular Associates Of The Delaware Valley (Cadv), P.A. - Elmer Physicians Care Center - Elmer, Elmer, New Jersey, United States|Queens Heart Institute, Rosedale, New York, United States|Wake Med Health and Hospital, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health, Portland, Oregon, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Lancaster Heart And Stroke Foundation, Lancaster, Pennsylvania, United States|University of Texas - Southwestern Medical Center, Dallas, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03759392"
36,"NCT03757130","Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity",,"Completed","No Results Available","Obesity","Drug: AMG 598|Drug: Placebo|Drug: Liraglutide","Subject incidence of treatment-emergent adverse events|Pharmacokinetics parameter of maximum observed concentration (Cmax)|Pharmacokinetics parameter of time of maximum observed concentration (tmax)|Pharmacokinetics parameter of area under the concentration time curve (AUC)","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","20170139","November 26, 2018","December 16, 2019","December 16, 2019","November 28, 2018",,"December 24, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Tustin, California, United States|Research Site, South Miami, Florida, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03757130"
37,"NCT03638128","Open-label Extension Denosumab Study in Children and Young Adults With Osteogenesis Imperfecta",,"Recruiting","No Results Available","Osteogenesis Imperfecta (OI)","Drug: Denosumab","Subject incidence of treatment-emergent adverse events.|Changes in bone mineral density (BMD) of lumbar spine.|Changes in bone mineral density (BMD) of proximal femur (femoral neck).|Incidence of X-ray confirmed long bone fractures.|Incidence of X-ray confirmed new vertebral fractures.|Incidence of X-ray confirmed worsening vertebral fractures.|Incidence of vertebral fractures.|Incidence of nonvertebral fractures.|Change in growth velocity.|Changes in bone mineral density (BMD) of total hip.","Amgen","All","5 Years to 20 Years   (Child, Adult)","Phase 3","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170534|2018-000550-21","July 26, 2018","March 15, 2024","March 15, 2024","August 20, 2018",,"November 29, 2019","Research Site, Indianapolis, Indiana, United States|Research Site, Bruxelles, Belgium|Research Site, Montreal, Quebec, Canada|Research Site, Köln, Germany|Research Site, Budapest, Hungary|Research Site, Roma, Italy|Research Site, Lodz, Poland|Research Site, Esplugues de Llobregat, Cataluña, Spain|Research Site, Birmingham, United Kingdom|Research Site, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03638128"
38,"NCT03633708","Study of Etelcalceide in Pediatric Subjects With Secondary Hyperparathyroidism and CKD on Hemodialysis",,"Recruiting","No Results Available","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Etelcalcetide","Change of intact parathyroid hormone (iPTH) levels in children ages 28d to <18y with secondary hyperparathyroidism (sHPT) receiving maintenance hemodialysis|Corrected serum calcium levels of < 8.0 mg/dL in children aged 2 years to <18 years old|Corrected serum calcium levels of < 8.6 mg/dL in children aged 28 days to <18 years old","Amgen","All","up to 18 Years   (Child, Adult)","Phase 3","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140315","April 29, 2019","January 31, 2023","January 31, 2023","August 16, 2018",,"November 7, 2019","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Belagavi, Karnataka, India|Research Site, Seoul, Korea, Republic of|Research Site, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Seremban, Negri Sembilan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Singapore, Singapore|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT03633708"
39,"NCT03626662","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)",,"Active, not recruiting","No Results Available","Cardiovascular Disease","Drug: AMG 890|Drug: Placebo","Subject incidence of treatment-emergent adverse events|Changes in blood pressure|Changes in heart rate|Changes in respiratory rate|Changes in temperature|Changes in QRS interval|Changes in PR interval|Changes in QT interval|Changes in RR interval|Changes in red blood cells|Changes in platelets|Changes in white blood cells|Changes in prothrombin time (PT)|Changes in international normalized ratio (INR)|Changes in activated partial thromboplastin time (aPTT)|Changes in Thrombin time (TT)|Changes in aspartate aminotransferase (AST) levels (units: U/L)|Changes in alanine aminotransferase (ALT) levels (units: U/L)|Changes in total bilirubin levels (units: μmol/L)|Changes in direct bilirubin levels (units: μmol/L)|Changes in alkaline phosphatase levels (units: U/L)|Changes in total protein levels (units: g/L)|Changes in albumin levels (units: g/L)|Pharmacokinetics parameter of maximum observed concentration (Cmax)|Pharmacokinetics parameter of time of maximum observed concentration (tmax)|Pharmacokinetics parameter of area under the concentration time curve (AUC)|Change in plasma Lp(a) over time|Percent change in plasma Lp(a) over time","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","20170544","July 30, 2018","March 3, 2020","March 3, 2020","August 13, 2018",,"October 30, 2019","Research Site, Tustin, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03626662"
40,"NCT03619187","An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients",,"Withdrawn","No Results Available","Heart Transplantation, Elevated Resting Heart Rate","Drug: Ivabradine","pVO2|Resting Heart Rate","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20180037","November 2, 2018","February 19, 2020","February 19, 2020","August 7, 2018",,"November 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03619187"
41,"NCT03600883","A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)",,"Recruiting","No Results Available","KRAS p.G12C Mutant Advanced Solid Tumors","Drug: AMG 510","Number of Participants With Abnormal Laboratory Values|Number of subjects with clinically significant changes in vital signs.|Number of subjects with changes on ECG.|Objective response rate (ORR) assessed by RECIST 1.1 criteria of AMG 510 as monotherapy in subjects with KRAS p.G12C mutated advanced tumors|Plasma concentration (Cmax)|Time to achieve Cmax (tmax)|Area under the plasma concentration-time curve (AUC)|Duration of overall response|Progression-free survival|Duration of stable disease","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","350","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170543","August 27, 2018","August 10, 2023","March 8, 2024","July 26, 2018",,"January 18, 2020","Research Site, Duarte, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Monica, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Gainesville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Randwick, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Krems, Austria|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Bordeaux, France|Research Site, Marseille cedex 5, France|Research Site, Toulouse cedex 9, France|Research Site, Villejuif, France|Research Site, Essen, Germany|Research Site, Köln, Germany|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Geneve, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03600883"
42,"NCT03571828","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma(DLBCL)|Mantle Cell Lymphoma (MCL)|Follicular Lymphoma (FL)","Drug: AMG 562","Incidence of dose limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events|Incidence of treatment-related adverse events|Incidence of disease-related events|Incidence of clinically-significant changes in vital signs|Incidence of clinically-significant changes in physical examinations|Incidence of clinically-significant changes in electrocardiograms (ECG)s|Incidence of clinically-significant changes in clinical laboratory tests|Maximum observed concentration (Cmax) of AMG 562|minimum concentration (Cmin)|time of maximum concentration (Tmax)|area under the concentration-time curve (AUC)|Half Life (t1/2)|Efficacy-Overall Response|Efficacy-Objective Response Rate (ORR)|Efficacy-Duration of Response (DOR)|Efficacy-Progression Free Survival (PFS)|Efficacy-Overall Survival (OS)","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170533","October 29, 2018","August 30, 2021","August 16, 2023","June 28, 2018",,"October 30, 2019","Research Site, Duarte, California, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Buffalo, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, München, Germany|Research Site, Ulm, Germany|Research Site, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03571828"
43,"NCT03570697","Imaging of Coronary Plaques in Subjects Treated With Evolocumab",,"Active, not recruiting","No Results Available","Coronary Artery Disease (CAD)","Biological: Evolocumab|Other: Placebo","Absolute change in minimum fiberous cap thickness (FCT)|Percent change in minimum FCT in a matched segment of artery|Absolute change in minimum FCT, maximum lipid arc, and lipid core length in lipid rich plaques|Absolute change in mean mínimum FCT for all images assessed|Absolute change in the maximum lipid arc in a matched segment of artery","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160184|2017-003236-37","November 19, 2018","December 24, 2020","December 24, 2020","June 27, 2018",,"January 2, 2020","Research Site, Los Angeles, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Elkhart, Indiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Cleveland, Ohio, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, München, Germany|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Pecs, Hungary|Research Site, Bergamo, Italy|Research Site, Cuneo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT03570697"
44,"NCT03541369","Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia","20170528","Recruiting","No Results Available","Relapsed/Refractory Acute Myeloid Leukemia (AML)","Drug: AMG 427","subject incidence of dose limiting toxicities (DLTs)|subject incidence of treatment-emergent adverse events (TEAEs)|subject incidence of treatment-related adverse events (TRAEs)|Maximum observed concentration (Cmax) of AMG 427|minimum concentration (Cmin) of AMG 427|area under the concentration-time curve (AUC) of AMG 427|Half Life (t1/2) of AMG 427|complete response/remission [CR]|complete response/remission with incomplete recovery of peripheral blood counts [CRi]|partial remission (per modified International Working Group IWG criteria)|morphologic leukemia-free state|complete remission with partial hematologic recovery (CRh)|duration of response|relapse free survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170528|BB-IND 138440","September 14, 2018","December 20, 2021","December 20, 2021","May 30, 2018",,"November 29, 2019","Research Site, Duarte, California, United States|Research Site, Houston, Texas, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03541369"
45,"NCT03512353","A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers",,"Active, not recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Combination Product: Dexamethasone|Combination Product: Carfilzomib","Proportion of subjects completing|Cumulative Dose|Relative Dose Intensity|Treatment - Emergent|Dose intensity|Dose Intensity|Dose reduction|Treatment discontinuation|Assess response to the Kd regimen","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170596","July 5, 2018","January 16, 2020","January 16, 2020","April 30, 2018",,"October 30, 2019","Research Site, Palm Springs, California, United States|Research Site, Riverside, California, United States|Research Site, Glenwood Springs, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, River Forest, Illinois, United States|Research Site, Tinley Park, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Paducah, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Midland, Michigan, United States|Research Site, Jackson, Mississippi, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Florham Park, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Zanesville, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Fredericksburg, Virginia, United States|Research Site, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03512353"
46,"NCT03499119","AMG 334 20160172 Pediatric Migraine PK Study.",,"Recruiting","No Results Available","Migraine","Drug: AMG 334 Dose 1|Drug: AMG 334 Dose 2|Drug: AMG 334 Dose 3","Serum PK parameter of AMG 334 time to maximum observed concentration [Cmax]|Serum PK parameter of AMG 334 time to maximum concentration [tmax]|Serum PK parameter of AMG 334 area under the concentration time curve from 0 to 28 days [AUC 0-28days]|Serum PK parameter of AMG 334 area under concentration time curve [AUC]|Serum PK parameter of AMG 334 time to trough concentration [Ctrough]|Treatment-emergent adverse events|Heart Rate|Body Temperature|Blood Pressure|Duration and morphology of P, QRS and T waves in 12-lead electrocardiograms (ECGs)|Standard Hematology Lab Assessments|Standard Chemistry|Standard sensory assessment of body and peripheral and central nervous systems|Standard motor assessment of body peripheral and central nervous systems","Amgen","All","6 Years to 17 Years   (Child)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20160172","May 4, 2018","June 21, 2020","June 21, 2021","April 17, 2018",,"November 15, 2019","Research Site, Little Rock, Arkansas, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03499119"
47,"NCT03476239","Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",,"Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Blinatumomab","Change in rate of hematological response [CR/CRh] induced by blinatumomab","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","121","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130316","October 18, 2017","August 21, 2019","April 25, 2021","March 26, 2018",,"October 29, 2019","Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Hefei, China|Research Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03476239"
48,"NCT03465540","Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML",,"Active, not recruiting","No Results Available","Multiple Myeloma|Non-Hodgkin's Lymphoma|Acute Myeloid Leukemia|AML|NHL|DLBCL","Drug: AMG 397","Subject incidence of dose limiting toxicity|Incidence of treatment-emergent adverse events, treatment-related adverse events|Incidence of Clinically-significant changes in vital signs|Incidence of Clinically significant changes in ECGs|Incidence of clinically-significant changes in physical examinations|Incidence of Clinically significant changes in clinical laboratory tests|Objective response rate (ORR)|Duration of response|Progression-free survival (PFS)|Overall survival (OS)|AMG 397 PK parameter of maximum observed concentration|PK parameter of time of maximum observed concentration (tmax)|PK parameter of area under the concentration time curve (AUC)|PK parameter of clearance (CL)|PK parameter of half-life (t1/2)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170173","August 17, 2018","March 29, 2023","April 27, 2023","March 14, 2018",,"October 22, 2019","Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Woolloongabba, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Marseille Cedex 09, France|Research Site, Athens, Greece",,"https://ClinicalTrials.gov/show/NCT03465540"
49,"NCT03456856","A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.",,"Completed","No Results Available","Heart Failure (HF)","Drug: 5mg Ivabradine","Change in HR from baseline to day 57","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160231","September 28, 2017","April 19, 2019","May 20, 2019","March 7, 2018",,"October 30, 2019","Research Site, Wilmington, Delaware, United States|Research Site, Detroit, Michigan, United States|Research Site, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03456856"
50,"NCT03451422","Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 592|Drug: Placebo","Number of participants with Treatment-emergent Adverse Events.|SRI-4 (Systemic Lupus Erythematosus Responder Index) response in subjects with a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2K) score ≥ 6 at baseline.|CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index score) activity score change from baseline at week 24 in subjects with a CLASI activity score ≥ 10 at baseline.|Changes in blood pressure.|Physical examination will be performed as per standard of care.|Changes in heart rate.|Changes in respiratory rate.|Changes in temperature.|Changes in laboratory test results.|Area under the concentration-time curve over a dosing interval (AUCtau) of AMG 592.|Maximum observed concentration (Cmax) for AMG 592.|Time of maximum observed concentration (Tmax) for AMG 592.|Area under the concentration-time curve over a dosing interval (AUCtau).|Incidence of anti‑AMG 592 antibodies, week 18.|SRI-4 response in subjects with a SLEDAI 2K score ≥ 6 at baseline.|SRI-4 response at week 52 in subjects with baseline SLEDAI 2K score ≥ 6 who achieve a prednisone dose reduction to ≤ 10 mg/day and ≤ their baseline prednisone dose at week 44 and maintained through week 52.|Change from baseline in SLEDAI 2K at week 24 and week 52 in subjects with a SLEDAI 2K score ≥ 6 at baseline.|CLASI activity score 50% improvement from baseline at weeks 12, 24, 36, and 52 in subjects with a CLASI activity score ≥ 10 at baseline.|CLASI activity score change from baseline at weeks 12, 36 and 52, in subjects with a CLASI activity score ≥ 10 at baseline.|SRI-4 response at week 24 in subjects with baseline SLEDAI 2K score ≥ 6 who achieve a prednisone dose reduction to ≤ 10 mg/day and ≤their baseline prednisone dose at week 16 and maintained through week 24.|Proportion of subjects at week 16 and maintained through week 24 with a prednisone dose reduction to ≤ 7.5 mg/day and ≤ their baseline prednisone dose.|Proportion of subjects at week 44 and maintained through week 52 with a prednisone dose reduction to ≤ 7.5mg/day and ≤ their baseline prednisone dose.|Treatment-emergent adverse events.|Incidence of anti‑AMG 592 antibodies.|Cross‑reactivity of anti‑AMG 592 antibodies with IL‑2.|Incidence of anti‑AMG 592 and anti‑IL 2 neutralizing antibodies.|Maximum observed concentration (Cmax) of AMG 592.|Change from baseline in Physician Global Assessment (PGA) at week 24 and week 52 in subjects with a SLEDAI 2K score ≥ 6 at baseline.|Time of maximum observed concentration (Tmax) of AMG 592.","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20170103|2017-002564-40","April 10, 2018","June 15, 2023","June 15, 2023","March 1, 2018",,"October 24, 2019","Research Site, Anniston, Alabama, United States|Research Site, Beverly Hills, California, United States|Research Site, Aventura, Florida, United States|Research Site, Great Neck, New York, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Lille cedex 01, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Strasbourg, France|Research Site, Berlin, Germany|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT03451422"
51,"NCT03445663","Study Evaluating AMG 424 in Subjects With Multiple Myeloma",,"Recruiting","No Results Available","Relapsed/ Refractory Multiple Myeloma","Drug: AMG 424","Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0|Subject incidence of dose limiting toxicities (DLTs)|Anti-tumor activity|Duration of Response|Maximum concentration (Cmax) of AMG 424|Minimum concentration (Cmin) of AMG 424|Time of maximum concentration (Tmax) of AMG 424|Area under the concentration-time curve (AUC) of AMG 424|Time to progression|Progression-Free Survival|Overall Survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160445","July 31, 2018","March 1, 2023","March 1, 2023","February 26, 2018",,"November 27, 2019","Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Fitzroy, VIC, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03445663"
52,"NCT03439475","AMG 714 Expanded Access Program",,"Available","No Results Available","Celiac Disease","Biological: AMG 714",,"Amgen",,"18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"AMG714 Expanded Access Program",,,,"February 20, 2018",,"November 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03439475"
53,"NCT03433755","Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia",,"Recruiting","No Results Available","Primary Hypercholesterolemia|Mixed Dyslipidemia","Drug: Evolocumab 140 mg SC Q2W|Drug: Evolocumab 420 mg SC QM|Other: Placebo SC Q2W|Other: Placebo SC QM","Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 10 and 12|Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12|The mean of weeks 10 and 12 in low-density lipoprotein cholesterol (LDL-C)|The mean of weeks 10 and 12 in non-high-density lipoprotein cholesterol (non-HDL-C)|The mean of weeks 10 and 12 in apolipoprotein B (ApoB)|The mean of weeks 10 and 12 in total cholesterol|The mean of weeks 10 and 12 of target low-density lipoprotein cholesterol (LDL-C) < 70 mg/dL (1.8 mmol/L)|The mean of weeks 10 and 12 of low-density lipoprotein cholesterol (LDL-C) response|The mean of weeks 10 and 12 in lipoprotein(a) [Lp(a)]|The mean of weeks 10 and 12 in triglycerides|The mean of weeks 10 and 12 in high-density lipoprotein cholesterol (HDL-C)|The mean of weeks 10 and 12 in very low-density lipoprotein cholesterol (VLDL-C)|For week 12 change from baseline in low-density lipoprotein cholesterol (LDL-C)|For week 12 percent change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C)|For week 12 percent change from baseline in apolipoprotein B (ApoB)|For week 12 percent change from baseline in total cholesterol|For week 12 achievement of target low-density lipoprotein cholesterol (LDL-C) < 70 mg/dL (1.8 mmol/L)|For week 12 low-density lipoprotein cholesterol (LDL-C) response (50% reduction of low-density lipoprotein cholesterol (LDL-C) from baseline)|For week 12 percent change from baseline in lipoprotein(a) [Lp(a)]|For week 12 percent change from baseline in triglycerides|For week 12 percent change from baseline in high-density lipoprotein cholesterol (HDL-C)|For week 12 percent change from baseline in very low-density lipoprotein cholesterol (VLDL-C)","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150172","May 9, 2019","October 9, 2020","October 23, 2020","February 15, 2018",,"December 13, 2019","Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shenzhen, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Harbin, Heilongjiang, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Huhehaote, Inner Mongolia, China|Research Site, Suzhou, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Zhenjiang, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03433755"
54,"NCT03432533","A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis",,"Completed","No Results Available","Post-Menopausal Osteoporosis","Drug: HCP administration with PFS|Device: Subject self-administration with AI/Pen","Percent change from baseline in bone mineral density (BMD) at the lumbar spine|Percent changes from baseline in BMD at the total hip.|Incidence of treatment-emergent adverse events|Incidence of subjects developing anti-romosozumab antibodies|Serum Chemistry|Percent changes from baseline in BMD at femoral neck.|Incidence of treatment-emergent serious adverse events|Incidence of treatment-emergent adverse device effects|Systolic Blood Pressure|Diastolic Blood Pressure|Respiratory Rate|Heart Rate|Temperature|Hematology","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","283","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150120|2017-003512-40","February 6, 2018","April 11, 2019","January 8, 2020","February 14, 2018",,"January 22, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Cypress, California, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Santa Maria, California, United States|Research Site, Tustin, California, United States|Research Site, Denver, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Delray Beach, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Franklin, Wisconsin, United States|Research Site, Bialystok, Poland|Research Site, Lodz, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Chorley, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Romford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03432533"
55,"NCT03422627","Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease",,"Recruiting","No Results Available","Chronic Graft Versus Host Disease cGVHD","Drug: AMG 592","Phase 1b: Incidence of dose limiting toxicities|Phase 1b: Incidence of all treatment-related and treatment-emergent adverse events and serious adverse events|Phase 2: Best overall response rate defined as the proportion of subjects achieving a Complete Response (CR) or Partial Response (PR) during the study according to the 2014 cGVHD NIH Consensus Criteria|Phase 2: Incidence of treatment-emergent and treatment-related and treatment-emergent adverse events and serious adverse events|Phase 2: Failure free survival rate|Phase 2: Changes in symptom burden over time|Phase 2: Changes in quality of life","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","124","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160283|2017-000763-33","April 30, 2018","October 7, 2022","November 18, 2022","February 6, 2018",,"November 29, 2019","Research Site, Duarte, California, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Dallas, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Leuven, Belgium|Research Site, Grenoble Cedex 09, France|Research Site, Paris Cedex 10, France|Research Site, Okayama-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03422627"
56,"NCT03410056","Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis RA","Drug: AMG 592|Drug: Placebo","ACR 20|ACR 50/70|DAS28-ESR|DAS 28-CRP|Maximum observed concentration (Cmax) of AMG592|Time of maximum observed concentration (Tmax) of AMG592|Area under the concentration-time curve (AUCtau) of AMG592","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170149|2017‐001944‐36","May 22, 2018","September 9, 2022","September 9, 2022","January 25, 2018",,"January 22, 2020","Research Site, Anniston, Alabama, United States|Research Site, Torrance, California, United States|Research Site, Lansing, Michigan, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Sofia, Bulgaria|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Jozefow, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Stalowa Wola, Poland|Research Site, Swidnik, Poland|Research Site, Wroclaw, Poland|Research Site, A Coruña, Galicia, Spain",,"https://ClinicalTrials.gov/show/NCT03410056"
57,"NCT03403374","Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia",,"Completed","No Results Available","Homozygous Familial Hypercholesterolemia HoFH","Drug: Repatha® (evolocumab)","Number of participants with treatment related Adverse Events|Change in LDC-C|Change in ApoB|Change in Lp(a)","Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170199","August 4, 2018","November 27, 2019","November 27, 2019","January 18, 2018",,"December 5, 2019","Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT03403374"
58,"NCT03392064","A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC",,"Active, not recruiting","No Results Available","Small Cell Lung Cancer","Biological: AMG 119","Incidence of dose limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events and treatment-related adverse events|Incidence of clinically significant changes in vital signs|Incidence of clinically significant changes in physical examinations|Incidence of clinically significant changes in clinical laboratory tests|Objective Response (OR)|Duration of Response (DOR)|Progression-Free Survival (PFS)|1-year Overall Survival (1-year OS)|Overall Survival (OS)|Measurement of expansion and persistence of CAR T cells in peripheral blood post-infusion|Evidence of CAR T cells in tumor tissue post dose","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170124","September 10, 2018","March 10, 2020","March 10, 2020","January 5, 2018",,"November 22, 2019","Research Site, Tampa, Florida, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03392064"
59,"NCT03362177","Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer",,"Recruiting","No Results Available","Chemotherapy-induced Thrombocytopenia","Biological: Romiplostim|Other: Placebo","Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.|Depth of Platelet Count|First platelet response|Bleeding Events|Overall Survival|Subject incidence of Platelet Transfusion|Platelet Count|AEs/SAEs overall safety of romiplostim","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140346|2017-002992-25","September 30, 2019","October 17, 2021","September 18, 2022","December 5, 2017",,"January 18, 2020","Research Site, Jonesboro, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Orange City, Florida, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Springfield, Missouri, United States|Research Site, Sparta, New Jersey, United States|Research Site, Fort Worth, Texas, United States|Research Site, Cordoba, Córdoba, Argentina|Research Site, Viedma, Río Negro, Argentina|Research Site, Curitiba, Paraná, Brazil|Research Site, Teresina, Piauí, Brazil|Research Site, Caxias do Sul, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Kitchener, Ontario, Canada|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Budapest, Hungary|Research Site, Oaxaca, Mexico|Research Site, Biala Podlaska, Poland|Research Site, Brzeziny, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tambov, Russian Federation|Research Site, Granada, Andalucía, Spain|Research Site, Ourense, Galicia, Spain|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT03362177"
60,"NCT03343847","Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.",,"Withdrawn","No Results Available","Chemotherapy-induced Thrombocytopenia","Biological: Romiplostim|Other: Placebo","Chemotherapy dose delay or reduction|Platelet recovery|Platelet count|Depth of the platelet count|Subject Incidence of Platelet Transfusion|Bleeding events|Adverse Events, Serious Adverse Events, clinically significant lab value changes|Antibody Formation|Vital Status|Changes in health","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140347|2017-002995-16","January 27, 2018","July 17, 2021","July 17, 2021","November 17, 2017",,"January 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03343847"
61,"NCT03340766","Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)",,"Recruiting","No Results Available","Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Drug: Blinatumomab|Drug: Pembrolizumab","Incidence of dose limiting toxicities (DLTs)|Objective Response|Progression Free Survival|Overall Survival|Complete Remission|Duration of response|Blinatumomab Steady state concentration|Blinatumomab Clearance rate|Pembrolizumab Peak Plasma Concentration|Pembrolizumab Minimum plasma concentration|Pembrolizumab PK Parameter - AUC","Amgen|Merck Sharp & Dohme Corp.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150290|2016-002191-27","March 16, 2018","October 30, 2021","September 3, 2025","November 14, 2017",,"December 13, 2019","Research Site, La Jolla, California, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Créteil Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Pierre Benite Cedex, France|Research Site, Heidelberg, Germany|Research Site, Ulm, Germany|Research Site, Würzburg, Germany|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03340766"
62,"NCT03319940","Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer",,"Recruiting","No Results Available","Small Cell Lung Carcinoma","Drug: AMG 757","Subject incidence of dose limiting toxicity|Subject incidence of treatment-emergent and treatment-related adverse events|Subject change in health status|Objective Response|Duration of Response|Progression-Free Survival|Overall Survival|Relapse Free Survival|Maximum observed concentration (Cmax) of AMG 757|Minimum concentration (Cmin)|Area under the concentration-time curve (AUC)|Half Life (t1/2)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","132","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160323","December 26, 2017","June 14, 2022","June 13, 2023","October 24, 2017",,"December 10, 2019","Research Site, Duarte, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Villejuif, France|Research Site, Wurzburg, Germany|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Madrid, Spain|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03319940"
63,"NCT03318809","AMG 986 20150186 Renal Impairment Study",,"Completed","No Results Available","Heart Failure","Drug: AMG 986","AMG 986 PK parameters - Area under the plasma concentration time curve from time 0 to the time of the last quantifiable sample|AMG 986 PK parameters - Maximum observed plasma concentration after dosing|AMG 986 PK parameters -Terminal phase half-life|AMG 986 PK parameters - Time of maximum plasma concentration|AMG 986 PK parameters - AUC from time 0 to infinity|Adverse Event assessment|Change in Heart rate|Physical Examination Assessment|Change in total Creatine kinase|ECG assessments|Change in Blood Pressure|Change in Respiratory rate|Change in Troponin 1|Change in total bilirubin|Change in alanine aminotransferase|Change in Aspartate aminotransferase","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150186","December 12, 2017","March 12, 2018","April 5, 2018","October 24, 2017",,"October 22, 2019","Research Site, Tustin, California, United States|Research Site, Orlando, Florida, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03318809"
64,"NCT03301857","Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004",,"Active, not recruiting","No Results Available","Giant Cell Tumor of Bone","Drug: Denosumab (Cohort A)","Rate of adverse events of interest in subjects with GCTB treated with denosumab|Rate of treatment-emergent adverse events for subjects who are receiving denosumab.|Rate of serious adverse events for all subjects.|Rate of disease progression or recurrence of GCTB for all subjects.|Rate of GCTB interventions for all subjects.","Amgen","All","Child, Adult, Older Adult","Phase 4","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20140114|2017-001758-32","November 13, 2017","July 25, 2023","July 25, 2023","October 4, 2017",,"October 21, 2019","Research Site, Santa Monica, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Lyon CEDEX 08, France|Research Site, Villejuif, France|Research Site, Bologna, Italy|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Lund, Sweden|Research Site, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03301857"
65,"NCT03299244","Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT",,"Recruiting","No Results Available","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Etelcalcetide|Drug: Cinacalcet",">30% reduction predialysis serum PTH|> 50% reduction predialysis serum PTH|Percent change from baseline in mean predialysis serum cCa|Serum P ≤ 4.5 mg/dL during the EAP","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","660","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150238","May 15, 2018","April 13, 2020","April 13, 2020","October 3, 2017",,"October 21, 2019","Research Site, Beijing, Beijing, China|Research Site, Lanzhou, Gansu, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shenzhen, Guangdong, China|Research Site, Zhanjiang, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Nanning, Guangxi, China|Research Site, Zhengzhou, Henan, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changzhou, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Dalian, Liaoning, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Xian, Shaanxi, China|Research Site, Qingdao, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Nadiad, Gujarat, India|Research Site, Belagavi, Karnataka, India|Research Site, Mysuru, Karnataka, India|Research Site, Kozhikode, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Chandigarh, Punjab, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Dehradun, Uttaranchal, India|Research Site, Wardha, India|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gumi-si, Gyeongsangbuk-do, Korea, Republic of|Research Site, Guri-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ipoh, Perak, Malaysia|Research Site, George Town, Pinang, Malaysia|Research Site, Kuching, Sarawak, Malaysia|Research Site, Batu Caves, Selangor (incl. Putrajaya), Malaysia|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT03299244"
66,"NCT03298412","Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT",,"Terminated","No Results Available","High-risk Diffuse Large B-cell Lymphoma","Drug: Blinatumomab","Minimal residual disease|Progression-free survival|Duration of MRD-negative status|Overall Survival|Adverse Events","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150291|2016-003255-30","May 23, 2018","September 30, 2019","September 30, 2019","October 2, 2017",,"October 15, 2019","Research Site, Atlanta, Georgia, United States|Research Site, Maywood, Illinois, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Charleroi, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Créteil Cedex, France|Research Site, Lille, France|Research Site, Marseille, France|Research Site, Montpellier cedex 5, France|Research Site, Paris Cedex 10, France|Research Site, Pessac Cedex, France|Research Site, Pierre Benite Cedex, France|Research Site, Rouen, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Bergamo, Italy|Research Site, Brescia, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Torino, Italy|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03298412"
67,"NCT03296696","Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma",,"Recruiting","No Results Available","Glioblastoma or Malignant Glioma","Drug: AMG 596","Number of subject with treatment-emergent adverse events|Objective response (OR) as per modified RANO|Area under the concentration-time curve (AUC) for serum AMG 596|Volume of distribution for serum AMG 596|Average steady-state concentration (Css) for serum AMG 596","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","82","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160132|2017-001658-32","April 18, 2018","August 16, 2024","August 16, 2024","September 28, 2017",,"December 3, 2019","Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Villejuif, France|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Würzburg, Germany|Research Site, Amsterdam, Netherlands|Research Site, Badalona, Cataluña, Spain",,"https://ClinicalTrials.gov/show/NCT03296696"
68,"NCT03287908","A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma",,"Recruiting","No Results Available","Relapsed/Refractory Multiple Myeloma","Drug: AMG 701","Subject incidence of adverse events as a Measure of Safety|Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety|Anti-tumor activity|Pharmacokinetic parameter of AMG 701","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20170122|2017-001997-41","November 13, 2017","May 27, 2022","April 25, 2026","September 19, 2017",,"January 10, 2020","Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Groningen, Netherlands|Research Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03287908"
69,"NCT03283098","A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416",,"Completed","No Results Available","Secondary Hyperparathyroidism","Device: Hemodialysis|Procedure: Hemodialysis","Maximum plasma concentration (Cmax) over the interdialytic interval following the first and last dose|Area under the plasma concentration-time curve (AUClast) over the interdialytic interval following the first and last dose|Incidence of adverse events|Number of participants with clinically-significant changes in vital signs|Number of participants with clinically-significant changes in electrocardiograms (ECGs)|Incidence of clinically-significant changes in laboratory safety tests including cCa (Calcium)|Subject incidence of anti-AMG 416 antibodies","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20140197","March 1, 2018","February 4, 2019","February 4, 2019","September 14, 2017",,"December 6, 2019","Research Site, Beijing, Beijing, China|Research Site, Nanjing, Jiangsu, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03283098"
70,"NCT03276728","Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients",,"Terminated","No Results Available","Heart Failure","Drug: AMG 986 IV Dose Level A or matching Placebo|Drug: AMG 986 IV Dose Level B or matching Placebo|Drug: AMG 986 IV Dose Level C or matching placebo|Drug: AMG 986 IV Dose Level D or matching placebo|Drug: AMG 986 IV Dose Level E or matching Placebo|Drug: AMG 986 IV Dose Level F or matching Placebo|Drug: AMG 986 IV Dose Level G or matching Placebo|Drug: AMG 986 Oral Dose Level A or matching Placebo|Drug: AMG 986 Oral Dose Level B or matching Placebo|Drug: AMG 986 Oral Dose Level C or matching Placebo|Drug: AMG 986 Oral Dose Level D or matching Placebo|Drug: AMG 986 Oral Dose Level E or matching Placebo|Drug: AMG 986 Oral Dose Level F or matching Placebo|Drug: AMG 986 Oral Dose Regimen or matching placebo - R|Drug: AMG 986 Oral Dose Regimen or matching placebo - P","Subject incidence of treatment-emergent adverse events.|Oral bioavailability for AMG 986|Area under the plasma concentration versus time curve (AUC) for AMG 986|Peak Plasma Concentration (Cmax) for AMG 986|the time of maximum observed concentration (tmax) for AMG 986","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150183","August 12, 2016","April 18, 2019","April 18, 2019","September 8, 2017",,"October 30, 2019","Research Site, Anaheim, California, United States|Research Site, Tustin, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Durham, North Carolina, United States|Research Site, Auchenflower, Queensland, Australia|Research Site, Bundaberg, Queensland, Australia|Research Site, Leabrook, South Australia, Australia|Research Site, Berwick, Victoria, Australia|Research Site, Bundoora, Victoria, Australia|Research Site, Sherbrooke, Quebec, Canada|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Rennes Cedex 9, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Groningen, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Jozefow, Poland|Research Site, Wroclaw, Poland|Research Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03276728"
71,"NCT03256344","Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases",,"Recruiting","No Results Available","Metastatic Triple Negative Breast Cancer|Metastatic Colorectal Cancer","Biological: Talimogene Laherparepvec|Biological: Atezolizumab","Subject's incidence of dose limiting toxicities (DLTs)|Subject's incidence of treatment-emergent adverse events|Number of subject with clinically relevant laboratory abnormalities|Objective response rate (ORR)|Best overall response (BOR)|Duration of response (DOR)|Disease control rate (DCR)|Durable response rate (DRR)|Progression-free survival (PFS)|Overall survival (OS)|Lesion level responses in injected and uninjected tumor lesions","Amgen|Roche-Genentech","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20140299","March 19, 2018","December 9, 2020","May 13, 2022","August 22, 2017",,"December 6, 2019","Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Tübingen, Germany|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland",,"https://ClinicalTrials.gov/show/NCT03256344"
72,"NCT03238781","Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention",,"Completed","No Results Available","Chronic Migraine or Episodic Migraine","Drug: Placebo|Drug: AMG 301","Change from the baseline period in monthly migraine days. The monthly migraine days will be calculated using the migraine days over the last 4 weeks of the 12-week double-blind treatment period.|At least a 50% reduction from the baseline period in monthly migraine days in the last 4 weeks of the 12-week double-blind treatment period|Change from the baseline period in monthly acute migraine-specific medication days in the last 4 weeks of the 12-week double-blind treatment period.|Change from the baseline period in mean physical impairment domain scores as measured by the MPFID over the last 4 weeks of the 12-week double-blind treatment period.|Change from the baseline period in mean impact on everyday activities domain scores as measured by the MPFID over the last 4 weeks of the 12-week double-blind treatment period.","Amgen","All","18 Years to 60 Years   (Adult)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20150308|2017-000630-57","September 6, 2017","October 16, 2018","February 4, 2019","August 3, 2017",,"July 18, 2019","Research Site, Long Beach, California, United States|Research Site, Santa Monica, California, United States|Research Site, Boulder, Colorado, United States|Research Site, East Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Peters, Missouri, United States|Research Site, Plainview, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Wien, Austria|Research Site, Calgary, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Markham, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Prerov, Czechia|Research Site, Aarhus, Denmark|Research Site, Glostrup, Denmark|Research Site, Viborg, Denmark|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Jyvaskyla, Finland|Research Site, Oulu, Finland|Research Site, Turku, Finland|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03238781"
73,"NCT03224819","Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: AMG 673","Subject incidence and grade of adverse events|Dose limiting toxicities (DLTs)|Pharmacokinetic parameter - half-life|Pharmacokinetic parameter - steady state|Pharmacokinetic parameter - Concentration|Pharmacokinetic parameter - Volume of distribution|Pharmacokinetic parameter - Clearance of AMG 673|Efficacy parameters - response rate|Efficacy parameters - duration of response|Efficacy parameters - time to progression|Efficacy parameters - time to response","Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160377","September 7, 2017","October 31, 2022","October 31, 2022","July 21, 2017",,"November 20, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, München, Germany",,"https://ClinicalTrials.gov/show/NCT03224819"
74,"NCT03170193","AMG 529 First in Human Study",,"Completed","Has Results","Cardiovascular","Drug: AMG 529|Drug: Placebo","Number of Participants With Adverse Events (AEs)|Maximum Observed Concentration (Cmax) of AMG 529|Time to Maximum Observed Concentration (Tmax) of AMG 529|Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast) for AMG 529|Change From Baseline in Blood Alkaline Phosphatase Concentration Over Time|Change From Baseline in Total Cholesterol Concentration Over Time|Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration Over Time|Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) Concentration Over Time|Change From Baseline in Triglycerides Concentration Over Time","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160338","May 15, 2017","November 17, 2017","November 17, 2017","May 30, 2017","July 5, 2019","July 5, 2019","Research Site, Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03170193/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03170193"
75,"NCT03164928","Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis",,"Recruiting","No Results Available","Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With|Glucocorticoid-induced Osteoporosis","Drug: Denosumab|Other: Placebo","Change from baseline in lumbar spine BMD Z-score as assessed by DXA at 12 months|Change from baseline in lumbar spine BMD Z-score as assessed by DXA at 6, 18, 24, and 36 months.|Change from baseline in proximal femur BMD Z-score as assessed by DXA at 6, 12, 18, 24, and 36 months.|Subject incidence of X-ray confirmed long-bone fractures and new and worsening vertebral fractures at 12, 24, and 36 months compared to pre-treatment|Subject incidence of improving vertebral fractures at 12, 24, and 36 months compared to pretreatment|Subject incidence of vertebral and nonvertebral fractures at 12, 24, and 36 months compared to pretreatment.|Change from baseline in CHQ-PF-50 Physical Summary Score at 12, 24, and 36 months.|Change from baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 months|Change from baseline in CHAQ Disability Index Score at 12, 24, and 36 months|Change from baseline WBFPRS at 12, 24, and 36 months|Change from baseline in growth velocity, determined by calculating age-adjusted Z-scores for height, weight, and Body Mass Index at 12, 24, and 36 months|Serum concentration of denosumab at 1, 10, and 30 days, and 3, 6, 12, and 18 months","Amgen","All","5 Years to 17 Years   (Child)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140444|2016-003083-39","May 7, 2018","March 31, 2026","March 27, 2029","May 24, 2017",,"November 15, 2019","Research Site, Los Angeles, California, United States|Research Site, Wilmington, Delaware, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Columbus, Ohio, United States|Research Site, Bruxelles, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Belagavi, Karnataka, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Firenze, Italy|Research Site, Milan, Italy|Research Site, Roma, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Brena, Lima, Peru|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Dnipro, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03164928"
76,"NCT03158688","Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.","CANDOR","Active, not recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Drug: Dexamethasone|Drug: Daratumumab|Drug: Carfilzomib","Progression Free Survival (PFS)|Overall Response Rate (ORR)|Rate of minimal residual disease negative-complete response|Duration of response (DOR)|Overall survival (OS)|Time to next treatment|time to progression (TTP)|Time to response|Persistence of MRD[-]CR|Complete response rate (CRR)|MRD[-] rate|Quality of life questionnaire - core 30 items|Quality of Life (QoL) measured by European Organization|Subject incidence of treatment-emergent adverse events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160275|2016-003554-33","June 13, 2017","July 14, 2019","July 21, 2022","May 18, 2017",,"December 6, 2019","Research Site, Boca Raton, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, VIC, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Graz, Austria|Research Site, Salzburg, Austria|Research Site, Antwerpen, Belgium|Research Site, Brussel, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, La Roche Sur Yon Cedex 9, France|Research Site, Le Chesnay cedex, France|Research Site, Lille Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite cedex, France|Research Site, Poitiers Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Szeged, Hungary|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Shibukawa-city, Gunma, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Tokushima-shi, Tokushima, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Hwasun, Jeollanam-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bialystok, Poland|Research Site, Chorzow, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Changhua, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Samsun, Turkey|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03158688"
77,"NCT03156023","Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis","Drug: AMG 570|Drug: Placebo","Number of participants with treatment-emergent adverse events|Number of participants with clinically significant changes in physical examinations|Number of participants with clinically significant changes in vital signs|Number of participants with clinically significant changes in laboratory safety tests|Number of participants with clinically significant changes in electrocardiograms (ECGs)|Serum PK parameter of maximum-observed concentration (Cmax)|Serum PK parameter of time at Cmax [tmax]|Serum PK parameter of area under the curve (AUC)","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150196","August 14, 2017","October 17, 2019","October 29, 2020","May 16, 2017",,"October 23, 2019","Research Site, Anniston, Alabama, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03156023"
78,"NCT03117621","Observational Study of Blinatumomab",,"Recruiting","No Results Available","Blincyto Use in Routine Clinical Practice",,"Proportion of subjects with specified AEs as mentioned in description|Time to onset of first specified AEs|Summary of duration of specified AEs as detailed in the description (all events and resolved/recovered events)|Proportion of Blincyto administrations with medication errors|Proportion of subjects with AEs as detailed in the description|Proportion of patients achieving Complete Remission overall and amongst patient sub-groups|Blincyto utilisation|Select healthcare resource use|Proportion of patients receiving allogeneic HSCT overall and amongst patient sub-groups|1-year and 100-day mortality proportion after allogeneic HSCT overall and amongst patient sub-groups|Relapse-free survival (RFS) time overall and amongst patient sub-groups|Overall survival (OS) time overall and amongst patient sub-groups|Proportion of patients with MRD achieving CR/CRh*/CRi within 2 cycles of Blincyto|Disease Free Survival (DFS) time|Proportion of patients achieving CR/CRh*/CRi overall and amongst patient sub-groups","Amgen","All","Child, Adult, Older Adult",,"360","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20150136","March 22, 2017","March 22, 2023","March 22, 2023","April 18, 2017",,"December 19, 2019","Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Hradec Kralove, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Helsinki, Finland|Research Site, Angers cedex 09, France|Research Site, Besançon, France|Research Site, Clamart, France|Research Site, Clermont-Ferrand, France|Research Site, Créteil, France|Research Site, Lille, France|Research Site, Montpellier cedex 5, France|Research Site, Nice cedex 3, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite, France|Research Site, Poitiers, France|Research Site, Strasbourg, France|Research Site, Toulouse cedex 9, France|Research Site, Vandoeuvre les Nancy Cedex, France|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Halle (Saale), Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pagani (SA), Italy|Research Site, Pavia, Italy|Research Site, Pescara, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, S Andrea Delle Fratte Perugia, Italy|Research Site, Torino, Italy|Research Site, Venezia, Italy|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Basel, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneve, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Luzern, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Harrow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03117621"
79,"NCT03091127","Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe",,"Active, not recruiting","No Results Available","Multiple Myeloma",,"Carfilzomib starting dose|Carfilzomib dose|Carfilzomib dose modification|Time to carfilzomib dose modification|Reason for dose modification|Number of cycles started|Carfilzomib regimen|Carfilzomib dosing frequency|Carfilzomib dosing schedule|Carfilzomib duration of treatment|Starting dose of concomitant anti-myeloma agents|Dose modification for concomitant anti-myeloma agents|Reason for frequency modification|Reason for change in frequency of concomitant multiple myeloma therapies|International Staging System (ISS) score and revised ISS stage at diagnosis and carfilzomib regimen initation|Eastern Cooperative Oncology Group (ECOG) performance status|Cytogenetic risk profile at diagnosis|Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain)|Presence of comorbidities|Previously received anti-myeloma treatment|Response to prior treatment|Number of prior relapses|Adverse event|Time to adverse event|Electrocardiogram (ECG) changes|Decrease in left ventricular ejection fraction (LVEF)|Initiation or dose increase of antihypertensive treatment|Initiation or dose increase of existing heart failure treatment|Response to carfilzomib treatment|Type of relapse|Number of unplanned hospitalisations|Concomitant therapy not part of the carfilzomib regimen|Planned subsequent treatment regimen|Patient age|Patient sex|Patient height|Patient weight|MRI (magnetic resonance imaging) performed at MM diagnosis and carfilzomib regimen initiation.|PET-CT (positron emission tomography-computed tomography) performed at MM diagnosis and carfilzomib regimen initiation.|Measurement of Serum M component at MM diagnosis and carfilzomib regimen initiation.|Measurement of Urine M component at MM diagnosis and carfilzomib regimen initiation.|Measurement of serum albumin at MM diagnosis and carfilzomib regimen initiation.|Measurement of serum beta-2-microglobulin at MM diagnosis and carfilzomib regimen initiation.|Measurement of percent of plasma cells in bone marrow at MM diagnosis and carfilzomib regimen initiation.|Baseline measurement of lactate dehydrogenase at MM diagnosis and carfilzomib regimen initiation.|ECG (electrocardiogram)|Echocardiogram|LVEF (left ventricular ejection fraction) assessment|Computed Tomography (CT) performed at MM diagnosis and carfilzomib regiment initiation.|Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation","Amgen","All","18 Years and older   (Adult, Older Adult)",,"705","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","20150262","March 14, 2017","March 17, 2020","March 17, 2020","March 27, 2017",,"November 6, 2019","Research Site, Braunau, Austria|Research Site, Innsbruck, Austria|Research Site, Leoben, Austria|Research Site, Linz, Austria|Research Site, Rankweil, Austria|Research Site, Salzburg, Austria|Research Site, Schwarzach im Pongau, Austria|Research Site, Steyr, Austria|Research Site, Waidhofen an der Ybbs, Austria|Research Site, Wels, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Geel, Belgium|Research Site, Gent, Belgium|Research Site, Haine Saint Paul - La Louviere, Belgium|Research Site, Ieper, Belgium|Research Site, Liege, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Tournai, Belgium|Research Site, Verviers, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Avignon Cedex 9, France|Research Site, Bayonne, France|Research Site, Creteil, France|Research Site, Grenoble Cedex 9, France|Research Site, Limoges Cedex, France|Research Site, Montpellier cedex 5, France|Research Site, Nimes cedex 09, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Pontoise Cedex, France|Research Site, Reims cedex, France|Research Site, Saint Quentin, France|Research Site, Strasbourg, France|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Patra, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Petah Tiqva, Israel|Research Site, Tel Aviv, Israel|Research Site, Alessandria, Italy|Research Site, Bagno A Ripoli (FI), Italy|Research Site, Barletta, Italy|Research Site, Benevento, Italy|Research Site, Bergamo, Italy|Research Site, Brindisi, Italy|Research Site, Cagliari, Italy|Research Site, Cuneo, Italy|Research Site, Lecco, Italy|Research Site, Livorno, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Pagani (SA), Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Pescara, Italy|Research Site, Potenza, Italy|Research Site, Reggio Calabria, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Salerno, Italy|Research Site, Taranto, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Verona, Italy|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT03091127"
80,"NCT03080935","Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries",,"Active, not recruiting","No Results Available","Dyslipidemia","Drug: Evolocumab","Adverse event measurement|Percent change of LDL-C|Achievement of an LDL-C < 40 mg/dL","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","1600","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160250|2016-004066-26","March 13, 2017","December 4, 2022","December 4, 2022","March 15, 2017",,"November 7, 2019","Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Turnhout, Belgium|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kobenhavn S, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Koge, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Besancon cedex, France|Research Site, Chambray les Tours, France|Research Site, Le Coudray, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau, France|Research Site, Reims cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Vesoul, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Stuttgart, Germany|Research Site, Ulm, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Siena, Italy|Research Site, Almada, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Setubal, Portugal|Research Site, Falun, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Lulea, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Orebro, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden",,"https://ClinicalTrials.gov/show/NCT03080935"
81,"NCT03064763","Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma",,"Active, not recruiting","No Results Available","Unresectable Stage IIIB-IV Malignant Melanoma","Drug: Talimogene laherparepvec","Incidence of dose limiting toxicities (DLTs)of talimogene laherparepvec|The anti-tumor activity of T-VEC as assessed by DRR using modified WHO response criteria.|Incidence of dose limiting toxicities (DLTs) of talimogene laherparepvec|Evaluate the anti-tumor activity of talimogene laherparepvec|Evaluate overall survival (OS)","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","20140270","March 7, 2017","March 27, 2020","April 16, 2021","February 27, 2017",,"November 7, 2019","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03064763"
82,"NCT03029234","Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma",,"Active, not recruiting","Has Results","Relapsed and Refractory Multiple Myeloma","Drug: Dexamethasone|Drug: Carfilzomib","Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee|Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Investigator|Overall Response Rate After at Least 12 Cycles of Treatment Assessed by the Independent Review Committee|Overall Response Rate After at Least 12 Cycles of Treatment Assessed by the Investigator|Clinical Benefit Rate After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee|Clinical Benefit Rate After at Least 6 Cycles of Treatment Assessed by the Investigator|Clinical Benefit Rate After at Least 12 Cycles of Treatment Assessed by the Independent Review Committee|Clinical Benefit Rate After at Least 12 Cycles of Treatment Assessed by the Investigator|Duration of Overall Response (DOR)|Duration of Clinical Benefit (DCB)|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Response (TTR)|Maximum Observed Plasma Concentration (Cmax) of Carfilzomib|Time to Maximum Plasma Concentration (Tmax) of Carfilzomib|Area Under the Plasma Concentration Curve From Time 0 to the Last Measurable Concentration (AUClast) for Carfilzomib|Area Under the Plasma Concentration Curve From Time 0 Extrapolated to Infinity (AUC0-inf) for Carfilzomib|Terminal Elimination Half-Life (T½) for Carfilzomib|Systemic Clearance (CL) of Carfilzomib After Intravenous Infusion|Volume of Distribution (Varea) of Carfilzomib|Volume of Distribution at Steady State (Vss) for Carfilzomib|Mean Residence Time Observed From Time Zero to the Last Quantifiable Concentration (MRTlast) for Carfilzomib","Amgen|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","126","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140242|CFZ005","March 31, 2017","November 5, 2018","June 3, 2021","January 24, 2017","November 21, 2019","November 21, 2019","Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Suzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03029234/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03029234/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03029234"
83,"NCT03023878","Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","High-risk Diffuse Large B-Cell Lymphoma","Drug: Blinatumomab|Drug: Investigator's Choice Chemotherapy","Overall incidence and severity of treatment-emergent adverse events|Tumor response based on objective response rate.|Duration of response|Complete response rate|Progression free survival|Hematopoietic stem cell transplantation rate|Overall survival|Blinatumomab pharmacokinetic parameters","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150288|2016-002190-35","March 13, 2017","April 4, 2019","October 28, 2019","January 18, 2017",,"November 7, 2019","Research Site, Chicago, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Créteil Cedex, France|Research Site, Paris Cedex 10, France|Research Site, Dresden, Germany|Research Site, Ulm, Germany|Research Site, Sevilla, Andalucía, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A coruña, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Bristol, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03023878"
84,"NCT02993120","Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States",,"Active, not recruiting","No Results Available","Medical Conditions to be Studied|Dyslipidemia|ASCVD Management",,"Low-density lipoprotein (LDL) treatment patterns|LDL-C levels and measurement patterns|Subject Characteristics|Subject understanding of CV risk|Goals of Lipid Management|Attitudes towards lipid lowering treatment (LLT)","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)",,"5006","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","20150230","December 6, 2016","July 31, 2020","July 31, 2020","December 15, 2016",,"November 12, 2019","Research Site, Chandler, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Canoga Park, California, United States|Research Site, Cerritos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Oxnard, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Sacramento, California, United States|Research Site, Wildomar, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Lafayette, Colorado, United States|Research Site, Bloomfield, Connecticut, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Rockledge, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Cumming, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Morton, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, Des Moines, Iowa, United States|Research Site, Covington, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Eunice, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Great Barrington, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Coon Rapids, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cedar Knolls, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Kingston, New York, United States|Research Site, Rochester, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Wynnewood, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Humble, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Lufkin, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Missouri City, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Hopewell, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02993120"
85,"NCT02986139","Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis",,"Completed","Has Results","Arthritis, Rheumatoid; Arthritis, Psoriatic","Drug: Commercial Formulation Etanercept|Drug: New Formulation Etanercept","Injection Site Pain|Injection Site Pain by Disease Indication|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20140339","November 29, 2016","September 8, 2017","October 9, 2017","December 8, 2016","October 31, 2018","July 18, 2019","Research Site, Birmingham, Alabama, United States|Research Site, El Cajon, California, United States|Research Site, Lomita, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Cutler Bay, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Quincy, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Flowood, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Freehold, New Jersey, United States|Research Site, Smithtown, New York, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Bothell, Washington, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Ponce, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02986139/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02986139/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02986139"
86,"NCT02961881","A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma",,"Recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: blinatumomab","Subject grade of dose limiting toxicities (DLTs)|Incidence of dose limiting toxicities (DLTs)|Severity of dose limiting toxicities (DLTs)|Adverse Events|Blinatumomab PK parameters (clearance of blinatumomab) under cIV|Blinatumomab PK parameters (volume of distribution of blinatumomab) under cIV|Blinatumomab PK parameters (clearance of blinatumomab) under SC administrations|Blinatumomab PK parameters (volume of distribution of blinatumomab) under SC administrations|Maximum Tolerated Dose|Incidence of anti-blinatumomab antibodies|Overall Response Rate (ORR)|Complete Response (CR)|Partial Response (PR) as determined by best overall response (ORR) using Cheson criteria","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140286","September 18, 2017","February 17, 2022","February 17, 2022","November 11, 2016",,"December 19, 2019","Research Site, Duarte, California, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Concord, New South Wales, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Créteil Cedex, France|Research Site, Paris Cedex 10, France|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Ulm, Germany|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Rozzano MI, Italy",,"https://ClinicalTrials.gov/show/NCT02961881"
87,"NCT02957604","Evolocumab Pregnancy Exposure Registry",,"Recruiting","No Results Available","Hypercholesterolemia; ASCVD; Pregnancy","Drug: evolocumab","Rate of major structural defects|Pregnancy Outcome: Rate of spontaneous abortion|Pregnancy Outcome: Rate of elective abortion|Pregnancy Outcome: Rate of stillbirth|Pregnancy Outcome: Rate of premature delivery|Infant Outcome: Rate of minor structural defects|Infant Outcome: Rate of small for gestational age|Infant Outcome: Rate of postnatal growth deficiency|Infant Outcome: Rate of postnatal hospitalizations|Infant Outcome: Rate of infant reactions to scheduled vaccinations|Infant Outcome: Infant response to IgG-tetanus antibody|Infant Outcome: Adverse neurodevelopment outcomes|Breastfeeding/Lactation Outcome: Proportion of women who breastfed|Breastfeeding/Lactation Outcome: Proportion who breastfed exclusively|Infant Outcome: Pattern of minor structural defects|Infant Outcome: Rate of postnatal serious infections","Amgen|Organization of Teratology Information Specialists (OTIS) Research Center - tel: 1-866-626-6847 or www.mothertobaby.org","Female","1 Year to 100 Years   (Child, Adult, Older Adult)",,"375","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20150338","December 22, 2016","April 28, 2032","April 28, 2032","November 8, 2016",,"October 17, 2019","Research Site, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02957604"
88,"NCT02939183","Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma","INTREPID-1","Active, not recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Drug: Immediate Release (IR) Formulation|Drug: Gastro-Retentive (GR) Formulation|Drug: Dexamethasone|Drug: Pomalidomide","Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone|Incidence of treatment-related adverse events for all subjects on continued oprozomib treatment|Incidence of treatment-emergent adverse events|Number of patients with changes in laboratory test results|Maximum observed concentration (Cmax)|Time to Cmax (tmax)|Area under the concentration-time curve|Overall response|Best overall response|Progression free survival|Duration of response","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160104","January 17, 2017","December 23, 2020","December 23, 2020","October 19, 2016",,"December 24, 2019","Research Site, West Hollywood, California, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Bethesda, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, San Antonio, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Clayton, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Gent, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Rotterdam, Netherlands|Research Site, Salamanca, Castilla León, Spain|Research Site, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT02939183"
89,"NCT02937701","Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab",,"Completed","Has Results","Arthritis, Rheumatoid","Biological: ABP 710|Biological: Infliximab","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 22|Percentage of Participants With an ACR20 Response Through Week 14|Percentage of Participants With an ACR20 Response After Week 22|Percentage of Participants With an ACR50 Response Through Week 22|Percentage of Participants With an ACR50 Response After Week 22|Percentage of Participants With an ACR70 Response Through Week 22|Percentage of Participants With an ACR70 Response After Week 22|Change From Baseline in Disease Activity Score 28 (DAS28) Through Week 22|Change From Baseline in Disease Activity Score 28 (DAS28) After Week 22","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","558","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20140111|2014-004704-29","October 10, 2016","April 16, 2018","August 13, 2018","October 19, 2016","August 28, 2019","August 28, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Peoria, Arizona, United States|Research Site, Covina, California, United States|Research Site, Hemet, California, United States|Research Site, Upland, California, United States|Research Site, Van Nuys, California, United States|Research Site, Aventura, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Lexington, Kentucky, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Flowood, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, League City, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Woodville, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Victoria, British Columbia, Canada|Research Site, Saint Johns, Newfoundland and Labrador, Canada|Research Site, Brno, Jihormoravsky KRAJ, Czechia|Research Site, Hlučín, Moravskoslezsky, Czechia|Research Site, Praha 2, Praha, Czechia|Research Site, Praha 3, Praha, Czechia|Research Site, Liberec, Severocesky KRAJ, Czechia|Research Site, Ostrava, Severomoravsky KRAJ, Czechia|Research Site, Zlín, Severomoravsky KRAJ, Czechia|Research Site, Pardubice, Vychodocesky KRAJ, Czechia|Research Site, Bad Doberan, Mecklenburg-vorpommern, Germany|Research Site, Hildesheim, Niedersachsen, Germany|Research Site, Magdeburg, Sachsen-anhalt, Germany|Research Site, Hamburg, Germany|Research Site, Gyula, Bekes, Hungary|Research Site, Szentes, Csongrad, Hungary|Research Site, Győr, Gyor-moson-sopron, Hungary|Research Site, Veszprém, Veszprem, Hungary|Research Site, Wroclaw, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Toruń, Kujawsko-pomorskie, Poland|Research Site, Łódź, Lodzkie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Stalowa Wola, Podkarpackie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Elbląg, Warminsko-mazurskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02937701/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02937701/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02937701"
90,"NCT02929329","Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction","GALACTIC-HF","Active, not recruiting","No Results Available","Heart Failure","Drug: Omecamtiv Mecarbil|Drug: Placebo","Measure time to cardiovascular death or first heart failure event|Measure time to cardiovascular death|Measure changes in patient reported outcomes Kansas City Cardiomyopathy Questionnaire Total Symptom Score|Measure time to first heart failure hospitalization|Measure time to all-cause death","Amgen|Cytokinetics|Servier","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","8256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110203|2016-002299-28","January 6, 2017","January 27, 2021","January 27, 2021","October 11, 2016",,"November 22, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Fort Payne, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Scottsboro, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Carmichael, California, United States|Research Site, Fresno, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Loma Linda, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, San Pedro, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Stanford, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, West Haven, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Zephyrhills, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, 'Aiea, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Fairview Heights, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Oak Lawn, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Richmond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, West Monroe, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Moorestown, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Kingston, New York, United States|Research Site, Laurelton, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Lumberton, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Wiloughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Fort Mill, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Powell, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Denison, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Murray, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, White River Junction, Vermont, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Manitowoc, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Coronel Suarez, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Merlo, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Ramos Meija, Buenos Aires, Argentina|Research Site, San Fernando, Buenos Aires, Argentina|Research Site, San Isidro, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Villa Maria, Córdoba, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Venado Tuerto, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Garran, Australian Capital Territory, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Bundoora, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Sankt Poelten, Austria|Research Site, Villach, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Roeselare, Belgium|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Uberlandia, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Londrina, Paraná, Brazil|Research Site, Natal, Rio Grande Do Norte, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Aracaju, Sergipe, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Marilia, São Paulo, Brazil|Research Site, Ribeirao Preto, São Paulo, Brazil|Research Site, Sao Jose do Rio Preto, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São José do Rio Preto, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, North Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Temuco, Cautín, Chile|Research Site, Talcahuano, Concepción, Chile|Research Site, San Miguel, Santiago, Chile|Research Site, Vina del Mar, Valparaíso, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Haikou, Hainan, China|Research Site, Harbin, Heilongjiang, China|Research Site, Luoyang, Henan, China|Research Site, Luoyang, Henan, China|Research Site, Xinxiang, Henan, China|Research Site, Zhengzhou, Henan, China|Research Site, Hengyang, Hunan, China|Research Site, Xiangtan, Hunan, China|Research Site, Huhehaote, Inner Mongolia, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Heze, Shandong, China|Research Site, Jinan, Shandong, China|Research Site, Jining, Shandong, China|Research Site, QingDao, Shandong, China|Research Site, Taiyuan, Shanxi, China|Research Site, Taiyuan, Shanxi, China|Research Site, Yuncheng, Shanxi, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Cartagena, Bolívar, Colombia|Research Site, Manizales, Caldas, Colombia|Research Site, Armenia, Quindío, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Cali, Valle Del Cauca, Colombia|Research Site, Santiago de Cali, Valle Del Cauca, Colombia|Research Site, Bogota D.C., Colombia|Research Site, Beroun, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Frydek Mistek, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kladno, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Kolin III, Czechia|Research Site, Liberec, Czechia|Research Site, Louny, Czechia|Research Site, Marianske Lazne, Czechia|Research Site, Mohelnice, Czechia|Research Site, Opava, Czechia|Research Site, Ostrava, Czechia|Research Site, Policka, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hellerup, Denmark|Research Site, Hillerod, Denmark|Research Site, Køge, Denmark|Research Site, Odense, Denmark|Research Site, Svendborg, Denmark|Research Site, Beziers cedex, France|Research Site, Caen Cedex 9, France|Research Site, Chambray les Tours, France|Research Site, Corbeil Essonnes, France|Research Site, Créteil Cedex, France|Research Site, Dijon, France|Research Site, Grenoble Cedex 9, France|Research Site, Le Chesnay, France|Research Site, Lille Cedex, France|Research Site, Lille, France|Research Site, Limoges Cedex, France|Research Site, Lyon Cedex 03, France|Research Site, Montauban, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nimes cedex 9, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Rennes Cedex 9, France|Research Site, Saint Denis, France|Research Site, Toulon Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Tourcoing cedex, France|Research Site, Valenciennes, France|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Düsseldorf, Germany|Research Site, Erfurt, Germany|Research Site, Erfurt, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Greifswald, Germany|Research Site, Göttingen, Germany|Research Site, Haßloch, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Langen, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mainz, Germany|Research Site, Markleeberg, Germany|Research Site, Witten, Germany|Research Site, Würzburg, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chaidari, Athens, Greece|Research Site, Chalkida, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Komarom, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ariccia, Italy|Research Site, Arzignano, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Catanzaro, Italy|Research Site, Cona FE, Italy|Research Site, Cuneo, Italy|Research Site, Foggia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Monza (MB), Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Rimini, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Seriate, Italy|Research Site, Siena, Italy|Research Site, Torrette Di Ancona, Italy|Research Site, Trieste, Italy|Research Site, Vimercate MB, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Nagakute-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Seto-shi, Aichi, Japan|Research Site, Asahi-shi, Chiba, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Funabashi-shi, Chiba, Japan|Research Site, Urayasu-shi, Chiba, Japan|Research Site, Imabari-shi, Ehime, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kasuya-gun, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Onga-gun, Fukuoka, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Fukuyama-shi, Hiroshima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Hakodate-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Nishinomiya-shi, Hyogo, Japan|Research Site, Takarazuka-shi, Hyogo, Japan|Research Site, Higashiibaraki-gun, Ibaraki, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Hayama, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Odawara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Nankoku-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Nagano-shi, Nagano, Japan|Research Site, Kashihara-shi, Nara, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Naha-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Higashiosaka-shi, Osaka, Japan|Research Site, Matsubara-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Ureshino-shi, Saga, Japan|Research Site, Ageo-shi, Saitama, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Wako-shi, Saitama, Japan|Research Site, Kusatsu-shi, Shiga, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Akishima-shi, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Fussa-shi, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Kodaira-shi, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Torreon, Coahuila, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Xalapa, Veracruz, Mexico|Research Site, Aguascalientes, Mexico|Research Site, 's Hertogenbosch, Netherlands|Research Site, Almelo, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle Aan De IJssel, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Emmen, Netherlands|Research Site, Goes, Netherlands|Research Site, Groningen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Takapuna, Auckland, New Zealand|Research Site, Bialystok, Poland|Research Site, Bytom, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Kazimierza Wielka, Poland|Research Site, Kielce, Poland|Research Site, Klodzko, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Miechow, Poland|Research Site, Olawa, Poland|Research Site, Piotrkow Trybunalski, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Stalowa Wola, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Aveiro, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Setubal, Portugal|Research Site, San Juan, Puerto Rico|Research Site, Bucarest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Pitesti, Romania|Research Site, Targoviste, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Korolev, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Lomonosov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Village Novoseltsy, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Bloemfontein, Free State, South Africa|Research Site, Parktown, Gauteng, South Africa|Research Site, Soweto, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Umhlanga, KwaZulu-Natal, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Ubeda, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, La laguna, Canarias, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Falun, Sweden|Research Site, Jonkoping, Sweden|Research Site, Lidköping, Sweden|Research Site, Linkoping, Sweden|Research Site, Lund, Sweden|Research Site, Orebro, Sweden|Research Site, Skelleftea, Sweden|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Fribourg, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Zurich, Switzerland|Research Site, Adana, Turkey|Research Site, Afyonkarahisar, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Corum, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kirikkale, Turkey|Research Site, Kocaeli, Turkey|Research Site, Konya, Turkey|Research Site, Mersin, Turkey|Research Site, Sakarya, Turkey|Research Site, Sivas, Turkey|Research Site, Van, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsya, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Ayr, United Kingdom|Research Site, Basingstoke, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Dudley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Gillingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harlow, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Merthyr Tydfil, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Shipley, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Solihull, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Sunderland, United Kingdom|Research Site, Swindon, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02929329"
91,"NCT02910557","Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection",,"Recruiting","No Results Available","Melanoma|Herpetic Infection",,"Incidence Rate|Herpectic Infection with T-VEC for Close Contacts and HCPs|Incidence of Herpetic Infection with TVEC in Patients during treatment|Incidence of Herpetic Infection with TVEC in Patients after treatment|Incidence of HSV-1 DNA in Patients during Treatment|Incidence of HSV-1 DNA in Patients after Treatment|Patient Demographics|Use of drug therapies|Incidence of Adverse Events and Serious Adverse Events in Patients|Overall Survival","Amgen","All","Child, Adult, Older Adult",,"920","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20130193","August 10, 2017","August 28, 2026","August 28, 2026","September 22, 2016",,"October 22, 2019","Research Site, Jefferson City, Missouri, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Murray, Utah, United States|Research Site, Madison, Wisconsin, United States|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Sankt Poelten, Austria|Research Site, Haifa, Israel|Research Site, Ramat Gan, Israel|Research Site, Basel, Switzerland|Research Site, Chur, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Cheltenham, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02910557"
92,"NCT02910063","Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL",,"Active, not recruiting","No Results Available","B-Cell Non Hodgkin Lymphoma","Drug: Blinatumomab","Phase 2 Complete Metabolic Response|Phase 2 Objective Response Rate|Phase 2 Progression-Free Survival|Phase 2 Duration of Response|Phase 2 Successful Mobilization Rate|Phase 2 Hematopoietic Stem Cell Transplant rates (both autologous and allogeneic)|Phase 2 100 Day non-relapse mortality after autologous HSCT|Phase 2 Blinatumomab concentration steady state|Phase 2 Incidence and severity of adverse events|Phase 2 Blinatumomab clearance|Phase 2 Blinatumomab half life","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150292|2016-002044-16","January 23, 2017","March 12, 2020","March 12, 2020","September 21, 2016",,"October 25, 2019","Research Site, Duarte, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Greenville, South Carolina, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Montreal, Quebec, Canada|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Udine, Italy|Research Site, San Juan, Puerto Rico|Research Site, Cordoba, Andalucía, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Murcia, Spain|Research Site, Bristol, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02910063"
93,"NCT02906124","Study to Evaluate the Safety of Repatha® in Pregnancy",,"Recruiting","No Results Available","Hypercholesterolaemia|Pregnancy",,"Any incident of congenital anomaly|End product of pregnancy summarised within 3 main categories: Fetal death, termination of pregnancy and live birth|Status of infant at delivery|Details of any hospitalisations of infant, documented from delivery to 12 months of age.|Mode of delivery of infant|Growth of infant at 6 months post delivery|Details of any chronic medication taken by infant from birth to 12 months of age|Developmental milestones measured at 6 and 12 months of age|Details of any complication of delivery|Growth of infant at 12 months post delivery","Amgen","Female","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20150162","January 12, 2017","June 19, 2026","June 19, 2026","September 19, 2016",,"January 18, 2020","Research Site, Camperdown, New South Wales, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Graz, Austria|Research Site, Aalst, Belgium|Research Site, Edegem, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Hradec Kralove, Czechia|Research Site, Liberec, Czechia|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aarhus N, Denmark|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Piraeus, Greece|Research Site, Cagliari, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Cona FE, Italy|Research Site, Genova, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Oslo, Norway|Research Site, Bratislava, Slovakia|Research Site, Cordoba, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Malmo, Sweden|Research Site, Uppsala, Sweden|Research Site, Geneva 14, Switzerland|Research Site, Reinach, Switzerland|Research Site, Bournemouth, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02906124"
94,"NCT02867813","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension","FOURIER OLE","Active, not recruiting","No Results Available","Dyslipidemia","Biological: Evolocumab","Subject incidence of adverse events|Percent change of LDL-C from baseline at each scheduled visit|Achieve an LDL-C < 40 mg/dL (1.03 mmol/L) at each scheduled visit","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","5037","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130295|2015-004780-36","September 2, 2016","September 29, 2021","September 29, 2021","August 16, 2016",,"October 18, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Banning, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Hammond, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Mohelnice, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Znojmo, Czechia|Research Site, Bekescsaba, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Nysa, Poland|Research Site, Olsztyn, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pszczyna, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Kosice, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT02867813"
95,"NCT02833857","A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis",,"Completed","Has Results","Chronic Kidney Disease, Secondary Hyperparathyroidism","Drug: Etelcalcetide","Common Treatment-emergent Adverse Events|Change From Baseline in Serum Corrected Calcium Concentration Over Time|Change From Baseline in Serum Phosphorus Concentration at End of Study|Change From Baseline in Serum Potassium Concentration at End of Study|Change From Baseline in Intact Parathyroid Hormone (iPTH) Levels Over Time|Change From Baseline in Heart Rate at End of Study|Change From Baseline in Temperature at End of Study|Change From Baseline in Blood Pressure at End of Study|Change From Baseline in PR Interval at End of Study|Change From Baseline in QRS Interval at End of Study|Change From Baseline in QT Interval at End of Study|Change From Baseline in Corrected (Bazett) QT Interval at End of Study|Change From Baseline in Corrected (Fridericia) QT Interval at End of Study|Change From Baseline in Serum Total Calcium Concentration|Change From Baseline in Serum Ionized Calcium Concentration|Maximum Observed Plasma Concentration (Cmax) of Etelcalcetide|Time to Maximum Concentration (Tmax) of Etelcalcetide|Area Under the Plasma Etelcalcetide Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)|Area Under the Plasma Etelcalcetide Concentration-Time Curve From Time Zero Infinity (AUCinf)|Terminal Half-life (T1/2,z) of Etelcalcetide|Number of Participants Who Developed Anti-etelcalcetide Binding Antibodies|Number of Participants With Treatment-emergent Adverse Events","Amgen","All","2 Years to 17 Years   (Child)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140336|2015-005051-28","March 14, 2017","October 31, 2018","October 31, 2018","July 14, 2016","July 10, 2019","July 10, 2019","Research Site, Los Angeles, California, United States|Research Site, Louisville, Kentucky, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Marburg, Germany|Research Site, Vilinus, Lithuania|Research Site, Krakow, Poland|Research Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02833857/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02833857/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02833857"
96,"NCT02833844","Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia",,"Active, not recruiting","No Results Available","Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection","Drug: Repatha (Evolocumab)|Drug: Placebo","Effect of Repatha (Evolocumab) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in human immunodeficiency virus (HIV)-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on change from baseline in LDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining LDL-C < 70 mg/dL (1.8 mmol/L) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent of subjects attaining a 50% reduction in LDL-C from baseline in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in ApoB in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in TC in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent chang from baseline in Lp(a) in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in triglycerides in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in non-HDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia|Effect of Repatha (Evolocumab) on percent change from baseline in VLDL-C in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","467","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130286|2015-004735-12","May 22, 2017","July 9, 2019","January 22, 2020","July 14, 2016",,"January 13, 2020","Research Site, Los Angeles, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Berkley, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Camden, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Falls Church, Virginia, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, East Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Fortitude Valley, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Antwerp, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Lyon cedex 04, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Warszawa, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Coimbra, Portugal|Research Site, Porto, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Timisoara, Romania|Research Site, Pretoria, Gauteng, South Africa|Research Site, Westdene, Gauteng, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Zuerich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02833844"
97,"NCT02808403","Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan",,"Recruiting","No Results Available","Hypercholesterolemia|Familial Hypercholesterolemia","Other: No intervention","Incidence of adverse events and adverse drug reactions|Laboratory values for LDL-C|Laboratory values for HDL-C|Laboratory values for total cholesterol|Laboratory values for triglycerides|Laboratory values for Apolipoprotein (Apo) A1|Laboratory values for Apolipoprotein (Apo) Apo B|Laboratory values for Apolipoprotein (Apo) Apo E|Laboratory values for lipoprotein(a)","Amgen","All","Child, Adult, Older Adult",,"6000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20140409","June 24, 2016","April 30, 2022","April 30, 2022","June 21, 2016",,"October 25, 2019","Research Site, Ichinomiya city, Aichi Prefecture, Japan|Research Site, Ichinomiya city, Aichi Prefecture, Japan|Research Site, Inuyama city, Aichi Prefecture, Japan|Research Site, Kasugai city, Aichi Prefecture, Japan|Research Site, Komaki city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Nagoya city, Aichi Prefecture, Japan|Research Site, Tsushima city, Aichi Prefecture, Japan|Research Site, Akita city, Akita Prefecture, Japan|Research Site, Yuzawa city, Akita Prefecture, Japan|Research Site, Asahi city, Chiba Prefecture, Japan|Research Site, Chiba City, Chiba Prefecture, Japan|Research Site, Chosei Gun, Chiba Prefecture, Japan|Research Site, Ichihara city, Chiba Prefecture, Japan|Research Site, Ichikawa city, Chiba Prefecture, Japan|Research Site, Kisarazu city, Chiba Prefecture, Japan|Research Site, Matsudo city, Chiba Prefecture, Japan|Research Site, Matsuyama city, Ehime Prefecture, Japan|Research Site, Fukuoka city, Fukuoka Prefecture, Japan|Research Site, Fukuoka city, Fukuoka Prefecture, Japan|Research Site, Fukuoka city, Fukuoka Prefecture, Japan|Research Site, Itoshima city, Fukuoka Prefecture, Japan|Research Site, Kitakyushu city, Fukuoka Prefecture, Japan|Research Site, Kitakyushu city, Fukuoka Prefecture, Japan|Research Site, Omuta city, Fukuoka Prefecture, Japan|Research Site, Futaba gun, Fukushima Prefecture, Japan|Research Site, Iwaki city, Fukushima Prefecture, Japan|Research Site, Koriyama city, Fukushima Prefecture, Japan|Research Site, Kani city, Gifu Prefecture, Japan|Research Site, Mino city, Gifu Prefecture, Japan|Research Site, Nagahama city, Gifu Prefecture, Japan|Research Site, Fujioka city, Gunma Prefecture, Japan|Research Site, Kiryu city, Gunma Prefecture, Japan|Research Site, Takasaki city, Gunma Prefecture, Japan|Research Site, Takasaki, Gunma Prefecture, Japan|Research Site, Fukuyama city, Hiroshima Prefecture, Japan|Research Site, Higashihiroshima city, Hiroshima Prefecture, Japan|Research Site, Hiroshima city, Hiroshima Prefecture, Japan|Research Site, Onomichi city, Hiroshima Prefecture, Japan|Research Site, Iwamizawa city, Hokkaido, Japan|Research Site, Sapporo city, Hokkaido, Japan|Research Site, Sapporo city, Hokkaido, Japan|Research Site, Sapporo city, Hokkaido, Japan|Research Site, Sapporo city, Hokkaido, Japan|Research Site, Himeji city, Hyogo Prefectural, Japan|Research Site, Kobe city, Hyogo Prefectural, Japan|Research Site, Kobe city, Hyogo Prefectural, Japan|Research Site, Sanda city, Hyogo Prefectural, Japan|Research Site, Kobe city, Hyogo Prefecture, Japan|Research Site, Kobe city, Hyogo Prefecture, Japan|Research Site, Kobe city, Hyogo Prefecture, Japan|Research Site, Kobe city, Hyogo Prefecture, Japan|Research Site, Higashiibaraki Gun, Ibaraki Prefecture, Japan|Research Site, Hitachi city, Ibaraki Prefecture, Japan|Research Site, Mito city, Ibaraki Prefecture, Japan|Research Site, Kahoku gun, Ishikawa Prefecture, Japan|Research Site, Kanazawa city, Ishikawa Prefecture, Japan|Research Site, Kanazawa city, Ishikawa Prefecture, Japan|Research Site, Kanazawa city, Ishikawa Prefecture, Japan|Research Site, Kanazawa city, Ishikawa Prefecture, Japan|Research Site, Uchinada, Ishikawa Prefecture, Japan|Research Site, Kitakami city, Iwate Prefecture, Japan|Research Site, Morioka city, Iwate Prefecture, Japan|Research Site, Kita gun, Kagawa Prefecture, Japan|Research Site, Sakaide City, Kagawa Prefecture, Japan|Research Site, Zentsuji City, Kagawa Prefecture, Japan|Research Site, Kagoshima city, Kagoshima Prefecture, Japan|Research Site, Kagoshima city, Kagoshima Prefecture, Japan|Research Site, Kanoya city, Kagoshima Prefecture, Japan|Research Site, Fujisawa city, Kanagawa Prefecture, Japan|Research Site, Kawasaki city, Kanagawa Prefecture, Japan|Research Site, Kawasaki city, Kanagawa Prefecture, Japan|Research Site, Miura city, Kanagawa Prefecture, Japan|Research Site, Yokohama city, Kanagawa Prefecture, Japan|Research Site, Yokohama city, Kanagawa Prefecture, Japan|Research Site, Yokohama city, Kanagawa Prefecture, Japan|Research Site, Yokosuka city, Kanagawa Prefecture, Japan|Research Site, Yokosuka city, Kanagawa Prefecture, Japan|Research Site, Yokosuka city, Kanagawa Prefecture, Japan|Research Site, Kumamoto city, Kumamoto Prefecture, Japan|Research Site, Kumamoto city, Kumamoto Prefecture, Japan|Research Site, Yamaga city, Kumamoto Prefecture, Japan|Research Site, Kyoto city, Kyoto Prefecture, Japan|Research Site, Kyoto city, Kyoto Prefecture, Japan|Research Site, Maizuru city, Kyoto Prefecture, Japan|Research Site, Uji city, Kyoto Prefecture, Japan|Research Site, Yosa Gun, Kyoto Prefecture, Japan|Research Site, Ise city, Mie Prefecture, Japan|Research Site, Tsu city, Mie Prefecture, Japan|Research Site, Sendai city, Miyagi Prefecture, Japan|Research Site, Miyazaki city, Miyazaki Prefecture, Japan|Research Site, Matsumoto city, Nagano Prefecture, Japan|Research Site, Niigata city, Niigata Prefecture, Japan|Research Site, Oita city, Oita Prefecture, Japan|Research Site, Okayama city, Okayama Prefecture, Japan|Research Site, Okayama city, Okayama Prefecture, Japan|Research Site, Okayama city, Okayama Prefecture, Japan|Research Site, Okayama city, Okayama Prefecture, Japan|Research Site, Izumisano city, Osaka Prefecture, Japan|Research Site, Kawachinagano City, Osaka Prefecture, Japan|Research Site, Osaka city, Osaka Prefecture, Japan|Research Site, Osaka city, Osaka Prefecture, Japan|Research Site, Osaka city, Osaka Prefecture, Japan|Research Site, Suita city, Osaka Prefecture, Japan|Research Site, Suita city, Osaka Prefecture, Japan|Research Site, Suita city, Osaka Prefecture, Japan|Research Site, Takaishi city, Osaka Prefecture, Japan|Research Site, Takatsuki city, Osaka Prefecture, Japan|Research Site, Saga city, Saga Prefecture, Japan|Research Site, Taku city, Saga Prefecture, Japan|Research Site, Ageo city, Saitama Prefecture, Japan|Research Site, Koshigaya city, Saitama Prefecture, Japan|Research Site, Saitama city, Saitama Prefecture, Japan|Research Site, Saitama city, Saitama Prefecture, Japan|Research Site, Moriyama city, Shiga Prefecture, Japan|Research Site, Hamada city, Shimane Prefecture, Japan|Research Site, Nikko city, Tochigi Prefecture, Japan|Research Site, Tokushima city, Tokushima Prefecture, Japan|Research Site, Higashikurume city, Tokyo Prefecture, Japan|Research Site, Shinagawa City, Tokyo Prefecture, Japan|Research Site, Chuoku, Tokyo, Japan|Research Site, Hachioji city, Tokyo, Japan|Research Site, Hachioji city, Tokyo, Japan|Research Site, Kodaira city, Tokyo, Japan|Research Site, Ota ku, Tokyo, Japan|Research Site, Shibuyaku, Tokyo, Japan|Research Site, Sinagawa Ku, Tokyo, Japan|Research Site, Taitoku, Tokyo, Japan|Research Site, Toshimaku, Tokyo, Japan|Research Site, Gobo city, Wakayama Prefecture, Japan|Research Site, Shingu city, Wakayama Prefecture, Japan|Research Site, Wakayama city, Wakayama Prefecture, Japan|Research Site, Wakayama city, Wakayama Prefecture, Japan|Research Site, Kofu city, Yamanashi Prefecture, Japan",,"https://ClinicalTrials.gov/show/NCT02808403"
98,"NCT02799498","Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection",,"Completed","No Results Available","Healthy Men and Women","Device: Auto-injector device|Other: Etanercept (ENBREL®) via Manual injection|Drug: Etanercept (ENBREL®)","Ratio of the geometric means of etanercept by auto-injector to etanercept by manual injection for the PK parameter of AUC (0-t)|Profile PK parameters of AUC (0-∞)|Safety Events measured by adverse events and how they relate to study drug|Measure of vital signs changes from baseline to end of each treatment period|Any Clinically Significant changes in clinical laboratory tests will be noted|Blood samples obtained to measure seroreactivitiy to etanercept at baseline and following treatment|Profile PK parameters of AUC (C max )|PK parameters of the area under the serum drug concentration (t 1/2)|PK parameters of the area under the serum drug concentration (t z)","Amgen",,"Child, Adult, Older Adult","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030121","October 2003","January 2004","January 2004","June 15, 2016",,"June 15, 2016",,,"https://ClinicalTrials.gov/show/NCT02799498"
99,"NCT02792699","Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab",,"Completed","Has Results","Arthritis, Rheumatoid","Drug: ABP 798|Drug: Rituximab (US)|Drug: Rituximab (EU)","Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) After the Second Infusion of the First Dose|Maximum Observed Drug Concentration (Cmax) After the Second Infusion of the First Dose|Area Under the Serum Concentration-time Curve From Predose on Day 1 to 14 Days Postdose (AUC0-14day)|Area Under the Serum Concentration-time Curve From Predose on Day 1 to Week 12 (AUC0-12wk)|Maximum Observed Drug Concentration (Cmax) After the First Infusion of the First Dose|Time of Maximum Observed Drug Concentration (Tmax) After the First and Second Infusions of the First Dose|Last Measurable Serum Concentration After the Second Infusion up to Week 12 (Clast)|Terminal Elimination Half-life (t1/2)|Terminal Elimination Rate Constant (λz)|Clearance (CL)|Mean Residence Time (MRT)|Percent of AUC Extrapolation (AUC%Extrap)|AUC0-12 wk/AUCinf|Change From Baseline in Disease Activity Score 28-CRP at Week 24|Change From Baseline in Disease Activity Score 28-CRP at Weeks 8, 12, 40, and 48|Percentage of Participants With an ACR20 Response|Percentage of Participants With an ACR50 Response|Percentage of Participants With an ACR70 Response|Hybrid ACR|Percentage of Participants With Complete Depletion in CD19+ Cell Count on Day 3|Duration of Complete Depletion in CD19+ Cell Count|Number of Participants With Adverse Events After the First Dose|Number of Participants Who Developed Anti-drug Antibodies|Number of Participants With Clinically Significant Laboratory Findings","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","311","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130108|2013-005543-90","May 17, 2016","October 8, 2018","October 8, 2018","June 7, 2016","October 23, 2019","October 23, 2019","Research Site, Tuscaloosa, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Upland, California, United States|Research Site, Aventura, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lansing, Michigan, United States|Research Site, Flowood, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, League City, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Tallinn, Harjuma, Estonia|Research Site, Tartu, Estonia|Research Site, Bad Nauheim, Hessen, Germany|Research Site, Magdeburg, Sachsen-anhalt, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Gyula, Bekes, Hungary|Research Site, Szentes, Csongrad, Hungary|Research Site, Budapest, Pest, Hungary|Research Site, Szombathely, VAS, Hungary|Research Site, Veszprém, Veszprem, Hungary|Research Site, Wrocław, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Łódź, Lodzkie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Stalowa Wola, Podkarpackie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Elbląg, Warminsko-mazurskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02792699/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02792699/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02792699"
100,"NCT02792517","Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females",,"Completed","Has Results","Headache, Migraine","Drug: Erenumab|Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive","Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Ethinyl Estradiol|Maximum Observed Plasma Concentration (Cmax) of Norgestrel|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Norgestrel|Maximum Observed Plasma Concentration (Cmax) of Norelgestromin|Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Norelgestromin|Time to Reach the Maximum Concentration (Tmax) of Ethinyl Estradiol|Time to Reach the Maximum Concentration (Tmax) of Norgestrel|Time to Reach the Maximum Concentration (Tmax) of Norelgestromin|Number of Participants With Treatment-emergent Adverse Events|Number of Participants Who Developed Anti-erenumab Binding Antibodies","Amgen","Female","18 Years to 45 Years   (Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20150334","February 12, 2016","September 9, 2016","September 9, 2016","June 7, 2016","December 20, 2018","December 20, 2018","Research Site, Anaheim, California, United States|Research Site, Cypress, California, United States|Research Site, Dallas, Texas, United States|Research Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02792517"
101,"NCT02792478","Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study","PERSEIDA","Recruiting","No Results Available","RAS Wild Type mCRC",,"Detection rate of RAS mutations in liquid biopsies in subjects with RAS wild-type mCRC at baseline.|Description of RAS mutations using liquid biopsies at the moment of disease progression|Description of the RAS mutations using liquid biopsies at 20 +/-2 weeks after starting treatment and prior to the second radiological assessment of the disease.","Amgen","All","18 Years and older   (Adult, Older Adult)",,"119","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20140381","May 6, 2016","January 31, 2021","January 31, 2021","June 7, 2016",,"January 18, 2020","Research Site, Almeria, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Aviles, Asturias, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, La Laguna, Canarias, Spain|Research Site, Burgos, Castilla León, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Terrassa, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Castellon, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Caceres, Extremadura, Spain|Research Site, Ourense, Galicia, Spain|Research Site, Cartagena, Murcia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02792478"
102,"NCT02791516","A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Romosozumab|Drug: Placebo","Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine|Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip|Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20150242","January 16, 2017","February 12, 2018","December 21, 2018","June 6, 2016","July 5, 2019","October 7, 2019","Research Site, Busan, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Namdong-gu, Incheon, Korea, Republic of|Research Site, Seongnam Si Gyeonggi Do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02791516/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02791516/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02791516"
103,"NCT02783651","An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US",,"Recruiting","No Results Available","Relapsed/Refractory Acute Lymphoblastic Leukemia","Other: Other","Treatment patterns in patients with Ph- R/R ALL|Drug utilization in patients with Ph- R/R ALL|Healthcare resource utilization in patients with Ph- R/R ALL|Receipt of allogeneic stem cell transplantation following salvage treatment|Incidence of selected adverse events including cytokine release syndrome, neurologic events, any events resulting in hospitalizations, and other serious adverse events.|Best response to salvage treatment (chemotherapy or blinatumomab) within 8 weeks and within 12 weeks of initiation of salvage treatment.|MRD status within 12 weeks of initiation of salvage treatment|Overall survival from the time of initiation of salvage treatment|RFS from time remission achieved with salvage treatment","Amgen","All","Child, Adult, Older Adult",,"235","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","20150253","June 30, 2016","March 31, 2020","March 31, 2020","May 26, 2016",,"December 19, 2019","Research Site, Tucson, Arizona, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Ames, Iowa, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02783651"
104,"NCT02770131","Chart Review of Repatha® in Subjects With Hyperlipidaemia","HEYMANS","Recruiting","No Results Available","Hypercholesterolaemia",,"Description of clinical characteristics of subjects initiated on Repatha®|Describe LDL-C and other cholesterol values over time|Describe Repatha® dose over time|Describe use of other lipid-modifying therapies|Describe Physician visits|Describe hospitalizations|Describe Repatha® dose frequency over time|Describe Repatha® administrative device use over time","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20130296","May 4, 2016","June 24, 2021","June 24, 2021","May 12, 2016",,"January 18, 2020","Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Villach, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Kostenets, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Aachen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Bochum, Germany|Research Site, Borsdorf, Germany|Research Site, Detmold, Germany|Research Site, Garbsen, Germany|Research Site, Germering, Germany|Research Site, Göttingen, Germany|Research Site, Halberstadt, Germany|Research Site, Halle (Saale), Germany|Research Site, Hamburg, Germany|Research Site, Langenhagen, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Markleeberg, Germany|Research Site, Muenchen, Germany|Research Site, Mönchengladbach, Germany|Research Site, Mühldorf, Germany|Research Site, Mülheim an der Ruhr, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Neuwied, Germany|Research Site, Nürnberg, Germany|Research Site, Oschatz, Germany|Research Site, Pirna, Germany|Research Site, Potsdam, Germany|Research Site, Rostock, Germany|Research Site, Rotenburg, Germany|Research Site, Viersen-Dülken, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Zwickau, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Acerra, Italy|Research Site, Arzignano, Italy|Research Site, Asti, Italy|Research Site, Bassano Del Grappa (VI), Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Brindisi, Italy|Research Site, Catanzaro, Italy|Research Site, Catanzaro, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Cona FE, Italy|Research Site, Cosenza, Italy|Research Site, Foggia, Italy|Research Site, Lido Di Camaiore LU, Italy|Research Site, Messina, Italy|Research Site, Mestre (VE), Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Pescara, Italy|Research Site, Reggio Calabria, Italy|Research Site, Rivoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Salerno, Italy|Research Site, Seriate, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Taranto, Italy|Research Site, Torrette Di Ancona, Italy|Research Site, Treviglio (BG), Italy|Research Site, Trieste, Italy|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Handlova, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Martin, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Myjava, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Mesto nad Vahom, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Cadiz, Andalucía, Spain|Research Site, Huelva, Andalucía, Spain|Research Site, Jaen, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Sabadell, Cataluña, Spain|Research Site, Ferrol, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Alcala de Henares, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Malmo, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Basel, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lugano, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02770131"
105,"NCT02756845","Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors",,"Recruiting","No Results Available","Advanced Non CNS Tumors","Drug: Talimogene Laherparepvec","Subject incidence of DLT|Subject incidence of adverse events.|Subject incidence of laboratory abnormalities|Overall Response Rate (ORR)|Duration of Response (DOR)|Time to Response (TTR)|Time to Progression (TTP)|Progression-free Survival (PFS)|Overall Survival (OS)","Amgen","All","2 Years to 21 Years   (Child, Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110261|2015-003645-25","August 16, 2017","February 4, 2022","December 31, 2023","April 29, 2016",,"December 19, 2019","Research Site, Wilmington, Delaware, United States|Research Site, Jacksonville, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Gent, Belgium|Research Site, Montreal, Quebec, Canada|Research Site, Lyon cedex 08, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Roma, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Esplugues de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, Basel, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02756845"
106,"NCT02749370","Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast",,"Completed","Has Results","Plaque Psoriasis","Drug: Etanercept","Percentage of Participants With a PASI 75 Response at Week 12|Percentage of Participants With a PASI 75 Response at Each Visit|Percentage of Participants With a PASI 50 Response at Each Visit|Percentage of Participants With a PASI 90 Response at Each Visit|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI)|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Each Visit|Percentage of Participants With an sPGA Score of 0, 1 or 2 at Each Visit|Static Physician Global Assessment (sPGA) at Each Visit|Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline|Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline|Percent Change From Baseline in the Percentage of Body Surface Area (BSA) Involved With Psoriasis at Each Visit|Psoriasis Symptom Inventory (PSI) Total Score at Each Visit|PSI ""Itch From Psoriasis"" Component Score at Each Visit|PSI ""Redness of Skin Lesions"" Component Score at Each Visit|PSI ""Scaling of Skin Lesions"" Component Score at Each Visit|PSI ""Burning of Skin Lesions"" Component Score at Each Visit|PSI ""Stinging of Skin Lesions"" Component Score at Each Visit|PSI ""Cracking of Skin Lesions"" Component Score at Each Visit|PSI ""Flaking of Skin Lesions"" Component Score at Each Visit|PSI ""Pain From Skin Lesions"" Component Score at Each Visit|Patient Assessment of Treatment Satisfaction at Week 12|Patient Assessment of Treatment Satisfaction at Week 24|Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 12 and 24|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150252","May 18, 2016","August 14, 2017","December 6, 2017","April 25, 2016","August 27, 2018","August 27, 2018","Research Site, Scottsdale, Arizona, United States|Research Site, Beverly Hills, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Ramon, California, United States|Research Site, Santa Monica, California, United States|Research Site, Coral Gables, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Macon, Georgia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Rockville, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Clarkston, Michigan, United States|Research Site, Fort Gratiot, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, East Windsor, New Jersey, United States|Research Site, Verona, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02749370/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02749370/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02749370"
107,"NCT02747043","Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","JASMINE","Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: ABP 798|Drug: Rituximab","Risk difference (RD) of objective response rate (ORR)|Risk difference (RD) of overall response rate (ORR)|Risk difference of ORR|Percent of subjects with complete depletion of CD19 cell count and total Immunoglobin G (IgG) and IgM antibody levels|Subject incidence of treatment-emergent AEs and serious adverse events|Incidence of anti-drug antibodies|On study progression-free survival|On study overall survival|Geometric mean ratio (GMR) of test (ABP 798)-to-reference (rituximab)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130109","May 25, 2016","June 28, 2019","June 28, 2019","April 21, 2016",,"October 24, 2019","Research Site, Encinitas, California, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Billings, Montana, United States|Research Site, Zanesville, Ohio, United States|Research Site, Roanoke, Virginia, United States|Research Site, Gosford, New South Wales, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Plovdiv, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Windsor, Ontario, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Praha 5, Praha, Czechia|Research Site, Ostrava - Poruba, Severomoravsky KRAJ, Czechia|Research Site, Bordeaux Cedex, Aquitaine, France|Research Site, Clermont Ferrand, Auvergne, France|Research Site, Cesson-Sevigne, Bretagne, France|Research Site, Boulogne sur Mer, NORD Pas-de-calais, France|Research Site, La Rochelle, Poitou-charentes, France|Research Site, Poitiers Cedex, Poitou-charentes, France|Research Site, Batumi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Augsburg, Bayern, Germany|Research Site, Würzburg, Bayern, Germany|Research Site, Kassel, Hessen, Germany|Research Site, Münster, Nordrhein-westfalen, Germany|Research Site, Leipzig, Sachsen, Germany|Research Site, Flensburg, Schleswig-holstein, Germany|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Patra, Peloponnese, Greece|Research Site, Surat, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Be'er Ya'akov, Rehoboth, Israel|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Bergamo, Lombardia, Italy|Research Site, Pesaro, Pesaro E Urbino, Italy|Research Site, Aviano, Pordenone, Italy|Research Site, Candiolo, Torino, Italy|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Terni, Italy|Research Site, Chiba-city, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Maebashi-city, Gunma, Japan|Research Site, Kobe-city, Hyogo, Japan|Research Site, Tsu, MIE, Japan|Research Site, Utsunomiya City, Tochigi, Japan|Research Site, Tachikawa-city, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Gyeongsangnam-do, Korea, Republic of|Research Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Chihuahua, Mexico|Research Site, Legnica, Dolnoslaskie, Poland|Research Site, Toruń, Kujawsko-pomorskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Targu-Mures, Mures, Romania|Research Site, Targu-Mures, Mures, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Bucuresti, Romania|Research Site, Sabadell, Barcelona, Spain|Research Site, Córdoba, Cordoba, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, La Laguna Tenerife, Santa CRUZ DE Tenerife, Spain|Research Site, Barcelona, Spain|Research Site, Caceres, Spain|Research Site, Cadiz, Spain|Research Site, Madrid, Spain|Research Site, Salamanca, Spain|Research Site, Kyiv, Kiev, Ukraine|Research Site, Kyiv, Kiev, Ukraine|Research Site, Uzhgorod, Transcarpathia, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine",,"https://ClinicalTrials.gov/show/NCT02747043"
108,"NCT02741310","Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan",,"Completed","Has Results","Healthy Subjects","Drug: Placebo|Drug: Sumatriptan|Drug: Erenumab","Time-weighted Averages of Mean Arterial Pressure|Number of Participants With Adverse Events|Area Under the Concentration-time Curve From Time 0 to 6 Hours for Sumatriptan|Area Under the Concentration-time Curve From Time 0 to Infinity for Sumatriptan|Maximum Observed Plasma Concentration (Cmax) of Sumatriptan|Number of Participants Who Developed Anti-erenumab Antibodies","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140255|2015-004537-28","February 22, 2016","August 11, 2016","August 11, 2016","April 18, 2016","March 5, 2019","April 2, 2019","Research Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT02741310"
109,"NCT02739984","Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","BANTING","Completed","Has Results","Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes","Biological: Evolocumab|Drug: Placebo to Evolocumab","Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12|Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","424","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20130287|2015-004711-21","May 17, 2016","August 3, 2017","August 3, 2017","April 15, 2016","August 31, 2018","August 31, 2018","Research Site, Tuscumbia, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Roseville, California, United States|Research Site, San Ramon, California, United States|Research Site, Spring Valley, California, United States|Research Site, Tarzana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boca Raton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Shelby, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chihuahua, Mexico|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almeria, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02739984"
110,"NCT02732210","Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Osteoporosis, Age-Related",,"Percentage of Participants With Persistence With Prolia® at 12 Ponths|Percentage of Participants With Persistence With Prolia® at 24 Months|Time to Non-persistence|Number of Prolia® Injections Received|Percentage of Participants Satisfying Medication-taking Behavior at 12 Months|Percentage of Participants Satisfying Medication-taking Behavior at 24 Months","Amgen","Female","Child, Adult, Older Adult",,"935","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20101218","July 6, 2011","April 7, 2014","April 14, 2014","April 8, 2016","December 14, 2016","February 20, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Hemet, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Murrieta, California, United States|Research Site, Oxnard, California, United States|Research Site, Santa Maria, California, United States|Research Site, Santa Monica, California, United States|Research Site, South Lake Tahoe, California, United States|Research Site, Victorville, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, Alton, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Bettendorf, Iowa, United States|Research Site, Detroit, Michigan, United States|Research Site, East Lansing, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Springfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Butler, New Jersey, United States|Research Site, Dover, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Plainview, New York, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Bend, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Glendale, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victora, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Corunna, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, St. Jean-Sur-Richelieu, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Westmount, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02732210"
111,"NCT02729025","Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))","ANITSCHKOW","Completed","Has Results","Subjects With Hyperlipidemia, Dyslipidemia","Drug: Evolocumab|Drug: Placebo","Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16|Percent Change From Baseline in Lipoprotein(a) Concentration at Week 16|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration at Week 16|Percent Change From Baseline in Apolipoprotein B Concentration at Week 16","Amgen","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20130293|2015-003731-35","April 14, 2016","April 5, 2018","April 5, 2018","April 6, 2016","April 23, 2019","April 23, 2019","Research Site, Miami, Florida, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Hurst, Texas, United States|Research Site, Newmarket, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Waalwijk, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02729025/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02729025"
112,"NCT02713529","Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer",,"Completed","No Results Available","Pancreatic Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer","Biological: AMG820 and pembrolizumab","Number of participants with treatment related adverse events as assessed by CTCAE version 4.0|Objective response rate of tumors using irRECIST criteria for total measureable tumor burden|Number of participants with treatment emergent adverse events as assessed by CTCAE version 4.0|Objective response rate of tumors using RECIST 1.1 criteria for total measurable tumor burden|Maximum observed concentration [Cmax] of AMG820|CD4, CD8, and CD68 cell numbers in pre-treatment tumor biopsy tissue|Minimum observed concentration [Cmin] of AMG 820|Area Under the Curve [AUC] of AMG820","Amgen|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","116","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150195|MASTERKEY","April 14, 2016","January 2, 2019","May 17, 2019","March 18, 2016",,"December 11, 2019","Research Site, Atlanta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Wilrijk, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Research Site, Heidelberg, Germany|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02713529"
113,"NCT02695420","Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction",,"Completed","No Results Available","Heart Failure With Reduced Ejection Fraction","Drug: 25 mg Omecamtiv Mecarbil|Drug: Placebo|Drug: 37.5 mg Omecamtiv Mecarbil|Drug: 50 mg Omecamtiv Mecarbil","Pharmacokinetics (Cpredose)|Pharmacokinetics (AUC)|Systolic ejection time (SET)","Amgen","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120227","April 14, 2016","April 6, 2017","May 8, 2017","March 1, 2016",,"February 9, 2018","Research Site, Kasugai-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Asahi-shi, Chiba, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Imabari-shi, Ehime, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Hakodate-shi, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Takarazuka-shi, Hyogo, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Nankoku-shi, Kochi, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Kishiwada-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saitama-shi, Saitama, Japan|Research Site, Wako-shi, Saitama, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02695420"
114,"NCT02675452","AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia",,"Active, not recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma|Relapsed or Refractory Acute Myeloid Leukemia","Drug: AMG 176|Drug: Dexamethasone|Drug: Carfilzomib|Drug: Azacitidine","Multiple Myeloma Part 1a Incidence of Dose-Limiting Toxicities (DLTs)|MM Part 1a Incidence of treatment-related adverse events|MM Part 1a Incidence of treatment-emergent adverse events|MM Part 1a Incidence of clinically significant changes in vital signs|MM Part 1a Incidence of clinically significant changes in electrocardiograms (ECGs)|MM Part 1a Incidence of clinically significant changes in clinical laboratory tests|MM Part 1a Pharmacokinetic parameters for AMG 176, including, but not limited to, maximum observed concentration (Cmax)|MM Part 1a Pharmacokinetic parameters for AMG 176, including, but not limited to, area under the concentration-time curve (AUC)|MM Part 1a Pharmacokinetic parameters for AMG 176, including, but not limited to, clearance (CL)|MM Part 1a Pharmacokinetic parameters for AMG 176, including, but not limited to, half-life (t1/2)|MM Part 1b Incidence of DLTs|MM Part 1b Incidence of treatment-related adverse events|MM Part 1b Incidence of treatment-emergent adverse events|MM Part 1b Incidence of clinically significant changes in vital signs|MM Part 1b Incidence of clinically significant changes in physical examinations|MM Part 1b Incidence of clinically significant changes in ECGs|MM Part 1b Incidence of clinically significant changes in clinical laboratory tests|MM Part 1b Pharmacokinetic parameters for AMG 176 including, but not limited to Cmax|MM Part 1b Pharmacokinetic parameters for AMG 176 including, but not limited to AUC|MM Part 1b Pharmacokinetic parameters for AMG 176 including, but not limited to CL|MM Part 1b Pharmacokinetic parameters for AMG 176 including, but not limited to t1/2|MM Part 2 Incidence of DLTs|MM Part 2 Incidence of treatment-related adverse events|MM Part 2 Incidence of treatment-emergent adverse events|MM Part 2 Incidence of clinically significant changes in vital signs|MM Part 2 Incidence of clinically significant changes in physical examinations|MM Part 2 Incidence of clinically significant changes in ECGs|MM Part 2 Incidence of clinically significant changes in clinical laboratory tests|MM Part 2 Pharmacokinetic parameters for AMG 176 and carfilzomib including, but not limited to Cmax|MM Part 2 Pharmacokinetic parameters for AMG 176 and carfilzomib including, but not limited to AUC|MM Part 2 Pharmacokinetic parameters for AMG 176 and carfilzomib including, but not limited to CL|MM Part 2 Pharmacokinetic parameters for AMG 176 and carfilzomib including, but not limited to t1/2|Acute Myeloid Leukemia (AML) Part 3 Incidence of DLTs|AML Part 3 Incidence of treatment-related adverse events|AML Part 3 Incidence of treatment-emergent adverse events|AML Part 3 Incidence of clinically significant changes in vital signs|AML Part 3 Incidence of clinically significant changes in physical examinations|AML Part 3 Incidence of clinically significant changes in ECGs|AML Part 3 Incidence of clinically significant changes in clinical laboratory tests|AML Part 3 Pharmacokinetic parameters for AMG 176 including, but not limited to Cmax|AML Part 3 Pharmacokinetic parameters for AMG 176 including, but not limited to AUC|AML Part 3 Pharmacokinetic parameters for AMG 176 including, but not limited to CL|AML Part 3 Pharmacokinetic parameters for AMG 176 including, but not limited to t1/2|AML Part 4 Incidence of DLTs|AML Part 4 Incidence of treatment-related adverse events|AML Part 4 Incidence of treatment-emergent adverse events|AML Part 4 Incidence of clinically significant changes in vital signs|AML Part 4 Incidence of clinically significant changes in physical examinations|AML Part 4 Incidence of clinically significant changes in ECGs|AML Part 4 Incidence of clinically significant changes in clinical laboratory tests|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine including, but not limited to, Cmax|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine including, but not limited to, AUC|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine including, but not limited to, CL|AML Part 4 Pharmacokinetic parameters for AMG 176 and azacitidine including, but not limited to, t1/2|MM Part 1a BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts|MM Part 1a Overall response (OR) according to International Myeloma Working Group uniform response criteria (IMWG-URC) for MM subjects|MM Part 1a OR according to IMWG-URC for MM progression-free survival (PFS)|MM Part 1a OR according to IMWG-URC for MM time to response|MM Part 1a OR according to IMWG-URC for MM duration of response (DOR)|MM Part 1b BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts|MM Part 1b OR according to IMWG-URC for MM subjects|MM Part 1b OR according to IMWG-URC for MM PFS|MM Part 1b OR according to IMWG-URC for MM time to response|MM Part 1b OR according to IMWG-URC for MM DOR|MM Part 2 BAX and caspase 3 expression in circulating monocytes and /or circulating monocyte counts|MM Part 2 OR according to IMWG-URC for MM subjects|MM Part 2 OR according to IMWG-URC for MM PFS|MM Part 2 OR according to IMWG-URC for MM time to response|MM Part 2 OR according to IMWG-URC for MM DOR|AML Part 3 OR according to the 2017 European Leukemia Net (ELN) criteria (Döhner et al, 2017) in AML subjects|AML Part 3 OR according to the 2017 ELN criteria (Döhner et al, 2017) in AML event free survival (EFS)|AML Part 3 OR according to the 2017 ELN criteria (Döhner et al, 2017) in AML time to response|AML Part 3 OR according to the 2017 ELN criteria (Döhner et al, 2017) in AML DOR|AML Part 4 OR according to the 2017 ELN criteria in AML subjects|AML Part 4 OR according to the 2017 ELN criteria in AML EFS|AML Part 4 OR according to the 2017 ELN criteria in AML time to response|AML Part 4 OR according to the 2017 ELN criteria in AML DOR","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150161|2015-004777-32","June 13, 2016","January 16, 2022","January 16, 2022","February 5, 2016",,"November 8, 2019","Research Site, Duarte, California, United States|Research Site, Sacramento, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Aachen, Germany|Research Site, Ulm, Germany|Research Site, Würzburg, Germany|Research Site, Shinagawa-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02675452"
115,"NCT02662569","Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia","BERSON","Completed","Has Results","Diabetes, Hyperlipidemia, Mixed Dyslipidemia","Biological: Evolocumab|Drug: Atorvastatin|Other: Placebo","Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B100 at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B100 at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B100/Apolipoprotein A1 Ratio at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C Less Than 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","986","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120119|2013-000723-14","April 14, 2016","December 6, 2017","December 6, 2017","January 25, 2016","January 11, 2019","January 11, 2019","Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Monroe, Louisiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, Beijing, Beijing, China|Research Site, Chongqing, Chongqing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Guiyang, Guizhou, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Hengyang, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Zhenjiang, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, ChangChun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Pasto, Nariño, Colombia|Research Site, Dijon, France|Research Site, Nantes Cedex 1, France|Research Site, Toulouse Cedex 9, France|Research Site, Bucheon-si, Wonmi-gu, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02662569"
116,"NCT02637141","A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease",,"Completed","Has Results","Celiac Disease","Biological: AMG 714|Biological: Placebo|Other: Placebo Gluten Challenge|Other: Gluten Challenge","Percent Change From Baseline in Villous Height to Crypt Depth Ratio (VH:CD) at Week 12|Percent Change From Baseline in Intraepithelial Lymphocyte Density at Week 12|Number of Participants With Improvement in Marsh Score at Week 12|Percent Change From Baseline in Anti-Tissue Transglutaminase (tTG) Immunoglobulin A (IgA) Antibodies at Week 12|Change From Baseline in Anti-Deamidated Gliadin Peptide (DGP) Antibodies at Week 12|Number of Weekly Bowel Movements at Baseline and Week 12|Number of Participants With Diarrhoea at Baseline and Week 12|Percent Change From Baseline in Total Weekly Gastrointestinal Symptom Rating Scale (GSRS) Score at Week 12|Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CELIM-NRCD-001|2015-003647-19","April 13, 2016","February 15, 2017","March 14, 2017","December 22, 2015","December 3, 2019","December 3, 2019","ODL, Oulu, Finland|Tampere University Hospital, Tampere, Finland|CRST, Turku, Finland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02637141/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02637141/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02637141"
117,"NCT02634580","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4","GAUSS-4","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo Ezetimibe","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved a LDL-C of Less Than 70 mg/dL at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140234","February 27, 2016","August 10, 2017","May 26, 2018","December 18, 2015","August 31, 2018","August 31, 2018","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Kisarazu-shi, Chiba, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Sukagawa-shi, Fukushima, Japan|Research Site, Sukagawa-shi, Fukushima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ohsaki-shi, Miyagi, Japan|Research Site, Nakagami-gun, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-Shi, Osaka, Japan|Research Site, Fujimi-shi, Saitama, Japan|Research Site, Iruma-gun, Saitama, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Hamamatsu-shi, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Higashiyamato-shi, Tokyo, Japan|Research Site, Musashino-shi, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02634580/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02634580/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02634580"
118,"NCT02633020","Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease",,"Completed","Has Results","Type II Refractory Celiac Disease (RCD-II)|In-situ Small Bowel T-cell Lymphoma","Biological: AMG 714|Biological: Placebo","Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intraepithelial Lymphocytes|Percent Change From Baseline in the Percentage of Aberrant Intestinal Intraepithelial Lymphocytes With Respect to All Intestinal Epithelial Cells|Percent Change From Baseline in Villous Height to Crypt Depth (VH:CD) Ratio|Percentage of Participants With Improvement in Marsh Score at Week 12|Percent Change From Baseline in Total Intraepithelial Lymphocyte Count at Week 12|Number of Weekly Bowel Movements at Baseline and Week 12|Percentage of Participants With Diarrhea at Baseline and Week 12|Change From Baseline in Total Weekly Gastrointestinal Symptom Rating Scale (GSRS) Score at Week 12|Change From Baseline in Total Celiac Disease GSRS (CeD-GSRS) Score at Week 12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CELIM-RCD-002|2015-004063-36","April 13, 2016","April 11, 2017","May 2, 2017","December 17, 2015","December 27, 2019","December 27, 2019","Clinical Site, San Diego, California, United States|Clinical Site, New York, New York, United States|Clinical Site, Tampere, Finland|Clinical Site, Paris, France|Clinical Site, Amsterdam, Netherlands|Clinical Site, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02633020/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02633020/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02633020"
119,"NCT02630459","A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention",,"Completed","Has Results","Migraine","Drug: Placebo|Drug: Erenumab","Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6|Percentage of Participants With at Least a 50% Reduction From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6|Change From Baseline in Mean Monthly Acute Migraine-Specific Medication Treatment Days at Months 4, 5 and 6","Amgen","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","475","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20120309","January 6, 2016","September 25, 2017","June 5, 2019","December 15, 2015","March 13, 2019","November 20, 2019","Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Ota-shi, Gunma, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Tsukuba-shi, Ibaraki, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osakasayama-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Iruma-gun, Saitama, Japan|Research Site, Saitama-shi, Saitama, Japan|Research Site, Tokorozawa-shi, Saitama, Japan|Research Site, Shizuoka-shi, Shizuoka, Japan|Research Site, Shimotsuga-gun, Tochigi, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Yonago-city, Tottori, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Hofu-shi, Yamaguchi, Japan|Research Site, Yamaguchi-shi, Yamaguchi, Japan|Research Site, Kai-shi, Yamanashi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02630459/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02630459/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02630459"
120,"NCT02626000","Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)","MASTERKEY232","Active, not recruiting","Has Results","Carcinoma of the Head and Neck","Drug: Talimogene Laherparepvec|Biological: Pembrolizumab","Number of Participants With a Dose Limiting Toxicity (DLT)|Objective Response Rate|Complete Response Rate|Best Overall Confirmed Response|Duration of Confirmed Response|Disease Control Rate|Progression Free Survival|Overall Survival|Number of Participants With Adverse Events","Amgen|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130232|20130232 / KEYNOTE-137|2015-003011-38","April 6, 2016","November 2, 2017","August 28, 2020","December 10, 2015","June 10, 2019","December 16, 2019","Research Site, Newark, Delaware, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Billings, Montana, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Salzburg, Austria|Research Site, Bruxelles, Belgium|Research Site, Wilrijk, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, Bordeaux, France|Research Site, Pierre-Benite, France|Research Site, Toulouse cedex 9, France|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Milano, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wirral, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02626000/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02626000/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02626000"
121,"NCT02624895","ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line","SILQ","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer",,"EORTC QLQ C30 questionnaire score|QoL questionnaire DLQI questionnaire score|%of patients of enrolled subjects, experiencing a specific adverse event according to NCI CTC-AE version 4.0|Recording of number of concomitant medications, to prevent or treat dermatological adverse events|Time to onset of the dermtological toxicity|Dose reduction|""number of administered cycles""|average relative dose intensity of every drug""|Score scale on questionnaire answers|Number of cycles on treatment before and of treatment due to AE|dose delay|Questionnaire score","Amgen","All","18 Years and older   (Adult, Older Adult)",,"296","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20140383","December 30, 2015","December 31, 2020","December 31, 2020","December 9, 2015",,"January 13, 2020","Research Site, Brescia, Italy|Research Site, Castellana Grotte, Italy|Research Site, Castellanza (VA), Italy|Research Site, Catania, Italy|Research Site, Cona FE, Italy|Research Site, Confreria - Cuneo, Italy|Research Site, Crema, Italy|Research Site, Fano PU, Italy|Research Site, Foggia, Italy|Research Site, Frattamaggiore NA, Italy|Research Site, Isernia, Italy|Research Site, L Aquila, Italy|Research Site, Lecce, Italy|Research Site, Mirano VE, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Poggibonsi SI, Italy|Research Site, Potenza, Italy|Research Site, Rionero In Vulture (PZ), Italy|Research Site, Roma (RM), Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Sanremo (IM), Italy|Research Site, Savona, Italy|Research Site, Sora (FR), Italy|Research Site, Taormina ME, Italy|Research Site, Taranto, Italy|Research Site, Torino, Italy|Research Site, Torino, Italy|Research Site, Viterbo, Italy",,"https://ClinicalTrials.gov/show/NCT02624895"
122,"NCT02624869","Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).","HAUSER-OLE","Active, not recruiting","No Results Available","Familial Hypercholesterolemia","Biological: evolocumab (AMG 145)","Number of participants with treatment-related Adverse Events as assessed by CTCAE V4.0|Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)|Percent change from baseline in non-HDL-C (non high density lipoprotein cholesterol)|Percent change from baseline in apoliprotein-b (ApoB)|Percent change from baseline total cholesterol/HDL-C ratio|Percent change from baseline ApoB/ApoA1 ratio|Change from baseline in LDL-C|Change from baseline in steroid hormones|Change from baseline in Carotid intima-media thickness (cIMT) at week 80|Subject incidence of abnormal muscle enzyme levels|Subject incidence of abnormal liver enzyme levels|Change from baseline in height|Change from baseline in weight.|Change from baseline in pubertal development|Number of participants with abnormal neurological examination findings|Change from baseline score in the components of the Cogstate battery (cognitive function assessments)","Amgen","All","10 Years to 17 Years   (Child)","Phase 3","163","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120124|2015-002276-25","September 10, 2016","June 7, 2021","June 7, 2021","December 9, 2015",,"December 10, 2019","Research Site, Bronx, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Feldkirch, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Chicoutimi, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Svitavy, Czechia|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Gdansk, Poland|Research Site, Guimaraes, Portugal|Research Site, Saint Petersburg, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Parktown, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Geneva 14, Switzerland|Research Site, Reinach, Switzerland|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02624869"
123,"NCT02618967","Single Ascending Dose Study of AMG 570 in Healthy Subjects",,"Completed","No Results Available","Systemic Lupus Erythematosus","Biological: AMG 570|Biological: AMG 570 Matching Placebo","Subject incidences of treatment-emergent adverse events.|Clinically significant changes in physical examinations.|Clinically significant changes in vital signs.|Clinically significant changes in laboratory safety tests.|Clinically significant changes in electrocardiograms (ECGs).|PK parameter of maximum observed concentration [Cmax].|PK parameter of time at Cmax [tmax].|PK parameter of area under the concentration-time curve [AUC].|Peripheral Blood Receptor Occupancy Assessments.|Change in lymphocyte subset counts.|Anti-AMG 570 binding antibodies.","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140322","March 28, 2016","October 22, 2018","December 3, 2018","December 2, 2015",,"January 7, 2020","Research Site, Evansville, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02618967"
124,"NCT02601001","Safety Study of Omecamtiv Mecarbil in Healthy Japanese Subjects",,"Completed","No Results Available","Heart Failure","Drug: AMG 423|Drug: Placebo","Pharmacokinetics (Cmax)|Incidence of Emergent Adverse Events (Safety and Tolerability)|Pharmacokinetics (AUC)|Pharmacokinetics (Tmax)","Amgen","All","20 Years to 45 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20150134","November 2015","January 2016","January 2016","November 10, 2015",,"January 28, 2016","Research Site, Kagoshima-shi, Kagoshima, Japan",,"https://ClinicalTrials.gov/show/NCT02601001"
125,"NCT02588534","Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects",,"Completed","No Results Available","Healthy Men and Women","Device: etanercept (ENBREL®) via auto-injector device|Other: Etanercept (ENBREL®) via Manual injection","Ratio of the geometric mean of etanercept (ENBREL®) administered by auto-injector Scandinavian Health Limited-SHL) to etanercept administered by manual injection for the pharmacokinetic (PK) parameter of AUC(0-t)|Secondary includes the pharmokinetic parameter to measure the etanercept (ENBREL®) AUC (0-x), area under the curve|Safety Events measured by number of adverse events and retationship to treatment|Any significant changes from baseline in Vital Signs and physical examinations|Any Clinically Significant changes in clinical laboratory tests will be noted.|12-lead Electrocardiograms will be performed and saved with subject source records|Blood samples obtained to measure seroreactivitiy to etanercept at baseline and following treatment|Secondary includes measure of pharmacokinetic parameter of Tmax, the time to reach maximum concentration|Secondary outcome to measure t 1/2: elimination half-life for etanercept|Secondary to include etanercept pharmacokinetic parameter of CL/F: apparent clearance","Amgen",,"Child, Adult, Older Adult","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040136","August 2004","October 2004","October 2004","October 28, 2015",,"October 28, 2015",,,"https://ClinicalTrials.gov/show/NCT02588534"
126,"NCT02585895","Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",,"Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Procedure: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis","Percentage of Participants With Apheresis Avoidance at the End of Randomized Therapy|Percent Change From Baseline in Low-density Lipoprotein Cholesterol|Percent Change From Baseline in Non-high-density Lipoprotein-Cholesterol|Percent Change From Baseline in Total Cholesterol/High-density Lipoprotein Cholesterol Ratio","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140316|2015-001343-37","December 21, 2015","September 1, 2016","January 20, 2017","October 26, 2015","September 19, 2017","September 19, 2017","Research Site, Boca Raton, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Grandville, Michigan, United States|Research Site, Portland, Oregon, United States|Research Site, Heidelberg, Victoria, Australia|Research Site, Hradec Kralove, Czechia|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Flensburg, Germany|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, Harefield, United Kingdom|Research Site, Penarth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02585895"
127,"NCT02576652","Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement",,"Completed","Has Results","Osteoporosis","Other: Tetracycline|Other: Demeclocycline|Procedure: Total Hip Replacement","Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck|Modeling Based Formation Units in the Femoral Neck|Overfilled Remodeling-based Formation Units in the Femoral Neck|Remodeling-based Formation Units Including Overfilled Units in the Femoral Neck","Amgen","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 4","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20140259","December 22, 2015","December 18, 2017","December 18, 2017","October 15, 2015","April 26, 2019","April 26, 2019","Helen Hayes Hospital, West Haverstraw, New York, United States|Research Site, West Haverstraw, New York, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02576652/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02576652/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02576652"
128,"NCT02575833","Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",,"Completed","Has Results","Stable Angina","Drug: Erenumab|Drug: Placebo","Change From Baseline in Total Exercise Time|Time to Onset of Exercise-induced Angina|Time to Onset of ≥ 1 mm ST-segment Depression","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140254|2015-002322-40","November 23, 2015","January 23, 2017","April 13, 2017","October 15, 2015","July 5, 2018","August 24, 2018","Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Jackson, Tennessee, United States|Research Site, New Braunfels, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Haskovo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Brandys nad Labem, Czechia|Research Site, Chomutov, Czechia|Research Site, Praha 4, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Riga, Latvia|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Zabrze, Poland|Research Site, Timisoara, Romania|Research Site, Bardejov, Slovakia|Research Site, Brezno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Piestany, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Zilina, Slovakia|Research Site, Parow, Western Cape, South Africa|Research Site, Geneva 14, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02575833/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02575833/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02575833"
129,"NCT02567370","Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581","FIH","Completed","No Results Available","Schizophrenia or Schizoaffective Disorder","Drug: AMG 581|Drug: Placebo","Reported treatment-emergent adverse events|Changes in systolic/diastolic blood pressure|Changes in heart rate|Changes in respiratory rate|Changes in temperature|Changes in ECGs|Scores at each study visit for Simpson Angus Scale (SAS)|Scores at each study visit and summary by cohort for Barnes Akathisia Rating Scale (BARS)|Subject incidence of treatment-emergent suicidal ideation and behavior as measured by Columbia-Suicide Severity Rating Scale (C-SSRS)|Peak plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Median of tmax","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130100","August 2015","October 2015","October 2015","October 5, 2015",,"October 23, 2015","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02567370"
130,"NCT02561962","A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: AMG 224","Incidence of dose limiting toxicities (DLTs)|Incidence of treatment-related adverse events|Incidence of treatment-emergent adverse events|Number of subjects with clinically significant changes in vital signs|Number of subjects with clinically significant changes in physical examinations|Number of subjects with clinically significant changes in ECGs|Number of subjects with clinically significant changes in clinical laboratory tests|Maximum observed concentration (Cmax)|Minimum observed concentration (Cmin)|Area under the concentration-time curve (AUC)|Clearance (CL)|Half-life (t1/2), if feasible|Overall response according to International Myeloma Working Group (IMWG) uniform response criteria|Relative reduction in M-component|Time to progression (TTP)|Duration of response (DOR)|Conversion to MRD negativity|Incidence of anti-AMG 224 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130314","November 20, 2015","November 30, 2018","March 15, 2022","September 28, 2015",,"December 11, 2019","Research Site, West Hollywood, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02561962"
131,"NCT02542605","To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients",,"Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo|Drug: PACAP-38 Challenge Agent","Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion|Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS|Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS|Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS|Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS|Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS|Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS|Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS|Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS|Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS|Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS|Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS|Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS|Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS|Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h)|PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d)|Number of Participants With Anti-Erenumab Antibodies|Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters|Number of Participants With Clinically Significant Changes in Physical Parameters|Number of Participants With Clinically Significant Changes in Neurological Assessments","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20140207","November 11, 2015","September 28, 2017","November 8, 2017","September 7, 2015","June 3, 2019","June 3, 2019","Research Site, Anaheim, California, United States|Research Site, Leuven, Belgium|Research Site, Leiden, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02542605/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02542605/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02542605"
132,"NCT02520427","A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Relapsed/Refractory AML","Drug: AMG 330","Subject incidence of adverse events as a Measure of Safety|Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety|Incidence of anti-AMG 330 antibody formation|Efficacy parameter: Response rate|Efficacy parameter: duration of response|Efficacy parameter: time to progression|Efficacy parameter: time to response|Pharmacokinetic parameter: Half-life of AMG330|Pharmacokinetic parameter: Steady state concentration of AMG330|Pharmacokinetic parameter: Volume of distribution of AMG330|Pharmacokinetic parameter: Clearance of AMG330","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120252|2014-004462-20","August 31, 2015","May 16, 2021","May 16, 2021","August 11, 2015",,"November 25, 2019","Research Site, Duarte, California, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, München, Germany|Research Site, Ulm, Germany|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02520427"
133,"NCT02520362","Denosumab Safety Assessment in Multiple Observational Databases",,"Active, not recruiting","No Results Available","Osteoporosis","Drug: denosumab|Drug: bisphosphonate","Incidence rates of Adverse Events of Special Interest (AESI)|Characteristics and Adverse Events of Special Interest (AESI) risk factors|Compare the incidence of the Adverse Events of Special Interests|Describe incidence rates of Adverse Events of Special Interest (AESI)|Describe denosumab utilization patterns|Describe Prolia utilization patterns","Amgen|Aarhus University Hospital|Optum, Inc.|University of Alabama at Birmingham","All","55 Years to 99 Years   (Adult, Older Adult)",,"508215","Industry|Other","Observational","Observational Model: Other|Time Perspective: Prospective","20090522","May 31, 2010","May 25, 2020","May 25, 2020","August 11, 2015",,"January 2, 2020",,,"https://ClinicalTrials.gov/show/NCT02520362"
134,"NCT02509507","Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab","MASTERKEY-318","Recruiting","No Results Available","Hepatocellular Carcinoma|Liver Metastases","Drug: Talimogene Laherparepvec|Drug: Pembrolizumab","Subject incidence DLTs separately in Group A and B observed in monotherapy and combination cohorts and in each tumor type seperately in Part 2|To evaluate in Part 2 ORR per modified irRC‑RECIST separately by tumor type (BC, CRC, GEC, melanoma, NSCLC, RCC, and HCC)|Safety: Subject incidence of treatment-related and treatment-emergent adverse events in monotherapy and combination of Part 1 and each separate tumour type in Part 2|Safety: To estimate the incidence of detectable talimogene laherparepvec DNA in blood and urine|Safety: To estimate the incidence of clearance of talimogene laherparepvec DNA from blood and urine|Safety: To estimate the rate of detection and incidence of talimogene laherparepvec DNA and virus at the surface of talimogene laherparepvec injection site, the exterior of the occlusive dressing, and the oral mucosa|Safety: To estimate the incidence of talimogene laherparepvec DNA detection in lesions suspected to be herpetic in origin|Efficacy: Objective response rate (ORR)|Efficacy: Best overall response (BOR)|Efficacy: Durable response rate (DRR)|Efficacy: Duration of response (DOR)|Efficacy: Response in injected and uninjected lesions|Efficacy: Disease control rate (DCR)|Efficacy Progression-free survival (PFS)|Efficacy: Overall survival (OS)","Amgen|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","244","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140318|2014-005386-67","February 5, 2016","June 30, 2022","December 10, 2023","July 28, 2015",,"December 9, 2019","Research Site, Los Angeles, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Salzburg, Austria|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Berlin, Germany|Research Site, Tübingen, Germany|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02509507"
135,"NCT02504476","Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective","MAD","Completed","No Results Available","Schizophrenia or Schizoaffective Disorder","Drug: AMG 581|Drug: Placebo|Drug: Midazolam","Reported treatment-emergent adverse events|Changes in systolic/diastolic blood pressure|Changes in heart rate|Changes in respiratory rate|Changes in temperature|Changes in ECGs|Maximum change from baseline in QTc in ECGs and number and percentage of subjects with maximum changes exceeding prespecified limits in each group|Maximum post-baseline QTc values and number and percentage of subjects with maximum post-baseline QTc values exceeding prespecified limits in each group|Scores at each study visit for Simpson Angus Scale (SAS)|Scores at each study visit for Barnes Akathisia Rating Scale (BARS)|Subject incidence of treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)|Compare PK parameter (Cmax) between Day 1 and Day 18|Compare PK parameter (AUC) between Day 1 and Day 18|Compare PK parameter (tmax) Compare PK parameter (tmax) between Day 1 and Day 18|Plasma PK parameters of midazolam and 1-OH midazolam","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130259","August 2015","February 2016","February 2016","July 22, 2015",,"March 7, 2016","Research Site, Glendale, California, United States|Parexel, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02504476"
136,"NCT02499315","Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis",,"Terminated","No Results Available","Rheumatoid Arthritis","Drug: AMG 357|Drug: Placebo","The number of subjects reporting of treatment-emergent adverse events or clinically significant changes in physical examinations, vital signs, laboratory safety tests, and ECGs|AMG 357 pharmacokinetic profile (eg, plasma concentration, maximum observed concentration [Cmax], time at Cmax [Tmax], and area under the concentration-time curve [AUC])","Amgen","Female","25 Years to 70 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110247","April 2015","February 2016","February 2016","July 16, 2015",,"May 6, 2016","Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02499315"
137,"NCT02483585","Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention","ARISE","Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo","Change From Baseline in Monthly Migraine Days at Week 12|Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12|Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days at Week 12|Percentage of Participants With at Least a 5-point Reduction From Baseline in Average Impact on Everyday Activities Domain Score Measured by MPFID at Week 12|Percentage of Participants With at Least a 5-Point Reduction From Baseline in Average Impact on Physical Impairment Domain Score Measured by MPFID at Week 12|Number of Participants With Adverse Events|Number of Participants Who Developed Antibodies to Erenumab","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","577","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120297|2014-004463-20","July 20, 2015","July 11, 2016","March 20, 2017","June 29, 2015","June 25, 2018","December 11, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Culver City, California, United States|Research Site, Long Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gurnee, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Lenexa, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Princeton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Vejle, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Nice cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pringy Cedex, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Amadora, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Torres Vedras, Portugal|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Zaragoza, Aragón, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Bad Zurzach, Switzerland|Research Site, Biel, Switzerland|Research Site, Geneve, Switzerland|Research Site, Lugano, Switzerland|Research Site, St Gallen, Switzerland|Research Site, Zollikon, Switzerland",,"https://ClinicalTrials.gov/show/NCT02483585"
138,"NCT02456740","Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","STRIVE","Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo","Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period|Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days in the Last 3 Months of the Double-blind Treatment Phase|Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days to the Last 3 Months of the Double-blind Treatment Period|Change From Baseline in Mean Monthly Average Physical Impairment Domain Score Measured by MPFID in the Last 3 Months of the Double-blind Treatment Phase|Change From Baseline in Mean Monthly Average Impact on Everyday Activities Score Measured by MPFID in the Last 3 Months of the Double-blind Treatment Phase","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","955","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120296|2014-004464-38","July 17, 2015","September 5, 2016","June 19, 2017","May 28, 2015","July 10, 2018","October 9, 2019","Research Site, Phoenix, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Encino, California, United States|Research Site, Irvine, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Newport Beach, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Redlands, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Simi Valley, California, United States|Research Site, Spring Valley, California, United States|Research Site, Boulder, Colorado, United States|Research Site, East Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Evansville, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Newton, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Metairie, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New Bedford, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Amherst, New York, United States|Research Site, Plainview, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Willoughby Hills, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Port Royal, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Brussel, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Surrey, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Turku, Finland|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hüttenberg, Germany|Research Site, Kiel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Wiesbaden, Germany|Research Site, Würzburg, Germany|Research Site, Leiden, Netherlands|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Bratislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Falköping, Sweden|Research Site, Helsingborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Stoke on Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02456740"
139,"NCT02443506","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 623|Drug: Placebo","Incidence of treatment emergent adverse events|Incidence of abnormal clinically significant vital signs|Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results|Incidence of abnormal clinically significant ECG results|Pharmacokinetics profile of AMG 623 including Tmax, AUClast and Cmax","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040147","October 2004","April 2007","June 2007","May 14, 2015",,"May 14, 2015",,,"https://ClinicalTrials.gov/show/NCT02443506"
140,"NCT02437916","Safety Study of AMG 228 to Treat Solid Tumors",,"Terminated","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Transitional Cell Carinoma of Bladder|Colorectal Cancer","Drug: AMG 228","Subject incidence of dose limiting toxicities (DLT)|Subject incidence of treatment-emergent adverse events|Subject incidence of treatment-related adverse events|Subject incidence of clinically significant changes in vital signs and physical assessments|Subject incidence of clinically significant changes in ECGs|Subject incidence of clinically significant changes in clinical laboratory tests|AMG 228 maximum observed concentration (Cmax)|AMG 228 minimum observed concentration (Cmin)|AMG 228 area under the concentration-time curve (AUC)|AMG 228 half-life (t1/2)|Subject objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Incidence of anti-AMG 228 antibody formation|Activation status and changes in numbers of T regulator cells (Treg)|Subject objective response per immune-related Response Criteria (irRC)|Activation status of cytotoxic T lymphocytes (CTL)|Changes in numbers of cytotoxic T lymphocytes (CTL)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140131","April 2015","December 2016","December 2016","May 8, 2015",,"February 6, 2017","Research Site, La Jolla, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, New York, New York, United States|Research Site, Parkville, Victoria, Australia|Research Site, Leuven, Belgium|Research Site, Villejuif, France|Research Site, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT02437916"
141,"NCT02429882","Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis",,"Withdrawn","No Results Available","Axial Spondyloarthritis","Drug: Brodalumab 210 mg|Drug: Placebo","Assessment of SpondyloArthritis international Society (ASAS)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20101228|2014-003701-15","May 2015","May 2015","May 2015","April 29, 2015",,"June 19, 2015","Research Site, Scottsdale, Arizona, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Winnipeg, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT02429882"
142,"NCT02412878","Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma","ARROW","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone","Progression Free Survival|Overall Response Rate|Overall Survival|Number of Participants With Adverse Events (AEs)|Plasma Carfilzomib Concentration During Cycle 2","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","478","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFZ014|2014-005325-12|20140355","September 9, 2015","June 15, 2017","January 7, 2019","April 9, 2015","December 13, 2018","December 16, 2019","Research Site, Scottsdale, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Research Site, Bethesda, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Research Site, Rockville, Maryland, United States|Maryland Oncology Hematology, P.A, Rockville, Maryland, United States|Research Site, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Tyler, Texas, United States|Blood and Cancer Center of East Texas, Tyler, Texas, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Ghent, Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha, Czechia|Research Site, Aalborg, Denmark|Research Site, Copenhagen, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Bayonne, France|Research Site, Brest, France|Research Site, Dijon, France|Research Site, Nantes Cedex 1, France|Research Site, Nimes cedex 09, France|Research Site, Paris, France|Research Site, Pierre-Benite cedex, France|Research Site, Rennes, France|Research Site, Tours Cedex 1, France|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Rostock, Germany|Research Site, Tubingen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Ancona, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Shibukawa-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Isehara-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Tachikawa-shi, Tokyo, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Tokushima-shi, Japan|Research Site, Christchurch, New Zealand|Research Site, Otahuhu, Auckland, New Zealand|Research Site, Oslo, Norway|Research Site, Trondheim, Norway|Research Site, Brzozow, Poland|Research Site, Chorzow, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Brazov, Romania|Research Site, Bucharest, Romania|Research Site, Sevilla, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Girona, Cataluña, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Goteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Bournemouth, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02412878/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02412878/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02412878"
143,"NCT02411136","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 623|Drug: Placebo","Incidence of treatment emergent adverse events|Incidence of abnormal clinically significant vital signs|Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results|Incidence of abnormal clinically significant ECG results|Pharmacokinetics profile of AMG 623 including Tmax, AUClast and Cmax","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040250","May 2005","August 2007","October 2007","April 8, 2015",,"April 8, 2015",,,"https://ClinicalTrials.gov/show/NCT02411136"
144,"NCT02393859","Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL",,"Active, not recruiting","No Results Available","Leukemia, Acute Lymphoblastic","Drug: Blinatumomab|Drug: Conventional Consolidation Chemotherapy","Event-free survival|Overall survival|MRD response|Adverse events|Survival|Anti-blinatumomab antibody|Relapse Incidence|Css|Steady-state concentrations","Amgen","All","up to 17 Years   (Child)","Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120215|2014-002476-92","November 10, 2015","July 17, 2019","September 23, 2022","March 20, 2015",,"November 1, 2019","Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Randwick, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Wien, Austria|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Curitba, Paraná, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Praha 5, Czechia|Research Site, Kobenhavn O, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Marseille cedex 5, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Strasbourg Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Berlin, Germany|Research Site, Duesseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Jena, Germany|Research Site, Kiel, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Tübingen, Germany|Research Site, Ulm, Germany|Research Site, Würzburg, Germany|Research Site, Goudi, Greece|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Monza (MB), Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Bydgoszcz, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Boadilla del Monte, Madrid, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Adana, Turkey|Research Site, Antalya, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02393859"
145,"NCT02392559","Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders","HAUSER-RCT","Completed","No Results Available","Heterozygous Familial Hypercholesterolemia","Drug: Evolocumab|Drug: Placebo","Percentage change from baseline in low density lipoprotein-cholesterol levels|Change from baseline in LDL-C levels|Percentage change from baseline in apoliprotein-b (ApoB)|Percentage change from baseline in total cholesterol:HDL-C ratio|Change in ApoB:ApoA1 ratio|Percentage change in from baseline in non-HDL-C|Mean percentage change from baseline in low density lipoprotein-cholesterol levels at week 22 and week 24","Amgen","All","10 Years to 17 Years   (Child)","Phase 3","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120123|2014-002277-11","February 15, 2016","November 25, 2019","November 25, 2019","March 19, 2015",,"December 10, 2019","Research Site, Farmington, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Iowa City, Iowa, United States|Research Site, Towson, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Feldkirch, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Chicoutimi, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Floridablanca, Santander, Colombia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 5, Czechia|Research Site, Svitavy, Czechia|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Bergen, Norway|Research Site, Oslo, Norway|Research Site, Gdansk, Poland|Research Site, Guimaraes, Portugal|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Pretoria, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Geneva 14, Switzerland|Research Site, Reinach, Switzerland|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02392559"
146,"NCT02391259","A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 557|Drug: Placebo","Safety and tolerability|Pharmacokinetic profile of AMG 557 including Tmax, AUClast and Cmax","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060132","November 2006","September 2011","November 2011","March 18, 2015",,"March 30, 2015","Research Site, Anniston, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Michigan City, Indiana, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02391259"
147,"NCT02376790","Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis",,"Completed","Has Results","Psoriatic Arthritis","Drug: Etanercept|Drug: Methotrexate|Drug: Placebo to Etanercept|Drug: Placebo to Methotrexate","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24|Percentage of Participants With a Minimal Disease Activity (MDA) Response at Week 24|Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response Over Time|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response Over Time|Change From Baseline in Tender Joint Count Over Time|Change From Baseline in Swollen Joint Count Over Time|Change From Baseline in Physician Global Assessment of Disease Activity Over Time|Change From Baseline in Patient Global Assessment of Disease Activity Over Time|Change From Baseline in Patient Global Assessment of Joint Pain Over Time|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Over Time|Change From Baseline in C-reactive Protein Concentration Over Time|Percentage of Participants With a American Minimal Disease Activity (MDA) Response Over Time|Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Over Time|Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time|Change From Baseline in Simplified Disease Activity Index (SDAI) Over Time|Change From Baseline in the Disease Activity Score 28 (DAS28) Over Time|Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24|Change From Baseline in Medical Outcomes Health Survey Short Form 36 Items Version 2 (SF-36 v2) at Week 24|Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) at Week 24|Percentage of Participants With Clear mNAPSI at Week 24|Change From Baseline in Leeds Dactylitis Index (LDI) at Week 24|Percentage of Participants With Clear LDI at Week 24|Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index at Week 24|Percentage of Participants With Clear SPARCC Enthesitis Index Score at Week 24|Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis at Week 24|Percent Improvement From Baseline in the Percentage of Body Surface Area (BSA) Involved in Psoriasis by Baseline BSA Involvement Subgroups|Static Physician Global Assessment (sPGA) at Week 24|Static Physician Global Assessment (sPGA) at Week 24 by Baseline BSA Involvement Subgroups|Mean Static Physician Global Assessment (sPGA) Score at Week 24|Mean Static Physician Global Assessment (sPGA) Score at Week 24 by Baseline BSA Involvement Subgroups|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 24 by Baseline BSA Involvement Subgroups|Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24|Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups|Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24|Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline at Week 24 by Baseline BSA Involvement Subgroups","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","851","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130207|2014-004869-24","March 3, 2015","January 9, 2018","July 6, 2018","March 3, 2015","February 22, 2019","March 6, 2019","Research Site, Tuscaloosa, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Escondido, California, United States|Research Site, Hemet, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mather, California, United States|Research Site, Palm Desert, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Ocoee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Zephyrhills, Florida, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Frederick, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Wheaton, Maryland, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Lansing, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Saint Clair Shores, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Clifton, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Burgas, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Rouse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Ostrava-Trebovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Lyon Cédex 3, France|Research Site, Poitiers, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szolnok, Hungary|Research Site, Szombathely, Hungary|Research Site, Veszprem, Hungary|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Mexicali, Baja California Norte, Mexico|Research Site, Mexicalli, Baja California Norte, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Chihuahua, Mexico|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Ponte de Lima, Portugal|Research Site, Ponce, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Panorama, Western Cape, South Africa|Research Site, Pinelands, Western Cape, South Africa|Research Site, Stellenbosch, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, La Vila-Joiosa, Comunidad Valenciana, Spain|Research Site, Merida, Extremadura, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Bradford, United Kingdom|Research Site, Dudley, United Kingdom|Research Site, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02376790/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02376790/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02376790"
148,"NCT02373813","Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: etanercept pre-filled syringe sq injection|Drug: Oral methotrexate|Drug: Placebo for etanercept sq injection|Drug: Placebo for methotrexate","Simplified Disease Activity Index (SDAI) remission (≤ 3.3) at week 48|SDAI score and change from baseline at all measured timepoints|Disease activity score (28 joint) calculated using the erythrocyte sedimentation rate formula (DAS-28-ESR) and change from baseline at all measured timepoints|Disease activity score (28 joint) using the C-reactive protein formula (DAS-28-CRP) and change from baseline at all measured timepoints|Clinical Disease Activity Index (CDAI) and change from baseline at all measured timepoints|Disease worsening defined as an SDAI > 3.3 and ≤ 11 during two consecutive visits at least 2 weeks apart or SDAI > 3.3 and ≤ 11 on three or more separate visits or SDAI > 11 after randomization.|Time to disease worsening defined as an SDAI > 3.3 and ≤ 11 during two consecutive visits at least 2 weeks apart or SDAI > 3.3 and ≤ 11 on three or more separate visits or SDAI > 11 after randomization.|In subjects that receive rescue treatment:Time to recapture SDAI remission after starting rescue treatment and SDAI remission at week 48|SDAI remission (≤ 3.3) at all measured timepoints|Boolean remission (at a single time point a subject must satisfy all of the following: tender joint count, swollen joint count, c-reactive protein and patient global assessment must each be less than or equal to 1) at all measured timepoints.|Time to recapture SDAI remission after starting rescue treatment|SDAI remission at week 48 for subjects that receive rescue treatment.|Safety of etanercept and methotrexate by assessing the adverse events, serious adverse events and lab parameters of participants in the study.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","371","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110186","February 20, 2015","December 6, 2019","December 6, 2019","February 27, 2015",,"December 12, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Escondido, California, United States|Research Site, Fontana, California, United States|Research Site, Hemet, California, United States|Research Site, Huntington Beach, California, United States|Research Site, La Jolla, California, United States|Research Site, Murrieta, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Maria, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Victorville, California, United States|Research Site, West Hills, California, United States|Research Site, Doral, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Blue Island, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Granger, Indiana, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Wheaton, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Clifton, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Great Neck, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wynnewood, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, League City, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Danville, Virginia, United States|Research Site, Buenos Aires, Argentina|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Winnipeg, Manitoba, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Cahors Cedex, France|Research Site, Montpellier cedex 05, France|Research Site, Orleans cedex 2, France|Research Site, Paris, France|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hildesheim, Germany|Research Site, Leipzig, Germany|Research Site, Püttlingen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Veszprem, Hungary|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Napoli, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Mexicali, Baja California Norte, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Chihuahua, Mexico|Research Site, Bydgoszcz, Poland|Research Site, Karwiany, Poland|Research Site, Sopot, Poland|Research Site, Stalowa Wola, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Ponte de Lima, Portugal|Research Site, Panorama, Western Cape, South Africa|Research Site, Sevilla, Andalucía, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Bilbao, País Vasco, Spain",,"https://ClinicalTrials.gov/show/NCT02373813"
149,"NCT02366195","Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma","TVEC-325","Active, not recruiting","Has Results","Unresected Stage IIIb to IVM1c Melanoma","Drug: Talimogene Laherparepvec","Correlation Between Baseline Intratumoral CD8+ Cell Density and Objective Response Rate|Correlation Between Baseline Intratumoral CD8+ Cell Density and Durable Response Rate|Correlation Between Baseline Intratumoral CD8+ Cell Density and Duration of Response|Correlation Between Baseline Intratumoral CD8+ Cell Density and Changes in Tumor Burden|Correlation Between Change From Baseline Intratumoral CD8+ Cell Density and Objective Response Rate|Correlation Between Change From Baseline in Intratumoral CD8+ Cell Density and Durable Response Rate|Correlation Between Change From Baseline in Intratumoral CD8+ Cell Density and Duration of Response|Correlation Between Change From Baseline in Intratumoral CD8+ Cell Density and Changes in Tumor Burden|Objective Response Rate|Duration of Response|Time to Treatment Failure|Durable Response Rate|Overall Survival|Change From Baseline in Tumor Burden|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120325|2013-005552-15","April 7, 2015","June 26, 2017","September 30, 2020","February 19, 2015","July 18, 2018","January 13, 2020","Research Site, Salt Lake City, Utah, United States|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Liege, Belgium|Research Site, Boulogne Billancourt, France|Research Site, Marseille cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bergamo, Italy|Research Site, Milano, Italy|Research Site, Siena, Italy|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Konin, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, London, United Kingdom|Research Site, Wirral, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02366195/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02366195/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02366195"
150,"NCT02352753","Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI","OI","Active, not recruiting","No Results Available","Osteogenesis Imperfecta","Drug: Denosumab","Change from baseline in lumbar spine BMD Z-score, as assessed by DXA,|Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24,|Change in proximal femur BMD Z-score, as assessed by DXA|Incidence of new and worsening fractures (X-ray confirmed long bone and vertebral|Incidence of improving vertebral fractures from pre-treatment to post-treatment|Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral|Change in Child Health Questionnaire (CHQ)-Parent Form (PF)-50 Physical Summary|Change in CHQ-PF-50 Psychological Summary score|Childhood Health Assessment Questionnaire (CHAQ) Disability Index score|Change in Wong-Baker Faces Pain Rating Scale (WBFPRS)|Serum concentration of denosumab|Change in growth velocity at 36 months","Amgen","All","2 Years to 17 Years   (Child)","Phase 3","153","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130173|2014-000184-40","June 24, 2015","January 24, 2020","February 1, 2022","February 2, 2015",,"November 1, 2019","Research Site, Los Angeles, California, United States|Research Site, Torrance, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Decatur, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Omaha, Nebraska, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Zlin, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Paris Cedex 15, France|Research Site, Paris, France|Research Site, Saint Priest en Jarez, France|Research Site, Toulouse Cedex 9, France|Research Site, Köln, Germany|Research Site, Budapest, Hungary|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Bialystok, Poland|Research Site, Lodz, Poland|Research Site, Rzeszow, Poland|Research Site, Warszawa, Poland|Research Site, Esplugues de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Getafe, Madrid, Spain|Research Site, Birmingham, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02352753"
151,"NCT02348879","A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject",,"Completed","No Results Available","Chronic Pain","Drug: AMG 403|Drug: Placebo","Incidence of treatment emergent adverse events|Incidence of abnormal clinically significant vital signs|Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results|Incidence of abnormal clinically significant ECG results|Pharmacokinetics profile of AMG 403 including Tmax, AUClast and Cmax","Amgen",,"Child, Adult, Older Adult","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040195","January 2005","January 2006","March 2006","January 28, 2015",,"January 30, 2015",,,"https://ClinicalTrials.gov/show/NCT02348879"
152,"NCT02347865","Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France","PILOTE","Completed","No Results Available","Post Menopausal Osteoporosis","Drug: AMG 162 - Prolia","patient occurence of persistence (persistence is defined in the outcome description) at 12 months|patient occurence of persistence (persistence is defined in the outcome description) at 24 months and time to non-persistence at 24 months|describe the use of Prolia in routine clinical practice during approximately 30 months from the first injection|patient occurence of Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs) as collected in routine clinical practice|Occurrence of patient reported osteoporosis related vertebral and non vertebral fractures reported during the study","Amgen","Female","40 Years to 95 Years   (Adult, Older Adult)",,"777","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20130240","June 16, 2015","October 26, 2017","September 27, 2018","January 27, 2015",,"October 12, 2018","Amgen, Paris, France",,"https://ClinicalTrials.gov/show/NCT02347865"
153,"NCT02346877","Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis",,"Terminated","Has Results","Persistence to Enbrel","Behavioral: Personalized Patient Counselling","Persistence of Study Drug Measured at 52 Weeks|Adherence to Study Drug up to 52 Weeks|Beliefs About Medicines Questionnaire (BMQ)","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20130340","April 2015","October 2015","October 2015","January 27, 2015","March 27, 2017","March 27, 2017","Research Site, Winnipeg, Manitoba, Canada|Research Site, Fredericton, New Brunswick, Canada|Research Site, Quispamsis, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02346877"
154,"NCT02341417","Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis",,"Completed","Has Results","Secondary Hyperparathyroidism, Chronic Kidney Disease","Drug: Cinacalcet","Number of Participants With Adverse Events|Percentage of Participants Achieving ≥ 30% Reduction in iPTH From Baseline to Mean Value During Weeks 11 and 15|Percentage of Participants Achieving ≥ 30% Reduction in iPTH From Baseline to Mean Value During Weeks 23 and 28|Percent Change From Baseline in iPTH to the Mean Value During Weeks 23 and 28|Percentage of Participants Who Achieved Mean iPTH ≤ 300 pg/mL During Weeks 23 and 28|Change From Baseline in Corrected Serum Calcium to the Mean Value During Weeks 23 to 28|Change From Baseline in Serum Phosphorus to the Mean Value During Weeks 23 to 28|Serum Corrected Calcium at Baseline, Week 11, and Week 28|Serum Phosphorus at Baseline, Week 11, and Week 28|Percentage of Participants Achieving ≥ 30% Reduction in iPTH From Day 1 of Cinacalcet Treatment to Mean Value During Weeks 11 and 15|Percentage of Participants Achieving ≥ 30% Reduction in iPTH From Day 1 of Cinacalcet Treatment to Mean Value During Weeks 23 and 28|Percent Change From Day 1 of Cinacalcet Treatment in iPTH Over Time|Change From Day 1 of Cinacalcet Treatment in Serum Corrected Calcium Over Time|Change From Day 1 of Cinacalcet Treatment in Serum Phosphorus Over Time","Amgen","All","up to 18 Years   (Child, Adult)","Phase 3","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140159|2014-003563-38","June 10, 2015","March 15, 2017","March 15, 2017","January 19, 2015","May 18, 2018","May 18, 2018","Research Site, Los Angeles, California, United States|Research Site, Tucker, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, West Orange, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bruxelles, Belgium|Research Site, Praha 5, Czechia|Research Site, Paris, France|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Marburg, Germany|Research Site, Athens, Greece|Research Site, Szeged, Hungary|Research Site, Genova, Italy|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Kyiv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02341417/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02341417/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02341417"
155,"NCT02335983","Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Laboratory Values|Total Plasma Exposure - Area Under the Curve (AUC)|Maximum plasma concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax)|Total Plasma Clearance|Plasma Terminal Half-life|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Progression-free survival (PFS)|Duration of Response (DOR)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFZ013","April 2015","October 28, 2019","October 28, 2019","January 12, 2015",,"November 4, 2019","CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Los Angeles Hematology / Oncology Medical Group, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|Lombardi Cancer Center, Pediatric Hematology Oncology, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Dana Farber Partners Cancer Care, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Clinical Research Alliance, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Morton Coleman, MD, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Durham Veterans Affairs Medical Center, Durham, North Carolina, United States|Sarah Cannon Research Institute, Cincinnati, Ohio, United States|Bend Memorial Clinic, Bend, Oregon, United States|Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|The West Clinic, PC, Memphis, Tennessee, United States|Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Cancer Institute, Seattle, Washington, United States|Aurora Health Care, Aurora Cancer Care, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02335983"
156,"NCT02322736","Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR","VISION","Completed","No Results Available","Metastatic Colorectal Cancer",,"To describe the pattern of use of Vectibix® in combination with chemotherapy in 1st line or in 2nd line mCRC treatments as per approved Vectibix® indication.|To investigate the rate of objective response (ORR, defined as either a Complete Response or a Partial Response) and the rate of stable disease as best response in 1st line or in 2nd line chemotherapy regimens of mCRC including Vectibix®.","Amgen|ZeinCRO Hellas SA","All","18 Years and older   (Adult, Older Adult)",,"218","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120286","November 21, 2014","August 3, 2018","August 3, 2018","December 23, 2014",,"November 13, 2019","Research Site, Ampelokipoi, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Maroussi, Athens, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Papagou, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT02322736"
157,"NCT02318407","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain",,"Completed","No Results Available","Osteoarthritis","Drug: AMG 403|Drug: Placebo","Safety and tolerability as measured by subject incident of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations endpoints, clinical laboratory safety tests, and ECGs|Pharmacokinetics profile of AMG 403 including Tmax, AUClast and Cmax","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060145","December 2006","January 2008","March 2008","December 17, 2014",,"December 17, 2014",,,"https://ClinicalTrials.gov/show/NCT02318407"
158,"NCT02304484","Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab",,"Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab","Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","770","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140128|2014-001524-30","November 24, 2014","March 9, 2018","March 9, 2018","December 2, 2014","March 19, 2019","March 19, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Long Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Munster, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Bay City, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Zlin, Czechia|Research Site, Besancon cedex, France|Research Site, Chambray les Tours, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Essen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Novara, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Geneva 14, Switzerland|Research Site, New Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02304484/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02304484"
159,"NCT02303821","Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Mitoxantrone|Drug: PEG-asparaginase|Drug: Vincristine|Drug: Intrathecal (IT) Methotrexate|Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|Drug: 6-Mercaptopurine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin","Adverse Events (AEs) and Serious Adverse Events (SAEs)|Key Laboratory Analytes|Vital Signs|Physical Findings|Time to Toxicity|Maximum Tolerated Dose (MTD)|Maximum plasma concentration (Cmax)|Total Plasma Exposure - Area Under the Curve (AUC)|Time to Peak Concentration (Tmax)|Total Plasma Clearance|Plasma Terminal Half-life|Minimal Residual Disease (MRD) Status","Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium","All","1 Year to 21 Years   (Child, Adult)","Phase 1","39","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFZ008|2014‐001633‐84","February 16, 2015","May 20, 2020","May 20, 2020","December 1, 2014",,"January 18, 2020","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Randwick, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Wien, Austria|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Kobenhavn O, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Lille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Tel Hashomer, Israel|Research Site, Monza (MB), Italy|Research Site, Roma, Italy|Research Site, Rotterdam, Netherlands|Research Site, Madrid, Spain|Research Site, Zuerich, Switzerland|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02303821"
160,"NCT02303522","Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)",,"Completed","No Results Available","B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","Other: Other: not applicable - observational study","Hematological Complete Remission (CR)|Overall survival|Molecular CR|Relapse Free Survival (RFS)|Time to hematological CR|Receipt of HSCT after salvage treatment","Amgen","All","up to 17 Years   (Child)",,"207","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20120299","December 2014","January 2015","January 2015","December 1, 2014",,"April 7, 2016","Research Site, Wien, Austria|Research Site, Berlin, Germany|Research Site, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT02303522"
161,"NCT02297529","Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma",,"No longer available","No Results Available","Unresected Stage IIIB to IVM1c Melanoma","Drug: Talimogene Laherparepvec",,"Amgen","All","18 Years to 95 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients|Treatment IND/Protocol",,"20120328|2014-002834-30",,,,"November 21, 2014",,"October 31, 2019","Research Site, Chur, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02297529"
162,"NCT02291614","A Phase 1 Study of AMG 211 in Subjects With Advanced Gastrointestinal Cancer",,"Completed","No Results Available","GI Adenocarcinoma","Drug: AMG 211","Subject incidence of treatment emergent adverse events (TEAEs) as a Measure of Safety|Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety|Subject incidence of clinically significant changes in vital signs, electrocardiograms, physical examination findings, and clinical laboratory tests as a Measure of Safety|Determination of serum concentrations of AMG 211 after continuous intravenous (cIV) infusion as PK Measure|Incidence of anti-AMG 211 antibody formation|Time to progression (TTP)|Progression-free rate|Efficacy parameters: overall response rate (ORR; per modified irRC), duration of response, time to response","Amgen|MedImmune LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130354|2014-000201-12","November 27, 2014","November 6, 2017","January 9, 2018","November 14, 2014",,"August 10, 2018","Research Site, Hamburg, Germany|Research Site, München, Germany|Research Site, Ulm, Germany|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02291614"
163,"NCT02291588","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 811|Drug: Placebo","Safety and tolerability as measured by subject incident of treatment-emergent adverse events, clinically significant changes in vital signs, physical examination endpoints, clinical laboratory safety tests, and ECGs|Pharmacokinetic profile of AMG 811 including tmax, AUClast and Cmax","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060203","December 2007","March 2010","June 2010","November 14, 2014",,"November 14, 2014",,,"https://ClinicalTrials.gov/show/NCT02291588"
164,"NCT02279173","Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)",,"Completed","Has Results","Immune Thrombocytopenia","Drug: Romiplostim","Percentage of Time With a Platelet Response During the First 6 Months of Treatment|Percentage of Participants Who Developed Collagen After Exposure to Romiplostim|Percentage of Participants With Increased Modified Bauermeister Grade|Percentage of Participants Who Developed Bone Marrow Abnormalities|Percentage of Time With a Platelet Response During the Overall Treatment Period|Percentage of Time With an Increase in Platelet Count ≥ 20 x10⁹/L Above Baseline|Number of Participants Reporting Use of Rescue Medications for ITP During the Treatment Period|Number of Participants Who Developed Anti-Romiplostim or Anti- Thrombopoietin Neutralizing Antibodies|Number of Participants With Adverse Events|Percentage of Participants Who Developed Increased Reticulin","Amgen","All","1 Year to 18 Years   (Child, Adult)","Phase 3","204","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101221|2011-005019-96","December 10, 2014","August 30, 2018","August 15, 2019","October 30, 2014","August 28, 2019","September 17, 2019","Research Site, Roseville, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Randwick, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Belem, Pará, Brazil|Research Site, Jau, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Olomouc, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 5, Czechia|Research Site, Montpellier cedex 05, France|Research Site, Nice Cedex 3, France|Research Site, Paris, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikvah, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Bydgoszcz, Poland|Research Site, Lodz, Poland|Research Site, Olsztyn, Poland|Research Site, Zabrze, Poland|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Parktown, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Tygerberg, Western Cape, South Africa|Research Site, Barcelona, Cataluña, Spain|Research Site, Esplugues de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Basel, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Adana, Turkey|Research Site, Antalya, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02279173/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02279173/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02279173"
165,"NCT02275156","Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab",,"Completed","Has Results","Hyperlipidemia|Mixed Dyslipidemia","Biological: Evolocumab","Maximum Observed Serum Concentration (Cmax) of Evolocumab|Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-last) for Evolocumab|Number of Participants With Adverse Events|Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes|Number of Participants With Anti-evolocumab Antibodies|Area Under the Effect Curve From Baseline to Day 57 (AUECday1-57) for Low-density Lipoprotein Cholesterol (LDL-C)|Mean Percent Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140213","August 19, 2014","December 19, 2014","December 19, 2014","October 27, 2014","January 29, 2016","November 29, 2018","Research Site, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02275156"
166,"NCT02274792","Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis",,"Completed","Has Results","Plaque Psoriasis","Drug: Etanercept","Percentage of Participants With Positive Anti-etanercept Binding Antibody Response During the Study|Percentage of Participants With Positive Anti-etanercept Binding Antibody Response at Week 24|Percentage of Participants With Positive Anti-etanercept Binding Antibody Response at Week 12|Percentage of Participants With Positive Anti-etanercept Neutralizing Antibody Response at Week 24|Percentage of Participants With Positive Anti-etanercept Neutralizing Antibody Response at Week 12","Amgen","All","18 Years to 125 Years   (Adult, Older Adult)","Phase 4","132","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101177","January 2015","November 2015","November 2015","October 24, 2014","December 29, 2016","December 29, 2016","Research Site, Mobile, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Fremont, California, United States|Research Site, Los Angeles, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Aventura, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Carmel, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, New Albany, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Rockville, Maryland, United States|Research Site, Andover, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Clarkston, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Verona, New Jersey, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Bellaire, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Surrey, British Columbia, Canada|Research Site, Bathurst, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02274792"
167,"NCT02263508","Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)",,"Active, not recruiting","No Results Available","Melanoma","Drug: talimogene laherparepvec|Drug: pembrolizumab (MK-3475)|Drug: placebo","Incidence of dose limiting toxicities (DLT)|Progression Free Survival (PFS) (response evaluation by blinded central review assessed modified RECIST 1.1)|Overall Survival|Incidence of adverse events (AEs)|Objective Response Rate (ORR)|Best overall response (BOR)|Durable response rate (DRR) defined as rate of objective responses for a duration of 6 months or longer|Duration of response (DOR)|Disease Control Rate (DCR)|Overall survival (OS)|As assessed by the QLQ-C30 subject questionnaires|Complete response rate (CRR)","Amgen|Merck Sharp & Dohme Corp.","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","713","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20110265|2014-000185-22|KEYNOTE-034","December 8, 2014","July 29, 2022","April 28, 2023","October 13, 2014",,"October 28, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Beverly Hills, California, United States|Research Site, Duarte, California, United States|Research Site, Encinitas, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Riverside, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Fridley, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Germantown, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Seattle, Washington, United States|Research Site, North Sydney, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Southport, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Liege, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Helsinki, Finland|Research Site, Bordeaux Cedex, France|Research Site, Grenoble Cedex 9, France|Research Site, Lille, France|Research Site, Lyon cedex 08, France|Research Site, Marseille cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Tübingen, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Ioannina, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bergamo, Italy|Research Site, Brescia, Italy|Research Site, Meldola FC, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Siena, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Konin, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almada, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Parktown, Gauteng, South Africa|Research Site, Kraaifontein, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Birmingham, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02263508"
168,"NCT02253654","Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis",,"Completed","Has Results","Renal Insufficiency, Chronic|Anemia|Renal Dialysis|Erythrocyte Transfusion","Drug: Epoetin alfa","Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period|Hemoglobin Concentration at Each Visit|Percentage of Participants With Transfusion Events Overall and During Each Study Period|Hemoglobin Rate of Change at Each Visit|Hemoglobin Intra-subject Variability|Percentage of Participants With Hemoglobin Excursions at Each Visit|Weekly Epoetin Alfa Dose at Each Visit|Number of RBC Units Transfused Overall and During Each Study Period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110208","April 1, 2015","April 27, 2016","May 25, 2016","October 1, 2014","May 12, 2017","May 19, 2017","Research Site, Cerritos, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Montebello, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, Simi Valley, California, United States|Research Site, Vacaville, California, United States|Research Site, Whittier, California, United States|Research Site, Miami Gardens, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Macon, Georgia, United States|Research Site, Statesboro, Georgia, United States|Research Site, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Roseville, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Astoria, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Rosedale, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Carrboro, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Meadville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Hampton, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02253654"
169,"NCT02244112","A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies",,"Completed","No Results Available","Advanced Non-Central Nervous System (CNS) Malignancies","Drug: Oprozomib|Drug: Midazolam","Food Effect/QTc - Cmax|Food Effect/QTc - AUC|Food Effect - tmax and t1/2|Food Effect - QT/QTc interval|Drug-Drug Interaction (DDI) - Cmax|Drug-Drug Interaction (DDI) - AUC|Adverse Events (AEs) and Serious Adverse Events (SAEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPZ009","August 2014","May 15, 2015","July 10, 2019","September 18, 2014",,"July 19, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02244112"
170,"NCT02227914","Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",,"Withdrawn","No Results Available","Advanced Hepatocellular Carcinoma","Drug: Oprozomib|Drug: Sorafenib","Maximum Tolerated Dose (MTD) - Phase 1b|Time To Progression (TTP) - Phase 2|Adverse Events (AEs) and Serious Adverse Events (SAEs) - Phase 1b & Phase 2|Pharmacokinetics (PK) parameters - Phase 1b|Pharmacodynamic (PDn) parameter - Phase 1b|Overall Response Rate (ORR) - Phase 2|Progression-free Survival (PFS) - Phase 2|Overall Survival (OS) - Phase 2","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPZ011|2014-003149-85","December 2014","March 2015","March 2015","August 28, 2014",,"May 2, 2017","Lahey Hospital & Medical Center, Burlington, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|The Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02227914"
171,"NCT02211131","Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma",,"Active, not recruiting","No Results Available","Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma","Drug: Talimogene Laherparepvec|Procedure: Immediate surgical resection of melanoma lesion(s)","Efficacy|Overall Response|Safety","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110266|2014-001146-13","February 3, 2015","April 30, 2019","April 30, 2022","August 7, 2014",,"October 24, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Orange, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Louisville, Kentucky, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Omaha, Nebraska, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, North Sydney, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Florianopolis, Santa Catarina, Brazil|Research Site, Barretos, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Dijon, France|Research Site, Marseille cedex 05, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Toulouse cedex 9, France|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Malaga, Andalucía, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02211131"
172,"NCT02207634","Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects","EBBINGHAUS","Completed","Has Results","Dyslipidemia","Biological: Evolocumab|Drug: Placebo|Drug: Background Statin Therapy","Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score|Mean Change From Baseline in Spatial Working Memory (SWM) Between-errors Z Score|Mean Change From Baseline in Paired Associated Learning (PAL) Total Errors Adjusted Z Score|Mean Change From Baseline in Reaction Time (RTI) Median 5-choice Reaction Time Z Score","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","1974","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","20130385|2014-001976-75","September 10, 2014","November 11, 2016","November 11, 2016","August 4, 2014","January 16, 2018","January 16, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Harbor City, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Pedro, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Hammond, Indiana, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Biddeford, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Rochester, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Calabash, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Fort Mill, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, West Jordan, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Liberec, Czechia|Research Site, Litomysl, Czechia|Research Site, Mohelnice, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Vitkovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Prerov, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, Køge, Denmark|Research Site, Vejle, Denmark|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, OYS, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Le Coudray, France|Research Site, Montepellier Cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Stuttgart, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Piraeus, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szikszo, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Pavia, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Chikushi-gun, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Itoshima-shi, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Okinawa-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Daugavpils, Latvia|Research Site, Kuldiga, Latvia|Research Site, Liepaja, Latvia|Research Site, Ogre, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Vilnius, Lithuania|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Arnhem, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Uden, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Carnaxide, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Pretoria west, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Kempton Park, South Africa|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Helsingborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Västerås, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02207634"
173,"NCT02191150","Study of Haemodialysis Patients Switching From Aranesp to Biosimilar","SHADE","Completed","No Results Available","Anaemia",,"Haemoglobin Concentration|ESA Doses|Dose ratio|Haemoglobin excursions|Haemglobin within range|TSAT, ferritin and albumin values|Iron Use|Red cell transfusions (including number of units transfused)|Hospitalisations (including primary cause)","Amgen","All","18 Years and older   (Adult, Older Adult)",,"272","Industry","Observational","Time Perspective: Retrospective","20130300","June 2014","April 2015","May 2015","July 16, 2014",,"February 8, 2016","Research Site, Herston, Queensland, Australia|Research Site, Nambour, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Burgas, Bulgaria|Research Site, Lemgo, Germany|Research Site, Lich, Germany|Research Site, Minden, Germany|Research Site, Egaleo, Athens, Greece|Research Site, Egaleo, Greece|Research Site, Kallithea, Athens, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Patra, Greece|Research Site, Milazzo ME, Italy|Research Site, Pisa, Italy|Research Site, Chojnice, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Rybnik, Poland|Research Site, Jaen, Andalucía, Spain|Research Site, Zamora, Castilla León, Spain",,"https://ClinicalTrials.gov/show/NCT02191150"
174,"NCT02189837","Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody","FLOREY","Completed","Has Results","Primary Hyperlipidemia and Mixed Dyslipidemia","Biological: Evolocumab|Drug: Atorvastatin|Drug: Placebo to Evolocumab|Drug: Placebo to Atorvastatin","Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR)|Percent Change From Baseline in LDL-C at Day 50|Percent Change From Baseline in LDL Apolipoprotein B-100 Production Rate (PR)|Percent Change From Baseline in Lipoprotein (a) Fractional Catabolic Rate (FCR)|Percent Change From Baseline in Lipoprotein(a) Production Rate (PR)","Amgen","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20130194|FLOREY","July 8, 2014","February 13, 2015","March 5, 2015","July 15, 2014","August 31, 2016","October 3, 2018","Research Site, Adelaide, South Australia, Australia|Research Site, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02189837"
175,"NCT02187354","Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL","RIALTO","No longer available","No Results Available","Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia","Drug: Blinatumomab|Other: Extension of LTFU as per ProtocolAmendment7 7Jun18",,"Amgen","All","up to 17 Years   (Child)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"20130320|2014-001700-21",,,,"July 11, 2014",,"March 18, 2019","Research Site, Aurora, Colorado, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Memphis, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Wien, Austria|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Kiel, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Tübingen, Germany|Research Site, Würzburg, Germany|Research Site, Monza (MB), Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Zuerich, Switzerland|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02187354"
176,"NCT02186171","A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis","BRIDGE","Completed","Has Results","Osteoporosis in Men","Biological: Romosozumab|Drug: Placebo","Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12|Percent Change From Baseline in BMD at the Total Hip at Month 12|Percent Change From Baseline in BMD at the Femoral Neck at Month 12|Percent Change From Baseline in Lumbar Spine BMD at Month 6|Percent Change From Baseline in BMD at the Total Hip at Month 6|Percent Change From Baseline in BMD at the Femoral Neck at Month 6","Amgen","Male","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110174|2013-005551-32","June 16, 2014","February 15, 2016","April 20, 2016","July 10, 2014","May 28, 2019","May 28, 2019","Research Site, Lakewood, Colorado, United States|Research Site, Bethesda, Maryland, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Ostrava-Trebovice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 11 - Chodov, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Mizunami-shi, Gifu, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Bungoono-shi, Oita, Japan|Research Site, Takatsuki-shi, Osaka, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Mexicali, Baja California Norte, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Lodz, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bern, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02186171"
177,"NCT02185911","Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis","ADAPTATION","Completed","No Results Available","Anaemia|Chronic Kidney Disease (CKD)",,"Monthly Haemoglobin values|Doses of darbepoetin alfa/other ESAs over time|Haemoglobin values|Change in Haemoglobin values|Increase in haemoglobin from baseline|Haemoglobin excursions|First haemoglobin within 10-12g/dL|first dose frequency change after third dose of darbepoetin alfa QM|Subjects remaining on darbepoetin alfa QM|TSAT, ferritin and albumin values|Iron Use|Transfusions|Hospitalisations","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)",,"308","Industry","Observational","Observational Model: Cohort","20130301","June 2014","April 2015","April 2015","July 10, 2014",,"March 8, 2016","Research Site, Feldkirch, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Dobrich, Bulgaria|Research Site, Montana, Bulgaria|Research Site, Pazardjik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Havlickuv Brod, Czech Republic|Research Site, Nove Mesto na Morave, Czech Republic|Research Site, Trebic, Czech Republic|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Kecskemet, Hungary|Research Site, Szeged, Hungary|Research Site, Szigetvar, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Albano Laziale RM, Italy|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Stalowa Wola, Poland|Research Site, Cordoba, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain",,"https://ClinicalTrials.gov/show/NCT02185911"
178,"NCT02178475","Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy",,"Completed","Has Results","Chemotherapy-induced Febrile Neutropenia",,"Percentage of Participants With Febrile Neutropenia|Number of Participants Who Discontinued Pegfilgrastim Prophylaxis|Number of Participants Who Discontinued G-CSF Prophylaxis|Characteristics of Participants Who Discontinued Pegfilgrastim Prophylaxis|Characteristics of Participants Who Discontinued G-CSF Prophylaxis|Number of Cycles With No Pegfilgrastim Prophylaxis|Number of Cycles With no G-CSF Prophylaxis|Reasons for Discontinuation of Pegfilgrastim Prophylaxis|Reasons for Discontinuation of G-CSF Prophylaxis|Percentage of Participants Who Experienced Complications of Febrile Neutropenia|Number of Febrile Neutropenia Events That Occurred During Cycles With No G-CSF Prophylaxis|Number of Participants Who Experienced Febrile Neutropenia During Cycles With No G-CSF Prophylaxis|Number of Participants Who Experienced Complications of Febrile Neutropenia During Cycles With No G-CSF Prophylaxis|Number of Cycles With No G-CSF Prophylaxis in Which Febrile Neutropenia Events Occurred|Number of Cycles With No G-CSF Prophylaxis in Which Complications of Febrile Neutropenia Occurred|Number of Participants Who Permanently Switched From Pegfilgrastim Prophylaxis to Other G-CSF Prophylaxis|Characteristics of Participants Who Received On-schedule Pegfilgrastim Primary Prophylaxis","Amgen","All","18 Years and older   (Adult, Older Adult)",,"943","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20120214","July 18, 2014","October 28, 2016","October 28, 2016","June 30, 2014","July 23, 2018","July 23, 2018","Research Site, Eggenburg, Austria|Research Site, Graz, Austria|Research Site, Leoben, Austria|Research Site, Schwarzach im Pongau, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Arlon, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Aix en Provence, France|Research Site, Amiens, France|Research Site, Beuvry, France|Research Site, Marseille cedex 5, France|Research Site, Marseille, France|Research Site, Meaux Cedex, France|Research Site, Nancy, France|Research Site, Nimes cedex 09, France|Research Site, Orleans Cedex, France|Research Site, Perpignan, France|Research Site, Pierre Benite Cedex, France|Research Site, Périgueux cedex, France|Research Site, Saint Priest en Jarez Cedex, France|Research Site, Sarcelles, France|Research Site, Strasbourg, France|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Fulda, Germany|Research Site, Hildesheim, Germany|Research Site, Kassel, Germany|Research Site, Stolberg, Germany|Research Site, Troisdorf, Germany|Research Site, Velbert, Germany|Research Site, Westerstede, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Kalamata, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Papagou, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Bialystok, Poland|Research Site, Gdynia, Poland|Research Site, Koszalin, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Poznan, Poland|Research Site, Walbrzych, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Baia Mare, Romania|Research Site, Braila, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Campina, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania",,"https://ClinicalTrials.gov/show/NCT02178475"
179,"NCT02175277","Darbepoetin Alfa MDS Companion Protocol",,"Completed","Has Results","Myelodysplastic Syndrome (MDS)","Drug: Darbepoetin Alfa","Number of Participants With Treatment-emergent Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130113|2013-000727-13","June 12, 2014","March 20, 2017","March 20, 2017","June 26, 2014","October 11, 2018","November 14, 2018","Research Site, Charleroi, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Sint-Niklaas, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02175277/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02175277/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT02175277"
180,"NCT02174861","A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.",,"Completed","Has Results","Treatment for Prevention of Chronic Migraine","Drug: Erenumab","Number of Participants With Adverse Events|CHU Substudy: Number of Participants Able to Administer a Full Dose of Erenumab in Home-use|Change From Study 20120295 Baseline in Monthly Migraine Days|Percentage of Participants With at Least a 50% Reduction in Monthly Migraine Days From Study 20120295 Baseline|Change From Study 20120295 Baseline in Monthly Acute Migraine-Specific Medication Treatment Days|Change From Study 20120295 Baseline in Cumulative Monthly Headache Hours|CHU Substudy: Number of Participants With Adverse Events","Amgen","All","18 Years to 66 Years   (Adult, Older Adult)","Phase 2","609","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130255|2013-005311-27","June 30, 2014","May 26, 2017","May 26, 2017","June 26, 2014","June 19, 2018","June 19, 2018","Research Site, Newport Beach, California, United States|Research Site, Palo Alto, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Pikesville, Maryland, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Amherst, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Calgary, Alberta, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Glostrup, Denmark|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Kiel, Germany|Research Site, Lillehammer, Norway|Research Site, Sandvika, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Falköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Vällingby, Sweden|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, London, United Kingdom|Research Site, Stoke on Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02174861/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02174861/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02174861"
181,"NCT02173171","Registry Study for Talimogene Laherparepvec",,"Enrolling by invitation","No Results Available","Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial","Other: Information collection","Talimogene Laherparepvec Related Adverse Events|Subject overall survival|Use of subsequent anti-cancer therapy","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)",,"340","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120139","April 27, 2010","March 23, 2023","March 23, 2023","June 24, 2014",,"November 6, 2019","Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Santa Rosa, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Morristown, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Franklin, Wisconsin, United States|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Nantes Cedex 1, France|Research Site, Heidelberg, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Szeged, Hungary|Research Site, Bergamo, Italy|Research Site, Milano, Italy|Research Site, Siena, Italy|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Pretoria, South Africa|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zuerich, Switzerland|Research Site, London, United Kingdom|Research Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02173171"
182,"NCT02170337","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps",,"Completed","No Results Available","Chronic Rhinosinusitis With Nasal Polyps","Drug: AMG 282|Drug: Placebo","Safety and tolerability|Immunogenicity|Pharmacokinetic profile of AMG 282","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110236","July 2014","May 2016","May 2016","June 23, 2014",,"June 1, 2016","Research Site, Santa Monica, California, United States|Research Site, Aurora, Colorado, United States|Research Site, South Miami, Florida, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02170337"
183,"NCT02157948","A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Denosumab (CP2)|Drug: Denosumab (CP4)","Percent Change From Baseline in Lumbar Spine BMD|Percent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)|Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)","Amgen","Female","55 Years to 100 Years   (Adult, Older Adult)","Phase 3","394","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120187|2013-001279-19","May 2014","July 2015","July 2015","June 6, 2014","August 16, 2017","August 16, 2017","Research Site, Santa Maria, California, United States|Research Site, South Lake Tahoe, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Gainesville, Georgia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Akron, Ohio, United States|Research Site, Bend, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Bialystok, Poland|Research Site, Gliwice, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT02157948"
184,"NCT02147951","Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma",,"No longer available","No Results Available","Unresected Stage IIIb to IVM1c Melanoma","Drug: Talimogene Laherparepvec",,"Amgen","All","18 Years to 95 Years   (Adult, Older Adult)",,,"Industry","Expanded Access",,"20120166",,,,"May 28, 2014",,"March 1, 2016","Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Morristown, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Franklin, Wisconsin, United States|Research Site, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02147951"
185,"NCT02138838","Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis",,"Terminated","Has Results","Chronic Kidney Disease, Secondary Hyperparathyroidism","Drug: Cinacalcet HCl|Dietary Supplement: Standard of Care","Percentage of Participants Who Achieved a ≥ 30% Reduction From Baseline In Mean Plasma iPTH During Weeks 11 to 15|Percentage of Participants Who Achieved a ≥ 30% Reduction From Baseline in Mean Plasma Intact Parathyroid Hormone During the Efficacy Assessment Period|Percentage of Participants Who Achieved a Mean iPTH ≤ 300 pg/mL (31.8 Pmol/L) During Weeks 17 to 20|Percent Change in iPTH From Baseline to the Mean Value During Weeks 17 to 20|Change in Corrected Serum Calcium From Baseline to the Mean Value During Weeks 17 to 20|Change in Serum Phosphorus From Baseline to the Mean Value During Weeks 17 to 20","Amgen","All","6 Years to 17 Years   (Child)","Phase 3","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130356|2013-004958-18","November 7, 2014","June 23, 2016","June 23, 2016","May 15, 2014","September 14, 2017","June 17, 2019","Research Site, Los Angeles, California, United States|Research Site, Wilmington, Delaware, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, West Orange, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Praha 5, Czechia|Research Site, Bron cedex, France|Research Site, Lille, France|Research Site, Marseille cedex 05, France|Research Site, Nice cedex 3, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Marburg, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Szeged, Hungary|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Torino, Italy|Research Site, Vilinus, Lithuania|Research Site, Grafton, Auckland, New Zealand|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Porto, Portugal|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Kosice, Slovakia|Research Site, Barcelona, Cataluña, Spain|Research Site, Espluques De LLobregat, Cataluña, Spain|Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT02138838"
186,"NCT02137343","A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","RILOMET-2","Terminated","No Results Available","Gastric Cancer","Drug: Rilotumumab|Drug: Placebo|Drug: Cisplatin|Drug: Capecitabine","Progression-free survival|Overall Survival|TTP|ORR|DCR|TTR|Incidence of subject adverse events, laboratory abnormalities and immunogenicity","Amgen","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 3","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120142","July 2014","June 2015","June 2015","May 13, 2014",,"April 4, 2016","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Akashi-shi, Hyogo, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osakasayama-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Takatsuki-shi, Osaka, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Hwasun, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02137343"
187,"NCT02132429","Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects",,"Terminated","No Results Available","Migraine","Drug: AMG 333|Drug: Placebo","Treatment-emergent AEs|Plasma PK Parameter|Blood Pressure response to CPT","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20130246","May 2014","October 2014","December 2014","May 7, 2014",,"April 1, 2015","CRI Lifetree, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02132429"
188,"NCT02114931","Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis",,"Completed","Has Results","Arthritis, Rheumatoid","Biological: ABP 501","Number of Participants With Adverse Events|Number of Participants With Grade ≥ 3 Hematology and Chemistry Laboratory Results|Percentage of Participants Who Developed Antibodies to ABP 501|Percentage of Participants With an American College of Rheumatology (ACR) 20 Response|Change From Parent Study Baseline in Disease Activity Score 28-C-reactive Protein (DAS28-CRP)","Amgen","All","18 Years to 81 Years   (Adult, Older Adult)","Phase 3","467","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130258|2013-004654-13","April 2014","April 2016","April 2016","April 15, 2014","April 24, 2017","April 24, 2017","Research Site, Huntsville, Alabama, United States|Research Site, Peoria, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Covina, California, United States|Research Site, El Cajon, California, United States|Research Site, Hemet, California, United States|Research Site, Palm Desert, California, United States|Research Site, Van Nuys, California, United States|Research Site, Whittier, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sandy Springs, Georgia, United States|Research Site, Lexington, Kentucky, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Wheaton, Maryland, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Brooklyn, New York, United States|Research Site, Mineola, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Soifia, Sofiya, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Praha 2, Praha, Czech Republic|Research Site, Praha 4, Praha, Czech Republic|Research Site, Hlučín, Severomoravsky Kraj, Czech Republic|Research Site, Ostrava, Severomoravsky Kraj, Czech Republic|Research Site, Zlín, Severomoravsky Kraj, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Göttingen, Niedersachsen, Germany|Research Site, Ratingen, Nordrhein-westfalen, Germany|Research Site, Leipzig, Sachsen, Germany|Research Site, Hamburg, Germany|Research Site, Szentes, Csongrad, Hungary|Research Site, Balatonfüred, Veszprem, Hungary|Research Site, Veszprém, Veszprem, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Wrocław, Dolnoslaskie, Poland|Research Site, Wrocław, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Toruń, Kujawsko-pomorskie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Białystok, Podlaskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Gdynia, Pomorskie, Poland|Research Site, Działdowo, Warminsko-mazurskie, Poland|Research Site, Elbląg, Warminsko-mazurskie, Poland|Research Site, Kościan, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Braila, Romania|Research Site, Petrozavodsk, Russian Federation|Research Site, Santiago de Compostela, A Coruna, Spain|Research Site, La Coruña, La Coruna, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Suffolk, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02114931"
189,"NCT02110355","A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Melanoma","Drug: AMG 232|Drug: Trametinib|Drug: Dabrafenib","Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate|Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival","Amgen|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120238","December 19, 2014","December 27, 2018","December 27, 2018","April 10, 2014",,"October 8, 2019","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Boston, Massachusetts, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, North Sydney, New South Wales, Australia|Research Site, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT02110355"
190,"NCT02102204","Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Etelcalcetide","Number of Participants With Adverse Events|Percentage of Participants With Parathyroid Hormone Levels Between Two to Nine-times the Upper Limit of Normal|Percentage of Participants With Serum Phosphorus ≤ the ULN|Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL|Number of Participants With Shifts From Baseline Grade 0 or 1 to Postbaseline Grade 3 or 4 for Laboratory Parameters|Number of Participants Who Developed Positive Binding Anti-Etelcalcetide Antibodies","Amgen","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","902","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130213|2013-004136-30|KAI-4169","March 25, 2014","November 4, 2016","June 26, 2017","April 2, 2014","November 17, 2017","November 17, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Alhambra, California, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Cudahy, California, United States|Research Site, Granada Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Simi Valley, California, United States|Research Site, Vacaville, California, United States|Research Site, Whittier, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Dublin, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Highland Park, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, College Point, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, Rosedale, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Prahan, Victoria, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Fredericia, Denmark|Research Site, København, Denmark|Research Site, Caen, France|Research Site, La Tronche cedex, France|Research Site, Lille Cedex, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Reims Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Saint-Ouen, France|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Langenhagen, Germany|Research Site, Minden, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wiesbaden, Germany|Research Site, Zwickau, Germany|Research Site, Alexandroupoli, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szigetvar, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Lucca, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Pordenone, Italy|Research Site, Verona, Italy|Research Site, Riga, Latvia|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Hamilton, New Zealand|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Wadowice, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Zamosc, Poland|Research Site, Zyrardow, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Forte da Casa, Portugal|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Santo Tirso, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Franca de Xira, Portugal|Research Site, Mitishi, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Torrevieja, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Badajoz, Extremadura, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zurich, Switzerland|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT02102204"
191,"NCT02101164","Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease",,"Withdrawn","No Results Available","Solid Tumor|Metastatic Bone Disease","Biological: denosumab|Drug: pamidronate","Total duration (in hours, minutes and seconds) for investigational product preparation and administration","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","20120127","November 2014","November 2014","November 2014","April 2, 2014",,"February 18, 2015",,,"https://ClinicalTrials.gov/show/NCT02101164"
192,"NCT02099461","Effect of Denosumab on Cellular Biomarkers in the Human Breast",,"Completed","Has Results","Healthy Volunteer, Female, Breast","Drug: Denosumab|Procedure: Percutaneous core needle breast biopsy","Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells","Amgen","Female","18 Years to 45 Years   (Adult)","Phase 1","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20130349","April 2014","July 2014","July 2014","March 31, 2014","September 24, 2015","September 24, 2015","Research Site, Cypress, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02099461"
193,"NCT02096666","A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects",,"Completed","No Results Available","Stomach Neoplasms","Drug: AMG 337","Phase 1- Adverse events and clinical laboratory abnormalities|Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)|Phase 1- Pharmacokinetic parameters|Phase 1- Other adverse events, clinical laboratory abnormalities and ECG parameters|Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2)|Phase 2- Duration of Response (cohort 1 and subjects with measurable disease at baseline in cohort 2)|Phase 2- Time to response (cohort 1 and subjects with measurable disease at baseline in cohort 2)|Phase 2- Progression Free Survival|Phase 2- Overall Survival|Phase 2- Incidence and severity of adverse events and significant laboratory abnormalities|Phase 2- AMG 337 exposure and dose intensity|Phase 2- Pharmacokinetic parameters|Phase 1- Overall Response Rate|Phase 1- Duration of Response|Phase 1- Time to Response|Phase 1- Progression-Free Survival (per RECIST v1.1)|Phase 1- Overall Survival","Amgen","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120370","April 15, 2014","November 5, 2015","December 7, 2018","March 26, 2014",,"December 19, 2018","Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Suntou-gun, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT02096666"
194,"NCT02090088","Nplate® Pregnancy Exposure Registry","NPER","Terminated","Has Results","Birth Defect|Spontaneous Abortions|Low Birth Weight","Drug: Not applicable- observational study","Number of Children Born With Major Birth Defects|Number of Children Born With Any 3 or More Minor Birth Defects|Number of Children Born With a Specific Pattern of Minor Birth Defects|Number of Participants With Spontaneous and Elective Abortions or Stillbirths|Number of Children With Preterm Birth or Low Birth Weight|Number of Children Born With Intrauterine Growth Restriction|Number of Infants With Adverse Events|Number of Participants With Adverse Events","Amgen",,"Child, Adult, Older Adult",,"4","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","20080046","May 2009","January 2014","January 2014","March 18, 2014","January 6, 2015","January 6, 2015",,,"https://ClinicalTrials.gov/show/NCT02090088"
195,"NCT02085993","Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training",,"Completed","No Results Available","Immune Thrombocytopenic Purpura",,"Successful self administration of romiplostim|successful reconstitution of romiplostim|Accuracy in administering the prescribed dose of romiplostim|Injects romiplostim|Administers romiplostim","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)",,"41","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20120269","July 2014","November 2015","November 2015","March 13, 2014",,"December 22, 2015","Research Site, Innsbruck, Austria|Research Site, Leoben, Austria|Research Site, Brugge, Belgium|Research Site, Ghent, Belgium|Research Site, Créteil Cedex, France|Research Site, Limoges Cedex, France|Research Site, Montpellier, France|Research Site, Paris cedex 12, France|Research Site, Pessac Cedex, France|Research Site, Berlin, Germany|Research Site, Kronach, Germany|Research Site, Athens, Greece|Research Site, Kalamata, Greece|Research Site, Thessaloniki, Greece|Research Site, Den Haag, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Avila, Castilla León, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02085993"
196,"NCT02072863","A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Oprozomib|Drug: Melphalan|Drug: Prednisone","Maximum Tolerated Dose (MTD) - Phase 1b|Overall Response Rate (ORR) - Phase 2|Complete Response Rate (CRR) - Phase 2|Adverse Events (AEs) and Serious Adverse Events (SAEs) - Phase 2|Population Pharmacokinetic (PK) parameters - apparent clearance and volume of distribution|Duration of Response (DOR)|Progression-free Survival (PFS)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPZ006|2013-002125-27","January 2014","January 2015","September 2015","February 27, 2014",,"May 2, 2017","Department of Clinical Therapeutics, University of Athens, Athens, Attica, Greece|Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy|Azienda Ospedaliera Universitaria S Martino, Genova, Italy|AOU Maggiore della Carita, SCDU Heamatology, Novara, Italy|University of Rome, Rome, Italy|Hospital City of Health and Science of Turin, Hematology 1 Division, Turin, Italy|Vrijc Universiteit Medisch Centrum, Department of Hematology, Amsterdam, Netherlands|Erasmus MC, Department of Hematology, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02072863"
197,"NCT02066805","Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark",,"Completed","No Results Available","XGEVA Off-label Use","Drug: Database assessment of off-label XGEVA use","on or off label individual prescription type|on or off label patient treatment|type of off-label use|off-label use stratified by administering department","Amgen|University of Aarhus",,"Child, Adult, Older Adult",,"142","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20101335","January 2014","February 2015","February 2015","February 20, 2014",,"May 29, 2015",,,"https://ClinicalTrials.gov/show/NCT02066805"
198,"NCT02066415","A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention",,"Completed","Has Results","Treatment for Prevention of Chronic Migraine","Biological: Erenumab|Drug: Placebo","Change From Baseline in Monthly Migraine Days|Percentage of Participants With at Least a 50% Reduction in Monthly Migraine Days From Baseline|Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days|Change From Baseline in Cumulative Monthly Headache Hours|Number of Participants With Adverse Events|Number of Participants Who Developed Antibodies to Erenumab","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","667","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20120295|2013-001707-36","March 5, 2014","February 24, 2016","April 28, 2016","February 19, 2014","June 21, 2018","December 17, 2019","Research Site, La Jolla, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Stanford, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Pikesville, Maryland, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Amherst, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Calgary, Alberta, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Glostrup, Denmark|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Kiel, Germany|Research Site, Königstein im Taunus, Germany|Research Site, Lillehammar, Norway|Research Site, Sandvika, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Falköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Vällingby, Sweden|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, London, United Kingdom|Research Site, Stoke on Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02066415"
199,"NCT02054572","Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis",,"Completed","Has Results","Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis","Drug: [¹⁴C]Etelcalcetide","Cumulative Excretion of Radioactivity|Time to Maximum Observed Concentration (Tmax) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Maximum Observed Concentration (Cmax) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Time to Last Observed Plasma Concentration of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Last Observed Plasma Concentration (Clast) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Apparent Terminal Half-life (T½) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Area Under the Curve From Time Zero to 3 Days Post-dose (AUC3d) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Area Under the Curve From Time Zero to 10 Days Post-dose (AUC10d) of [¹⁴C]Etelcalcetide-derived Radioactivity in Plasma|Area Under the Arterial Plasma Concentration-time Curve Obtained During Hemodialysis on Day 4 for Etelcalcetide|Area Under the Venous Plasma Concentration-time Curve Obtained During Hemodialysis on Day 4 for Etelcalcetide|Time to Maximum Observed Concentration (Tmax) of Etelcalcetide|Maximum Observed Concentration (Cmax) of Etelcalcetide|Time to Last Observed Plasma Concentration of Etelcalcetide|Last Observed Plasma Concentration (Clast) of Etelcalcetide|Area Under the Curve From Time Zero to 3 Days Post-dose (AUC3d) of Etelcalcetide|Area Under the Curve From Time Zero to 10 Days Post-dose (AUC10d) of Etelcalcetide|Hemodialysis Clearance of Etelcalcetide During Hemodialysis on Day 4|Hemodialysis Extraction Ratio for Etelcalcetide During Hemodialysis on Day 4|Number of Participants With Adverse Events|Number of Participants With Anti-etelcalcetide Antibodies","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20130147","February 7, 2014","April 15, 2014","August 15, 2014","February 4, 2014","April 14, 2017","August 31, 2018","DaVita Clinical Research Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02054572"
200,"NCT02053753","Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product",,"Completed","Has Results","Healthy Volunteer","Drug: Denosumab CP4|Drug: Denosumab CP2","Maximum Observed Drug Concentration (Cmax) of Denosumab|Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab|Time to Maximum Observed Concentration (Tmax) of Denosumab|Half-life (T1/2) of Denosumab|Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)|Maximum Percent Inhibition (Imax) of Serum CTX1|Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1|Number of Participants With Adverse Events|Number of Participants Who Developed Anti-denosumab Antibodies","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120186","February 2014","August 2014","August 2014","February 4, 2014","December 29, 2017","December 29, 2017","Research Site, Cypress, California, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02053753"
201,"NCT02024646","Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis","AMVISION-2","Completed","No Results Available","Psoriatic Arthritis","Drug: 210 mg brodalumab|Drug: 140 mg brodalumab|Drug: Placebo","American College of Rheumatology (ACR) 20 Response|Psoriasis Area and Severity Index (PASI) 75|Health Assessment Questionnaire-Disability Index (HAQ-DI)|Psoriasis Symptom Inventory responder definition","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","484","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110144|2013-003553-16","March 2014","October 2015","October 2015","December 31, 2013",,"June 10, 2016","Research Site, Peoria, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Cypress, California, United States|Research Site, Hemet, California, United States|Research Site, Huntington Beach, California, United States|Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, Victorville, California, United States|Research Site, Sarasota, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Wheaton, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, St. Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Rochester, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bordeaux Cedex, France|Research Site, Le Kremlin Bicetre, France|Research Site, Lille cedex, France|Research Site, Lyon Cédex 3, France|Research Site, Nantes cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Paris, France|Research Site, Reims Cedex, France|Research Site, Frankfurt, Germany|Research Site, Hannover, Germany|Research Site, Hildesheim, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szolnok, Hungary|Research Site, Szombathely, Hungary|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Mexicali, Baja California Norte, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Ciudad Obregon, Sonora, Mexico|Research Site, Merida, Yucatán, Mexico|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Stalowa Wola, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Voronezh, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02024646"
202,"NCT02016716","A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Romosozumab 90 mg/mL|Drug: Placebo 90 mg/mL|Drug: Romosozumab 70 mg/mL|Drug: Placebo 70 mg/mL","Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine|Percent Change From Baseline in Total Hip BMD|Percent Change From Baseline in Femoral Neck BMD|Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)|Percent Change From Baseline in Serum C-Telopeptide (CTX)","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120156|2013-000434-35","December 3, 2013","September 8, 2014","December 8, 2014","December 20, 2013","November 8, 2018","November 8, 2018","Research Site, Gainesville, Georgia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Brno, Czechia|Research Site, Klatovy, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Gdynia, Poland|Research Site, Gliwice, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT02016716"
203,"NCT02016534","Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors",,"Terminated","No Results Available","Stomach Neoplasms","Drug: AMG 337","Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)|Duration of response (cohort 1 and subjects with measurable disease at baseline in cohort 2)|Time to response (Cohort 1 and subjects with measurable disease at baseline in cohort 2)|Progression free survival|Overall survival|Incidence and severity of adverse events and significant laboratory abnormalities|AMG 337 exposure and dose intensity|Pharmacokinetic parameters|Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20130111|2013-001277-24","February 2014","October 2016","October 2016","December 20, 2013",,"July 2, 2017","Research Site, New Haven, Connecticut, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Kurralta Park, South Australia, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Angers, France|Research Site, Bordeaux, France|Research Site, Lille Cedex, France|Research Site, Lyon cedex 8, France|Research Site, Marseille cedex 5, France|Research Site, Reims, France|Research Site, Saint Herblain, France|Research Site, Villejuif, France|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Ioannina, Greece|Research Site, Piraeus, Greece|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kaposvar, Hungary|Research Site, Szolnok, Hungary|Research Site, Ancona, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cremona, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Hwasun, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bialystok, Poland|Research Site, Elblag, Poland|Research Site, Konin, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Edinburgh, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02016534"
204,"NCT02014441","Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec",,"Completed","Has Results","Melanoma","Drug: Talimogene laherparepvec","Percentage of Participants With Detectable Talimogene Laherparepvec Deoxyribonucleic Acid (DNA) During the First Three Cycles|Percentage of Participants With Clearance of Talimogene Laherparepvec DNA From Blood|Percentage of Participants With Clearance of Talimogene Laherparepvec DNA From Urine|Percentage of Samples With Detectable Talimogene Laherparepvec DNA on the Exterior of the Occlusive Dressing During the First Three Cycles|Percentage of Samples With Detectable Talimogene Laherparepvec Virus on the Exterior of the Occlusive Dressing During the First Three Cycles|Percentage of Participants With Detectable Talimogene Laherparepvec DNA on the Exterior of the Occlusive Dressing During the First Three Cycles|Percentage of Participants With Detectable Talimogene Laherparepvec Virus on the Exterior of the Occlusive Dressing During the First Three Cycles|Percentage of Samples From the Surface of Injected Lesions With Detectable Talimogene Laherparepvec DNA During the First Three Cycles|Percentage of Samples From the Surface of Injected Lesions With Detectable Talimogene Laherparepvec Virus During the First Three Cycles|Percentage of Participants With Detectable Talimogene Laherparepvec DNA on the Surface of Injected Lesions During the First Three Cycles|Percentage of Participants With Detectable Talimogene Laherparepvec Virus on the Surface of Injected Lesions During the First Three Cycles|Percentage of Samples From Oral Mucosa With Detectable Talimogene Laherparepvec DNA During Treatment|Percentage of Samples From Oral Mucosa With Detectable Talimogene Laherparepvec Virus During Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Oral Mucosa During Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec Virus in Oral Mucosa During Treatment|Percentage of Samples From the Anogenital Area With Detectable Talimogene Laherparepvec DNA During Treatment|Percentage of Samples With Detectable Talimogene Laherparepvec Virus in Swabs From the Anogenital Area During Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Swabs From the Anogenital Area During Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec Virus in Swabs From the Anogenital Area During Treatment|Percentage of Samples From Oral Mucosa With Detectable Talimogene Laherparepvec DNA After the End of Treatment|Percentage of Samples From Oral Mucosa With Detectable Talimogene Laherparepvec Virus After the End of Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Oral Mucosa After the End of Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec Virus in Oral Mucosa After the End of Treatment|Percentage of Samples From the Anogenital Area With Detectable Talimogene Laherparepvec DNA After the End of Treatment|Percentage of Samples From the Anogenital Area With Detectable Talimogene Laherparepvec Virus After the End of Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec DNA in Swabs From the Anogenital Area After the End of Treatment|Percentage of Participants With Detectable Talimogene Laherparepvec Virus in Swabs From the Anogenital Area After the End of Treatment|Number of Samples With Detectable Talimogene Laherparepvec in Lesions Suspected to be Herpetic in Origin|Best Overall Response|Objective Response Rate|Time to Response|Duration of Response|Durable Response Rate|Overall Survival|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120324","April 7, 2014","January 25, 2016","April 19, 2018","December 18, 2013","February 14, 2017","November 20, 2019","Research Site, Tampa, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Fridley, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02014441"
205,"NCT02013167","Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",,"Terminated","Has Results","Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","Drug: Blinatumomab|Drug: Standard of Care Chemotherapy","Overall Survival|Percentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation|Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation|Event Free Survival (EFS)|Duration of Complete Remission|Duration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)|Percentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Number of Participants With Adverse Events|100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant|Number of Participants With Anti-blinatumomab Antibodies|Time to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","405","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00103311|2013-000536-10","January 3, 2014","December 29, 2015","March 14, 2017","December 17, 2013","August 9, 2017","November 28, 2018","Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Ghent, Belgium|Research Site, Leuven, Belgium|Research Site, Yvoir, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Creteil Cedex, France|Research Site, Le Chesnay, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite, France|Research Site, Toulouse cedex 9, France|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Tübingen, Germany|Research Site, Ulm, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Dublin, Ireland|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Venezia, Italy|Research Site, Verona, Italy|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Lublin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Oviedo, Asturias, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, ChangHua, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Bristol, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02013167"
206,"NCT02010931","Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients",,"Completed","No Results Available","Acute Lymphoblastic Leukemia",,"hematological relapse free survival|overall survival|mortality rate","Amgen|European EWALL study groups","All","15 Years and older   (Child, Adult, Older Adult)",,"310","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20120148","September 2013","March 2014","June 2014","December 13, 2013",,"July 10, 2014","Research Site, Brno, Czech Republic|Research Site, Paris Cedex 10, France|Research Site, Frankfurt am Main, Germany|Research Site, Bologna, Italy|Research Site, Roma, Italy|Research Site, Venezia, Italy|Research Site, Gliwice, Poland|Research Site, Moscow, Russian Federation|Research Site, Badalona, Cataluña, Spain|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02010931"
207,"NCT02003612","Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia",,"Completed","No Results Available","Acute Lymphoblastic Leukemia","Other: Not applicable - observational study","hematological complete remission|overall survival|duration of complete remission|proportion of patients receiving allogeneic hematological stem cell transplantation","Amgen","All","15 Years and older   (Child, Adult, Older Adult)",,"2373","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20120310","October 2013","January 2014","April 2014","December 6, 2013",,"January 25, 2017","Research Site, Boston, Massachusetts, United States|Research Site, Cleveland, Ohio, United States|Research Site, Brno, Czech Republic|Research Site, Paris Cedex 10, France|Research Site, Frankfurt am Main, Germany|Research Site, Bologna, Italy|Research Site, Venezia, Italy|Research Site, Gliwice, Poland|Research Site, Badalona, Cataluña, Spain|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02003612"
208,"NCT02000427","Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia",,"Completed","Has Results","Relapsed/Refractory Philadelphia Positive B-precursor ALL","Drug: Blinatumomab","Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles|Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment|Duration of CR or CRh* Response|Percentage of Participants With Complete Remission (CR) During the First Two Treatment Cycles|Percentage of Participants With Complete Remission With Partial Hematological Recovery (CRh*) During the First Two Treatment Cycles|Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) During the First Two Treatment Cycles|Overall Survival|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission|100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant|Number of Participants With Adverse Events|Number of Participants Who Developed Anti-blinatumomab Antibodies|Steady State Concentration of Blinatumomab","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120216|2006-006520-19","January 3, 2014","May 20, 2015","January 6, 2017","December 4, 2013","August 9, 2017","January 2, 2018","Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 10, France|Research Site, Toulouse cedex 9, France|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Würzburg, Germany|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Roma, Italy|Research Site, Venezia, Italy|Research Site, Verona, Italy|Research Site, London, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02000427"
209,"NCT01999335","A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Oprozomib|Drug: Pomalidomide|Drug: Dexamethasone","Progression-free Survival (PFS) - Phase 3|Maximum Tolerated Dose (MTD) - Phase 1b|Adverse Events (AEs) - Phase 1b & Phase 3|Overall Survival (OS) - Phase 3|Overall Response Rate (ORR) - Phase 1b & Phase 3|Clinical Benefit Rate (CBR) - Phase 1b & Phase 3|Duration of Response (DOR) - Phase 3|Health-Related Quality of Life (HRQOL) - Phase 3|Bone Pain - Phase 3|Improvement in Renal Function - Phase 3|Improvement in Hemoglobin - Phase 3|Maximum Plasma Concentration (Cmax) - Phase 1b & Phase 3|Time of Maximum Plasma Concentration (Tmax) - Phase 1b & Phase 3|Total Plasma Exposure (AUC) - Phase 1b & Phase 3","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","OPZ007","November 2013","April 25, 2019","April 25, 2019","December 3, 2013",,"October 17, 2019","California Cancer Associates For Research and Exellence, cCare, Encinitas, California, United States|James R. Berenson, MD, Inc., West Hollywood, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Oncology Hematology West PC, dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC / Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas-HOAST, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01999335"
210,"NCT01998607","Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw",,"Completed","No Results Available","Solid Tumours|Bone Metastasis","Other: Physician Survey","Proportion of participating oncology practitioners prescribing XGEVA® who are aware of the SPC statements pertaining to ONJ (each question pertaining to a SPC statement will be assessed seperately at the end of each survey round)","Amgen","All","Child, Adult, Older Adult",,"420","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","20110102","February 4, 2013","May 15, 2015","May 15, 2015","December 2, 2013",,"January 9, 2018",,,"https://ClinicalTrials.gov/show/NCT01998607"
211,"NCT01997892","TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta","TRANSFORM","Completed","Has Results","Anemia",,"Hemoglobin Concentration at Monthly Intervals|PEG Epoetin Beta Dose From the Start of the Observation Period Until the Switch|Darbepoetin Alfa Dose From the Switch Date Until the End of the Observation Period|Dose Ratio Measured at the Time of Switch From PEG Epoetin Beta to Darbepoetin Alfa|Hemoglobin Concentration Rate of Change by Period|Percentage of Participants With Hemoglobin Excursions","Amgen","All","18 Years and older   (Adult, Older Adult)",,"1027","Industry","Observational","Observational Model: Cohort","20120126","August 2012","June 2013","July 2013","November 28, 2013","May 15, 2014","June 9, 2014","Research Site, Edegem, Belgium|Research Site, Antony, France|Research Site, Aurillac, France|Research Site, Blois, France|Research Site, Boulogne sur Mer, France|Research Site, Béziers, France|Research Site, Cahors, France|Research Site, Essey lès Nancy, France|Research Site, Grabels, France|Research Site, La Roche sur Yon Cedex 9, France|Research Site, La Réunion, France|Research Site, Libourne, France|Research Site, Lille Cedex, France|Research Site, Metz, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Saint Nazaire, France|Research Site, Saint Pierre, France|Research Site, Saint Priest en Jarez, France|Research Site, Saint-Denis de la Réunion, France|Research Site, Strasbourg, France|Research Site, Vandoeuvre Les Nancy Cedex, France|Research Site, Kiel, Germany|Research Site, Nordhorn, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Arnhem, Netherlands|Research Site, Ribeira, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Sion, Switzerland",,"https://ClinicalTrials.gov/show/NCT01997892"
212,"NCT01992341","AMG 386 Drug-Drug Interaction Study With Paclitaxel",,"Completed","No Results Available","Advanced Solid Tumors","Drug: AMG 386|Drug: Paclitaxel","Paclitaxel PK parameters|AMG 386 PK parameters|Safety","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101151","July 2012","August 2013","September 2014","November 25, 2013",,"September 23, 2014","University of Colorado Cancer Center, Aurora, Colorado, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01992341"
213,"NCT01992159","Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis (PMO)","Drug: Romosozumab|Drug: Placebo","Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine|Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine|Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip|Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip|Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck|Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck|Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)|Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)|Percent Change From Baseline in Osteocalcin|Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)|Area Under the Curve Through Month 12 of P1NP","Amgen","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101291","October 12, 2012","October 9, 2014","June 17, 2015","November 25, 2013","March 25, 2019","March 25, 2019","Research Site, Anjyo-shi, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Yanagawa-shi, Fukuoka, Japan|Research Site, Mizunami-shi, Gifu, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Saito-shi, Miyazaki, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Ueda-shi, Nagano, Japan|Research Site, Ueda-shi, Nagano, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Takatsuki-shi, Osaka, Japan|Research Site, Kita-adachi-gun, Saitama, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Kiyose-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Suginami-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01992159"
214,"NCT01987232","Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer",,"Completed","Has Results","Extensive-Stage Small-Cell Lung Cancer","Drug: Carfilzomib|Drug: Carboplatin|Drug: Etoposide","Number of Participants With Dose-limiting Toxicities|Number of Participants With Adverse Events (AEs)|Overall Survival (OS) - Phase 2|Maximum Plasma Concentration - Phase 2|Time of Maximum Plasma Concentration - Phase 2|Area Under Plasma Concentration-Time Curve - Phase 2","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","32","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CFZ004|2013-002597-44|20130399","November 5, 2013","August 2016","May 4, 2017","November 19, 2013","August 28, 2017","August 28, 2017","Yale University, Yale Cancer Center, New Haven, Connecticut, United States|UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Indiana University Health Ball Memorial Hospital, Muncie, Indiana, United States|Baptist Health Lexington Clinical Research Center, Lexington, Kentucky, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Regional Budgetary Healthcare Institution ""Kursk Regional Clinical Oncology Dispensary"", Kislino, Kursk, Russian Federation|State budgetary healthcare institution of Arkhangelsk Region ""Arkhangelsk Clinical Oncological Dispensary"", Arkhangelsk, Russian Federation|Federal State Budgetary Scientific Institution ""N.N. Blokhin Russian Cancer Research Center"", Moscow, Russian Federation|State Budgetary Educational Inslitution of Higher Professional Education ""First St. Petersburg I.P.Pavlov State Medical University"", St. Petersburg, Russian Federation|State Budgetary Healthcare Institution of Yaroslavl Region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01987232"
215,"NCT01984424","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3","GAUSS-3","Completed","Has Results","Hyperlipidemia","Drug: Atorvastatin|Drug: Placebo to Atorvastatin|Other: Placebo to Ezetimibe|Drug: Ezetimibe|Other: Placebo to Evolocumab|Drug: Evolocumab","Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24|Percent Change From Baseline in LDL-C at Week 24|Change From Baseline in LDL-C at the Mean of Weeks 22 and 24|Change From Baseline in LDL-C at Week 24|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24|Percent Change From Baseline in Total Cholesterol at Week 24|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24|Percent Change From Baseline in Non-HDL-C at Week 24|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24|Percent Change From Baseline in Apolipoprotein B at Week 24|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24|Percent Change From Baseline in Lipoprotein(a) at Week 24|Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24|Percent Change From Baseline in Triglycerides at Week 24|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24|Percent Change From Baseline in HDL-C at Week 24|Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24|Percent Change From Baseline in VLDL-C at Week 24","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","511","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120332|2013-000935-29","December 10, 2013","November 10, 2015","November 21, 2017","November 14, 2013","March 13, 2018","November 29, 2018","Research Site, Beverly Hills, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Pedro, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Sterling, Illinois, United States|Research Site, Kansas City, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, York, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Aarhus N, Denmark|Research Site, Glostrup, Denmark|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Berlin, Germany|Research Site, Köln, Germany|Research Site, München, Germany|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Ferrara, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Ålesund, Norway|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Birmingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01984424"
216,"NCT01980589","A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects","CHAMPION 2","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Number of Participants With Dose-limiting Toxicities (DLTs)|Overall Response Rate (ORR)|Time To Response (TTR)|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003","August 2013","March 2016","March 2016","November 11, 2013","October 31, 2016","May 30, 2017","California Cancer Associates for Research and Excellence, Encinitas, California, United States|James R. Berenson, MD, West Hollywood, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Horizon Oncology Research, Lafayette, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Clinical Research Alliance, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01980589"
217,"NCT01970488","Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Biological: Adalimumab|Biological: ABP 501","Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16|Percentage of Participants With a PASI 75 Response at Week 16|Percentage of Participants With a PASI 75 Response at Week 32|Percentage of Participants With a PASI 75 Response at Week 50|Percent Improvement From Baseline in PASI at Week 32|Percent Improvement From Baseline in PASI at Week 50|Percentage of Participants With a Static Physician's Global Assessment (sPGA) Response at Week 16|Percentage of Participants With a sPGA Response at Week 32|Percentage of Participants With a sPGA Response at Week 50|Change From Baseline in the Percentage of Body Surface Area (BSA) Involved With Psoriasis at Week 16|Change From Baseline in the Percentage of BSA Involved With Psoriasis at Week 32|Change From Baseline in the Percentage of BSA Involved With Psoriasis at Week 50|Number of Participants With Adverse Events|Percentage of Participants Developing Antibodies to ABP 501 or Adalimumab","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120263|2013-000537-12","October 18, 2013","August 14, 2014","March 18, 2015","October 28, 2013","December 13, 2016","April 3, 2019","Research Site, Saint Leonards, New South Wales, Australia|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Nyíregyháza, Szabolcs-szatmar-bereg, Hungary",,"https://ClinicalTrials.gov/show/NCT01970488"
218,"NCT01970475","Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis",,"Completed","Has Results","Arthritis, Rheumatoid","Biological: ABP 501|Biological: Adalimumab","Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24|Change From Baseline in Disease Activity Score 28-C-reactive Protein (DAS28-CRP)|Percentage of Participants With an ACR20 Response at Week 2 and Week 8|Percentage of Participants With an ACR50 Response at Week 24|Percentage of Participants With an ACR70 Response at Week 24|Number of Participants With Adverse Events|Percentage of Participants Who Developed Antibodies to ABP 501 or Adalimumab","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","526","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120262|2013-000525-31","October 2013","November 2014","November 2014","October 28, 2013","December 13, 2016","December 13, 2016","Research Site, Victorville, California, United States|Research Site, Jupiter, Florida, United States|Research Site, Sandy Springs, Georgia, United States|Research Site, Lansing, Michigan, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hattingen, Nordrhein-westfalen, Germany|Research Site, Barnsley, England, United Kingdom|Research Site, North Shields, England, United Kingdom|Research Site, Suffolk, England, United Kingdom|Research Site, Cardiff, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01970475"
219,"NCT01967160","Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid",,"Completed","No Results Available","Osteonecrosis of the Jaw|Infection Leading to Hospitalization",,"1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts|2. Incidence proportions of infections leading to hospitalization in XGEVA and zoledronic acid inception cohorts|1. Incidence proportions of medically confirmed ONJ in the cohort switching from an oral or IV bisphosphonate (at the dose indicated for cancer patients to prevent skeletal related events) to XGEVA|2. Incidence proportions of medically confirmed ONJ in the cohort switching from an oral or IV bisphosphonate (at the dose indicated for cancer patients to prevent SREs) to XGEVA stratified by number of prior cancer-related bisphosphonate treatments|3. Characterize the XGEVA inception, zoledronic acid inception, and the XGEVA-switch cohorts with respect to patient characteristics, cancer type, medical history, and number of bisphosphonate or XGEVA treatments at the dose indicated for SRE prevention|4. Summarize oral risk factor information for medically confirmed ONJ cases|5. Summarize for medically confirmed ONJ cases information on ONJ stage, treatment, clinical course, and resolution","Amgen|Aarhus University Hospital",,"Child, Adult, Older Adult",,"2560","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20101363","January 2, 2012","August 5, 2019","August 5, 2019","October 22, 2013",,"October 24, 2019",,,"https://ClinicalTrials.gov/show/NCT01967160"
220,"NCT01966003","Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-small Cell Lung Cancer Metastatic","Drug: Carboplatin|Drug: Paclitaxel|Drug: ABP 215|Drug: Bevacizumab","Percentage of Participants With an Objective Response|Duration of Response|Progression-free Survival|Number of Participants With Adverse Events|Number of Participants Who Developed Anti-drug Antibodies|Overall Survival","Amgen|Actavis Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","642","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120265|2013-000738-36","November 11, 2013","July 23, 2015","July 23, 2015","October 21, 2013","October 19, 2017","October 19, 2017","Research Site, Bismarck, North Dakota, United States|Research Site, Fremantle, Western Australia, Australia|Research Site, Veliko Tarnovo, Veliko Turnovo, Bulgaria|Research Site, Ruse, Bulgaria",,"https://ClinicalTrials.gov/show/NCT01966003"
221,"NCT01953341","Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines",,"Completed","No Results Available","Migraine","Drug: AMG 333|Drug: Placebo","Primary|Secondary Outcome Measures|Secondary","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20130102","October 2013","September 2014","November 2014","September 30, 2013",,"December 9, 2014","Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01953341"
222,"NCT01953328","Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","AMG145","Completed","Has Results","Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events","Drug: Atorvastatin|Biological: Evolocumab|Other: Placebo to Evolocumab","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 3","409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120122","October 2013","June 2014","June 2014","September 30, 2013","December 23, 2015","December 23, 2015","Research Site, Akita-shi, Akita, Japan|Research Site, Noda-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyusyu-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Tsuchiura-shi, Ibaraki, Japan|Research Site, Hanamaki-shi, Iwate, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Kumagaya-shi, Saitama, Japan|Research Site, Niiza-shi, Saitama, Japan|Research Site, Arakawa-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Edogawa-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01953328"
223,"NCT01952574","A Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention",,"Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo","Change From Baseline in Monthly Migraine Days at Week 12|Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12|Change From Baseline in Monthly Migraine Attacks at Week 12","Amgen","All","18 Years to 60 Years   (Adult)","Phase 2","483","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20120178|2012-005331-90","August 6, 2013","September 25, 2014","November 12, 2019","September 30, 2013","July 10, 2018","December 10, 2019","Research Site, Phoenix, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, National City, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Spring Valley, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Rochester, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Falls Church, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Aarhus C, Denmark|Research Site, Glostrup, Denmark|Research Site, Helsinki, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Hamar, Norway|Research Site, Sandvika, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Falköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Vällingby, Sweden",,"https://ClinicalTrials.gov/show/NCT01952574"
224,"NCT01951586","Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Denosumab|Drug: Zoledronic acid|Drug: Placebo to Denosumab|Drug: Standard Chemotherapy|Drug: Placebo to Zoledronic Acid","Overall Survival (OS)|Correlation of Tumor Tissue RANK Expression With Overall Survival|Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival|Objective Response Rate|Correlation of Tumor Tissue RANK Expression With Objective Response Rate|Correlation of Tumor Tissue RANKL Expression With Objective Response Rate|Clinical Benefit Rate|Progression-free Survival (PFS)|Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing|Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing|Number of Participants With Treatment-emergent Adverse Events","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120249|2013-001662-42","December 31, 2013","July 29, 2016","November 28, 2017","September 26, 2013","August 28, 2017","July 12, 2019","Research Site, Goodyear, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Farmington, Connecticut, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Brewer, Maine, United States|Research Site, Westminster, Maryland, United States|Research Site, Fairhaven, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, East Setauket, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Kogarah, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Edmonton, Alberta, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Chomutov, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 8, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Caen Cedex 5, France|Research Site, Dijon cedex, France|Research Site, Nantes Cedex 2, France|Research Site, Paris Cedex 10, France|Research Site, Paris Cedex 14, France|Research Site, Paris Cedex 20, France|Research Site, Pessac Cedex, France|Research Site, Reims Cedex, France|Research Site, Saint Quentin, France|Research Site, Tours Cedex 9, France|Research Site, Berlin, Germany|Research Site, Grosshansdorf, Germany|Research Site, Köln-Merheim, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Monza (MB), Italy|Research Site, Orbassano (TO), Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Saronno VA, Italy|Research Site, 's Hertogenbosch, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Bristol, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01951586"
225,"NCT01949545","Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment",,"Completed","Has Results","Solid Tumors|Hematologic Malignancies|Hepatic Impairment","Drug: Carfilzomib","Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 27 mg/m²|Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 27 mg/m²|Maximum Plasma Concentration (Cmax) of Carfilzomib 27 mg/m²|Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 27 mg/m²|Clearance of Carfilzomib 27 mg/m²|Terminal Half-life of Carfilzomib 27 mg/m²|Mean Residence Time (MRT) of Carfilzomib 27 mg/m²|Volume of Distribution at Steady State (Vss) of Carfilzomib 27 mg/m²|Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) of Carfilzomib 56 mg/m²|Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carfilzomib 56 mg/m²|Maximum Plasma Concentration (Cmax) of Carfilzomib 56 mg/m²|Time to Maximum Plasma Concentration (Tmax) of Carfilzomib 56 mg/m²|Terminal Half-life of Carfilzomib 56 mg/m²|Clearance of Carfilzomib 56 mg/m²|Mean Residence Time (MRT) of Carfilzomib 56 mg/m²|Volume of Distribution at Steady State (Vss) of Carfilzomib 56 mg/m²|Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-389/M14|Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-389/M14|Maximum Plasma Concentration (Cmax) for Metabolite PR-389/M14|Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-389/M14|Terminal Half-life for Metabolite PR-389/M14|Mean Residence Time (MRT) for Metabolite PR-389/M14|Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-413/M15|Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-413/M15|Maximum Plasma Concentration (Cmax) for Metabolite PR-413/M15|Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-413/M15|Terminal Half-life for Metabolite PR-413/M15|Mean Residence Time (MRT) for Metabolite PR-413/M15|Area Under the Concentration Time Curve From Time Zero to Last Concentration Measured (AUC0-last) for Metabolite PR-519/M16|Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Metabolite PR-519/M16|Maximum Plasma Concentration (Cmax) for Metabolite PR-519/M16|Time to Maximum Plasma Concentration (Tmax) for Metabolite PR-519/M16|Terminal Half-life for Metabolite PR-519/M16|Mean Residence Time (MRT) for Metabolite PR-519/M16|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CFZ002|20130402","October 2013","August 2015","September 2015","September 24, 2013","October 21, 2016","May 2, 2017","Karmanos Cancer Institute, Detroit, Michigan, United States|Duke Cancer Institute, Durham, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Evergreen Hematology and Oncology, Spokane, Washington, United States|Institut Gustave Roussy, Paris, Villejuif Cedex, France|University Medical Centre Utrecht, Utrecht, Netherlands|Northern Ireland Cancer Trials Centre - Queen's University Belfast TriaIs Centre, Belfast, Northern Ireland, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom|Velindre Hospital, Cardlff, Wales, United Kingdom|Sir Bobby Robson Cancer Trials Research Centre, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01949545"
226,"NCT01949532","Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease",,"Completed","Has Results","Relapsed Multiple Myeloma|End-stage Renal Disease","Drug: Carfilzomib","Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2|Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1|Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14|Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14|Maximum Observed Plasma Concentration for Metabolite PR-389/M14|Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14|Terminal Half-life (T½) of Metabolite PR-389/M14|Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15|Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15|Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15|Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15|Terminal Half-life (T½) of Metabolite PR-413/M15|Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16|Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16|Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16|Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16|Terminal Half-life (T½) of Metabolite PR-519/M16|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CFZ001|20130401","January 2014","April 2015","January 2017","September 24, 2013","May 4, 2016","May 2, 2017","Karmanos Cancer Institute, Detroit, Michigan, United States|North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital, Lake Success, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Monash Health, Monash Medical Centre, Clayton, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Malignant Haematology and Stem Cell Transplant Department, Melbourne, Victoria, Australia|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01949532"
227,"NCT01932970","Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Etelcalcetide","Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period|Percent Change From Baseline in Parathyroid Hormone During the Treatment Period|Percentage of Participants With Serum Corrected Calcium < 8.3 mg/dL During the 4-week Treatment Period","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","158","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120359|2013-000964-28|KAI-4169","August 12, 2013","January 14, 2014","February 14, 2017","August 30, 2013","April 4, 2017","October 17, 2018","Research Site, Alhambra, California, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, La Mesa, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Riverside, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, North Haven, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Evergreen Park, Illinois, United States|Research Site, Michigan City, Indiana, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Farmington, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Eatontown, New Jersey, United States|Research Site, College Point, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Arlington, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01932970"
228,"NCT01928368","A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.",,"Completed","No Results Available","Asthma","Drug: AMG 282|Drug: AMG 282 Matching Placebo","Incidence of treatment emergent adverse events|Incidence of abnormal clinically significant vital signs|Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results|Incidence of abnormal clinically significant ECG results|Incidence of anti-AMG 282 antibodies|Determination of various PK parameters including tmax, AUClast and Cmax","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20110235","August 2013","March 2016","March 2016","August 23, 2013",,"December 14, 2016","Research Site, Cypress, California, United States|Research Site, Aventura, Florida, United States|Research Site, Lenexa, Kansas, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01928368"
229,"NCT01927757","Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","ROCkIES","Terminated","Has Results","Moderate to Severe Rheumatoid Arthritis","Biological: Etanercept|Drug: Methotrexate","Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 12|Percentage of Participants With an ACR 20 Response at Week 12 by Anti-adalimumab Antibody Subgroup|Percentage of Participants With an ACR 20 Response at Week 12 by Response Failure Type Subgroup|Percentage of Participants With an ACR 20 Response at Week 24|Percentage of Participants With an ACR 50 Response at Weeks 12 and 24|Percentage of Participants With an ACR 70 Response at Weeks 12 and 24|Change From Baseline in Disease Activity Score 28-C-Reactive Protein (DAS28-CRP)|Percentage of Participants With DAS28-CRP Improvement of ≥ 1.2 Units From Baseline|Percentage of Participants With DAS 28-CRP < 3.2|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)|Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 12|Change From Baseline in 36-item Short Form Health Survey (SF-36) at Week 24|Work Productivity and Activity Impairment (WPAI)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120125","May 6, 2013","June 11, 2015","June 11, 2015","August 23, 2013","July 11, 2016","January 30, 2018","Research Site, Tuscaloosa, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Covina, California, United States|Research Site, Hemet, California, United States|Research Site, Murrieta, California, United States|Research Site, San Diego, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Brandon, Florida, United States|Research Site, Dunedin, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Hixson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Clarksburg, West Virginia, United States|Research Site, Victoria, British Columbia, Canada|Research Site, Quispamsis, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Caguas, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01927757"
230,"NCT01902290","Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility",,"Terminated","No Results Available","Asthma","Biological: Placebo|Biological: 210 mg brodalumab","Asthma Control Questionnaire|asthma exacerbations","Amgen|Kyowa Kirin Co., Ltd.|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120141|2012-003351-11","May 2013","May 2015","May 2015","July 18, 2013",,"April 13, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Encinitas, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, North Hollywood, California, United States|Research Site, Orange, California, United States|Research Site, Palmdale, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Jose, California, United States|Research Site, Santa Monica, California, United States|Research Site, Stockton, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Aventura, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lynn Haven, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Talahassee, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Ocean, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Lake Oswego, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Upland, Pennsylvania, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Bellingham, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, New Lambton, New South Wales, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Sherwood Park, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Le Kremlin Bicetre, France|Research Site, Marseille, France|Research Site, Montpellier cedex 05, France|Research Site, Pessac Cedex, France|Research Site, Saint Herblain, France|Research Site, Strasbourg cedex, France|Research Site, Tours Cedex 9, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Cottbus, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Mainz, Germany|Research Site, Radebeul, Germany|Research Site, Rüdersdorf, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chaidari, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Catania, Italy|Research Site, Ferrara, Italy|Research Site, Genova, Italy|Research Site, Modena, Italy|Research Site, Padova, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Tradate (VA), Italy|Research Site, Bucheon-si, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Gangwon-do, Korea, Republic of|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Remuera, New Zealand|Research Site, Bialystok, Poland|Research Site, Bialystok, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Skierniewice, Poland|Research Site, Tarnow, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, San Juan, Puerto Rico|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01902290"
231,"NCT01901185","Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept",,"Completed","Has Results","Rheumatoid Arthritis|Psoriatic Arthritis","Drug: Etanercept / Autoinjector A","Percentage of Successful Self-injections to Total Non-missed Injections|Percentage of Autoinjector A System Failures|Percentage of Errors in Each Step of the Self-injection Process","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110107","June 11, 2013","December 18, 2013","December 30, 2013","July 17, 2013","November 21, 2014","September 4, 2018","Research Site, Huntsville, Alabama, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Santa Maria, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Paducah, Kentucky, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Orchard Park, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01901185"
232,"NCT01901146","Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer","Lilac","Completed","Has Results","Breast Cancer","Drug: ABP 980|Drug: Trastuzumab|Drug: Paclitaxel|Procedure: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection","Percentage of Participants With a Pathologic Complete Response|Percentage of Participants With a Pathologic Complete Response in Breast Tissue Only|Percentage of Participants With a Pathologic Complete Response in Breast Tissue and Axillary Lymph Nodes and Absence of DCIS","Amgen|Actavis Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","725","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120283|2012-004319-29","April 29, 2013","May 5, 2016","January 27, 2017","July 17, 2013","August 7, 2019","August 7, 2019","Research Site, Brest, Belarus|Research Site, Grodno, Belarus|Research Site, Minsk, Belarus|Research Site, Minsk, Belarus|Research Site, Salvador, Bahia, Brazil|Research Site, Ijuí, RIO Grande DO SUL, Brazil|Research Site, Porto Alegre, RIO Grande DO SUL, Brazil|Research Site, Jaú, SAO Paulo, Brazil|Research Site, Santo André, SAO Paulo, Brazil|Research Site, São Paulo, SAO Paulo, Brazil|Research Site, Sofia, Sofiya, Bulgaria|Research Site, Veliko Tarnovo, Veliko Turnovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Moncton, New Brunswick, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Fürstenwalde, Brandenburg, Germany|Research Site, Frankfurt am Main, Hessen, Germany|Research Site, Frankfurt, Hessen, Germany|Research Site, Bonn, Nordrhein-westfalen, Germany|Research Site, Bottrop, Nordrhein-westfalen, Germany|Research Site, Berlin, Germany|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Thessaloniki, Nea Efkarpia, Greece|Research Site, Debrecen, Hajdu-bihar, Hungary|Research Site, Szolnok, Jasz-nagykun-szolnok, Hungary|Research Site, Nyíregyháza, Szabolcs-szatmar-bereg, Hungary|Research Site, Szekszárd, Tolna, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, San Fermo della Battaglia, Como, Italy|Research Site, Bari, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Piacenza, Italy|Research Site, Varese, Italy|Research Site, Monterrey, Nuevo LEON, Mexico|Research Site, San Luis Potosí, SAN LUIS Potosi, Mexico|Research Site, Queretaro, Mexico|Research Site, Toluca, Estado De Mexico, Mexico|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Warszawa, Lubelskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Rybnik, Slaskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Poznań, Wielkopolskie, Poland|Research Site, Cluj-Napoca, Cluj, Romania|Research Site, Ploiesti, Prahova, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Brasov, Romania|Research Site, Cluj, Romania|Research Site, Obninsk, Kaluzhskaya, Russian Federation|Research Site, Saransk, Mordovia, Russian Federation|Research Site, Moscow Region, Moscow, Russian Federation|Research Site, Arkhangelsk, Primorskiy, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Chelaybinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Sabadell, Barcelona, Spain|Research Site, A Coruña, LA Coruna, Spain|Research Site, Lérida, Lleida, Spain|Research Site, Alcorcón, Madrid, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Kyiv, Kiev, Ukraine|Research Site, Uzhgorod, Transcarpathia, Ukraine|Research Site, Lutsk, Volyn, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Nottingham, England, United Kingdom|Research Site, Peterborough, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01901146"
233,"NCT01896232","Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet",,"Completed","Has Results","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Etelcalcetide|Drug: Cinacalcet|Drug: Oral Placebo|Drug: Intravenous Placebo","Percentage of Participants With > 30% Reduction From Baseline in Mean Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis|Percentage of Participants With > 50% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase|Percentage of Participants With > 30% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase|Mean Number of Days of Vomiting or Nausea Per Week in the First 8 Weeks|Percent Change From Baseline in Mean Corrected Calcium During the Efficacy Assessment Phase|Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase|Mean Severity of Nausea in the First 8 Weeks|Mean Number of Episodes of Vomiting Per Week in the First 8 Weeks","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","683","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120360|2013-000192-33","August 13, 2013","November 12, 2014","January 8, 2015","July 11, 2013","February 8, 2017","July 18, 2019","Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, Covina, California, United States|Research Site, Granada Hills, California, United States|Research Site, La Mesa, California, United States|Research Site, La Puente, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Gabriel, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Aurora, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Orange, Connecticut, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Southgate, Michigan, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Sewell, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Feldkirch, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Roeselare, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Novy Jicin, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Trinec, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aalborg, Denmark|Research Site, Fredericia, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Boulogne sur Mer, France|Research Site, Lille Cedex, France|Research Site, Nouilly, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Saint Ouen, France|Research Site, Saint Priest en Jarez, France|Research Site, Saint-Ouen, France|Research Site, Sainte Foy les Lyon, France|Research Site, Aachen, Germany|Research Site, Coburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Magdeburg, Germany|Research Site, Mettmann, Germany|Research Site, Minden, Germany|Research Site, München, Germany|Research Site, Wiesbaden, Germany|Research Site, Zwickau, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Pecs, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szigetvar, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Cagliari, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Lecco, Italy|Research Site, Lucca, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Pordenone, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kedainiai, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Hamilton, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Takapuna, Auckland City, New Zealand|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Sieradz, Poland|Research Site, Wadowice, Poland|Research Site, Warsawa, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Zyrardow, Poland|Research Site, Almada, Portugal|Research Site, Aveiro, Portugal|Research Site, Estoril, Portugal|Research Site, Forte Da Casa, Portugal|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Santo Tirso, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Franca de Xira, Portugal|Research Site, Mitishi, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Puerto Real, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Torrevieja, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Badajoz, Extremadura, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Aarau, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zurich, Switzerland|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01896232"
234,"NCT01890577","Study of South African Dialysis Patients",,"Terminated","Has Results","Chronic Kidney Disease, Receiving Dialysis","Drug: Aranesp","Haemoglobin Concentration|Hemoglobin Excursions|Hemoglobin Within the Range 10-12 g/dL Over Time|Erythropoiesis Stimulating Agent (ESA) Usage|ESA/Aranesp Dose Ratio|Iron Therapy Use|Use of Concomitant Therapies: Immunosuppressants, Cardiovascular Medications, Secondary Hypoparathyroidism Medications, Anti-retroviral Therapy|C-Reactive Protein, Albumin, Transferrin Saturation and Serum Ferritin Concentration|Number of Red Blood Cell Transfusions|Number of Hospitalisations","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)",,"28","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20110243","April 2013","January 2014","January 2014","July 2, 2013","April 13, 2015","July 12, 2016","Research Site, Glenwood, KwaZulu-Natal, South Africa|Research Site, Umhlanga Rocks, KwaZulu-Natal, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Durban, South Africa|Research Site, Kimberley, South Africa|Research Site, Lenasia, South Africa|Research Site, Roodepoort, South Africa",,"https://ClinicalTrials.gov/show/NCT01890577"
235,"NCT01890109","Study of Erenumab (AMG 334) in Women With Hot Flashes",,"Completed","Has Results","Vasomotor Symptoms; Hot Flashes","Biological: Erenumab|Drug: Placebo","Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes|Ratio of Week 4 to Baseline Daily Hot Flash Severity Score|Number of Participants With Treatment-emergent Adverse Events|Maximum Observed Concentration (Cmax) of Erenumab After a Single Dose|Time to Maximum Observed Concentration (Tmax) of Erunumab After a Single Dose|Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) for Erenumab|Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Erenumab|Terminal Half-life (T1/2) of Erenumab|Number of Participants With Treatment-emergent Suicidal Ideation|Number of Participants Who Developed Anti-erenumab Antibodies After a Single Dose","Amgen","Female","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20120180","May 13, 2013","March 11, 2014","March 11, 2014","July 1, 2013","January 14, 2019","January 14, 2019","Research Site, San Diego, California, United States|Research Site, Miami, Florida, United States|Research Site, Winston-Salem, North Carolina, United States|Eugene Andruczyk, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01890109"
236,"NCT01881789","Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Oprozomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","Maximum Tolerated Dose (MTD)|Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Population Pharmacokinetic (PK) Parameters - Apparent Clearance|Population Pharmacokinetic (PK) Parameters - Volume of Distribution|Duration of Response (DOR)|Progression-Free Survival (PFS)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPZ003","August 2013","September 23, 2019","September 23, 2019","June 20, 2013",,"October 17, 2019","Clearview Cancer Institute, Huntsville, Alabama, United States|Providence St. Joseph's Hospital, Burbank, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Monterey Bay Oncology Corp DBA Pacific Cancer Care, Salinas, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|H. Lee Moffit Cancer Center & Research Institute, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Center for Cancer & Blood Disorders, Bethesda, Maryland, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01881789"
237,"NCT01879319","Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen",,"Completed","Has Results","Primary Hypercholesterolemia|Mixed Dyslipidemia","Biological: Evolocumab AMD|Biological: Evolocumab AI/pen","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120356","July 2013","December 2013","December 2013","June 17, 2013","December 23, 2015","December 23, 2015","Research Site, Phoenix, Arizona, United States|Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lewiston, Maine, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Manlius, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Burnaby, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01879319"
238,"NCT01875991","Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept",,"Completed","Has Results","Rheumatoid Arthritis|Plaque Psoriasis","Drug: Etanercept via Autoinjector A|Drug: Etanercept via Autoinjector B","Percentage of Participants With a Preference for Autoinjector A Versus Autoinjector B|Change From Baseline in Needle Apprehension at Week 4|Ease of Use|Certainty of Completing the Injection With the Autoinjector|Convenience|Discomfort|Satisfaction|Pain Associated With Use of the Autoinjector|Strength of Preference for Autoinjector A and Autoinjector B","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090176","June 5, 2013","March 4, 2014","March 4, 2014","June 12, 2013","May 20, 2015","September 4, 2018","Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, San Diego, California, United States|Research Site, San Ramon, California, United States|Research Site, Santa Maria, California, United States|Research Site, Tustin, California, United States|Research Site, Denver, Colorado, United States|Research Site, Dunedin, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Frederick, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Orchard Park, New York, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Hixson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Clarksburg, West Virginia, United States|Research Site, Victoria, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Peterborough, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01875991"
239,"NCT01869686","Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose",,"Completed","Has Results","Healthy Volunteer","Biological: Denosumab","Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid|Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid|Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid|Maximum Observed Concentration (Cmax) of Denosumab in Serum|Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum|Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum|Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)|Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period|Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).","Amgen","Male","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","20120351","June 2013","September 2013","September 2013","June 5, 2013","September 26, 2014","November 6, 2014","Research Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01869686"
240,"NCT01856881","Multiple Ascending Dose Study in Subjects With Type 2 Diabetes",,"Terminated","No Results Available","Diabetes Mellitus","Drug: AMG 876","Subject incidence of treatment-emergent adverse events|Subject incidence of anti-AMG 876 antibodies|AMG 876 serum PK parameters|Pharmacodynamic parameters","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20100018","March 2013","November 2014","March 2015","May 20, 2013",,"November 6, 2015","Research Site, Chula Vista, California, United States|Research Site, Miramar, Florida, United States|Research Site, Overland Park, Kansas, United States|Research Site, Cincinnati, Ohio, United States|Research Site, San Antonio, Texas, United States|Research Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01856881"
241,"NCT01854918","Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia","OSLER-2","Completed","Has Results","Hyperlipidemia and Mixed Dyslipidemia","Biological: Evolocumab|Drug: Standard of Care","Number of Participants With Adverse Events|Percent Change From Baseline in LDL-C at Weeks 48 and 104|Change From Baseline in LDL-C at Weeks 48 and 104","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","3681","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120138|2012-004357-83","April 23, 2013","May 31, 2018","May 31, 2018","May 16, 2013","June 11, 2019","June 11, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Carmichael, California, United States|Research Site, Encinitas, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Spring Valley, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Sterling, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, Manlius, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Sherwood, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Salzburg, Austria|Research Site, Anthée, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Chênée, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Hasselt, Belgium|Research Site, La Louvière, Belgium|Research Site, Linkebeek, Belgium|Research Site, Oostende, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, München, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Noda-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyusyu-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Tsuchiura-shi, Ibaraki, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Tomigusuku-shi, Okinawa, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Niiza-shi, Saitama, Japan|Research Site, Arakawa-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chofu-shi, Tokyo, Japan|Research Site, Edogawa-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Ålesund, Norway|Research Site, Lodz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Örebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, Reinach, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01854918/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01854918/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01854918"
242,"NCT01849497","Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen",,"Completed","Has Results","Primary Hypercholesterolemia|Mixed Dyslipidemia","Biological: Evolocumab Pre-filled Syringe|Biological: Evolocumab AI/pen","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4|Percent Change From Baseline in LDL-C at Week 6","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120348","April 18, 2013","September 2, 2013",,"May 8, 2013","October 9, 2015","November 29, 2018","Research Site, Encino, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Auburn, Maine, United States|Research Site, Manlius, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cadiz, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01849497"
243,"NCT01833754","Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis",,"Completed","Has Results","Osteoporosis","Drug: Romosozumab","Number of Participants With Adverse Events|Number of Participants Who Developed Anti-Romosozumab Antibodies|Albumin-Adjusted Serum Calcium Concentrations by Visit|Intact Parathyroid Hormone (iPTH)Concentrations by Visit|Maximum Observed Serum Concentration (Cmax) of Romosozumab|Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab|Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)|Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)","Amgen","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110227","April 22, 2013","February 19, 2014","February 19, 2014","April 17, 2013","February 25, 2019","February 25, 2019","Research Site, Tempe, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Denver, Colorado, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Orangeburg, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01833754"
244,"NCT01832727","Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Oprozomib|Drug: Dexamethasone","Determine the MTD (Phase 1b)|Determine the ORR (Phase 2)|PK parameters - maximum plasma concentration (Cmax)|PK parameters - time of maximum plasma concentration (tmax)|PK parameters - plasma concentration-time curve (AUC)|clinical benefit rate (CBR)|duration of response (DOR)|progression-free survival (PFS)|time to progression (TTP)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-001","May 2013","June 25, 2019","June 25, 2019","April 16, 2013",,"November 12, 2019","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Division of Hematology/ Oncology, UNC at Chapel Hill, Chapel Hill, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France|CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France|CHU de NANCY - Hopital de BRABOlS, Vandoeuvre Les Nancy, France",,"https://ClinicalTrials.gov/show/NCT01832727"
245,"NCT01825785","A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)",,"Completed","Has Results","Postmenopausal|Osteopenia","Drug: Romosozumab|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants Who Developed Antibodies to Romosozumab|Time to Maximum Observed Concentration (Tmax) of Romosozumab|Maximum Observed Concentration (Cmax) of Romosozumab|Area Under the Concentration-time Curve for the Dosing Interval (AUC0-tau) for Romosozumab|Half-life Associated With the Terminal Phase of Elimination (T1/2) for Romosozumab|Accumulation Ratio (AR) for Romosozumab|Percent Change From Baseline in Bone Mineral Density of the Total Spine|Percent Change From Baseline in Bone Mineral Density at the Total Hip|Percent Change From Baseline in Bone Mineral Density at the Femoral Hip|Percent Change From Baseline in Bone Mineral Density at the Distal One-third Radius|Percent Change From Baseline in Bone Mineral Density at the Total Wrist|Percent Change From Baseline in Bone Mineral Density of the Whole Body|Percent Change From Baseline in Procollagen Type 1 N-terminal Propeptide (P1NP)|Percent Change From Baseline in Osteocalcin|Percent Change From Baseline in Bone-specific Alkaline Phosphatase (BSAP)|Percent Change From Baseline in Serum C-telopeptide (sCTX)|Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)|Percent Change From Baseline in Sclerostin|Change From Baseline in Ionized Calcium","Amgen",,"Child, Adult, Older Adult","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060221","November 14, 2007","December 2, 2008","December 2, 2008","April 8, 2013","July 5, 2019","July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT01825785"
246,"NCT01824342","Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer",,"Completed","Has Results","Castrate-resistant Prostate Cancer","Biological: Denosumab","Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths|Percent Change From Baseline in Laboratory Values|Number of Participants With Anti-denosumab Neutralizing Antibody Formation|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080585|2010-021846-23","January 2011","February 2014","February 2014","April 4, 2013","March 5, 2015","March 5, 2015","Research Site, Hradec Kralove, Czech Republic|Research Site, Pelhrimov, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Newcastle, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01824342"
247,"NCT01818752","Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","CLARION","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Bortezomib|Drug: Melphalan|Drug: Prednisone","Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate|Complete Response Rate|Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy|European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","955","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-005|2012-005283-97|20130397","July 8, 2013","July 15, 2016","November 4, 2016","March 26, 2013","August 1, 2017","August 26, 2019","California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States|Marin Cancer Care, Greenbrae, California, United States|Sutter Gould Medical Foundation, Modesto, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|UF Health Shands Cancer Hospital, Gainesville, Florida, United States|Evanston KelIogg Cancer Center, Evanston, Illinois, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Maimonides Cancer Center, Brooklyn, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Saint Francis Health System, Greenville, South Carolina, United States|Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Centro de educacion medica c investigacioncs clinicas ""Norberto Quimo' (CEMIC), Buenos Aires, Argentina|Sanatorio Britanico S.A., Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Central Coast Local Health District, North Gosford, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Health - Box Hill Hospital, Box Hill, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Royal North Shore Hospital, Haematology Department, New South Wales, Australia|Medical University of Innsbruck, University Clinic for Internal Medicine V, Innsbruck, Austria|Elisabeth Linz Hospital, Linz, Austria|Vienna Wilhelminen Hospital, Vienna, Austria|ZNA, Stuivenberg, Antwerp, Antwerpen, Belgium|Saint Joseph Clinic Arlon, Department of Hematology, Arlon, Luxembourg, Belgium|CHR de La Citadelle (ENG: Citadelle Regional Hospital Center), Liège, Belgium|CHU Mont-Godinne, Yvoir, Belgium|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Hematology Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Oncology and Hematology Clinic, Plovdiv, Bulgaria|Military Medical Academy - Multiprofile Hospital for Active Treatment, Sofia, Hematology and Oncology Clinic, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Hematology Clinic, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Varna, Bulgaria|CSSS-Champlain-Charles LeMoyne, Greenfield Park, Quebec, Canada|Fujian Medical University Union Hospital, Fuzhou City, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of the Fourth Military Medical University of PLA, Xi'an City, Shanxi, China|The First Affiliated Hospital of College of Medicine, Zhejiang University - Dr. Jie Jin, Hangzhou, Zhejiang, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|307 Hospital of PLA, Beijing, China|Beijing Chao Yang Hospital, Capital Medical University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, China|Institute on Hematology & Blood Diseases Hospital Chinese Academy of Medical Scicnces & Peking Union Medical University, Tianjin, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|University Hospital Brno, Department of Internal Hematology and Oncology, Brno, Czechia|University Hospital Brno, Hospital Pharmacy - Department of Dilution of Cytostasis, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Olomouc, 3rd Clinic of Internal Medicine, Nephrology, Rheumatology and Endocrinology, Olomouc, Czechia|University Hospital Ostrava, Clinic of Hematooncology of UHO and MFUO, Ostrava, Czechia|University Hospital Kralovske Vinohrady - Internal Hematology Clinic, Prague, Czechia|General University Hospital Prague, 1st Department of Medicine - Department of Hematology, Prague, Czechia|CHU de Caen, Côte de Nacre, Caen Cedex 9, France|CHU Estaing, Clermont-Ferrand, France|UHC Dijon, Children's Hospital, Dijon, France|CHRU Hopital Huriez, Departement of Hematology, Lille Cedex, France|CHRU Lille Hôpital Claude Huriez, Lille, France|Paoli Calmettes Institute, Department ofHematology 2, Marseille cedex, France|Nantes University Hospital Center, Nantes Cedex 1, France|Centre Hospitalier Regional Universitaire de Nimes, Groupe Hospitalo-Universitaire Caremeau, Nimes cedex 9, France|Hopital Saini Louis, Service d'immuno-Hematologie, Paris, France|Hopital Saint Antoine, Paris, France|Hospital Necker, Paris, France|South Lyon Hospital Center, Pierre Bénite, cedex, France|Centre Hospitalier Lyon Sud, Service d'hématologie Clinique, Pierre Bénite, Cedex, France|Hopital Pontchaillou, Rennes Cedex 9, France|Hospital Purpan, Toulouse Cedex 9, France|CHU de Tours Hopital Bretonneau, Tours Cedex 1, France|Freiburg University Medical Center, Freiburg, Baden-Wuerttemberg, Germany|Ulm University Hospital, Center for Internal Medicine, Clinic of Internal Medicine III, Ulm, Baden-Wuerttemberg, Germany|Ludwig Maximilians University Hospital - Medical Clinic III, Munich, Bavaria, Germany|University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany|Johannes Gutenberg-University Mainz, Medical Clinic and Policlinic III, Mainz, Rhineland-Palatinate, Germany|Saarland University Hospital, Homburg / Saar, Saarland, Germany|Group Practice for Hematology and Oncology, Dresden, Germany|Stiftungsklinikum Mittelrhein GmbH, Clinic of Internal Medicine, Koblenz, Germany|Evangelismos Hospital, Athens, Attica, Greece|University of Athens, Alexandra Hospital, Athens, Greece|St. Istvan and St. Laszlo Hospital of Budapest, Department of Haematology and Stem-cell Transplant, Budapest, Hungary|National Institute of Oncology, Department of Oncology, Internal Medicine ""A"" and Hematology, Budapest, Hungary|University of Debrecen, Medical and Health Science Center, Institute for Medicine, Chair of Hematology, Debrecen, Hungary|Bekes County Pandy Kalman Hospital 1st Department of Internal Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, 2nd Department of Internal Medicine, Hematology, Kaposvar, Hungary|Bacs-Kiskun County Teaching Hospital, II. Department of Internal Medicine, Kecskemet, Hungary|Medical Center of the University of Pecs, 1st Clinic for Internal Medicine, Pecs, Hungary|Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Department of Hematology, Haifa, Israel|Ein Kerem Hospital, Department of Hematology, Jerusalem, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|UO Clinica Ematologica, IRCCS A.O.U. San Martino, Genova, GE, Italy|A.O.U. San Luigi Gonzaga, Orbassano, TO, Italy|Ospedali Riuniti di Ancona Umberto I, G.M. Lancisi, G. Salesi, Ancona, Italy|Maggiore della Carita Hospital of Novara, Novara, Italy|Local NHS of Piacenza Hospital Guglielmo da Saliceto Department Oncology-Hematology, Unit of Hema, Piacenza, Italy|Ospedale S. Eugenio, Roma, Italy|Policlinico Universitario ""Umberto I"", Rome, Italy|AO Città della Salute e della Scienza di Torino, Division of Hematology, Torino, Italy|Nagoya City University Hospital, Nagoya, Aichi, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Kyushu University Hospital, Fukuoka, Fukuoka-Ken, Japan|National Hospitalization Organization Kyushu Cancer Center, Minami-ku, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Sapporo Medical University Hospital, Sapporo-shi, Hokkaidou, Japan|National Hospital Organization Okayama Medical Center, Okayama-city, Okayama, Japan|Osaka University Hospital, Suita, Osaka, Japan|Japanese Red Cross Medical Center, Tokyo, Shibuya-ku, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto, Tokyo, Japan|National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa-city, Tokyo, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo Leon, Mexico|Fundacion Centro Oncologieo de Integracion Regional - COIR, Mendoza, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico|Consultorio Privado del Dr. Guillermo Jose Ruiz y Arguelles, Puebla, Mexico|Vrije Universiteit Medisch Centrum (VUMC), Department of Hematology, Amsterdam, Netherlands|St. Antonius Ziekenhuis, Department of Hematology, Nieuwegein, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Isala Clinics in Zwolle, Department of Oncology, Zwolle, Netherlands|North Shore Hospital, Auckland, New Zealand|Auckland City Hospital, Auckland, New Zealand|Canterbury Health Laboratories, Christchurch, New Zealand|Wellington Hospital, Wellington, New Zealand|Independent Public Healthcare Facility of the Ministry of Internal Affairs & Warminsko-Mazurskie Oncology Centre in Olsztyn, Olsztyn, OIsztyn, Poland|Independent Public Healthcare Facility Municipal Hospital Group, Department of Hematology, Chorzow, Slaskie, Poland|Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice, Poland|Independent Public Healthcare Facility University Hospital, Krakow, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital, Lodz, Poland|Independent Public Teaching Hospital No.1 in Lublin, Dept. of Hematology-Oncology, Lublin, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Department of Hematology, Torun, Poland|Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland|""Prof. Dr. Ion Chiricuta"" Institut of Oncology, Hematology Department, Cluj-Napoca, Cluj County, Romania|Iasi Regional Institute for Oncology, Medical Hematology Department, Iasi, Iasi County, Romania|Brasov County Emergency Clinical Hospital, Hematology Department, Brasov, Romania|Fundeni Clinical Institute, Hematology Department, Bucharest, Romania|Coltea Clinical Hospital, Hematology Department, Bucharest, Romania|Bucharest Emergency University Hospital, Hematology Department, Bucharest, Romania|Targu-Mures County Emergency Clinical Hospital, Clinic of Hematology and Bone Marrow Transplantation, Targu-Mures, Romania|State Medical Institution: Republican Hospital n a.V.A. Baranov, Department of Hematology, Petrozavodsk, Republic Of Karelia, Russian Federation|Arkhangelsk Regional Clinical Hospital, Department of internal diseases #2, Arkhangelsk, Russian Federation|State Medical Institution: First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia, Izhevsk, Russian Federation|Institution of the Russian Academy of Medical Sciences Russian Oncological Research Center n.a. N.N.Blokhin under the Russian Academy of Medical Sciences, Moscow, Russian Federation|City Clinical Hospital N.A.S.P. Botkin, Department of Bone Marrow Transplantation and Intensive Chemotherapy for Patients with Myeloproliferative Disorders, Moscow, Russian Federation|State Higher Educational Institution St. Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation|The Federal State Budget Institute The Nikiforov Russian Center of Emergency and Radiation Medicine the Ministry of Russian, Saint Petersburg, Russian Federation|Federal State Institution: Russian Research Institute of Hematology and Blood Transfusion under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation|City Clinical Hospital #31, Department of Bone Marrow Transplantation and Intensive Chemotherapy for Patients with Myeloproliferative Disorders, St. Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Singapore Oncology Consultants, Gleneagles Hospital, Singapore, Singapore|OncoCare Cancer Center, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol, Badalona, Barselona, Spain|University Hospital of Navarra, Pamplona, Navarra, Spain|Hospital Clinic i Provincial Barcelona, Barcelona, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Universitario, Salamanca, Salamanca, Spain|Hospital Virgen del Rocio University, Sevilla, Spain|Universitari i Politècnic la Fe de Valencia Consulta Externa de Hematología, Valencia, Spain|Hospital Quiron Zaragoza, Zaragoza, Spain|University Hospital Center Vaudois, Lausanne, Switzerland|County Hospital Saint Gallen, Saint Gallen, Switzerland|Changhua Christian Hospital, Changhua, Taiwan|Kuohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou, Tapei, Taiwan|Ege University Medical Faculty, Izmir, Bornova, Turkey|Ankara University Medical Faculty, Cebeci Research and Application Hospital, Hematology Department, Ankara, Cebeci, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Pendik, Turkey|Cherkasy Regional Oncology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Hematology Centre, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Department of Hematology, Kharkiv, Ukraine|Khmelnytskyi Regional Hospital, Hematology Department, Khmelnytskyi, Ukraine|Kyiv Center for Bone Marrow Transplantation, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|Poltava M.V. Sklifosovskyi Regional Clinical-Hospital, Poltava, Ukraine|A. Novak Zakarpattia Regional Clinical Hospital, Uzhgorod, Ukraine|M.I. Pyrohov Vinnytsya Regional Clinical Hospital, Hematology Department, Vinnitsya, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Hematology Center, Zhytomyr, Ukraine|Kent and Canterbury Hospital, Canterbury, Kent, United Kingdom|Maidstone Hospital, Kent Oncology Centre, Maidstone, Kent, United Kingdom|Northwick Park Hospital, Harrow, Middlesex, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|University College London, Cancer Centre, London, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom|Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom|The Royal Wolverhampton Hospitals NHS Trust, New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01818752"
248,"NCT01813721","Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.",,"Completed","Has Results","Chemotherapy-induced Febrile Neutropenia",,"Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia|Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia (FN)|Percentage of Participants for Whom Age and Chemotherapy Regimen Were Ranked as an Important Risk Factor|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important|Percentage of Investigators Who Ranked Each Factor in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important|Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Clinical Specialty|Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology|Percentage of Investigators Who Ranked Each Factor in the G-CSF PP Decision as Important by Institution Type|Percentage of Participants for Whom Each Factor Was Ranked in the Granulocyte Colony Stimulating Factor (G-CSF) Primary Prophylaxis (PP) Decision as Important|Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Country|Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Clinical Specialty|Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Number of Years in Clinical Practice in Oncology / Hematology|Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Institution Type|Percentage of Participants for Whom Each Factor Was Ranked in the G-CSF PP Decision as Important by Tumor Type|Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Clinical Specialty|Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Number of Years in Clinical Practice in Oncology / Hematology|Percentage of Investigators Who Ranked Each Factor as a Risk Factor for Febrile Neutropenia by Institution Type|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Country|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Clinical Specialty|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Number of Years in Clinical Practice in Oncology / Hematology|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Institution Type|Percentage of Participants for Whom Each FN Risk Factor Was Ranked as Important by Tumor Type|Percentage of Participants With an Investigator-assessed FN Risk at or Above the Investigator Self-reported FN-risk Intervention Threshold Who Were Planned to Receive G-CSF PP","Amgen","All","18 Years and older   (Adult, Older Adult)",,"1007","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20110146","December 2012","December 2013","December 2013","March 19, 2013","December 24, 2014","March 15, 2017","Research Site, Tweed Heads, New South Wales, Australia|Research Site, Bendigo, Victoria, Australia|Research Site, Shepparton, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Eggenburg, Austria|Research Site, Graz, Austria|Research Site, Leoben, Austria|Research Site, Vöcklabruck, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Moncton, New Brunswick, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Alès Cédex, France|Research Site, Arras, France|Research Site, Besançon Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Créteil, France|Research Site, Grenoble Cedex 9, France|Research Site, Marseille, France|Research Site, Montluçon, France|Research Site, Neuilly sur Seine, France|Research Site, Nimes Cedex 2, France|Research Site, Pierre Benite Cedex, France|Research Site, Saint Quentin, France|Research Site, Toulon Cedex, France|Research Site, Villefranche Sur Saone Cedex, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Fulda, Germany|Research Site, Mainz, Germany|Research Site, Neustadt/Sachsen, Germany|Research Site, Rostock, Germany|Research Site, Stralsund, Germany|Research Site, Twistringen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Cork, Ireland|Research Site, Galway, Ireland|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Monza (MB), Italy|Research Site, Pordenone, Italy|Research Site, Reggio Calabria, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Varese, Italy|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Focsani, Romania|Research Site, Iasi, Romania|Research Site, Onesti, Romania|Research Site, Oradea, Romania|Research Site, Pitesti, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Huelva, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, La laguna, Canarias, Spain|Research Site, Avila, Castilla León, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pamplona, Navarra, Spain",,"https://ClinicalTrials.gov/show/NCT01813721"
249,"NCT01813422","GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound","GLAGOV","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Drug: Placebo","Change From Baseline in Percent Atheroma Volume at Week 78|Change From Baseline in Total Atheroma Volume at Week 78|Percentage of Participants With Regression in Percent Atheroma Volume|Percentage of Participants With Regression in Total Atheroma Volume","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","970","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120153|2012-004208-37","April 18, 2013","July 12, 2016","July 29, 2016","March 19, 2013","January 4, 2018","February 20, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Torrance, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Springfield, Oregon, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Cariacica, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Aarhus N, Denmark|Research Site, Odense C, Denmark|Research Site, Besançon Cedex, France|Research Site, Chambray les Tours, France|Research Site, Creteil, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, München, Germany|Research Site, Neuss, Germany|Research Site, Regensburg, Germany|Research Site, Ulm, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Rehovot, Israel|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Puebla, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Tromso, Norway|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Singapore, Singapore|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Pinelands, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden|Research Site, Geneva 14, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01813422"
250,"NCT01796301","An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women","STRUCTURE","Completed","Has Results","Postmenopausal Osteoporosis","Drug: Romozosumab|Drug: Teriparatide","Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)|Percent Change From Baseline in Total Hip BMD at Month 6|Percent Change From Baseline in Total Hip BMD at Month 12|Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6|Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12|Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6|Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12|Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6|Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12|Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6|Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12|Percent Change From Baseline in Femoral Neck BMD at Month 6|Percent Change From Baseline in Femoral Neck BMD at Month 12|Percent Change From Baseline in Lumbar Spine BMD at Month 6|Percent Change From Baseline in Lumbar Spine BMD at Month 12","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","436","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080289|2012-002948-24","January 31, 2013","May 14, 2015","May 14, 2015","February 21, 2013","November 8, 2018","November 8, 2018","Research Site, Gainesville, Georgia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liege 1, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Brno, Czechia|Research Site, Ostrava 1, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 11 - Chodov, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus C, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hillerød, Denmark|Research Site, Hvidovre, Denmark|Research Site, Odense, Denmark|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Granada, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, LHospitalet de Llobregat, Cataluña, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Cardiff, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Sidcup, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01796301"
251,"NCT01791374","Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ",,"Completed","No Results Available","Part 1- Advanced Solid Tumors|Part 2- Advanced or Metastatic Gastric Cancer|Part 2- Advanced or Metastatic GEJ","Drug: Rilotumumab","Part1: Dose-limiting toxicities (DLT) for each dose level of rilotumumab tested|Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested|Part 1: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies.|Part 1: Pharmacokinetics parameters of rilotumumab monotherapy as measured by: Maximum concentration, time to achieve maximum concentration, observed minimum concentration, area under the concentration-time curve, terminal elimination half-life.|Part 1: Evaluate efficacy based on the treatment effects of rilotumumab monotherapy as measured by the following: Objective Response Rate, duration of response, progression-free survival.|Part 2: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies not defined as DLTs.|Part 2: Pharmacokinetics parameters of rilotumumab in combination with cisplatin and capecitabine as measured by: Maximum concentration, observed minimum concentration, area under the concentration-time curve.|Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.","Amgen","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110251","November 2012","August 2013","March 2015","February 15, 2013",,"February 29, 2016","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Kashiwa-shi, Chiba, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT01791374"
252,"NCT01791361","Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe",,"Completed","No Results Available","Metastatic Colorectal Cancer","Other: Other","The prevalence of KRAS testing and impact of the KRAS test results on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix|The proportion of oncologists who agree to participate in the study|The proportion of oncologists that conduct a KRAS testing prior to Vectibix prescription in patients with mCRC treated with Vectibix|The proportion of laboratories that participate in the European Society of Pathology (ESP) Quality Assurance Scheme or are certified by an ESP approved accreditation body|The proportion of laboratories that use a CE-marked or otherwise validated KRAS detection method|To characterize the results of KRAS testing in the three rounds of chart abstraction that will be carried out at 0, 12 and 24 months to indicate if there are any differences in results from each of the three rounds","Amgen","All","18 Years and older   (Adult, Older Adult)",,"439","Industry","Observational","Time Perspective: Retrospective","20101120","September 2012","June 2015","June 2015","February 15, 2013",,"October 26, 2015","Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Haine St. Paul - La Louviere, Belgium|Research Site, Liège, Belgium|Research Site, Merksem, Belgium|Research Site, Brno, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Esbjerg, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, København, Denmark|Research Site, Ajaccio, France|Research Site, Avignon, France|Research Site, Bordeaux Cedex, France|Research Site, Brest, France|Research Site, Clermont Ferrand cedex 1, France|Research Site, Evry cedex, France|Research Site, Grenoble Cedex 9, France|Research Site, La Tronche, France|Research Site, Limoges Cedex 1, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille Cedex 08, France|Research Site, Muret Cedex, France|Research Site, Nancy, France|Research Site, Perpignan, France|Research Site, Périgueux cedex, France|Research Site, Reims, France|Research Site, Saint Grégoire cedex, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Ahaus, Germany|Research Site, Amberg, Germany|Research Site, Arnsberg, Germany|Research Site, Aschersleben, Germany|Research Site, Bonn, Germany|Research Site, Dessau, Germany|Research Site, Duisburg, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Goslar, Germany|Research Site, Halle (Saale), Germany|Research Site, Hamburg, Germany|Research Site, Köln, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leverkusen, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Osnabrück, Germany|Research Site, Pforzheim, Germany|Research Site, Recklinghausen, Germany|Research Site, Regensburg, Germany|Research Site, Saarbrücken, Germany|Research Site, Wilhelmshaven, Germany|Research Site, Foggia, Italy|Research Site, Legnago VR, Italy|Research Site, Napoli, Italy|Research Site, Ravenna, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Vimercate MB, Italy|Research Site, Amstelveen, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Oviedo, Asturias, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Burgos, Castilla León, Spain|Research Site, Granollers, Cataluña, Spain|Research Site, Castellon, Comunidad Valenciana, Spain|Research Site, Ourense, Galicia, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Bilbao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Eskilstuna, Sweden|Research Site, Göteborg, Sweden|Research Site, Karlskrona, Sweden|Research Site, Skövde, Sweden|Research Site, Västerås, Sweden",,"https://ClinicalTrials.gov/show/NCT01791361"
253,"NCT01788046","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Etelcalcetide|Drug: Placebo","Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase|Percentage of Participants With Mean Predialysis Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product (cCa x P) During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","515","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120230|KAI-4169-007|2012-002806-31","March 12, 2013","April 14, 2014","May 9, 2014","February 11, 2013","March 27, 2017","August 20, 2019","Research Site, Mobile, Alabama, United States|Research Site, Azusa, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Norwalk, California, United States|Research Site, Riverside, California, United States|Research Site, Simi Valley, California, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Fort Washington, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbia, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Rutland, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Liege, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, New Westminister, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Caen, France|Research Site, Grenoble, France|Research Site, Marseille cedex 5, France|Research Site, Marseille, France|Research Site, Perpignan Cedex, France|Research Site, Erfurt, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Quartu Sant'Elena CA, Italy|Research Site, Amsterdam, Netherlands|Research Site, Enschede, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01788046"
254,"NCT01786512","COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.","COSMIC-HF","Completed","No Results Available","Modified Release Oral Formulation|Left Ventricular Systolic Dysfunction|Chronic Heart Failure|History of Chronic Heart Failure|Left Ventricular Ejection Fraction|Pharmacokinetics|Echocardiogram","Drug: Omecamtiv Mecarbil|Drug: Placebo","Dose Escalation - Characterize Pharmacokinetics - Cmax|Dose Escalation - Characterize Pharmacokinetics -Cmin|Dose Escalation - Characterize Pharmacokinetics-Tmax|Dose Escalation - Characterize Pharmacokinetics - AUC12h|Dose Expansion - Characterize Pharmacokinetics - Cmax|Dose Expansion - Characterize Pharmacokinetics - Cpredose|Systolic Ejection Time(SET) (msec)|Left Ventricular End-Systolic Diameter (LVESD) (cm)|Left Ventricular End-Diastolic Diameter (LVEDD) (cm)|Heart Rate (beats per minute)|Stroke Volume (ml)|Effect of omecamtiv mecarbil on NT-proBNP (pg/mL)|Dose Escalation - Safety and tolerability of oral omecamtiv mecarbil|Dose Expansion - Safety and tolerability of oral omecamtiv mecarbil","Amgen|Cytokinetics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","544","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110151","February 26, 2013","July 22, 2015","August 19, 2015","February 8, 2013",,"August 16, 2017","Research Site, Mobile, Alabama, United States|Research Site, Costa Mesa, California, United States|Research Site, Fresno, California, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Peekskill, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Ieper, Belgium|Research Site, Liege, Belgium|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Bad Krozingen, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Greifswald, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Brescia, Italy|Research Site, Pavia, Italy|Research Site, Verona, Italy|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Amersfoort, Netherlands|Research Site, Groningen, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Bialystok, Poland|Research Site, Klodzko, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Ruda Slaska, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Dudley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01786512"
255,"NCT01785875","Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Etelcalcetide","Number of Participants With Adverse Events (AEs)|Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4|Number of Participants Who Developed Anti-etelcalcetide Antibodies|Change From Baseline in Blood Pressure|Percentage of Participants With > 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase|Percentage of Participants With > 30% Reduction From Baseline in PTH During the EAP12|Percentage of Participants With PTH ≤ 300 pg/mL During the EAP|Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12|Percent Change From Baseline in Mean PTH During the EAP|Percent Change From Baseline in Mean PTH During the EAP12|Percent Change From Baseline in Mean Corrected Calcium During the EAP|Percent Change From Baseline in Mean Corrected Calcium During the EAP12|Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP|Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12|Percent Change From Baseline in Mean Phosphorus During the EAP|Percent Change From Baseline in Mean Phosphorus During the EAP12","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","891","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120231|KAI-4169-008|2012-002808-41","July 31, 2013","July 1, 2015","July 1, 2015","February 7, 2013","March 27, 2017","April 10, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Chula Vista, California, United States|Research Site, Cudahy, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Northridge, California, United States|Research Site, Norwalk, California, United States|Research Site, Ontario, California, United States|Research Site, Riverside, California, United States|Research Site, San Gabriel, California, United States|Research Site, Simi Valley, California, United States|Research Site, Whittier, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Evanston, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Merrillville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Brookhaven, Mississippi, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Carrboro, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Columbia, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Grand Prairie, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Mansfield, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Alexandria, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Roeselare, Belgium|Research Site, Tournai, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Caen, France|Research Site, La Tronche cedex, France|Research Site, Marseille cedex 5, France|Research Site, Marseille, France|Research Site, Poitiers, France|Research Site, Reims Cedex, France|Research Site, Saint-Ouen, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Nahariya, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Pavia, Italy|Research Site, Verona, Italy|Research Site, Amsterdam, Netherlands|Research Site, Enschede, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zamosc, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cordoba, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01785875"
256,"NCT01785849","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Etelcalcetide|Drug: Placebo","Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase|Percentage of Participants With Mean Predialysis Parathyroid Hormone ≤ 300 pg/mL During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis PTH During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Corrected Calcium During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Corrected Calcium Phosphorus Product During the Efficacy Assessment Phase|Percent Change From Baseline in Predialysis Phosphorus During the Efficacy Assessment Phase","Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120229|KAI-4169-006|2012-002805-23","March 12, 2013","May 22, 2014","June 12, 2014","February 7, 2013","March 27, 2017","August 26, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Pine Bluff, Arkansas, United States|Research Site, Azusa, California, United States|Research Site, Covina, California, United States|Research Site, Lakewood, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Northridge, California, United States|Research Site, Ontario, California, United States|Research Site, Panorama City, California, United States|Research Site, Sacramento, California, United States|Research Site, Whittier, California, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Meridian, Idaho, United States|Research Site, Evanston, Illinois, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Southgate, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Amherst, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, Columbia, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Grand Prairie, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mansfield, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahan, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Baudour, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Brampton, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 4 - Nusle, Czechia|Research Site, Praha 6, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Trinec, Czechia|Research Site, Nantes Cedex 01, France|Research Site, Poitiers, France|Research Site, Reims Cedex, France|Research Site, Saint-Ouen, France|Research Site, Salouel Cedex 1, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Kiel, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Pecs, Hungary|Research Site, Ashkelon, Israel|Research Site, Nahariya, Israel|Research Site, Tel Aviv, Israel|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, San Fermo Della Battaglia (CO), Italy|Research Site, Verona, Italy|Research Site, Bialystok, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01785849"
257,"NCT01764633","Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","FOURIER","Completed","Has Results","Dyslipidemia","Biological: Evolocumab|Drug: Placebo","Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization|Time to Cardiovascular Death, Myocardial Infarction, or Stroke|Time to Cardiovascular Death|Time to All Cause Death|Time to First Myocardial Infarction|Time to First Stroke|Time to First Coronary Revascularization|Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure|Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack","Amgen","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","27564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110118|2014/01/004324|2012-001398-97","February 8, 2013","November 11, 2016","November 11, 2016","January 9, 2013","February 15, 2018","August 21, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Banning, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Harbor City, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Pedro, California, United States|Research Site, Santa Ana, California, United States|Research Site, Tarzana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Valley Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Greeley, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, East Point, Georgia, United States|Research Site, Eatonton, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Addison, Illinois, United States|Research Site, Belleville, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Charlotte Hall, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Billerica, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Newton, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Dearborn, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grandville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Missoula, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Troy, New York, United States|Research Site, West Seneca, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Garfield Heights, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Westlake, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Pryor, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Cranston, Rhode Island, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Fountain Inn, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Moncks Corner, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerrville, Texas, United States|Research Site, Longview, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Murray, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, White River Junction, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Federal Way, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Selah, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Salta, Argentina|Research Site, Salta, Argentina|Research Site, Woden, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Woolloongabba, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Ieper, Belgium|Research Site, La Louviere, Belgium|Research Site, La Louvière, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Natoye, Belgium|Research Site, Turnhout, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Campina Grande do Sul, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Sao Jose do Rio Preto, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Strathroy, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Temuco, Cautín, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Harbin, Heilongjiang, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changde, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Xiangtan, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Hohhot, Inner Mongolia, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Yinchuan, Ningxia, China|Research Site, Qingdao, Shandong, China|Research Site, Taiyuan, Shanxi, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Tianjin, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Cartagena, Bolívar, Colombia|Research Site, Manizales, Caldas, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Armenia, Quindío, Colombia|Research Site, Floridablanca, Santander, Colombia|Research Site, Santiago de Cali, Valle Del Cauca, Colombia|Research Site, Benatky nad Jizerou, Czechia|Research Site, Benesov, Czechia|Research Site, Beroun, Czechia|Research Site, Bilovec, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Cesky Krumlov, Czechia|Research Site, Chomutov, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hranice na Morave, Czechia|Research Site, Jihlava, Czechia|Research Site, Kladno, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Liberec, Czechia|Research Site, Litomerice, Czechia|Research Site, Litomysl, Czechia|Research Site, Milevsko, Czechia|Research Site, Mlada Boleslav, Czechia|Research Site, Mohelnice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Nymburk, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Policka, Czechia|Research Site, Prachatice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Prerov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, København S, Denmark|Research Site, København, Denmark|Research Site, Køge, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Harjumaa, Estonia|Research Site, Paide, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Hämeenlinna, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Oulo, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Besançon Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Chambray les Tours, France|Research Site, Clermont Ferrand, France|Research Site, Créteil, France|Research Site, Dijon cedex, France|Research Site, Le Coudray, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille Cedex 08, France|Research Site, Metz cedex 03, France|Research Site, Montpellier cedex 05, France|Research Site, Montpellier cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nice, France|Research Site, Nimes, France|Research Site, Orleans, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau, France|Research Site, Perpignan Cedex, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Reims cedex, France|Research Site, Rennes, France|Research Site, Saint Priest en Jarez, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Vesoul, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Demmin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Giessen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Ingelheim, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Lahr, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Stuttgart, Germany|Research Site, Ulm, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chalkida, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Nikaia, Piraeus, Greece|Research Site, Piraeus, Greece|Research Site, Rhodes, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Kopavogur, Iceland|Research Site, Reykjavik, Iceland|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Gurgaon, Haryana, India|Research Site, Belgaum, Karnataka, India|Research Site, Mysore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkata, West Bengal, India|Research Site, Ballinasloe, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Herzliya-on-sea, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Nahariya, Israel|Research Site, Netanya, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Ascoli Piceno, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Chieti, Italy|Research Site, Colleferro RM, Italy|Research Site, Cortona AR, Italy|Research Site, Firenze, Italy|Research Site, L' Aquila, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Sanremo (IM), Italy|Research Site, Siena, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Kasugai-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Matsudo-shi, Chiba, Japan|Research Site, Niihama-shi, Ehime, Japan|Research Site, Saijo-shi, Ehime, Japan|Research Site, Chikushi-gun, Fukuoka, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Itoshima-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Okawa-shi, Fukuoka, Japan|Research Site, Koriyama-shi, Fukushima, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Otake-shi, Hiroshima, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Sanuki-shi, Kagawa, Japan|Research Site, Fujisawa-shi, Kanagawa, Japan|Research Site, Odawara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Higashisonogi-gun, Nagasaki, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Omura-shi, Nagasaki, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Okinawa-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research Site, Kusatsu-shi, Shiga, Japan|Research Site, Hamada-shi, Shimane, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Musashimurayama-shi, Tokyo, Japan|Research Site, Tachikawa-shi, Tokyo, Japan|Research Site, Chuo-shi, Yamanashi, Japan|Research Site, Busan, Seo-gu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Daugavpils, Latvia|Research Site, Kuldiga, Latvia|Research Site, Liepaja, Latvia|Research Site, Ogre, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Johor Bahru, Johor, Malaysia|Research Site, Taiping, Perak, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Georgetown, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Melaka, Malaysia|Research Site, Penang, Malaysia|Research Site, Torreon, Coahuila, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Tampico, Tamaulipas, Mexico|Research Site, Xalapa, Veracruz, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Amstelveen, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Gorinchem, Netherlands|Research Site, Gouda, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leiden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Purmerend, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Venlo, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Bekkestua, Norway|Research Site, Bodø, Norway|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ålesund, Norway|Research Site, Davao City, Davao, Philippines|Research Site, Angeles, Philippines|Research Site, Baguio City, Philippines|Research Site, Dasmariñas Cavite, Philippines|Research Site, Iloilo, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Marikiina, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bielsko-Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Jelenia Gora, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Nowa Sol, Poland|Research Site, Nysa, Poland|Research Site, Olsztyn, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Pszczyna, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Starogard Gdanski, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Amadora, Portugal|Research Site, Carnaxide, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Setubal, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pushkin, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Banovce nad Bebravou, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Moldava nad Bodvou, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Port Elizabeth, Eastern Cape, South Africa|Research Site, Bloemfontein, Free State, South Africa|Research Site, Alberton, Gauteng, South Africa|Research Site, Alberton, Gauteng, South Africa|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Pretoria west, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Soweto, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Tongaat, KwaZulu-Natal, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Kempton Park, South Africa|Research Site, Almeria, Andalucía, Spain|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, San Juan de Alicante, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Galdakao, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bollnäs, Sweden|Research Site, Eksjö, Sweden|Research Site, Eskilstuna, Sweden|Research Site, Falun, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Linköping, Sweden|Research Site, Luleå, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Umeå, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Baden, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Sion, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Zurich, Switzerland|Research Site, New Taipei City, Taipei, Taiwan|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Konya, Turkey|Research Site, Sivas, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Addlestone, United Kingdom|Research Site, Arnsley, United Kingdom|Research Site, Basildon, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bury St Edmunds, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Haxey, Doncaster, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Hitchin, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Luton, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesbrough, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Rugby, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, St Austell, United Kingdom|Research Site, St. Leonards-on-Sea, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Welwyn Garden City, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Wiltshire, United Kingdom|Research Site, Wirral, United Kingdom|Research Site, Wolverhampton, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Wrexham, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01764633"
258,"NCT01763918","Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","RUTHERFORD-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Placebo","Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","331","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110117|2012-001365-32","February 7, 2013","November 27, 2013","December 19, 2013","January 9, 2013","December 22, 2015","June 17, 2019","Research Site, Scottsdale, Arizona, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bron, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Köln, Germany|Research Site, New Territories, Hong Kong|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Oslo, Norway|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Reinach, Switzerland|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763918"
259,"NCT01763905","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","GAUSS-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Placebo to Evolocumab|Drug: Ezetimibe|Drug: Placebo to Ezetimibe","Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)|Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12|Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110116|2012-001364-30","January 24, 2013","November 19, 2013","November 19, 2013","January 9, 2013","December 22, 2015","June 14, 2019","Research Site, Carmichael, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Traverse City, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Milton, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, La Louvière, Belgium|Research Site, Newmarket, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Lille Cedex, France|Research Site, Paris Cedex 13, France|Research Site, Vénissieux, France|Research Site, Bad Krozingen, Germany|Research Site, Dresden, Germany|Research Site, Heppenheim, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Lugano, Switzerland|Research Site, Reinach, Switzerland|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Telford, United Kingdom|Research Site, West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763905"
260,"NCT01763866","LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","LAPLACE-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Ezetimibe|Drug: Placebo to Evolocumab|Drug: Placebo to Ezetimibe|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Simvastatin","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein(a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12|Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","2067","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110115|2012-001363-70","January 15, 2013","November 12, 2013","December 4, 2013","January 9, 2013","December 22, 2015","June 14, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Carmichael, California, United States|Research Site, Encino, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Westlake Village, California, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Billings, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Manlius, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cadiz, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Sydney, New South Wales, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg Heights, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Blankenberge, Belgium|Research Site, ChÃªnÃ©e, Belgium|Research Site, Hasselt, Belgium|Research Site, Oostende, Belgium|Research Site, Tremelo, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Saint Johnâ€™s, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Kladno, Czechia|Research Site, Litomerice, Czechia|Research Site, Moravske Budejovice, Czechia|Research Site, Olomouc, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Brest Cedex 2, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Le Creusot, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris cedex 12, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Strasbourg, France|Research Site, Bad Krozingen, Germany|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Messkirch, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Baja, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Komarom, Hungary|Research Site, Marcali, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Bologna, Italy|Research Site, Cagliari, Italy|Research Site, Chieti, Italy|Research Site, Ferrara, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Trieste, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Tampico, Tamaulipas, Mexico|Research Site, Durango, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Alberton, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Lyttelton, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Almeria, AndalucÃ-a, Spain|Research Site, AlmerÃ-a, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Pozuelo De AlarcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, GÃ¶teborg, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Uddevalla, Sweden|Research Site, Ã-rebro, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zurich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Whitby, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01763866"
261,"NCT01763827","Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","MENDEL-2","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Ezetimibe|Biological: Placebo to Evolocumab|Other: Placebo to Ezetimibe","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at the Mean of Weeks 10 and 12|Change From Baseline in LDL-C at Week 12|Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL|Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12|Percent Change From Baseline in Lipoprotein (a) at Week 12|Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12|Percent Change From Baseline in Triglycerides at Week 12|Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in VLDL-C at Week 12|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12|Percent Change From Baseline in HDL-C at Week 12","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","615","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110114","January 21, 2013","October 10, 2013","October 29, 2013","January 9, 2013","December 30, 2015","June 14, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Carmichael, California, United States|Research Site, Encinitas, California, United States|Research Site, San Diego, California, United States|Research Site, Tustin, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Edina, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Sherwood, Queensland, Australia|Research Site, Anthée, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Retie, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Gières, France|Research Site, Grenoble Cedex 9, France|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alberton, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01763827"
262,"NCT01755442","Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects",,"Terminated","No Results Available","Diabetes Mellitus","Other: Placebo|Drug: AMG 151","Mean 24-hour systolic blood pressure|Mean 24-hour diastolic blood pressure|Mean 24-hour heart rate|24-hour concentration time profile of glucose level from continuous glucose monitoring|Fasting plasma glucose and fructosamine|Plasma glucose 2 hours after time 0 of mixed meal tolerance test|4-hour concentration time profile of glucose after the mixed meal tolerance test|Safety end points will include the incidence of treatment emergent adverse events.|Serum AMG 151 concentration|Safety end points will include laboratory safety tests.|Safety end points will include vital signs.|Safety end points will include ECGs.","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120189","November 2012","January 2013","January 2013","December 24, 2012",,"April 22, 2013","Research Site, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01755442"
263,"NCT01752907","Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim","VINE","Completed","Has Results","Breast Cancer","Other: General Education DVD|Other: Bone Pain Education DVD","Maximum Patient-reported Bone Pain in Cycle 1|Maximum Patient-reported Bone Pain by Cycle and Across All Cycles|Mean Patient-reported Bone Pain by Cycle and Across All Cycles|Patient-reported Bone Pain Area Under the Curve (AUC) by Cycle and Across All Cycles|Percentage of Participants With Any Grade Bone Pain as Captured in Standard Adverse Event Reporting|Percentage of Participants With Grade 3 or 4 Bone Pain Captured in Standard Adverse Event Reporting|Percentage of Participants Who Used Analgesics for the Treatment of Bone Pain by Cycle and Across Cycles","Amgen","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","20110148","January 2013","December 2014","December 2014","December 19, 2012","January 11, 2016","January 11, 2016","Research Site, Fountain Valley, California, United States|Research Site, Mission Hills, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Vallejo, California, United States|Research Site, Whittier, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Greenwich, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Naperville, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Cedar Rapids, Iowa, United States|Research Site, Mason City, Iowa, United States|Research Site, Mt Sterling, Kentucky, United States|Research Site, Lewiston, Maine, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fairhaven, Massachusetts, United States|Research Site, Lansing, Michigan, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, St. Louis Park, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Englewood, New Jersey, United States|Research Site, Hamilton, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Vineland, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Cooperstown, New York, United States|Research Site, Glens Falls, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Suffern, New York, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Massillon, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Bend, Oregon, United States|Research Site, Gettysburg, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, El Paso, Texas, United States|Research Site, Danville, Virginia, United States|Research Site, Burien, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01752907"
264,"NCT01740297","Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma",,"Active, not recruiting","Has Results","Melanoma","Drug: Talimogene laherparepvec|Drug: Ipilimumab","Phase 1b: Number of Participants With Dose-limiting Toxicities|Phase 2: Objective Response Rate|Phase 1b: Objective Response Rate|Phase 2: Best Overall Response|Phase 2: Disease Control Rate|Phase 2: Durable Response Rate|Phase 2: Time to Response|Phase 2: Duration of Response|Phase 2: Progression-free Survival|Phase 2: Resection Rate|Phase 2: Overall Survival|Phase 2: Kaplan-Meier Estimate of Percentage of Participants Alive at Month 12 and 24|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110264|2012-000307-32","February 7, 2013","August 23, 2016","February 25, 2021","December 4, 2012","October 9, 2017","November 6, 2019","Research Site, Tucson, Arizona, United States|Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Morristown, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Charleston, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bordeaux, France|Research Site, Grenoble Cedex 9, France|Research Site, Lille, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Göttingen, Germany|Research Site, Kiel, Germany|Research Site, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT01740297"
265,"NCT01737879","Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis",,"Terminated","Has Results","Anemia","Drug: Peginesatide|Drug: Epoetin alfa","Mean Hemoglobin Concentration During the Evaluation Period|Mean Dose of Epoetin Alfa During the Evaluation Period|Hemoglobin Concentration by Visit|Peginesatide Dose by Visit","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110209","October 2012","March 2013","July 2013","November 30, 2012","April 21, 2014","April 21, 2014","Research Site, Phoenix, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Granada Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Paramount, California, United States|Research Site, Riverside, California, United States|Research Site, Whittier, California, United States|Research Site, Orange, Connecticut, United States|Research Site, Meridian, Idaho, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bayonne, New Jersey, United States|Research Site, Amherst, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Dyersburg, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Chesapeake, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01737879"
266,"NCT01737866","Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency",,"Completed","No Results Available","Heart Failure","Drug: AMG 423","AMG 423 Pharmacokinetic Parameters|Other Total AMG 423 PK Parameters|AMG 423 Dialysis Clearance|AMG 423 Metabolites|Safety","Amgen|Cytokinetics","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080676","November 2012","January 2013","May 2013","November 30, 2012",,"August 13, 2013","Research Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01737866"
267,"NCT01732783","Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients",,"Completed","Has Results","Wild-type RAS Metastatic Colorectal Cancer","Other: Panitumumab + Chemotherapy","Total Number of Panitumumab Infusions|Cumulative Dose of Panitumumab|Maximum Dose of Panitumumab|Duration of Panitumumab Exposure|Mean Interval Between Panitumumab Infusions|Percentage of Participants With at Least One Panitumumab Dose Reduction|Percentage of Participants With at Least One Panitumumab Dose Delay|Reasons for Discontinuation of Panitumumab|Duration of Exposure of All Concomitant Chemotherapy|Percentage of Participants With at Least One Concomitant Chemotherapy Dose Reduction|Percentage of Participants With at Least One Concomitant Chemotherapy Dose Delay|Number of Participants With at Least One Hospitalization|Types of Hospital Visit|Duration of Hospital Stay|Reasons for Hospitalization|Percentage of Participants With an Overall Response|Number of Participants With Resectability|Number of Participants With Anti-cancer Treatment After Panitumumab Discontinuation|Type of Post-Panitumumab Anti-cancer Treatment","Amgen","All","18 Years and older   (Adult, Older Adult)",,"213","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120100","December 10, 2012","November 30, 2016","November 30, 2016","November 26, 2012","August 20, 2018","October 18, 2018",,,"https://ClinicalTrials.gov/show/NCT01732783"
268,"NCT01732770","Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Post Menopausal Osteoporosis","Biological: Denosumab|Drug: Zoledronic Acid|Drug: Placebo to Denosumab|Drug: Placebo to Zoledronic Acid","Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority Analysis|Percent Change From Baseline in Total Hip BMD at Month 12 - Non-inferiority Analysis|Percent Change From Baseline in Lumbar Spine BMD at Month 12 - Superiority Analysis|Percent Change From Baseline in Total Hip BMD at Month 12 - Superiority Analysis","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 4","643","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20110153|2012-001821-28","November 7, 2012","January 7, 2015","January 7, 2015","November 26, 2012","January 25, 2016","June 7, 2018","Research Site, Santa Monica, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, West Haverstraw, New York, United States|Research Site, Houston, Texas, United States|Research Site, Maroubra, New South Wales, Australia|Research Site, Penrith, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Merksem, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Bialystok, Poland|Research Site, Kraków, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Granada, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01732770"
269,"NCT01723514","Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients",,"Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants With Suicidal Ideation and Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)|Number of Participants Who Developed Anti-erenumab Antibodies|Maximum Observed Serum Concentration (Cmax) of Erenumab|Time to Maximum Observed Concentration (Tmax) of Erenumab|Area Under the Serum Concentration-Time Curve From 0 to 28 Days (AUC0-28day)|Area Under the Serum Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)|Ratio of Post-capsaicin Dermal Blood Flow to Pre-capsaicin Dermal Blood Flow","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20101268|2012-003594-26","November 14, 2012","July 10, 2014","July 10, 2014","November 8, 2012","January 18, 2019","January 18, 2019","Research Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01723514"
270,"NCT01723020","A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Glioblastoma|Multiple Myeloma","Drug: AMG 232","Safety|Objective Tumor Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","107","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20120106","December 27, 2012","March 15, 2017","September 25, 2017","November 7, 2012",,"December 15, 2017","Research Site, Santa Monica, California, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Greenville Hospital System, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Lyon CEDEX 08, France|Research Site, Villejuif, France|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT01723020"
271,"NCT01717989","Study to Evaluate the Prospective Payment System","STEPPS™","Completed","Has Results","Chronic Kidney Disease",,"Percentage of Participants Per Facility With Hemoglobin < 10 g/dL|Percentage of Participants Per Facility With Hemoglobin > 12 g/dL|Percentage of Participants Per Facility With Urea Reduction Ratio (URR) ≥ 65%|Percentage of Participants Treated by Each Dialysis Modality|Percentage of Participants in Each Vascular Access Type Category|Percentage of Participants Per Facility Receiving Erythropoietin Stimulation Agents (ESA)|Percentage of Participants Receiving Cinacalcet|Percentage of Participants Receiving Phosphate Binding Agents|Percentage of Participants Receiving a Vitamin D Sterol|Mean Hemoglobin Concentration by Quarter|Distribution of Facilities With Percentage of Participants With Hemoglobin < 10 g/dL Over Time|Percentage of Participants Per Facility With Transferrin Saturation < 20% and Ferritin Level < 100 ng/mL|Cumulative Monthly Dose of Epoetin Alfa Administered|Number of Participants Taking Epoetin Alfa by Month|Number of Participants With Transfusions, Hospitalizations, Mortality, and Transfers Out","Amgen","All","Child, Adult, Older Adult",,"2248","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20080234","June 2010","September 2012","September 2012","October 31, 2012","January 14, 2014","January 14, 2014","Research Site, Gulf Shores, Alabama, United States|Research Site, Siloam Springs, Arkansas, United States|Research Site, Springdale, Arkansas, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Covina, California, United States|Research Site, Glendale, California, United States|Research Site, Hacienda Heights, California, United States|Research Site, Inglewood, California, United States|Research Site, Lancaster, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, San Dimas, California, United States|Research Site, West Covina, California, United States|Research Site, Whittier, California, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Blairsville, Georgia, United States|Research Site, East Point, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Quincy, Illinois, United States|Research Site, Columbia, Mississippi, United States|Research Site, Pachuta, Mississippi, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Livingston, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Maspeth, New York, United States|Research Site, New York, New York, United States|Research Site, King, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Yadkinville, North Carolina, United States|Research Site, Arlington, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, South Charleston, West Virginia, United States|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01717989"
272,"NCT01712009","NOLAN: Naproxen or Loratadine and Neulasta","NOLAN","Completed","Has Results","Bone Pain in Stage I - III Breast Cancer","Drug: Naproxen|Drug: Loratadine|Biological: Pegfilgrastim|Drug: Chemotherapy","Percentage of Participants With Bone Pain (All Grades) in Cycle 1|Percentage of Participants With Bone Pain (All Grades) by Cycle (2-4) and Across Cycles|Percentage of Participants With Severe Bone Pain by Cycle and Across Cycles|Mean Patient-reported Bone Pain by Cycle and Across Cycles|Maximum Patient-reported Bone Pain by Cycle and Across Cycles|Area Under the Curve (AUC) for Patient-reported Bone Pain|Number of Participants With Adverse Events (AEs)","Amgen","Female","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110147","November 1, 2012","March 18, 2015","March 18, 2015","October 23, 2012","March 9, 2016","January 30, 2018","Research Site, Muscle Shoals, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Fullerton, California, United States|Research Site, Santa Maria, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Torrance, California, United States|Research Site, Whittier, California, United States|Research Site, Denver, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Thomasville, Georgia, United States|Research Site, Elmhurst, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Mount Vernon, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, South Bend, Indiana, United States|Research Site, Sioux City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Cumberland, Maryland, United States|Research Site, Randallstown, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Lowell, Massachusetts, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Joseph, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Denville, New Jersey, United States|Research Site, East Syracuse, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Massillon, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Bend, Oregon, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Watertown, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Janesville, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Racine, Wisconsin, United States|Research Site, Wauwatosa, Wisconsin, United States|Research Site, Weston, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01712009"
273,"NCT01697072","First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","RILOMET-1","Terminated","No Results Available","Gastric Cancer","Drug: Rilotumumab|Other: Placebo|Drug: Epirubicin|Drug: Cisplatin|Drug: Capecitabine","Overall Survival|PFS|TTP|ORR|DCR|TTR|Safety|Immunogenicity","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20070622|2011-004923-11","October 2012","November 2014","August 2015","October 2, 2012",,"February 9, 2016","Research Site, Tucson, Arizona, United States|Research Site, Aurora, Colorado, United States|Research Site, Pueblo, Colorado, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Henderson, Nevada, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Randwick, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Douglas, Queensland, Australia|Research Site, Elizabeth Vale, South Australia, Australia|Research Site, Kurralta Park, South Australia, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Liege, Belgium|Research Site, Roeselare, Belgium|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Pelotas, Rio Grande do Sul, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Horovice, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Copenhagen, Denmark|Research Site, Odense, Denmark|Research Site, Århus C, Denmark|Research Site, Bayonne, France|Research Site, Bordeaux, France|Research Site, Clermont Ferrand Cedex 1, France|Research Site, Dijon cedex, France|Research Site, Le Mans, France|Research Site, Limoges Cedex, France|Research Site, Lyon Cedex 03, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille cedex 5, France|Research Site, Montpellier Cedex 5, France|Research Site, Nice cedex 2, France|Research Site, Périgueux cedex, France|Research Site, Saint Priest en Jarez Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Strasbourg, France|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Schweinfurt, Germany|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Szolnok, Hungary|Research Site, Aviano PN, Italy|Research Site, Brescia, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Toluca, Mexico|Research Site, Bialystok, Poland|Research Site, Elblag, Poland|Research Site, Gdansk, Poland|Research Site, Konin, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Aveiro, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Vila Real, Portugal|Research Site, Alba Iulia, Romania|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Lasi, Romania|Research Site, Timisoara, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Poprad, Slovakia|Research Site, Trencin, Slovakia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kraaifontein, South Africa|Research Site, Pretoria, South Africa|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Terrassa, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Eskilstuna, Sweden|Research Site, Stockholm, Sweden|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Ankara, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mariupol, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Belfast, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Salisbury, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01697072"
274,"NCT01696396","Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease",,"Completed","Has Results","Crohn's Disease","Drug: Abrilumab|Drug: Placebo","Percentage of Participants With Remission at Week 8|Percentage of Participants With Remission at Week 12|Percentage of Participants With Response at Week 12|Percentage of Participants With Response at Week 8|Percentage of Participants With Sustained Remission at Both Week 12 and Week 24|Percentage of Participants With Sustained Remission at Both Week 8 and Week 24|Change From Baseline in CDAI Score at Week 12|Change From Baseline in CDAI Score at Week 8","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110232|2012-000529-31","December 4, 2012","December 26, 2014","April 10, 2018","October 1, 2012","June 27, 2019","June 27, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Dothan, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Goodyear, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Chesterfield, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Mexico, Missouri, United States|Research Site, Great Neck, New York, United States|Hospital, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Mentor, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Germantown, Tennessee, United States|Research Site, Seattle, Washington, United States|Research Site, Innsbruck, Austria|Research Site, St Veit an der Glan, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, London, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 7, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Aalborg, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, Køge, Denmark|Research Site, Odense C, Denmark|Research Site, Århus C, Denmark|Research Site, Amiens Cedex 1, France|Research Site, Caen Cedex 9, France|Research Site, Clichy, France|Research Site, Lille, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 10, France|Research Site, Paris cedex 12, France|Research Site, Pessac Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Minden, Germany|Research Site, Stuttgart, Germany|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Szekszard, Hungary|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Leiden, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Zurich, Switzerland|Research Site, Birmingham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01696396"
275,"NCT01695876","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects",,"Completed","No Results Available","Inflammatory Disease","Drug: AMG 357|Drug: Placebo","Safety and Tolerability|Pharmacodynamics|Effect of Food on AMG 357","Amgen","All","25 Years to 55 Years   (Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110246|Inflammation","October 2012","September 2014","October 2014","September 28, 2012",,"March 4, 2015","Research Site, Christchurch, New Zealand|Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT01695876"
276,"NCT01694485","Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis",,"Completed","Has Results","Ulcerative Colitis","Biological: Abrilumab|Drug: Placebo","Percentage of Participants With Remission at Week 8|Percentage of Participants With Response at Week 8|Percentage of Participants With Mucosal Healing at Week 8|Percentage of Participants With Sustained Remission at Week 8 and Week 24","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","359","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110166|2011-005251-13","November 16, 2012","July 13, 2015","April 10, 2018","September 27, 2012","June 27, 2019","June 27, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Dothan, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Torrance, California, United States|Research Site, Lone Tree, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Hammond, Louisiana, United States|Research Site, Chesterfield, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Great Neck, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Mentor, Ohio, United States|Research Site, Germantown, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Bankstown, New South Wales, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Innsbruck, Austria|Research Site, St Veit an der Glan, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Hradec Kralove, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 7, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Aalborg, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, Køge, Denmark|Research Site, Odense C, Denmark|Research Site, Århus C, Denmark|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Amiens, France|Research Site, Caen, France|Research Site, Lille, France|Research Site, Nice Cedex 3, France|Research Site, Paris cedex 12, France|Research Site, Pessac Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Halle (Saale), Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Athens, Greece|Research Site, Haidari, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Piraeus, Greece|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Leiden, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Oslo, Norway|Research Site, Tromsø, Norway|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Samara, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petrsburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Zurich, Switzerland|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Derby, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01694485"
277,"NCT01688739","Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients",,"Completed","Has Results","Migraine","Drug: Erenumab|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants Who Developed Anti-erenumab Antibodies|Maximum Observed Concentration (Cmax) of Erenumab|Time to Maximum Observed Concentration (Tmax) of Erenumab|Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Erenumab|Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Erenumab|Ratio of Post-capsaicin Dermal Blood Flow to Pre-capsaicin Dermal Blood Flow","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20101267|2011-005600-15","March 13, 2012","March 27, 2013","March 27, 2013","September 20, 2012","January 18, 2019","January 18, 2019","Research Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01688739"
278,"NCT01683695","Safety Study of AMG 557 in Subjects With Lupus Arthritis",,"Completed","No Results Available","Lupus Arthritis, Systemic Lupus Erythematosus","Drug: AMG 557|Drug: Matching Placebo","Treatment-emergent adverse events, vital signs, physical examinations, clinical laboratory tests, ECGs, and the incidence of binding and neutralizing antibodies to AMG 557.|Lupus Arthritis Response Rate|Proportion of subjects achieving a) one letter improvement; and b) 'C' or better score in the Musculoskeletal system from BILAG index at Day 169 compared to baseline, by treatment group.|Percentage change in the tender and swollen joint counts at Day 169 relative to baseline.|Proportion of subjects achieving reduction in and maintenance ≤ 7.5 mg/day of prednisone (or equivalent) from Day 85- Day 169 and discontinuation of immunosuppressants by Day 29 in subjects treated with immunosuppressants at baseline.|Proportion of subjects achieving reduction in and maintenance of prednisone (or its|Physician Global Assessment of Disease Activity (PGADA).|Subject Global Assessment of Disease Activity (SGADA).|Serum PK profile of AMG 557 after multiple dose administrations.|Proportion of subjects who discontinued immunosuppressants by Day 29 in subjects|Cumulative dose of prednisone (or its equivalent) from Day 85 to Day 169.","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101103","June 2012","March 2016","March 2016","September 12, 2012",,"January 24, 2017","Research Site, Los Angeles, California, United States|Research Site, San Leandro, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Manhasset, New York, United States|Research Site, St Leonards, New South Wales, Australia|Research Site, Odense, Denmark|Research Site, Lille cedex 01, France|Research Site, Berlin, Germany|Research Site, Kuching, Sarawak, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01683695"
279,"NCT01677858","A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma","CHAMPION 1","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone","Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)|Overall Response Rate (ORR)|Clinical Benefit Response Rate|Progression-free Survival|Time To Progression|Duration of Response|Number of Participants With Adverse Events|Time to Maximum Plasma Concentration of Carfilzomib|Maximum Plasma Concentration of Carfilzomib|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib|Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib|Volume of Distribution Observed at Steady State (Vss) for Carfilzomib|Terminal Half-life (T1/2,z) for Carfilzomib|Clearance of Carfilzomib After IV Infusion|Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","116","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-002|20130403","July 4, 2012","July 22, 2016","October 31, 2018","September 3, 2012","August 9, 2017","December 19, 2018","Arizona Oncology Associates, Tucson, Arizona, United States|Comprehensive Blood and Cancer Center (CCBC), Bakersfield, California, United States|California Cancer Associates for Research and Excellence, Encinitas, California, United States|Robert A. Moss, M.D., FACP, Inc., Fountain Valley, California, United States|California Cancer Associates for Research and Excellence, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Monterey Bay Oncology, Salinas, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|The Oncology Insititute of Hope and Innovation, Whittier, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists - South, Fort Myers, Florida, United States|Florida Cancer Specialists - North, Tampa, Florida, United States|Illinois Cancer Care, Galesburg, Illinois, United States|Illinois Cancer Specialists, Hinsdale, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Fort Wayne Oncology & Hematology, Fort Wayne, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Clinical Research Alliance, New York, New York, United States|Hudson Valley Hematology Oncology Associates, Poughkeepsie, New York, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|St. Joseph Regional Cancer Center, Bryan, Texas, United States|Millennium Oncology, Houston, Texas, United States|Waldron Medical Research and Development Center, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Center at Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Blood and Cancer Center of East Texas, Tyler, Texas, United States|Shenandoah Oncology, PC, Winchester, Virginia, United States|Northwest Cancer Specialists, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01677858"
280,"NCT01668589","Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis",,"Percentage of Participants Persistent With Denosumab Injections at 12 Months and 24 Months|Percentage of Participants Adherent to Denosumab Injection at 12 Months and 24 Months|Medication Coverage Ratio (MCR) for Denosumab Injection at 12 Months and 24 Months|Time to Non-persistence With Denosumab Injection|Percentage of Participants Who Received Denosumab Injections Within the Specified Window|Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at 24 Months|Percent Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 24 Months|Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 24 Months","Amgen","Female","Child, Adult, Older Adult",,"1501","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20110126","November 28, 2011","August 31, 2015","August 31, 2015","August 20, 2012","September 20, 2016","January 30, 2018","Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Klagenfurt, Austria|Research Site, Landeck, Austria|Research Site, Leibnitz, Austria|Research Site, Lieboch, Austria|Research Site, Salzburg, Austria|Research Site, Sankt Stefan, Austria|Research Site, Voecklabruck, Austria|Research Site, Voitsberg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Aarschot, Belgium|Research Site, Alsemberg, Belgium|Research Site, Baisy-Thy, Belgium|Research Site, Blankenberge, Belgium|Research Site, Bornem, Belgium|Research Site, Brain-Le-Comte, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, ChÃªnÃ©e, Belgium|Research Site, Dour, Belgium|Research Site, Eisden Maasmechelen, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Gribomont, Belgium|Research Site, Grimbergen, Belgium|Research Site, Haine Saint Paul, Belgium|Research Site, Halen, Belgium|Research Site, Ham-Sur-Heure, Belgium|Research Site, Ham, Belgium|Research Site, Harelbeke, Belgium|Research Site, Hasselt, Belgium|Research Site, Heusden, Belgium|Research Site, Heusy, Belgium|Research Site, Hoeilaart, Belgium|Research Site, Knokke-Heist, Belgium|Research Site, Kortrijk, Belgium|Research Site, Kraainem, Belgium|Research Site, Landen, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Lummen, Belgium|Research Site, Marchovelette, Belgium|Research Site, Mont-Godinne, Belgium|Research Site, Mont-sur-Marchienne, Belgium|Research Site, Mouscron, Belgium|Research Site, Natoye, Belgium|Research Site, Paal-Beringen, Belgium|Research Site, Retie, Belgium|Research Site, Seraing, Belgium|Research Site, Steenokkerzeel, Belgium|Research Site, Stoumont, Belgium|Research Site, Thuilles, Belgium|Research Site, Tongeren, Belgium|Research Site, Vilvoorde, Belgium|Research Site, Vlijtingen-Riemst, Belgium|Research Site, Wetteren, Belgium|Research Site, Aachen, Germany|Research Site, Augsburg, Germany|Research Site, Bad Kreuznach, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Bammental, Germany|Research Site, Bautzen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Cottbus, Germany|Research Site, Dresden, Germany|Research Site, DÃ¼sseldorf, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Friedrichroda, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hattingen, Germany|Research Site, Heidelberg, Germany|Research Site, Heinsberg, Germany|Research Site, Herne, Germany|Research Site, Hettstedt, Germany|Research Site, Hildesheim, Germany|Research Site, Immenstadt, Germany|Research Site, Lahnstein, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Leverkusen, Germany|Research Site, Marburg, Germany|Research Site, MÃ¶nchengladbach-Rheydt, Germany|Research Site, MÃ¼llheim, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nster, Germany|Research Site, Neustadt, Germany|Research Site, Nienburg, Germany|Research Site, NÃ¼rnbrecht, Germany|Research Site, OsnabrÃ¼ck, Germany|Research Site, Potsdam, Germany|Research Site, SaarbrÃ¼cken, Germany|Research Site, Stockach, Germany|Research Site, Ulm, Germany|Research Site, VÃ¶lklingen, Germany|Research Site, Wadgassen, Germany|Research Site, Wittstock, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Zerbst, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chaidari, Athens, Greece|Research Site, Chania, Crete, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Heraklion, Greece|Research Site, Levadia, Greece|Research Site, Maroussi, Athens, Greece|Research Site, Patra, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01668589"
281,"NCT01666977","Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: AMG 386|Drug: AMG 386 Placebo|Drug: Pemetrexed|Drug: Carboplatin","Progression Free Survival","Amgen","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101128|2011-001111-31","August 2012","November 2015","November 2015","August 17, 2012",,"June 3, 2016","Research Site, Fayetteville, Arkansas, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Pleasant Hill, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Peoria, Illinois, United States|Research Site, Paducah, Kentucky, United States|Research Site, Hannover, New Hampshire, United States|Research Site, Bronx, New York, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Greenville, South Carolina, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Bruxelles, Belgium|Research Site, Hamilton, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Málaga, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01666977"
282,"NCT01666106","Osteonecrosis of the Jaw (ONJ) Case Registry",,"Active, not recruiting","No Results Available","Osteonecrosis of the Jaw",,"Resolution rate and time to ONJ resolution|The clinical features of ONJ, including severity and staging at enrollment|The frequency of risk factors for incident ONJ|Therapeutic treatment patterns for ONJ|Treatment patterns of antiresorptive agents subsequent to incident ONJ","Amgen","All","18 Years and older   (Adult, Older Adult)",,"327","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20101102","October 1, 2012","April 9, 2021","April 9, 2021","August 16, 2012",,"October 31, 2019","Research Site, Beverly Hills, California, United States|Research Site, Duarte, California, United States|Research Site, Denver, Colorado, United States|Research Site, Farmington, Connecticut, United States|Research Site, Stratford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Baltimore, Maryland, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Mineola, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Québec, Quebec, Canada|Research Site, Aarhus C, Denmark|Research Site, Kobenhavn O, Denmark|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Bordeaux, France|Research Site, Brest Cedex 2, France|Research Site, Lyon, France|Research Site, Paris Cedex 13, France|Research Site, Saint Herblain, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Düsseldorf, Germany|Research Site, Köln, Germany|Research Site, Mühlhausen, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Alessandria, Italy|Research Site, Brescia, Italy|Research Site, Lecce, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Sevilla, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Cardiff, United Kingdom|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01666106"
283,"NCT01652872","Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","START-CKD","Completed","Has Results","Anemia in Chronic Kidney Disease Patients Not on Dialysis","Biological: Darbepoetin alfa|Other: Placebo","Percentage of Participants in Receipt of 1 or More RBC Transfusions|Mean Number of Units of RBC Transfused|Time to First RBC Transfusion|Mean Achieved Hb Concentration While Receiving Investigational Product|Geometric Mean Cumulative Dose of Darbepoetin Alfa Per 4 Weeks","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","756","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110226","July 30, 2012","October 19, 2017","October 19, 2017","July 30, 2012","November 8, 2018","December 12, 2018","Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Goodyear, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Azusa, California, United States|Research Site, Bakersfield, California, United States|Research Site, Bakersfield, California, United States|Research Site, Bell Gardens, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Cerritos, California, United States|Research Site, Chula Vista, California, United States|Research Site, Cudahy, California, United States|Research Site, El Centro, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fullerton, California, United States|Research Site, Garden Grove, California, United States|Research Site, Glendale, California, United States|Research Site, Granada Hills, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Lakewood, California, United States|Research Site, Lancaster, California, United States|Research Site, Lomita, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Mission Hills, California, United States|Research Site, Modesto, California, United States|Research Site, Northridge, California, United States|Research Site, Northridge, California, United States|Research Site, Orange, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Dimas, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, Yuba City, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Westminster, Colorado, United States|Research Site, Middlebury, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, North Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hudson, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Summerfield, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Canton, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Newnan, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Columbus, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Natchitoches, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Ruston, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Rockport, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Framingham, Massachusetts, United States|Research Site, Plymouth, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Southgate, Michigan, United States|Research Site, Columbus, Mississippi, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Peters, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, North Platte, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Livingston, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Flushing, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Poland, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Willoughby Hills, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Roseburg, Oregon, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Columbia, Tennessee, United States|Research Site, Dyersburg, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Corsicana, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Frisco, Texas, United States|Research Site, Greenville, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Lufkin, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Hampton, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Mechanicsville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Silverdale, Washington, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Caguas, Puerto Rico|Research Site, Ponce, Puerto Rico|Research Site, Ponce, Puerto Rico|Research Site, Rio Piedras, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT01652872/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT01652872/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01652872"
284,"NCT01652833","European Physician Survey of EGFR Inhibitor Prescribing Patterns",,"Completed","No Results Available","Metastatic Colorectal Cancer","Other: Physician Survey","Proportion of oncologists who are aware of the correct indication of Vectibix, with regard to tumor KRAS status and who conduct a KRAS test prior to initiation of Vectibix treatment|Proportion of oncologists who conduct a KRAS test prior to the initiation of Vectibix treatment|Proportion of oncologists who administer Vectibix in mCRC patients with mutant KRAS tumors or with KRAS status unknown|Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown","Amgen","All","18 Years and older   (Adult, Older Adult)",,"453","Industry","Observational","Time Perspective: Cross-Sectional","20101121","March 2012","November 2014","November 2014","July 30, 2012",,"March 1, 2016",,,"https://ClinicalTrials.gov/show/NCT01652833"
285,"NCT01652703","A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects","AMG145","Completed","Has Results","Hypercholesterolemia and High Risk for Cardiovascular Events","Biological: Evolocumab|Other: Placebo","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percentage of Participants With an LDL-C Response at Week 12|Percent Change From Baseline to Week 12 in Non-HDL-C|Percent Change From Baseline to Week 12 in Apolipoprotein B|Percent Change From Baseline to Week 12 in VLDL-C|Percent Change From Baseline to Week 12 in Total Cholesterol/HDL-C Ratio|Percent Change From Baseline to Week 12 in Apolipoprotein B/Apolipoprotein A-1 Ratio","Amgen","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110231","July 10, 2012","May 14, 2013",,"July 30, 2012","October 5, 2015","November 28, 2018","Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Fujioka-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Kawani-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Hitachi-shi, Ibaraki, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Mito-shi, Ibaraki, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kochi-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ina-shi, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Suwa-shi, Nagano, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Hanyu-shi, Saitama, Japan|Research Site, Sayama-shi, Saitama, Japan|Research Site, Toda-shi, Saitama, Japan|Research Site, Otsu-shi, Shiga, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Taito-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01652703"
286,"NCT01631214","Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","ARCH","Completed","Has Results","Postmenopausal Women With Osteoporosis","Biological: Romosozumab|Drug: Alendronate|Drug: Placebo to Romosozumab|Drug: Placebo to Alendronate","Percentage of Participants With New Vertebral Fractures Through Month 24|Percentage of Participants With a Clinical Fracture at the Primary Analysis|Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis|Percentage of Participants With Any Fracture at the Primary Analysis|Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24|Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis|Percentage of Participants With a Hip Fracture at the Primary Analysis|Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24|Percentage of Participants With a Clinical Fracture Through Month 24|Percentage of Participants With a Nonvertebral Fracture Through Month 24|Percentage of Participants With a Hip Fracture Through Month 24|Percentage of Participants With a Clinical Vertebral Fracture Through Month 24|Percentage of Participants With a Clinical Fracture Through Month 12|Percentage of Participants With New Vertebral Fractures Through Month 12|Percentage of Participants With Any Fracture Through Month 12|Percentage of Participants With a Nonvertebral Fracture Through Month 12|Percentage of Participants With a Hip Fracture Through Month 12|Percentage of Participants With a Major Osteoporotic Fracture Through Month 12|Percentage of Participants With a Clinical Vertebral Fracture Through Month 12|Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24|Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24|Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24|Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12|Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12|Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12|Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36|Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36|Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","4093","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110142|2011-003142-41","May 4, 2012","February 27, 2017","June 29, 2017","June 29, 2012","December 12, 2018","December 17, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Downey, California, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, South Lake Tahoe, California, United States|Research Site, Tustin, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Maywood, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Cruces, New Mexico, United States|Research Site, Great Neck, New York, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Richmond, Virginia, United States|Research Site, Port Angeles, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Brugge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Vitória, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Klatovy, Czechia|Research Site, Opava, Czechia|Research Site, Ostrava-Trebovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, Koge, Denmark|Research Site, Odense, Denmark|Research Site, Vejle, Denmark|Research Site, Århus C, Denmark|Research Site, Santo Domingo, Distrito Nacional, Dominican Republic|Research Site, Santo Domingo, Distrito Nacional, Dominican Republic|Research Site, Santiago, Dominican Republic|Research Site, Santo Domingo, Dominican Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Kuopio, Finland|Research Site, Turku, Finland|Research Site, Bordeaux Cedex, France|Research Site, Cahors Cedex, France|Research Site, Lille cedex, France|Research Site, Lyon Cédex 3, France|Research Site, Orleans Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heinsberg, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Antigua, Sacatepéquez, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Guatemala, Guatemala|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kiskunhalas, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Bnei Brak, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Aviv, Israel|Research Site, Arenzano GE, Italy|Research Site, Bologna, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Milan, Italy|Research Site, Pisa, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Verona, Italy|Research Site, Verona, Italy|Research Site, Daegu, Korea, Republic of|Research Site, Guri-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Mexicali, Baja California Norte, Mexico|Research Site, Mexicalli, Baja California Norte, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, Ciudad Obregon, Sonora, Mexico|Research Site, Leiden, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Venlo, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Elverum, Norway|Research Site, Hamar, Norway|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bialystok, Poland|Research Site, Bialystok, Poland|Research Site, Dabrowka Dopiewo, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Gliwice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Swidnik, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Oradea, Romania|Research Site, Targu Mures, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice-Saca, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Piestany, Slovakia|Research Site, Trencin, Slovakia|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Tygerberg, South Africa|Research Site, Granada, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Sant Joan Despi, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Linköping, Sweden|Research Site, Mölndal, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Adana, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Staffordshire, United Kingdom|Research Site, Warwick, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01631214/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01631214/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01631214"
287,"NCT01624142","Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders","TAUSSIG","Completed","Has Results","Severe Familial Hypercholesterolemia","Biological: Evolocumab","Number of Participants With Adverse Events|Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)|Percent Change From Baseline in Lipoprotein (a)|Percent Change From Baseline in Apolipoprotein B|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio|Percentage of Participants With a 15% or Greater Reduction in LDL-C","Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110271|2011-005400-15","June 1, 2012","May 11, 2018","May 11, 2018","June 20, 2012","January 28, 2019","January 28, 2019","Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Hobart, Tasmania, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, Athens, Greece|Research Site, New Territories, Hong Kong|Research Site, Ramat Gan, Israel|Research Site, Cinisello Balsamo (MI), Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Suita, Osaka, Japan|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01624142/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01624142"
288,"NCT01588509","Transition From Alendronate to Romosozumab (AMG 785)",,"Completed","Has Results","Osteoporosis","Drug: Romosozumab","Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine|Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck|Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip|Percent Change From Baseline in Serum Type-1 Aminoterminal Propeptide (P1NP)|Percent Change From Baseline in Serum C-telopeptide (sCTX)|Number of Participants With Adverse Events|Number of Participants Who Developed Anti-romosozumab Antibodies|Mean Serum Concentration of Romosozumab","Amgen","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110253","March 30, 2012","November 21, 2012","November 21, 2012","May 1, 2012","March 4, 2019","March 26, 2019","Research Site, Tucson, Arizona, United States|Research Site, Walnut Creek, California, United States|Research Site, Gainesville, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Bethesda, Maryland, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, West Haverstraw, New York, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01588509"
289,"NCT01588496","Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","TESLA","Completed","Has Results","Homozygous Familial Hypercholesterolemia","Biological: Evolocumab|Drug: Placebo","Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Part A: Change From Baseline in LDL-C at Week 12|Part A: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B at Week 12|Part A: Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Part A: Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Part A: Percentage of Participants With 15% or Greater Reduction in LDL-C From Baseline at Week 12|Part A: Change From Baseline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) at Week 12|Part B: Percent Change From Baseline in LDL-C at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Apolipoprotein B at Week 12|Part B: Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 6 and 12|Part B: Percent Change From Baseline in Lipoprotein (a) at Week 12|Part B: Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 6 and 12","Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110233|2011-005399-40","April 5, 2012","January 31, 2014","January 31, 2014","May 1, 2012","October 2, 2015","November 29, 2018","Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bruxelles, Belgium|Research Site, La Louvière, Belgium|Research Site, London, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Dijon, France|Research Site, Paris Cedex 13, France|Research Site, New Territories, Hong Kong|Research Site, Pisa, Italy|Research Site, Beirut, Lebanon|Research Site, Amsterdam, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Lugo, Galicia, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01588496"
290,"NCT01575873","Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","GIOP","Completed","Has Results","Steroid-induced Osteopor, Glucocorticoid-induced Ostepor","Drug: Denosumab|Drug: Placebo for risendronate|Drug: Risendronate|Drug: Placebo for denosumab","Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis)|Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Superiority Analysis)|Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12|Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 24|Percent Change From Baseline in Total Hip Bone Mineral Density at Month 24","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20101217|2010-024393-19","March 28, 2012","June 21, 2016","June 29, 2017","April 12, 2012","July 27, 2018","July 27, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Sacramento, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Cumberland, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Mayfield, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Beckley, West Virginia, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Wilrijk, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Westmout, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Brno, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 11 - Chodov, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Århus C, Denmark|Research Site, Lyon Cédex 3, France|Research Site, Orleans Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Bad Nauheim, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Hildesheim, Germany|Research Site, Köln, Germany|Research Site, Vogelsang-Gommern, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Szeged, Hungary|Research Site, Szikszo, Hungary|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Morelia, Michoacán, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Helmond, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Bialystok, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Stalowa Wola, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01575873"
291,"NCT01575834","Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","FRAME","Completed","Has Results","Postmenopausal Osteoporosis","Drug: Romosozumab|Drug: Placebo|Drug: Denosumab","Percentage of Participants With New Vertebral Fracture Through Month 12|Percentage of Participants With New Vertebral Fracture Through Month 24|Percentage of Participants With a Clinical Fracture Through Month 12|Percentage of Participants With a Nonvertebral Fracture Through Month 12|Percentage of Participants With a Nonvertebral Fracture Through Month 24|Percentage of Participants With a Clinical Fracture Through Month 24|Percentage of Participants With a Major Nonvertebral Fracture Through Month 12|Percentage of Participants With a Major Nonvertebral Fracture Through Month 24|Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12|Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24|Percentage of Participants With a Hip Fracture Through Month 12|Percentage of Participants With a Hip Fracture Through Month 24|Percentage of Participants With a Major Osteoporotic Fracture Through Month 12|Percentage of Participants With a Major Osteoporotic Fracture Through Month 24|Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12|Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24|Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12|Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24|Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12|Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24|Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12|Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24","Amgen","Female","55 Years to 90 Years   (Adult, Older Adult)","Phase 3","7180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070337|2011-001456-11","March 15, 2012","December 14, 2015","December 28, 2016","April 12, 2012","November 8, 2018","August 21, 2019","Research Site, Tucson, Arizona, United States|Research Site, Laguna Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Maria, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Leesburg, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Asheville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Mayfield, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Denton, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Maroubra, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Keswick, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Ghent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Lommel, Belgium|Research Site, Yvoir, Belgium|Research Site, Curitiba, Paraná, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Bogota, Colombia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Klatovy, Czechia|Research Site, Ostrava-Trebovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 11 - Chodov, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 3, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Glostrup, Denmark|Research Site, Hvidovre, Denmark|Research Site, Odense, Denmark|Research Site, Vejle, Denmark|Research Site, Århus C, Denmark|Research Site, Santo Domingo, Distrito Nacional, Dominican Republic|Research Site, Santo Domingo, Distrito Nacional, Dominican Republic|Research Site, Santo Domingo, Dominican Republic|Research Site, Pärnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Berlin (Hellersdorf), Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Görlitz, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heinsberg, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, Schkeuditz, Germany|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Heviz, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Anjyo-shi, Aichi, Japan|Research Site, Urayasu-shi, Chiba, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukutsu-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Chitose-shi, Hokkaido, Japan|Research Site, Ishikari-shi, Hokkaido, Japan|Research Site, Sunagawa-shi, Hokkaido, Japan|Research Site, Akashi-shi, Hyogo, Japan|Research Site, Kako-gun, Hyogo, Japan|Research Site, Toride-shi, Ibaraki, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kirishima-shi, Kagoshima, Japan|Research Site, Minamikyusyu-shi, Kagoshima, Japan|Research Site, Atugi-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Chiisagata-gun, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Ueda-shi, Nagano, Japan|Research Site, Ueda-shi, Nagano, Japan|Research Site, Bungoono-shi, Oita, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Takatsuki-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Fujimi-shi, Saitama, Japan|Research Site, Matsue-shi, Shimane, Japan|Research Site, Fujinomiya-shi, Shizuoka, Japan|Research Site, Kikugawa-shi, Shizuoka, Japan|Research Site, Tokushima-Shi, Tokushima, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Kiyose-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Setagaya-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Suginami-ku, Tokyo, Japan|Research Site, Suginami-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Kofu-shi, Yamanashi, Japan|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Ciudad Obregon, Sonora, Mexico|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Dabrowka Dopiewo, Poland|Research Site, Elblag, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Swidnik, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Timisoara, Romania|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pozuelo de Alarcon, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bern, Switzerland|Research Site, Fribourg, Switzerland|Research Site, Genève 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Chorley, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Reading, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01575834"
292,"NCT01568866","Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients","ENDEAVOR","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Bortezomib|Drug: Dexamethasone","Progression-free Survival|Overall Survival|Overall Response|Duration of Response|Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy|Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Right Ventricular Fractional Area Change (FAC)|Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","929","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-003|2012-000128-16","June 20, 2012","November 10, 2014","February 5, 2018","April 2, 2012","December 11, 2015","April 10, 2019","Providence St. Joseph Medical Center, Burbank, California, United States|UCSD Moore Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|MAB Oncology/Hematology, Melbourne, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Hematology Oncology of Indiana, PC, Indianapolis, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Associates in Oncology/Hematology PC, Rockville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Kansas, Kansas City, Missouri, United States|Hackensack University Medical Ctr, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Clinical Research Alliance Inc., New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Wake Forest University Health Sciences, Section on Hematology and Oncology, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Hematology/Oncology Associates of SC, Greenville, South Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|The Methodist Cancer Center, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Haematology & Oncology Clinics of Australia, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Chermside, South Brisbane, Queensland, Australia|Haematology and Oncology Clinics of Australia at Wesley, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Saint Vincent's Hospital, East Melbourne, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria|Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz, Upper Austria, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Universitair Ziekenhuis Leuven, Leuven, Flemish Brabant, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Gent, Ghent, Oost-vlaanderen, Belgium|Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium|Cliniques Universitaires Saint Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel, Brussels, Belgium|Liga Norte Riograndense Contra o Câncer, Natal, RIO Grande DO Norte, Brazil|Clínica de Oncologia de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RIO Grande DO SUL, Brazil|Hemocentro Campinas-Unicamp, Campinas, SAO Paulo, Brazil|Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|Instituto Centros Oncológicos Integrados de Educação e Pesquisa, Rio de Janeiro, Brazil|Instituto Nacional do Câncer-INCA, Rio de Janeiro, Brazil|Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil|Military Medical Academy Hospital for Active Treatment, Sofia, Sofiya, Bulgaria|Shato, Ead, Sofia, Sofiya, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"" EAD, Plovdiv, Bulgaria|Multiprofile Hospital for Active Treatment, ""Sveta Marina'', Varna, Bulgaria|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Windsor Regional Hospital, Windsor, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Fakultní nemocnice Královské Vinohrady, Praha 10, Praha, Czechia|Fakultní nemocnice Olomouc, Olomouc, Severomoravsky KRAJ, Czechia|FN Ostrava, Ostrava, Severomoravsky KRAJ, Czechia|Fakultní nemocnice Hradec Králové, Hradec Kralové, Vychodocesky KRAJ, Czechia|Fakultní nemocnice Brno, Brno, Czechia|Všeobecná fakultní nemocnice v Praze, Praha, Czechia|Centre Hospitalier de la Cote Basque, Bayonne, Aquitaine, France|Centre Hospitalier Universitaire Brest, Brest Cedex, Bretagne, France|Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Rennes Cedex 9, Bretagne, France|Hopital Hotel-Dieu - Service d'Hematologie, Nantes, Cedex 1, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Centre Hospitalier de Versailles, Le Chesnay, Ile-de-france, France|Hôpital Saint Louis, Paris, Ile-de-france, France|Hôpital Saint-Antoine, Paris, Ile-de-france, France|Hôpital Claude Huriez, Lille Cedex, NORD Pas-de-calais, France|Hôpital Hôtel-Dieu, Nantes cedex 1, PAYS DE LA Loire, France|Institut Paoli Calmettes, Marseille Cedex 9, Provence Alpes COTE D'azur, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, Rhone-alpes, France|Universitätsklinik Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-wuerttemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|Medizinische Klinik der Universität Würzburg, Würzburg, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Aachen, Aachen, Nordrhein-westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Saarland, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Sachsen, Germany|Universitätsklinikum Carl Gustav Carus, Med. Klinik und Poliklinik I, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätsklinikum Jena, Jena, Thuringen, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Alexandra General Hospital, Athens, Attica, Greece|Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza, Kecskemét, Bacs-kiskun, Hungary|Pécsi Tudományegyetem, Pécs, Baranya, Hungary|Szegedi Tudományegyetem, Szeged, Csongrad, Hungary|Debreceni Egyetem Klinikai Központ, Debrecen, Hajdu-bihar, Hungary|Egyesített Szent István és Szent László Kórház-Rendelointézet, Budapest, Hungary|Somogy Megyei Kaposi Mac okato Korhoz, Kaposvár, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Rambam Health Corp., Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel|IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture, Rionero in Vulture, Potenza, Italy|Azienda Ospedaliero-Univesitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Ospedaliera Pisana Ospedale Santa Chiara, Pisa, Italy|Aienda Policknico Umberto I di Roma, Roma, Italy|Azienda Policknico Umberto l di Roma, Roma, Italy|Università Tor Vergata Ospedale Sant Eugenio, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Nagoya City University Hospital, Nagoya City, Aichi, Japan|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, Japan|Ogaki Municipal Hospital, Ogaki City, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Nishigunma National Hospital, Shibukawa, Gunma, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan|Osaka University Hospital, Suita, Osaka, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan|Toranornon Hospital, Shinagawa, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Social Insurance Kyoto Hospital of All Japan Federation of Social Insurance Associations, Kyoto, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|Japanese Red Cross Medical Center, Tokyo, Japan|Gachon University Gil Medical Center, Incheon, Gyeonggi-Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Gyeongsangnam-Do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|North Shore Hospital, North Shore City, Auckland, New Zealand|Middlemore Hospital, Otahuhu, Auckland, New Zealand|Auckland City Hospital, Grafton, Aukland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Specjalistyczny Szpital Miejski im. Mikolaja Kopernika, Torun, Kujawsko-Pomorskie, Poland|Zamojski Szpital Niepubliczny Sp. z o.o., Zamosc, Lubelskie, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Pomorskie, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich, Chorzów, Slaskie, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland|Spitalul Universitar de Urgenta Bucuresti, Bucharest, Bucuresti, Romania|Policlinica de Diagnostic Rapid SA, Compartiment Medical Oncologie-Hematologie, Brasov, Romania|Spitalul Clinic Judetean de Urgenta Brasov (Bumbea, Horia), Brasov, Romania|Institutul Clinic Fundeni, Bucuresti, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Republican Clinical Hospital #1, Izhevsk, Russian Federation|City Clinical Hospital n.a. S. P. Botkin, Moscow, Russian Federation|Non-state Healthcare Institution ""N.A. Semashko Central Clinical Hospital #2 of JSC ""Russian Railway, Moscow, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Clinical Hospital Number 31, Saint Petersburg, Russian Federation|Federal Almazov Medical Research Centre, Saint Petersburg, Russian Federation|FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation|First Saint Petersburg I.P. Pavlov State Medical University, Saint Petersburg, Russian Federation|GUZ Samara Regional Clinical Hospital n.a. M.I. Kalinin, Samara, Russian Federation|National University Cancer Institute, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Singapore Oncology Consultants, Singapore, Singapore|Univerzitná nemocnica Bratislava, Bratislava, Slovakia|Hospital Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Institut Universitari Dexeus, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-LinKou Branch, Tao-Yuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Bangkok Metropolis, Thailand|Ramathibodi Hospital, Bangkok, Bangkok Metropolis, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|City Hematology Center, Dnepropetrovsk, Dnipropretrovsk, Ukraine|Municipal Institution of Health Protection ""Clinical Hospital #8"", Kharkov, Kharkiv, Ukraine|Cherkassy Regional Oncology Center, Cherkassy, Ukraine|MI ""Dnipropetrovsk City Multifield Clinical Hospital #4"" of Dnipropetrovsk Regional Council"", City Hematology Center, Dnipropetrovsk, Ukraine|Institute of Urgent and Reparative Surgury of Ukraine Academy of Medical Sciences, Donetsk, Ukraine|Khmelnytsky Regional Clinical Hospital, Khmelnytsky, Ukraine|Khmelnytsky Regional Hospital, Department of Hematology, Khmelnytsky, Ukraine|National Institute of Cancer, Oncohematology Department, Kiev, Ukraine|Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine|Lviv Regional Oncology Dispensary, Lviv, Ukraine|Lviv State Oncology Regional Treatment-Prophylactic Center, Department of Chemotherapy, Lviv, Ukraine|Regional Clinical Hospital, Mykolayiv, Ukraine|Royal Free Hospital, London, England, United Kingdom|University College Hospital, London, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|Churchill Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Royal Marsden Hospital, Surrey, England, United Kingdom|Royal Wolverhampton Hospitals Trust, Wolverhampton, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01568866"
293,"NCT01568229","20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)",,"Terminated","No Results Available","Schizophrenia","Drug: AMG 747|Drug: Placebo","Change from baseline to week 12 in negative symptoms, as measured by the NSA-16 total score|Response defined as a ≥ 20% decrease in the NSA-16 total score at week 12|Change from baseline to week 12 on the PANSS total score and Marder factor scores|Change from baseline to week 12 on the CGI-S|CGI-I scores at week 12|Change on cognition battery|Change in personal and social functioning|Change on patient reported outcomes","Amgen","All","18 Years to 60 Years   (Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110165|2011-004845-42","May 2012","June 2013","August 2013","April 2, 2012",,"October 1, 2014","Research Site, Little Rock, Arkansas, United States|Research Site, Springdale, Arkansas, United States|Research Site, Long Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Orange, California, United States|Research Site, Hialeah, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Rockville, Maryland, United States|Research Site, Flowood, Mississippi, United States|Research Site, Princeton, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 9, Czech Republic|Research Site, Prerov, Czech Republic|Research Site, Strakonice, Czech Republic|Research Site, Créteil cedex, France|Research Site, Dôle, France|Research Site, Montauban cedex, France|Research Site, Nimes, France|Research Site, Ipoh, Perak, Malaysia|Research Site, Ipoh, Perak, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Bydgoszcz, Poland|Research Site, Chelmno, Poland|Research Site, Katowice, Poland|Research Site, Skorzewo, Poland|Research Site, Torun, Poland|Research Site, Zuromin, Poland|Research Site, Barnet, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01568229"
294,"NCT01568216","20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms",,"Terminated","No Results Available","Schizophrenia","Drug: AMG 747|Drug: Placebo","Change from baseline to week 12 in negative symptoms, as measured by the NSA-16 total score|Response defined as a ≥ 20% decrease in the NSA-16 total score at week 12|Change from baseline to week 12 on the PANSS total score and Marder factor scores|Change from baseline to week 12 on the CGI-S|CGI-I scores at week 12|Change on cognition battery|Change in personal and social functioning|Change on patient reported outcomes","Amgen","All","18 Years to 60 Years   (Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101299|2011-004844-23","May 2012","June 2013","June 2013","April 2, 2012",,"July 30, 2015","Research Site, Anaheim, California, United States|Research Site, Cerritos, California, United States|Research Site, Culver City, California, United States|Research Site, Garden Grove, California, United States|Research Site, Los Angeles, California, United States|Research Site, Norwalk, California, United States|Research Site, San Bernardino, California, United States|Research Site, Torrance, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, North Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Marlton, New Jersey, United States|Research Site, Glen Oaks, New York, United States|Research Site, Rochester, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Houston, Texas, United States|Research Site, Glenside, South Australia, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Mt Claremont, Western Australia, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Takapuna, Auckland, New Zealand|Research Site, Khotkovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Singapore, Singapore|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Cornellá de Llobregat, Cataluña, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01568216"
295,"NCT01568203","First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia",,"Terminated","No Results Available","Schizophrenia","Drug: AMG 579|Drug: Placebo","Number of adverse events per subject to include clinically significant changes in neurological examinations, safety laboratory tests, electrocardiograms, and vital signs|Incidence of treatment-emergent suicidal ideation and behavior|Peak plasma and cerebrospinal fluid (CSF; cohort 4 healthy subjects only) concentration (Cmax) of AMG 579|Time of peak plasma and CSF (cohort 4 only healthy subjects only) concentration (tmax) of AMG 579|Area under the plasma and CSF (cohort 4 healthy subjects only) concentration versus time curve (AUC) of AMG 579|Terminal phase half-life (t1/2) in plasma and CSF (cohort 4 healthy subjects only) of AMG 579|Scores on Simpson Angus Scale (SAS) and Barnes Akathesia Rating Scale (BARS)","Amgen","All","18 Years to 60 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20101275","September 2011","June 2012","June 2012","April 2, 2012",,"October 10, 2012","Research Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01568203"
296,"NCT01543204","Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab",,"Terminated","Has Results","Psoriasis","Drug: Etanercept","Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 12|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at Week 12 by Anti-adalimumab Antibody Status|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at All Other Visits|Percentage of Participants With an sPGA Score of 0 (Clear) or 1 (Almost Clear) at All Other Visits by Anti-adalimumab Antibody Status|Percentage of Participants With an sPGA Score of 0, 1 or 2 at Each Visit|Percentage of Participants With an sPGA Score of 0, 1 or 2 by Anti-adalimumab Antibody Status at Each Visit|Static Physician Global Assessment (sPGA) at Each Visit|Static Physician Global Assessment (sPGA) by Anti-adalimumab Antibody Status at Each Visit|Percentage of Participants With a PASI 50 Response at Each Visit|Percentage of Participants With a PASI 50 Response by Anti-adalimumab Antibody Status at Each Visit|Percentage of Participants With a PASI 75 Response at Each Visit|Percentage of Participants With a PASI 75 Response by Anti-adalimumab Antibody Status at Each Visit|Percentage of Participants With a PASI 90 Response at Each Visit|Percentage of Participants With a PASI 90 Response by Anti-adalimumab Antibody Status at Each Visit|Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline|Percentage of Participants With at Least a 1 Grade Improvement in sPGA From Baseline by Anti-adalimumab Antibody Status|Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline|Percentage of Participants With at Least a 2 Grade Improvement in sPGA From Baseline by Anti-adalimumab Antibody Status|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI)|Percent Change From Baseline in PASI by Anti-adalimumab Antibody Status|Percent Change From Baseline in the Percentage of Body Surface Area (BSA) Involved With Psoriasis|Percent Change From Baseline in the Percentage of BSA Involved With Psoriasis by Anti-adalimumab Antibody Status|Patient Satisfaction With Treatment at Week 12|Patient Satisfaction With Treatment at Week 24|Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI)|Change From Baseline in Patient Assessment of Itch|Change From Baseline in Patient Assessment of Pain|Change From Baseline in Patient Assessment of Flaking|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","64","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101145","February 1, 2012","May 29, 2015","May 29, 2015","March 2, 2012","June 27, 2016","December 29, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Encino, California, United States|Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, San Ramon, California, United States|Research Site, Santa Monica, California, United States|Research Site, Denver, Colorado, United States|Research Site, Farmington, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Skokie, Illinois, United States|Research Site, New Albany, Indiana, United States|Research Site, Plainfield, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, East Windsor, New Jersey, United States|Research Site, Verona, New Jersey, United States|Research Site, Rochester, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Plymouth Meeting, Pennsylvania, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Bartlett, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Walla Walla, Washington, United States|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Markham, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01543204"
297,"NCT01516957","AMG 827 in Subjects With Psoriatic Arthritis",,"Terminated","No Results Available","Psoriatic Arthritis","Drug: AMG 827|Drug: Placebo","To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20% response at week 12|To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an ACR 50 response at week 12|To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an ACR 70 response at Week 12|To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by Clinical Disease Activity Index (CDAI) change from baseline at week 12|To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by Disease Activity Score with a 28 joint count (DAS 28) change from baseline at week 12|To evaluate the safety of AMG 827 in psoriatic arthritis as measured by development of antibodies to AMG 827|To evaluate the safety of AMG 827 in psoriatic arthritis as measured by number of subjects with AE","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101227","October 2011","September 2012","September 2015","January 25, 2012",,"April 13, 2016","Research Site, Peoria, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hemet, California, United States|Research Site, Huntington Beach, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, Victorville, California, United States|Research Site, Sarasota, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Frederick, Maryland, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Rochester, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Seattle, Washington, United States|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, QC, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01516957"
298,"NCT01516879","Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","DESCARTES","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Biological: Placebo|Drug: Atorvastatin|Drug: Ezetimibe|Other: Diet Only","Percent Change From Baseline in LDL-C at Week 52|Change From Baseline in LDL-C at Week 52|Percentage of Participants With an LDL-C Response at Week 52|Percent Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Total Cholesterol at Week 12|Percent Change From Baseline in Total Cholesterol at Week 52|Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52|Percent Change From Baseline in Apolipoprotein B at Week 52|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52|Percent Change From Baseline in Lipoprotein(a) at Week 52|Percent Change From Baseline in Triglycerides at Week 52|Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52|Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52|Percent Change From Week 12 to Week 52 in LDL-C","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","905","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110109","January 5, 2012","October 14, 2013","October 14, 2013","January 25, 2012","September 29, 2015","November 28, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Encinitas, California, United States|Research Site, Spring Valley, California, United States|Research Site, Westlake Village, California, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Houston, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Feldkirch, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, AnthÃ©e, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Gozee, Belgium|Research Site, Ham, Belgium|Research Site, Oostende, Belgium|Research Site, Victoria, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Slany, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Komarom, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Lyttelton, Gauteng, South Africa|Research Site, Amanzimtoti, KwaZulu-Natal, South Africa|Research Site, Chatsworth, Durban, KwaZulu-Natal, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Paarl, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Bloemfontein, South Africa",,"https://ClinicalTrials.gov/show/NCT01516879"
299,"NCT01514981","AMG 761 in Adults With Asthma",,"Terminated","No Results Available","Asthma","Drug: AMG 761|Drug: Placebo","The number of treatment emergent adverse events per subject including clinically significant changes in vital signs, physical examinations, laboratory safety tests and ECGs.|The number of subjects with anti-AMG 761 antibodies after a single dose of AMG 761.|The maximum observed concentration, time to maximum concentration and the area under the serum concentration-time curve after a single dose of AMG 761.|The circulating CD4+ CCR4+ T cell count.","Amgen","All","18 Years to 60 Years   (Adult)","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20080451","December 2011","January 2014","February 2014","January 23, 2012",,"April 21, 2014","Research Site, Denver, Colorado, United States|Research Site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01514981"
300,"NCT01510951","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: AMG 811 or Placebo","Evaluate the number of adverse events per subject, including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 811|Evaluate the efficacy of AMG 811 as measured by the following: the proportion of subjects with a PASI 50, 75 and 90|Measure the area under the serum concentration curve versus time of AMG 811 after a single dose administration in subjects with moderate to severe psoriasis|Measure the peak serum concentration (Cmax) of AMG 811 after a single dose administration in subjects with moderate to severe psoriasis","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20101147","August 2011","October 2012","October 2012","January 18, 2012",,"March 27, 2013","Research Site, Herston, Queensland, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT01510951"
301,"NCT01497821","AMG 172 First in Human Study in Patients With Kidney Cancer",,"Completed","No Results Available","Renal Cell Adenocarcinoma|Clear Cell Renal Carcinoma|Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma","Drug: AMG 172","Clinically significant or ≥ Grade 3 CTCAE changes in safety laboratory tests, physical examinations, ECGs, or vital signs|PK parameters including but not limited to, maximum observed concentration (Cmax), area under the concentration-time curve (AUC) and half life (t1/2)|Objective response rate for subjects treated at MTD based on RECIST 1.1|The MTD for at least one of two dosing schedules: every two weeks or every three weeks|Development of human anti-human antibody against AMG 172|Objective response rate for subjects not treated at MTD based on RECIST 1.1|Clinical benefit as measured by duration of response per RECIST 1.1","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090515","January 2012","November 2014","January 2015","December 23, 2011",,"March 25, 2016","Research Site, Scottsdale, Arizona, United States|Research Site, St Louis, Missouri, United States|Research Site, Villejuif, France|Research Site, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT01497821"
302,"NCT01493518","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis",,"Terminated","No Results Available","Psoriasis","Drug: AMG 557 or PLACEBO","Evaluate the number of adverse events per subject, including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 557|Evaluate the efficacy of AMG 557 as measured by the proportion of subjects with a PASI 50, 75 and 90 at week 28|Measure the area under the serum concentration curve versus time of AMG 557 after multiple dose administration in subjects with moderate to severe psoriasis|Measure the peak serum concentration (Cmax) of AMG 557 after multiple dose administration in subjects with moderate to severe psoriasis","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20110105","November 2011","May 2013","June 2013","December 16, 2011",,"November 19, 2013","Research Site, Birmingham, Alabama, United States|Research Site, Reno, Nevada, United States|Research Site, Portland, Oregon, United States|Research Site, Dallas, Texas, United States|Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01493518"
303,"NCT01493505","TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer",,"Terminated","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer","Drug: AMG 386|Drug: Paclitaxel|Drug: AMG 386 Placebo|Drug: Carboplatin","Progression free survival|Overall survival (OS)|Incidence of adverse events and significant laboratory abnormalities|Pharmacokinetics of AMG 386 (Cmax and Cmin)|Incidence of anti-AMG 386 antibody formation|Patient reported ovarian cancer-specific symptoms and health related quality of life|Patient reported status as measured by the EuroQOL (EQ-5D)|AMG 386 exposure-response relationships for PFS and OS|Correlation of serum biomarkers with measures of response","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1015","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20101129|TRINOVA-3 20101129/ENGOT-ov2","January 2012","March 2016","December 2016","December 16, 2011",,"February 23, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Gilbert, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Berkeley, California, United States|Research Site, Burbank, California, United States|Research Site, Concord, California, United States|Research Site, Corona, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, Oxnard, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Englewood, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Farmington, Connecticut, United States|Research Site, Hartford, Connecticut, United States|Research Site, New Britain, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Decatur, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Oak Lawn, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, South Bend, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis Park, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Neptune, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brightwaters, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Concord, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Mayfield Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Radnor, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Annandale, Virginia, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Woodbridge, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Oshkosh, Wisconsin, United States|Research Site, Sheboygan, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, West Allis, Wisconsin, United States|Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Duffel, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, Oostende, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Turnhout, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Roskilde, Denmark|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Düsseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Kiel, Germany|Research Site, Konstanz, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigsburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Ravensburg, Germany|Research Site, Rostock, Germany|Research Site, Stuttgart, Germany|Research Site, Tübingen, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Avellino, Italy|Research Site, Aviano PN, Italy|Research Site, Bari, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Nagoya-city, Aichi, Japan|Research Site, Kashiwa, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kurume-city, Fukuoka, Japan|Research Site, Kure-city, Hiroshima, Japan|Research Site, Sapporo-city, Hokkaido, Japan|Research Site, Morioka-city, Iwate, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Yonago-city, Tottori, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Deventer, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Zaragoza, Aragón, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Girona, Cataluña, Spain|Research Site, Lleida, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01493505"
304,"NCT01492465","Single Ascending Dose Trial in Patients With Type 2 Diabetes",,"Terminated","No Results Available","Diabetes Mellitus","Drug: AMG 876","Subject incidence of treatment-emergent adverse events|Safety laboratory analytes, vital signs, and ECGs|Subject incidence of anti-AMG 876 antibodies.|AMG 876 serum PK parameters|Pharmacodynamic parameters:","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20100015","November 2011","July 2012","October 2012","December 15, 2011",,"February 15, 2013","Research Site, Omaha, Nebraska, United States|Research Site, San Antonio, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01492465"
305,"NCT01475006","AMG 595 First-in-Human in Recurrent Gliomas",,"Completed","No Results Available","Advanced Malignant Glioma|Anaplastic Astrocytomas|Glioblastoma Multiforme","Drug: AMG 595","Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK Parameters: Cmax, Cmin, and if feasible half life - 8 time points up to 6 weeks|Objective response in GBM tumors as assessed by Macdonald criteria|Dose limiting toxicity used to estimate the MTD|Clinical benefit rate|Progressive free survival|Overall survival|Anti-AMG 595 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090505","February 2012","April 2016","April 2016","November 21, 2011",,"April 15, 2016","Research Site, Los Angeles, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01475006"
306,"NCT01464931","Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis",,"Completed","Has Results","Renal Impairment","Drug: Denosumab","Number of Participants With Clinically Significant Hypocalcemia|Number of Participants With Hypocalcemia Determined by CTCAE v.4.0 Criteria|Number of Participants With Hypophosphatemia Determined by CTCAE v.4.0 Criteria|Number of Participants With Hypomagnesemia Determined by CTCAE v.4.0 Criteria|Percent Change From Baseline in Albumin-adjusted Serum Calcium Over Time|Percent Change From Baseline in Serum Phosphorus Over Time|Percent Change From Baseline in Serum Magnesium Over Time|Number of Participants With Adverse Events|Maximum Observed Serum Denosumab Concentration (Cmax)|Time to Maximum Observed Serum Denosumab Concentration (Tmax)|Area Under the Serum Concentration-time Curve From Time 0 to 4 Weeks (AUC0-4wks) After Dose 1|Area Under the Serum Concentration-time Curve From Time 0 to 12 Weeks (AUC0-12wks) After Dose 2|Percent Change From Baseline in Serum C-Telopeptide Over Time|Number of Participants Who Developed Anti-denosumab Antibodies","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101361","November 2011","January 2013","March 2013","November 4, 2011","February 19, 2016","February 19, 2016","Research Site, Tempe, Arizona, United States|Research Site, Denver, Colorado, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Meridian, Idaho, United States|Research Site, Detroit, Michigan, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01464931"
307,"NCT01464437","AMG 151 Amgen Protocol Number 20100761",,"Completed","No Results Available","Diabetes Mellitus","Drug: AMG 151|Drug: Placebo|Drug: Metformin","To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin|To assess the effect of AMG 151 on postprandial glucose levels in response to a meal tolerance test|Adverse events","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20100761","September 2011","October 2012","December 2012","November 3, 2011",,"May 13, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, Inglewood, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Desert, California, United States|Research Site, Roseville, California, United States|Research Site, San Diego, California, United States|Research Site, San Jose, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Watsonville, California, United States|Research Site, Bradenton, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chigago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, St. Louis, Missouri, United States|Research Site, Bozeman, Montana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Mineola, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Draper, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Midlothian, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Brno, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Praha 3, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Carolina, Puerto Rico|Research Site, Cidra, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01464437"
308,"NCT01444456","Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia",,"Completed","Has Results","Anemia|Breast Cancer|Cancer|Colorectal Cancer|Lung Cancer|Ovarian Cancer|Prostate Cancer|Solid Tumors|Bladder Cancer|Endometrial Cancer|Renal Cancer|Pancreatic Cancer|Esophageal Cancer|Gastric Cancer",,"Percentage of Participants Receiving Darbepoetin Alfa With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL|Percentage of Participants by Tumor Type With Improvement in Patient Perceived Fatigue (PPF) and Increase in Hemoglobin ≥ 1 g/dL|Mean Change From Baseline in FACT-F Score for Participants With a VAS Improvement of 5 ± 3 Points|Time to First Increase in Hemoglobin|Percentage of Participants With Improvement in Patient-perceived Fatigue (PPF) at Any Time|Percentage of Participants With Increase in Hemoglobin ≥ 1 g/dL at Any Time","Amgen","All","18 Years and older   (Adult, Older Adult)",,"1262","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20101123","October 2011","August 2013",,"September 30, 2011","August 15, 2014","March 20, 2017","Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, St Poelten, Austria|Research Site, Vöcklabruck, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Eupen, Belgium|Research Site, Gilly, Belgium|Research Site, Mechelen, Belgium|Research Site, Namur, Belgium|Research Site, Oostende, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Verviers, Belgium|Research Site, Aix en Provence cedex 01, France|Research Site, Aix en Provence, France|Research Site, Aix en Provence, France|Research Site, Amiens, France|Research Site, Aubagne, France|Research Site, Bayonne, France|Research Site, Besançon Cedex, France|Research Site, Bordeaux, France|Research Site, Boulogne sur Mer Cédex, France|Research Site, Bourg en Bresse, France|Research Site, Brive la Gaillarde, France|Research Site, Carcassonne, France|Research Site, Clermont Ferrand, France|Research Site, Clermont Ferrand, France|Research Site, Colmar Cedex, France|Research Site, Dijon, France|Research Site, Draguignan Cedex, France|Research Site, La Seyne Sur Mer, France|Research Site, Le Mans Cedex 9, France|Research Site, Longjumeau cedex 1, France|Research Site, Marseille Cedex 03, France|Research Site, Marseille, France|Research Site, Mont de Marsan, France|Research Site, Montauban cedex, France|Research Site, Nancy, France|Research Site, Orléans, France|Research Site, Paris Cedex 20, France|Research Site, Pontoise Cedex, France|Research Site, Pringy Cedex, France|Research Site, Périgueux cedex, France|Research Site, Reims Cedex, France|Research Site, Reims, France|Research Site, Reims, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Saint Grégoire cedex, France|Research Site, Saint Quentin, France|Research Site, Soissons Cedex, France|Research Site, Soyaux, France|Research Site, Strasbourg, France|Research Site, Vichy cedex, France|Research Site, Villefranche Sur Saone Cedex, France|Research Site, Villejuif Cedex, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bremerhaven, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Goslar, Germany|Research Site, Halle (Saale), Germany|Research Site, Köln, Germany|Research Site, Mannheim, Germany|Research Site, Neunkirchen, Germany|Research Site, Rotenburg (Wümme), Germany|Research Site, Soest, Germany|Research Site, Stralsund, Germany|Research Site, Würselen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Marousi, Greece|Research Site, Papagou, Greece|Research Site, Cefalù PA, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Amstelveen, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Enschede, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Purmerend, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Vlissingen, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Konin, Poland|Research Site, Koszalin, Poland|Research Site, Krakow, Poland|Research Site, Lubin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Walbrzych, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Alba Iulia, Romania|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Oradea, Romania|Research Site, Ramnicu Valcea, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT01444456"
309,"NCT01444417","Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura|Immune Thrombocytopenia","Drug: Romiplostim|Drug: Placebo","Percentage of Participants With a Durable Platelet Response|Percentage of Participants With an Overall Platelet Response|Number of Weeks With Platelet Response|Percentage of Participants Who Received Rescue Medication During the Treatment Period|Total Number of Composite Bleeding Episodes|Number of Participants With Adverse Events","Amgen","All","1 Year to 17 Years   (Child)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080279|2010-018426-39","January 2012","February 2015","February 2015","September 30, 2011","January 19, 2017","February 10, 2017","Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, La Crosse, Wisconsin, United States|Research Site, Randwick, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01444417"
310,"NCT01444404","A Study of AMG 820 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors","Drug: AMG 820","Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 8, 24 hours post-dose|Dose of AMG 820 where clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled is greater than 33%.|Change in tumor associated macrophages (TAMS) as assessed by tumor biopsy at 9 weeks.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060347","March 31, 2008","February 6, 2014","February 6, 2014","September 30, 2011",,"November 6, 2017","Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01444404"
311,"NCT01439880","Open Label Study of Long Term Evaluation Against LDL-C Trial","OSLER","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Other: Standard of care","Number of Participants With Adverse Events|Low-density Lipoprotein Cholesterol (LDL-C) Level at Week 24 and Week 52|Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Level at Week 24 and Week 52|Apolipoprotein B Level at Week 24 and Week 52|Total Cholesterol/HDL-C Ratio at Week 24 and Week 52|Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24 and Week 52","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","1324","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110110|2011-001915-29","October 7, 2011","June 20, 2018","June 20, 2018","September 23, 2011","July 10, 2019","July 10, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Carmichael, California, United States|Research Site, Inglewood, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Marquette, Michigan, United States|Research Site, Brooklyn Center, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Great Falls, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Endwell, New York, United States|Research Site, New York, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Maroubra, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Anthée, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Ukkel, Belgium|Research Site, Kelowna, British Columbia, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, OYS, Finland|Research Site, Berlin, Germany|Research Site, Köln, Germany|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Kasuga-shi, Fukuoka, Japan|Research Site, Fujioka-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Hitachi-shi, Ibaraki, Japan|Research Site, Koga-shi, Ibaraki, Japan|Research Site, Mito-shi, Ibaraki, Japan|Research Site, Komatsu-shi, Ishikawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Kochi-shi, Kochi, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Ina-shi, Nagano, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Suwa-shi, Nagano, Japan|Research Site, Ibaraki-shi, Osaka, Japan|Research Site, Toyonaka-shi, Osaka, Japan|Research Site, Hanyu-shi, Saitama, Japan|Research Site, Sayama-shi, Saitama, Japan|Research Site, Toda-shi, Saitama, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Amsterdam, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Singapore, Singapore|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Midrand, Gauteng, South Africa|Research Site, Observatory, Western Cape, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT01439880/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT01439880/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01439880"
312,"NCT01439867","Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism",,"Terminated","Has Results","Chronic Kidney Disease|Hyperparathyroidism, Secondary","Drug: Cinacalcet hydrochloride|Drug: Standard of Care","Percentage of Participants With Hypocalcemia|Percentage of Participants With Corrected Serum Calcium Levels < 8.8 mg/dL (2.2 mmol/L) During the Study|Percent Change From Baseline in Intact Parathyroid Hormone (iPTH)|Percent Change From Baseline in Corrected Serum Calcium|Percent Change From Baseline in Serum Phosphorous|Percent Change From Baseline in Calcium Phosphorus Product (Ca x P)|Percentage of Participants Who Achieved > 30% Reduction in iPTH From Baseline at Any Two Consecutive Measurements|Percentage of Participants Who Achieved ≥ 30% Reduction in iPTH From Baseline During the Study|Percentage of Participants Who Achieved iPTH Values Between 200 and 300 pg/mL at Any Two Consecutive Measurements|Percentage of Participants Who Achieved iPTH Values < 300 pg/mL During the Study|Dose- and Weight-Normalized Maximum Plasma Concentration (Cmax) of Cinacalcet|Dose- and Weight-Normalized Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Cinacalcet","Amgen","All","up to 2189 Days   (Child)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110100|2011-004618-40","June 22, 2012","June 3, 2016","June 3, 2016","September 23, 2011","August 11, 2017","June 13, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Praha 5, Czechia|Research Site, Bron cedex, France|Research Site, Lille, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Heidelberg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Genova, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Chihuahua, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Grafton, Auckland, New Zealand|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Kosice, Slovakia",,"https://ClinicalTrials.gov/show/NCT01439867"
313,"NCT01428154","Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease",,"Withdrawn","No Results Available","Anemia|Chronic Kidney Disease","Drug: Darbepoetin alfa","Number of subjects with clinically significant changes in physical examinations, laboratory safety tests, and vital signs|Number of subjects with treatment-emergent adverse events|Maximum observed concentration (Cmax) of darbepoetin alfa|Time at which maximum concentration is observed (Tmax) of darbepoetin alfa|Area under the concentration curve (AUC) of darbepoetin alfa|Terminal half-life (t½) of darbepoetin alfa|Clearance (CL) of darbepoetin alfa|Change in reticulocytes|Change in hemoglobin concentration|Change in iron|Change in ferritin|Change in transferrin saturation","Amgen","All","up to 1 Year   (Child)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090302","April 2016","November 2016","November 2016","September 2, 2011",,"June 17, 2016",,,"https://ClinicalTrials.gov/show/NCT01428154"
314,"NCT01419717","Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer",,"Completed","Has Results","Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer","Drug: Denosumab","Number of Participants With Adverse Events|Number of Participants With Anti-denosumab Binding Antibodies","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","129","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20110113","November 22, 2011","August 10, 2018","August 10, 2018","August 18, 2011","September 9, 2019","September 24, 2019","Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Wien, Austria|Research Site, Namur, Belgium|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sorocaba, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, Kromeriz, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Saint Cloud, France|Research Site, Debrecen, Hungary|Research Site, Dombovar, Hungary|Research Site, Haifa, Israel|Research Site, Rehovot, Israel|Research Site, Tel-Aviv, Israel|Research Site, Zerifin, Israel|Research Site, Meldola (FC), Italy|Research Site, Sora, Italy|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Isehara-shi, Kanagawa, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Panama, Panama|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Krasnogorsky District, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Pretoria, South Africa|Research Site, Sevilla, Andalucía, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Lviv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01419717/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01419717/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01419717"
315,"NCT01416428","Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies",,"Completed","No Results Available","Multiple Myeloma|Waldenstrom Macroglobulinemia","Drug: oprozomib","Determine the MTD (Phase 1) and ORR (Phase 2).|Evaluate the duration of response (DOR)|Estimate the clinical benefit response (CBR)|Estimate the major response for Waldenström macroglobulinemia (WM)|Evaluate progression-free survival (PFS) for multiple myeloma (MM) subjects|Evaluate the PFS for Waldenström macroglobulinemia (WM) subjects|PK parameters - maximum plasma concentration (Cmax)|PK parameters - time of maximum plasma concentration (tmax)|PK parameters - plasma concentration-time curve (AUC)|Assess renal elimination of oprozomib and its metabolites (Phase 1b only)|Change from Baseline in hematology laboratory results|Change from Baseline in serum chemistry results|Change from Baseline in vital signs|Change from Baseline in weight|Evaluate safety of oprozomib in Phase 2|Assess the effect on transfusion/ red blood cell (RBC) growth factor requirements (Phase 2 only) for WM only|Assess the effect on plasmapheresis requirements (Phase 2 only) for WM only|Assess the effect on lymphoplasmacytic cells in the bone marrow (Phase 2 only) for WM only","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","210","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-001","September 2011","August 12, 2019","August 12, 2019","August 15, 2011",,"November 12, 2019","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Pacific Cancer Care, Salinas, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine Division of Oncology, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Hematology Oncology of Northern New Jersey, Morristown, New Jersey, United States|New York Oncology Hematology, Albany, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01416428"
316,"NCT01412957","Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Other: Best Supportive Care (BSC)|Drug: Panitumumab","Overall Survival|Progression-free Survival|Overall Survival in Participants With Wild-type RAS|Progression Free Survival (PFS) in Participants With Wild-type RAS|Objective Response Rate|Objective Response Rate in Participants With Wild-type RAS|Number of Participants With Adverse Events (AEs)|Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20100007|2010-022951-49","November 2011","June 2014","November 2016","August 9, 2011","April 8, 2016","March 15, 2017","Research Site, Curitiba, Paraná, Brazil|Research Site, Natal, Rio Grande do Norte, Brazil|Research Site, Ijui, Rio Grande do Sul, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Vina del Mar, Valparaíso, Chile|Research Site, Fuzhou, Fujian, China|Research Site, Fuzhou, Fujian, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Xi An, Shaanxi, China|Research Site, Xi An, Shaanxi, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Shanghai, China|Research Site, Osijek, Croatia|Research Site, Pula, Croatia|Research Site, Rijeka, Croatia|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Visakhapatnam, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Nilai, Negri Sembilan, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Oaxaca, Mexico|Research Site, Davao City, Davao, Philippines|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Lasi, Romania|Research Site, Ploiesti, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia",,"https://ClinicalTrials.gov/show/NCT01412957"
317,"NCT01410500","Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease",,"Approved for marketing","No Results Available","Multiple Myeloma","Drug: Carfilzomib",,"Amgen|Multiple Myeloma Research Foundation","All","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access",,"2011-002",,,,"August 5, 2011",,"May 2, 2017",,,"https://ClinicalTrials.gov/show/NCT01410500"
318,"NCT01405963","Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma",,"Completed","No Results Available","Asthma","Drug: AMG 157 Matching Placebo|Drug: AMG 157","Evaluate late asthmatic response, as measured by area under the curve (AUC) in the forced expiratory volume (FEV1) in 1 sec btwn 3 & 7 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects|Evaluate late asthmatic response, as measured by the max percentage fall in the forced expiratory volume (FEV1) in 1 sec btwn 3 & 7 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects|Evaluate early asthmatic response, as measured by area under the curve (AUC) in forced expiratory volume (FEV1) in 1 sec btwn 0 & 2 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects|Evaluate early asthmatic response, as measured by the max percentage fall in forced expiratory volume (FEV1) in 1 sec btwn 0 & 2 hrs after an allergen inhalation challenge in mild atopic asthmatic subjects|Measure the area under the plasma concentration curve versus time of AMG 157 after multiple dose administration in subjects with mild atopic asthma|Examine the number of adverse events per subject, after multiple dose administration of AMG 157 in subjects with mild atopic asthma","Amgen","All","18 Years to 60 Years   (Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101183","September 2011","April 2013","June 2013","July 29, 2011",,"September 18, 2013","Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Sainte-Foy, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT01405963"
319,"NCT01395485","Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma",,"Withdrawn","No Results Available","Asthma","Drug: AMG 827 or Placebo","Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adolescent subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability|Area under the AMG 827 concentration versus time curve (AUC) for times 0 to infinity (AUC 0-inf) and 0 to last sampling time point (AUC 0-tlast), peak plasma concentration (Cmax) and Time to peak plasma concentration (tmax) will be determined for AMG 827|Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adult subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability","Amgen","All","12 Years to 50 Years   (Child, Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20101281","June 2011","June 2012","June 2012","July 15, 2011",,"November 25, 2013",,,"https://ClinicalTrials.gov/show/NCT01395485"
320,"NCT01389895","Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus",,"Terminated","No Results Available","Cutaneous Lupus|Lupus","Drug: AMG 557|Drug: AMG 557 Placebo","Safety evaluation: Subject incidence of treatment-emergent adverse events, vital signs, physical examinations, clinical laboratory safety tests, ECGs, and the incidence of binding and neutralizing antibodies to AMG 557|Determine the pharmacokinetic (PK) profile of AMG 557 after multiple subcutaneous (SC) doses in subacute cutaneous lupus erythematosus (SCLE) subjects.|Characterize the mean change and variability in serum SS-A and SS-B autoantibodies.|Characterize change in Cutaneous Lupus Erythematosus Disease Area and Severity Index score (CLASI-a) score.","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20100037","October 2011","March 2013","March 2013","July 8, 2011",,"January 10, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Woolloongabba, Queensland, Australia|Research Site, Carlton, Victoria, Australia|Research Site, Peterborough, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01389895"
321,"NCT01386866","Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: AMG 706","Profile and identification of metabolites of [14C]-AMG 706 in plasma, urine, and faeces|Pharmacokinetics of total radioactivity in plasma and whole blood|The mass balance of [14C]-AMG 706 (as the percentage of the dose administered) in urine and faeces|• Measure the area under the plasma concentration curve versus time of AMG 706, as well as determine half-life and time of maximum concentration of AMG 706.|The subject incidences of serious adverse events, adverse events, and clinically significant changes in vital signs and clinical laboratory tests","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20080639","May 2009","November 2010","December 2010","July 1, 2011",,"July 15, 2011",,,"https://ClinicalTrials.gov/show/NCT01386866"
322,"NCT01380756","Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia",,"Completed","No Results Available","Cancer|Hematologic Malignancies|Leukemia|Myeloid Leukemia","Drug: Arm 1- Dose Escalation|Drug: Arm 2- Dose Expansion","Subject incidence of adverse events|Subject incidence of dose limiting toxicities (DLTs)|Maximum observed concentration of AMG 900|Time to maximum observed concentration of AMG 900|Area under the plasma concentration-time curve (AUC) of AMG 900|Half life of AMG 900|Objective response as per Cheson Response Criteria|Change in the number of p-Histone H3 positive cells from baseline","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101351","October 4, 2011","September 4, 2014","September 4, 2014","June 27, 2011",,"November 6, 2017","Research Site, Stony Brook, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01380756"
323,"NCT01380730","LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","LAPLACE","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Other: Placebo to Evolocumab","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12","Amgen|TIMI Study Group","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","631","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101155","July 1, 2011","April 5, 2012","April 5, 2012","June 27, 2011","October 1, 2015","November 2, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Carmichael, California, United States|Research Site, Newport Beach, California, United States|Research Site, Roseville, California, United States|Research Site, Westlake Village, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Peoria, Illinois, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Lexington, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Great Falls, Montana, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Florence, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Burnaby, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Slany, Czechia|Research Site, Svitavy, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary",,"https://ClinicalTrials.gov/show/NCT01380730"
324,"NCT01375777","Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels","MENDEL","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","411","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101154","July 6, 2011","March 2, 2012","March 2, 2012","June 17, 2011","October 5, 2015","November 28, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Encinitas, California, United States|Research Site, Inglewood, California, United States|Research Site, San Diego, California, United States|Research Site, Tustin, California, United States|Research Site, DeLand, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Brooklyn Center, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Renton, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Maroubra, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, AnthÃ©e, Belgium|Research Site, Dour, Belgium|Research Site, Gozee, Belgium|Research Site, Gribomont, Belgium|Research Site, Halen, Belgium|Research Site, Ham, Belgium|Research Site, Linkebeek, Belgium|Research Site, Retie, Belgium|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark",,"https://ClinicalTrials.gov/show/NCT01375777"
325,"NCT01375764","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects","GAUSS","Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Drug: Ezetimibe|Other: Placebo to Evolocumab","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Change From Baseline in LDL-C at Week 12|Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Non-HDL-C at Week 12|Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090159","July 28, 2011","May 8, 2012","May 8, 2012","June 17, 2011","December 23, 2015","November 2, 2018","Research Site, Anaheim, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Westlake Village, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Auburn, Maine, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Butte, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bristol, Tennessee, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Sydney, New South Wales, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Uccle, Belgium|Research Site, Saint Johnâ€™s, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, OYS, Finland|Research Site, Zaragoza, AragÃ³n, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Reus, CataluÃ±a, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L'Hospitalet de Llobregat, Cataluña, Spain|Research Site, Reus, Cataluña, Spain|Research Site, GÃ¶teborg, Sweden|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01375764"
326,"NCT01375751","Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study","RUTHERFORD","Completed","Has Results","Hypercholesterolemia, Familial","Biological: Evolocumab|Biological: Placebo","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12|Absolute Change From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12|Percent Change From Baseline in Apolipoprotein B at Week 12|Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12|Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090158","August 2, 2011","May 16, 2012","May 16, 2012","June 17, 2011","September 29, 2015","November 2, 2018",,,"https://ClinicalTrials.gov/show/NCT01375751"
327,"NCT01362140","Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",,"Completed","Has Results","MDS","Drug: Darbepoetin alfa|Drug: Placebo","Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period|Percentage of Participants Who Achieved an Erythroid Response Based on International Working Group (IWG) 2006 Criteria in the Double-blind Treatment Period|Number of Participants With Adverse Events|Number of Participants With Disease Progression to Acute Myeloid Leukemia (AML)|Number of Participants With Malignancies Other Than AML, Basal Cell Carcinoma, or Squamous Cell Carcinoma of the Skin|Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa|Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)|Change From Baseline in EuroQol-5D (EQ-5D) Visual Analog Scale (VAS)|Percentage of Participants With a Clinically Meaningful Improvement in Fatigue","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20090160|2009-016522-14","December 21, 2011","February 11, 2015","September 14, 2017","May 30, 2011","December 5, 2016","December 19, 2017","Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Brugge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Haine Saint Paul - La Louviere, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Ottignies, Belgium|Research Site, Roeselare, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Zlin, Czechia|Research Site, Avignon Cedex 9, France|Research Site, Bobigny cedex, France|Research Site, Caen, France|Research Site, Lyon Cédex 3, France|Research Site, Lyon, France|Research Site, Nantes Cedex 1, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 10, France|Research Site, Paris, France|Research Site, Pontoise Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Dresden, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Mannheim, Germany|Research Site, Regensburg, Germany|Research Site, Rotenburg (Wümme), Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Alessandria, Italy|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Pesaro, Italy|Research Site, Pisa, Italy|Research Site, Reggio Calabria, Italy|Research Site, Rionero In Vulture PZ, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Udine, Italy|Research Site, Zaragoza, Aragón, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Basel, Switzerland|Research Site, Luzern, Switzerland|Research Site, Muensterlingen, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01362140"
328,"NCT01345019","Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma",,"Completed","Has Results","Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions","Drug: Denosumab|Drug: Zoledronic acid|Drug: Placebo to Denosumab|Drug: Placebo to zoledronic acid","Time to First On-study Skeletal Related Event|Percentage of Participants With an On-study Skeletal Related Event|Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event|Time to First On-study Skeletal Related Event - Superiority Analysis|Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient|Time to First and Subsequent On-Study Skeletal Related Event - Number of Events|Overall Survival|Percentage of Participants Who Died","Amgen|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1718","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20090482|2010-020454-34","May 17, 2012","July 19, 2016","March 29, 2019","April 29, 2011","March 7, 2018","April 10, 2019","Research Site, Tucson, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Campbell, California, United States|Research Site, Encinitas, California, United States|Research Site, Fresno, California, United States|Research Site, Pleasant Hill, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Niles, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Paducah, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, Fairhaven, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Jackson, Mississippi, United States|Research Site, Springfield, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Christiansburg, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Minocqua, Wisconsin, United States|Research Site, Wauwatosa, Wisconsin, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Douglas, Queensland, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Krems an der Donau, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Burnaby, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Amiens Cedex 1, France|Research Site, Avignon Cedex 9, France|Research Site, Creteil, France|Research Site, Le Kremlin Bicetre, France|Research Site, Le Mans Cedex 9, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Lyon Cédex 3, France|Research Site, Marseille cedex 5, France|Research Site, Marseille Cedex 9, France|Research Site, Nantes Cedex 1, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 14, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite cedex, France|Research Site, Pontoise Cedex, France|Research Site, Reims Cedex, France|Research Site, Rouen cedex, France|Research Site, Saint Quentin, France|Research Site, Strasbourg, France|Research Site, Villefranche Sur Saone Cedex, France|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Münster, Germany|Research Site, Regensburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Szeged, Hungary|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Limerick, Ireland|Research Site, Tullamore, Ireland|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Busto Arsizio, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Vimercate MB, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Akita-shi, Akita, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Shibukawa-shi, Gunma, Japan|Research Site, Fukuyama-shi, Hiroshima, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Tokushima-shi, Tokushima, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Anyang, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Ipoh, Perak, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kuching, Sarawak, Malaysia|Research Site, Ampang, Malaysia|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Slupsk, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Matosinhos, Portugal|Research Site, Porto, Portugal|Research Site, Dzerzhinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Sevilla, Andalucía, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Ourense, Galicia, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Khmelnitskiy, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Harrow, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01345019"
329,"NCT01331941","A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function",,"Completed","No Results Available","Advanced Solid Tumors|Kidney Disease|Renal Impairment","Drug: AMG 386 + Paclitaxel|Drug: AMG 386","Area under the serum concentration-time curve (AUC)|Maximum observed concentration (Cmax)|Time to maximum concentration (tmax)|Minimum observed concentration (Cmin)|Clearance (CL) of AMG 386 calculated as dose divided by AUC on week 5.|Adverse events as a measure of safety|Changes in vital signs as a measure of safety|Changes in clinical laboratory tests as a measure of safety|Anti-AMG 386 antibody formation|Tumor objective response measured by CT or MRI (without Gadolinium contrast agents) and assessed by RECIST 1.1 criteria.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090277","September 19, 2011","February 26, 2013",,"April 8, 2011",,"November 6, 2017","Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01331941"
330,"NCT01327612","Open Label Extension Study of Conatumumab and AMG 479",,"Active, not recruiting","No Results Available","Advanced Solid Tumors|Carcinoid|Colorectal Cancer|Locally Advanced|Lymphoma|Metastatic Cancer|Non-Small Cell Lung Cancer|Sarcoma|Solid Tumors","Drug: FOLFOX6|Biological: Conatumumab|Biological: Ganitumab|Biological: Bevacizumab","Incidence of Adverse events|Incidence of Serious adverse events|Number of participants with changes in vital signs|Number of participants with changes in clinical laboratory tests|Tumor response|Number of subjects determined to have Disease progression|Number of deaths due to progressive disease","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101116","March 3, 2011","March 31, 2020","March 31, 2020","April 1, 2011",,"December 19, 2019","Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Denver, Colorado, United States|Research Site, Tampa, Florida, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Buffalo, New York, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Szczecin, Poland|Research Site, Barcelona, Cataluña, Spain",,"https://ClinicalTrials.gov/show/NCT01327612"
331,"NCT01318642","Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas",,"Terminated","No Results Available","Adenocarcinoma of the Pancreas|Locally Advanced|Unresectable","Drug: Gemcitabine|Drug: AMG 479|Drug: Placebo","The primary endpoint is progression-free survival (PFS) as defined as the time from randomization to progression (per RECIST v1.1) or death.|Progression-free survival and overall survival rates at 3, 6, 9, 12, 18, and 24 months|Objective response rate (complete or partial response) per RECIST v1.1|Overall survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20080261|2010-023978-39","May 2012","November 2012","December 2012","March 18, 2011",,"August 8, 2014","Research Site, San Francisco, California, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Salzburg, Austria|Research Site, Steyer, Austria|Research Site, Wien, Austria|Research Site, Edegem, Belgium|Research Site, Haine St. Paul - La Louviere, Belgium|Research Site, Hradec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Herlev, Denmark|Research Site, Hamburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Szolnok, Hungary|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Guys Hospital, United Kingdom|Research Site, London, United Kingdom|Research Site, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01318642"
332,"NCT01313221","Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis","REFINE","Completed","Has Results","Psoriasis","Biological: etanercept|Drug: Topical agents","Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24|Percent Change in PASI From Week 12 to Weeks 16 and 20|Percent Change in PASI From Baseline to Weeks 12, 16, 20, and 24|Percentage of Participants With a PASI 50 Response|Percentage of Participants With a PASI 75 Response|Percentage of Participants With a PASI 90 Response|Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Psoriasis Score of 0 (Clear) or 1 (Almost Clear)|Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Week 12 to Weeks 16, 20, and 24|Percent Change in the Percentage of Body Surface Area (BSA) Involvement From Baseline to Weeks 12, 16, 20, and 24|Change From Week 12 to Week 24 in Dermatology Quality of Life Index (DQLI) Total Score|Change From Baseline to Weeks 12 and 24 in Dermatology Quality of Life Index (DQLI) Total Score|Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Week 12 to Week 24|Change in Treatment Satisfaction Questionnaire for Medications (TSQM) Scores From Baseline to Weeks 12 and 24|Health Resource Utilization: Number of Participants With Visits to a Healthcare Provider|Health Resource Utilization: Number of Participants With Home Healthcare Visits|Health Resource Utilization: Number of Participants Requiring Paid Help With Chores|Health Resource Utilization: Number of Participants Who Needed Friend or Family Care|Health Resource Utilization: Out of Pocket Expenses|Health Resource Utilization: Employment Status|Health Resource Utilization: Productivity While Working|Health Resource Utilization: Number of Participants With Missed Hours From Work|Health Resource Utilization: Ability to Perform Daily Activities|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20090647","April 2011","December 2012","May 2013","March 11, 2011","May 2, 2014","March 15, 2017","Research Site, Calgary, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North Bay, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Richmond Hill, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Hyacinthe, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01313221"
333,"NCT01313208","Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: etanercept|Drug: Placebo|Drug: DMARD Therapy","Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12|Percentage of Participants Achieving DAS28 Remission at Week 12|Percentage of Participants Achieving DAS28 Low Disease Activity at All Other Timepoints|Percentage of Participants Achieving DAS28 Remission at All Other Timepoints|Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Each Timepoint|Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Each Timepoint|Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Each Timepoint|Percentage of Participants With RAPID3 Remission or Low Severity at Each Time Point|Percentage of Participants Achieving Count Remission at Each Time Point|Percentage of Participants Achieving CDAI Remission at Each Time Point|Percentage of Participants Achieving CDAI Low Disease Activity at Each Time Point|Clinical Disease Activity Index (CDAI) Score at Each Time Point|Percentage of Participants Achieving SDAI Remission at Each Time Point|Percentage of Participants Achieving SDAI Low Disease Activity at Each Time Point|Simplified Clinical Disease Activity Index (SDAI) Score at Each Time Point|Tender 28-Joint Count (TJC28) at Each Time Point|Swollen 28-Joint Count (SJC28) at Each Time Point|Patient Global Assessment of Joint Pain at Each Time Point|Patient's Global Assessment of Disease Activity at Each Time Point|Physician Global Assessment of Disease Activity at Each Time Point|Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Each Time Point|C-reactive Protein Levels at Each Time Point|Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Vitality Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Role-Physical Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) General Health Perceptions Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Social Functioning Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Role-Emotional Domain Score at Each Time Point|Short Form 36 Health Survey (SF-36) Mental Health Domain Score at Each Time Point|Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Work Time Missed (Absenteeism) at Each Time Point|Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Impairment While Working (Presenteeism) at Each Time Point|Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Activity Impairment at Each Time Point|Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Overall Work Impairment at Each Time Point|Participant Assessment of Fatigue at Each Time Point|Medical Outcomes Study (MOS) Sleep Disturbance Scale at Each Time Point|Medical Outcomes Study (MOS) Sleep Shortness of Breath or Headache Scale at Each Time Point|Medical Outcomes Study (MOS) Sleep Snoring Scale at Each Time Point|Medical Outcomes Study (MOS) Sleep Adequacy Scale at Each Time Point|Medical Outcomes Study (MOS) Sleep Daytime Somnolence Scale at Each Time Point|Medical Outcomes Study (MOS) Sleep Problems Index I at Each Time Point|Medical Outcomes Study (MOS) Sleep Problems Index II at Each Time Point","Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070561","March 2011","February 2013","May 2013","March 11, 2011","June 17, 2014","February 10, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Peoria, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Encino, California, United States|Research Site, Hemet, California, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, Murrieta, California, United States|Research Site, Santa Maria, California, United States|Research Site, Tustin, California, United States|Research Site, Upland, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Springfield, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Frederick, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, St. Clair Shores, Michigan, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Mayfield Village, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Greer, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Eustache, Quebec, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01313208"
334,"NCT01302392","A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","FOCUS","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Best Supportive Care","Overall Survival|Progression-free Survival|Overall Response|Duration of Response|Clinical Benefit Response|Duration of Clinical Benefit|Disease Control|Duration of Disease Control","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-011","September 2010","July 2014","September 2015","February 24, 2011","August 4, 2015","May 2, 2017","Nedlands, Australia|Perth, Australia|Linz, Austria|Salzburg, Austria|Vienna, Austria|Arlon, Belgium|Brugge, Belgium|Brussels, Belgium|Roeselare, Belgium|Brno, Czechia|Hradec Kralov, Czechia|Olomouc, Czechia|Prague, Czechia|Lyon, France|Nantes, France|Nimes, France|Dresden, Germany|Giessen, Germany|Koblenz, Germany|Mainz, Germany|Muenchen, Germany|Ulm, Germany|Athens, Greece|Rio Patras, Greece|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Kaposvar, Hungary|Pecs, Hungary|Szeged, Hungary|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariva, Israel|Petah-Tikva, Israel|Sheba, Israel|Ancona, Italy|Novara, Italy|Roma, Italy|Torino, Italy|Incheon, Korea, Republic of|Seoul, Korea, Republic of|North Shore City, New Zealand|Gdansk, Poland|Lodz, Poland|Pila, Poland|Torum, Poland|Warsaw, Poland|Wroclaw, Poland|Zamosc, Poland|Moscow, Russian Federation|St. Petersburg, Russian Federation|Beograd, Serbia|Nis, Serbia|Bratislava, Slovakia|Barcelona, Spain|Guipuzcoa, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Uppsala, Sweden|Hampshire, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01302392"
335,"NCT01300026","AMG 319 Lymphoid Malignancy FIH",,"Completed","No Results Available","Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors","Drug: AMG 319","Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK parameters|Clinical/radiological response rate for CLL subjects|Treatment-emergent adverse events|Phospho-AKT level in circulating CLL cells|Number of patients with clinical/radiological response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101262|AMG 319 FIH Lymphoid","April 2011","October 2013","December 2016","February 21, 2011",,"February 10, 2017","Research Site, Hackensack, New Jersey, United States|Research Site, Durham, North Carolina, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01300026"
336,"NCT01300013","Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)",,"Completed","No Results Available","Heart Failure","Drug: Placebo|Drug: Omecamtiv mecarbil","The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.|To characterize pharmacokinetics of omecamtiv mecarbil including metabolites following IV infusion and to evaluate the relationship between omecamtiv mecarbil plasma concentration and echocardiographic parameters in subjects with AHF|To assess the safety and tolerability of 3 dose levels of IV omecamtiv mecarbil compared with placebo in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure|To evaluate the effects of 48 hours treatment with IV omecamtiv mecarbil on additional measures of dyspnea, patient global assessment (PGA), change in NT-proBNP, incidence of worsening heart failure, and short term clinical outcomes","Amgen|Cytokinetics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20100754","April 2011","April 2013","September 2013","February 21, 2011",,"April 21, 2014","Research Site, Moblie, Alabama, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, San Francisco, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Newark, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Fairfield, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Roeselare, Belgium|Research Site, Blagoevgrad, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, QuÃ©bec, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Caen Cedex 9, France|Research Site, Lille Cedex, France|Research Site, Montpellier cedex 05, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 09, France|Research Site, Bad Nauheim, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Greifswald, Germany|Research Site, Halle/Saale, Germany|Research Site, Hamburg, Germany|Research Site, Homburg, Germany|Research Site, Langen, Germany|Research Site, Regensburg, Germany|Research Site, Stuttgart, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Haidari, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Pecs, Hungary|Research Site, Szolnok, Hungary|Research Site, Brescia, Italy|Research Site, Cagliari, Italy|Research Site, Pavia, Italy|Research Site, Udine, Italy|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Delft, Netherlands|Research Site, Deventer, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petrsburg, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Bristol, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01300013"
337,"NCT01294397","Effects of Denosumab on the Pharmacokinetics of Etanercept",,"Terminated","Has Results","Postmenopausal|Osteopenia|Rheumatoid Arthritis|Osteoporosis","Drug: Etanercept|Drug: Denosumab","Area Under the Serum Concentration-time Curve From 0 to 168 Hours (AUC0-168) for Etanercept|Maximum Observed Serum Concentration (Cmax) of Etanercept|Time to Maximum Serum Concentration (Tmax) of Etanercept|Serum Denosumab Concentration|Percent Change From Baseline in Serum C-telopeptide (sCTx) Concentrations","Amgen","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101324","March 2011","January 2016","January 2016","February 11, 2011","June 20, 2017","June 20, 2017","Research Site, Duncansville, Pennsylvania, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01294397"
338,"NCT01290042","Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.",,"Completed","No Results Available","Ulcerative Colitis|Crohn's Disease","Drug: AMG 181|Other: Placebo for AMG 181","To assess the number of adverse events per subject, after multiple subcutaneous doses of AMG 181 in in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.|To measure the area under the plasma concentration curve versus time of drug AMG 181.|To assess receptor saturation percentages relative to baseline after multiple doses of AMG 181.|To evaluate changes in peripheral blood T lymphocyte subsets counts relative to baseline after multiple doses of AMG 181.","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20101261","February 2011","April 2014","May 2014","February 4, 2011",,"March 17, 2015","Research Site, Glendale, California, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Danbury, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Prahran, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01290042"
339,"NCT01290029","Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease",,"Completed","Has Results","Chronic Kidney Disease|Hyperparathyroidism, Secondary|Secondary Hyperparathyroidism","Drug: Cinacalcet","Number of Participants With Adverse Events|Area Under the Plasma Concentration Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) for Cinacalcet|Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUCinf) for Cinacalcet|Maximum Observed Plasma Concentration (Cmax) of Cinacalcet|Time to Reach Maximum Observed Plasma Concentration of Cinacalcet (Tmax)|Terminal Half-life of Cinacalcet|Percent Change From Baseline in Intact Parathyroid Hormone|Percent Change From Baseline in Total Calcium|Percent Change From Baseline in Albumin Corrected Calcium|Percent Change From Baseline in Ionized Calcium","Amgen","All","up to 2190 Days   (Child)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090005","January 25, 2011","September 23, 2015","September 23, 2015","February 4, 2011","December 19, 2016","July 16, 2019","Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Louisville, Kentucky, United States|Research Site, Kansas City, Missouri, United States|Research Site, Heidelberg, Germany|Research Site, Bristol, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01290029"
340,"NCT01281254","AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)",,"Terminated","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer","Drug: AMG386 plus PLD|Drug: Placebo plus PLD","To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by progression-free survival, defined as the time from randomization to the earliest of the dates of first radiologic disease progression per RECIST 1.1 with modifications|• To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by overall survival","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","223","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060517|2009-017946-30|ENGOT-ov-6|TRINOVA-2","April 18, 2011","August 29, 2014","April 19, 2017","January 21, 2011",,"December 2, 2017","Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Evanston, Illinois, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Annandale, Virginia, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, West Allis, Wisconsin, United States|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, East Bentleigh, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Ieper, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Herlev, Denmark|Research Site, København, Denmark|Research Site, Amiens, France|Research Site, Avignon cedex 9, France|Research Site, Lyon cedex 8, France|Research Site, Poitiers, France|Research Site, Saint Cloud, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Düsseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Hannover, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Rostock, Germany|Research Site, Tübingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg - Pozva, Hungary|Research Site, Campobasso, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Grafton, Auckland, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia|Research Site, Aarau, Switzerland|Research Site, Chur, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Poole, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01281254"
341,"NCT01277510","Pediatric Chronic Kidney Disease Safety and Efficacy",,"Terminated","Has Results","Chronic Kidney Disease|Hyperparathyroidism|Hyperparathyroidism, Secondary|Kidney Disease|Secondary Hyperparathyroidism","Drug: cinacalcet capsule|Drug: placebo|Drug: Standard of Care","Percentage of Participants Achieving ≥ 30% Reduction in Mean iPTH From Baseline to the Efficacy Assessment Phase|Percentage of Participants Achieving Mean iPTH ≤ 300 pg/mL (31.8 Pmol/L) During the Efficacy Assessment Phase|Percent Change From Baseline in Mean Corrected Total Serum Calcium During the Efficacy Assessment Period|Percent Change From Baseline in Mean Serum Phosphorus During the Efficacy Assessment Phase|Percent Change From Baseline in Mean Phosphorous Product (Ca x P) During the Efficacy Assessment Phase|Growth Velocity From Baseline to End of Double-blind Phase|Growth Velocity From End of Double-blind Phase to End of Open-label Phase|Percent Change From Baseline in Mean Ionized Calcium During the Efficacy Assessment Phase","Amgen","All","6 Years to 17 Years   (Child)","Phase 3","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070208","June 2011","April 2014","April 2014","January 17, 2011","May 15, 2015","February 4, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Livingston, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Randwick, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Heidelberg, Germany|Research Site, Marburg, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Gdansk, Poland|Research Site, Gorzow Wielkopolski, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Baracaldo, PaÃ-s Vasco, Spain|Research Site, Baracaldo, País Vasco, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01277510"
342,"NCT01253707","A Study of AMG 337 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors","Drug: AMG 337","To evaluate the safety and tolerability of AMG 337 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.|Characterize the pharmacokinetics of AMG 337 when administered orally. PK parameters will include, but are not limited to, area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax).|Determine the maximum tolerated dose of AMG 337, if possible. The MTD is defined at the highest dose level with an observed incidence of dose limiting toxicity in < 33% of subjects enrolled in a cohort.|Evaluate for clinical responses associated with AMG 337 treatment according to Response Evaluation Criteria In Solid Tumors 1.1 criteria","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","111","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101132","December 2010","October 2015","December 2016","December 3, 2010",,"December 23, 2016","Research Site, Los Angeles, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01253707"
343,"NCT01253681","Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer",,"Completed","No Results Available","Carcinoma|Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer","Drug: AMG 386, paclitaxel and carboplatin","To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers.|To evaluate the pharmacokinetics (Cmax, AUC and Cmin) of AMG 386 in combination with carboplatin and paclitaxel|To estimate the incidence of anti-AMG 386 antibody formation|To evaluate the objective response rate (ORR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel|To evaluate the duration of response (DOR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel|To evaluate progression-free survival (PFS) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel|To evaluate the number of participants with adverse events and clinical laboratory abnormalities|To evaluate the effect of AMG 386 on the pharmacokinetics (Cmax, AUC and Cmin) of carboplatin and paclitaxel","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090155","November 2010","October 2012","January 2015","December 3, 2010",,"October 14, 2015","Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Barcelona, Cataluña, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01253681"
344,"NCT01235442","Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: 1=Etanercept|Drug: 2=Clobetasol propionate foam","PASI 75 at Week 12|sPGA (0,1) at Week 12|PASI 90 at Week 12|Patient Satisfaction at Week 12|Percent PASI Improvement From Baseline at Week 12|PASI 75 at Week 24|sPGA (0,1) at Week 24","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","592","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","20080470","September 2010","October 2011","December 2011","November 5, 2010","October 31, 2013","August 7, 2018",,,"https://ClinicalTrials.gov/show/NCT01235442"
345,"NCT01235416","A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors",,"Completed","No Results Available","Histologically or Cytologically Documented Solid Tumors","Drug: AMG 706","incidence of dose-limiting toxicities|Incidence of adverse events (including serious and treatment-related) and significant laboratory values other than those defined as dose-limiting toxicities|pharmacokinetic profiles of erlotinib and AMG 706","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050107","September 2005","April 2008","February 2010","November 5, 2010",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT01235416"
346,"NCT01221727","The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Denosumab|Drug: Midazolam","Ratio of Pharmcokinetic (PK) Area Under the Concentration Time Curve (AUC) Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)|Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam With Denosumab Group|Estimates of Inter- and Intra-subject Variability for PK Maximum Observed Plasma Concentration (Cmax) Parameter for Midazolam With Denosumab Group|Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1 (Midazolam Only)|Ratio of PK AUC Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)|Estimates of Inter- and Intra-subject Variability for the PK AUC Parameters for Midazolam Only Group|Estimates of Inter- and Intra-subject Variability for PK Cmax Parameter for Midazolam Only Group|Summary of Serum Denosumab Concentration|Summary of Serum C-Telopeptide Concentration|Summary of Percent Change From Baseline to Day 16 for Serum C-Telopeptide Concentration|Ratio of PK Cmax Parameter Estimates Between Day 16 (Midazolam Only) and Day 1(Midazolam Only)","Amgen","Female","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20101131","November 2010","July 2011","July 2011","October 15, 2010","November 7, 2013","August 7, 2018",,,"https://ClinicalTrials.gov/show/NCT01221727"
347,"NCT01204749","TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer",,"Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer","Drug: AMG 386|Drug: AMG 386 Placebo|Drug: Paclitaxel","Progression-Free Survival|Overall survival|Objective Response Rate|Duration of response|CA-125 response rate per Gynecologic Cancer Intergroup (GCIG) and change in CA-125|Incidence of adverse events and significant laboratory abnormalities|Pharmacokinetics of AMG 386 (Cmax and Cmin)|Incidence of the occurrence of anti-AMG 386 antibody formation|Patient reported Health Related Quality of Life (HRQOL) and ovarian cancer related symptoms using Functional Assessment of Cancer Therapy - Ovary questionnaire (FACT-O)|Overall health status using EuroQOL(EQ-5D)","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","919","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090508","November 2010","March 2013","December 2016","September 17, 2010",,"December 15, 2016","Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Peoria, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Brightwaters, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Bendigo, Victoria, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, ItajaÃ-, Santa Catarina, Brazil|Research Site, Ribeirao Preto, SÃ£o Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Gabrovo, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, CautÃ-n, Chile|Research Site, Valparaiso, ValparaÃ-so, Chile|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Amiens, France|Research Site, Angers, France|Research Site, Avignon Cedex 2, France|Research Site, Bayonne, France|Research Site, Besancon Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille cedex 05, France|Research Site, Marseille Cedex 09, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Nancy, France|Research Site, Nantes Cedex 2, France|Research Site, Nice cedex 2, France|Research Site, OrlÃ©ans cedex 2, France|Research Site, Paris cedex 15, France|Research Site, PÃ©rigueux cedex, France|Research Site, Reims Cedex, France|Research Site, Saint GrÃ©goire cedex, France|Research Site, Saint Herblain, France|Research Site, Strasbourg, France|Research Site, Villejuif cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Kefar Sava, Israel|Research Site, Tel Hashomer, Israel|Research Site, Tel-Aviv, Israel|Research Site, Benevento, Italy|Research Site, Catania, Italy|Research Site, Cosenza (CS), Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Potenza, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Nagoya-city, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kure-city, Hiroshima, Japan|Research Site, Sapporo-city, Hokkaido, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Morioka-city, Iwate, Japan|Research Site, Niigata-city, Niigata, Japan|Research Site, Osakasayama-city, Osaka, Japan|Research Site, Hidaka-Shi, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Yonago-city, Tottori, Japan|Research Site, Kurume-city, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Johor Bahru, Johor, Malaysia|Research Site, Kota Bahru, Kelantan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Coimbra, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Suceava, Romania|Research Site, Targu Mures, Romania|Research Site, Ivanovo, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kraaifontein, Western Cape, South Africa|Research Site, Observatory, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, Huelva, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Sevilla, AndalucÃ-a, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla LeÃ³n, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Elche, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, San SebastiÃ¡n, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, UmeÃ¥, Sweden|Research Site, Uppsala, Sweden|Research Site, Baden, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, Chur, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01204749"
348,"NCT01199302","Safety Study in Subjects With Crohn's Disease",,"Terminated","No Results Available","Crohn's Disease","Drug: AMG 827","To evaluate the efficacy of AMG 827 as measured by the Harvey-Bradshaw Index (HBI) and Crohn's Disease Activity Index (CDAI). To evaluate the maintenance of effect as measured by the HBI and CDAI|To evaluate the safety of long-term exposure with AMG 827 in subjects with Crohn's disease.|To determine if subjects develop anti-AMG 827 antibodies; to evaluate the change of EQ-5D from baseline at all timepoints, the effect of treatment on inflammatory markers (C-reactive protein [CRP]) at post-base, and the pharmacokinetics of AMG 827.","Amgen","All","Child, Adult, Older Adult","Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20100008|Crohn's OLE","December 2010","August 2011","August 2011","September 10, 2010",,"January 14, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Jacksonville, Florida, United States|Research Site, Hammond, Louisiana, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Mexico, Missouri, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Lille cedex, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 10, France|Research Site, Paris, France|Research Site, Toulouse Cedex 09, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Amsterdam, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Sopot, Poland|Research Site, Barcelona, Cataluña, Spain|Research Site, Pontevedra, Galicia, Spain",,"https://ClinicalTrials.gov/show/NCT01199302"
349,"NCT01199289","A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma",,"Completed","No Results Available","Asthma","Drug: AMG 827|Drug: Placebo","The primary objective is to determine if AMG 827 is effective compared to placebo as mesasured by change in Asthma Control Questionnaire (ACQ) composite scores from baseline to week 12.|Evaluate the efficacy of AMG 827 as measured by Pre- and post-bronchodilator FEV1 (forced expiratory volume in 1 second)|Evaluate the efficacy of AMG 827 as measured by am and pm Peak expiratory flow rate (PEFR)|Evaluate the efficacy of AMG 827 as measured by use of rescue Short Acting β-Agonist (SABA) use|Evaluate the efficacy of AMG 827 as measured by daily asthma symptoms (aggregate/night and individual)|Evaluate the efficacy of AMG 827 as measured by Asthma Quality of Life Questionnaire (AQLQ) score","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090203","October 2010","December 2011","December 2011","September 10, 2010",,"May 15, 2015","Research Site, Encinitas, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Stockton, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, St Louis, Missouri, United States|Research Site, Bozeman, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Skillman, New Jersey, United States|Research Site, Rockville Centre, New York, United States|Research Site, High Point, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Lake Oswego, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Madison, Wisconsin, United States|Research Site, Feldbach, Austria|Research Site, Hallein, Austria|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Helsinki, Finland|Research Site, Jyväskylä, Finland|Research Site, Turku, Finland|Research Site, Edeleny, Hungary|Research Site, Matrahaza, Hungary|Research Site, Tatabanya, Hungary|Research Site, Torokbalint, Hungary|Research Site, Zalaegerszeg - Pozva, Hungary|Research Site, Bucheon-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Rotterdam, Netherlands|Research Site, Bialystok, Poland|Research Site, Chodziez, Poland|Research Site, Gdansk, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01199289"
350,"NCT01181531","Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis",,"Completed","Has Results","Hyperparathyroidism, Secondary","Drug: Traditional Vitamin D Therapy|Drug: Cinacalcet","Percent Change From Baseline in Mean PTH During Efficacy Assessment Phase (EAP)|Treatment Comparison of >=30% Reduction From Baseline in Mean PTH During the Efficacy Assessment Phase (EAP)|Treatment Comparison of Plasma PTH < 300 pg/mL During Efficacy Assessment Phase (EAP)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090686|PARADIGM","October 1, 2010","July 17, 2012","August 14, 2012","August 13, 2010","April 25, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT01181531"
351,"NCT01164917","Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus",,"Terminated","No Results Available","Cutaneous Lupus|Discoid Lupus|Lupus|Systemic Lupus Erythematosus","Drug: AMG811|Drug: AMG811 Placebo","Safety evaluation: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examination endpoints, clinical laboratory safety tests, ECGs and the development of anti-AMG811 antibodies|PK parameters, Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score and IFN-gamma related gene expression in skin biopsy samples","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20100011","August 2010","September 2012","March 2013","July 19, 2010",,"September 16, 2014","Research Site, Santa Monica, California, United States|Research Site, Stanford, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Durham, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01164917"
352,"NCT01164904","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis",,"Terminated","No Results Available","Ulcerative Colitis","Drug: Amg 181","To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)|To characterize the pharmacokinetics (PK) of ascending single doses of AMG 181|To characterize the pharmacodynamic (PD) effects of AMG 181 on receptor occupancy and on cell counts in selected lymphocyte subset populations","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090107","July 2010","January 2013","March 2013","July 19, 2010",,"July 25, 2013","Research Site, Glendale, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT01164904"
353,"NCT01150890","AMG 827 in Subjects With Moderate to Severe Crohn's Disease",,"Terminated","No Results Available","Crohn's Disease","Drug: AMG 827 350 MG|Drug: AMG 827 210 MG|Drug: AMG 827 700 MG|Drug: Placebo","To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving Crohn's Disease Activity Index (CDAI) remission (≤ 150) at week 6.|To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with a CDAI response (reduction from baseline of ≥ 100) at week 6|To evaluate improvement from baseline in CDAI at week 6|To evaluate the short term safety profile of AMG 827 in subjects with Crohn's disease|To characterize the pharmacokinetics (PK) of AMG 827 in subjects with Crohn's disease","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090072","July 2010","August 2011","August 2011","June 25, 2010",,"January 14, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Dithan, Alabama, United States|Research Site, Lowell, Arkansas, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Hammond, Louisiana, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Mexico, Missouri, United States|Research Site, Egg Harbor Township, New Jersey, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Logan, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Box Hill, Australia|Research Site, Fitzroy, Australia|Research Site, Fremantle, Australia|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Lille cedex, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 10, France|Research Site, Paris, France|Research Site, Toulouse Cedex 09, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Sopot, Poland|Research Site, Pontevedra, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01150890"
354,"NCT01143038","Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura","Biological: Romiplostim","Number of Months With Platelet Response During the 12-Month Treatment Period|Percentage of Participants With ITP Remission|Percentage of Participants With Splenectomy During the 12-month Treatment Period|Number of Participants With Adverse Events|Number of Participants Who Developed Antibodies to Romiplostim","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080435|2010-019987-35","November 30, 2010","September 20, 2013","December 26, 2013","June 14, 2010","February 24, 2016","May 22, 2019","Research Site, Anaheim, California, United States|Research Site, Orange, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hickory, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Richlands, Virginia, United States|Research Site, Randwick, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Brno, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 2, Czechia|Research Site, Bondy Cedex, France|Research Site, Créteil Cedex, France|Research Site, Dijon, France|Research Site, Pessac Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Düsseldorf, Germany|Research Site, Köln, Germany|Research Site, Bari, Italy|Research Site, Catania, Italy|Research Site, Monza (MB), Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Vicenza, Italy|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Wroclaw, Poland|Research Site, Málaga, Andalucía, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Alcorcon, Madrid, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Coventry, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01143038"
355,"NCT01137565","Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma",,"Completed","No Results Available","Asthma","Drug: AMG 853|Drug: Placebo","Evaluation of treatment-emergent adverse events, safety and laboratory assessments in adolescent subjects with intermittent or mild to moderate asthma as a measure of safety and tolerability|Pharmacokinetic parameters (including Cmax and AUC) for a single dose administration of AMG 853 in adolescent and adult subjects","Amgen","All","12 Years to 50 Years   (Child, Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","20090223","June 2010","January 2011","January 2011","June 4, 2010",,"March 4, 2014",,,"https://ClinicalTrials.gov/show/NCT01137565"
356,"NCT01137552","A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors",,"Terminated","No Results Available","Advanced Solid Tumors","Drug: AMG 780","To assess the safety and tolerability of AMG 780 in subjects with advanced solid malignancies (including adverse event rate, incidence of dose-limiting toxicities, and determination of maximum tolerated dose)|To evaluate the pharmacokinetic (PK) parameters of AMG 780 including, but not limited to Cmax, AUC, and accumulation ratio|To evaluate tumor response using RECIST criteria (measured by CT/MRI)|To evaluate changes in tumor volume (measured by volumetric CT/MRI)|To evaluate changes in tumor vascularity and to estimate the relationship between dose/pharmacokinetics and vascular response (measured by DCE-MRI)|To evaluate the incidence of anti-AMG 780 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070879","June 2010","December 2013","April 2014","June 4, 2010",,"March 4, 2015","Research Site, Los Angeles, California, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01137552"
357,"NCT01133522","Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin",,"Completed","Has Results","Hyperlipidemia","Biological: Evolocumab|Biological: Placebo","Number of Participants With Adverse Events|Number of Participants With Anti-Evolocumab Antibodies|Maximum Observed Plasma Concentration (Cmax) of Evolocumab|Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Evolocumab|Percent Change From Baseline to End of the Dosing Interval in LDL-C|Percent Change From Baseline to End of the Dosing Interval in PCSK9","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080398","June 1, 2010","September 14, 2011","September 14, 2011","May 31, 2010","October 22, 2015","November 2, 2018",,,"https://ClinicalTrials.gov/show/NCT01133522"
358,"NCT01129349","Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: Oprozomib","Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)|Overall response rate (ORR), duration of responses (DOR), progression-free survival (PFS), and time to progression (TTP)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-003","April 2010","November 2012","March 2013","May 24, 2010",,"May 2, 2017","Oncology Research Associates, Scottsdale, Arizona, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01129349"
359,"NCT01124279","Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: AMG 853","Pharmacokinetic parameters|Treatment-emergent adverse events, safety and laboratory assessments","Amgen","All","18 Years to 55 Years   (Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20090226","May 2010","August 2010","October 2010","May 17, 2010",,"January 7, 2011",,,"https://ClinicalTrials.gov/show/NCT01124279"
360,"NCT01101061","A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women",,"Completed","Has Results","Osteopenia","Drug: Romosozumab|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants Who Developed Anti-romosozumab Binding Antibodies|Serum Calcium Levels|Serum Intact Parathyroid Hormone (iPTH) Levels|Maximum Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)|Maximum Percent Change From Baseline in Serum C-telopeptide (CTX)|Percent Change From Baseline in Sclerostin|Time to Maximum Observed Concentration of Romosozumab|Maximum Observed Concentration of Romosozumab|Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUClast) of Romosozumab|Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf) for Romosozumab|Apparent Clearance (CL/F) of Romosozumab|Half-life Associated With Beta (Plateau) Phase of Elimination (T1/2,β) for Romosozumab|Half-life Associated With Gamma (Terminal) Phase of Elimination (T1/2,ɣ) for Romosozumab","Amgen","Female","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090378","May 3, 2010","November 1, 2010","November 1, 2010","April 9, 2010","July 31, 2019","July 31, 2019",,,"https://ClinicalTrials.gov/show/NCT01101061"
361,"NCT01101048","An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density",,"Completed","No Results Available","Osteopenia","Drug: Placebo|Drug: AMG 167","The number (percent) of subjects experiencing clinically significant changes in safety laboratory tests, physical examinations, vital signs, or electrocardiograms (ECGs)|The number (percent) of subjects reporting treatment-emergent adverse events|The number (percent) of subjects who develop anti-AMG 167 antibodies|Pharmacodynamic parameters [bone mineral density as assessed by dual energy X-ray absorptiometry (DXA), serum procollagen type 1 N-terminal propeptide (P1NP), osteocalcin, bone-specific alkaline phosphatase (BSAP), and serum CTX levels] and sclerostin|Pharmacokinetics","Amgen","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20080389","June 2010","February 2012","February 2012","April 9, 2010",,"September 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01101048"
362,"NCT01081678","Study To Assess FRacTure Healing With SclerosTin Antibody - Hip","STARTT-Hip","Completed","Has Results","Fracture Healing","Drug: Placebo|Drug: Romosozumab","Timed-Up-and-Go (TUG) Over Week 6 Through Week 20|Timed-Up-and-Go (TUG) at Each Visit|Time to Radiographic Healing|Radiographic Union Scale for Hip (RUSH) Score At Each Visit|Harris Hip Score At Each Visit|Hip Pain Score at Each Visit","Amgen","All","55 Years to 95 Years   (Adult, Older Adult)","Phase 2","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080394","June 20, 2010","June 30, 2012","May 10, 2013","March 5, 2010","May 2, 2019","May 2, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Pomona, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Brooklyn, New York, United States|Research Site, Rochester, New York, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, State College, Pennsylvania, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Brugge, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Blagoevgrad, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Red Deer, Alberta, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Hvidovre, Denmark|Research Site, KÃ¸benhavn NV, Denmark|Research Site, Viborg, Denmark|Research Site, Ã…rhus C, Denmark|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Turku, Finland|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Muenchen, Germany|Research Site, Muenster, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Mangalore, India|Research Site, Nashik, India|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Roma (RM), Italy|Research Site, Verona, Italy|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Christchurch, New Zealand|Research Site, KrakÃ³w, Poland|Research Site, Lublin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Celje, Slovenia|Research Site, Izola, Slovenia|Research Site, Jesenice, Slovenia|Research Site, Sempeter pri Gorici, Slovenia|Research Site, LinkÃ¶ping, Sweden|Research Site, Lund, Sweden|Research Site, Basel, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Luzern, Switzerland|Research Site, Zurich, Switzerland|Research Site, Barnet, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01081678"
363,"NCT01080391","Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma",,"Completed","Has Results","Relapsed Multiple Myeloma","Drug: Dexamethasone|Drug: Lenalidomide|Drug: Carfilzomib","Progression-free Survival (PFS)|Overall Survival|Overall Response Rate|Disease Control Rate|Duration of Response|Duration of Disease Control|Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","792","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-009","July 14, 2010","June 16, 2014","December 5, 2017","March 4, 2010","July 8, 2015","January 14, 2019","Mayo Clinic, Scottsdale, Arizona, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|The University of Michigan - Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Clinical Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|The Don & Sybil Harrington Cancer Center, Amarillo, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medizinische Universitat Wien, Wien, Austria|Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie, Wien, Austria|Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg, Antwerpen, Belgium|AZ Sint-Jan AV, Brugge, Belgium|UZ Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|University Multiprofile Hospital for Active Treatment, ""Dr. Georgi Stranski"", Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Bulgaria|Military Medical Academy Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|General Hospital, Health Sciences Centre, St John's, Newfoundland and Labrador, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada|Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada|University Hospital Brno, Department of Internal Medicine - Hematooncology, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Olomouc, Olomouc, Czechia|University Hospital Kralovske Vinohrady - Prague, Praha 10, Czechia|General University Hospital Prague, Praha 2, Czechia|Hospital Antoine Beclere, Clamart, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Hopital Claude Huriez, Lille, France|CH de Mulhouse, Hopital Emile Muller, Mulhouse, France|CHU Nantes Hotel Dieu, Nantes, France|Hopital Saint-Antoine, Paris, France|Groupe Hospitalier Necker - Enfants Malades, Paris, France|Cancer Institut Universitaire de Toulouse-Oncopole (iUCT), Toulouse, France|Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France|University of Dusseldorf, Dusseldorf, Germany|Krankenhaus Nordwest, Frankfurt am Main, Germany|University of Hamburg-Eppendorf, Hamburg, Germany|Universitat Heidelberg, Heidelberg, Germany|Stiftungsklinikum Mittelrhein, Koblenz, Germany|LMU Klinikum der Universitat, Munchen, Germany|Universitatsklinikum Munster, Munster, Germany|Universitatsklinikum Wurzburg, Wurzburg, Germany|Alexandra Hospital, Athens, Greece|University General Hospital of Patras, Patras, Greece|St. Istvan and St. Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Medical and Health Science Center, Debrecen, Hungary|Petz Aladar County Teaching Hospital, Gyor, Hungary|Bekes County Pandy Kalman Hospital, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Pecs, Pecs, Hungary|University of Szeged, Albert Szent-Gyorgi Clinical Center, Szeged, Hungary|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Ein Kerem, Jerusalem, Israel|Western Gailee Hospital - Nahariya, Nahariya, Israel|Rabin Medical Center, Petach Tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Azienda Ospedallera Niguarda Ca Granda, Milano, Italy|Azienda Ospedllero Maggiore della Carita, Novara, Italy|Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main, Pisa, Italy|Ospedale S. Eugenio, Roma, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Erasmus MC, Department of Haematology, Rotterdam, Netherlands|University Clinical Centre, Department of Hematologii Transplantologii, Gdansk, Poland|Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp., Gorzow Wielkopolski, Poland|Independent Public Teaching Hospital of Medical University of Silesia in Katowice, Katowice, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Lodz, Poland|Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach, Suwalki, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Maria Sklodowska-Curie Institute of Oncology, Warszawa, Poland|Zamojski Non-Public Hospital, Zamosc, Poland|Fundeni Clinical Institute, ""Stefan Berceanu"" Center for Hematology and Bone Marrow Transplantation, Bucharest, Romania|Coltea Clinical Hospital, Bucharest, Romania|Bucharest University Emergency Hospital, Bucharest, Romania|Regional Institute of Iasi, Iasi, Romania|State Medical Institution Komi Republican Oncological Center, Syktyvkar, Komi Republic, Russian Federation|First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia, Izhevsk, Russian Federation|Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation|Federal State Budget Institution: Hematology Research Center under MoH, Moscow, Russian Federation|FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&B, St. Petersburg, Russian Federation|State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov, St. Petersburg, Russian Federation|SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant, St. Petersburg, Russian Federation|Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare, St. Petersburg, Russian Federation|Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Military Medical Academy, Clinic of Hematology, Belgrade, Serbia|Clinical Center Nis, Clinic of Hematology, Nis, Serbia|Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, Serbia|Hospital Universitario Germans Trias i Pujol, Badalona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Donostia, San Sebastian, Spain|Hospital Universitario y Politeecnico La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Karolinska Universitetsjukhuset i Huddinge, Stockholm, Sweden|Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum, Stockholm, Sweden|St. Bartholomew's Hospital, London, United Kingdom|Royal Free Hampstead, London, United Kingdom|St. Georges Hospital, London, United Kingdom|Nottingham University Hospitals (City Campus), Nottingham, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|The Royal Wolverhampton Hospital NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01080391"
364,"NCT01077167","Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients",,"Withdrawn","No Results Available","Heart Failure","Drug: Omecamtiv mecarbil","Pharmacokinetic profile of oral formulations of Omecamtiv mecarbil following the morning dose on Days 7 and 8|Safety and tolerability of oral formulations of Omecamtiv mecarbil at steady state","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20090618","July 2010","May 2011","May 2011","February 26, 2010",,"May 30, 2011",,,"https://ClinicalTrials.gov/show/NCT01077167"
365,"NCT01077154","Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)",,"Terminated","Has Results","Breast Cancer","Drug: Placebo|Drug: Denosumab","Bone Metastasis-free Survival (BMFS)|Disease-free Survival (DFS)|Disease-free Survival (DFS) in the Postmenopausal Subset|Overall Survival|Distant Recurrence-free Survival","Amgen|Daiichi Sankyo, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","4509","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060359|2009-011299-32","June 2, 2010","August 31, 2017","March 26, 2018","February 26, 2010","October 3, 2018","April 5, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Campbell, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, La Verne, California, United States|Research Site, Lancaster, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Grand Junction, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Niles, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Cedar Rapids, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Denville, New Jersey, United States|Research Site, Hackensack, New Jersey, United States|Research Site, East Setauket, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Abilene, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Garland, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richlands, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, Neuquen, NeuquÃ©n, Argentina|Research Site, Provincia De Santa Fe, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Caringbah, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Warrnambool, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Namur, Belgium|Research Site, Oostende, Belgium|Research Site, Ottignies, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Tournai, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Salvador, Bahia, Brazil|Research Site, Salvador, Bahia, Brazil|Research Site, Curitiba, ParanÃ¡, Brazil|Research Site, Londrina, ParanÃ¡, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, ItajaÃ-, Santa Catarina, Brazil|Research Site, Barretos, SÃ£o Paulo, Brazil|Research Site, Santo Andre, SÃ£o Paulo, Brazil|Research Site, Sao Paulo, SÃ£o Paulo, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, CautÃ-n, Chile|Research Site, Vina del Mar, ValparaÃ-so, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Herning, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Ã…rhus C, Denmark|Research Site, Angers, France|Research Site, Bordeaux Cedex, France|Research Site, Dijon, France|Research Site, Grenoble, France|Research Site, HyÃ¨res, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Monaco, France|Research Site, Nantes Cedex 2, France|Research Site, Paris, France|Research Site, Pierre-Benite, France|Research Site, Saint Priest en Jarez Cedex, France|Research Site, Strasbourg cedex, France|Research Site, Villejuif cedex, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Bottrop, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Kiel, Germany|Research Site, Koblenz, Germany|Research Site, Mannheim, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, Recklinghausen, Germany|Research Site, Rostock, Germany|Research Site, Trier, Germany|Research Site, TÃ¼bingen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Limerick, Ireland|Research Site, Waterford, Ireland|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Sava, Israel|Research Site, Petah Tikva, Israel|Research Site, Poria Eylit, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Aviv, Israel|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Meldola FC, Italy|Research Site, Milano, Italy|Research Site, Monza (MB), Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Treviglio (BG), Italy|Research Site, Varese, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Akashi-shi, Hyogo, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Isehara-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Miyazaki-shi, Miyazaki, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Kurashiki-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Hidaka-Shi, Saitama, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Shimotsuke-shi, Tochigi, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Subang Jaya, Selangor (incl. Putrajaya), Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Pachuca de Soto, Hidalgo, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, Queretaro, QuerÃ©taro, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Colima, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Durango, Mexico|Research Site, Toluca, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Bergen op Zoom, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle aan den ijssel, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Venlo, Netherlands|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Metro Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Rzeszow, Poland|Research Site, Szczecin, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Bardejov, Slovakia|Research Site, Kosice, Slovakia|Research Site, Michalovce, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Ljublijana, Slovenia|Research Site, Maribor, Slovenia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Cape Town, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, CÃ¡diz, AndalucÃ-a, Spain|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Sevilla, AndalucÃ-a, Spain|Research Site, Zaragoza, AragÃ³n, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Girona, CataluÃ±a, Spain|Research Site, Lleida, CataluÃ±a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Elche, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, AlcorcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Putzu City, Chiayi, Taiwan|Research Site, Keelung City, Keelung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bornova-Izmir, Turkey|Research Site, Ä°zmir, Turkey|Research Site, Bebington, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Dorset, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/Prot_000.pdf|""Statistical Analysis Plan: SAP 3.0"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/SAP_001.pdf|""Statistical Analysis Plan: SAP 3.0 Addendum"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01077154"
366,"NCT01071954","A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura",,"Completed","Has Results","Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP","Biological: Romiplostim","Number of Participants With Adverse Events|Duration Adjusted Rate of Treatment Emergent Adverse Events|Number of Participants Who Developed Antibodies to Romiplostim|Number of Participants Who Developed Antibodies to Endogenous Thrombopoietin|Percentage of Participants With a Platelet Response|Percentage of Participants Who Used Concomitant ITP Therapy","Amgen","All","1 Year and older   (Child, Adult, Older Adult)","Phase 3","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20090340|2009-016203-32","December 30, 2009","January 12, 2017","January 12, 2017","February 19, 2010","January 29, 2019","January 18, 2020","Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Randwick, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Barcelona, Cataluña, Spain",,"https://ClinicalTrials.gov/show/NCT01071954"
367,"NCT01059448","Safety and Efficacy of AMG 827 in Subjects With RA",,"Terminated","No Results Available","Rheumatoid Arthritis","Drug: AMG 827","To evaluate the safety of long-term exposure with AMG 827 is subjects with rheumatoid arthritis.|To evaluate the efficacy of AMG 827 as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20, 50, and 70 response|To evaluate the efficacy of AMG 827 as measured by the change in Disease Activity Score 28 joint (DAS28) score|To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with DAS28<2.6|To evaluate the efficacy of AMG 827 as measured by the DAS28 score|To evaluate the efficacy of AMG 827 as measured by the ACR individual components|To evaluate the effect of treatment on patient-reported outcomes, including the Medical Outcomes Short Form-36 (SF-36), Medical Outcomes Study (MOS) Sleep Scale, and Health Assessment Questionnaire Disability Index (HAQ-DI)|To determine the proportion of subjects who develop anti-AMG 827 anti-bodies|To explore lipid profiles in subjects receiving AMG 827","Amgen","All","Child, Adult, Older Adult","Phase 2","211","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090402","May 2010","April 2011","April 2011","February 1, 2010",,"September 2, 2015","Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Victorville, California, United States|Research Site, Sarasota, Florida, United States|Research Site, Rock Island, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Freehold, New Jersey, United States|Research Site, Portland, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Tacoma, Washington, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Praha 11, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Bauska, Latvia|Research Site, Daugavpils, Latvia|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Tijuana, Baja Calif, Mexico|Research Site, Mexico City, Distrito F, Mexico|Research Site, Mexico City, Distrito F, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Morelia, MichoacÃ¡n, Mexico|Research Site, San Luis Potosi, San Luis P, Mexico|Research Site, Bialystok, Poland|Research Site, Bialystok, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, ToruÅ"", Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zyrardow, Poland|Research Site, Merseyside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01059448"
368,"NCT01059435","A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women",,"Completed","Has Results","Osteopenia","Drug: Romosozumab|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants Who Developed Anti-romosozumab Antibodies|Maximum Observed Concentration (Cmax) of Romosozumab|Time to Maximum Observed Concentration (Tmax) of Romosozumab|Initial Concentration Following IV Administration (C0) of Romosozumab|Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab|Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab|Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab|Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab|Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP)|Time to Maximum Effect of P1NP|Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP|Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP|Maximum Effect for Serum C-telopeptide (sCTX)|Time to Maximum Effect of sCTX|Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX|Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX|Maximum Effect for Osteocalcin|Time to Maximum Effect of Osteocalcin|Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin|Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin|Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP)|Time to Maximum Effect of BSAP|Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP|Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP|Maximum Effect for Intact Parathyroid Hormone (iPTH)|Time to Maximum Effect of iPTH|Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH|Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH|Percent Change From Baseline in Sclerostin|Serum Calcium Over Time|Ionized Calcium Over Time","Amgen","All","45 Years to 59 Years   (Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060220","December 13, 2006","July 6, 2007","July 6, 2007","February 1, 2010","July 5, 2019","July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT01059435"
369,"NCT01018550","AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma",,"Completed","No Results Available","Asthma","Drug: AMG 853|Drug: Placebo","The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.|Evaluate the efficacy of AMG 853 as measured by use of rescue short-acting β-agonist (SABA)|Evaluate the efficacy of AMG 853 as measured by daily symptom score (aggregate/night and individual symptoms; and symptom free days)|Evaluate the efficacy of AMG 853 as measured by pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1)|Evaluate the efficacy of AMG 853 as measured by AM and PM peak expiratory flow rate (PEFR)|Evaluate the efficacy of AMG 853 as measured by asthma quality of life questionnaire (AQLQ)","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","397","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20080615","October 2009","December 2010","March 2011","November 23, 2009",,"March 23, 2016",,,"https://ClinicalTrials.gov/show/NCT01018550"
370,"NCT01001377","ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Panitumumab","Overall Survival|Progression-free Survival|Objective Response|Duration of Response|Time to Response|Time to Treatment Failure|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)|Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score|Change From Baseline in NCCN FCSI Physical Well-being Scale Score|Change From Baseline in NCCN FCSI Functional Well-being Scale Score|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1010","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080763|ASPECCT|2009-010715-32","February 2, 2010","February 5, 2013","March 7, 2017","October 26, 2009","March 24, 2014","December 26, 2018","Research Site, Stockton, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Wichita, Kansas, United States|Research Site, Temple, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Ballarat, Victoria, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Edegem, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Harbin, Heilongjiang, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, XI An, Shaanxi, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Chongqing, Sichuan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Horovice, Czechia|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Pribram, Czechia|Research Site, Znojmo, Czechia|Research Site, Besançon Cedex, France|Research Site, Montbéliard, France|Research Site, Saint Brieuc, France|Research Site, Saint Herblain, France|Research Site, Villejuif cedex, France|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Kochi, Kerala, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Beer Sheva, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovot, Israel|Research Site, Ancona, Italy|Research Site, Cesena, Italy|Research Site, Cremona, Italy|Research Site, Faenza RA, Italy|Research Site, Genova, Italy|Research Site, Lugo, Italy|Research Site, Meldola FC, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Torino, Italy|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Rotterdam, Netherlands|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Elblag, Poland|Research Site, Gdansk, Poland|Research Site, Jelenia Gora, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kraaifontein, Western Cape, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Växjö, Sweden|Research Site, Putzu City, Chiayi, Taiwan|Research Site, Keelung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Belfast, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01001377"
371,"NCT01001208","The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis",,"Completed","Has Results","Psoriasis","Drug: Methotrexate|Drug: Etanercept|Drug: Placebo","PASI 75 Response at Week 24|PASI 50 Response at Week 24|Static Physician Global Assessment (sPGA) Response at Week 24|PASI 50 Response at Week 12|PASI 75 Response at Week 12|Static Physician Global Assessment (sPGA) Response at Week 12|PASI 90 Response at Week 12|PASI 90 Response at Week 24|Change From Baseline in the Percentage of Body Surface Area Involved With Psoriasis at Week 12|Change Form Baseline in Percentage of Body Surface Area Involved With Psoriasis at Week 24","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","478","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070559","November 2009","December 2010","February 2011","October 26, 2009","August 12, 2013","August 12, 2013",,,"https://ClinicalTrials.gov/show/NCT01001208"
372,"NCT00989092","Darbepoetin Alfa and Anemia of Cancer",,"Terminated","Has Results","Anemia|Anemia of Cancer|Cancer|Carcinoma|Neoplasms|Non-Myeloid Malignancies","Biological: darbepoetin alfa","Number of Participants Hospitalized During the Test Period|Days of Hospitalization During the Test Period|Number of Hospitalizations During the Test Period|Total Hospital Costs During the Test Period|Change in Functional Assessment of Cancer Therapy (FACT)-Fatigue Score at Week 13|Hemoglobin Response During the Test Period|Hematopoietic Response During the Test Period|Change From Baseline in Hemoglobin Level|Number of Participants With Red Blood Cell (RBC) Transfusions During the Test Period|Number of Units of Red Blood Cells Transfused During the Test Period|Number of Days of Red Blood Cell Transfusions During the Test Period|Number of Participants With Red Blood Cell (RBC) Transfusions During Weeks 5-12|Number of Units of Red Blood Cells Transfused During Weeks 5-12|Number of Days of Red Blood Cell Transfusions During Weeks 5-12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20000219","May 2002","January 2004","June 2004","October 2, 2009","January 29, 2014","January 29, 2014",,,"https://ClinicalTrials.gov/show/NCT00989092"
373,"NCT00980174","Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis",,"Completed","Has Results","Low Bone Mass|Low Bone Mineral Density|Males With Osteoporosis|Osteopenia|Osteoporosis","Drug: 60 mg denosumab|Other: Placebo","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12|Total Hip Bone Mineral Density Percent Change From Baseline at Month 12|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12|Trochanter Bone Mineral Density Percent Change From Baseline at Month 12|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12|Serum Type 1 Collagen C-telopeptide (CTX) Percent Change From Baseline at Day 15","Amgen","Male","30 Years to 85 Years   (Adult, Older Adult)","Phase 3","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20080098","October 1, 2009","June 21, 2011","May 23, 2012","September 18, 2009","November 29, 2012","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00980174"
374,"NCT00975221","Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy",,"Completed","Has Results","Hyperparathyroidism, Primary|Hypercalcemia","Drug: Cinacalcet|Drug: Placebo","Percentage of Participants With Mean Corrected Total Serum Calcium Concentration ≤ 10.3 mg/dL (2.57 mmol/L) During the EAP|Percentage of Participants With a ≥ 1 mg/dL (0.25 mmol/L) Decrease From Baseline in Mean Corrected Total Serum Calcium Concentration During the EAP|Percent Change From Baseline in Corrected Total Serum Calcium Concentration During the EAP|Percent Change From Baseline in Plasma Parathyroid Hormone Level During the EAP","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070277","March 10, 2010","July 12, 2012","December 21, 2012","September 11, 2009","January 25, 2016","October 17, 2018","Research Site, Lake Forest, California, United States|Research Site, Lancaster, California, United States|Research Site, Los Gatos, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kenner, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Randwick, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Calgary, Alberta, Canada|Research Site, London, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Szeged, Hungary|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Rostov-na-Dony, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00975221"
375,"NCT00975104","AMG 745 in Subjects With Age-associated Muscle Loss",,"Withdrawn","No Results Available","Age-associated Muscle Loss","Drug: AMG 745 0.3 mg/kg|Drug: AMG 745 1.0 mg/kg|Drug: AMG 745 3.0 mg/kg|Drug: Placebo","To evaluate the effect of AMG 745 weekly IV doses of 0.3 mg/kg, 1.0 mg/kg, or 3.0 mg/kg, compared with weekly IV placebo on thigh muscle CSA in subjects ≥ 65 yrs old with limited exercise tolerance and functional limitations|To evaluate the effect of treatment with AMG 745 on muscle strength (hand grip strength) and function (gait speed, 10-step stair climb power, chair stand and 6 minute walk distance) and to evaluate the PK of AMG 745 following multiple IV administrations","Amgen","All","65 Years and older   (Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20080733","April 2010","May 2011","August 2011","September 11, 2009",,"October 4, 2018",,,"https://ClinicalTrials.gov/show/NCT00975104"
376,"NCT00975000","Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients",,"Completed","Has Results","Chronic Allograft Nephropathy|Chronic Kidney Disease|Chronic Renal Failure|Disordered Mineral Metabolism|End Stage Renal Disease|Hyperparathyroidism|Hypophosphatemia|Kidney Disease|Kidney Transplantation|Post Renal Transplantation","Drug: Cinacalcet|Drug: Placebo","Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP)|Percent Change From Baseline to Week 52 in Bone Mineral Density at the Femoral Neck|Change From Baseline to the EAP in Mean Serum Phosphorus|Change From Baseline to Week 52 in eGFR|Change From Baseline to the EAP in Corrected Total Calcium|Change From Baseline to the EAP in Intact Parathyroid Hormone (iPTH)|Change From Baseline to the EAP in Urine Phosphorus|Percentage of Participants With a Parathyroidectomy|Time to Parathyroidectomy","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20062007","December 3, 2009","September 13, 2012","April 16, 2013","September 11, 2009","January 29, 2016","October 17, 2018","Research Site, Phoenix, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Gainesville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Wien, Austria|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Bordeaux Cedex, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 15, France|Research Site, Toulouse Cedex 09, France|Research Site, Berlin, Germany|Research Site, Kiel, Germany|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Madrid, Spain|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00975000"
377,"NCT00972179","Safety Study of AMG 157 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: AMG 157 Placebo|Drug: AMG 157","Safety evaluations: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations, laboratory safety tests, ECGs, and the development of anti-AMG 157 antibodies|Serum PK parameters","Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20080390","September 2009","December 2010","December 2010","September 4, 2009",,"August 26, 2011",,,"https://ClinicalTrials.gov/show/NCT00972179"
378,"NCT00950989","AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 827 70 mg|Drug: AMG 827 140 mg|Drug: AMG 827 210 mg|Drug: Placebo|Drug: Stable weekly dose of methotrexate","To evaluate the efficacy of AMG 827 compared with placebo as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 50 response at week 12.|To evaluate the efficacy of AMG 827 as measured by the following: The proportion of subjects with an ACR 20 and 70 at week 12 and Disease Activity Score 28 joint (DAS28) at week 12.|To evaluate the short term safety profile of AMG 827 in subjects with rheumatoid arthritis (RA)|To characterize the pharmacokinetics (PK) of AMG 827 in subjects with Rheumatoid Arthritis (RA)","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090061","December 2009","February 2011","February 2011","August 3, 2009",,"September 5, 2016",,,"https://ClinicalTrials.gov/show/NCT00950989"
379,"NCT00950950","A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass",,"Completed","Has Results","Osteopenia","Drug: Romosozumab|Drug: Placebo","Percent Change From Baseline in Polar Cross-sectional Moment of Inertia at the Distal Radius|Percent Change From Baseline in Total Bone Area at the Distal Radius|Percent Change From Baseline in Total Bone Mineral Content at the Distal Radius|Percent Change From Baseline in Total Bone Mineral Density at the Distal Radius|Percent Change From Baseline in Cortical Bone Area at the Distal Radius|Percent Change From Baseline in Cortical Bone Mineral Content at the Distal Radius|Percent Change From Baseline in Cortical Bone Mineral Density at the Distal Radius|Percent Change From Baseline in Endocortical Circumference at the Distal Radius|Percent Change From Baseline in Periosteal Circumference at the Distal Radius|Percent Change From Baseline in Cortical Thickness at the Distal Radius|Percent Change From Baseline in Polar Section Modulus at the Distal Radius|Percent Change From Baseline in Polar Strength Strain Index at the Distal Radius|Percent Change From Baseline in Axial Moment of Inertia at the Distal Radius|Percent Change From Baseline in Total Bone Area at the Ultradistal Radius|Percent Change From Baseline in Total Bone Mineral Content at the Ultradistal Radius|Percent Change From Baseline in Total Bone Mineral Density at the Ultradistal Radius|Percent Change From Baseline in Trabecular Bone Area at the Ultradistal Radius|Percent Change From Baseline in Trabecular Bone Mineral Content at the Ultradistal Radius|Percent Change From Baseline in Trabecular Bone Mineral Density at the Ultradistal Radius|Percent Change From Baseline in Polar Strength Strain Index at the Ultradistal Radius|Percent Change From Baseline in Bone Mineral Density at the One-third Radius|Percent Change From Baseline in Bone Mineral Density at the Total Wrist|Percent Change From Baseline in Bone Mineral Density at the Total Lumbar Spine|Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)|Percent Change From Baseline in Serum C-Telopeptide (sCTX)|Time to Maximum Serum Concentration (Tmax) of Romosozumab|Maximum Serum Concentration (Cmax) of Romosozumab|Area Under the Serum Concentration-time Curve From Time 0 to Tau (AUC0-28)|Area Under the Serum Concentration-time Curve From Time 0 to Infinity (AUCinf)|Apparent Clearance (CL/F) of Romosozumab|Terminal Half-life (t1/2,z) of Romosozumab|Accumulation Ratio","Amgen","Female","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20090153","August 18, 2009","August 19, 2010","August 19, 2010","August 3, 2009","July 5, 2019","July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT00950950"
380,"NCT00950911","Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only",,"Completed","Has Results","Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer|Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma","Drug: amg 162","Number of Participants Survived","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20080540","July 2009","February 2012","April 2012","August 3, 2009","February 11, 2014","February 11, 2014","Research Site, Jindrichuv Hradec, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 1, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Chichester, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00950911"
381,"NCT00936988","A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism",,"Completed","No Results Available","Hyperparathyroidism, Primary","Drug: cinacalcet","Nature, frequency, severity, and relationship to treatment of adverse events|Calcium levels and plasma iPTH during the maintenance phase|Percentage changes in BMD from baseline of the parent study to each measurement time point and absolute BMD values, as assessed by DXA scans of proximal femur, lumbar spine (L1-L4), forearm, and total body scans","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000159","November 2000","June 2005","December 2005","July 10, 2009",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00936988"
382,"NCT00936897","A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Ibandronate|Drug: Denosumab","Total Hip Bone Mineral Density Percent Change From Baseline at Month 12|Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 3","833","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080562","July 2009","November 2011","January 2012","July 10, 2009","November 29, 2012","February 11, 2013",,,"https://ClinicalTrials.gov/show/NCT00936897"
383,"NCT00936650","A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)",,"Completed","No Results Available","Hyperparathyroidism, Primary","Drug: placebo|Drug: cinacalcet","Proportion of subjects with the mean of the maintenance phase serum calcium measurements ≤ 10.3 mg/dL and with a mean decrease of at least 0.5 mg/dL|The change from baseline and percent change from baseline in maintenance phase mean for the following variables: serum BALP, serum 1,25(OH)2D3, serum NTx, serum phosphorus, urinary calcium/creatinine ratio, urinary DPD/creatinine ratio, and urinary NTx/c|The internal consistency reliability, discriminant validity, criterion validity, and responsiveness of the Medical Outcomes Short Form-36 (SF-36), Brief Symptom Inventory (BSI), and Visual Analogue Scale (VAS)|Change from baseline in serum calcium, percent change from baseline in serum calcium, and the proportion of subjects maintaining a 12-week maintenance phase mean reduction of serum calcium from baseline of at least 0.5 mg/dL|Change from baseline in iPTH, percent change from baseline in PTH, the proportion with baseline > 65 pg/mL who decrease to ≤ 65 pg/mL, and the proportion of all subjects with iPTH ≤ 65 pg/mL|The percent change from baseline in BMD at weeks 24 and 52 as assessed by DXA scans of proximal femur (total femur and femoral neck), lumbar spine (L1-L4), forearm (ultra distal radius and 1/3 radius), and total body|The pharmacokinetic profile of AMG 073 as determined with population-based methods","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","990120","November 1999","March 2001","June 2001","July 10, 2009",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00936650"
384,"NCT00928408","PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice",,"Completed","Has Results","Hyperparathyroidism, Primary","Drug: Cinacalcet","Cinacalcet Dose|Cinacalcet Dosing Frequency|Occurrence of a Change in Cinacalcet Dose or Frequency During the First 3 Months After Initiation|Occurrence of a Change in Cinacalcet Dose or Frequency >3 to 6 Months After Initiation|Occurrence of a Change in Cinacalcet Dose or Frequency >6 Months After Initiation|Duration of Exposure to Cinacalcet|Achievement of a Reduction From Baseline of Albumin-corrected Serum Calcium ≥ 0.25 mmol/L (1 mg/dL) at Month 3|Achievement of a Reduction From Baseline of Albumin-corrected Serum Calcium ≥ 0.25 mmol/L (1 mg/dL) at Month 6|Achievement of a Reduction From Baseline of Albumin-corrected Serum Calcium ≥ 0.25 mmol/L (1 mg/dL) at Month 12|Incidence of an Albumin-corrected Serum Calcium Concentration ≤ 2.6 mmol/L (10.3 mg/dL) at Month 3|Incidence of an Albumin-corrected Serum Calcium Concentration ≤ 2.6 mmol/L (10.3 mg/dL) at Month 6|Incidence of an Albumin-corrected Serum Calcium Concentration ≤ 2.6 mmol/L (10.3 mg/dL) at Month 12|Change From Baseline to Month 3 in Albumin-corrected Serum Calcium|Change From Baseline to Month 6 in Albumin-corrected Serum Calcium|Change From Baseline to Month 12 in Albumin-corrected Serum Calcium|Percent Change From Baseline to Month 12 in Bone Mineral Density (g/cm^2). Anatomic Site: Femoral Neck; Densitometer: Hologic|Percent Change From Baseline to Month 12 in Bone Mineral Density (g/cm^2). Anatomic Site: Lumbar Spine; Densitometer: Hologic|Reason for Prescribing Cinacalcet","Amgen","All","18 Years and older   (Adult, Older Adult)",,"305","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20070363|PRIMARA","October 2009","December 2011","February 2012","June 26, 2009","November 14, 2013","August 1, 2018",,,"https://ClinicalTrials.gov/show/NCT00928408"
385,"NCT00925600","Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss",,"Completed","Has Results","Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer","Biological: Denosumab|Biological: Placebo","Percentage of Participants With Lens Opacification Event Development or Progression by Month 12","Amgen","Male","30 Years to 120 Years   (Adult, Older Adult)","Phase 3","769","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20080560|2009-012076-26","November 30, 2009","May 12, 2016","May 12, 2016","June 22, 2009","May 30, 2017","May 30, 2017","Research Site, Anaheim, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Murrieta, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Englewood, Colorado, United States|Research Site, Middlebury, Connecticut, United States|Research Site, New Britain, Connecticut, United States|Research Site, Trinity, Florida, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Greenwood, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Sartell, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Berlin, New Jersey, United States|Research Site, Bricktown, New Jersey, United States|Research Site, Englewood, New Jersey, United States|Research Site, Lawrenceville, New Jersey, United States|Research Site, Mount Laurel, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Garden City, New York, United States|Research Site, Kingston, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bala-Cynwyd, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Wahroonga, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brantford, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North Bay, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Kromeriz, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 6, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Lyon Cédex 3, France|Research Site, Paris Cedex 5, France|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Ludhiana, Punjab, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Jelgava, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Christchurch, New Zealand|Research Site, Takapuna, North Shore City, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Whangarei, New Zealand|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Myslowice, Poland|Research Site, Opole, Poland|Research Site, Poznan, Poland|Research Site, Rzeszow, Poland|Research Site, Siedlce, Poland|Research Site, Slupsk, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Trencin, Slovakia|Research Site, Celje, Slovenia|Research Site, Ljubljana, Slovenia|Research Site, Slovenj Gradec, Slovenia|Research Site, Paarl, Western Cape, South Africa|Research Site, George, South Africa|Research Site, Kempton Park, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Tygerberg, South Africa|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00925600"
386,"NCT00925587","Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease",,"Completed","Has Results","Anemia|Chronic Kidney Disease","Drug: darbepoetin alfa","Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33)|Achievement of Both a Hb >= 10.0 g/dL and a >= 1.0 g/dL Increase From Baseline at Any Time Point Following de Novo Darbepoetin Alfa Administration.|Hb at Baseline|Hb at Week 3|Hb at Week 5|Hb at Week 7|Hb at Week 9|Hb at Week 11|Hb at Week 13|Hb at Week 15|Hb at Week 17|Hb at Week 19|Hb at Week 21|Hb at Week 23|Hb at Week 25|Hb at Week 27|Hb at Week 29|Hb at Week 31|Hb at Week 33|Darbepoetin Alfa Dose at Week 1|Darbepoetin Alfa Dose at Week 3|Darbepoetin Alfa Dose at Week 5|Darbepoetin Alfa Dose at Week 7|Darbepoetin Alfa Dose at Week 9|Darbepoetin Alfa Dose at Week 11|Darbepoetin Alfa Dose at Week 13|Darbepoetin Alfa Dose at Week 15|Darbepoetin Alfa Dose at Week 17|Darbepoetin Alfa Dose at Week 19|Darbepoetin Alfa Dose at Week 21|Darbepoetin Alfa Dose at Week 23|Darbepoetin Alfa Dose at Week 25|Darbepoetin Alfa Dose at Week 27|Darbepoetin Alfa Dose at Week 29|Darbepoetin Alfa Dose at Week 31|Darbepoetin Alfa Dose During the Evaluation Period (Average of Weeks 29-33)|Ratio of Darbepoetin Alfa Dose to Baseline at Week 3|Ratio of Darbepoetin Alfa Dose to Baseline at Week 5|Ratio of Darbepoetin Alfa Dose to Baseline at Week 7|Ratio of Darbepoetin Alfa Dose to Baseline at Week 9|Ratio of Darbepoetin Alfa Dose to Baseline at Week 11|Ratio of Darbepoetin Alfa Dose to Baseline at Week 13|Ratio of Darbepoetin Alfa Dose to Baseline at Week 15|Ratio of Darbepoetin Alfa Dose to Baseline at Week 17|Ratio of Darbepoetin Alfa Dose to Baseline at Week 19|Ratio of Darbepoetin Alfa Dose to Baseline at Week 21|Ratio of Darbepoetin Alfa Dose to Baseline at Week 23|Ratio of Darbepoetin Alfa Dose to Baseline at Week 25|Ratio of Darbepoetin Alfa Dose to Baseline at Week 27|Ratio of Darbepoetin Alfa Dose to Baseline at Week 29|Ratio of Darbepoetin Alfa Dose to Baseline at Week 31|Dose of Darbepoetin Alfa at the First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)|Time to First Achievement of a Hb ≥10.0 g/dL and a ≥1.0 g/dL Increase From Baseline (Weeks 1-33)|Ratio of Darbepoetin Alfa Dose to Baseline at the Evalaution Period (Average of Weeks 29-33)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","358","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060163|2006-003173-27","June 2009","April 2012","May 2012","June 22, 2009","June 4, 2014","June 4, 2014","Research Site, Gosford, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Reservoir, Victoria, Australia|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Roeselare, Belgium|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Chrudim, Czech Republic|Research Site, Jilemnice, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Liberec 1, Czech Republic|Research Site, Novy Jicin, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 4 - Nusle, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Slavkov u Brna, Czech Republic|Research Site, Sternberk, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Roskilde, Denmark|Research Site, Viborg, Denmark|Research Site, Ã…rhus, Denmark|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Annonay, France|Research Site, Creil, France|Research Site, Grenoble, France|Research Site, Metz, France|Research Site, Montivilliers, France|Research Site, Nice, France|Research Site, Poissy, France|Research Site, Reims Cedex, France|Research Site, Rouen Cedex, France|Research Site, Saint Priest en Jarez, France|Research Site, Bernkastel-Kues, Germany|Research Site, Coesfeld, Germany|Research Site, DÃ¼sseldorf, Germany|Research Site, Hamburg, Germany|Research Site, Leverkusen, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Pecs, Hungary|Research Site, Szekszard, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ashkelon, Israel|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Albano Laziale RM, Italy|Research Site, Ancona, Italy|Research Site, Cagliari, Italy|Research Site, Firenze, Italy|Research Site, Lecco, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Torino, Italy|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Ventspils, Latvia|Research Site, Saltillo, Coahuila, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Queretaro, QuerÃ©taro, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Choszczno, Poland|Research Site, Golub-Dobrzyn, Poland|Research Site, Koscierzyna, Poland|Research Site, Koszalin, Poland|Research Site, Legnica, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Zamosc, Poland|Research Site, Evora, Portugal|Research Site, Faro, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, SetÃºbal, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Krgujevac, Serbia|Research Site, Zemun, Serbia|Research Site, Bratislava, Slovakia|Research Site, Galanta, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Sala, Slovakia|Research Site, Trstena, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Jesenice, Slovenia|Research Site, Novo mesto, Slovenia|Research Site, Sempeter pri Gorici, Slovenia|Research Site, Slovenj Gradec, Slovenia|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Galdakao, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Birmingham, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Shrewsbury, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stoke On Trent, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00925587"
387,"NCT00919711","Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy",,"Completed","Has Results","Osteoporosis","Drug: Actonel®|Drug: Denosumab","Total Hip BMD Percent Change From Baseline at Month 12|Serum CTX Percent Change From Baseline at Month 1|Femoral Neck BMD Percent Change From Baseline at Month 12|Lumbar Spine BMD Percent Change From Baseline at Month 12","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 3","870","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080099","September 2009","December 2011","March 2012","June 12, 2009","December 12, 2012","September 12, 2018",,,"https://ClinicalTrials.gov/show/NCT00919711"
388,"NCT00911170","PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",,"Completed","Has Results","Cancer|Colon Cancer|Colorectal Cancer|Fever|Locally Advanced|Metastatic Colorectal Cancer|Neutropenia|Rectal Cancer","Drug: Pegfilgrastim|Drug: Placebo|Biological: Bevacizumab|Drug: Standard Chemotherapy","Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy|Overall Survival|Progression Free Survival|Time to Progression|Percentage of Participants With an Objective Response|Percentage of Participants With Grade 4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy|Percentage of Participants With Grade 3/4 Neutropenia Across the First 4 Cycles of Chemotherapy|Percentage of Participants With Grade 4 Neutropenia Across the First 4 Cycles of Chemotherapy|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","847","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20080259","November 3, 2009","September 17, 2012","January 2, 2015","June 1, 2009","January 7, 2014","December 29, 2017","Research Site, Muscle Shoals, Alabama, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Modesto, California, United States|Research Site, San Diego, California, United States|Research Site, Greenwich, Connecticut, United States|Research Site, Dover, Delaware, United States|Research Site, Gainesville, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Gurnee, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, New Albany, Indiana, United States|Research Site, South Bend, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Sioux City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Hazard, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Cumberland, Maryland, United States|Research Site, Randallstown, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Kearney, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Portsmouth, New Hampshire, United States|Research Site, Little Silver, New Jersey, United States|Research Site, Somerville, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Lake Success, New York, United States|Research Site, Nyack, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Massillon, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Reading, Pennsylvania, United States|Research Site, Upland, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Bryan, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Abingdon, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Hobart, Tasmania, Australia|Research Site, Ballarat, Victoria, Australia|Research Site, Coburg, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Roeselare, Belgium|Research Site, Verviers, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Brampton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Horovice, Czechia|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Olomouc, Czechia|Research Site, Znojmo, Czechia|Research Site, Amiens, France|Research Site, Bordeaux Cedex, France|Research Site, Cahors Cedex, France|Research Site, Lille cedex 01, France|Research Site, Rouen, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Szeged, Hungary|Research Site, Szolnok, Hungary|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Waterford, Ireland|Research Site, Benevento, Italy|Research Site, Palermo, Italy|Research Site, Roma (RM), Italy|Research Site, Rozzano (MI), Italy|Research Site, Taormina (ME), Italy|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, San Luis Potosi, San Luis P, Mexico|Research Site, Colima, Mexico|Research Site, Toluca, Mexico|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Olsztyn, Poland|Research Site, Suwalki, Poland|Research Site, Warszawa, Poland|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Sibiu, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Trnava, Slovakia|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT00911170"
389,"NCT00907478","Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)",,"Completed","Has Results","Thrombocytopenia|Idiopathic Thrombocytopenic Purpura","Biological: romiplostim","Percentage of Participants With Collagen Fibrosis|Number of Participants With Collagen Fibrosis 12 Weeks After Romiplostim Discontinuation in Participants Who Developed Collagen Fibrosis at Years 1, 2, or 3|Percentage of Participants Who Developed an Increased Modified Bauermeister Grade|Percentage of Participants With Clinically Relevant Changes in Total Cardiac Output Corrected (QTc) Intervals|Number of Participants With Improvement of Reticulin to a Grade of ≤ 2 for Participants Who Developed Grade 3 Reticulin|Percentage of Participants With CTCAE Grade ≥ 2 Shift in Anemia or Neutropenia|Number of Participants With Adverse Events (AEs)|Number of Participants Who Developed Antibodies or Neutralizing Antibodies to Romiplostim or to Endogenous Thrombopoietin","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","169","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080009","August 11, 2009","January 9, 2014","January 14, 2014","May 22, 2009","January 1, 2015","May 22, 2019",,,"https://ClinicalTrials.gov/show/NCT00907478"
390,"NCT00907296","Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing","STARTT","Completed","Has Results","Fracture Healing","Biological: Romosozumab|Drug: Placebo","Time to Radiographic Healing|Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain|Number of Participants With Unplanned Revision Surgeries|Time to Clinical Healing","Amgen|UCB Pharma","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20062017|2008-008392-34","September 2, 2009","March 6, 2012","May 10, 2013","May 22, 2009","May 1, 2019","May 1, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Orange, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Jacksonville, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Brooklyn, New York, United States|Research Site, Rochester, New York, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Sandy, Utah, United States|Research Site, Geelong, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Blagoevgrad, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Red Deer, Alberta, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hvidovre, Denmark|Research Site, KÃ¸benhavn NV, Denmark|Research Site, Ã…rhus C, Denmark|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Lille, France|Research Site, Marseille, France|Research Site, Nantes Cedex 1, France|Research Site, Paris Cedex 12, France|Research Site, Aachen, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Mannheim, Germany|Research Site, Muenster, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Gandhinagar, India|Research Site, Mangalore, India|Research Site, Nashik, India|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Roma (RM), Italy|Research Site, Verona, Italy|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, Christchurch, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Kongsvinger, Norway|Research Site, Bialystok, Poland|Research Site, Bytom, Poland|Research Site, Krakow, Poland|Research Site, KrakÃ³w, Poland|Research Site, Lublin, Poland|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Timisoara, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Piestany, Slovakia|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Stanmore, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00907296"
391,"NCT00903812","IMPACT Non Hodgkins Lymphoma (NHL) Study",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Other: No intervention","Proportion of subjects who had an investigator assessed risk of FN ≥20% and received primary prophylaxis G-CSF","Amgen","All","18 Years and older   (Adult, Older Adult)",,"1837","Industry","Observational","Observational Model: Other|Time Perspective: Other","20060297","February 2007","December 2008","March 2014","May 18, 2009",,"July 6, 2018",,,"https://ClinicalTrials.gov/show/NCT00903812"
392,"NCT00902356","A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women",,"Completed","No Results Available","Osteopenia","Drug: AMG 167|Drug: Placebo","The number (percent) of subjects reporting treatment-emergent adverse events.|The number of subjects experiencing clinically significant changes in safety laboratory tests, physical examinations, vital signs, or electrocardiograms (ECGs).|The number of subjects who develop anti-AMG 167 antibodies.|Pharmacokinetic and phamacodynamic parameters [serum procollagen type 1 N-terminal propeptide (P1NP), BSAP, osteocalcin, sCTX, sclerostin levels, and bone mineral density (BMD) for higher dose levels] after single dose SC or IV administration of AMG 167.","Amgen","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20080049","May 2009","November 2009","November 2009","May 15, 2009",,"April 2, 2010",,,"https://ClinicalTrials.gov/show/NCT00902356"
393,"NCT00896532","Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density",,"Completed","Has Results","Low Bone Mineral Density|Postmenopausal Osteoporosis","Drug: Placebo to Romosozumab|Drug: Alendronate|Drug: Teriparatide|Drug: Romosozumab|Drug: Denosumab|Drug: Placebo to Denosumab|Drug: Zoledronic acid","Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine|Percent Change From Baseline at Month 6 in BMD at the Lumbar Spine|Percent Change From Baseline at Month 6 in BMD of the Total Hip|Percent Change From Baseline at Month 6 in BMD of the Femoral Neck|Percent Change From Baseline at Month 12 in BMD of the Total Hip|Percent Change From Baseline at Month 12 in BMD of the Femoral Neck|Percent Change From Baseline at Month 12 in BMD of the Distal Radius|Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP)|Percent Change From Baseline in Type 1 Collagen C-telopeptide (CTX)|Percent Change From Baseline in Osteocalcin|Percent Change From Baseline in Bone-specific Alkaline Phosphatase (BSAP)","Amgen","Female","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","419","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060326|2008-005991-28","June 3, 2009","February 21, 2011","February 18, 2016","May 11, 2009","December 14, 2018","December 14, 2018",,,"https://ClinicalTrials.gov/show/NCT00896532"
394,"NCT00896454","Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium",,"Completed","Has Results","Breast Cancer|Hypercalcemia of Malignancy|Colon Cancer|Endocrine Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Metastatic Cancer|Multiple Myeloma|Parathyroid Neoplasms|Renal Cancer|Thyroid Cancer|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Non-Small Cell Lung Cancer","Drug: denosumab","Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab|Percentage of Participants With a Response by Visit|Percentage of Participants With a Complete Response by Visit|Time to Response|Time to Complete Response|Duration of Response|Duration of Complete Response|Time to Relapse/Nonresponse of Hypercalcemia of Malignancy|Change From Baseline in Corrected Serum Calcium","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070315","November 16, 2009","September 13, 2012","August 21, 2013","May 11, 2009","January 1, 2015","October 17, 2018","Research Site, Encinitas, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Salisbury, Maryland, United States|Research Site, Dearborn, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, Houston, Texas, United States|Research Site, QuÃ©bec, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Limoges Cedex, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, Villejuif cedex, France|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT00896454"
395,"NCT00891930","Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab",,"Completed","Has Results","Metastatic Colorectal Cancer","Biological: Panitumumab|Biological: Ganitumab|Drug: Irinotecan","Part 1: Emergence of Mutant KRAS|Part 2: Objective Response Rate (ORR)|Part 1: Objective Response Rate|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Objective Response|Duration of Response|Number of Participants Who Developed Antibodies to Panitumumab|Number of Participants Who Developed Antibodies to Ganitumab|Number of Participants With Adverse Events|Number of Subjects With Worst Post-baseline Grade 3 or Higher Laboratory Toxicities","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070820|2008-004752-77","May 2009","July 2013","July 2013","May 1, 2009","February 8, 2016","February 8, 2016",,,"https://ClinicalTrials.gov/show/NCT00891930"
396,"NCT00890981","A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab",,"Completed","Has Results","Low Bone Mass|Low Bone Mineral Density|Osteoporosis|Postmenopausal Osteoporosis","Procedure: high-resolution peripheral quantitative computed tomography (HR-pQCT)|Procedure: Dual energy X-ray absorptiometry (DXA)|Biological: Denosumab|Drug: Placebo","Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT|Percent Change From the Parent Study Baseline in Total Bone Mineral Density (BMD) at the Distal Radius by HR-pQCT|Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT|Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Radius by HR-pQCT|Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Tibia by HR-pQCT|Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT|Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Tibia by HR-pQCT|Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT|Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA|Percent Change of Ultradistal Radius BMD From the Parent Study Baseline by DXA|Percent Change of Total Radius BMD From the Parent Study Baseline by DXA|Actual Value of Serum Type I C-telopeptide|Actual Value of Procollagen Type 1 N-terminal Peptide","Amgen","Female","Child, Adult, Older Adult","Phase 3","79","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20080747","July 2009","June 2010","August 2010","April 30, 2009","July 28, 2011","April 2, 2014",,,"https://ClinicalTrials.gov/show/NCT00890981"
397,"NCT00887965","A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab",,"Completed","Has Results","Low Bone Mass|Low Bone Mineral Density|Osteoporosis|Postmenopausal Osteoporosis","Drug: Previous denosumab","Number of Participants With Normal/Abnormal Bone Histology|Bone Histomorphometry: Cancellous Bone Volume|Bone Histomorphometry: Trabecular Number|Bone Histomorphometry: Trabecular Separation|Bone Histomorphometry: Trabecular Thickness|Bone Histomorphometry: Cortical Width|Bone Histomorphometry: Surface Density|Bone Histomorphometry: Osteoblast - Osteoid Interface|Bone Histomorphometry: Osteoid Surface|Bone Histomorphometry: Osteoid Width|Bone Histomorphometry: Wall Thickness|Bone Histomorphometry: Eroded Surface/Bone Surface|Bone Histomorphometry: Osteoclast Number - Length Based|Bone Histomorphometry: Osteoclast Number - Surface Based|Bone Histomorphometry: Single-label Surface|Bone Histomorphometry: Double-label Surface|Bone Histomorphometry: Total Mineralizing Surface|Bone Histomorphometry: Mineral Apposition Rate|Bone Histomorphometry: Adjusted Mineral Apposition Rate|Bone Histomorphometry: Bone Formation Rate - Surface Based|Bone Histomorphometry: Bone Formation Rate - Volume Based|Bone Histomorphometry: Formation Period|Bone Histomorphometry: Activation Frequency|Bone Histomorphometry: Osteoid Volume|Bone Histomorphometry: Mineralization Lag Time|C-Telopeptide (CTX-1)|Procollagen Type 1 N-terminal Peptide (P1NP)","Amgen","Female","Child, Adult, Older Adult","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20080287","June 2009","June 2010","August 2010","April 24, 2009","October 17, 2013","November 15, 2013",,,"https://ClinicalTrials.gov/show/NCT00887965"
398,"NCT00884312","A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols",,"Completed","Has Results","Multiple Myeloma|Solid Tumors","Drug: Carfilzomib","Number of Participants With Peripheral Neuropathy|Number of Participants With Adverse Events|Overall Survival|Progression-free Survival|Time to Progression","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-010|20130394","April 9, 2009","May 17, 2017","May 17, 2017","April 20, 2009","May 14, 2018","May 14, 2018","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope National Medial Center, Duarte, California, United States|University of California Medical Center, San Francisco, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute - Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Cancer Center, Austin, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT00884312/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT00884312/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00884312"
399,"NCT00883181","A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy",,"Completed","Has Results","Breast Cancer|Non-Small Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer",,"Percentage of Participants With Febrile Neutropenia (FN)|Percentage of Participants Who Received No Prophylaxis or Treatment With Granulocyte Colony-stimulating Factors (G-CSF) Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Primary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Primary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Secondary Prophylaxis With Pegfilgrastim Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Secondary Prophylaxis With Any Daily G-CSF Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Primary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Secondary Prophylaxis With an Other G-CSF Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Treatment With Pegfilgrastim Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Treatment With Any Daily G-CSF Who Experienced Febrile Neutropenia|Percentage of Participants Receiving Treatment With Any Other G-CSF Who Experienced Febrile Neutropenia|Number of Participants Who Received G-CSF During Cycles 1 to 8|Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Pegfilgrastim|Number of Days of Prophylaxis in Participants Receiving Primary Prophylaxis With Any Daily G-CSF|Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Pegfilgrastim|Number of Days of Prophylaxis in Participants Receiving Secondary Prophylaxis With Any Daily G-CSF|Number of Days of Treatment in Participants Receiving Treatment With Pegfilgrastim|Number of Days of Treatment in Participants Receiving Treatment With Any Daily G-CSF|Percentage of Participants With Chemotherapy Dose Delays in Cycles 2 Through 8|Percentage of Cycles With Chemotherapy Dose Delays|Percentage of Participants With Chemotherapy Dose Reductions|Percentage of Cycles With Chemotherapy Dose Reductions|Reasons for Cycles With > 3 Days Chemotherapy Dose Delays in Cycles 2 to 8|Reasons for Cycles With ≥ 15% Chemotherapy Dose Reductions in Cycles 1-8|Number of Participants With Systemic Anti-infective Use in Cycles 1 to 8|Number of Participants With Unplanned Hospitalizations|Investigator Assessed Clinical Response at End of Treatment|Number of Participants With Hematological Toxicities|Time to Disease Progression|Duration of Treatment With Erythropoiesis-stimulating Agents (ESAs)|Reason for Treatment With Erythropoiesis-stimulating Agents|Hemoglobin Level at Initiation of Erythropoiesis-stimulating Agent Treatment|Number of Clinical Visits in Cycles 1-8 by ESA Use|Percentage of Participants Who Received ESAs and Required a Red Blood Cell (RBC) Transfusion After 5 Weeks of ESA Treatment|Change in Hemoglobin During ESA Treatment Phase|Percentage of Participants Who Received ESAs and Achieved Hematopoietic Response|Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 9 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 10 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 11 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin ≥ 12 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 12 to 13 g/dL After 5 Weeks ESA Treatment|Percentage of Participants Who Received ESAs and Achieved Hemoglobin From 10 to 12 g/dL 9 Weeks After Initiation of ESA Treatment|Number of Participants With Systemic Transfusions in Cycles 1 to 8|Number of Transfusions Per Participant in Cycles 1 to 8","Amgen","All","18 Years and older   (Adult, Older Adult)",,"1370","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","20060445","November 2006","October 2009","September 2014","April 17, 2009","April 8, 2016","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT00883181"
400,"NCT00872014","A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer",,"Completed","No Results Available","Advanced Hepatocellular Carcinoma|Inoperable Hepatocellular Carcinoma","Drug: AMG 386|Drug: Sorafenib","Progression free survival (PFS) rate at 4 months|Incidence of adverse events and significant laboratory abnormalities|Objective response rate, Disease control rate, Progression free survival, Overall survival, Time to progression|Pharmacokinetic parameters for AMG 386 when used in combination with Sorafenib|Pharmacokinetic parameter for Sorafenib when used in combination with AMG 386|Incidence of the occurrence of anti-AMG 386 antibody formation|Baseline values of and changes from baseline in pharmacodynamic, immunologic, biochemical, transcriptional, pharmacogenetic and angiogenic markers","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080580","August 2009","October 2011","June 2015","March 30, 2009",,"April 4, 2016",,,"https://ClinicalTrials.gov/show/NCT00872014"
401,"NCT00861419","To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.",,"Completed","No Results Available","Advanced Solid Tumors","Drug: Sorafenib|Drug: AMG 706|Drug: AMG 386|Drug: Sunitinib|Drug: Bevacizumab","Safety including adverse events, clinically significant changes in laboratory results, ECG, and vital signs, to be measured throughout the study. Pharmacokinetic Profile of AMG 386 - blood levels of AMG 386 to be measured throughout the study.|Response based on biomarker, anti-AMG 386 antibody formation and tumor response measure by RECIST.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","88","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050170","December 2005",,,"March 13, 2009",,"February 8, 2017",,,"https://ClinicalTrials.gov/show/NCT00861419"
402,"NCT00861224","Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology",,"Completed","No Results Available","Idiopathic Thrombocytopenic Purpura","Other: No Intervention for Observational Study","The changes from baseline in bone marrow morphology by subject|The changes from baseline in bone marrow morphology by dose range|The changes from baseline in bone marrow morphology by length of treatment with AMG 531|The changes from baseline bone marrow morphology for splenectomized and non-splenectomized subjects","Amgen","All","18 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20050123","August 2005","October 2006","May 2007","March 13, 2009",,"July 16, 2010",,,"https://ClinicalTrials.gov/show/NCT00861224"
403,"NCT00858377","A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors",,"Completed","No Results Available","Advanced Malignancy|Advanced Solid Tumors|Cancer|Solid Tumors|Tumors","Drug: Arm 1- Dose Escalation|Drug: Arm 1- Dose Expansion","Safety: subject incidence of adverse events, first-cycle DLTs and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests|PK profile: AMG 900 PK parameters including, but not limited to, maximum observed concentration (Cmax), minimum observed concentration, area under the plasma concentration-time curve and, if feasible, half-life|Change in levels of p-Histone H3 from baseline (part 1 - dose escalation only)|Response rate in each taxane-resistant tumor type assessed per RECIST guidelines (part 2 - dose expansion only)|Change in tumor volume from baseline measured by volumetric CT or MRI|Tumor response measured by CT or MRI and assessed per RECIST guidelines|Change from baseline in maximum standardized uptake value (SUVmax) using 18FLT-PET/CT (part 2 - dose expansion only)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","95","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080016","August 10, 2009","December 31, 2014","April 3, 2019","March 9, 2009",,"May 6, 2019","Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Baltimore, Maryland, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00858377"
404,"NCT00858364","Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy",,"Terminated","Has Results","Non-Small Cell Lung Cancer|Anemia|Cancer|Lung Cancer","Drug: Darbepoetin alfa|Drug: Placebo","Overall Survival (OS)|Progression-free Survival (PFS)|Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 5 to End of the Efficacy Treatment Period|Number of Participants With Adverse Events of Special Interest|Percentage of Participants With an Objective Tumor Response|Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa|Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 1 to End of the Efficacy Treatment Period|Change From Baseline in Hemoglobin to End of Efficacy Treatment Period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","2549","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20070782|2007-005792-34","July 17, 2009","June 7, 2017","June 7, 2017","March 9, 2009","July 6, 2018","July 6, 2018","Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Tucson, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Arcadia, California, United States|Research Site, Berkeley, California, United States|Research Site, Burbank, California, United States|Research Site, Downey, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fresno, California, United States|Research Site, Fresno, California, United States|Research Site, La Verne, California, United States|Research Site, Lancaster, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Merced, California, United States|Research Site, Mission Hills, California, United States|Research Site, Montebello, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Pismo Beach, California, United States|Research Site, Pomona, California, United States|Research Site, Redlands, California, United States|Research Site, Saint Helena, California, United States|Research Site, Salinas, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Simi Valley, California, United States|Research Site, Soquel, California, United States|Research Site, Torrance, California, United States|Research Site, Vallejo, California, United States|Research Site, West Covina, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Englewood, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Southington, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Holiday, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Lecanto, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Rockledge, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Titusville, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Thomasville, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Galesburg, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Mount Vernon, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Dubuque, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Sioux City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Morehead, Kentucky, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Ruston, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Lewiston, Maine, United States|Research Site, Rockport, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Cumberland, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Attleboro, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Clarkston, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Southgate, Michigan, United States|Research Site, Willmar, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Manchester, New Hampshire, United States|Research Site, Sparta, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Vineland, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Santa Fe, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Glens Falls, New York, United States|Research Site, Goshen, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Latham, New York, United States|Research Site, Nyack, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Concord, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Washington, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Massillon, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Port Clinton, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Wooster, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Gettysburg, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Upland, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wynnewood, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Woonsocket, Rhode Island, United States|Research Site, Aiken, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Abilene, Texas, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Bryan, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Garland, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Longview, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Midland, Texas, United States|Research Site, Paris, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Temple, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, White River Junction, Vermont, United States|Research Site, Christiansburg, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Bremerton, Washington, United States|Research Site, Burien, Washington, United States|Research Site, Edmonds, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Vancouver, Washington, United States|Research Site, Yakima, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Janesville, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Research Site, San Salvador de Jujuy, Jujuy, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, La Rioja, Argentina|Research Site, Santa Fe, Argentina|Research Site, Steyr, Austria|Research Site, Wien, Austria|Research Site, Ieper, Belgium|Research Site, Libramont, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, Ottignies, Belgium|Research Site, Salvador, Bahia, Brazil|Research Site, Salvador, Bahia, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Cachoeiro de Itapemirim, Espírito Santo, Brazil|Research Site, Campo Grande, Mato Grosso Do Sul, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Londrina, Paraná, Brazil|Research Site, Belem, Pará, Brazil|Research Site, Ijui, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Pelotas, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Itajaí, Santa Catarina, Brazil|Research Site, Ribeirao Preto, São Paulo, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Sao Jose dos Campos, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Moncton, New Brunswick, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Renaca, Valparaíso, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Chongqing, Chongqing, China|Research Site, Fuzhou, Fujian, China|Research Site, Fuzhou, Fujian, China|Research Site, Lanzhou, Gansu, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Zhongshan, Guangdong, China|Research Site, Haikou, Hainan, China|Research Site, Haikou, Hainan, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Harbin, Heilongjiang, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Chengdu, Sichuan, China|Research Site, Chengdu, Sichuan, China|Research Site, Urumqi, Xinjiang, China|Research Site, Kunming, Yunnan, China|Research Site, Kunming, Yunnan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Rijeka, Croatia|Research Site, Zagreb, Croatia|Research Site, Benesov U Prahy, Czechia|Research Site, Horovice, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Kyjov, Czechia|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 8, Czechia|Research Site, Pribram, Czechia|Research Site, Bad Berka, Germany|Research Site, Bad Saarow, Germany|Research Site, Bamberg, Germany|Research Site, Grosshansdorf, Germany|Research Site, Halle (Saale), Germany|Research Site, Hemer, Germany|Research Site, Köln-Merheim, Germany|Research Site, Köln, Germany|Research Site, Moers, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, New Delhi, Delhi, India|Research Site, Panaji, Goa, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Belgaum, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Thane, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkata, West Bengal, India|Research Site, Bangalore, India|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Jerusalem, Israel|Research Site, Kefar Saba, Israel|Research Site, Poria Eylit, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Catania, Italy|Research Site, Faenza RA, Italy|Research Site, Grosseto, Italy|Research Site, Lecce, Italy|Research Site, Legnago VR, Italy|Research Site, Lugo RA, Italy|Research Site, Meldola FC, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Ravenna, Italy|Research Site, Reggio Calabria, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-Shi, Fukui, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Nishinomiya-shi, Hyogo, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Yonago-shi, Tottori, Japan|Research Site, Kyoto, Japan|Research Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Gyeonggi-do, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Esch-Sur-Alzette, Luxembourg|Research Site, Luxembourg, Luxembourg|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Kuantan, Pahang, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Saltillo, Coahuila, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Merida, Yucatán, Mexico|Research Site, Chihuahua, Mexico|Research Site, Colima, Mexico|Research Site, Oaxaca, Mexico|Research Site, Puebla, Mexico|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Davao City, Davao, Philippines|Research Site, Baguio City, Philippines|Research Site, Cebu City, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Metro Manila, Philippines|Research Site, Pasig City, MetroManila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Glucholazy, Poland|Research Site, Konin, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lomza, Poland|Research Site, Olsztyn, Poland|Research Site, Olsztyn, Poland|Research Site, Rzeszow, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Lasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Belgorod, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Tula, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Gornji Matejevac, Serbia|Research Site, Kragujevac, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Golnik, Slovenia|Research Site, Pohorje, Slovenia|Research Site, Umhlanga, KwaZulu-Natal, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Johannesburg, South Africa|Research Site, Overport, South Africa|Research Site, Polokwane, South Africa|Research Site, Granada, Andalucía, Spain|Research Site, Las Palmas de Gran Canaria, Canarias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Benidorm, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pontevedra, Galicia, Spain|Research Site, Aarau, Switzerland|Research Site, Aarau, Switzerland|Research Site, Chur, Switzerland|Research Site, Sursee, Switzerland|Research Site, Zurich, Switzerland|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Chernihiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kirovograd, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Bebington, United Kingdom|Research Site, Dorechester, United Kingdom|Research Site, Dorset, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT00858364/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT00858364/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT00858364"
405,"NCT00853372","AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib",,"Completed","No Results Available","Advanced Renal Cell Carcinoma","Drug: Sunitinib|Drug: AMG386|Drug: AMG 386","Safety and tolerability of AMG 386 in combination with Sunitinib in subjects with metastatic renal cell carcinoma.|Objective response rate (ORR)|Duration of response (DOR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Change in continuous measures of tumor burden|Pharmacokinetic parameters (Cmax and Cmin) for AMG 386|Pharmacokinetic parameter (Cmin) for sunitinib and its primary active metabolite|Incidence of the occurrence of anti-AMG 386 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080579","May 28, 2009","August 8, 2011","June 24, 2019","March 2, 2009",,"July 18, 2019",,,"https://ClinicalTrials.gov/show/NCT00853372"
406,"NCT00838201","Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer",,"Completed","Has Results","Cancer|Carcinoma|Castrate-Resistant Prostate Cancer|Prostate Cancer|Tumors","Drug: Denosumab","Overall Survival Through Month 24","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","384","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080537","February 1, 2009","May 3, 2012","May 3, 2012","February 6, 2009","September 24, 2013","October 18, 2018","Research Site, Huntsville, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, San Bernardino, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Middlebury, Connecticut, United States|Research Site, New Britain, Connecticut, United States|Research Site, Trinity, Florida, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Sartell, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, Albany, New York, United States|Research Site, Bay Shore, New York, United States|Research Site, Garden City, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Salem, Virginia, United States|Research Site, Burien, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brantford, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North Bay, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Mexico City, Distrito F, Mexico|Research Site, Mexico City, Distrito F, Mexico|Research Site, Toluca, Mexico|Research Site, Veracruz, Mexico|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Opole, Poland|Research Site, Siedlce, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT00838201"
407,"NCT00838097","European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa",,"Completed","Has Results","Chronic Kidney Disease",,"Number of Participants With Serious Adverse Drug Reactions (SADR), Serious Adverse Events (SAEs) or Events of Medical Interest (EMIs)|Hemoglobin Concentration by Three Monthly Intervals|Weight Adjusted Darbepoetin Alfa Monthly Dose by Monthly Intervals|Parathyroid Hormone Level by Three Monthly Intervals|Number of Participants With Non-serious Adverse Drug Reactions (ADRs)","Amgen","All","up to 16 Years   (Child)",,"321","Industry","Observational","Time Perspective: Prospective","20070211","February 2008","February 2013","February 2013","February 6, 2009","July 9, 2014","August 1, 2014",,,"https://ClinicalTrials.gov/show/NCT00838097"
408,"NCT00819780","PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors",,"Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Bevacizumab|Drug: mFOLFOX6","Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With an Objective Response|Duration of Response|Time to Disease Progression|Time to Initial Objective Response|Resection Rate|Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)|Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)|Overall Survival in Participants With Wild-type RAS|Overall Survival in Participants With Wild-type RAS / BRAF|Percentage of Participants With an Objective Response for Participants With Wild-type RAS|Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070509","April 24, 2009","May 30, 2012","July 7, 2016","January 9, 2009","August 6, 2014","August 21, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Fountain Valley, California, United States|Research Site, La Verne, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Post Falls, Idaho, United States|Research Site, Gurnee, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Danville, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lambertville, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Mountain Lakes, New Jersey, United States|Research Site, Sparta, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, East Setauket, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, White River Junction, Vermont, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Vancouver, Washington, United States|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Libramont, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Magdeburg, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, Passau, Germany|Research Site, Regensburg, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Alba (CN), Italy|Research Site, Fano, Italy|Research Site, Genova, Italy|Research Site, Mantova, Italy|Research Site, Udine, Italy|Research Site, Varese, Italy|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Elche, Comunidad, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, San SebastiÃ¡n De Los Reyes, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00819780"
409,"NCT00818948","Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis",,"Completed","No Results Available","Nephritis|Systemic Lupus Erythematosus","Drug: AMG 811","Safety evaluation: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examination endpoints, clinical laboratory safety tests, ECGs and the development of anti-AMG811 antibodies|Serum and urine PK parameters of AMG 811","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070283","March 2009","June 2014","August 2014","January 8, 2009",,"September 15, 2014","Research Site, Phoenix, Arizona, United States|Research Site, Danbury, Connecticut, United States|Research Site, Kansas City, Kansas, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Paris Cedex 13, France|Research Site, Hong Kong, Hong Kong|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico, Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT00818948"
410,"NCT00813384","A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients","Drug: AMG 208","To determine the maximum tolerated dose (MTD) of AMG 208, if possible|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies|To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI)|To assess skin specimens for potential biomarkers|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080895","December 2008","February 2013","December 2014","December 23, 2008",,"December 16, 2014","Research Site, Beverly Hills, California, United States|Research Site, St Louis, Missouri, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00813384"
411,"NCT00807859","Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer",,"Completed","No Results Available","Breast Cancer|Breast Neoplasms|Breast Tumors|Cancer|Locally Recurrent and Metastatic Breast Cancer|Metastases|Metastatic Cancer|Oncology|Solid Tumors|Tumors","Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib|Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab|Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib","Primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as a dose limiting toxicity in subjects treated with AMG 386 plus paclitaxel and trastuzumab or with AMG 386 plus capecitabine and lapatinib|To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs|To evaluate the pharmacokinetics (PK) of AMG 386, trastuzumab, and paclitaxel (cohort A) or AMG 386, lapatinib, and capecitabine (and its active metabolite, 5-FU; cohort B) when administered in combination|To estimate the incidence of anti AMG 386 antibody formation|To evaluate the treatment effect as measured by the following: objective response rate (ORR), duration of response (DOR), change in tumor burden and progression-free survival (PFS)","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062042","March 9, 2009","February 27, 2014","October 19, 2015","December 12, 2008",,"April 4, 2019","Research Site, Tucson, Arizona, United States|Research Site, Boca Raton, Florida, United States|Research Site, Iowa City, Iowa, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Great Neck, New York, United States|Research Site, New City, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Middletown, Ohio, United States|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Wilrijk, Belgium|Research Site, Bordeaux, France|Research Site, Caen Cedex 05, France|Research Site, La Roche Sur Yon Cedex 9, France|Research Site, Marseille, France|Research Site, Nantes Cedex 2, France|Research Site, Pierre BÃ©nite Cedex, France|Research Site, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT00807859"
412,"NCT00803712","20070360 Incident Dialysis",,"Completed","Has Results","Chronic Kidney Disease|Secondary Hyperparathyroidism","Drug: Cinacalcet|Drug: Vitamin D","Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean PTH <= 300 pg/mL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean PTH <= 300 pg/mL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During the Efficacy Assessment Phase at Month 12 (Weeks 48 to 52)|Achievement of a >= 30% Reduction in Mean iPTH From Baseline to During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean iPTH <=300 pg/mL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean Corrected Serum Calcium < 10.2 mg/dL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Achievement of a Mean Serum Phosphorus < 5.5 mg/dL During Both Efficacy Assessment Phases at Month 6 (Weeks 22 to 26) and Month 12 (Weeks 48 to 52)|Summary of iPTH (pg/mL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in iPTH (pg/mL) at Month 6 Efficacy Assessment Phase|Summary of iPTH (pg/mL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in iPTH (pg/mL) at Month 12 Efficacy Assessment Phase|Summary of Corrected Serum Calcium (mg/dL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Corrected Serum Calcium at Month 6 Efficacy Assessment Phase|Summary of Corrected Serum Calcium (mg/dL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Corrected Serum Calcium at Month 12 Efficacy Assessment Phase|Summary of Serum Phosphorus (mg/dL) at Month 6 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Serum Phosphorus at Month 6 Efficacy Assessment Phase|Summary of Serum Phosphorus (mg/dL) at Month 12 Efficacy Assessment Phase|Summary of Percent Change From Baseline in Serum Phosphorus at Month 12 Efficacy Assessment Phase|Subject Incidence of Hypercalcemia During the Efficacy Assessment Phase at Month 6|Subject Incidence of Hypercalcemia During the Maintenance Phase|Subject Incidence of Hypercalcemia During the Efficacy Assessment Phase at Month 12|Subject Incidence of Hyperphosphatemia During the Efficacy Assessment Phase at Month 6|Subject Incidence of Hyperphosphatemia During the Maintenance Phase|Subject Incidence of Hyperphosphatemia During the Efficacy Assessment Phase at Month 12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070360","February 1, 2009","December 9, 2010","July 5, 2011","December 5, 2008","March 12, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00803712"
413,"NCT00791765","Moderate to Severe Plaque Psoriasis With Scalp Involvement",,"Completed","Has Results","Psoriasis","Biological: Etanercept|Biological: Placebo","Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12|Percentage of Participants With PSSI 75% Response at Week 12|Percent Change From Baseline in PSSI at Week 24 in Participants Switching From Placebo to Etanercept at Week 12|Patient Satisfaction With Treatment at Week 12","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20080014","October 2008","January 2010","March 2010","November 17, 2008","November 7, 2013","July 23, 2014",,,"https://ClinicalTrials.gov/show/NCT00791765"
414,"NCT00791011","Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat",,"Completed","No Results Available","Hodgkin's Lymphoma|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Diffuse Large Cell Lymphoma","Drug: AMG 655|Other: Vorinostat|Other: Bortezomib","Part 1: Safety: Subject incidence of treatment emergent adverse events, Dose Limiting Toxicities, the severity of adverse events and clinically significant changes in safety laboratory tests, physical examinations, or vital signs.|Part 2: Objective response rate of AMG 655 Therapy as determined by using IWG criteria at the dose selected in Part 1, in combination with Bortezomib in subjects with mantle cell lymphoma|Part 2: Overall survival (OS).|Part 2: Progression-Free Survival (PFS).|Part 2: PK parameters for AMG 655 on a 3 week dosing schedule.|Part 2: Subject incidence of anti-AMG 655 antibody formation.|Part 2: Duration of response.|Part 1: Subject incidence of anti-AMG 655 antibody formation.|Part 1: Best tumor response, objective response rate and duration of response.|Part 1: Maximum tolerated dose of AMG 655 administered with bortezomib or vorinostat, if reached.|Part 1: PK parameters for AMG 655 on a 3 week dosing schedule.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060340","February 2008","July 2010","August 2011","November 14, 2008",,"March 5, 2014",,,"https://ClinicalTrials.gov/show/NCT00791011"
415,"NCT00788957","Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)",,"Completed","Has Results","Colon Cancer|Colorectal Cancer|Gastrointestinal Cancer|Metastatic Colorectal Cancer|Rectal Cancer","Drug: Panitumumab|Drug: Ganitumab|Drug: Rilotumumab|Drug: Placebo","Part 1: Number of Participants With Dose-limiting Toxicities (DLT)|Part 2: Percentage of Participants With an Objective Response|Part 2: Duration of Response|Part 2: Time to Response|Part 2: Percentage of Participants With Disease Control|Progression-free Survival|On-treatment Progression-free Survival|Overall Survival|Number of Participants With Adverse Events (AEs)|Number of Participants With Grade 3 or Higher Laboratory Toxicities|Number of Participants With Antibody Formation to Panitumumab, Rilotumumab and Ganitumab|Part 1: Maximum Observed Drug Concentration (Cmax) and Minimum Drug Concentration (Cmin) for Panitumumab and Rilotumumab|Part 1: Area Under the Drug Concentration-time Curve During a Dosing Interval (AUCtau) for Panitumumab and Rilotumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Panitumumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Panitumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Rilotumumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Rilotumumab|Part 2: Maximum Observed Drug Concentration During the Dosing Interval (Cmax) for Ganitumab|Part 2: Minimum Observed Drug Concentration During the Dosing Interval (Cmin) for Ganitumab","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20060447","October 2008","February 2012","October 2013","November 11, 2008","July 20, 2015","July 20, 2015",,,"https://ClinicalTrials.gov/show/NCT00788957"
416,"NCT00774943","A Study of AMG 557 in Adults With Systemic Lupus Erythematosus",,"Completed","No Results Available","Systemic Lupus Erythematosus","Drug: AMG 557","Subject incidence of treatment-emergent adverse events and the incidence of antibodies to AMG 557.|Serum PK profile of AMG 557 after multiple dose administrations. Biomarkers of pharmacodynamic activity for AMG 557.","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20060169","December 2008","May 2012","May 2012","October 17, 2008",,"April 9, 2013","Research Site, Anniston, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, San Leandro, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Michigan City, Indiana, United States|Research Site, Manhasset, New York, United States|Research Site, Rochester, New York, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Newmarket, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00774943"
417,"NCT00771030","Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 827|Other: Placebo","Part B:Primary efficacy outcome is the bdACR Hybrid response in active or placebo groups|Safety & tolerability: 1. treatment-emergent AE(s) 2. clinically significant changes in safety labs, PE, vital signs and 3. development of anti-AMG 827 antibodies.","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20070264","November 2008","May 2010","July 2010","October 10, 2008",,"November 1, 2016",,,"https://ClinicalTrials.gov/show/NCT00771030"
418,"NCT00770848","AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer",,"Completed","No Results Available","Cancer|Castrate-Resistant Prostate Cancer|Mestastatic Prostate Cancer|Prostate Cancer","Drug: AMG 102|Drug: Mitoxantrone|Drug: Placebo|Drug: Prednisone","Phase 1b - Incidence of adverse events defined by dose-limiting toxicities|Phase 2 - Overall survival|Phase 1b - Incidence of adverse events, abnormal laboratory values not defined as dose limiting toxicities|Phase 1b - Incidence of anti-AMG 102 antibody formation|Phase 1b - Cmax and Cmin of AMG 102 concentration|Phase 2 - Progression-free survival|Phase 2 - Maximum percentage reduction in PSA level|Phase 2 - PSA response rate (≥50% reduction in PSA values from baseline)|Phase 2 - Objective response rate (CR and PR per RECIST with modifications)|Phase 2 - Patient Report Outcome including pain-specific measures|Phase 2 - Incidence of adverse events and significant laboratory value changes from baseline|Phase 2 - Incidence of anti-AMG 102 antibody formation|Phase 2 - Cmax and Cmin of AMG 102; Cmax and AUC for Mitoxantrone|Phase 2 - Percentage change in PSA levels from baseline to 12 weeks (or earlier for those who discontinue therapy)","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070611","November 2008","January 2011","April 2012","October 10, 2008",,"March 10, 2014",,,"https://ClinicalTrials.gov/show/NCT00770848"
419,"NCT00770536","AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR",,"Completed","No Results Available","Cancer|Carcinoma|Fallopian Tube Cancer|Gynecological Malignancies|Metastases|Oncology|Ovarian Cancer|Solid Tumors|Tumors","Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin|Drug: B1: AMG 386 10 mg/kg + Topotecan|Drug: B3: AMG 386 15mg/kg + Topotecan","The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan|To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor burden, CA 125 Response and Progression by GCIG and CA-125 duration of response|To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs.|To determine the pharmacokinetics of pegylated liposomal doxorubicin (and its metabolite, doxorubicinol), topotecan and AMG 386 (Cmax, AUC, and Cmin for intensive assessment; Cmax and Cmin for sparse assessment).|To estimate the incidence of anti AMG 386 antibody formation.","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 1","103","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070182","January 2009","January 2012","June 2015","October 10, 2008",,"September 29, 2015","Research Site, Tucson, Arizona, United States|Research Site, Sacramento, California, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, St. Louis Park, Minnesota, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Adelaide, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Leuven, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Liège, Belgium|Research Site, Wilrijk, Belgium",,"https://ClinicalTrials.gov/show/NCT00770536"
420,"NCT00757042","Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis|Healthy Volunteers","Drug: AMG 157","Safety evaluations: Subject incidence of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations, laboratory safety tests, ECGs, and the development of anti-AMG 157 antibodies|Eczema Area & Severity Index (EASI) score and Investigator's Global Assessment (IGA) score|Serum PK parameters","Amgen","All","18 Years to 60 Years   (Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070620","October 2008","January 2011","January 2011","September 22, 2008",,"May 20, 2011",,,"https://ClinicalTrials.gov/show/NCT00757042"
421,"NCT00756444","A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck",,"Completed","Has Results","Squamous Cell Carcinoma of Head and Neck","Drug: Panitumumab|Drug: Cisplatin|Drug: 5FU","Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab|Steady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab","Amgen|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080008","October 21, 2008","March 30, 2012","March 30, 2012","September 22, 2008","December 13, 2013","November 15, 2018",,,"https://ClinicalTrials.gov/show/NCT00756444"
422,"NCT00752570","A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma",,"Completed","No Results Available","Cancer|Carcinoma|Colon Cancer|Colorectal Cancer|Gastrointestinal Cancer|Metastases|Metastatic Cancer|Metastatic Colorectal Cancer|Oncology|Rectal Cancer","Drug: AMG 386|Drug: AMG 386 Placebo|Drug: FOLFIRI","To estimate the treatment effect as measured by progression free survival (PFS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo.|To evaluate other measures of efficacy or clinical response including objective response rate (ORR), duration of response (DOR), overall survival (OS) in subjects treated with AMG 386 + FOLFIRI relative to subjects treated with FOLFIRI + placebo|To evaluate progression free survival and measures of efficacy by KRAS status|To evaluate patient reported outcomes (PROs), relative dose intensity, incidence of anti AMG 386 antibody formation, pharmacokinetics of AMG 386 (Cmax and AUC) and safety (incidence of AEs and significant laboratory changes)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","144","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20070307","November 2008","September 2010","June 2012","September 15, 2008",,"September 2, 2015",,,"https://ClinicalTrials.gov/show/NCT00752570"
423,"NCT00727571","LEARN-6™: A Prospective, Observational Nursing Home Study",,"Completed","Has Results","Anemia|Chronic Kidney Disease","Other: Observations","Total Distance Walked or Wheeled in a Maximum of 10 Minutes at Each Visit|Number of Participants With Anemia|Percentage of Participants With Anemia Related Conditions at Baseline|Estimated Glomerular Filtration Rate (GFR) for Participants With CKD|Physical Performance: Speed Walked or Wheeled in a Maximum of 10 Minutes at Each Visit|Physical Performance: Duration Walked or Wheeled at Each Visit|Physical Performance: Time to Rise From Sitting to Standing|Physical Performance: Grip Strength|Physical Performance: Lower Extremity Strength, Left Leg.|Physical Performance: Lower Extremity Strength, Right Leg","Amgen","All","65 Years and older   (Older Adult)",,"815","Industry","Observational","Time Perspective: Prospective","20050239","September 2006","June 2008","July 2008","August 4, 2008","November 27, 2013","July 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00727571"
424,"NCT00721734","Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function",,"Completed","Has Results","Multiple Myeloma|Renal Insufficiency","Drug: Carfilzomib","Clearance (CL) of Carfilzomib on Day 1 of Cycle 1|Clearance (CL) of Carfilzomib on Day 15 of Cycle 1|Clearance (CL) of Carfilzomib on Day 15 of Cycle 2|Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1|Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1|Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2|Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1|Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1|Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1|Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1|Plasma Protein Binding (PPB) of Carfilzomib|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of Response|Time to Progression (TTP)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-005","November 2008","November 2012","November 2012","July 24, 2008","December 9, 2015","May 2, 2017","University of California- San Francisco, San Francisco, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00721734"
425,"NCT00719550","AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer",,"Completed","No Results Available","Esophagogastric Junction Adenocarcinoma|Gastric Cancer|Esophageal Cancer","Drug: Capecitabine|Drug: Epirubicin|Drug: AMG 102|Drug: Cisplatin|Drug: Placebo","Progression free survival (PFS), as measured by RECIST per local review|Overall survival, objective response rate, disease control rate, time to response (for responders only), and duration of response (for responders only).|Incidence of adverse events, significant laboratory value changes form baseline and anti-AMG 102 antibody formation.|Cmax and Cmin for AMG 102; Cmax and AUC for epirubicin and cisplatin with or without AMG 102","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060317","February 2009","November 2010","June 2013","July 21, 2008",,"December 5, 2013",,,"https://ClinicalTrials.gov/show/NCT00719550"
426,"NCT00680992","Study of Denosumab in Subjects With Giant Cell Tumor of Bone",,"Completed","Has Results","Cancer|Giant Cell Tumors|Giant Cell Tumor of Bone|Benign Giant Cell Tumors","Drug: Denosumab","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants Who Experienced the Maximum Toxicity Grade (CTCAE Grade ≥ 3) in the Indicated Clinical Chemistry Parameters|Time to Disease Progression or Recurrence During the On-Study Period for Cohort 1, Presented as Kaplan-Meier Estimates of Probability|Percentage of Participants Without Any On-Study Surgery at Month 6 for Cohort 2|Mean Serum Denosumab Trough Concentrations","Amgen","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","535","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062004","September 9, 2008","May 17, 2018","May 17, 2018","May 20, 2008","December 10, 2018","February 19, 2019","Research Site, Santa Monica, California, United States|Research Site, Stanford, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Wien, Austria|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Lyon cedex 8, France|Research Site, Marseille cedex 05, France|Research Site, Villejuif cedex, France|Research Site, Bad Saarow, Germany|Research Site, Stuttgart, Germany|Research Site, Bologna, Italy|Research Site, Milano, Italy|Research Site, Leiden, Netherlands|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Lund, Sweden|Research Site, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT00680992/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT00680992/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00680992"
427,"NCT00661921","A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus",,"Withdrawn","No Results Available","Diabetes Mellitus","Biological: AMG 108|Biological: Placebo","Change from baseline in HbA1c at week 14 (end of treatment)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20070212","June 2008","June 2009","October 2009","April 21, 2008",,"September 6, 2018",,,"https://ClinicalTrials.gov/show/NCT00661921"
428,"NCT00658658","Panitumumab in Children With Solid Tumors",,"Completed","Has Results","Solid Tumors","Biological: Panitumumab","Number of Participants With Dose-limiting Toxicities (DLTs)|Number of Participants With Adverse Events (AEs)|Maximum Observed Concentration (Cmax) of Panitumumab|Minimum Observed Concentration (Cmin) of Panitumumab|Area Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab|Half-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab|Serum Clearance (CL) of Panitumumab|Number of Participants Who Developed Antibodies to Panitumumab|Percentage of Participants With an Objective Response|Percentage of Participants With Disease Control","Amgen","All","1 Year to 17 Years   (Child)","Phase 1","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050252|2014-005190-36","March 2008","March 2015","March 2015","April 15, 2008","May 18, 2016","May 18, 2016","Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Chicago, Illinois, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00658658"
429,"NCT00654368","CAMEO: Canadian Methotrexate and Etanercept Outcome Study",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Etanercept|Drug: Methotrexate","Change From Month 6 to Month 12 in Disease Activity Sscore 28 (DAS28)|Disease Activity Score (DAS) 28 Response|Change From Baseline in Disease Activity Score 28 (DAS28)|Drug Persistence|Change From Baseline in Modified Total Sharp Score (mTSS)|Change From Baseline in Joint Erosion Score|Change From Baseline in Joint Space Narrowing|Change From Month 6 in Health Assessment Questionnaire Disability Index (HAQ DI)|Change From Month 6 in Health Assessment Questionnaire Pain Visual Analog Scale (VAS)|Change From Month 6 in Short Form 36 Health Survey (SF-36)|Change From Month 6 in Work Productivity and Activity Impairment (WPAI)|Change From Month 6 in Treatment Satisfaction Questionnaire for Medication (TSQM)|Number of Participants With Adverse Events (AEs)","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070301","June 2008","December 2012","February 2013","April 8, 2008","June 13, 2014","July 23, 2014","Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Quispamsis, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Bowmanville, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, St Catharines, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Saint Leonard, Quebec, Canada|Research Site, Saint-Eustache, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00654368"
430,"NCT00630786","Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study",,"Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Metastatic Colorectal Cancer|Oncology","Drug: Panitumumab|Drug: Conatumumab","Part 1: Number of Participants With Dose-limiting Toxicities|Number of Participants With an Objective Response|Progression-free Survival|Overall Survival|Number of Participants With Disease Control|Time to Response|Duation of Response|Number of Participants With Anti-therapeutic Antibodies|Number of Participants With Adverse Events (AEs)|Number of Participants With Post-baseline Laboratory Values Grade 3 or Higher","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","53","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060332|2007-004722-25","January 2008","May 2009","November 2010","March 7, 2008","February 6, 2014","February 6, 2014",,,"https://ClinicalTrials.gov/show/NCT00630786"
431,"NCT00626704","Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma",,"Completed","No Results Available","Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma|Sarcoma|Soft Tissue Sarcoma","Drug: AMG 655|Other: Placebo|Drug: Doxorubicin","Progression-Free Survival|Objective response rate, time to response, duration of response, clinical benefit rate, overall survival, incidence of adverse events and clinical laboratory abnormalities, and incidence of anti-AMG 655 antibody formation.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060324","November 2007","August 2009","March 2011","February 29, 2008",,"May 25, 2015",,,"https://ClinicalTrials.gov/show/NCT00626704"
432,"NCT00625651","Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer",,"Completed","No Results Available","Metastatic Colorectal Cancer|Colon Cancer|Colorectal Cancer|Rectal Cancer","Drug: Placebo|Drug: AMG 655|Drug: Modified FOLFOX6|Drug: Bevacizumab","Progression-free survival|Objective response rate|Duration of response|Time-to-response|Overall survival|AMG 655 pharmacokinetic parameters|The incidence of anti-AMG 655 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20060464","October 2007","August 2010","September 2011","February 28, 2008",,"April 25, 2014","Research Site, Hot Springs, Arkansas, United States|Research Site, Downey, California, United States|Research Site, La Jolla, California, United States|Research Site, Loma Linda, California, United States|Research Site, Orange, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, San Diego, California, United States|Research Site, Denver, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Harvey, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, St. Joseph, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Long Branch, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hudson, New York, United States|Research Site, New York, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pottsville, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00625651"
433,"NCT00614523","Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",,"Completed","Has Results","MDS|Myelodysplastic Syndromes|Thrombocytopenia","Drug: Placebo|Biological: Romiplostim","Number of Clinically Significant Bleeding Events|Annualized Rate of Platelet Transfusion Events|Annualized Rate of Overall Bleeding Events|Annualized Rate of Total Platelet Transfusion Units|Number of Participants With Platelet Hematologic Improvement (HI-P)|Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions|Number of Participants Who Died|Time to Death|Kaplan-Meier Estimate of Survival at Month 12|Annualized Rate of Patient-reported Bleeding Events","Amgen","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20060198","July 21, 2008","March 31, 2011","November 30, 2015","February 13, 2008","August 13, 2013","January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT00614523"
434,"NCT00613730","Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint","APPRISE 1","Terminated","Has Results","Cancer of Pancreas|Cancer of the Pancreas|Pancreas Cancer|Pancreatic Cancer","Drug: Gemcitabine|Drug: panitumumab","Overall Survival at 1 Year|Progression-free Survival|Percentage of Participants With Overall Response","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060542","January 2007","April 2009","April 2009","February 13, 2008","January 6, 2014","January 6, 2014",,,"https://ClinicalTrials.gov/show/NCT00613730"
435,"NCT00603642","P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura","Drug: Placebo|Drug: AMG 531","Weeks With Weekly Platelet Response|Increased Platelet Count From Baseline of at Least 20 x 10^9/L|Change From Baseline in Mean of Last 4 Weekly Platelet Counts|Weeks With Platelet Count Between 50 and 200|Rescue Medication(s)","Amgen","All","20 Years and older   (Adult, Older Adult)","Phase 3","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060216","October 1, 2007","April 13, 2009","April 13, 2009","January 29, 2008","December 10, 2010","May 9, 2019",,,"https://ClinicalTrials.gov/show/NCT00603642"
436,"NCT00603447","Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma",,"Completed","Has Results","Relapsed Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Number of Participants With Adverse Events (AEs)|Number of Participants With Dose-limiting Toxicities","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","84","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-006","May 2008","May 2013","January 2016","January 29, 2008","June 3, 2015","May 30, 2017","Pacific Shores Medical Group, Long Beach, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cornell University, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutch Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00603447"
437,"NCT00583674","Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma",,"Completed","No Results Available","Gastrointestinal Cancer","Drug: AMG 386 placebo|Drug: AMG 386 10mg/kg|Drug: AMG 386 3mg/kg|Drug: Cisplatin|Drug: Capecitabine","Progression Free Survival (PFS)|Safety and Tolerability|Objective Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Time to Progression (TTP)|Time to Response|Pharmacokinetics|Patient Reported Outcomes","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060439","December 2007","March 2010","June 2012","December 31, 2007",,"May 7, 2014",,,"https://ClinicalTrials.gov/show/NCT00583674"
438,"NCT00563316","Effect of Panitumumab on the Pharmacokinetics of Irinotecan",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Irinotecan","Maximum Observed Plasma Concentration (Cmax) of Irinotecan|Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUCinf) for Irinotecan|Area Under the Plasma Concentration-time Curve From the Time of the Last Quantifiable Concentration (AUClast) for Irinotecan|Number of Participants With Clinically Significant Adverse Events (AEs)","Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062010","March 2008","March 2009","June 2010","November 26, 2007","April 12, 2016","April 12, 2016","Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00563316"
439,"NCT00556374","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy",,"Active, not recruiting","Has Results","Breast Cancer","Drug: Placebo|Biological: Denosumab|Drug: Non-steroidal aromatase inhibitor therapy|Drug: Zoledronic Acid|Other: Standard of Care","Time to First Clinical Fracture|Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites|Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites|Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites|Number of Participants With New Vertebral Fractures|Number of Participants With New or Worsening Vertebral Fractures|Disease-free Survival|Bone Metastases-free Survival|Overall Survival","Amgen|Austrian Breast and Colorectal Cancer Study Group","Female","45 Years to 100 Years   (Adult, Older Adult)","Phase 3","3420","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20050209|ABCSG-18|2005-005275-15","December 18, 2006","October 7, 2014","August 2, 2022","November 12, 2007","November 6, 2015","January 13, 2020","Research Site, Baden, Austria|Research Site, Braunau, Austria|Research Site, Dornbirn, Austria|Research Site, Feldkirch, Austria|Research Site, Gmunden, Austria|Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Güssing, Austria|Research Site, Hall in Tirol, Austria|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Krems, Austria|Research Site, Kufstein, Austria|Research Site, Leoben, Austria|Research Site, Lienz, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Oberpullendorf, Austria|Research Site, Ried, Austria|Research Site, Rottenmann, Austria|Research Site, Salzburg, Austria|Research Site, Schärding, Austria|Research Site, St Poelten, Austria|Research Site, St Veit an der Glan, Austria|Research Site, St. Poelten, Austria|Research Site, Steyr, Austria|Research Site, Villach, Austria|Research Site, Villach, Austria|Research Site, Voecklabruck, Austria|Research Site, Weiz, Austria|Research Site, Wels, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wolfsberg, Austria|Research Site, Gävle, Sweden|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00556374"
440,"NCT00547157","Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",,"Completed","Has Results","Cancer|Head and Neck Cancer|Oncology|Squamous Cell Carcinoma","Drug: Panitumumab|Drug: Cisplatin","Local Regional Control Rate at 2 Years|Duration of Local Regional Control|Progression-free Survival|Overall Survival|ORR by 6 Months - Central|CRR by 6 Months - Central","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062079|CONCERT2","November 2007","December 2011","March 2012","October 22, 2007","May 23, 2014","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT00547157"
441,"NCT00540696","Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa",,"Completed","No Results Available","Anemia|Non-Myeloid Malignancies","Drug: darbepoetin alfa","Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score|Relationship between hemoglobin (hgb) response and change in functional capacity|Estimates of the sensitivity and specificity of the FCST|Relationship between hgb variables and changes on the MHST score, the FCST and its components|Maximum change in hgb from baseline to any point during the study, excluding hgb measurements obtained within 28 days of a red blood cell (RBC) transfusion|Number and proportion of subjects who achieve a hgb response as defined by an increase of greater than or equal to 2.0 g/dL from the baseline hgb in absence of any RBC transfusion within the prior 28 days at any point during the study (hgb response)|Hgb improvement (defined as correction and/or response)|Change in hgb from baseline to week 17, or the subject's last hgb value excluding hgb measurements obtained within 28 days of a RBC transfusion|Number and proportion of subjects who receive any RBC transfusions, the number of units of RBC transfused, and the number of days with at least 1 RBC transfusion from weeks 1 to end of treatment phase, weeks 1 to 4, and weeks 5 to end of treatment phase|Safety of this dosing regimen of darbepoetin alfa by incidence of clinical adverse events|Safety of darbepoetin alfa as determined by antibody formation|Changes in concomitant medications|Rapid rise in hgb (a greater than or equal to 2.0 g/dL increase in hgb concentration within a 28-day window during the treatment period)|Proportion of subjects who achieve a hgb of greater than or equal to 12.0 g/dL at any point during the study (hgb correction)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000220","September 2001","June 2003","September 2003","October 8, 2007",,"April 26, 2013",,,"https://ClinicalTrials.gov/show/NCT00540696"
442,"NCT00540384","Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy",,"Completed","No Results Available","Anemia|Solid Tumors","Drug: Placebo|Drug: Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)","Occurence of adverse events and antibody formation to NESP|Number and proportion of subjects who receive any RBC transfusion, number of units of RBC transfused, and number of days with at least one RBC transfusion during weeks 1-12, 1-4, 5-8, 9-12, and 5-12, with emphasis on the 5-12 week window|Selected domains of quality of life (QOL) measured by FACT-G and FACT-anaemia scales, BSI depression and BSI anxiety scales, and de novo questions|Relationship between these QOL measurements and hgb|Hgb correction to greater than or equal to 12.0 g/dL in the absence of a red blood cell (RBC) transfusion during the preceding 4 weeks during treatment phase|Number and proportion of subjects, during the treatment phase, who achieve a hemoglobin (hgb) response|Time to hgb response and hgb correction after the initiation of treatment|Change in hgb measured at the end of the treatment phase compared to baseline","Amgen",,"Child, Adult, Older Adult","Phase 1|Phase 2","405","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","980291","July 1999","March 2002","June 2002","October 8, 2007",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00540384"
443,"NCT00534456","An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial",,"Terminated","No Results Available","Anemia|Cardiovascular Disease|Congestive Heart Failure|Heart Failure|Ventricular Dysfunction","Drug: Placebo|Drug: Darbepoetin alfa","To determine whether treatment of anemia with darbepoetin alfa, in patients with heart failure and anemia, results in changes in cardiac structure and function.|Explore correlations among measures of cardiac systolic and diastolic function, surrogate markers of cardiac injury and function, and clinical outcomes in heart failure subjects treated with darbepoetin alfa or placebo.|Investigate the effect of treatment of anemia with darbepoetin alfa on novel biomarkers relevant to the pathophysiology and progression of heart failure","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060172","January 2007","October 2007","October 2007","September 24, 2007",,"April 8, 2011",,,"https://ClinicalTrials.gov/show/NCT00534456"
444,"NCT00534027","A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: AMG 655|Other: AMG 655 placebo","Progression free survival|Objective response rate, duration of response, time to response, overall survival and incidence of adverse events and clinical laboratory abnormalities","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060295","January 2008","March 2011","March 2011","September 24, 2007",,"January 14, 2016",,,"https://ClinicalTrials.gov/show/NCT00534027"
445,"NCT00531284","Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma",,"Completed","Has Results","Ovarian Cancer|Renal Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Multiple Myeloma|Lymphoma","Drug: Carfilzomib|Drug: Dexamethasone","Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)|Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles|Percentage of Participants With an Overall Response Throughout the Study|Duration of Response|Progression-Free Survival|Time to Progression|Maximum Observed Plasma Concentration of Carfilzomib|Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib|Elimination Half-life (t½) of Carfilzomib|Clearance (CL) of Carfilzomib|Volume of Distribution at Steady State (Vss) of Carfilzomib|Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","184","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-007","September 2007","October 2014","May 22, 2017","September 18, 2007","December 9, 2015","August 15, 2017","Pinnacle Oncology, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00531284"
446,"NCT00530816","Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: carfilzomib","Best Overall Response Rate (ORR) in the Response Evaluable Subset Population|Best Overall Response Rate (ORR) in the Response Evaluable Population|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Time to Progression (TTP)|Progression-free Survival (PFS)|Overall Survival (OS)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-004","September 2007","January 2013","July 2013","September 18, 2007","December 3, 2015","May 2, 2017","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Therapeutic Research Institute of Orange County, Laguna Hills, California, United States|Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States|Oncology & Hematology Assoc. of W. Broward, Tamarac, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Orchard Research, Skokie, Illinois, United States|University of Kentucky College of Medicine, Lexington, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States|Summa Health System, Akron, Ohio, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Dayton Clinical Oncology Program, Dayton, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Harrington Cancer Center, Amarillo, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada|University of Toronto Princess Margaret Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00530816"
447,"NCT00530114","Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia",,"Completed","No Results Available","End Stage Renal Disease|Chronic Kidney Disease|Hyperphosphatemic|Kidney Disease","Drug: AMG 223|Drug: Placebo","To demonstrate the AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with CKD receiving dialysis|To describe a dose response for AMG 223|To evaluate the safety and tolerability of AMG 223","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","167","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20070664","March 2008","November 2008","February 2009","September 17, 2007",,"March 14, 2016",,,"https://ClinicalTrials.gov/show/NCT00530114"
448,"NCT00527267","Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects",,"Completed","No Results Available","Hyperparathyroidism","Drug: Placebo|Drug: AMG 073","To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.|To evaluate the efficacy of AMG 073 compared with placebo by determining: the proportion of subjects with a reduction from baseline in iPTH of >= during the efficacy assessment phase|To evaluate the efficacy of AMG 073 compared with placebo by determining: percentage change from baseline in calcium x phosphorus (Ca x P) during the efficacy assessment phase|To evaluate the efficacy of AMG 073 compared with placebo by determining: changes in self-reported cognitive function from baseline to the end of the efficacy assessment phase|To evaluate the safety of AMG 073 compared with placebo.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20000183","February 2002","April 2003","April 2003","September 10, 2007",,"January 26, 2009",,,"https://ClinicalTrials.gov/show/NCT00527267"
449,"NCT00527215","Phase 2 Study of Darbepoetin Alfa Extended Dosing",,"Completed","No Results Available","Pre-Dialysis","Drug: darbepoetin alfa","To assess the proportion of CRI subjects maintaining a target hemoglobin (Hb) range of 10.0 to 12.0 g/dL when administered subcutaneous (SC) darbepoetin alfa once every 4 weeks|To assess the safety, toleratbility, and pharmacokinetic (PK) profile of darbepoetin alfa when administered once every 4 weeks.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010212","March 2002","October 2003","October 2003","September 10, 2007",,"May 22, 2009",,,"https://ClinicalTrials.gov/show/NCT00527215"
450,"NCT00527137","NESP Pediatric Study",,"Completed","No Results Available","Pre-dialysis|End Stage Renal Disease","Drug: darbepoetin alfa|Drug: rHuEPO","To demonstrate that NESP is comparable (not inferior) to rHuEPO for the treatment of anemia in pediatric subjects with CRI or ESRD receiving dialysis|To determine the safety and tolerability of NESP in the treatment of anemia in the pediatric population with CRI or ESRD","Amgen",,"Child, Adult, Older Adult","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000100","August 2000","November 2004","November 2004","September 10, 2007",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00527137"
451,"NCT00527085","12-month Study of AMG 073 in Renal Osteodystrophy",,"Completed","No Results Available","Renal Osteodystrophy","Drug: AMG 073|Drug: Placebo","To evaluate the effects of AMG 073 compared with placebo on renal osteodystrophy as assessed by bone histomorphometry|To evaluate the effects of AMG 073 compared with placebo on intact parathyroid hormone (iPTH), bone-specific alkaline phosphatase (BALP), serum N-Telopeptide (N-Tx), and calcium x phosphorus product concentrations|To evaluate the feasibility of measuring physical activity with accelerometry|To evaluate the safety and tolerability of AMG 073 compared with placebo","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20010141","October 2001","August 2003","August 2003","September 10, 2007",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00527085"
452,"NCT00526929","Fixed Dose NESP Study in Subjects With CRI",,"Completed","No Results Available","Pre-Dialysis","Drug: darbepoetin alfa","To determine the effectiveness of fixed dose(s) of NESP, administered once every other week, in the treatment of anemia in subjects with CRI|To assess the safety and tolerability of chronic NESP therapy","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","990151","May 2000","February 2002","February 2002","September 10, 2007",,"May 22, 2009",,,"https://ClinicalTrials.gov/show/NCT00526929"
453,"NCT00523341","Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis",,"Completed","Has Results","Osteopenia|Osteoporosis","Biological: Denosumab","Number of Participants With Adverse Events (AEs)|Number of Participants With Laboratory Toxicities of Grade ≥ 3|Number of Participants With Antibodies to Denosumab|Percent Change From Baseline in Lumbar Spine Bone Mineral Density by Visit|Percent Change From Baseline in Total Hip Bone Mineral Density by Visit|Percent Change From Baseline in Femoral Neck Bone Mineral Density by Visit|Percent Change From Baseline in 1/3 Radius Bone Mineral Density by Visit|Percent Change From Study 20030216 Baseline in Lumbar Spine Bone Mineral Density by Visit|Percent Change From Study 20030216 Baseline in Total Hip BMD by Visit|Percent Change From Study 20030216 Baseline in Femoral Neck BMD by Visit|Percent Change From Study 20030216 Baseline in 1/3 Radius BMD by Visit|Number of Participants With New Vertebral Fractures|Number of Participants With Non-Vertebral Fractures|Percent Change From Baseline in C-Telopeptide 1 (CTX-1) by Visit|Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP) by Visit|Percent Change From Study 20030216 Baseline in CTX-1 by Visit|Percent Change From Study 20030216 Baseline in P1NP by Visit|Percent Change From Baseline in Albumin-adjusted Serum Calcium at Day 10|Serum Denosumab Concentration|Bone Histomorphometry: Cancellous Bone Volume|Bone Histomorphometry: Trabecular Number|Bone Histomorphometry: Trabecular Separation|Bone Histomorphometry: Trabecular Thickness|Bone Histomorphometry: Cortical Width|Bone Histomorphometry: Cancellous Bone Volume by TRAP Histomorphometry|Bone Histomorphometry: Surface Density|Bone Histomorphometry: Osteoblast - Osteoid Interface|Bone Histomorphometry: Osteoid Surface|Bone Histomorphometry: Osteoid Thickness|Bone Histomorphometry: Wall Thickness|Bone Histomorphometry: Eroded Surface/Bone Surface|Bone Histomorphometry: Osteoclast Number - Length Based|Bone Histomorphometry: Osteoclast Number - Surface Based|Bone Histomorphometry: Osteoclast Number by TRAP - Length Based|Bone Histomorphometry: Osteoclast Number by TRAP - Surface Based|Bone Histomorphometry: Single-label Surface|Bone Histomorphometry: Double-label Surface|Bone Histomorphometry: Mineralizing Surface|Bone Histomorphometry: Mineral Apposition Rate|Bone Histomorphometry: Adjusted Apposition Rate|Bone Histomorphometry: Bone Formation Rate - Surface Based|Bone Histomorphometry: Bone Formation Rate - Volume Based|Bone Histomorphometry: Formation Period|Bone Histomorphometry: Activation Frequency|Bone Histomorphometry: Osteoid Volume|Bone Histomorphometry: Mineralization Lag Time|Bone Histology at Month 24|Bone Histology at Month 84","Amgen","Female","60 Years to 94 Years   (Adult, Older Adult)","Phase 3","4550","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060289","August 7, 2007","July 19, 2015","July 19, 2015","August 31, 2007","July 12, 2016","July 16, 2019",,,"https://ClinicalTrials.gov/show/NCT00523341"
454,"NCT00518531","Denosumab Adherence Preference Satisfaction Study",,"Completed","Has Results","Osteoporosis","Drug: alendronate|Drug: denosumab","Adherence With Treatment in the First Treatment Period|Adherence With Treatment in the Second Treatment Period|Compliance With Treatment in the First Treatment Period|Compliance With Treatment in the Second Treatment Period|Persistence With Treatment in the First Treatment Period|Persistence With Treatment in the Second Treatment Period|Time to Non-adherence to Alendronate Treatment in the First Treatment Period|Time to Non-adherence to Alendronate Treatment in the Second Treatment Period|Time to Non-compliance to Alendronate Treatment in the First Treatment Period|Time to Non-compliance to Alendronate Treatment in the Second Treatment Period|Time to Non-persistence to Alendronate Treatment in the First Treatment Period|Time to Non-persistence to Alendronate Treatment in the Second Treatment Period|Overall Satisfaction to Study Treatment|Beliefs About Medicines Questionnaire (BMQ): Necessity Score|Beliefs About Medicines Questionnaire (BMQ) Concern Score|Beliefs About Medicines Questionnaire (BMQ) Preference Score|Medication Adherence Rating Scale (MARS) to Alendronate in the First Treatment Period|Medication Adherence Rating Scale (MARS) to Alendronate in the Second Treatment Period","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060232|DAPS","September 1, 2007","June 1, 2009","June 1, 2010","August 20, 2007","January 7, 2014","December 3, 2019",,,"https://ClinicalTrials.gov/show/NCT00518531"
455,"NCT00515463","A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density",,"Completed","Has Results","Low Bone Mineral Density|Osteopenia|Osteoporosis","Biological: denosumab","Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6|Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 12|Number of Participants With Neutralizing Antibodies Against Denosumab at Month 12|Sodium Change From Baseline at Month 1|Sodium Change From Baseline at Month 6|Sodium Change From Baseline at Month 12|Potassium Change From Baseline at Month 1|Potassium Change From Baseline at Month 6|Potassium Change From Baseline at Month 12|Chloride Change From Baseline at Month 1|Chloride Change From Baseline at Month 6|Chloride Change From Baseline at Month 12|Bicarbonate Change From Baseline at Month 1|Bicarbonate Change From Baseline at Month 6|Bicarbonate Change From Baseline at Month 12|Magnesium Change From Baseline at Month 1|Magnesium Change From Baseline at Month 6|Magnesium Change From Baseline at Month 12|Blood Urea Nitrogen Change From Baseline at Month 1|Blood Urea Nitrogen Change From Baseline at Month 6|Blood Urea Nitrogen Change From Baseline at Month 12|Creatinine Change From Baseline at Month 1|Creatinine Change From Baseline at Month 6|Creatinine Change From Baseline at Month 12|Aspartate Amino Transferase Change From Baseline at Month 1|Aspartate Amino Transferase Change From Baseline at Month 6|Aspartate Amino Transferase Change From Baseline at Month 12|Alanine Amino Transferase Change From Baseline at Month 1|Alanine Amino Transferase Change From Baseline at Month 6|Alanine Amino Transferase Change From Baseline at Month 12|Total Bilirubin Change From Baseline at Month 1|Total Bilirubin Change From Baseline at Month 6|Total Bilirubin Change From Baseline at Month 12|Albumin Change From Baseline at Month 1|Albumin Change From Baseline at Month 6|Albumin Change From Baseline at Month 12|Total Protein Change From Baseline at Month 1|Total Protein Change From Baseline at Month 6|Total Protein Change From Baseline at Month 12|Glucose Change From Baseline at Month 1|Glucose Change From Baseline at Month 6|Glucose Change From Baseline at Month 12|Red Blood Cells Change From Baseline at Month 1|Red Blood Cells Change From Baseline at Month 6|Red Blood Cells Change From Baseline at Month 12|Hemoglobin Change From Baseline at Month 1|Hemoglobin Change From Baseline at Month 6|Hemoglobin Change From Baseline at Month 12|Reticulocytes Change From Baseline at Month 1|Reticulocytes Change From Baseline at Month 6|Reticulocytes Change From Baseline at Month 12|Platelets Change From Baseline at Month 1|Platelets Change From Baseline at Month 6|Platelets Change From Baseline at Month 12|White Blood Cells Change From Baseline at Month 1|White Blood Cells Change From Baseline at Month 6|White Blood Cells Change From Baseline at Month 12|Total Neutrophils Change From Baseline at Month 1|Total Neutrophils Change From Baseline at Month 6|Total Neutrophils Change From Baseline at Month 12|Eosinophils Change From Baseline at Month 1|Eosinophils Change From Baseline at Month 6|Eosinophils Change From Baseline at Month 12|Basophils Change From Baseline at Month 1|Basophils Change From Baseline at Month 6|Basophils Change From Baseline at Month 12|Lymphocytes Change From Baseline at Month 1|Lymphocytes Change From Baseline at Month 6|Lymphocytes Change From Baseline at Month 12|Monocytes Change From Baseline at Month 1|Monocytes Change From Baseline at Month 6|Monocytes Change From Baseline at Month 12|Number of Participants With Laboratory Toxicity CTCAE Grade Greater or Equal to 3","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","311","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060237","May 2007","March 2008","March 2009","August 13, 2007","October 31, 2013","October 31, 2013",,,"https://ClinicalTrials.gov/show/NCT00515463"
456,"NCT00515203","Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura|Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","Drug: Placebo|Drug: AMG 531","Adverse Events|Weeks With Platelet Count ≥ 50 x 10^9/L|Bleeding Events (Grade 2 or Higher)|Platelet Count ≥ 50 x 10^9/L for Two Consecutive Weeks|Increase in Platelet Count ≥ 20 x 10^9/L Above Baseline for Two Consecutive Weeks|Requirement for Rescue Therapy (as Defined Per Protocol)","Amgen","All","1 Year to 17 Years   (Child)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060195","July 2007","March 2009","August 2009","August 13, 2007","March 1, 2011","July 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00515203"
457,"NCT00511459","Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients",,"Completed","No Results Available","Locally Recurrent and Metastatic Breast Cancer","Drug: AMG 386 Placebo|Drug: AMG 386|Drug: Bevacizumab|Drug: Paclitaxel","Progression-free survival (PFS)|Objective Response (OR)|Duration of Response (DOR)|Time to response|Overall Survival|Time to progression (TTP)|Incidence of AEs and significant laboratory changes|AMG 386 Pharmakokinetic parameters|Incidence of the occurrence of anti-AMG 386 antibody formation","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060341","July 2007","August 2010","May 2014","August 3, 2007",,"October 29, 2015","Research Site, Litchfield Park, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Campbell, California, United States|Research Site, Los Angeles, California, United States|Research Site, Murrieta, California, United States|Research Site, Santa Maria, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Orlando, Florida, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, Henderson, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Edison, New Jersey, United States|Research Site, Mountain Lakes, New Jersey, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Richardson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Innsbruck, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Wilrijk, Belgium|Research Site, Herlev, Denmark|Research Site, Helsinki, Finland|Research Site, La Roche Sur Yon Cedex 9, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Paris Cedex 20, France|Research Site, Paris Cedex 5, France|Research Site, Toulouse Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Szombathely, Hungary|Research Site, Veszprem, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Maastricht, Netherlands|Research Site, Gdansk, Poland|Research Site, Lubin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00511459"
458,"NCT00511238","Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: carfilzomib","Best Overall Response Rate (ORR)|Clinical Benefit Response (CBR) (A0 Only)|Clinical Benefit Response (CBR) (A1 Only)|Duration of Response (A0 Only)|Duration of Response (A1 Only)|Time to Progression (A0 Only)|Time to Progression (A1 Only)|Progression-free Survival (A0 Only)|Progression-free Survival (A1 Only)|Overall Survival (A1 Only)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","312","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-003","August 2007","November 2010","October 2012","August 3, 2007","December 9, 2013","August 31, 2017","Southern Cancer Center, Mobile, Alabama, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Clinic, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern Universtiy, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|St. Vincent Catholic Medical Center, New York, New York, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology & Hematology Care, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00511238"
459,"NCT00508820","An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenic Purpura","Biological: Romiplostim","Adverse Events|Platelet Response (Definition 1)|Platelet Response (Definition 2)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","407","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040209","February 1, 2005","January 1, 2011","March 1, 2011","July 30, 2007","February 13, 2012","May 9, 2019",,,"https://ClinicalTrials.gov/show/NCT00508820"
460,"NCT00508625","A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: AMG 951 (rhApo2L/TRAIL)|Drug: Bevacizumab|Drug: Carboplatin|Drug: Paclitaxel","Objective response rate (CR and PR) by modified RECIST|Progression free survival|Time to response|Duration of response|Time to progression|Overall response rate (complete, partial or stable response)|Overall Survival","Amgen|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050190","June 2006","March 2009","November 2011","July 30, 2007",,"June 14, 2016",,,"https://ClinicalTrials.gov/show/NCT00508625"
461,"NCT00508404","Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFIRI","Objective Response Rate|Objective Response by 17 Weeks|Disease Control Rate|Duration of Response|Time to Initial Objective Response|Progression-free Survival|Time to Disease Progression|Duration of Stable Disease|Time to Treatment Failure|Time to Disease Relapse Following Surgical Intervention|Resection Rate","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","154","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060314|EUDRACT Number 2006-006739-36","May 9, 2007","June 1, 2009","June 12, 2012","July 30, 2007","January 26, 2016","November 19, 2019",,,"https://ClinicalTrials.gov/show/NCT00508404"
462,"NCT00500760","Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer",,"Completed","Has Results","Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Cisplatin|Radiation: Standard Fractionation Radiotherapy|Drug: Panitumumab","Local Regional Control Rate at 2 Years|Local Regional Control Rate at 6 Months and 12 Months|Duration of Local-regional Control|Progression-Free Survival|Overall Survival|Percentage of Participants With an Objective Response at 6 Months|Percentage of Participants With a Complete Response at 6 Months","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062080","October 1, 2007","March 29, 2011","April 26, 2011","July 13, 2007","August 5, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00500760"
463,"NCT00479817","Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer",,"Completed","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: AMG 386|Drug: Paclitaxel|Drug: AMG 386 Placebo","Progression Free Survival|Safety and Tolerability|Objective Response Rate|Duration of Response|Modified RECIST/CA-125 Progression Free Survival|CA-125 Response Rate|Estimate of reduction in tumor burden|Incidence of AEs and significant laboratory changes|Overall Survival|Time to Progression|Time to Response|Change from baseline in blood levels of CA-125|Time-adjusted area under the curve for PROs|AMG 386 Pharmacokinetic parameters|Incidence of the occurence of AMG 386 Antibody formation","Amgen","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060342","July 5, 2007","August 11, 2009","December 9, 2019","May 28, 2007",,"December 18, 2019",,,"https://ClinicalTrials.gov/show/NCT00479817"
464,"NCT00472290","Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)",,"Completed","Has Results","Hematology|MDS|Myelodysplastic Syndromes|Thrombocytopenia","Drug: Romiplostim (formerly AMG 531)","Overall Summary of Adverse Events|Incidence of Antibody (AB) Formation|Weekly Bleeding Events Per 100 Subject Years|Platelet Transfusion Events Per 100 Subject Years|Weeks With Platelet Response Per Year|Time to First Platelet Response|Duration of Platelet Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060197","April 1, 2007","July 18, 2011","December 26, 2011","May 11, 2007","July 15, 2013","December 29, 2017",,,"https://ClinicalTrials.gov/show/NCT00472290"
465,"NCT00467025","AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib",,"Completed","No Results Available","Advanced Renal Cell Carcinoma","Drug: AMG 386|Drug: Sorafenib|Drug: AMG 386 placebo IV","Progression Free Survival|Objective response rate (ORR)|Duration of response (DOR)|Change in continuous measures of tumor burden|Time-adjusted area under the curve (AUC) for the FACT-Kidney Cancer Symptom Index (FKSI-15) scale score from baseline through disease progression with imputation for missing data|Incidence of AEs and significant laboratory changes|Incidence of the occurrence of anti-AMG 386 antibody formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060159","May 2007","April 2010","June 2014","April 27, 2007",,"March 23, 2016",,,"https://ClinicalTrials.gov/show/NCT00467025"
466,"NCT00460317","MONET1-MOtesanib NSCLC Efficacy and Tolerability Study",,"Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: AMG 706|Drug: placebo|Drug: paclitaxel|Drug: carboplatin","Overall survival time. Time from randomization to death. Subjects who have not died while on study or are lost to follow up will be censored at their last contact date.|Duration of response (calculated for only those subjects who respond)|Pharmacokinetics of AMG 706 when administered in combination with paclitaxel and carboplatin.|Association of AMG 706 treatment-induced PlGF increase with OS in subjects with non-squamous NSCLC and in subjects with adenocarcinoma histology|Evaluation of OS, PFS, AMG 706 treatment-induced PlGF increase association with OS, ORR (only in subjects with measurable disease) and duration of response in subjects with non-squamous, non-adenocarcinoma histology|Evaluation of the pharmacokinetics of AMG 706 and metabolites when administered with paclitaxel and carboplatin (in approximately 250 subjects at selected centers)|Safety and tolerability of AMG 706 in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin in subjects with non-squamous NSCLC histology and in subjects with adenocarcinoma histology.|Progression free survival time: Subjects who have not progressed or died on study will be censored at their last evaluable assessment date.|Objective tumour response rate (complete and partial response) according to modified RECIST criteria in subjects with measurable disease at baseline.","Amgen|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","1450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20050201","July 2007","March 2011","August 2013","April 13, 2007",,"September 7, 2015",,,"https://ClinicalTrials.gov/show/NCT00460317"
467,"NCT00460265","Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer","SPECTRUM","Completed","Has Results","Recurrent and/or Metastatic Head and Neck Cancer","Drug: ARM 2|Drug: ARM 1","Overall Survival|Overall Response Rate|Duration of Response|Time to Progression|Time to Response|Progression Free Survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","658","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050251","May 2007","May 2010","May 2012","April 13, 2007","June 14, 2011","March 7, 2014",,,"https://ClinicalTrials.gov/show/NCT00460265"
468,"NCT00454857","Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura","Other: Retrospective Chart Review|Other: Patient-reported Outcome Questionnaires|Other: Physician Survey","Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment|The Number of Participants Utilizing ITP Therapies for Second-line Treatment.|The Number of Participants Utilizing ITP Therapies for Third-line Treatment.|The Number of Participants Utilizing ITP Therapies for Fourth-line Treatment.|The Number of Participants Utilizing ITP Therapies for Fifth-line Treatment|The Number of Participants Utilizing ITP Therapies for Sixth-line Treatment.|The Number of Participants Utilizing ITP Therapies for Seventh or Greater-line Treatment.|The Number of Participants Utilizing ITP Therapies: Treatments With Unknown Starting Date.|Change From Baseline to Month 12 in Quality of Life Measured by the ITP-Patient Assessment Questionnaire (PAQ)|Change From Baseline to Month 12 in Health-related Quality of Life Assessed by EuroQol Visual Analog Scale (EQ-5D VAS)|Change From Baseline to Month 12 in Treatment Satisfaction|Number of Participants Receiving Drug Therapies for Treatment of ITP During the Prospective Phase|Duration of Exposure to ITP Medication|Number of Participants Requiring Splenectomy","Amgen","All","18 Years and older   (Adult, Older Adult)",,"326","Industry","Observational","Observational Model: Cohort","20050237","May 2006","June 2008","August 2008","April 2, 2007","May 12, 2010","November 26, 2013",,,"https://ClinicalTrials.gov/show/NCT00454857"
469,"NCT00454779","PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response",,"Completed","Has Results","Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck","Drug: Cisplatin|Drug: Panitumumab|Drug: Docetaxel","Progression Free Survival (PFS) During the First-line Treatment Phase|Overall Response Rate (ORR) During the First-line Treatment Phase|Rate of Disease Control (RDC) During the First-line Treatment Phase|Duration of Response (DOR) During the First-line Treatment Phase|Time to Response (TTR) During the First-line Treatment Phase|Overall Survival (OS) for the First-line Treatment|Progression Free Survival (PFS) During the Second-line Treatment Phase|Overall Response Rate (ORR) During the Second-line Treatment Phase|Rate of Disease Control (RDC) During the Second-line Treatment Phase|Duration of Response (DOR) During the Second-line Treatment Phase|Time to Response (TTR) During the Second-line Treatment Phase|Overall Survival (OS) for the Second-line Treatment","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050236","January 1, 2007","June 11, 2012","January 1, 2014","April 2, 2007","February 7, 2014","October 17, 2018","Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, La Verne, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Cruz, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Lakeland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Griffin, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Centralia, Illinois, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Zion, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Pascagoula, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Binghamton, New York, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Abingdon, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Marshfield, Wisconsin, United States|Research Site, Graz, Austria|Research Site, Leoben, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Kortrijk, Belgium|Research Site, Libramont, Belgium|Research Site, Liege, Belgium|Research Site, Ottignies, Belgium|Research Site, Wilrijk, Belgium|Research Site, Brno, Czechia|Research Site, Praha 5, Czechia|Research Site, Znojmo, Czechia|Research Site, Angers, France|Research Site, Lens cedex, France|Research Site, Perpignan, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, San Juan, Puerto Rico|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Presov, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Girona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00454779"
470,"NCT00448786","Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: AMG 706","Average change from baseline in gallbladder size (volume by ultrasound)|Average change from baseline in gallbladder function (ejection fraction)|Average changes from baseline in gallbladder size (volume by CT scan)|Maximum change from baseline in gallbladder size (volume) and function (ejection fraction)|Change in gallbladder size (volume) and function (ejection fraction) between the last on-treatment measurement and the last available off-treatment measurement|Objective response in subjects with measurable disease at baseline|Pharmacokinetics of AMG 706 monotherapy|Subject incidence of treatment-emergent adverse events (including all, serious, grade 3, grade 4 and treatment-related|Other selected gallbladder characteristics such as size, area, wall thickness, ductal size, presence of stones, pericholecystic fluid and sludge","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060443","February 2007","December 2008","March 2009","March 19, 2007",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00448786"
471,"NCT00446446","PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)",,"Completed","Has Results","Cancer|Carcinoma|Head and Neck Cancer|Metastases|Metastatic Cancer|Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck|Oncology|Squamous Cell Carcinoma|Tumors","Drug: Panitumumab","Objective Response Rate|Time to Response|Duration of Response|Rate of Disease Control|Time to Progression|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20062088","October 30, 2007","December 15, 2010","November 29, 2017","March 12, 2007","March 7, 2016","January 16, 2018",,,"https://ClinicalTrials.gov/show/NCT00446446"
472,"NCT00443326","AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects",,"Completed","No Results Available","Psoriasis","Drug: AMG 714","Psoriatic Assessment Score Index|Safety and Tolerability","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060349","March 2007","December 2008","May 2010","March 5, 2007",,"January 20, 2016",,,"https://ClinicalTrials.gov/show/NCT00443326"
473,"NCT00439894","Ancillary Study to Protocol 20060104",,"Completed","No Results Available","Rheumatoid Arthritis","Procedure: Blood draw","To explore the correlation between pheripheral blood cell protein phosphorylation assessemnts and rheumatoid arthritis disease activity.|Explore the correlations to etanercept clinical response (ACR and DAS scores) may also be explored.","Amgen","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational",,"20060364","December 2006","August 2007","October 2007","February 26, 2007",,"March 21, 2008",,,"https://ClinicalTrials.gov/show/NCT00439894"
474,"NCT00436995","Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis",,"Completed","No Results Available","Chronic Kidney Disease","Drug: Darbepoetin Alfa","Haemoglobin values to be maintained at greater than 11.0 g/dL during the evaluation period.|Q2W doses over duration of study.|Hb values during the evaluation period.|adverse events during study|Hb Rate of Rise during study and excursions above 14g/dL","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","114","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050210","April 2006","January 2007","December 2008","February 19, 2007",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00436995"
475,"NCT00436748","Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease",,"Terminated","Has Results","Anemia|Chronic Kidney Disease|Kidney Disease","Drug: Darbepoetin Alfa|Drug: Placebo","Proportion of Participants Achieving Hemoglobin ≥ 10.0 g/dL|Time to First Hemoglobin Value ≥ 10.0 g/dL|Hemoglobin Concentration Over Time|Weight-adjusted Darbepoetin Alfa Dose at Time of Achieving First Hemoglobin ≥ 10.0 g/dL|Darbepoetin Alfa Weight-Adjusted Dose Over Time|Change From Baseline at Week 13 and Week 25 in Parent-reported Pediatric Quality of Life Inventory (PedsQL) Scores|Change From Baseline at Week 13 and Week 25 in Child Self-reported Pediatric Quality of Life Inventory (PedsQL) Scores|Number of Participants With Treatment-emergent Adverse Events|Hemoglobin Serial Rate of Change (ROC) Over Time|Number of Participants With Hemoglobin > 12.0, > 13.0, and > 14.0 g/dL During the Study|Maximum Increase in Hemoglobin Over Any 2 Week Period|Change From Baseline in Systolic Blood Pressure Over Time|Change From Baseline in Diastolic Blood Pressure Over Time|Number of Participants Who Developed Anti-erythropoiesis Antibodies|Darbepoetin Alfa Serum Concentrations for Participants Less Than 6 Years of Age","Amgen","All","1 Year to 18 Years   (Child, Adult)","Phase 3","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20050256","September 16, 2008","March 3, 2014","March 3, 2014","February 19, 2007","March 31, 2015","January 30, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Stanford, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Kansas City, Missouri, United States|Research Site, Livingston, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Jurmala, Latvia|Research Site, Vilnius, Lithuania|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Puebla, Mexico|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Szczecin, Poland|Research Site, San Juan, Puerto Rico|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Birmingham, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00436748"
476,"NCT00436670","Phase II Study to Evaluate the Efficacy of AMG 317",,"Completed","No Results Available","Asthma","Biological: AMG 317 75 mg|Biological: AMG 317 150 mg|Biological: AMG 317 300 mg|Biological: Placebo","The primary objective is to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.|Change from baseline in frequency of rescue beta agonist use during week 12|Change from baseline PEFR during week 12 (morning/evening, diurnal and inter-day variation)|Change in pre and post bronchodilator FEV1 at week 12 from baseline|Number of asthma symptom-free days|Change from baseline in daily asthma symptoms during week 12|Safety endpoints: number of asthma exacerbations, antibodies, adverse events, and change in ECG, labs and vital signs|Change in AQLQ score at week 12 from baseline","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060161","March 2007","September 2008","February 2009","February 19, 2007",,"March 23, 2016",,,"https://ClinicalTrials.gov/show/NCT00436670"
477,"NCT00433875","Phase 2 AMG 714 in Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 714",,"Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20030210","December 2002",,,"February 12, 2007",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00433875"
478,"NCT00431496","A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)",,"Completed","Has Results","Anemia|Secondary Hyperparathyroidism","Drug: Cinacalcet","Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2|Number of Participants Who Achieved a Mean iPTH Value Between 150 and 300 pg/mL|Number of Participants Who Achieved a Mean Ca x P Value < 4.44 mmol^2/L^2 (55 mg^2/dL^2)|Number of Participants Who Achieved a Mean Calcium Value ≥ 2.1 and ≤ 2.37 mmol/L|Number of Participants Who Achieved a Mean Phosphorus Value ≥ 1.13 and ≤ 1.78 mmol/L|Number of Participants Who Achieved a Mean CRP < 0.6 mg/dL","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","71","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040196|To Target","September 2006","June 2009","October 2009","February 5, 2007","July 13, 2011","April 24, 2013",,,"https://ClinicalTrials.gov/show/NCT00431496"
479,"NCT00427440","A Phase II Study to Treat Advanced Malignant Glioma",,"Completed","No Results Available","Advanced Malignant Glioma","Drug: AMG 102 at 20 mg/kg|Drug: AMG 102 at 10 mg/kg","Assess best objective confirmed response rate in subjects with advanced malignant glioma receiving AMG 102 treatment|To assess the safety profile of AMG 102 in subjects with advanced malignant glioma|Estimate overall survival and progression-free survival rates in this population|Assess the duration of response and time to response in this population|Assess the pharmacokinetics of AMG 102 in subjects with advanced malignant glioma","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050253","November 2006","December 2008","April 2013","January 29, 2007",,"April 27, 2015",,,"https://ClinicalTrials.gov/show/NCT00427440"
480,"NCT00425204","Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment",,"Completed","No Results Available","Colorectal Cancer|Non-Small Cell Lung Cancer|Prostate Cancer|Solid Tumors|Advanced Renal Cell Carcinoma","Drug: Panitumumab (ABX-EGF)","To provide continued, extended panitumumab treatment to subjects who appeared to have benefited from and tolerated previous panitumumab treatment in Studies 20020374 Part 2 or 20030138 and its extension study, 20040116|To assess the safety of multidose administration of panitumumab in subjects who received continued and extended panitumumab treatment","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020375|Abgenix Protocol No. ABX-0311","March 2004","September 2007","March 2008","January 22, 2007",,"September 15, 2008",,,"https://ClinicalTrials.gov/show/NCT00425204"
481,"NCT00425035","Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2",,"Completed","No Results Available","Advanced Renal Cell Carcinoma","Drug: Panitumumab (ABX-EGF)","Part 2, Cohort 1: Efficacy: Tumor response rate (CR or PR) measured at 8 weeks|Part 2, Cohort 1: Safety: Incidence and severity of AEs|Part 2, Cohort 2: Time to disease progression|Part 2, Cohort 1: Time to disease progression|Part 2, Cohorts 1 & 2: Survival time|Part 2, Cohorts 1 & 2: PFS|Part 2, Cohorts 1 & 2: Best overall response rate|Part 2, Cohorts 1 & 2: Tumor response rate at Weeks 15, 23, 31, and 39|Part 2, Cohorts 1 & 2: Duration of response|Part 2, Cohorts 1 & 2: Percent of patients with progressive disease (measured at 8 weeks following initiation of panitumumab treatment)|Part 2, Cohorts 1 & 2: Time to CR|Part 2, Cohorts 1 & 2: Time to response (PR or CR)","Amgen",,"Child, Adult, Older Adult","Phase 2","115","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020374|Abgenix protocol No. ABX-0303|Immunex protocol No. 054.0003","February 2003",,,"January 22, 2007",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00425035"
482,"NCT00422019","A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma",,"Completed","No Results Available","Advanced Renal Cell Carcinoma","Drug: AMG 102 at 10 mg/kg|Drug: AMG 102 at 20 mg/kg","To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment|To estimate the overall survival and progression free survival rates in this population|To assess the duration of response and time to response in this population|To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma|To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060100","January 2007","March 2009","March 2009","January 15, 2007",,"April 10, 2015",,,"https://ClinicalTrials.gov/show/NCT00422019"
483,"NCT00418938","SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial",,"Completed","Has Results","Cancer|Colon Cancer|Colorectal Cancer|Metastatic Cancer|Rectal Cancer|Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: Bevacizumab|Drug: Leucovorin|Drug: Irinotecan|Drug: 5-Fluorouracil","Progression-free Survival (PFS)|Overall Survival|Objective Response Rate|Time to Response|Time to Progression|Disease Control|Duration of Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","266","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060141","November 1, 2006","May 10, 2012","April 1, 2013","January 5, 2007","March 28, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00418938"
484,"NCT00418665","A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid",,"Completed","Has Results","Myelodysplastic Syndromes|Thrombocytopenia","Biological: AMG 531|Drug: Placebo","Occurrence of a Clinically Significant Thrombocytopenic Event|Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia|Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines|Platelet Transfusion","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20060102","December 2006","March 2009","October 2010","January 5, 2007","December 22, 2010","January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00418665"
485,"NCT00415532","Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura|Thrombocytopenia|Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Thrombocytopenic Purpura","Drug: Medical Standard of Care for ITP|Biological: Romiplostim","Number of Participants With Splenectomy During 52-Week Treatment Period|Number of Participants With Treatment Failure During 52-Week Treatment Period|Time to Splenectomy|Percentage of Participants With Platelet Response|Change in ITP-PAQ Physical Health Domain of Symptoms|Change in ITP-PAQ Physical Health Domain of Fatigue|Change in ITP-PAQ Physical Health Domain of Bother|Change in ITP-PAQ Physical Health Domain of Activity","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","234","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060131","December 1, 2006","November 7, 2008","May 11, 2009","December 25, 2006","July 8, 2013","May 9, 2019",,,"https://ClinicalTrials.gov/show/NCT00415532"
486,"NCT00413452","Etanercept SFP in RA Patients",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","Etanercept seroreactivity response (ie, development of anti-etanercept antibodies) to etanercept (manufactured using the SFP)|Etanercept seroreactivity response to etanercept (manufactured using the SFP)|neutralizing antibodies to etanercept|Adverse events, serious adverse events (SAEs), serious infections and safety laboratory assessments","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","224","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060104","December 2006","August 2007","October 2007","December 19, 2006",,"February 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00413452"
487,"NCT00413283","Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Lung Cancer|Chemotherapy-Induced Thrombocytopenia|Non-Small Cell Lung Cancer|Cancer|Lung Neoplasms|Oncology|Solid Tumors|Thrombocytopenia","Biological: Romiplostim|Drug: Placebo|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin","Number of Participants With Adverse Events|Duration of Grade 3 or 4 Thrombocytopenia|Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.|Number of Participants With Platelet Transfusions|Platelet Count on Day 22|Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20050154","December 2006","December 2008","February 2009","December 19, 2006","October 21, 2010","October 24, 2013","Research Site, Glendale, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Anaheim, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Athens, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Sioux City, Iowa, United States|Research Site, Sioux City, Iowa, United States|Research Site, Paducah, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Sterling Heights, Michigan, United States|Research Site, Sterling Heights, Michigan, United States|Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Flemington, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Johnson City, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Drexel Hill, Pennsylvania, United States|Research Site, Drexel Hill, Pennsylvania, United States|Research Site, Dunmore, Pennsylvania, United States|Research Site, Dunmore, Pennsylvania, United States|Research Site, Radnor, Pennsylvania, United States|Research Site, Radnor, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Graz, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Innsbruck, Austria|Research Site, Klagenfurt, Austria|Research Site, Klagenfurt, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Rankweil, Austria|Research Site, Rankweil, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Sainte-Foy, Quebec, Canada|Research Site, Sainte-Foy, Quebec, Canada|Research Site, Bad Berka, Germany|Research Site, Bad Berka, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Halle/ Saale, Germany|Research Site, Halle/ Saale, Germany|Research Site, Hemer, Germany|Research Site, Hemer, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Edeleny, Hungary|Research Site, Edeleny, Hungary|Research Site, Gyula, Hungary|Research Site, Gyula, Hungary|Research Site, Matrahaza, Hungary|Research Site, Matrahaza, Hungary|Research Site, Pecs, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Torokbalint, Hungary|Research Site, Torokbalint, Hungary|Research Site, Zalaegerszeg - Pozva, Hungary|Research Site, Zalaegerszeg - Pozva, Hungary|Research Site, Cork, Ireland|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Novara, Italy|Research Site, Novara, Italy|Research Site, Orbassano, Italy|Research Site, Orbassano, Italy|Research Site, Palermo, Italy|Research Site, Palermo, Italy|Research Site, Torino, Italy|Research Site, Torino, Italy|Research Site, Coimbra, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Vila Nova de Gaia, Portugal",,"https://ClinicalTrials.gov/show/NCT00413283"
488,"NCT00411450","Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","PRECEPT","Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer|Cancer|Metastatic Cancer|Metastatic Colorectal Cancer|Oncology","Biological: Panitumumab|Drug: FOLFIRI","Objective Response Rate at Weeks 17 and 25|Best Response During Second-Line Treatment|Progression-free Survival Rate at Weeks 17 and 25|Progression-free Survival Time|Disease Control Rate at Weeks 17 and 25|Duration of Response|Overall Survival|Time to Treatment Failure|Time to Progression|Time to Response|Number of Participants With Adverse Events|Number of Participants With Grade 4 Laboratory Toxicities|Number of Participants Who Developed Antibodies to Panitumumab","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060277","November 2006","January 2009","October 2010","December 14, 2006","February 15, 2016","February 15, 2016",,,"https://ClinicalTrials.gov/show/NCT00411450"
489,"NCT00401544","Darbepoetin Alfa With or Without Intravenous (IV) Iron",,"Completed","Has Results","Anemia|Non-Myeloid Malignancies","Drug: darbepoetin alfa|Drug: IV iron dextran","Number of Participants Who Achieved the Target Hemoglobin Level, by Darbepoetin Alfa Dose|Number of Participants Who Achieved the Target Hemoglobin Levels, by IV Iron Usage|Time to Achieve Target Hemoglobin Level, by Darbepoetin Alfa Dose|Time to Achieve the Target Hemoglobin Level, by IV Iron Usage|Change From Baseline in Hemoglobin Concentration, by Darbepoetin Alfa Dose|Change From Baseline in Hemoglobin Concentration, by IV Iron Usage|Number of Participants With ≥ 1 Red Blood Cell Transfusion From Week 1 to End of Study, by Darbepoetin Alfa Dose|Number of Participants With ≥ 1 Red Blood Cell Transfusion From Week 1 to End of Study, by IV Iron Usage|Number of Participants With ≥ 1 Red Blood Cell Transfusion From Week 5 to End of Study|Number of Participants With a Hematopoietic Response, by Darbepoetin Alfa Dose|Number of Participants With a Hematopoietic Response, by IV Iron Usage|Time to Hematopoietic Response, by Darbepoetin Alfa Dose|Time to Hematopoietic Response, by IV Iron Usage|Change From Baseline in Functional Assessment of Cancer Therapy (FACT) - Fatigue Score, by Darbepoetin Alfa Dose|Change From Baseline in Functional Assessment of Cancer Therapy (FACT) - Fatigue Score, by IV Iron Usage","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060103","December 2006","December 2007","March 2008","November 20, 2006","January 29, 2014","January 29, 2014",,,"https://ClinicalTrials.gov/show/NCT00401544"
490,"NCT00396279","Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone",,"Completed","Has Results","GCT|Giant Cell Tumor of Bone","Biological: Denosumab|Dietary Supplement: Calcium/Vitamin D","Percentage of Participants With Giant Cell Tumor Response|Percent Change From Baseline in Urinary N-telopeptide Corrected for Urine Creatinine|Percent Change From Baseline in Serum C-terminus Peptide (of Type 1 Collagen)|Serum Denosumab Trough Concentrations|Number of Participants With Adverse Events (AEs)|Number of Participants With Anti-Denosumab Antibodies","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040215","July 10, 2006","April 7, 2008","February 1, 2011","November 6, 2006","March 5, 2014","February 19, 2019",,,"https://ClinicalTrials.gov/show/NCT00396279"
491,"NCT00395902","Post Transplant Study",,"Completed","No Results Available","Kidney Tansplant|Secondary Hyperparathyroidism|Hyperparathyroidism","Drug: Sensipar after Post Transplant",,"Amgen","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Time Perspective: Retrospective","20040261|2004261","August 2005",,,"November 6, 2006",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00395902"
492,"NCT00393822","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer",,"Completed","No Results Available","Colon Cancer","Drug: palifermin|Drug: placebo","Incidence of Grade ≥ 2 (WHO scale) oral mucositis|Incidence of chemotherapy (5-FU) dose reductions and dose delays|Average mouth and throat soreness (MTS) score|Duration of grade ≥ 2 (WHO scale) oral mucositis|Incidence and severity of adverse events|Changes in laboratory values|Incidence of serum anti-palifermin antibody formation|Progressive disease rate|Incidence of secondary primary tumors|Incidence of other malignancies|Progression-free survival (PFS)|Overall survival (OS)|Incidence of grade ≥ 2 (WHO scale) oral mucositis","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20040122","August 2005","December 2007","March 2014","October 29, 2006",,"July 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00393822"
493,"NCT00379899","ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis",,"Completed","Has Results","Chronic Kidney Disease|End Stage Renal Disease|Coronary Artery Calcification|Vascular Calcification|Calcification|Cardiovascular Disease|Chronic Renal Failure|Hyperparathyroidism|Kidney Disease|Nephrology|Secondary Hyperparathyroidism","Drug: cinacalcet","Percent Change From Baseline in CAC Score|Number of Participants Achieving > 15% Progression of CAC.|Absolute Change in PTH|Change From Baseline in AC Score|Change From Baseline of the Progression of AVC.|Percent Change in PTH|Absolute Change in Calcium|Percent Change in Calcium|Absolute Change in Phosphorus|Percent Change in Phosphorus|Absolute Change in Ca x P|Percent Change in Ca x P","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060111","September 2006","May 2009","November 2009","September 25, 2006","October 27, 2010","July 23, 2014",,,"https://ClinicalTrials.gov/show/NCT00379899"
494,"NCT00377819","Study of Transitioning From Alendronate to Denosumab",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: alendronate|Drug: Denosumab (AMG 162)","Percent Change From Baseline in Total Hip Bone Mineral Density|Percent Change From Baseline in Lumbar Spine Bone Mineral Density|Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)","Amgen","Female","55 Years and older   (Adult, Older Adult)","Phase 3","504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050234","September 2006","March 2008","July 2008","September 18, 2006","August 3, 2010","July 11, 2011",,,"https://ClinicalTrials.gov/show/NCT00377819"
495,"NCT00369772","STAAR-1 Clinical Study",,"Completed","No Results Available","Chronic Kidney Disease|Chronic Renal Insufficiency|Kidney Disease|Pre-dialysis|Pre-ESRD","Drug: darbepoetin alfa","Mean hemoglobin during the evaluation period.|Change in hemoglobin throughout the study|HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study|Health-related resource utilization, measured every 4 weeks, throughout the study|Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12|Iron requirement (dose, frequency, and route) of subjects during the study","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","2000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000256","February 2002",,"May 2004","August 29, 2006",,"October 16, 2009",,,"https://ClinicalTrials.gov/show/NCT00369772"
496,"NCT00369733","STAAR-3 Clinical Study",,"Completed","No Results Available","Chronic Kidney Disease|Chronic Renal Insufficiency|Kidney Disease|Pre-dialysis|Pre-ESRD","Drug: Darbepoetin alfa","Mean hemoglobin during the evaluation period.|Change in hemoglobin throughout the study|HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study|Health-related resource utilization, measured every 4 weeks, throughout the study|Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12|Iron requirement (dose, frequency, and route) of subjects during the study","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","443","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010243","May 2002","March 2004","May 2004","August 29, 2006",,"February 19, 2010",,,"https://ClinicalTrials.gov/show/NCT00369733"
497,"NCT00369473","Long-Term Assessment of Safety and Physical Function With AMG 108 in RA",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 108","To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168|To determine whether long-term use of AMG 108 improves function in subjects with RA","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060119","September 2006","June 2008","June 2008","August 29, 2006",,"December 13, 2016",,,"https://ClinicalTrials.gov/show/NCT00369473"
498,"NCT00369070","A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC",,"Terminated","No Results Available","Advanced Non-squamous NSCLC","Biological: Bevacizumab|Drug: AMG 706|Drug: Paclitaxel|Drug: Carboplatin","Objective tumor response rate|Duration of response|Progression free survival|Overall survival|Pharmacokinetics of AMG 706 when administered with paclitaxel and carboplatin in Arms A and B|Safety and tolerability in the 3 arms","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060136","January 31, 2007","April 23, 2008","August 3, 2011","August 29, 2006",,"January 4, 2018",,,"https://ClinicalTrials.gov/show/NCT00369070"
499,"NCT00368901","STAAR-2 Clinical Study",,"Completed","No Results Available","Chronic Kidney Disease|Chronic Renal Insufficiency|Kidney Disease|Pre-dialysis|Pre-ESRD","Drug: Darbepoetin alfa","Mean hemoglobin during the evaluation period|Change in hemoglobin throughout the study|HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study|Health-related resource utilization, measured every 4 weeks, throughout the study|Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12|Iron requirement (dose, frequency, and route) of subjects during the study","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","618","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010215","January 2002","March 2004","May 2004","August 29, 2006",,"March 5, 2010",,,"https://ClinicalTrials.gov/show/NCT00368901"
500,"NCT00364845","STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients",,"Terminated","Has Results","Anemia|Chronic Kidney Disease","Drug: Darbepoetin alfa|Drug: Placebo","Short Form 36 Health Survey Questionnaire (SF-36) Vitality Subscale Score at Week 24|Number of Participants With Hemoglobin (Hb) ≥ 110 g/L|Mean Hemoglobin During the Evaluation Period|Euroqol 5 Dimension (EQ-5D) Utility Score at Week 24","Amgen","All","70 Years and older   (Older Adult)","Phase 3","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20050122","September 2006","December 2008","February 2009","August 16, 2006","May 21, 2014","May 21, 2014",,,"https://ClinicalTrials.gov/show/NCT00364845"
501,"NCT00364013","PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFOX regimen","Progression-free Survival|Overall Survival|Percentage of Participants With an Objective Response|Time to Progression|Duration of Response|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050203","August 1, 2006","August 1, 2009","March 22, 2013","August 15, 2006","March 28, 2014","August 12, 2019",,,"https://ClinicalTrials.gov/show/NCT00364013"
502,"NCT00361634","Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Etanercept","Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-29|Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-57|Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-85|Percent Change in Synovial Initial Area Under the (Contrast-time) Curve (IAUC) From Days 1-29|Percent Change in the Synovial Initial Area Under the Contrast-Tme Curve (IAUC) From Days 1-57|Percent Change in the Synovial Initial Area Under the Contrast-Time Curve (IAUC) From Days 1-85|Percent Change in Synovial Volume From Days 1-29|Percent Change in Synovial Volume From Days 1-57|Percent Change in Synovial Volume From Days 1-85|Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 29|Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 57|Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 85|Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 29|Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 57|Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 85","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20060118","September 2006","August 2009","March 2010","August 8, 2006","September 17, 2013","September 17, 2013","Research Site, Los Angeles, California, United States|Research Site, Seattle, Washington, United States|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00361634"
503,"NCT00360867","An Open Label Treatment Extension Study of AMG 706",,"Terminated","No Results Available","Solid Tumors","Drug: AMG 706","Safety (serious adverse events, adverse events, blood pressure and laboratory tests)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050130","December 2005","July 2012","July 2012","August 7, 2006",,"October 15, 2015",,,"https://ClinicalTrials.gov/show/NCT00360867"
504,"NCT00358215","RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial",,"Completed","Has Results","Heart Failure|Anemia|Cardiovascular Disease|Ventricular Dysfunction|Congestive Heart Failure","Drug: Darbepoetin alfa|Drug: Placebo","Time to All Cause Death or First Hospitalization for Worsening Heart Failure|Time to Death From Any Cause|Time to Cardiovascular Death or First Hospital Admission for Worsening Heart Failure|Change From Baseline to Month 6 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score|Change From Baseline to Month 6 in KCCQ Symptom Frequency Score","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","2278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050222|RED-HF™ Trial","June 1, 2006","October 11, 2012","October 11, 2012","July 31, 2006","December 13, 2013","August 12, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Buena Park, California, United States|Research Site, Corona, California, United States|Research Site, Culver City, California, United States|Research Site, Downey, California, United States|Research Site, La Jolla, California, United States|Research Site, Lancaster, California, United States|Research Site, Larkspur, California, United States|Research Site, Loma Linda, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Modesto, California, United States|Research Site, Oakland, California, United States|Research Site, Pasadena, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Sylmar, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Westlake Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Covington, Georgia, United States|Research Site, Rome, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Elk Grove Village, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Oak Lawn, Illinois, United States|Research Site, Oakbrook Terrace, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Jeffersonville, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Olathe, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Madisonville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, South Portland, Maine, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, West Roxbury, Massachusetts, United States|Research Site, Whitman, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Missoula, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Westwood, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Flushing, New York, United States|Research Site, Garden City, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Kingston, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Troy, New York, United States|Research Site, West Islip, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Garfield Heights, Ohio, United States|Research Site, Mayfield Heights, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Annandale, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Bellingham, Washington, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Beloit, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Adrogue, Buenos Aires, Argentina|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, Argentina|Research Site, Coronel Suarez, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, Cordoba, CÃ³rdoba, Argentina|Research Site, Cipolletti, RÃ-o Negro, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Mendoza, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Coffs Harbour, New South Wales, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Gosford, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Kippa Ring, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Turnhout, Belgium|Research Site, Salvador, Bahia, Brazil|Research Site, Fortaleza, CearÃ¡, Brazil|Research Site, Goiania, GoiÃ¡s, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, ParanÃ¡, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Campinas, SÃ£o Paulo, Brazil|Research Site, RiberÃ£o Preto, SÃ£o Paulo, Brazil|Research Site, Sao Paulo, SÃ£o Paulo, Brazil|Research Site, Sao Paulo, SÃ£o Paulo, Brazil|Research Site, SÃ£o JosÃ© Do Rio Preto, SÃ£o Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Rouse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Campbell River, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, St-JÃ©rÃ´me, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Rancagua, Cachapoal, Chile|Research Site, La Serena, Elqui, Chile|Research Site, San Miguel, Santiago, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Jihlava, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 2, Czechia|Research Site, Pribram 8, Czechia|Research Site, Tabor, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Fredericia, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Frederikshavn, Denmark|Research Site, Glostrup, Denmark|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, Horsens, Denmark|Research Site, Hvidovre, Denmark|Research Site, KÃ¸benhavn S, Denmark|Research Site, KÃ¸benhavn Ã˜, Denmark|Research Site, KÃ¸ge, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Svendborg, Denmark|Research Site, PÃ¤rnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallinn, Estonia|Research Site, Espoo, Finland|Research Site, Helsinki, Finland|Research Site, Lahti, Finland|Research Site, Seinajoki, Finland|Research Site, Bron, France|Research Site, Caen Cedex 14, France|Research Site, Cholet Cedex, France|Research Site, CrÃ©teil Cedex, France|Research Site, Douai Cedex, France|Research Site, Grenoble Cedex 9, France|Research Site, Lille Cedex, France|Research Site, Montfermeil, France|Research Site, Montpellier cedex 05, France|Research Site, Nice Cedex 01, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Pontoise Cedex, France|Research Site, Rouen Cedex, France|Research Site, Saint Herblain, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 09, France|Research Site, Vandoeuvre-les-Nancy, France|Research Site, Bad TÃ¶lz, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bremen, Germany|Research Site, Frankfurt, Germany|Research Site, GeorgsmarienhÃ¼tte, Germany|Research Site, GÃ¶ttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Ingelheim, Germany|Research Site, KÃ¶ln, Germany|Research Site, Lahr, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Marburg, Germany|Research Site, NÃ¼rnberg, Germany|Research Site, Schwedt, Germany|Research Site, Stuttgart, Germany|Research Site, Witten, Germany|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemet, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szekszard, Hungary|Research Site, Szolnok, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Gurgaon, Haryana, India|Research Site, Bangalore, Karnataka, India|Research Site, Bangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Ludhiana, Punjab, India|Research Site, Bikaner, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Mumbai, India|Research Site, Askelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Beer Yaakov, Israel|Research Site, Givatayim, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Arezzo, Italy|Research Site, Bergamo, Italy|Research Site, Cesenatico (FC), Italy|Research Site, Cetraro CS, Italy|Research Site, Cortona AR, Italy|Research Site, Eboli, Italy|Research Site, Ferrara, Italy|Research Site, ForlÃ¬, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Oliveto Citra SA, Italy|Research Site, Palermo, Italy|Research Site, Palmanova UD, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, San Bonifacio VR, Italy|Research Site, Torino, Italy|Research Site, Trento, Italy|Research Site, Udine, Italy|Research Site, Daugavpils, Latvia|Research Site, Ogre, Latvia|Research Site, Rezekne, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Alytus, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Guadajalara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Xalapa, Veracruz, Mexico|Research Site, Merida, YucatÃ¡n, Mexico|Research Site, Baja California, Mexico|Research Site, Distrito Federal, Mexico|Research Site, 's Hertogenbosch, Netherlands|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Assen, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deventer, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Enschede, Netherlands|Research Site, Groningen, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Arendal, Norway|Research Site, Gjettum, Norway|Research Site, Kristiansand, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Ã…lesund, Norway|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Stalowa Wola, Poland|Research Site, Tarnow, Poland|Research Site, Walbrzych, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Zielona Gora, Poland|Research Site, Coimbra, Portugal|Research Site, Faro, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisbon, Portugal|Research Site, San Juan, Puerto Rico|Research Site, Arad, Romania|Research Site, Bacau, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Targu Mures, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania|Research Site, Timisoara, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Sankt-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Zilina, Slovakia|Research Site, Boksburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Soweto, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, Granada, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Tarragona, CataluÃ±a, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Majadhonda, Madrid, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Galdakao, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Danderyd, Sweden|Research Site, GÃ¶teborg, Sweden|Research Site, GÃ¶teborg, Sweden|Research Site, LinkÃ¶ping, Sweden|Research Site, MalmÃ¶, Sweden|Research Site, MÃ¶lndal, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, UmeÃ¥, Sweden|Research Site, Uppsala, Sweden|Research Site, Ã-rebro, Sweden|Research Site, Lugano, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Barnet, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Bridlington, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Kirkcaldy, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Livingston, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Worthing, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00358215"
505,"NCT00357903","Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Etanercept","Total Exposure to Etanercept With Gaps|Total Exposure Adjusted Rate of Malignancies|Total Exposure Adjusted Rate of Deaths|Total Exposure Adjusted Rate of Serious Infectious Events|Total Exposure Adjusted Rate of Lymphomas|Malignancy|Lymphoma|Serious Infectious Event|Death|Total Exposure Adjusted Rate of Serious Adverse Events|Dosing Period|Tender Joint Count|Swollen Joint Count|Health Assessment Questionnaire Disability Index|Childhood Health Assessment Questionnaire|C-Reactive Protein|ACR20 at Month 3 in Adults|JRA DOI 30 at Month 3 in Juveniles|Standardized Incidence Rate for All SEER Cancers","Amgen|Immunex Corporation","All","4 Years and older   (Child, Adult, Older Adult)","Phase 3","639","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20021618|16.0018","April 1997","December 2008","April 2009","July 28, 2006","December 6, 2010","February 10, 2017",,,"https://ClinicalTrials.gov/show/NCT00357903"
506,"NCT00356681","A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer",,"Terminated","No Results Available","Breast Neoplasms|Breast Tumors|Breast Cancer|Locally Recurrent and Metastatic Breast Cancer","Drug: AMG 706 placebo|Drug: Bevacizumab|Drug: AMG 706|Drug: Paclitaxel","Objective response rate, measured radiologically and assessed by an independent review committee.|Progression free survival, duration of response, clinical benefit rate (percentage of subjects with complete response, partial response or stable disease lasting >24 weeks), overall survival and incidence of adverse events.","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050225|CIRG/TORI 010","December 2006","February 2009","August 2012","July 26, 2006",,"October 15, 2015",,,"https://ClinicalTrials.gov/show/NCT00356681"
507,"NCT00356590","Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Etanercept","Total Exposure to Etanercept With Gaps|Total Exposure-Adjusted Rate of Malignancies|Total Exposure-Adjusted Rate of Deaths|Total Exposure Adjusted Rate of Serious Infectious Events|Total Exposure Adjusted Rate of Lymphomas|Malignancy|Lymphoma|Serious Infectious Event|Total Exposure Adjusted Rate of Serious Adverse Events|Death|ACR20 Response at Month 3|Dosing Period|ACR20 Response at Month 12|ACR50 Response at Month 12|ACR70 Response at Month 12|Standardized Incidence Rate for All SEER Cancers|Percent Improvement in Physician Global Assessment of Disease Status From Baseline to Month 12|Percent Improvement in Participant Global Assessment of Disease Status From Baseline to Month 12|Percent Improvement in Participant Pain Visual Analog Scale From Baseline to Month 12|Percent Improvement in Tender Joint Count From Baseline to Month 12|Percent Improvement in Swollen Joint Count From Baseline to Month 12|Percent Improvement in HAQ DI From Baseline to Month 12|Percent Improvement in the Physical Component Summary Score for SF-36 From Baseline to Month 12|Percent Improvement in Mental Component Summary Score of SF-36 From Baseline to Month 12|Percent Improvement in C-Reactive Protein From Baseline to Month 12|Percent Improvement in Duration of Morning Stiffness From Baseline to Month 12|Change From Baseline to Year 2 in Total Sharp Score|Change From Baseline to Year 2 in Sharp Score Erosion Subscale|Change From Baseline to Year 2 in Sharp Score Joint Space Narrowing Subscale","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","468","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20021623|16.0023","December 1998","December 2008","April 2009","July 26, 2006","December 8, 2010","May 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00356590"
508,"NCT00356356","16.0040 Ankylosing Spondylitis Study",,"Completed","No Results Available","Ankylosing Spondylitis","Drug: Etanercept","Treatment Response (using ASAS criteria) of at least 20% and absolute improvement of at least 10 units on a 0-100 scale in at least 3 of the 4 domains|Absence of deterioration (using ASAS criteria) of at least 20% and absolute improvement of at least 10 units on a 0-100 scale in the potential remaining ASAS domain|DXA and MRI scans (at selected sites)|X-rays of cervical spine and lumbosacral spine|Type and grade of toxicities|ASAS Response Criteria at weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, and the ASAS Response Criteria at 50% and 70% levels at weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, and 144.|Frequency and time to partial remission as defined in Anderson, 2001: Value of <20 (on a scale of 0-100) in each of the following 4 domains: VAS Patient Global Assessment, VAS Pain Score, BASFI, and BASDAI morning stiffness-related scores|Spinal mobility measured with Schober's test, chest expansion, and occiput to wall distance|Complete joint assessment|Laboratory assessment of inflammation using CRP|Ability to reduce and discontinue concomitant NSAIDs, prednisone, hydroxychloroquine, sulfasalazine, and methotrexate","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","257","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20021640|016.0040","April 2002","August 2006","September 2006","July 26, 2006",,"May 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00356356"
509,"NCT00352950","Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer",,"Withdrawn","No Results Available","Oncology|Non-Small Cell Lung Cancer","Drug: AMG 954/Panitumumab","safety within the first 3 weeks|pharmacodynamic analysis of mTOR","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040145","March 2006",,"February 2008","July 17, 2006",,"September 6, 2018",,,"https://ClinicalTrials.gov/show/NCT00352950"
510,"NCT00346294","An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","To estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.|To estimate the rate of failure of the Enbrel® SureClick™ Auto-injector at the subject level in RA subjects.|To determine the rate of failed drug deliveries (as opposed to device failures).","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","115","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050207","January 2006","March 2006","July 2006","June 29, 2006",,"January 22, 2020",,,"https://ClinicalTrials.gov/show/NCT00346294"
511,"NCT00345839","E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events","EVOLVE","Completed","Has Results","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Cinacalcet|Drug: Placebo","Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event)|Time to All-cause Mortality|Time to Myocardial Infarction|Time to Hospitalization for Unstable Angina|Time to Heart Failure|Time to Peripheral Vascular Event|Time to Cardiovascular Mortality|Time to Stroke|Time to Bone Fracture|Time to Parathyroidectomy","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","3883","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20050182","August 22, 2006","April 10, 2012","April 10, 2012","June 29, 2006","January 22, 2014","April 3, 2019",,,"https://ClinicalTrials.gov/show/NCT00345839"
512,"NCT00339183","Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Panitumumab|Drug: FOLFIRI","Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With an Objective Response|Time to Disease Progression|Duration of Response|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050181","June 30, 2006","April 1, 2009","November 1, 2010","June 20, 2006","May 6, 2014","August 31, 2018",,,"https://ClinicalTrials.gov/show/NCT00339183"
513,"NCT00332332","Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis",,"Completed","Has Results","Psoriasis","Biological: etanercept","Participants With a Status of Mild or Better on Physician Global Assessment at Month 12|Percent Change From Baseline to Month 12 in Patient Global Assessment|Percent Change From Baseline to Month 12 in Body Surface Area Affected by Psoriasis|Percent Change From Baseline to Month 12 in the Dermatology Life Quality Index Total Score","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","246","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050180","March 2006","July 2009","February 2010","June 1, 2006","June 14, 2011","July 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00332332"
514,"NCT00332163","Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","STEPP","Completed","Has Results","Metastatic Colorectal Cancer|Skin Rash|Skin Toxicities|Colon Cancer|Colorectal Cancer","Biological: Panitumumab|Drug: Irinotecan|Drug: FOLFIRI|Drug: Pre-emptive Skin Treatment|Drug: Reactive Skin Treatment","Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period|Percentage of Participants With Any Grade 2 or Higher Skin Toxicity of Any Type During the 6-week Skin Treatment Period|Time to First Occurrence of Specific Grade 2 or Higher Skin Toxicities of Interest|Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest|Time to First Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest|Percentage of Participants With Panitumumab Dose Reductions Due to the Specific Skin Toxicities of Interest|Response Rate at First Scheduled Assessment|Best Overall Response Rate|Rate of Disease Control at First Scheduled Assessment|Time to Treatment Failure|Time to Progression|Overall Survival|Progression-free Survival|Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score","Amgen","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050184","April 2006","January 2008","September 2008","June 1, 2006","February 23, 2016","February 23, 2016",,,"https://ClinicalTrials.gov/show/NCT00332163"
515,"NCT00330759","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.",,"Completed","Has Results","Bone Metastases","Biological: Denosumab|Drug: Zoledronic Acid","Time to the First On-Study Skeletal-Related Event (Non-Inferiority)|Time to First On-Study Skeletal-Related Event (Superiority)|Time to the First-and-Subsequent On-Study Skeletal-Related Event","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1779","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20050244","June 1, 2006","April 1, 2009","October 1, 2011","May 29, 2006","April 9, 2014","August 31, 2018",,,"https://ClinicalTrials.gov/show/NCT00330759"
516,"NCT00330460","A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.",,"Completed","Has Results","Osteoporosis|Osteopenia","Drug: Alendronate|Drug: Denosumab","Total Hip Bone Mineral Density Percent Change From Baseline at Month 12|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12|Trochanter Bone Mineral Density Percent Change From Baseline at Month 12|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050141","May 2006","November 2007","January 2008","May 26, 2006","July 19, 2010","January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00330460"
517,"NCT00327119","Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer",,"Completed","No Results Available","Metastatic Colorectal Cancer","Drug: ABX-EGF (panitumumab)",,"Amgen","All","20 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050216","April 2006",,,"May 18, 2006",,"September 14, 2009",,,"https://ClinicalTrials.gov/show/NCT00327119"
518,"NCT00325468","An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density",,"Completed","Has Results","Low Bone Mineral Density","Drug: AMG 162","Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8|Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8|Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8|Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8|Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8","Amgen","Female","Child, Adult, Older Adult","Phase 3","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050233","May 1, 2006","March 28, 2011","August 2, 2012","May 12, 2006","July 30, 2013","August 1, 2017",,,"https://ClinicalTrials.gov/show/NCT00325468"
519,"NCT00322439","Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis",,"Completed","Has Results","Psoriasis","Drug: Etanercept","Five-year Cumulative Incidence of Serious Adverse Events and Serious Infectious Events|Five-year Cumulative Incidence for Events of Medical Interest (EMIs)|Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Psoriasis Score of 0 (Clear) or 1 (Almost Clear)|Percentage of Participants With a Patient's Global Assessment of Psoriasis Score of 0 or 1|Percentage of Participants With a Dermatology Life Quality Index (DLQI) Response|Euroqol-5D (EQ-5D) Total Score|Euroqol-5D (EQ-5D) Visual Analog Scale (VAS)|Healthcare Resource Use|Work Productivity and Activity Impairment (WPAI)|Percentage of Body Surface Area Affected by Psoriasis","Amgen","All","18 Years and older   (Adult, Older Adult)",,"2511","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20040210","May 1, 2006","December 11, 2012","February 8, 2013","May 8, 2006","March 26, 2014","June 28, 2018",,,"https://ClinicalTrials.gov/show/NCT00322439"
520,"NCT00322400","Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer",,"Completed","No Results Available","Locally Recurrent and Metastatic Breast Cancer","Drug: Docetaxel|Drug: Paclitaxel|Drug: AMG 706","Incidence of dose limiting toxicities (DLTs)|Pharmacokinetics of AMG 706 when administered with paclitaxel (Arm A) or docetaxel (Arm B)|Pharmacokinetics of paclitaxel (Arm A) when administered with AMG 706|Pharmacokinetics of docetaxel (Arm B) when administered with AMG 706|Incidence of adverse events and clinical laboratory abnormalities not defined as DLTs|Objective tumor response (complete or partial response) according to modified RECIST|Duration of response (calculated for those subjects who respond): time from first objective tumor response to objective disease progression or death.","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050200","March 2006","April 2009","January 2012","May 5, 2006",,"July 31, 2013",,,"https://ClinicalTrials.gov/show/NCT00322400"
521,"NCT00321711","Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents",,"Completed","Has Results","MDS|Myelodysplastic Syndromes|Thrombocytopenia","Drug: Placebo|Biological: AMG 531 (Romiplostim)|Drug: Azacitidine|Drug: Decitabine","Occurrence of a Clinically Significant Thrombocytopenic Event|Hypomethylating Agent Dose Reduction and Delay Due to Thrombocytopenia|Achieving an Overall Response (Complete or Partial Response, CR or PR) at the End of the Treatment Period|Platelet Transfusion","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20050232","October 1, 2006","October 19, 2009","October 19, 2009","May 4, 2006","April 5, 2011","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00321711"
522,"NCT00321620","Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer",,"Completed","Has Results","Bone Metastases","Drug: zoledronic acid|Biological: denosumab","Time to the First On-Study SRE (Non-inferiority)|Time to the First On-Study SRE (Superiority)|Time to the First-And-Subsequent On-Study SRE","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1904","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20050103","April 1, 2006","October 1, 2009","February 24, 2012","May 4, 2006","March 21, 2014","August 29, 2018",,,"https://ClinicalTrials.gov/show/NCT00321620"
523,"NCT00321464","A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.",,"Completed","Has Results","Bone Metastases","Biological: Denosumab|Drug: Zoledronic Acid","Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)|Time to First On-Study Skeletal-Related Event (Superiority)|Time to First and Subsequent On-Study Skeletal-Related Event","Amgen|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","2049","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","20050136","April 1, 2006","July 20, 2009","April 4, 2012","May 3, 2006","March 10, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00321464"
524,"NCT00317499","Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis",,"Completed","No Results Available","Psoriatic Arthritis|Psoriasis","Other: Placebo|Drug: Etanercept",,"Amgen|Immunex Corporation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20021630","April 2000","June 2002","July 2002","April 25, 2006",,"December 23, 2010",,,"https://ClinicalTrials.gov/show/NCT00317499"
525,"NCT00306189","A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects",,"Completed","Has Results","Osteoporosis","Drug: 100 mg AMG 162|Drug: 60 mg AMG 162|Drug: 14 mg AMG 162|Drug: Placebo","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","Amgen","Female","up to 80 Years   (Child, Adult, Older Adult)","Phase 2","212","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20050172|NOT APPRICABLE","January 2006","June 2007","November 2007","March 23, 2006","January 27, 2010","June 20, 2013",,,"https://ClinicalTrials.gov/show/NCT00306189"
526,"NCT00303472","Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)",,"Completed","Has Results","Thrombocytopenia|MDS|Myelodysplastic Syndromes|Refractory Cytopenias","Drug: Romiplostim","Part A: Number of Participants With Adverse Events|Part B: Number of Participants With Adverse Events|Part A: Number of Participants With a Complete or Major Platelet Response|Part B: Number of Participants With a Complete or Major Platelet Response|Part A: Number of Participants With a Platelet Response Per IWG Criteria|Part B: Number of Participants With a Platelet Response Per IWG|Part B: Peak Platelet Count|Part B: Time to First Platelet Response|Part B: Duration of Platelet Response|Part B: Week 1 Cmax|Part B: Week 1 Ctrough|Part B: Week 1 AUC0-4|Part B: Week 7 Cmax|Part B: Week 7 Ctrough|Part B: Week 7 AUC0-4|Part B: Week 1 Tmax|Part B: Week 7 Tmax","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050159","February 2006","May 2008","May 2008","March 17, 2006","November 19, 2010","December 16, 2013",,,"https://ClinicalTrials.gov/show/NCT00303472"
527,"NCT00293826","A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: AMG 108|Drug: Placebo","ACR20 response|Change in subject reported outcomes|ACRn, AUC ACRn, ACR50, ACR70, and DAS28|PK parameters|Safety endpoints including AEs, SAEs, SIEs, and change in anti-AMG 108 antibody status","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","813","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050168","March 2006","November 2007","February 2008","February 20, 2006",,"March 5, 2010",,,"https://ClinicalTrials.gov/show/NCT00293826"
528,"NCT00293813","A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: Alendronate|Drug: Denosumab|Drug: Placebo","Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12|Cortical Thickness of Tibia by XtremeCT Percent Change From Baseline at Month 12","Amgen","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 2","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20050179","May 2006","March 2008","August 2008","February 20, 2006","January 27, 2010","July 25, 2014",,,"https://ClinicalTrials.gov/show/NCT00293813"
529,"NCT00286091","Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer",,"Completed","Has Results","Hormone Refractory Prostate Cancer","Biological: Denosumab|Biological: Placebo","Bone Metastasis-free Survival|Time to First Bone Metastasis|Overall Survival","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1435","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20050147","January 24, 2006","July 30, 2010","April 9, 2014","February 3, 2006","April 6, 2015","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00286091"
530,"NCT00283439","A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma",,"Completed","Has Results","Chemotherapy-Induced Thrombocytopenia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Cancer|Oncology|Thrombocytopenia","Biological: AMG 531","Change in Platelet Nadir|Percentage of Subjects Experiencing Grade 3 or 4 Thrombocytopenia|Duration of Grade 3 or 4 Thrombocytopenia|Percentage of Subjects That Received Platelet Transfusions","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20050144","October 2005","May 2008","September 2008","January 30, 2006","September 13, 2010","June 20, 2011",,,"https://ClinicalTrials.gov/show/NCT00283439"
531,"NCT00277160","A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer",,"Completed","No Results Available","Neutropenia|Breast Cancer|Lung Cancer|Non-Hodgkin's Lymphoma|Ovarian Cancer","Drug: Neulasta (pegfilgrastim)","Incidence of febrile neutropenia, defined by ANC < 1.0 x 10^9/L and temperature ≥ 38o C on the same day|Incidence of grade 3 and 4 neutropenia|Dose delays or dose reductions|Incidence of febrile neutropenia with a more strict definition (ANC < 0.5 x 10^9/L and temperature ≥ 38o C), on the same day","Amgen","All","65 Years and older   (Older Adult)","Phase 4","852","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20020122","June 2002","November 2004","January 2005","January 16, 2006",,"October 8, 2010",,,"https://ClinicalTrials.gov/show/NCT00277160"
532,"NCT00261950","Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease","BONAFIDE","Completed","Has Results","Secondary Hyperparathyroidism","Drug: Sensipar (Cinacalcet HCl)","Change From Baseline to End of Study in Bone Formation Rate (BFR)|Percent Change From Baseline in Serum Calcium During the Efficacy Assessment Phase (EAP)|Percent Change From Baseline in Serum Phosphorus During the Efficacy Assessment Phase (EAP)|Percent Change From Baseline in Ca x P During the Efficacy Assessment Phase (EAP)|Percent Change From Baseline in Bone Specific Alkaline Phosphatase (BALP) at Week 52|Percent Change From Baseline in N - Telopeptide (NTx) at Week 52|Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Assessment Phase (EAP)|Change From Baseline to End of Study in Osteoblast Perimeter (Osteoblast Perimeter/Osteoid Perimeter)|Change From Baseline to End of Study in Osteoclast Perimeter (Osteoclast Perimeter/Eroded Perimeter)|Change in Categorization From Baseline to End of Study in Fibrosis Area/Tissue Area|Change From Baseline to End of Study in Eroded Perimeter/Bone Perimeter|Percent Change From Baseline in Osteocalcin (OC) at Week 52|Percent Change From Baseline in Tartrate Resistant Acid Phosphatase(TRAP) at Week 52","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050104|BONAFIDE Study|IND #56,010","May 2006","May 2011","May 2011","December 6, 2005","December 4, 2013","July 21, 2014","Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Evanston, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, St Louis, Missouri, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Flushing, New York, United States|Research Site, Great Neck, New York, United States|Research Site, New York, New York, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Antwerpen, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Hradec Kralove, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Avellino, Italy|Research Site, Cremona, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Ortona CH, Italy|Research Site, Ostia RM, Italy|Research Site, Roma (RM), Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Skopje, Macedonia, The Former Yugoslav Republic of|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Wroclaw, Poland|Research Site, Porto, PR, Portugal|Research Site, Almada, Portugal|Research Site, Estoril, Portugal|Research Site, GuimarÃ£es, Portugal|Research Site, Porto, Portugal|Research Site, Vila Franca de Xira, Portugal|Research Site, Santander, Cantabria, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, AlcorcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Zurich, Switzerland|Research Site, Izmir, Turkey|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00261950"
533,"NCT00261313","ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Neulasta|Drug: Aranesp","The proportion of subjects experiencing any delay in any cycle of chemotherapy over the course of the study|Febrile neutropenic events and adverse event profile will be assessed|To assess chemotherapy and subject dose delays and reductions which are specific and/or non specific to haematological toxicities|Frequency of red blood cell (RBC) transfusions","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040137","December 2005","June 2007","December 2007","December 5, 2005",,"February 26, 2010",,,"https://ClinicalTrials.gov/show/NCT00261313"
534,"NCT00259740","Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab",,"Completed","Has Results","Relapsed or Plateau-Phase Multiple Myeloma","Drug: DENOSUMAB","Complete Response or Partial Response Based on M-Protein Assessments Only|Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only|Complete Response Based on M-Protein Assessments Only","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050134","November 2005","August 2007","December 2011","December 1, 2005","January 6, 2011","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT00259740"
535,"NCT00254267","Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors",,"Completed","No Results Available","Advanced Gastrointestinal Stromal Tumor","Drug: AMG 706","The objective response rate as assessed by modified RECIST|Duration of response, progression-free survival, time to response, overall survival, PK and safety profile","Amgen|Takeda Bio Development Center, Ltd","All","20 Years and older   (Adult, Older Adult)","Phase 2","35","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050129","November 2005","February 2007","December 2012","November 16, 2005",,"February 27, 2014",,,"https://ClinicalTrials.gov/show/NCT00254267"
536,"NCT00249041","Enbrel Liquid Immunogenicity Protocol",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: 50 mg Etanercept|Drug: Enbrel liquid","Rates of anti-etanercept antibody formation to etanercept liquid with or without concomitant methotrexate (MTX) therapy at week 24|Rates of anti-etanercept antibody formation to etanercept liquid at week 12, and the rates of neutralizing antibodies at Weeks 12 and 24. Safety of etanercept liquid in RA subjects receiving 50 mg once weekly up to 24 weeks.","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050145","October 2005","December 2006","March 2007","November 7, 2005",,"July 30, 2010",,,"https://ClinicalTrials.gov/show/NCT00249041"
537,"NCT00239239","Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies",,"Completed","No Results Available","Non-Myeloid Malignancies|Anemia|Cancer","Drug: Darbepoetin alfa","To characterize the PK of darbepoetin alfa administered at a SC dose of 0.45 mcg/kg TIW in the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy|To assess the effect of darbepoetin alfa treatment on hematopoietic response, red blood cell (RBC) transfusion requirements, and the safety of darbepoetin alfa in subjects receiving multicycle chemotherapy","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040232","August 2005","January 2007","March 2007","October 17, 2005",,"March 5, 2010",,,"https://ClinicalTrials.gov/show/NCT00239239"
538,"NCT00189501","A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Nephrology","Drug: Sensipar®",,"Amgen","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Time Perspective: Prospective","20040159","December 2004",,,"September 19, 2005",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00189501"
539,"NCT00156962","Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)",,"Terminated","No Results Available","Chronic Kidney Disease","Drug: Epoetin alfa DT|Drug: Epoetin alfa RB","Subject incidence of adverse events|Epoetin alfa antibodies|Changes from baseline laboratory and vital signs","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","850","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040259|NOT APPLILCABLE","April 2005","March 2007","March 2007","September 12, 2005",,"July 21, 2008",,,"https://ClinicalTrials.gov/show/NCT00156962"
540,"NCT00156949","EPO Deep Tank in Dialysis Subjects",,"Completed","No Results Available","Chronic Kidney Disease","Drug: Epoetin alfa DT",,"Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","580","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040268","April 2005","February 2007","February 2007","September 12, 2005",,"February 19, 2010",,,"https://ClinicalTrials.gov/show/NCT00156949"
541,"NCT00150462","Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies",,"Completed","Has Results","Waldenstrom's Macroglobulinemia|Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone","Number of Participants With Dose-limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration of Carfilzomib (Cmax)|Time to Maximum Observed Plasma Concentration of Carfilzomib (Tmax)|Area Under the Concentration-time Curve to Last Measureable Timepoint (AUClast) for Carfilzomib|Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) for Carfilzomib|Best Clinical Response to Treatment|Duration of Response|Time to Progression|Progression-free Survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PX-171-002","September 2005","October 2009","October 2009","September 8, 2005","December 3, 2015","May 2, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weil Medical College of Cornell University, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00150462"
542,"NCT00148421","Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.",,"Completed","No Results Available","Anemia","Drug: Darbepoetin alfa and Epoetin alfa","Reduced incidence of transfusions|Change in hemoglobin concentration","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030125",,,,"September 8, 2005",,"May 15, 2013",,,"https://ClinicalTrials.gov/show/NCT00148421"
543,"NCT00148369","A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin",,"Completed","No Results Available","Idiopathic Parkinson's Disease","Drug: Safety observation","Adverse Events","Amgen|Medtronic","All","35 Years to 70 Years   (Adult, Older Adult)",,"31","Industry","Observational","Time Perspective: Prospective","20040256","June 2005","November 2006","September 2007","September 8, 2005",,"February 19, 2010",,,"https://ClinicalTrials.gov/show/NCT00148369"
544,"NCT00146224","Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis",,"Completed","No Results Available","Nephrology","Drug: Epoetin alfa RB|Drug: Epoetin alfa DT","Ratio of weekly dose at the evaluation period to the weekly dose at baseline|Change in Heloglobin level between the screening period and the evaluation period|Change from baseline Hb at each measurement timepoint|Maintaining Hemoglobin within range at each measurement timepoint|Average Epoetin alfa dose over evaluation period|Change from baseline dose at each measurement timepoint|Epoetin alfa seroreactivity|Subject incidence, nature and severity of adverse events|Hemoglobin variability|changes from baseline laboraotry and vital sign parameters","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20050113","September 2005","January 2007","January 2007","September 7, 2005",,"February 26, 2010",,,"https://ClinicalTrials.gov/show/NCT00146224"
545,"NCT00144131","Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy",,"Completed","No Results Available","Anemia|Cancer","Drug: Aranesp®","Change in hemoglobin (Hb) in chemotherapy induced anemia|Patient-reported outcomes including overall health, fatigue, and daily activities","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040262","August 2005",,,"September 5, 2005",,"May 24, 2013",,,"https://ClinicalTrials.gov/show/NCT00144131"
546,"NCT00141921","Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis",,"Completed","Has Results","Pediatric Plaque Psoriasis","Drug: Etanercept","Number of Participants With Adverse Events|Number of Participants With Injection Site Reactions|Exposure-adjusted Adverse Event Rates|Number of Participants With Clinically Significant Changes in Vital Signs|Number of Participants With Grade 3 and 4 Laboratory Toxicities|Number of Participants Who Developed Anti-etanercept Antibodies|Percentage of Participants With a Psoriasis Area and Severity Index 50 Response (PASI 50)|Percentage of Participants With a PASI 75 Response|Percentage of Participants With a PASI 90 Response|Percent Improvement From Study 20030211 Baseline in PASI Score|Percentage of Participants With a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)|Percent Improvement From Study 20030211 Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score|Percent Improvement From Study 20030211 Baseline in CDLQI Symptoms and Feelings Score|Percent Improvement From Study 20030211 Baseline in CDLQI Leisure Score|Percent Improvement From Study 20030211 Baseline in CDLQI School or Holidays Score|Percent Improvement From Study 20030211 Baseline in CDLQI Personal Relationships Score|Percent Improvement From Study 20030211 Baseline in CDLQI Sleep Score|Percent Improvement From Study 20030211 Baseline in CDLQI Treatment Satisfaction Score|Improvement From Study 20030211 Baseline in Joint Pain","Amgen","All","Child, Adult, Older Adult","Phase 3","182","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050111","August 11, 2005","December 19, 2011","August 16, 2017","September 2, 2005","February 10, 2017","October 5, 2017",,,"https://ClinicalTrials.gov/show/NCT00141921"
547,"NCT00135317","AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies",,"Completed","No Results Available","Cancer","Drug: darbepoetin alfa","Proportion of subjects achieving a hematopoietic response (hemoglobin [hgb] greater than or equal to 12 g/dL or rise in hgb of greater than 2 g/dL) during the treatment period|Time to hematopoietic response in days|The proportion of subjects with at least one red blood cell (RBC) transfusion from week 5 (day 29) to end of treatment period (EOTP)|Change in hemoglobin from baseline to EOTP|The proportion of subjects achieving a hemoglobin concentration greater than or equal to 11.0 g/dL, in the absence of RBC transfusions in the preceding 28 days, from week 5 to EOTP|The average hgb after achieving a hgb level greater than or equal to 11.0 g/dL|Patient reported outcomes: Change in Functional Assessment of Cancer Therapy (FACT)-Fatigue subscale score from baseline to EOTP|Change in FACT-G Physical Well-being subscale from baseline to EOTP|Change in FACT-G total score from baseline to EOTP|Change in EuroQoL (EQ-5D) thermometer and ED-5D scores from baseline to EOTP","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040156","November 2004",,,"August 26, 2005",,"May 23, 2013",,,"https://ClinicalTrials.gov/show/NCT00135317"
548,"NCT00135304","ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism",,"Completed","No Results Available","Secondary Hyperparathyroidism","Drug: Sensipar®|Drug: Vitamin D","Achieving the NKF-K/DOQI targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (less than 55 mg^2/dL^2) during the assessment phase|Absolute Change from Baseline for P During the Assessment Phase|Proportion of Participants with ≥ 30% Reduction from Baseline in Mean iPTH During the Assessment Phase|Percent Change from Baseline for Calcium During the Assessment Phase|Percent Change from Baseline for Phosphorus During the Assessment Phase|Percent Change from Baseline for Ca x P During the Assessment Phase|Percent Change from Baseline for iPTH During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for Ca x P During the Assessment Phase.|Proportion of Participants who Attained the K/DOQI Target Range for Ca During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for iPTH During the Assessment Phase|Proportion of Participants who Attained the K/DOQI Target Range for P During the Assessment Phase.|Absolute Change from Baseline for iPTH During the Assessment Phase|Absolute Change from Baseline for Ca During the Assessment Phase|Absolute Change from Baseline for Ca x P During the Assessment Phase","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20050102","August 2005","October 2006","December 2006","August 26, 2005",,"February 11, 2014",,,"https://ClinicalTrials.gov/show/NCT00135304"
549,"NCT00132431","START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism",,"Completed","No Results Available","Kidney Disease|Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Sensipar","Proportion of subjects with a mean bio-intact parathyroid hormone (biPTH) >/= 80 pg/mL and </= 160 pg/mL (comparable to K/DOQI Guideline target range for intact parathyroid hormone [iPTH] of >/= 150 pg/mL and </= 300 pg/mL) during the assessment phase|Proportion of subjects with mean calcium-phosphorus product (Ca x P) < 55 mgÂ²/dLÂ² during the assessment phase","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20040123","July 2004",,"July 2005","August 22, 2005",,"February 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00132431"
550,"NCT00132418","Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Enbrel|Drug: Placebo","Incidence of medically important infections, defined as infections that result in hospitalization or treatment with intravenous antibiotics|Infections associated with antimicrobial use; physical examination, vital signs, clinical laboratory assessments; symptom assessment, withdrawals, deaths, and serious adverse events","Amgen|Immunex Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","564","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20021629","April 2000","February 2004","February 2004","August 22, 2005",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00132418"
551,"NCT00131638","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: Placebo|Drug: Palifermin","Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale)|Average patient-reported mouth and throat soreness score (as reported on Question 3 of the Oral Mucositis Weekly Questionnaire for patients with Head and Neck cancer [OMWQ-HN]|Time to onset of severe oral mucositis (WHO Grades 3 or 4)|Total dose of opioid analgesics used (mg of morphine equivalents)|Incidence of unplanned delays in CT for cisplatin administration on Day 22 (to include discontinuations of CT)|Incidence of xerostomia (CTCAE v3.0 Dry Mouth/Xerostomia scale Grade 2 or higher)|Duration of severe oral mucositis (WHO Grades 3 or 4)|Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","241","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040118","January 2005","November 2007","July 2016","August 19, 2005",,"December 16, 2016",,,"https://ClinicalTrials.gov/show/NCT00131638"
552,"NCT00127842","REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)",,"Completed","Has Results","Psoriatic Arthritis","Drug: Etanercept","Percentage of Participants With Improvement of ≥ 0.50 Units From Baseline to Month 24 in the HAQ DI|Change From Baseline to Month 24 in the Health and Labour Questionnaire (HLQ) Absence From Work Module|Change From Baseline to Month 24 in the HLQ Reduced Productivity at Paid Work Module|Change From Baseline to Month 24 in the HLQ Unpaid Labour Production Module|Change From Baseline to Month 24 in the HLQ Impediments to Paid and Unpaid Labour Module|Change From Baseline to Month 24 in the Physician Global Assessment|Percent Change From Baseline to Month 24 in Physician Global Assessment|Change From Baseline to Month 24 in Patient Global Assessment|Percent Change From Baseline to Month 24 in Patient Global Assessment|Percentage of Participants With Improvement of ≥ 75 Percent From Baseline to Month 24 in the Psoriasis Activity and Severity Index (PASI)|Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Month 24","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040131","August 2005","August 2005","September 2009","August 9, 2005","April 24, 2014","April 24, 2014",,,"https://ClinicalTrials.gov/show/NCT00127842"
553,"NCT00125723","FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy",,"Completed","No Results Available","Neutropenia","Other: PI Discretion","dose delays and dose reductions and neutropenic events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","2252","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030218","May 2004","December 2005","December 2005","August 2, 2005",,"December 23, 2010",,,"https://ClinicalTrials.gov/show/NCT00125723"
554,"NCT00124111","A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: pegfilgrastim|Drug: cyclophosphamide|Drug: methotrexate|Drug: 5-fluorouracil","To assess the relative dose intensity (RDI) of IV CMF Day 1 and 8 schedule given every 28 days with pegfilgrastim support in subjects with Stage I-III breast cancer.|Incidence of febrile neutropenic events over all cycles|Incidence of dose delays and dose reductions of planned chemotherapy due to neutropenic events|Safety profile over all cycles","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","20030156",,,,"July 27, 2005",,"February 26, 2010",,,"https://ClinicalTrials.gov/show/NCT00124111"
555,"NCT00124098","An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Kidney Disease","Drug: Aranesp® (darbepoetin alfa)","Haemoglobin level|Aranesp® doses|Adverse events|Laboratory parameters|Blood pressure","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030112",,,,"July 27, 2005",,"June 16, 2008",,,"https://ClinicalTrials.gov/show/NCT00124098"
556,"NCT00121628","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer","Drug: AMG 706","Objective Response Rate (complete response and partial response) as defined by modified RECIST|Duration of response|Progression Free Survival|Changes in tumor markers|overall survival time|time to response|Tumour Related Symptoms (medullary thyroid cancer arm)|AMG 706 pharmacokinetic profile|patient reported outcome (EQ-5D)|Safety Endpoint: Incidence of treatment-emergent adverse events (including all, serious, treatment-related, and each by maximum severity).|Pharmacokinetic Enpoint: AMG 706 pharmacokinetic parameters (Cmax, t1/2, AUC0-24,C24)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040273","July 2005","November 2006","October 2010","July 21, 2005",,"October 9, 2013",,,"https://ClinicalTrials.gov/show/NCT00121628"
557,"NCT00121615","Study of Etanercept in the Treatment of Psoriasis in Adult Subjects",,"Completed","No Results Available","Inflammation|Psoriasis","Drug: etanercept","Subject incidence of serious adverse events, including serious infections, non-melanoma skin cancer, and all malignancies, and all adverse events.|Longitudinal changes from baseline for the Physician and Patient Global Assessments and DLQI","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","391","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040216","October 2004",,,"July 21, 2005",,"March 6, 2009",,,"https://ClinicalTrials.gov/show/NCT00121615"
558,"NCT00121602","Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease",,"Completed","No Results Available","Anemia|Kidney Disease","Drug: Darbepoetin Alfa","Change in Hb level between the screening/baseline period and the evaluation period|The ratio of weekly dosing requirements between baseline and the evaluation period|Change from baseline Hb over time|Proportion of subjects maintaining mean Hb within target range during evaluation period|Average darbepoetin alfa dose over evaluation period|Change from baseline dose over time","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","446","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040104","March 2005","October 2005","October 2006","July 21, 2005",,"February 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00121602"
559,"NCT00121056","REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Enbrel®|Drug: Kineret®",,"Amgen","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Observational","Time Perspective: Prospective","20020145","September 2002",,,"July 21, 2005",,"December 5, 2008",,,"https://ClinicalTrials.gov/show/NCT00121056"
560,"NCT00121030","Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy",,"Completed","No Results Available","Gynecological Malignancies|Genital Neoplasms, Female|Anemia","Drug: darbepoetin alfa|Drug: recombinant human erythropoietin (rHuEPO)","Anemia correction|Patient preference|Activities of daily living","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020166","October 2002",,"December 2003","July 21, 2005",,"December 24, 2007",,,"https://ClinicalTrials.gov/show/NCT00121030"
561,"NCT00120705","Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy",,"Completed","No Results Available","Neoplasms|Anemia","Drug: darbepoetin alfa","To assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W)|Assess safety profile of subjects treated with darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020167","November 2002",,"September 2003","July 19, 2005",,"March 25, 2009",,,"https://ClinicalTrials.gov/show/NCT00120705"
562,"NCT00120692","Treatment for Patients Suffering From Anemia Due to Chemotherapy",,"Completed","No Results Available","Breast Cancer|Anemia","Drug: Darbepoetin Alfa|Drug: Recombinant Human Erythropoietin","Anemia correction|Activities of daily living, patient preference","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020152","October 2002",,"December 2003","July 19, 2005",,"December 24, 2007",,,"https://ClinicalTrials.gov/show/NCT00120692"
563,"NCT00120679","Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy",,"Completed","No Results Available","Non-Small Cell Lung Cancer|Anemia","Drug: darbepoetin alfa|Drug: recombinant human erythropoietin (rHuEPO)","Anemia correction|Patient preference|Activities of daily living","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020165","October 2002",,"December 2003","July 19, 2005",,"December 24, 2007",,,"https://ClinicalTrials.gov/show/NCT00120679"
564,"NCT00119613","A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: placebo|Drug: darbepoetin alfa","Change in hemoglobin concentration from baseline to the end of the chemotherapy treatment period|Survival time|Change in FACT-fatigue subscale scores from baseline to the end of study treatment|Incidence of Adverse Events (including serious and treatment related)|Changes in laboratory values, changes in vital signs and incidence of concomitant medications","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010145","December 2002","January 2007","April 2007","July 14, 2005",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00119613"
565,"NCT00119600","A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy",,"Terminated","No Results Available","Anemia|Cancer","Drug: AMG 114","Incidence and severity of adverse events|Change in hemoglobin concentration|Maximum observed concentration (Cmax)|Time Cmax is observed (Tmax)|AUC|Change in FACT-fatigue sub-scores","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20030205",,,,"July 14, 2005",,"May 11, 2009",,,"https://ClinicalTrials.gov/show/NCT00119600"
566,"NCT00119587","Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects",,"Completed","No Results Available","Anemia","Drug: darbepoetin alfa","Comparison between once a week and once every other week darbepoetin alfa on the change in Hb level between the screening/baseline period and the evaluation period (weeks 25-30)|Instability of Hb concentration during the evaluation period|Weekly dose and frequency of darbepoetin alfa during the evaluation period|RBC transfusions during the evaluation period.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20010219","August 2002",,"September 2003","July 14, 2005",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00119587"
567,"NCT00118638","A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",,"Completed","No Results Available","Anemia|Non-Myeloid Malignancies","Drug: Darbepoetin alfa - 2.25 mcg/kg|Drug: Darbepoetin alfa - 500mcg","Incidence of at least one RBC transfusion from week 5 to End of Treatment Period (EOTP)|Incidence of achieving a hemoglobin concentration of greater than or equal to 11.0 g/dL, in the absence of RBC transfusions in the preceding 28 days, from week 5 to EOTP|Incidence of at least one RBC transfusion from week 1 (day 1) to EOTP|Incidence of achieving a hemoglobin concentration greater than or equal to 11.0 g/dL, in the absence of RBC transfusions in the preceding 28 days, from week 1 to EOTP|Change in FACT-G Physical Well-being subscale from baseline to EOTP|Change in hemoglobin from baseline to EOTP|Change in FACT-Fatigue subscale score from baseline to EOTP|Change in FACT-G total score from baseline to EOTP|Change in EQ-5D Thermometer from baseline to EOTP|Change in BSI Anxiety scale score from baseline to EOTP|Change in BSI Depression scale score from baseline to EOTP|Incidence and severity of adverse events|Incidence of hemoglobin concentration greater than 13.0 g/dL at any time on study|Change in number of caregiver hours from baseline to EOTP|Incidence of an increase in hemoglobin concentration greater than or equal to 2 g/dL in a 28-day window and any negative clinical consequences|Incidence of an increase in hemoglobin concentration of greater than or equal to 1 g/dL in a 14-day window and any negative clinical consequences|Incidence of a confirmed antibody formation to darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","705","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20030231","March 2004","December 2004","January 2005","July 12, 2005",,"April 29, 2013",,,"https://ClinicalTrials.gov/show/NCT00118638"
568,"NCT00117910","Treatment for Elderly Patients With High Risk Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: pegfilgrastim","Provide preliminary information on the incidence of protocol defined neutropenic events in chemotherapy cycle 1.|Provide preliminary information on primary and secondary prophylaxis treatment with pegfilgrastim with respect to:|Incidence of protocol defined neutropenic events over all cycles|Incidence of dose reductions and dose delays of planned chemotherapy due to|hematological toxicity|Relative dose intensity|Safety profile over all cycles","Amgen","Female","65 Years and older   (Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020106","October 2002",,"May 2004","July 11, 2005",,"May 16, 2008",,,"https://ClinicalTrials.gov/show/NCT00117910"
569,"NCT00117897","Treatment for Subjects With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: pegfilgrastim|Drug: Filgrastim","The primary objective was to provide preliminary information on the ability of pegfilgrastim or Filgrastim to support planned dose on time (PDOT) application of CHOP chemotherapy with Rituximab given every 14 days, to subjects with NHL.|The proportion of chemotherapy cycles given at the PDOT in both arms.|Response rates (complete response and partial response) in both arms|The safety profile in cycles 1-6|Subject self-reported outcomes","Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010157","July 2002",,"February 2004","July 11, 2005",,"July 20, 2009",,,"https://ClinicalTrials.gov/show/NCT00117897"
570,"NCT00117624","A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy",,"Completed","No Results Available","Anemia","Drug: darbepoetin alfa","RBC transfusion during the treatment phase|The time to hemoglobin response during the treatment phase|The FACT-Fatigue score profile over time|The change in hemoglobin|Incidence and severity of adverse events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020118","December 2002",,"December 2003","July 8, 2005",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00117624"
571,"NCT00117455","A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: pegfilgrastim|Drug: filgrastim","Adequate collection of PBPC's to enable transplant following high dose chemotherapy|Time to engraftment post-transplant","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020113",,,,"July 7, 2005",,"May 16, 2008",,,"https://ClinicalTrials.gov/show/NCT00117455"
572,"NCT00117442","A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood",,"Completed","No Results Available","Breast Cancer|Lung Cancer|Ovarian Cancer","Drug: carboplatin|Drug: paclitaxel|Drug: pegfilgrastim","PBPC mobilization profiles and success rate of achieving planned chemotherapy administration on time.|PBPC kinetics and response to chemotherapy treatment","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010191","August 2002","August 2004","December 2004","July 7, 2005",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00117442"
573,"NCT00117247","A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects",,"Completed","No Results Available","Anemia|Congestive Heart Failure","Drug: darbepoetin alfa","Pharmacokinetic profiling of Aranesp® in HF pts|Pharmacodynamic responses (hgb) following Aranesp® administration in HF patients","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20010198","June 2002",,"July 2004","July 6, 2005",,"October 16, 2009",,,"https://ClinicalTrials.gov/show/NCT00117247"
574,"NCT00117234","Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia",,"Completed","No Results Available","Congestive Heart Failure|Anemia","Drug: darbepoetin alfa","Exercise tolerance, measured as peak VO(subscript)2|Exercise duration; *NYHA classification; *Patient-reported outcomes","Amgen","All","21 Years and older   (Adult, Older Adult)","Not Applicable",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020126","September 2002",,"July 2004","July 6, 2005",,"December 3, 2010",,,"https://ClinicalTrials.gov/show/NCT00117234"
575,"NCT00117143","Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Thrombocytopenic Purpura","Drug: Romiplostim","Number of Participants With Adverse Events|Number of Participants With Positive Anti-Romiplostim Antibodies|Number of Participants Who Achieved a Targeted Therapeutic Platelet Response|Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L From Baseline|Number of Participants With Peak Platelet Counts of ≥ 100 x 10⁹ Cells/L|Number of Participants With Peak Platelet Counts of ≥ 450 x 10⁹ Cells/L|Change From Baseline to Peak Platelet Level|Time to Peak Platelet Count|Duration Within the Targeted Therapeutic Range","Amgen",,"Child, Adult, Older Adult","Phase 1|Phase 2","16","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010218","December 2, 2002","July 19, 2004","July 19, 2004","July 4, 2005","December 20, 2019","December 20, 2019",,,"https://ClinicalTrials.gov/show/NCT00117143"
576,"NCT00117130","Study to Evaluate Effectiveness of Aranesp®",,"Completed","No Results Available","Kidney Disease","Drug: Aranesp®","Subject preference|Subject productivity and subject selection of Aranesp® or Procrit® therapy in the parallel arm portion and at study conclusion.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020147",,,,"July 4, 2005",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00117130"
577,"NCT00117117","A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®",,"Completed","No Results Available","Anemia","Drug: Aranesp","Patient reported outcomes|Changes in hemoglobin endpoints and RBC transfusion requirements","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","2423","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020132","September 2002",,"December 2003","July 4, 2005",,"March 25, 2009",,,"https://ClinicalTrials.gov/show/NCT00117117"
578,"NCT00117104","Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis",,"Completed","No Results Available","End Stage Renal Disease","Drug: Aranesp®","Target hemoglobin (Hgb)|Distribution of hemoglobin (Hgb) values by week","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030133",,,,"July 4, 2005",,"October 16, 2009",,,"https://ClinicalTrials.gov/show/NCT00117104"
579,"NCT00117091","Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Anakinra (Kineret®)","% of subjects continuing Kineret® therapy at the end of the study (I.e., responders according to pre-defined response assessment criteria.)|Change in Health Related Quality of Life (HRQOL) scores at the end of study weeks 12, 24, 36 and 48.|feasibility of simpleject device|treatment response (ACR scores, DAS 28) at the end of study weeks 12, 24, 36 and 48.|Safety of Kineret® when added to current DMARD therapy.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020364",,,,"July 4, 2005",,"December 24, 2007",,,"https://ClinicalTrials.gov/show/NCT00117091"
580,"NCT00117078","Aranesp® Monthly Preference Study - 2",,"Completed","No Results Available","Kidney Disease","Drug: Aranesp®","Subject preference|Subject productivity and subject selection of Aranesp® or Procrit® therapy in the parallel arm portion and at study conclusion.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020380",,,,"July 4, 2005",,"September 30, 2008",,,"https://ClinicalTrials.gov/show/NCT00117078"
581,"NCT00117065","Study of Transplant Related Anemia Treated With Aranesp® (STRATA)",,"Completed","No Results Available","Anemia","Drug: Aranesp®","Hemoglobin values|SF-36 summary and individual domain scores at week 24","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030139",,,,"July 4, 2005",,"April 26, 2013",,,"https://ClinicalTrials.gov/show/NCT00117065"
582,"NCT00117052","SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism",,"Completed","No Results Available","Secondary Hyperparathyroidism|End Stage Renal Disease","Drug: cinacalcet","Number of subjects with PTH less than or equal to 300pg/mL|Changes in Calcium (Ca), Phosphor (P), Ca X P, KDOQI guidelines, Rate of Nausea and Vomiting Aes|Safety of cinacalcet","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","673","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040143","September 2004","November 2005","February 2006","July 4, 2005",,"May 23, 2013",,,"https://ClinicalTrials.gov/show/NCT00117052"
583,"NCT00117039","A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia",,"Completed","No Results Available","Anemia|Neoplasms","Drug: Aranesp®","Hemoglobin maintenance|Quality of Life|Changes in measures of work productivity and anemia treatment convenience","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","1500","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030206","January 2004",,"April 2005","July 4, 2005",,"October 15, 2008",,,"https://ClinicalTrials.gov/show/NCT00117039"
584,"NCT00116727","Rheumatoid Arthritis DMARD Intervention and UtilizationStudy",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: ENBREL®",,"Amgen|Immunex Corporation|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)",,"5103","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20021635|016.0035","October 2002","June 2008","October 2008","July 1, 2005",,"May 6, 2011",,,"https://ClinicalTrials.gov/show/NCT00116727"
585,"NCT00116714","Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: DMARD",,"Amgen|Immunex Corporation|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)",,"4968","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20021634|016.0034","October 2001","December 2007","October 2008","July 1, 2005",,"May 6, 2011",,,"https://ClinicalTrials.gov/show/NCT00116714"
586,"NCT00116701","Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis",,"Completed","No Results Available","Kidney Disease","Drug: Aranesp®","Treatment period 1: Mean haemoglobin during the evaluation period (weeks 21-24)|Treatment period 2: Mean haemoglobin during evaluation period 2 (weeks 45-48)|Treatment period 2: Change in Hb between Evaluation Period 1 and Evaluation Period 2|Treatment period 2: The proportion of subjects with a change in Hb between Evaluation Period 1 and Evaluation Period 2 within the inclusive range -1.0 to +1.5 g/dL|Treatment period 2: The proportion of subjects with a mean Hb > 11.0 g/dL during Evaluation Period 2|Treatment period 2: Dose and frequency of darbepoetin alfa administration over the treatment period|Treatment period 1:The proportion of subjects with a mean Hb > 11.0 g/dL during the evaluation period|Treatment period 1: Change in Hb between screening/baseline and the evaluation period|Treatment period 1: Dose and frequency of darbepoetin alfa administration over the treatment period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040218","May 2005",,,"July 1, 2005",,"May 5, 2008",,,"https://ClinicalTrials.gov/show/NCT00116701"
587,"NCT00116688","Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Thrombocytopenia|Idiopathic Thrombocytopenic Purpura","Biological: Romiplostim","Number of Participants With Adverse Events|Number of Participants With a Platelet Response|Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies|Change From Baseline in ITP Patient Assessment Questionnaire|Change From Baseline in Short Form 36 (SF-36)|Change From Baseline in Euroqol-5D (EQ-5D) Index Score|Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)|Patient Global Assessment","Amgen","All","1 Year and older   (Child, Adult, Older Adult)","Phase 3","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030213","August 2004","January 2010","January 2010","July 1, 2005","April 6, 2011","December 18, 2013",,,"https://ClinicalTrials.gov/show/NCT00116688"
588,"NCT00116272","Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project",,"Completed","Has Results","Pregnancy","Drug: Etanercept","Percentage of Infants With Major Birth Defects in Pregnancies Ending With Live-born Infants|Percentage of Infants With Major Birth Defects in All Pregnancies|Percentage of Infants With Any 3 or More Minor Birth Defects|Percentage of Infants With a Specific Pattern of Any 3 or More Minor Birth Defects|Percentage of Pregnancies Ending in Spontaneous Abortion|Percentage of Participants With Pre-term Delivery|Gestational Age at Delivery (GAD) of Live Births|Birth Weight Among Full Term Infants|Birth Length Among Full Term Infants|Birth Head Circumference Among Full Term Infants|Percentage of Infants With Small for Gestational Age Birth Weight|Percentage of Infants With Small for Gestational Age Birth Length|Percentage of Infants With Small for Gestational Age Birth Head Circumference|Postnatal Weight Percentile at One Year|Postnatal Length Percentile at One Year|Postnatal Head Circumference Percentile at One Year|Percentage of Infants at One Year of Age With Small for Gestational Age Weight|Percentage of Infants at One Year of Age With Small for Gestational Age Length|Percentage of Infants at One Year of Age With Small for Gestational Age Head Circumference|Percentage of Infants With Reported Serious or Opportunistic Infections Through One Year|Percentage of Infants Diagnosed With Any Malignancy Through One Year of Age|Percentage of Infants With Abnormal Results on Ages and Stages Questionnaire (ASQ)","Amgen",,"Child, Adult, Older Adult",,"830","Industry","Observational","Observational Model: Cohort","20040246","April 2005","June 2014","June 2014","June 29, 2005","September 21, 2015","September 21, 2015","Research Site, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00116272"
589,"NCT00115765","PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study",,"Completed","Has Results","Colorectal Cancer","Drug: Oxaliplatin Based Chemotherapy|Drug: Panitumumab|Drug: Irinotecan Based Chemotherapy|Drug: Bevacizumab","Progression-Free Survival (Oxaliplatin)|Objective Tumor Response Through Week 12 (Irinotecan)|Overall Survival (Oxaliplatin)|Objective Tumor Response Rate (Oxaliplatin)|Time to Progression (Oxaliplatin)|Time to Treatment Failure (Oxaliplatin)|Overall Survival (Irinotecan)|Progression-free Survival (Irinotecan)|Objective Tumor Response Rate (Irinotecan)|Time to Progression (Irinotecan)|Time to Treatment Failure (Irinotecan)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1053","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040249","June 1, 2005","May 31, 2007","May 1, 2009","June 27, 2005","September 14, 2010","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00115765"
590,"NCT00115427","Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease",,"Completed","No Results Available","Idiopathic Parkinson's Disease","Drug: Liatermin (r-metHuGDNF)","United Parkinson's Disease Rating Scale|Timed Motor Tests|Dyskinesia ratings|Diary ratings|Patient reported outcomes measures","Amgen","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020168","March 2003",,,"June 23, 2005",,"January 11, 2008",,,"https://ClinicalTrials.gov/show/NCT00115427"
591,"NCT00115414","Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)",,"Completed","No Results Available","Breast Cancer|Fever|Neutropenia","Drug: pegfilgrastim|Drug: docetaxel|Drug: doxorubicin|Drug: cyclophosphamide","Neutropenia|Disease Response|Adverse Events","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020778",,,,"June 23, 2005",,"August 1, 2008",,,"https://ClinicalTrials.gov/show/NCT00115414"
592,"NCT00115219","Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","Proportion of subjects achieving a good or moderate DAS28 response (as defined by the EULAR28 response criteria) at Week 12|Proportion of subjects who achieve American College of Rheumatology (ACR) 20, 50, and 70 responses at Weeks 12 and 24|Proportion of subjects achieving a good or moderate DAS28 response (as defined by the EULAR28 response criteria at Week 24 and the proportion achieving clinical remission (DAS28<2.6) at Weeks 12 and 24|Changes from baseline with respect to the DAS28 score and ACR score (including HAQ) criteria at Weeks 12 and 24|Changes from baseline in patient-reported outcomes as measured by the SF-36 at Weeks 12 and 24|Proportion of etanercept 50mg BIW responders at Week 12 who mantain a clinical improvement with etanercept 50mg QW (defined as no DAS28 increase of greater than 0.6 from Week 12) at Week 24|Safety (SAEs and AEs) in three study periods (4-week open label run-in period, 12-week double blinded period A, and 12-week open-label period B)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","20040275","May 2005",,,"June 22, 2005",,"May 30, 2013",,,"https://ClinicalTrials.gov/show/NCT00115219"
593,"NCT00115206","Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Neulasta® (pegfilgrastim)","Quality of Life|Quality of Life, *Neutropenia, *Hospitalization, *Disease Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020121","July 2002",,"July 2004","June 22, 2005",,"April 6, 2009",,,"https://ClinicalTrials.gov/show/NCT00115206"
594,"NCT00115193","Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: pegfilgrastim","Reduce the duration of neutropenia and incidence of febrile neutropenia.|On the same day as chemotherapy as measured by the incidence of hematologic and non-hematologic toxicities, the number of subjects who received planned doses of chemotherapy on time and response rates.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20020134","February 2003","August 2005","August 2005","June 22, 2005",,"August 29, 2013",,,"https://ClinicalTrials.gov/show/NCT00115193"
595,"NCT00115167","A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study",,"Completed","No Results Available","Anemia|Cancer","Drug: Placebo|Drug: Darbepoetin alfa","Incidence of adverse events|Confirmed antibody formation to investigational product|Deaths on study|Laboratory parameters|Vital signs (blood pressure)|Change in PRO scores","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","371","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20020149","August 2004","January 2007","March 2007","June 22, 2005",,"May 11, 2009",,,"https://ClinicalTrials.gov/show/NCT00115167"
596,"NCT00115128","Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors",,"Completed","No Results Available","Normal PBPC Donors","Drug: filgrastim","Spleen fold change measured by ultrasound|Spleen change associations with filgrastim dose and hematologic variables","Amgen","All","18 Years and older   (Adult, Older Adult)",,"309","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20020143","November 2003","May 2007","September 2007","June 22, 2005",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00115128"
597,"NCT00114764","Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)",,"Completed","No Results Available","Myeloid Leukemia","Drug: filgrastim|Drug: pegfilgrastim","Time to recover from severe neutropenia (ANC less that 0.5 X 10^9/L in chemotherapy Induction 1.|Duration of severe neutropenia during induction chemotherapy","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20020163","March 2003","April 2004","August 2004","June 20, 2005",,"October 31, 2008",,,"https://ClinicalTrials.gov/show/NCT00114764"
598,"NCT00113958","Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels",,"Completed","No Results Available","End Stage Renal Disease","Drug: Cinacalcet","Secondary hyperparathyroidism in people with kidney failure.|Uncontrolled secondary hyperparathyroidism","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020389",,,,"June 13, 2005",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00113958"
599,"NCT00113945","Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)",,"Completed","No Results Available","End Stage Renal Disease","Drug: Cinacalcet","Secondary hyperparathyroidism in people with kidney failure.|Uncontrolled secondary hyperparathyroidism","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020390","July 2003",,,"June 13, 2005",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00113945"
600,"NCT00113789","Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer","Other: PI Discretion","Duration of Grade 4 Neutropenia","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20030122","October 2003","April 2005","April 2005","June 13, 2005",,"February 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00113789"
601,"NCT00113776","Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer",,"Completed","No Results Available","Colorectal Cancer","Drug: ABX-EGF","Incidence of Adverse events|Changes in Lab values|Incidence of HAHA formation","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030194",,,,"June 13, 2005",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00113776"
602,"NCT00113763","Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer|Metastases","Other: Best supportive care|Drug: Panitumumab","Progression-free Survival Time|Overall Survival|Objective Tumor Response|Duration of Response|Time to Response|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020408","January 2004","October 2008","June 2009","June 13, 2005","January 3, 2014","August 7, 2018",,,"https://ClinicalTrials.gov/show/NCT00113763"
603,"NCT00112008","Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis",,"Completed","No Results Available","Chronic Kidney Disease|Kidney Disease","Drug: De Novo Administration of Darbepoetin Alfa","The proportion of subjects achieving a Hb ≥ 11.0 g/dL|Hb values over the duration of the study|Darbepoetin alfa doses over the duration of the study|Frequency, severity, and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030237","May 2004","March 2005","March 2005","May 30, 2005",,"July 10, 2009",,,"https://ClinicalTrials.gov/show/NCT00112008"
604,"NCT00111995","Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis",,"Completed","No Results Available","Chronic Renal Failure|Anemia","Drug: Aranesp®","Mean hemoglobin level during the evaluation period|The nature, frequency, severity, relationship to treatment, and outcome of adverse events with specific attention to hypertensive events","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","20010125","May 2002",,,"May 30, 2005",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00111995"
605,"NCT00111982","Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin",,"Completed","No Results Available","Parkinson's Disease","Biological: Liatermin","Percent change in UPDRS|Incidence of treatment emergent and device related adverse events","Amgen|Medtronic","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030160","December 2003","November 2005","February 2006","May 30, 2005",,"February 26, 2010",,,"https://ClinicalTrials.gov/show/NCT00111982"
606,"NCT00111774","Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma",,"Completed","No Results Available","Colorectal Cancer|Carcinoma","Drug: ABX-EGF","To assess Objective Response at Week 8 of Cycle 1|To evaluate additional measures of the clinical efficacy of ABX-EGF in subjects with metastatic colorectal carcinoma. (progression free survival, survival time, best overall response, and time to disease progression)|To determine the safety of ABX-EGF in subjects with metastatic colorectal carcinoma. (incidence of AEs, laboratory abnormalities, and other safety parameters)|To evaluate the safety and efficacy of ABX-EGF in subjects with lower tumor epidermal growth factor receptor (EGFr) expression","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20025405","March 2002",,,"May 26, 2005",,"May 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00111774"
607,"NCT00111761","Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer","Drug: Irinotecan|Biological: Panitumumab|Drug: 5-Fluorouracil|Drug: Leucovorin","Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)|Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)|Number of Participants With an Objective Tumor Response (Part 2)|Time to Disease Progression (Part 2)|Progression-free Survival Time (Part 2)|Survival Time (Part 2)|Number of Participants Who Died (Part 2)|Number of Participants With Objective Tumor Response (Part 1)|Progression-free Survival Time (Part 1)|Time to Disease Progression (Part 1)|Survival Time (Part 1)|Time to Treatment Failure (Part 1)|Time to Initial Objective Tumor Response (Part 1)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20025409","July 2002","February 2008","October 2008","May 26, 2005","June 3, 2011","December 12, 2013",,,"https://ClinicalTrials.gov/show/NCT00111761"
608,"NCT00111475","Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)",,"Completed","Has Results","Idiopathic Thrombocytopenic Purpura","Drug: Romiplostim|Drug: Placebo","Number of Participants With Adverse Events|Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies|Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A|Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A|Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A|Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A|Peak Platelet Count After Each Dose in Part A|Change From Baseline in Peak Platelet Count After Each Dose in Part A|Time to Peak Platelet Count After Each Dose in Part A|Duration Within the Targeted Therapeutic Platelet Range In Part A|Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B|Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B|Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B|Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B|Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B|Peak Platelet Count in Part B|Change From Baseline in Peak Platelet Count in Part B|Time to Peak Platelet Count in Part B|Duration Within the Targeted Therapeutic Platelet Range in Part B","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20000137","July 1, 2002","June 17, 2004","June 17, 2004","May 23, 2005","January 10, 2020","January 10, 2020",,,"https://ClinicalTrials.gov/show/NCT00111475"
609,"NCT00111462","Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy",,"Completed","No Results Available","Anemia|Non-Myeloid Malignancies|Cancer","Drug: Darbepoetin alfa","Achieving a hemoglobin concentration greater than or equal to 12.0 g/dL or a greater than or equal to 2.0-g/dL increase in hemoglobin concentration compared to baseline|Time to and percentage of subjects with a hemoglobin response|Time to and percentage of subjects with hemoglobin correction|Hemoglobin concentration and change in hemoglobin concentration from baseline|Time to first RBC transfusion and percentage of subjects receiving a RBC transfusion","Amgen",,"Child, Adult, Older Adult","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010102",,,,"May 23, 2005",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00111462"
610,"NCT00111449","Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: Etanercept","Achievement of 75% or greater improvement from baseline in the Psoriasis Area and Severity Index (PASI) after 12 weeks of double-blind treatment.|Dermatology Live Quality Index (DLQI) response at week 12|Subject's assessment of itching and improvements from baseline in joint pain (visual analog scale [VAS]) at week 12|Psoriasis pain (VAS) at week 12|Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale at week 12|PASI 50, 75 and 90 response and improvement from baseline in PASI score during long-term therapy|Static physician's global assessment of psoriasis (sPGA) from baseline during long-term therapy|Adverse events, infections injection site reactions during long-term therapy|Serious adverse events and infections during long-term therapy|Clinical laboratory values, vital signs and antibodies to etanercept during long-term therapy","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20030117","June 2003",,,"May 23, 2005",,"May 15, 2013",,,"https://ClinicalTrials.gov/show/NCT00111449"
611,"NCT00111436","Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects",,"Completed","No Results Available","Psoriasis","Drug: Etanercept","Subject incidence of adverse events, including infectious episodes|Changes from baseline in laboratory values|Improvement in Psoriasis Area and Severity Index (PASI) Score in this study relative to baseline in the original study|Proportion of subjects who achieve 0 or 1 (clear or almost clear) in the Physician Global Assessment of psoriasis|Patient Global Assessment of psoriasis|Percent improvement from baseline in the Dermatology Life Quality Index (DLQI) scores|Changes from baseline in SF-36 Health Survey scores","Amgen|Immunex Corporation|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","912","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030115","April 2003","July 2005","July 2005","May 23, 2005",,"April 26, 2013",,,"https://ClinicalTrials.gov/show/NCT00111436"
612,"NCT00111423","Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Pegsunercept (PEG sTNF-RI)","Treatment-emergent adverse events|Description of RA assessment outcomes|Assessment of Compliance","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020133","August 2002",,,"May 23, 2005",,"March 6, 2009",,,"https://ClinicalTrials.gov/show/NCT00111423"
613,"NCT00111137","Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy",,"Completed","No Results Available","Cancer|Non-Myeloid Malignancies","Drug: rHuEPO|Drug: Darbepoetin alfa","Time to hematopoietic response during the comparative treatment period|Exploratory analyses for other patient reported outcome scales collected during the study (FACT-Anemia, BSI, EQ-5D, and Patient Satisfaction Questionnaire for Injectable Anemia Treatment)|Incidence, if any, of neutralizing antibody formation to study drug|Difference between the average hemoglobin after the first month of treatment compared to the baseline hemoglobin|Time to 2 g/dL increase in hemoglobin during the comparative treatment period|Change in FACT-Fatigue scale score over time during the comparative treatment period|Overall incidence of adverse events, serious adverse events and related adverse events as measured throughout study|Slope of change in hemoglobin after the first month of treatment|Red blood cell usage during the treatment period and other changes in hemoglobin during the comparative treatment period|Changes in hemoglobin during the maintenance period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","718","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020139","February 2003","November 2003","April 2004","May 18, 2005",,"February 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00111137"
614,"NCT00111124","Enbrel® in Psoriatic Arthritis",,"Completed","No Results Available","Psoriasis","Drug: Enbrel®","The proportion of subjects achieving a status on the Physician Global Assessment of Psoriasis of """"mild"""" or better at week 24.|Quality of life and disability as measured by the DLQI and HAQ|Financial impact of therapy on disease as measured by Patient Pharmacoeconomic Questionnaire|Serious Adverse Events|Patient Global Assessment of Psoriasis|Patient Global Assessment of Joint Disease|Patient Global Assessment of Joint Pain|Patient Assessment of Morning Stiffness Duration","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Primary Purpose: Treatment","20030106",,,,"May 18, 2005",,"May 15, 2013",,,"https://ClinicalTrials.gov/show/NCT00111124"
615,"NCT00111111","An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: Etanercept","Improvement in Physician's Global Assessment of Psoriasis|Patient-reported outcomes including Dermatology Life Quality Index, SF-36, Euro-QoL 5D, and Beck Depression Index","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030190",,,,"May 18, 2005",,"May 29, 2009",,,"https://ClinicalTrials.gov/show/NCT00111111"
616,"NCT00111098","Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis",,"Completed","No Results Available","Kidney Disease","Drug: Darbepoetin Alfa","The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL during the evaluation phase|To determine Hb values over the duration of the study|To determine darbepoetin alfa doses over the duration of the study|To assess the safety of darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030153","March 2004","November 2005","November 2005","May 18, 2005",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00111098"
617,"NCT00110981","Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis",,"Completed","No Results Available","Psoriasis","Device: NB-UVB|Drug: Etanerept|Drug: Etanercept","Proportion of subjects achieving Psoriasis Area Severity Area (PASI) 75 at Week 12|Time to PASI 75 responses|Proportion of subjects achieving PASI 90 at Week 12|Improvement in PASI at Week 12|Improvement in body surface area (BSA) involved with psoriasis at Week 12|Improvement in physician global assesssment of psoriasis, including an assessment of the proportion of subjects achieving clear or almost clear status at Week 12|Improvement in patient global assesssment of psoriasis at Week 12|Improvement in Dermatology Life Quality Index (DLQI) at Week 12|Subject incidence of serious adverse events (SAEs) and events of medical interests (EMI) at Week 12","Amgen|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040171","March 2005","February 2006","March 2006","May 17, 2005",,"May 24, 2013",,,"https://ClinicalTrials.gov/show/NCT00110981"
618,"NCT00110955","Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",,"Completed","No Results Available","Anemia|Non-Myeloid Malignancies","Drug: Darbepoetin alfa|Drug: Placebo","Incidence of red blood cell (RBC) transfusion from week 5 to End of Treatment Period (EOTP)|Incidence of achieving a hemoglobin concentration of greater than or equal to 11 g/dL in the absence of RBC transfusions in the preceding 28 days from week 5 to EOTP|Number of RBC transfusions from week 5 to EOTP|Change in FACT-Fatigue subscale score from baseline to EOTP|Change in FACT-G Physical Well-being subscale from baseline to EOTP|Incidence and severity of adverse events|Incidence of hemoglobin concentration greater than 13.0 g/dL at any time on study|Change in FACT-G total score from baseline to EOTP|Incidence of an increase in hemoglobin concentration greater than or equal to 2 g/dL in a 28-day window and any negative clinical consequences|Change in EQ-5D Thermometer from baseline to EOTP|Change in BSI Anxiety scale score from baseline to EOTP|Change in BSI Depression scale score from baseline to EOTP|Change in number of caregiver hours from baseline to EOTP|Incidence of a confirmed antibody formation to darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","391","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20030232","February 2004","March 2005","April 2005","May 17, 2005",,"January 15, 2010",,,"https://ClinicalTrials.gov/show/NCT00110955"
619,"NCT00110942","Treatment for Patients With Osteoarthritis (OA)",,"Completed","No Results Available","Osteoarthritis","Drug: Systemic AMG 108|Other: Placebo","Change in WOMAC pain score|Change in WOMAC composite score and function and stiffness index scores|Achieving 50% or more improvement from Day 1 in the WOMAC","Amgen","All","30 Years and older   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040166","February 2005","June 2005","November 2005","May 17, 2005",,"June 23, 2008",,,"https://ClinicalTrials.gov/show/NCT00110942"
620,"NCT00110929","Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)",,"Completed","No Results Available","End Stage Renal Disease","Drug: AMG 073","Examine PTH and Ca x P control when cinacalcet is administered in the setting of flexible dosing of vitamin D sterols.|Examine safety and tolerability of cinacalcet.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","850","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020158","November 2002",,,"May 17, 2005",,"April 23, 2010",,,"https://ClinicalTrials.gov/show/NCT00110929"
621,"NCT00110916","Treatment for Patients With Osteoarthritis (OA) of the Knee",,"Completed","No Results Available","Osteoarthritis","Drug: Intra-articular metHuIL-1ra (anakinra)|Drug: placebo","WOMAC|Pain Patient's global assessment","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040100","June 2004","February 2005","February 2005","May 17, 2005",,"February 22, 2008",,,"https://ClinicalTrials.gov/show/NCT00110916"
622,"NCT00110903","Treatment for Subjects With Active Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept Liquid","Proportion of subjects having positive immunoassay response to etanercept liquid during the treatment period.|Incidence of adverse events, infectious episodes, serious adverse events, serious infectious episodes|Measurements from safety laboratory assessments.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020378",,,,"May 17, 2005",,"April 26, 2013",,,"https://ClinicalTrials.gov/show/NCT00110903"
623,"NCT00110890","A Research Study for Patients With End-Stage Renal Disease (ESRD)",,"Completed","Has Results","End Stage Renal Disease","Drug: cinacalcet|Other: Standard of care","Number of Participants With Mean PTH ≤ 300 pg/mL|Number of Participants With Mean Ca x P < 55 mg^2/dL^2 and iPTH ≤ 300 pg/mL|Number of Participants With Mean Ca x P < 55 mg^2/dL^2|Number of Participants With Mean Serum Ca < 9.5 mg/dL|Number of Participants With Mean Serum P < 5.5 mg/dL","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","552","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030187","May 2004","April 2005","September 2007","May 17, 2005","March 7, 2011","March 7, 2011",,,"https://ClinicalTrials.gov/show/NCT00110890"
624,"NCT00110656","Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation",,"Completed","No Results Available","Kidney Transplantation","Other: Observations","PTH Values|Calcium and Phosphorus","Amgen","All","18 Years and older   (Adult, Older Adult)",,"38","Industry","Observational","Time Perspective: Retrospective","20030219","March 2004","September 2004","October 2004","May 13, 2005",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00110656"
625,"NCT00104650","Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates",,"Completed","Has Results","Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer|Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma","Genetic: AMG 162 180 mg (SC) q 12 weeks|Drug: IV Bisphosphonate q 4 weeks|Genetic: AMG 162- 180 mg q 4 weeks","uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 13|uNTx (Corrected by Creatinine) < 50 Nmol/mmol at Week 25|Percent Change of uNTx (Corrected by Creatinne) From Baseline to Week 25|Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol|Duration of Maintaining uNTX (Corrected by Creatinine) < 50nmol/mmol|Percent Change of Serum CTX From Baseline to Week 25|Time to First Skeletal Related Event|Skeletal Related Events|Hypercalcemia","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040114","January 2005","January 2008","March 2010","March 4, 2005","January 7, 2011","January 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00104650"
626,"NCT00102830","Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors",,"Completed","No Results Available","Tumors","Drug: AMG 386","Adverse events, clinically significant changes in laboratory results, ECG, and vital signs, to be measured throughout the study.|Pharmacokinetic Profile of AMG 386 - blood levels of AMG 386 to be measured throughout the study.|Changes in DCE-MRI imaging results measured at baseline, Week 1, and Week 4.|Changes in blood levels of angiogenic cytokines measured at baseline, Day 3, Weeks 2, 4, 10, and every 8 weeks thereafter.|Anti-AMG 386 antibody formation measured at baseline, weeks 2, 4, 6, and every 4 weeks thereafter.|Tumor response measure by CT scan at baseline, Week 4, and every 8 weeks thereafter.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Primary Purpose: Treatment","20040169",,,,"February 4, 2005",,"August 20, 2010",,,"https://ClinicalTrials.gov/show/NCT00102830"
627,"NCT00102336","AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy",,"Completed","No Results Available","Thrombocytopenia|Idiopathic Thrombocytopenic Purpura","Biological: AMG 531|Drug: Placebo","To evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by durable platelet response during the last 8 weeks of treatment and other platelet response parameters|To evaluate the overall safety of AMG 531|To evaluate possible reductions in the dose of concurrent ITP therapies while receiving AMG 531|To evaluate changes in Patient Reported Outcomes (PRO) and Health Resource Utilization (HRU) due to treatment with AMG 531","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20030212","April 7, 2005","December 1, 2006","April 1, 2007","January 28, 2005",,"May 9, 2019",,,"https://ClinicalTrials.gov/show/NCT00102336"
628,"NCT00102323","AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy",,"Completed","No Results Available","Thrombocytopenia|Idiopathic Thrombocytopenic Purpura","Drug: Placebo|Biological: AMG 531","To evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by durable platelet response during the last 8 weeks of treatment and other platelet response parameters|To evaluate the overall safety of AMG 531|To evaluate the possible reductions in concurrent ITP therapies while receiving AMG 531|To evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to treatment with AMG 531","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20030105","March 29, 2005","September 1, 2006","March 1, 2007","January 28, 2005",,"May 9, 2019",,,"https://ClinicalTrials.gov/show/NCT00102323"
629,"NCT00101920","ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-small Cell Lung Cancer|Neoplasm Metastasis|Lung Cancer","Drug: ABX-EGF","Objective Tumor Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20025408","June 2003","December 2004","December 2004","January 19, 2005",,"October 15, 2010",,,"https://ClinicalTrials.gov/show/NCT00101920"
630,"NCT00101907","Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer",,"Terminated","Has Results","Lung Cancer|Pancreatic Cancer|Esophageal Cancer","Drug: AMG 706|Biological: Panitumumab|Drug: Gemcitabine|Drug: Cisplatin","Participant Incidence of Adverse Events|Number of Participants With an Objective Tumor Response|Tmax|Cmax|AUC0-24|AUC0-inf","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040206","December 2004","June 2007","April 2008","January 19, 2005","March 20, 2014","March 20, 2014",,,"https://ClinicalTrials.gov/show/NCT00101907"
631,"NCT00101894","Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer",,"Completed","No Results Available","Rectal Cancer|Colon Cancer","Drug: FOLFOX-4|Drug: AMG 706|Biological: Panitumumab (Part 1a only)|Drug: FOLFIRI","Part 1a - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities|Part 1b - The incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities|Part 2 - The overall objective tumor response rate (complete and partial response) in subjects treated with AMG 706 (at the dose determined in Part 1b), with either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with panitumumab and AMG 706|Part 1a - The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with panitumumab and AMG 706|Part 1a - The objective tumor response rate (complete and partial response) throughout the study|Part 1b - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities|Part 1b - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1b - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with AMG 706|Part 2 - Duration of response: (Calculated for only those subjects who respond)|Part 2 - Time-to-progression|Part 1b - The PK of irinotecan (and its active metabolite SN38) when administered as a part of the FOLFIRI regimen with AMG 706|Part 1b- The PK of oxaliplatin when administered as a part of the FOLFOX-4 regimen with AMG 706|Part 1b - The objective tumor response rate (complete and partial response) throughout the study|Part 2 - Overall survival|Part 2 - The incidence of adverse events and clinical laboratory abnormalities|Part 2 - The PK of AMG 706 when administered with either the FOLFIRI or FOLFOX-4 chemotherapy regimen (at a subset of the study centers with the capabilities to draw, ship and process PK samples)|Exploratory - Potential biomarker development based on assessment of blood cells, tumor cells, and urine and the proposed mechanism of action of study drugs, and response|Exploratory - The effects of genetic variation in drug metabolism genes, cancer genes, and drug target genes on subject response to investigational products (separate informed consent)|Part 2 - Progression-free survival time|Part 2 - Incidence of subjects undergoing resection of metastases for curative intent|Part 1a - The incidence of adverse events and clinical laboratory abnormalities not defined as dose-limiting toxicities|Part 1a - The PK of AMG 706 when administered with panitumumab and either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The serum concentration of panitumumab when administered with AMG 706 and either the FOLFIRI or FOLFOX-4 chemotherapy regimen|Part 1a - The incidence of HAPA response following panitumumab administration|Part 1a - The PK of 5-FU when administered as a part of the FOLFIRI or FOLFOX-4 regimen with panitumumab and AMG 706","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","119","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040205","December 2004","April 2010","December 2011","January 19, 2005",,"September 17, 2012",,,"https://ClinicalTrials.gov/show/NCT00101894"
632,"NCT00099554","Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","Proportion of subjects achieving a ""good"" or ""moderate"" DAS28 response (as defined by EULAR28 criteria) at Week 16.|Proportion of subjects who achieve ACR 20, 50, and 70 responses at Weeks 8 and 16.|Proportion of subjects who achieve good or moderate DAS28 response at Week 8 and the proportion who achieve remission (DAS28 less than 2.6) at Weeks 8 and 16|Absolute and percent changes from baseline in components of the ACR and DAS28 criteria (including HAQ) at Weeks 8 and 16.|Absolute changes from baseline in SF-36 and Valued Life Activities at Weeks 8 and 16|Subject incidence rate of SAEs over 16 weeks","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030236","May 2004",,,"December 17, 2004",,"November 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00099554"
633,"NCT00096915","Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis",,"Completed","No Results Available","Kidney Disease|Chronic Kidney Disease","Drug: Darbepoetin Alfa","The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL and less than or equal to 13.0 g/dL during the evaluation phase|Hb values over the duration of the study|Darbepoetin alfa doses over the duration of the study|Frequency and relationship to treatment for adverse events and changes in laboratory parameters and blood pressure","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","110","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040202","October 2004","November 2005","November 2005","November 18, 2004",,"May 22, 2009",,,"https://ClinicalTrials.gov/show/NCT00096915"
634,"NCT00095498","Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis","Drug: placebo|Drug: denosumab","Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6|Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 12|Change From Baseline in Radiographic Total Modified Sharp Score (TSS) at Month 6|Change From Baseline in Radiographic Erosion Score at Month 12|Change From Baseline in Radiographic Erosion Score at Month 6|Change From Baseline in Radiographic Joint Space Narrowing Score at Month 12|Change From Baseline in Radiographic Joint Space Narrowing Score at Month 6|Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 1|Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 6|Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12|Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 1|Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 6|Percent Change From Baseline in Femoral Neck Bone Mineral Density at Month 12|Percent Change From Baseline in Total Hip Bone Mineral Density at Month 1|Percent Change From Baseline in Total Hip Bone Mineral Density at Month 6|Percent Change From Baseline in Total Hip Bone Mineral Density at Month 12|Percent Change From Baseline in Serum Collagen C-Telopeptide (CTX) at Month 3|Percent Change From Baseline in Serum CTX at Month 6|Percent Change From Baseline in Serum CTX at Month 12|Percent Change From Baseline in Procollagen 1 N-terminal Peptide (P1NP) at Month 3|Percent Change From Baseline in P1NP at Month 6|Percent Change From Baseline in P1NP at Month 12|Percent Change From Baseline in Urine Type II Collagen C-telopeptide (C-Tx) /Creatinine at Month 3|Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 6|Percent Change From Baseline in Urine Type II C-Tx /Creatinine at Month 12|Number of Participants With Anti-Denosumab Binding Antibodies|Number of Participants With Anti-Denosumab Binding Antibody and Neutralizing Antibody|Change From Baseline in Albumin at Month 1|Change From Baseline in Albumin at Month 3|Change From Baseline in Albumin at Month 6|Change From Baseline in Albumin at Month 12|Change From Baseline in Alkaline Phosphatase at Month 1|Change From Baseline in Alkaline Phosphatase at Month 3|Change From Baseline in Alkaline Phosphatase at Month 6|Change From Baseline in Alkaline Phosphatase at Month 12|Change From Baseline in Bicarbonate at Month 1|Change From Baseline in Bicarbonate at Month 3|Change From Baseline in Bicarbonate at Month 6|Change From Baseline in Bicarbonate at Month 12|Change From Baseline in Total Bilirubin at Month 1|Change From Baseline in Total Bilirubin at Month 3|Change From Baseline in Total Bilirubin at Month 6|Change From Baseline in Total Bilirubin at Month 12|Change From Baseline in Blood Urea Nitrogen at Month 1|Change From Baseline in Blood Urea Nitrogen at Month 3|Change From Baseline in Blood Urea Nitrogen at Month 6|Change From Baseline in Blood Urea Nitrogen at Month 12|Change From Baseline in Calcium at Month 1|Change From Baseline in Calcium at Month 3|Change From Baseline in Calcium at Month 6|Change From Baseline in Calcium at Month 12|Change From Baseline in Calcium (Corrected) at Month 1|Change From Baseline in Calcium (Corrected) at Month 3|Change From Baseline in Calcium (Corrected) at Month 6|Change From Baseline in Calcium (Corrected) at Month 12|Change From Baseline in Chloride at Month 1|Change From Baseline in Chloride at Month 3|Change From Baseline in Chloride at Month 6|Change From Baseline in Chloride at Month 12|Change From Baseline in Creatinine at Month 1|Change From Baseline in Creatinine at Month 3|Change From Baseline in Creatinine at Month 6|Change From Baseline in Creatinine at Month 12|Change From Baseline in Gamma-Glutamyl Transferase at Month 1|Change From Baseline in Gamma-Glutamyl Transferase at Month 3|Change From Baseline in Gamma-Glutamyl Transferase at Month 6|Change From Baseline in Gamma-Glutamyl Transferase at Month 12|Change From Baseline in Glucose at Month 1|Change From Baseline in Glucose at Month 3|Change From Baseline in Glucose at Month 6|Change From Baseline in Glucose at Month 12|Change From Baseline in Potassium at Month 1|Change From Baseline in Potassium at Month 3|Change From Baseline in Potassium at Month 6|Change From Baseline in Potassium at Month 12|Change From Baseline in Magnesium at Month 1|Change From Baseline in Magnesium at Month 3|Change From Baseline in Magnesium at Month 6|Change From Baseline in Magnesium at Month 12|Change From Baseline in Sodium at Month 1|Change From Baseline in Sodium at Month 3|Change From Baseline in Sodium at Month 6|Change From Baseline in Sodium at Month 12|Change From Baseline in Phosphorus at Month 1|Change From Baseline in Phosphorus at Month 3|Change From Baseline in Phosphorus at Month 6|Change From Baseline in Phosphorus at Month 12|Change From Baseline in Total Protein at Month 1|Change From Baseline in Total Protein at Month 3|Change From Baseline in Total Protein at Month 6|Change From Baseline in Total Protein at Month 12|Change From Baseline in Aspartate Amino Transferase at Month 1|Change From Baseline in Aspartate Amino Transferase at Month 3|Change From Baseline in Aspartate Amino Transferase|Change From Baseline in Aspartate Amino Transferase at Month 12|Change From Baseline in Alanine Amino Transferase at Month 1|Change From Baseline in Alanine Amino Transferase at Month 3|Change From Baseline in Alanine Amino Transferase at Month 6|Change From Baseline in Alanine Amino Transferase at Month 12|Change From Baseline in Basophils at Month 1|Change From Baseline in Basophils at Month 3|Change From Baseline in Basophils at Month 6|Change From Baseline in Basophils at Month 12|Change From Baseline in Eosinophils at Month 1|Change From Baseline in Eosinophils at Month 3|Change From Baseline in Eosinophils at Month 6|Change From Baseline in Eosinophils at Month 12|Change From Baseline in Hematocrit at Month 1|Change From Baseline in Hematocrit at Month 3|Change From Baseline in Hematocrit at Month 6|Change From Baseline in Hematocrit at Month 12|Change From Baseline in Hemoglobin at Month 1|Change From Baseline in Hemoglobin at Month 3|Change From Baseline in Hemoglobin at Month 6|Change From Baseline in Hemoglobin at Month 12|Change From Baseline in Lymphocytes at Month 1|Change From Baseline in Lymphocytes at Month 3|Change From Baseline in Lymphocytes at Month 6|Change From Baseline in Lymphocytes at Month 12|Change From Baseline in Monocytes at Month 1|Change From Baseline in Monocytes at Month 3|Change From Baseline in Monocytes at Month 6|Change From Baseline in Monocytes at Month 12|Change From Baseline in Total Neutrophils at Month 1|Change From Baseline in Total Neutrophils at Month 3|Change From Baseline in Total Neutrophils at Month 6|Change From Baseline in Total Neutrophils at Month 12|Change From Baseline in Platelets at Month 1|Change From Baseline in Platelets at Month 3|Change From Baseline in Platelets at Month 6|Change From Baseline in Platelets at Month 12|Change From Baseline in Red Blood Cells at Month 1|Change From Baseline in Red Blood Cells at Month 3|Change From Baseline in Red Blood Cells at Month 6|Change From Baseline in Red Blood Cells at Month 12|Change From Baseline in White Blood Cells at Month 1|Change From Baseline in White Blood Cells at Month 3|Change From Baseline in White Blood Cells at Month 6|Change From Baseline in White Blood Cells at Month 12|Number of Participants With Laboratory Common Terminology Criteria for Adverse Events (CTCAE) Grade Greater or Equal to 3","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040144","August 2004","April 2007","April 2007","November 8, 2004","January 13, 2014","March 15, 2017",,,"https://ClinicalTrials.gov/show/NCT00095498"
635,"NCT00095277","Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer",,"Completed","No Results Available","Anemia","Drug: Darbepoetin Alfa","To demonstrate benefit with respect to hematopoietic response in subjects with anemia of cancer randomized to darbepoetin alfa once every 4 weeks.|Assess efficacy|Assess PROs|Assess relationship between PROs and hemoglobin concentration|Assess safety of dose and frequency","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20030204","October 2004",,,"November 3, 2004",,"March 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00095277"
636,"NCT00095264","A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome",,"Completed","No Results Available","Myelodysplastic Syndromes","Drug: Darbepoetin Alfa","The proportion of subjects achieving an erythroid response during the 13-week test period|The proportion of subjects achieving an erythroid response during the 28-week treatment period|The change in Hb from baseline|The incidence of red blood cell (RBC) transfusions (greater than or equal to 1 unit)|The change in FACT-F from baseline","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","209","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030207","October 2004",,,"November 3, 2004",,"January 15, 2010",,,"https://ClinicalTrials.gov/show/NCT00095264"
637,"NCT00094835","Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Lung Cancer|Non-Small Cell Lung Cancer","Biological: Panitumumab|Drug: Motesanib diphosphate|Drug: Paclitaxel|Drug: Carboplatin","Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1|Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1|Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1|Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1|Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1|Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2|Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2|Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2|Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2|Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2|Percentage of Participants With an Overall Objective Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040153","January 2005","March 2007","March 2007","October 27, 2004","March 24, 2014","March 24, 2016",,,"https://ClinicalTrials.gov/show/NCT00094835"
638,"NCT00094822","Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Lung Cancer|Non-Small Cell Lung Cancer","Other: PI Discretion","incidence of infection","Amgen","All","18 Years and older   (Adult, Older Adult)",,"90","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20030123","July 2003","December 2005","February 2006","October 27, 2004",,"February 13, 2009",,,"https://ClinicalTrials.gov/show/NCT00094822"
639,"NCT00094809","Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer",,"Completed","Has Results","Colon Cancer|Colorectal Cancer|Rectal Cancer","Drug: Placebo|Drug: Pegfilgrastim","Grade 3 or 4 Neutropenia|Grade 4 Neutropenia|Dose Delay or Reduction Due to Neutropenia|Dose Delay or Reduction for Any Reason|Febrile Neutropenia|Hospitalization Due to a Neutropenia-Related Event|Progression-Free Survival|Objective Tumor Response|Survival|Antibiotic Use Due to Febrile Neutropenia","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20020715","February 1, 2003","May 19, 2006","January 23, 2008","October 26, 2004","January 6, 2011","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00094809"
640,"NCT00094484","Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis",,"Completed","No Results Available","Kidney Disease|Chronic Kidney Disease","Drug: Cinacalcet HCl","Proportion of subjects with a mean reduction of greater than or equal to 30% in iPTH at 32 weeks|Changes in iPTH at 32 weeks.|Safety and tolerability of cinacalcet at 32 weeks.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","20000178","October 2004",,,"October 20, 2004",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00094484"
641,"NCT00094341","Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","The proportion of patients preferring the etanercept auto-injector to the etanercept pre-filled syringe.|The proportion of patients preferring the etanercept auto-injector to the etanercept pre-filled syringe as well as to the lyophilized preparation in the following categories:|Ease of use|Hand discomfort during the injection|Satisfaction with number of steps|Time involved with the injection|Nervousness with injection|Confidence with the injection|Convenience of use and|Overall preference with the auto-injector or pre-filled syringes compared to the lyophilized preparation.|To characterize the ability of patients to properly use by themselves either device independently and identify any sections of the instructions that were not clear, that may have led to loss of sterility to incomplete dosing","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040201","October 2004",,,"October 18, 2004",,"December 5, 2008",,,"https://ClinicalTrials.gov/show/NCT00094341"
642,"NCT00093977","Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease",,"Completed","No Results Available","Kidney Disease|Chronic Kidney Disease","Drug: darbepoetin alfa SF","To determine whether darbepoetin alfa manufactured by a roler bottle technology (darbepoetin alfa RB) and darbepoetin alfa manufactured by a serum free process (darbepoetin alfa SF) have a comparable safety profile|To characterize laboratory parameters in subjects with CKD","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040180","October 2004","January 2007","January 2007","October 11, 2004",,"May 24, 2013",,,"https://ClinicalTrials.gov/show/NCT00093977"
643,"NCT00093873","Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Tumors","Drug: Anti-angiogenesis|Drug: AMG 706","Dose limiting toxicity|Dose selection","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","71","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030116","July 2003","February 2006","December 2006","October 8, 2004",,"May 15, 2013",,,"https://ClinicalTrials.gov/show/NCT00093873"
644,"NCT00093015","Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)",,"Completed","Has Results","Kidney Disease|Diabetes Mellitus|Anemia","Drug: Placebo|Drug: darbepoetin alfa","Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)|Time to All-cause Mortality or End Stage Renal Disease (ESRD)|Time to All-cause Mortality|Time to Cardiovascular Mortality|Time to Myocardial Infarction|Time to Cerebrovascular Accident|Time to Congestive Heart Failure|Time to End Stage Renal Disease|Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline|Change in Patient Reported Fatigue Relative to Baseline at Week 25|Time to Hospitalization Due to Acute Myocardial Ischemia","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","4038","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010184|TREAT","August 1, 2004","March 1, 2009","July 1, 2009","September 29, 2004","September 2, 2010","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00093015"
645,"NCT00091858","Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer",,"Completed","No Results Available","Anemia|Cancer","Drug: Darbepoetin Alfa|Drug: Placebo","Occurrences of red blood cell transfusion|Incidence of first red blood cell transfusion|Change in hemoglobin concentration measured|Adverse events and serious adverse events|Survival|Incidence, if any, of neutralizing antibody formation to investigational product","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010103","April 2004","October 2006","December 2006","September 21, 2004",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00091858"
646,"NCT00091832","Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer|Metastases|Bone Metastases in Subjects With Advanced Breast Cancer","Biological: Denosumab|Drug: IV Bisphosphonates","Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)|Percent Change From Baseline to Week 25 in Urinary N-telopeptide (uNTx)|Number of Participants Achieving 65% or More Reduction in Urinary N-telopeptide (uNTx) From Baseline at Week 13|Number of Participants Achieving 65% or More Reduction in uNTX From Baseline at Week 25|Time to 65% or More Reduction in Urinary N-telopeptide (uNTX) From Baseline|Percent Change From Baseline to Week 13 in Serum C-Telopeptide (CTX)|Percent Change From Baseline to Week 25 in Serum C-telopeptide (CTX)|Percent Change From Baseline to Week 13 in Procollagen I N-terminal Peptide (P1NP)|Percent Change From Baseline to Week 25 in P1NP|Percent Change From Baseline to Week 13 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)|Percent Change From Baseline to Week 25 in Tartrate-resistant Acid Phosphatase 5b (TRAP5b)|Percent Change From Baseline to Week 13 in Bone Specific Alkaline Phosphatase (BSAP)|Percent Change From Baseline to Week 25 in Bone Specific Alkaline Phosphatase (BSAP)|Percent Change From Baseline to Week 13 in Osteocalcin|Percent Change From Baseline to Week 25 in Osteocalcin|Time to First Skeletal Related Event|Number of Participants With Skeletal Related Events|Number of Participants With Hypercalcemia","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20040113","September 2004","November 2005","October 2006","September 21, 2004","January 7, 2011","January 28, 2014",,,"https://ClinicalTrials.gov/show/NCT00091832"
647,"NCT00091806","Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Tumors|Oncology|Solid Tumors","Drug: panitumumab (ABX-EGF)|Drug: Panitumumab","To evaluate the safety and PK of 2 dose schedules of panitumumab in subjects with advanced solid tumors, refractory to or with no available standard therapy.|To asses the immunogenicity and efficacy of 2 dose schedules of panitumumab in subjects with advanced solid tumors.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030251","August 2004","April 2006","October 2006","September 21, 2004",,"July 10, 2009",,,"https://ClinicalTrials.gov/show/NCT00091806"
648,"NCT00091793","Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis",,"Completed","Has Results","Postmenopausal Osteoporosis","Drug: AMG 162|Drug: Placebo","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24|Total Hip Bone Mineral Density Percent Change From Baseline at Month 24|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24|Trochanter Bone Mineral Density Percent Change From Baseline at Month 24|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24|Total Body (Without Head) Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Trabecular Volumetric Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Cortical Volumetric Bone Mineral Density Percent Change From Baseline at Month 24|Distal Radius Total Volumetric Bone Mineral Density Percent Change From Baseline at Month 24","Amgen","Female","up to 90 Years   (Child, Adult, Older Adult)","Phase 3","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20040132","August 2004","February 2009","March 2009","September 21, 2004","January 26, 2010","December 31, 2010",,,"https://ClinicalTrials.gov/show/NCT00091793"
649,"NCT00089960","Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)",,"Completed","No Results Available","Gastrointestinal Cancer","Drug: AMG 706","Objective response rate as defined using modified RECIST criteria.|Progression-free survival|Overall survival|Time to progression|Time to response|Patient-reported outcomes|Use of opioid analgesics after minimal 6 months treatment|Objective response by PET and tumor size/density changes at week 8|Objective response by size changes and/or target tumor density changes at week 8|Safety Endpoints: Incidence of adverse events (including all, serious, grade 3, grade 4 and treatment related)|Duration of response|Palliative response|Pharmacokinetic Endpoints: 1. The AMG 706 PK parameters (Cmax, t1/2, AUC0-24, C24); 2. To explore the PK/PD relationships","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040110","October 2004","June 2006","June 2008","August 20, 2004",,"April 29, 2013",,,"https://ClinicalTrials.gov/show/NCT00089960"
650,"NCT00089791","A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis",,"Completed","Has Results","Osteoporosis","Drug: placebo|Drug: Denosumab","Number of Participants With New Vertebral Fractures|Number of Participants With Nonvertebral Fractures|Number of Participants With a Hip Fracture","Amgen","Female","60 Years to 90 Years   (Adult, Older Adult)","Phase 3","7808","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20030216","August 1, 2004","June 17, 2008","June 17, 2008","August 16, 2004","January 10, 2014","February 4, 2019",,,"https://ClinicalTrials.gov/show/NCT00089791"
651,"NCT00089674","AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer",,"Completed","Has Results","Prostate Cancer","Drug: AMG 162|Drug: Placebo","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24|Total Hip Bone Mineral Density Percent Change From Baseline at Month 24|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36|Total Hip Bone Mineral Density Percent Change From Baseline at Month 36|Number of Participants With Any Fracture Through Month 36|Number of Participants With a New Vertebral Fracture Through Month 36|Time to First Clinical Fracture Through Month 36|Number of Participants With Any Fracture Through Month 24","Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040138|HALT Prostate Cancer","August 1, 2004","May 16, 2008","May 11, 2010","August 11, 2004","June 3, 2014","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00089674"
652,"NCT00089661","AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer|Low Bone Mineral Density|Osteopenia","Drug: Placebo|Drug: AMG 162 / Denosumab","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6|Total Hip Bone Mineral Density Percent Change From Baseline at Month 12|Total Hip Bone Mineral Density Percent Change From Baseline at Month 6|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12|Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20040135","October 1, 2004","May 11, 2007","May 27, 2009","August 11, 2004","January 26, 2010","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00089661"
653,"NCT00089635","Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer|Metastases","Drug: Panitumumab","Objective Tumor Response Through Week 16|Duration of Response|Objective Tumor Response Throughout the Study|Time to Initial Objective Response|Progression-free Survival Time|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease|Overall Survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","203","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030250","August 1, 2004","January 1, 2007","August 1, 2008","August 11, 2004","December 5, 2013","October 17, 2018",,,"https://ClinicalTrials.gov/show/NCT00089635"
654,"NCT00086086","Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia",,"Completed","No Results Available","Congestive Heart Failure|Anemia","Drug: Darbepoetin Alfa","Rate of rise of hemoglobin concentration|Change in left ventricular ejection fraction|Change in 6-minute walk distance|NYHA classification|Patient-reported outcomes","Amgen","All","21 Years and older   (Adult, Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020171","August 2003",,,"June 24, 2004",,"February 10, 2017",,,"https://ClinicalTrials.gov/show/NCT00086086"
655,"NCT00083616","Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy",,"Completed","Has Results","Colorectal Cancer|Metastatic Cancer","Biological: Panitumumab","Number of Participants With Objective Tumor Response Through Week 16|Duration of Response|Number of Participants With Objective Tumor Response Throughout Study|Time to Response|Progression-free Survival Time|Time to Disease Progression|Time to Treatment Failure|Duration of Stable Disease|Overall Survival","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","185","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20030167","March 2004","May 2007","December 2008","May 28, 2004","July 29, 2011","January 10, 2014",,,"https://ClinicalTrials.gov/show/NCT00083616"
656,"NCT00078819","Etanercept (Enbrel®) in Psoriasis - Pediatrics",,"Completed","Has Results","Psoriasis","Drug: Etanercept|Drug: Placebo","Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12|Percentage of Participants Achieving a ≥ 50% Improvement in PASI Score (PASI 50) at Week 12|Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) at Week 12|Percent Improvement From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 12|Percentage of Participants Achieving a ≥ 90% Improvement in PASI Score (PASI 90) at Week 12|Number of Participants With Adverse Events During the Double-blind Treatment Period|Etanercept Serum Concentration","Amgen","All","4 Years to 17 Years   (Child)","Phase 3","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20030211","September 8, 2004","February 1, 2006","June 1, 2007","March 9, 2004","July 29, 2019","July 29, 2019",,,"https://ClinicalTrials.gov/show/NCT00078819"
657,"NCT00078806","Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis",,"Terminated","Has Results","Juvenile Rheumatoid Arthritis","Drug: Etanercept|Drug: Placebo","Number of Participants in Part 2 With Disease Flare|Number of Participants With Adverse Events|Time to Flare in Part 2|Change From Baseline in Physician Global Assessment of Disease Severity in Part 1|Change From Baseline in Physician Global Assessment of Disease Severity in Part 2|Change From Baseline in Patient's/Parent's Global Assessment in Part 1|Change From Baseline in Patient's/Parent's Global Assessment of Disease Severity in Part 2|Change From Baseline in Number of Active Joints in Part 1|Change From Baseline in Number of Active Joints in Part 2|Change From Baseline in Number of Joints With Limitation of Motion in Part 1|Change From Baseline in Number of Joints With Limitation of Motion in Part 2|Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 1|Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2|Change From Baseline in C-reactive Protein (CRP) Levels in Part 1|Change From Baseline in C-reactive Protein (CRP) Levels in Part 2","Amgen|Immunex Corporation","All","2 Years to 18 Years   (Child, Adult)","Phase 3","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20021631","June 4, 2001","May 6, 2004","May 6, 2004","March 9, 2004","September 25, 2019","September 25, 2019",,,"https://ClinicalTrials.gov/show/NCT00078806"
658,"NCT00078793","Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis",,"Completed","No Results Available","Juvenile Rheumatoid Arthritis","Drug: Enbrel®","Adverse event rates and severity|Growth data and Tanner scores","Amgen|Immunex Corporation","All","2 Years to 18 Years   (Child, Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20021626|016.0026","June 2000","January 2008","January 2008","March 9, 2004",,"May 14, 2013",,,"https://ClinicalTrials.gov/show/NCT00078793"
659,"NCT00066092","Pegfilgrastim PBPC Mobilization Study",,"Completed","No Results Available","Lymphoma|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Hematology|Oncology","Drug: pegfilgrastim 12 mg|Drug: filgrastim|Drug: pegfilgrastim 6 mg","CD34+ collection during the collection phase|Time to ANC and platelet engraftment post-transplant","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20020112","April 2003","March 2004","October 2004","August 5, 2003",,"February 28, 2008",,,"https://ClinicalTrials.gov/show/NCT00066092"
660,"NCT00049985","Heart Failure and Anemia",,"Completed","No Results Available","Heart Failure|Anemia","Drug: Darbepoetin Alfa","Exercise tolerance|NYHA classification; patient-reported outcomes","Amgen","All","21 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20010170","July 2002",,,"November 19, 2002",,"August 7, 2009",,,"https://ClinicalTrials.gov/show/NCT00049985"
661,"NCT00044902","Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: epratuzumab",,"Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","20010138",,,,"September 9, 2002",,"December 28, 2007",,,"https://ClinicalTrials.gov/show/NCT00044902"
662,"NCT00043186","Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density",,"Completed","Has Results","Low Bone Mineral Density","Drug: Placebo|Drug: Denosumab|Drug: Alendronate","Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms|Serum CTX Percent Change From Baseline at Month 12|Urine NTX/Creatinine Percent Change From Baseline at Month 12|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Alendronate Arm|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 42|Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 48|Serum CTX Percent Change From Baseline at Month 24|Serum CTX Percent Change From Baseline at Month 36|Serum CTX Percent Change From Baseline at Month 42|Serum CTX Percent Change From Baseline at Month 48|Urine NTX/Creatinine Percent Change From Baseline at Month 24|Urine NTX/Creatinine Percent Change From Baseline at Month 36|Urine NTX/Creatinine Percent Change From Baseline at Month 42|Urine NTX/Creatinine Percent Change From Baseline at Month 48|Total Hip Bone Mineral Density Percent Change From Baseline at Month 12|Total Hip Bone Mineral Density Percent Change From Baseline at Month 24|Total Hip Bone Mineral Density Percent Change From Baseline at Month 36|Total Hip Bone Mineral Density Percent Change From Baseline at Month 42|Total Hip Bone Mineral Density Percent Change From Baseline at Month 48|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 24|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 36|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 42|Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 48|Total Body Bone Mineral Density Percent Change From Baseline at Month 12|Total Body Bone Mineral Density Percent Change From Baseline at Month 24|Total Body Bone Mineral Density Percent Change From Baseline at Month 36|Total Body Bone Mineral Density Percent Change From Baseline at Month 42|Total Body Bone Mineral Density Percent Change From Baseline at Month 48|Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 12|Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 24|Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 36|Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 42|Bone Specific Alkaline Phosphatase Percent Change From Baseline at Month 48","Amgen","Female","up to 80 Years   (Child, Adult, Older Adult)","Phase 2","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010223","May 2002","April 2007","June 2007","August 7, 2002","July 28, 2010","September 18, 2013",,,"https://ClinicalTrials.gov/show/NCT00043186"
663,"NCT00042653","A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis",,"Completed","No Results Available","Secondary Hyperparathyroidism|End Stage Renal Disease","Drug: Placebo|Drug: AMG 073","To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.|To evaluate the efficacy of AMG 073 compared with placebo by determining: the proportion of subjects with a reduction from baseline in mean iPTH of >= 30% during the efficacy assessment phase|To evaluate the efficacy of AMG 073 compared with placebo by determining: percentage change from baseline in iPTH during the efficacy assessment phase|To evaluate the safety of AMG 073 compared with placebo","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20000188","May 2002","July 2003","July 2003","August 6, 2002",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00042653"
664,"NCT00042432","Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients",,"Completed","Has Results","Secondary Hyperparathyroidism|Chronic Renal Insufficiency","Drug: cinacalcet (AMG 073)","Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase|Percentage Change From Baseline in Mean iPTH During the Efficacy Assessment Phase","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20010239","June 2002","March 2003","August 2003","August 1, 2002","March 1, 2011","May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00042432"
665,"NCT00041665","Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy",,"Completed","No Results Available","Stomatitis","Drug: Recombinant Human Keratinocyte Growth Factor",,"Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","20000162|NLM Identifier NCT00020813|UCLA-0012064|MSKCC-01065|FHCRC-161200",,,,"July 15, 2002",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00041665"
666,"NCT00038298","A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Placebo|Drug: AMG 719|Drug: AGM 719|Drug: placebo to AMG 719","AMG 719 has a favorable safety profile in subjects with RA receiving methotrexate.|To assess the effects of multiple doses of AMG 719 relative to placebo on signs and symptoms of RA","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20010238","April 2002","May 2004","May 2004","May 31, 2002",,"January 21, 2011",,,"https://ClinicalTrials.gov/show/NCT00038298"
667,"NCT00038064","Anemia in Patients With a Non-Myeloid Malignancy",,"Completed","No Results Available","Neoplasms|Anemia","Drug: Darbepoetin alfa|Drug: rHuEPO","Time to first hemoglobin response during the treatment period|Overall incidence of adverse events, serious adverse events, and severe or life threatening adverse events|Incidence, if any, of neutralizing antibody formation to study drug (darbepoetin alfa or rHuEPO)|Average weekly dosage of study drug during the 16-week treatment period|Receiving red blood cell (RBC) transfusion from week 5 to week 12|Change in FACT-Fatigue scale score from baseline to week 7|Percentage of subjects who have a rapid rate of hemoglobin concentration rise and negative clinical consequences associated with this rise|Profile of change in FACT-Fatigue scale score from baseline over the treatment period|Change in FACT-Fatigue scale score from baseline to End of Treatment Period (EOTP)|Change in FACT-Physical Well-being scale score from baseline to EOTP|Receiving RBC transfusion during the treatment period|Number of units of RBC transfused during the treatment period|Achieving a hemoglobin response by week 7|Change in hemoglobin concentration from baseline to EOTP|Time to first hematopoietic response|Achieving a hemoglobin correction|Number and percentage of subjects who exceed the hemoglobin concentration threshold","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","707","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010101","January 2002","October 2003","April 2004","May 29, 2002",,"September 15, 2008",,,"https://ClinicalTrials.gov/show/NCT00038064"
668,"NCT00037635","A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients",,"Completed","No Results Available","Secondary Hyperparathyroidism|End Stage Renal Disease","Drug: AMG 073|Drug: Placebo","To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.|To evaluate the efficacy of AMG 073 compared with placebo by determining: percentage change from baseline in mean calcium x phosphorus product (Ca x P) during the efficacy assessment phase|To evaluate the efficacy of AMG 073 compared with placebo by determining: changes in self-reported cognitive function from baseline to the end of the efficacy assessment phase|To evaluate the safety of AMG 073 compared with placebo.","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20000172","December 2001","March 2003","March 2003","May 20, 2002",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00037635"
669,"NCT00037518","A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer",,"Completed","No Results Available","Hyperparathyroidism|Parathyroid Neoplasms","Drug: AMG 073","Changes in serum calcium and PTH|Safety and tolerability of cinacalcet","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000204","April 2001",,,"May 20, 2002",,"May 8, 2013",,,"https://ClinicalTrials.gov/show/NCT00037518"
670,"NCT00036023","Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies",,"Completed","No Results Available","Lymphoma|Breast Neoplasms|Lung Neoplasms|Multiple Myeloma|Chronic Lymphocytic Leukemia","Drug: darbepoetin alfa",,"Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010162",,,,"May 8, 2002",,"May 11, 2009",,,"https://ClinicalTrials.gov/show/NCT00036023"
671,"NCT00035620","Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy",,"Completed","No Results Available","Sarcoma|Neutropenia","Drug: pegfilgrastim|Drug: filgrastim","Duration of severe neutropenia in chemotherapy in cycles 1 and 3|Time to ANC recovery to greater than or equal to 0.5 x 10^9/L in cycles 1 and 3|Pharmacokinetic profile in chemotherapy cycles 1 and 3|Incidence of adverse events across all cycles of chemotherapy|Overall rates of febrile neutropenia","Amgen","All","up to 21 Years   (Child, Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","990130","April 2000","January 2007","April 2007","May 6, 2002",,"February 26, 2010",,,"https://ClinicalTrials.gov/show/NCT00035620"
672,"NCT00035607","Chemotherapy Related Anemia",,"Completed","No Results Available","Anemia|Non-Myeloid Malignancies","Drug: Darbepoetin alfa SC|Drug: Darbepoetin alfa IV","Change in hemoglobin concentration measured from baseline to the end of treatment period (EOTP)|Percentage of subjects who have a rapid rise in hemoglobin concentration; negative clinical consequences potentially associated with this rise evaluated in subjects with and without a rapid rise in hemoglobin concentration|Change in hemoglobin concentration measured from baseline to week 7 and from week 7 to EOTP|Time to and percentage of subjects who achieve hemoglobin improvement during the treatment period|Time to and percentage of subjects with a hemoglobin response during the treatment period|Percentage of subjects who exceed the hemoglobin threshold|Incidence of all adverse events, serious adverse events, and severe or life-threatening adverse events|Incidence, if any, of neutralizing antibody formation to darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20010199","December 2001","December 2002","April 2003","May 6, 2002",,"May 13, 2013",,,"https://ClinicalTrials.gov/show/NCT00035607"
673,"NCT00035594","Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy",,"Completed","No Results Available","Neutropenia","Drug: pegfilgrastim","Proportion of subjects developing febrile neutropenia|Incidence of hospitalization and IV antiinfective use associated with FN; also chemotherapy planned dose on time","Amgen",,"Child, Adult, Older Adult","Phase 3","928","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","20010144","February 2002","February 2004","June 2004","May 6, 2002",,"May 9, 2013",,,"https://ClinicalTrials.gov/show/NCT00035594"
674,"NCT00034346","ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-Small Cell Lung Cancer|Neoplasm Metastasis|Lung Cancer","Drug: ABX-EGF|Drug: paclitaxel|Drug: carboplatin","Time to Disease Progression|Best Overall Response Rate|Response Rate at Week 5|Survival Time|Progression Free Survival|Rate of Progressive Disease at Week 11|Incidence of AEs|Lab Abnormalities and other Safety Parameters|PK of Panitumumab in Combination with Carboplatin and Paclitaxel|Quality of Life","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20025404","January 2002",,,"April 26, 2002",,"December 24, 2007",,,"https://ClinicalTrials.gov/show/NCT00034346"
675,"NCT00756860","A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)",,"Completed","No Results Available","Healthy Volunteers","Drug: AMG 223|Drug: Renagel® (sevelamer hydrochloride)","To compare the effects of 2g AMG 223 and 2g Renagel® on 24 hour urinary phosphorous excretion after multiple doses in healthy volunteers.|To compare the effects of 2g AMG 223 and 2g Renagel® on 24 hour fecal phosphorous excretion after multiple doses in healthy volunteers.|To assess safety and tolerability of multiple doses of 2g AMG 223 in healthy volunteers.","Amgen Research (Munich) GmbH|Amgen","All","18 Years to 45 Years   (Adult)","Phase 1","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20070885","May 2008","August 2008","September 2009","September 22, 2008",,"June 4, 2012",,,"https://ClinicalTrials.gov/show/NCT00756860"
676,"NCT01741792","Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Blinatumomab","Overall Objective Response Rate During Treatment Cycle 1|Percentage of Participants With a Best Overall Response of Complete Response|Percentage of Participants With a Best Overall Response of Partial Response|Duration of Objective Response|Duration of Complete Response|Duration of Partial Response|Progression-free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events|Blinatumomab Steady State Serum Concentration|Leukocyte Counts|Lymphocyte Counts|Monocyte Counts|Granulocyte Count|CD19+ B-Cell Count|CD19+ B-Cells as a Percentage of All Lymphocytes|CD3+ T-Cell Count|CD3+ T-Cells as a Percentage of All Lymphocytes|CD4+ T-Cell Count|CD4+ T-Cells as a Percentage of All Lymphocytes|CD8+ T-Cell Count|CD8+ T-Cells as a Percentage of All Lymphocytes|CD19+ B-Cell to CD3+ T-Cell Ratio|CD4+ T-Cell to CD8+ T-Cell Ratio|CD4+ Naive T Cell Count|CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells|CD4+ Central Memory T-Cell (TCM) Count|CD4+ TCM Cells as a Percentage of All CD4+ T-Cells|CD4+ Effector Memory T-Cell (TEM) Count|CD4+ TEM Cells as a Percentage of All CD4+ T-Cells|CD8+ Naive T-Cell Count|CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells|CD8+ TCM Cell Counts|CD8+ TCM Cells as a Percentage of All CD8+ T-Cells|CD8+ Effector Memory T-Cell (TEM) Count|CD8+ TEM Cells as a Percentage of All CD8+ T-Cells|CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count|CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-208|2011-005781-38","July 2012","July 2014","September 2015","December 5, 2012","July 27, 2015","January 6, 2017","Universitätsmedizin, Göttingen, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Schleswig Holstein, Kiel, Germany|Klinikum der Johannes-Gutenberg Universität, Mainz, Germany|Universitätsklinikum, Ulm, Germany|Universititätsklinikum, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01741792"
677,"NCT01471782","Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",,"Completed","Has Results","Acute Lymphoblastic Leukemia","Biological: Blinatumomab","Phase I: Number of Participants With Dose-limiting Toxicities (DLTs)|Percentage of Participants With Complete Remission in the First Two Cycles|Number of Participants With Adverse Events|Steady State Concentration of Blinatumomab|Time to Hematological Relapse (Duration of Response)|Overall Survival|Relapse-free Survival|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant During Blinatumomab Induced Remission|Number of Participants Who Developed Anti-blinatumomab Antibodies|Serum Cytokine Peak Levels","Amgen Research (Munich) GmbH","All","up to 17 Years   (Child)","Phase 1|Phase 2","93","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-205|2010-024264-18","January 2012","August 2014","May 2016","November 16, 2011","February 8, 2017","February 8, 2017","Children's Hospital Denver, Aurora, Colorado, United States|Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Washington University, ST. Louis, Missouri, United States|Memorial Sloan Kettering, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Cancer Center/ Baylor, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|St. Anna Kinderspital, Vienna, Austria|Hospital for Sick Children, Toronto, Ontario, Canada|(CHU Besancon) Hopital Saint-Jaques, Besancon, France|Hôpital de la Timone (Enfants), Marseille, France|Hopital Robert Debré (AP-HP), Paris Cedex 19, France|Charité Campus Virchow Klinikum, Otto-Heubner-Centrum (OHC) für Kinder- und Jugendmedizin, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main, Frankfurt am Main, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum der Universität München, Dr. von Haunersches Kinderspital, München, Germany|Universitätsklinik für Kinder- und Jugendmedizin Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|University of Milano-Bicocca, Hospital San Gerardo, Monza, Italy|Dipartimento della Donna e del Bambino, Padova, Italy|The Bambino Gesù Children's Hospital, Rome, Italy|Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01471782"
678,"NCT01466179","Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)",,"Completed","Has Results","Acute Lymphoblastic Leukemia","Biological: Blinatumomab","Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Time to Hematological Relapse (Duration of Response)|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission|Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment|Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment|Relapse-free Survival|Event-free Survival|Overall Survival|Number of Participants With Treatment-emergent Adverse Events|100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant|Serum Blinatumomab Concentration at Steady State|Serum Cytokine Peak Levels|Percentage of Participants With a Best Response of Blast Free Hypoplastic or Aplastic Bone Marrow Within 2 Cycles of Treatment|Best Response During the Core Study","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","225","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-211|2011-002257-61","December 2011","October 2013","January 2017","November 6, 2011","January 22, 2015","August 18, 2017","City of Hope, Duarte, California, United States|University of California Los Angeles, Los Angeles, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Streets, Buffalo, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CHU d'Angers, Angers, France|Hôpital de l'hôtel Dieu, Nantes, France|Hôpital Saint Louis, Paris, France|CHU de Purpan, Toulouse, France|Charité - Campus Benjamin Franklin, Berlin, Germany|Klinikum der Goethe Universität, Medizinische Klinik II, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Julius-Maximilians-Universität, Medizinische Klinik und Poliklinik II, Würzburg, Germany|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Antonio Cardarelli, Naples, Italy|Ospedali Riuniti ""Villa Sofia-Cervello"", Palermo, Italy|Università La Sapienza di Roma, Rome, Italy|Azienda Ospedaliero-Universitaria, Turin, Italy|Azienda Ospedaliera di Verona, Verona, Italy|ICO Hospital Germans Trias I Pujol, Badalona, Spain|Hospital Clínic Servei d´Hematologia, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|University Hospitals Bristol NHS, Bristol, United Kingdom|Royal Free Hampstead NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01466179"
679,"NCT01209286","Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)",,"Completed","Has Results","B-ALL","Biological: Blinatumomab","Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment|Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment|Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment|Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study|Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab|Time to Hematological Relapse|Relapse-free Survival|Overall Survival|Number of Participants With Treatment-emergent Adverse Events|Steady State Blinatumomab Concentration|Clearance of Blinatumomab|Serum Cytokine Peak Levels","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-206","October 2010","March 2012","October 2016","September 27, 2010","January 7, 2015","March 6, 2017","Frankfurt, Germany|Freiburg, Germany|Hannover, Germany|Kiel, Germany|Münster, Germany|Regensburg, Germany|Tübingen, Germany|Ulm, Germany|Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01209286"
680,"NCT01207388","Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)","BLAST","Completed","Has Results","B-cell Acute Lymphoblastic Leukemia","Drug: Blinatumomab","Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle|Hematological Relapse-free Survival (RFS)|Overall Survival|100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant|Time to Hematological Relapse|Duration of Complete MRD Response|Change in MRD Level From Baseline to End of Cycle 1 in Non-MRD Responders|Number of Participants With Adverse Events|Change From Baseline in EORTC-QLQ-C30 Scales|Change From Baseline in EuroQoL 5-Dimension (EQ-5D) Scales|Resource Utilization","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-203","November 2010","February 2014","January 7, 2019","September 22, 2010","February 12, 2015","February 26, 2019","1102 - LKH Graz, Graz, Austria|1107 - Krankenhaus der Elisabethinen, Linz, Austria|1106, Salzburg, Austria|1101 - AKH Wien, Vienna, Austria|1504, Antwerpen, Belgium|1502 - Cliniques Universitaires de Saint-Luc, Brussels, Belgium|1505, Brügge, Belgium|1503, Gent, Belgium|1501 - Cliniques Universitaires UCL de Mont Godinne, Yvoir, Belgium|1211 - CHU d'Angers, Angers, France|1210 - CHU de Besançon, Besançon, France|1206 - Hôpital de Pontoise, Cergy Pontoise, France|1205 - CHU Henri Mondor, Créteil, France|1209 - CHU de Lyon, Lyon, France|1212 - Hôpital de l'hôtel Dieu, Nantes, France|1213 - Centre Hospitalier Universitaire de Nice, Nice, France|1201 - Hôpital Saint Louis, Paris, France|1202 - CHU de Bordeaux - Hôpital Haut Lévêque, Pessac, France|1208 - CHU de Purpan, Toulouse, France|1011 - Charité Berlin, Berlin, Germany|1022 - Universitätsklinkum Carl Gustav Carus Dresden, Dresden, Germany|1009 - Universitätsklinikum Essen, Essen, Germany|1002 - Klinikum der Goethe Universität, Frankfurt, Germany|1014 - Asklepiosklinik St. Georg, Hamburg, Germany|1018 - Medizinische Hochschule Hannover, Hannover, Germany|1012 - Universitätsklinikum Heidelberg, Heidelberg, Germany|1003 - Universitätsklinikum Schleswig-Holstein, Kiel, Germany|1019 - Universitätsklinikum Leipzig, Leipzig, Germany|1010 - Klinikum der Universität München - Großhadern, Munich, Germany|1004 - Universitätsklinikum Münster, Münster, Germany|1016 - Universitätsklinikum Regensburg, Regensburg, Germany|1020 - Universitätsklinikum Rostock, Rostock, Germany|1007 - Robert-Bosch-Krankenhaus, Stuttgart, Germany|1015 - Universitätsklinikum Tübingen, Tübingen, Germany|1005 - Universitätsklinikum Ulm, Ulm, Germany|1001 - Julius-Maximilians-Universität Würzburg, Würzburg, Germany|1301 - Ospedali Riuniti di Bergamo, Bergamo, Italy|1303 - Istituto di Ematologia ""L.& A.Seràgnoli"" Azienda, Bologna, Italy|1314 - Azienda Ospedaliera Spedali Civili Brescia, Brescia, Italy|1313 - Universita di Catania, Catania, Italy|1312 - Azienda Ospedaliera Universitaria San Martino, Genoa, Italy|1305 - Ospedale San Gerardo, Monza, Italy|1309 - Azienda Ospedaliera Antonio Cardarelli, Napoli, Italy|1308 - Ospedali Riuniti ""Villa Sofia-Cervello"", Palermo, Italy|1302 - Università La Sapienza di Roma, Rome, Italy|1310 - Fondazione Policlinico Tor Vergata, Rome, Italy|1315 - Azienda Ospedaliero-Universitaria S. Giovanni Battista (Le Molinette), Torino, Italy|1311 - Azienda Ospedaliera di Verona, Verona, Italy|2204 - UMC Groningen, Groningen, Netherlands|2201 - Daniel Den Hoed Hospitaal, Rotterdam, Netherlands|1905 - Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Poland|1907 - Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|1908 - Swietokrzyskie Centrum Onkologii, Kielce, Poland|1902 - Uniwersytet Medyczny w Lublinie, Lublin, Poland|1901 - Klinika Hematologii - Instytut Hematologii i Transfuzjologii, Warsaw, Poland|1906 - MTZ Clinical Research Sp. z o.o., Warsaw, Poland|1904 - Samodzielny Publiczny, Wrocław, Poland|2101 - Institutul Clinic Fundeni, Hematologie II, Bucharest, Romania|2102 - Spitalul Clinic Coltea, Hematologie, Bucharest, Romania|2106 - Institutul Oncologic ""Prof. Dr. I. Chiricuta"", Cluj-Napoca, Romania|2105 - Institutul Regional de Oncologie, Iasi, Romania|2001 - Russian Hematology Research Center, Moscow, Russian Federation|2003 - Municipal Hospital No. 15, St. Petersburg, Russian Federation|1401 - ICO Hospital Germans Trias I Pujol, Badalona, Spain|1404 - Hospital Clínic Servei d´Hematologia, Barcelona, Spain|1402 - Complexo Hospitalario Universitario A Coruña, La Coruña, Spain|1408 - Hospital 12 de Octubre, Madrid, Spain|1405 - Hospital Universitari Son Espases, Mallorca, Spain|1407 - Unidad de Citogenética Oncológica, Salamanca, Spain|1406 - Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain|1605 - Queen Elizabeth Hospital, Birmingham, United Kingdom|1602 - Bristol Royal Infirmary, Bristol, United Kingdom|1604 - University Hospital of Wales, Cardiff, United Kingdom|1601 - Royal Free Hospital, London, United Kingdom|1607 - Nottingham City Hospital NHS Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01207388"
681,"NCT00866944","Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases","MT201-204","Completed","No Results Available","Liver Metastases|Colorectal Cancer","Drug: Adecatumumab|Drug: Adecatumumab and FOLFOX|Drug: FOLFOX 4","Disease free survival rate (DFS)|time to relapse|Incidence of AEs|Quality of Life","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT201-204","March 2009","July 2011","November 2011","March 23, 2009",,"November 11, 2011","Centre Paul Strauss, Strasbourg, France|Zentralklinikum Augsburg, Augsburg, Germany|Klinikum am Bruderwald, Sozialstiftung Bamberg, Bamberg, Germany|Charité Campus Virchow Klinikum, Berlin, Germany|Klinikum der Heinrich-Heine Universität, Düsseldorf, Germany|J.W. Goethe-Universität, Frankfurt, Germany|Martin-Luther Universität, Halle, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum Magdeburg gGmbH, Magdeburg, Germany|Klinikum der Johannes-Gutenberg Universität, Mainz, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany|Universitätsklinikum der LMU Grosshadern, München, Germany|Städtisches Klinikum Neuperlach, München, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Klinikum der Universität Regensburg, Regensburg, Germany",,"https://ClinicalTrials.gov/show/NCT00866944"
682,"NCT00635596","Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer","MT110-101","Completed","No Results Available","Solid Tumors","Biological: MT110","Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities)|Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT110-101|EUDRACT No: 2007-004437-42","March 2008","January 2014","January 2015","March 14, 2008",,"January 13, 2015","University Hospital Freiburg Gynecological Clinic, Freiburg, Baden-Württemberg, Germany|University Hospital Hamburg-Eppendorf, Hamburg, Germany|Hospital Kassel, Kassel, Germany|University Hospital Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00635596"
683,"NCT00560794","Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)",,"Completed","Has Results","Acute Lymphoblastic Leukemia","Biological: Blinatumomab (MT103)","Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment|Percentage of Participants With an MRD Response After Each Treatment Cycle|Time to Hematological Relapse|Time to MRD Progression|Time to MRD Relapse|Number of Participants With Adverse Events|Change From Screening Value in B-cell Count During Cycle 1|Change From Screening Value in T-cell Count During Cycle 1|Serum Cytokine Peak Levels in Cycle 1|Serum Blinatumomab Concentration at Steady State|Area Under the Drug Concentration-time Curve From Time Zero to Infinity|Apparent Volume of Distribution|Clearance of Blinatumomab|Terminal Half-life of Blinatumomab","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-202|2006-006520-19","January 2008","September 2009","November 2014","November 20, 2007","January 7, 2015","January 26, 2015","Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Julius-Maximilians-Universität Würzburg, Würzburg, Bayern, Germany|Klinikum der J.W. Goethe Universität, Frankfurt, Hessen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein im Städtischen Krankenhaus Kiel, Kiel, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT00560794"
684,"NCT00274742","Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL",,"Completed","Has Results","Non-Hodgkin's Lymphoma, Relapsed","Biological: Blinatumomab (MT103)","Number of Participants With Adverse Events|Serum Concentration of Blinatumomab|Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)|Objective Tumor Response According to the Cheson Criteria (With Minimal Response)","Amgen Research (Munich) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT103-104","June 2004","August 2011","April 2012","January 11, 2006","January 16, 2015","January 16, 2015","Medizinische Klinik 5, Hämatologie & Internistische Onkologie, Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Essen, Germany|Universtätsklinkum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Abteilung Innere Medizin III, Ulm, Germany|Medizinische Poliklinik der Julius-Maximilians-Universität Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00274742"
685,"NCT00562380","AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma",,"Completed","No Results Available","Lymphoma|Prostate Cancer|Sarcoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: ganitumab|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Safety|Pharmacokinetic profile|Level of insulin-like growth factor receptor-1 (IGF-1R) on peripheral blood cells|Tumor response measured by modified RECIST|Tumor glucose metabolism as measured by fludeoxyglucose F 18-PET/CT scan|Anti-AMG-479 antibody formation|The incidence of dose-limiting toxicities and the severity of adverse events|Levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase (may also include tartrate-resistant acid phosphatase 5b) in blood|Circulating levels of IGF-1R and IGF-BP3","Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry|NIH","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","AMGEN-479|CDR0000577404|AMGEN-20050118|VU-VICC-050630|VU-VICC-PHI-0542","October 2005","April 2010","June 2010","November 22, 2007",,"July 18, 2013","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00562380"
686,"NCT00537667","The SPECTRA Study",,"Terminated","No Results Available","Rheumatoid Arthritis","Drug: anakinra|Drug: anakinra and PEG sTNF-R1","Primary efficacy endpoint is the change from baseline at weeks 4, 26 and 52 in levels of select markers of inflammation (CD3 and CD 68) and destruction (MMP-1 and TIMP-1) in the synovium|Primary safety endpoint is the crude and exposure adjusted subject incidence and nature, frequency, severity, relationship to treatment, and outcome of all adverse events|Secondary efficacy endpoints are change from baseline at week 4 and 52 in selected markers of bone and cartilage degradation and inflammation|Secondary safety endpoints are changes from baseline in laboratory parameters","Amgen|Swedish Orphan Biovitrum","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20000211","August 2001","March 2003","June 2003","October 1, 2007",,"November 26, 2009",,,"https://ClinicalTrials.gov/show/NCT00537667"
687,"NCT00121043","Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire",,"Completed","No Results Available","Rheumatoid Arthritis","Device: SimpleJectTM|Drug: Kineret® (Anakinra)","Difference in the EAQ Part B Ease of Use Subscale Score between the two injection methods|Difference between the two injection methods for the following|EAQ Part B Total Score.|EAQ Part B Overall Satisfaction Subscale Score.|EAQ Part B Anxiety/Fear of Needles Subscale Score.|EAQ Part B Confidence in Ability of Use Subscale Score.|EAQ Part B Pain/Discomfort Subscale Score.|EAQ Part C Total Preference Score.|EAQ Quality Measures.|EAQ Item Performance Measures.|EAQ Instrument Reliability Measures.|Incidence and severity of AE's.|Incidence of concomitant medications.","Amgen|Swedish Orphan Biovitrum","All","18 Years and older   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20020125",,,,"July 21, 2005",,"November 26, 2009",,,"https://ClinicalTrials.gov/show/NCT00121043"
688,"NCT00111410","Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Anakinra (r-metHuIL-1ra)","Proportion of subjects that achieve an anti-tetanus antibody response rate at study week 8 (4 weeks after the tetanus injection), based on a 4-fold titer development relative to week 4 (pre-vaccination)|Anti-tetanus antibody titers at weeks 4 and 8|Anti-tetanus antibody level changes from baseline to week 4|Anti-tetanus antibody level changes from week 4 to week 8|Antibody level of at least 0.1 IU/mL at week 8.|Safety evaluation of serious adverse events, adverse events and laboratory assessments","Amgen|Swedish Orphan Biovitrum","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20020101",,,"November 2003","May 23, 2005",,"August 11, 2016",,,"https://ClinicalTrials.gov/show/NCT00111410"
689,"NCT00005960","Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",,"Unknown status","No Results Available","Pain|Prostate Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Procedure: pain therapy",,"Amgen|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","CDR0000067942|AMGEN-GCSF-980282|NCI-V00-1595","October 1999",,,"June 8, 2004",,"December 4, 2013","Wilshire Oncology Medical Group, Inc., Los Angeles, California, United States|Geffen Cancer Center and Research Institute, Vero Beach, Florida, United States|Arena Oncology Associates, Great Neck, New York, United States|New York Medical College, Valhalla, New York, United States|N.W. Carolina Oncology & Hematology, P.A., Hickory, North Carolina, United States|Associates of Hematology/Oncology, Upland, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00005960"
690,"NCT00005958","Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer",,"Unknown status","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Biological: filgrastim|Drug: docetaxel|Drug: gemcitabine hydrochloride",,"Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","CDR0000067939|AMGEN-GCSF-990125|NCI-V00-1594","October 1999",,,"April 20, 2004",,"December 4, 2013","University of California San Diego, La Jolla, California, United States|Sacramento Center for Hematology and Medical Oncology, Sacramento, California, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Center for Hematology-Oncology, Boca Raton, Florida, United States|Oncology-Hematology Associates of North Illinois, Ltd., Gurnee, Illinois, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|St. Joseph Medical Center, Towson, Maryland, United States|Hematology & Oncology Associates of Southern Michigan, Jackson, Michigan, United States|Hematology Oncology Associates of Central New York, Syracuse, New York, United States|Memphis Cancer Center, Inc., Memphis, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|Northern Virginia Oncology Group, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00005958"
691,"NCT00006215","Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",,"Unknown status","No Results Available","Lung Cancer","Biological: filgrastim|Drug: docetaxel|Drug: vinorelbine tartrate",,"Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","CDR0000067941|AMGEN-GCSF-990138|NCI-V00-1596","October 1999",,,"March 17, 2004",,"December 19, 2013","Gould Medical Group, Modesto, California, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|Georgia Cancer Treatment Center, P.C., Riverdale, Georgia, United States|Oncology and Hematology Associates, Westwood, Kansas, United States|Veterans Affairs Medical Center - Brooklyn, Brooklyn, New York, United States|Hematology-Oncology Associates of Rockland, P.C., New City, New York, United States|New York Medical College, Valhalla, New York, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Community Oncology Group, Independence, Ohio, United States|CCOP - Dayton, Kettering, Ohio, United States|CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States|Charleston Hematology-Oncology, P.A., Charleston, South Carolina, United States|Trident Palmetto Hematology/Oncology, North Charleston, South Carolina, United States|Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis, Tennessee, United States|Texas Cancer Care, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Hematology & Oncology Associates of Virginia, Richmond, Virginia, United States|Morgantown Internal Medicine Group, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00006215"
692,"NCT00005959","Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma",,"Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate",,"Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Primary Purpose: Treatment","CDR0000067940|AMGEN-GCSF-990756|NCI-V00-1593","December 1999",,,"December 17, 2003",,"December 4, 2013","Montgomery Cancer Center, Montgomery, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|Cancer and Blood Institute of the Desert, Rancho Mirage, California, United States|Southeast Florida Hematology-Oncology Group, Fort Lauderdale, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Oncology-Hematology Group of South Florida, Miami, Florida, United States|Hematology-Oncology Associates, PA, Pensacola, Florida, United States|Hutchinson Clinic, P.A., Hutchinson, Kansas, United States|Hematology/Oncology Care Inc., Crestview Hills, Kentucky, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Associates in Oncology and Hematology, Rockville, Maryland, United States|North Shore Cancer Center, Peabody, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, United States|Bond Clinic, Rolla, Missouri, United States|Midwest Hematology Oncology Consultants, Ltd., Saint Louis, Missouri, United States|Hematology Oncology Associates, Morristown, New Jersey, United States|New Mexico Oncology-Hematology, Albuquerque, New Mexico, United States|Our Lady of Mercy Medical Center, Bronx, New York, United States|HemOnCare, P.C., Brooklyn, New York, United States|N.W. Carolina Oncology & Hematology, P.A., Hickory, North Carolina, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|University of Tennessee, Memphis, Memphis, Tennessee, United States|Intermountain Hematology/Oncology Associates, Inc., Salt Lake City, Utah, United States|Vermont Center for Cancer Medicine, Inc., Colchester, Vermont, United States|Hematology & Oncology Associates of Virginia, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00005959"
693,"NCT00037700","Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: anakinra|Drug: pegsunercept",,"Amgen|Swedish Orphan Biovitrum","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","20000198","May 2001",,"December 2002","May 21, 2002",,"November 26, 2009",,,"https://ClinicalTrials.gov/show/NCT00037700"
694,"NCT00037648","Juvenile Rheumatoid Arthritis",,"Completed","No Results Available","Juvenile Chronic Arthritis","Drug: Anakinra|Drug: Placebo","The primary outcome of the study was to evaluate the safety of anakinra","Amgen|Swedish Orphan Biovitrum","All","2 Years to 17 Years   (Child)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","990758-990779","July 2000","November 2003","November 2003","May 20, 2002",,"November 26, 2009",,,"https://ClinicalTrials.gov/show/NCT00037648"
695,"NCT00002433","The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS",,"Completed","No Results Available","HIV Infections","Drug: Interferon gamma-1b",,"Amgen|NIH AIDS Clinical Trials Information Service","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Industry","Interventional","Primary Purpose: Treatment","062A|IFNG-8901",,,,"August 31, 2001",,"June 24, 2005","New York Hosp - Cornell Med Ctr, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00002433"
696,"NCT00002281","A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex",,"Completed","No Results Available","HIV Infections|Cytopenias","Drug: Filgrastim|Drug: Epoetin alfa|Drug: Zidovudine",,"Amgen|NIH AIDS Clinical Trials Information Service","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","061A|GCSF-8808-109",,,,"August 31, 2001",,"June 24, 2005","UCLA Med Ctr, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00002281"
697,"NCT00002255","An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)",,"Completed","No Results Available","HIV Infections","Drug: Filgrastim|Drug: Epoetin alfa|Drug: Zidovudine",,"Amgen|NIH AIDS Clinical Trials Information Service","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1",,"Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","077A|G-CSF 8808",,,,"August 31, 2001",,"June 24, 2005","UCLA Med Ctr, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00002255"
698,"NCT00002126","A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.",,"Completed","No Results Available","HIV Infections|Cytopenias","Drug: Filgrastim",,"Amgen|NIH AIDS Clinical Trials Information Service","All","13 Years and older   (Child, Adult, Older Adult)","Phase 2","250","Industry","Interventional","Primary Purpose: Treatment","087A|GCSF-930101",,,,"August 31, 2001",,"June 24, 2005","Univ of Alabama at Birmingham / AIDS Outpatient Clinic, Birmingham, Alabama, United States|Maricopa County Med Ctr, Phoenix, Arizona, United States|CARE Ctr / UCLA Med Ctr, Los Angeles, California, United States|UCSF - San Francisco Gen Hosp, San Francisco, California, United States|Univ Hosp / Univ of Colorado Health Sci Ctr, Denver, Colorado, United States|George Washington Univ Med Ctr, Washington, District of Columbia, United States|TheraFirst Med Ctrs Inc, Fort Lauderdale, Florida, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Univ of Kansas School of Medicine, Wichita, Kansas, United States|Tulane Univ Med School, New Orleans, Louisiana, United States|New England Deaconess Hosp, Boston, Massachusetts, United States|SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States|Nalle Clinic, Charlotte, North Carolina, United States|Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States|Kaiser Permanente Med Ctr, Portland, Oregon, United States|Univ TX San Antonio Health Science Ctr, San Antonio, Texas, United States|Saint Paul's Hosp, Vancouver, British Columbia, Canada|Sunnybrook Health Science Ctr, Toronto, Ontario, Canada|Toronto Gen Hosp, Toronto, Ontario, Canada|Wellesley Hosp, Toronto, Ontario, Canada|Hotel - Dieu de Montreal, Montreal, Quebec, Canada|Saint Michael's Hosp, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT00002126"
699,"NCT00002037","Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study",,"Completed","No Results Available","Mycobacterium Avium-Intracellulare Infection|HIV Infections","Drug: Trifluridine",,"Amgen|NIH AIDS Clinical Trials Information Service","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","062B|IFNG-8701",,,,"August 31, 2001",,"June 24, 2005","New York Hosp - Cornell Med Ctr, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00002037"
700,"NCT04231682","A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.",,"Not yet recruiting","No Results Available","Osteoporosis","Drug: Denosumab Injection|Drug: Placebos","The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine in the intervention and control groups at 12 months.|The percentage changes in bone mass calculated by DEXA scan t-score of Femoral Neck, Total Hip and Wrist in the intervention and control groups at 12 months.|The percentage changes in bone mass calculated by DEXA scan t-score of Lumbar Spine, Femoral Neck, Total Hip and Wrist in the intervention and control groups at 24 months.|The vertebral and non-vertebral fracture incidence at 12 and 24 months.|The percentage changes of biochemical markers of variables of bone turnover (BSAP, CTX and PINP) from baseline to 6, 12, 18 and 24 months after 1st medication administration.|The percentage changes of creatinine, Calcium, Magnesium, Phosphorus, PTH intact and 25-Vit D levels from baseline to 6, 12, 18 and 24 months after the 1st medication administration.|The percentage of patients developing infections, rejection episodes, hospitalizations or ED visits during the study period.","Albert Einstein Healthcare Network|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB-2020-300","March 1, 2020","January 1, 2024","January 1, 2025","January 18, 2020",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04231682"
701,"NCT04220164","Observation of Blood Lipid Outcomes in Lipid Clinic",,"Recruiting","No Results Available","Dyslipidemias","Other: Education and inform the optimal threshold of LDL-C levels","Lipid profile","Mackay Memorial Hospital|Amgen","All","20 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","18MMHIS083e","January 3, 2020","December 31, 2020","December 31, 2025","January 7, 2020",,"January 7, 2020","Taiwan, Taipei, Mackay Memorial hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04220164"
702,"NCT04169347","FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer",,"Recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Oxaliplatin","Efficacy/objective response rate|Evaluating progression free survival (PFS)|Evaluating overall survival (OS)|Evaluating toxicity of this regimen|Evaluating radiographic tumor regression|Evaluating for the velocity of tumor response to this regimen","Criterium, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Panit7156","December 2, 2019","September 2021","December 2021","November 19, 2019",,"January 22, 2020","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04169347"
703,"NCT04141579","Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody","FITTER","Not yet recruiting","No Results Available","Coronary Artery Disease|Atherosclerosis of Coronary Artery","Drug: Evolocumab 140 MG/ML [Repatha]","Change in FFR from baseline to follow-up in non-IRA lesions.|The correlation between baseline Near-InfraRed Spectroscopy (NIRS) derived lipid core burden (MaxLCBI4mm) and change in FFR of the non-IRA.|The correlation between LDL-C reduction and reduction of pro-inflammatory monocyte phenotypes.","Radboud University|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NL71538.091.19","December 2019","June 2022","June 2022","October 28, 2019",,"October 28, 2019",,,"https://ClinicalTrials.gov/show/NCT04141579"
704,"NCT04048343","Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma","NOZOMI","Recruiting","No Results Available","Severe Asthma","Drug: Biological: Experimental: Tezepelumab","Number of subjects with adverse events","AstraZeneca|Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5180C00019","June 10, 2019","May 14, 2021","May 14, 2021","August 7, 2019",,"January 13, 2020","Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan",,"https://ClinicalTrials.gov/show/NCT04048343"
705,"NCT04044560","Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant","OZM-097","Not yet recruiting","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|Stem Cell Leukemia|Minimal Residual Disease","Biological: blinatumomab","MRD Response|Safety and Tolerability|Survival|Incidence of MRD Post HSCT|Patient Recruitment (Number of Patients Recruited)|Turnaround time of centralized MRD testing (days)|Time to delivery of blinatumomab following MRD detection","University of British Columbia|Amgen","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H19-00893|CTTC 1902","September 2019","September 2021","September 2026","August 5, 2019",,"August 5, 2019",,,"https://ClinicalTrials.gov/show/NCT04044560"
706,"NCT04039113","Tezepelumab COPD Exacerbation Study","COURSE","Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease (COPD)","Biological: Tezepelumab|Other: Placebo","Moderate or severe COPD exacerbation rate ratio (tezepelumab vs placebo)|Time to first moderate or severe COPD exacerbation|Proportion with at least one moderate/severe COPD exacerbation|Severe COPD exacerbation rate ratio (tezepelumab vs. placebo)|Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)|Change in respiratory health status/health-related quality of life|Change from baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score|Change from baseline in the COPD Assessment Test (CAT) Total Score|Evaluate pharmacokinetics of tezepelumab|Evaluate immunogenicity of tezepelumab","AstraZeneca|Amgen","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5241C00001","July 30, 2019","February 14, 2022","May 9, 2022","July 31, 2019",,"December 24, 2019","Research Site, Dothan, Alabama, United States|Research Site, Huntington Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Westminster, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Brandon, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Calhoun, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Buckley, Michigan, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Abingdon, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Truro, Nova Scotia, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Aarhus N, Denmark|Research Site, Hvidovre, Denmark|Research Site, København NV, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Vejle, Denmark|Research Site, Ålborg, Denmark|Research Site, Amiens Cedex 1, France|Research Site, Brest Cedex 2, France|Research Site, Creteil, France|Research Site, Grenoble Cedex, France|Research Site, Lyon Cedex 04, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nantes Cedex 1, France|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Rehovot, Israel|Research Site, Daegu, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Assen, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Alzira, Spain|Research Site, Barcelona, Spain|Research Site, Málaga, Spain|Research Site, Mérida (Badajoz), Spain|Research Site, Bradford, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Larbert, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle-upon-Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04039113"
707,"NCT04004338","Carfilzomib in Combination for the Treatment of RR MM",,"Recruiting","No Results Available","Multiple Myeloma|Relapse Multiple Myeloma|Refractory Multiple Myeloma","Drug: Kyprolis","Progression free survival|Dyspnea Frequency","Black Sea Hematology Association|Amgen","All","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20187462","April 14, 2019","April 14, 2021","April 14, 2021","July 2, 2019",,"July 2, 2019","19 Mayıs University Faculty of Medicine, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT04004338"
708,"NCT03989544","A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects","PATH-BRIDGE","Completed","No Results Available","Asthma","Biological: Tezepelumab","The area under the time concentration curves from zero to infinity (AUCinf)|The maximum observed concentration (Cmax)|The areas under the time concentration curves from zero to last observation (AUClast)|Time to Cmax (tmax)|Terminal phase elimination half life (t½λz)|Apparent systemic clearance (CL/F)|Apparent terminal phase volume of distribution (Vz/F)|Presence of ADAs to tezepelumab|Number of subjects with adverse events (AEs)/ serious adverse events (SAEs)","AstraZeneca|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5180C00012","June 19, 2019","December 30, 2019","December 30, 2019","June 18, 2019",,"January 9, 2020","Research Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT03989544"
709,"NCT03982992","Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab","DLI-TARGET","Recruiting","No Results Available","B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation|B-Cell Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Lymphoblastic Leukemia, Adult","Drug: Blinatumomab in combination with donor lymphocyte infusion","Safety and tolerability of combined DLI and blinatumomab treatment in subjects with treatment-resistant MC or MRD of CD19+ B-precursor ALL after allogeneic SCT|Efficacy of a combined treatment of DLI and blinatumomab to induce a complete MRD/chimerism response|Duration of the response and survival after combined treatment of DLI and blinatumomab","Ludwig-Maximilians - University of Munich|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-002314-31","June 1, 2019","May 31, 2021","November 30, 2021","June 12, 2019",,"June 14, 2019","Klinikum der Universität München, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT03982992"
710,"NCT03970902","Quality of Life in Postmenopausal Women With Osteoporosis",,"Recruiting","No Results Available","Postmenopausal Osteoporosis","Other: Integrated Osteoporosis Care|Other: Care As Usual","Medication Possession Ratio (MPR)|Identification Failure rate|Correct use of the osteoporosis treatment guideline|Proportion of patients treated correctly|Percentage of family physicians who correctly register osteoporosis management in the EMR|Intensity of collaborative practices|Knowledge of osteoporosis management and treatment|Health-related competencies|Self-reported treatment adherence|Self-reported nutritional intake|Self-reported medication intake|Intensity of integrated osteoporosis care|Patient satisfaction with osteoporosis care|Patient Health Related Quality of Life (HRQoL)|Patient functional independence|Resource use|Informal caregivers Health Related Quality of Life (HRQoL)|Informal caregiver Quality of Life (QoL)|Informal caregiver Impact of Caregiving","University Ghent|Amgen","Female","Child, Adult, Older Adult",,"500","Other|Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","EC/2019/0578","June 2019","December 2021","December 2021","June 3, 2019",,"June 5, 2019","Family physician doctor's offices, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT03970902"
711,"NCT03968978","Tezepelumab Home Use Study","PATH-HOME","Active, not recruiting","No Results Available","Asthma","Biological: Tezepelumab (APFS)|Biological: Tezepelumab (AI)","Proportion of HCPs who successfully administered tezepelumab with the device in clinic|Proportion of HCPs or subjects/caregivers who successfully administered tezepelumab with the device in clinic|Proportion of subjects/caregivers who successfully administered tezepelumab with the device in clinic|Proportion of subjects/caregivers who successfully administered tezepelumab with the device at home|Proportion of used/returned devices that passed functional tests and visual inspection and showed no evidence of malfunction|Proportion of APFS devices that have been reported as malfunctioning (Product Complaints)|Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score.|Serum trough concentrations|Anti-drug antibodies (ADA)","AstraZeneca|Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5180C00011","May 21, 2019","June 9, 2020","June 9, 2020","May 30, 2019",,"December 24, 2019","Research Site, Hoover, Alabama, United States|Research Site, Northridge, California, United States|Research Site, Palm Desert, California, United States|Research Site, Westminster, California, United States|Research Site, Tampa, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Omaha, Nebraska, United States|Research Site, Northfield, New Jersey, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Białystok, Poland|Research Site, Kraków, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Strzelce Opolskie, Poland|Research Site, Tarnów, Poland|Research Site, Wieluń, Poland|Research Site, Wrocław, Poland",,"https://ClinicalTrials.gov/show/NCT03968978"
712,"NCT03951220","The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss","LOOMIS","Recruiting","No Results Available","Myeloma|Monoclonal Gammopathy of Undetermined Significance (MGUS)|Smouldering Myeloma","Other: Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Other: DXA scan|Other: Bloods and urine","1. DW-MRI: ADC change|2. Total spinal 'hole' volume|3. Total spine 'collapse' volume|4. FSA: trabecular wall thickness|Detect longitudinal changes in tumour load with therapy|Assess participants Quality of Life (EQ-5D) throughout the study|Assess participants experience of the novel MR imaging scan","Oxford University Hospitals NHS Trust|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","12548","March 29, 2018","September 30, 2019","September 30, 2020","May 15, 2019",,"May 15, 2019","Churchill Hospital, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03951220"
713,"NCT03944577","Impact of Evolocumab in Cardiac Transplant Patients With CAV",,"Recruiting","No Results Available","Heart Transplant","Drug: Evolocumab (Repatha)","To measure the effect of evolocumab on serum LDL as measured in mL/dL after 12 weeks of therapy in heart transplant patients.","University of Nebraska|Amgen","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20177584","July 15, 2019","July 1, 2021","September 1, 2021","May 9, 2019",,"July 29, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03944577"
714,"NCT03931642","BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation",,"Recruiting","No Results Available","Richter Syndrome","Drug: RCHOP|Drug: Blinatumomab","Complete remission (CR) rate according to the revised Lugano criteria|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0|overall response|CR rate","French Innovative Leukemia Organisation|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FILOCLL13-BLINART","July 5, 2019","July 4, 2021","July 4, 2022","April 30, 2019",,"July 19, 2019","Chu Amiens, Amiens, France|CHU ANGERS - Maladies du sang, Angers, France|Ch Cote Basque, Bayonne, France|Hopital Jean Minjoz, Besançon, France|Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France|CH de Béziers - Hématologie, Béziers, France|CHU Caen - IHBN - Hématologie Clinique, Caen, France|CHU Estaing - Hématologie Clinique Adulte, Clermont-Ferrand, France|CHU Grenoble - Hématologie, Grenoble, France|Centre Hospitalier du Mans, Le Mans, France|Hôpital Saint Vicent de Paul, Lille, France|Centre Léon Bérard - Hématologie, Lyon, France|Institut Paoli-Calmettes - Hématologie Clinique, Marseille, France|HOPITAL SAINT ELOI - Hematologie, Montpellier, France|Hopital E.Muller, Mulhouse, France|CHU DE NANTES - Hematologie clinique, Nantes, France|Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent, Paris, France|CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique, Perpignan, France|Bordeaux Pessac, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire, Poitiers, France|Hôpital Robert Debré - Hématologie Clinique, Reims, France|CHU Pontchaillou - Hématologie Clinique BMT-HC, Rennes, France|Centre Henri Becquerel - Service Hématologie Clinique, Rouen, France|Hôpital Hautepierre - Hématologie, Strasbourg, France|IUCT ONCOPOLE - Hématologie, Toulouse, France|Hôpital Bretonneau - Hématologie et Thérapie Cellulaire, Tours, France|Hôpitaux de Brabois - Hématologie Adulte, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT03931642"
715,"NCT03927157","Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma","DIRECTION","Recruiting","No Results Available","Asthma","Biological: Experimental: Tezepelumab|Other: Placebo","Annualized asthma exacerbation rate (AERR)|Change from baseline in pre-dose/pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)|Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(S)+12) total score|Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) Score|Change from baseline in weekly mean daily Asthma Symptom Diary score|Time to first asthma exacerbation|Change from baseline in fractional exhaled nitric oxide FENO (ppb)|Change from baseline in weekly mean rescue medication use|Asthma specific resource utilization (e.g.,eg, unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications)|Serum trough concentrations|European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score|Change from baseline in peripheral blood eosinophils|Change from baseline in total serum IgE|Change from baseline in weekly mean morning and evening peak expiratory flow (PEF)|Change from baseline in weekly mean number of night time awakenings|Immunogenicity anti-drug antibodies","AstraZeneca|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","396","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00021","June 14, 2019","December 25, 2023","December 25, 2023","April 25, 2019",,"January 21, 2020","Research Site, Baotou, China|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hengyang, China|Research Site, Hohhot, China|Research Site, Hohhot, China|Research Site, Huizhou, China|Research Site, Huzhou, China|Research Site, Jinan, China|Research Site, Jinhua, China|Research Site, Lanzhou, China|Research Site, Linhai, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Quanzhou, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shaoxing, China|Research Site, Shengyang, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Shenzhen, China|Research Site, Shenzhen, China|Research Site, Shijiazhuang, China|Research Site, Tianjin, China|Research Site, Urumchi, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Xian, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Zunyi, China|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Iloilo City, Philippines|Research Site, Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT03927157"
716,"NCT03925532","Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant",,"Recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Osteopenia|Osteoporosis","Biological: Denosumab","Changes in bone mineral density (BMD)|Slope in bone mineral density (g/cm^2) regressed on time in dual femur and lumbar spine (average of L1-L4)|Percent change in BMD|Frequency of bone fractures|Incidence of adverse events","Roswell Park Cancer Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","I 78618|NCI-2019-01921","December 19, 2019","December 20, 2020","December 20, 2021","April 24, 2019",,"December 23, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03925532"
717,"NCT03909412","Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","CarMob","Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Granulocyte Colony-Stimulating Factor","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum tolerated dose (MTD)","Hackensack Meridian Health|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro2018-0531","October 8, 2019","March 2021","March 2021","April 10, 2019",,"October 18, 2019","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03909412"
718,"NCT03861533","GOAL International QuERI","GOAL QuERI","Recruiting","No Results Available","Dyslipidemia","Other: survey","Proportion of patients achieving country specific guideline-recommended LDL-C levels after 18 month final visit or last available observation during follow up visits.|1. Relative and absolute reduction of LDL-C with lipid lowering medications added during the observation period.|Proportion of patients not achieving recommended LDL-C level based on high risk inclusion sub-group (e.g. FH), co-morbid conditions (diabetes mellitus), baseline treatment or baseline lipid profile.|Proportion of patients not achieving recommended LDL-C level at each of the follow up visits according to physician responses as to why country specific recommendation for LDL-C lowering opportunities was not followed.|Proportion of patients achieving LDL-C and non-HDL level across participating countries.","Dr. Anatoly Langer|Amgen|Canadian Heart Research Centre","All","18 Years and older   (Adult, Older Adult)",,"2500","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CHRC2019-GOAL INT","April 1, 2019","April 1, 2022","October 1, 2022","March 4, 2019",,"July 23, 2019","Centro de Estudios Clínicos de Querétaro (CECLIQ), Querétaro, Qro, Mexico",,"https://ClinicalTrials.gov/show/NCT03861533"
719,"NCT03812367","Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid",,"Withdrawn","No Results Available","Osteoporosis, Postmenopausal",,"Percent change in osteoclast circulation|Percent change in osteoclast maturation and activity|Percent change in number of TRAP cells|Percent change in bone mass density|Percent change in bone turnover markers","University of California, Davis|Amgen","Female","50 Years and older   (Adult, Older Adult)",,"0","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1030286","January 1, 2019","June 1, 2021","December 31, 2021","January 23, 2019",,"June 14, 2019","UC Davis Health, Center for Musculoskeletal Health, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT03812367"
720,"NCT03795597","Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)","BuMelCarAuto","Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Busulfan IV|Drug: Melphalan IV","36 participants evaluated for safety with treatment-related adverse events and grading by using CTCAE v4.0.|36 participants evaluated for tolerability with treatment-related adverse events and grading by using CTCAE v4.0.|36 participants evaluated for response to treatment by testing blood for multiple myeloma levels.|36 participants evaluated for progression by testing blood for multiple myeloma levels.|36 participants evaluated for overall survival by clinical visit or contact by phone.|36 participants evaluated for absolute neutrophil count by testing white blood cells levels.|36 participants evaluated for platelet engraftment by testing platelet count in blood cells.|36 participants evaluated by oral exam to assess mucositis events and grading levels by using CTCAE v4.0.|36 participants evaluated by the liver to assess Veno-occlusive disease and grading levels by using CTCAE v4.0.|36 participants evaluated by a physical exam to assess peripheral neuropathy and grading by using CTCAE v4.0.|36 participants evaluated for response to treatment by testing urine for multiple myeloma levels.|36 participants evaluated for progression by testing urine for multiple myeloma levels.","Loyola University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","209274","May 22, 2019","November 1, 2022","November 1, 2023","January 8, 2019",,"August 20, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03795597"
721,"NCT03795558","A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients",,"Recruiting","No Results Available","End Stage Renal Disease","Drug: Etelcalcetide","T50-Laboratory Test for measuring calcification","Prim. Priv. Doz. Dr. Daniel Cejka|Amgen|Elisabethinen Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Etelcalcetide-T50-CKD5D","May 1, 2019","September 1, 2020","December 1, 2020","January 7, 2019",,"July 23, 2019","Ordensklinikum Linz GmbH Elisabethinen, Linz, Upper Austria, Austria",,"https://ClinicalTrials.gov/show/NCT03795558"
722,"NCT03756896","Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma",,"Recruiting","No Results Available","Plasma Cell Myeloma","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Pomalidomide","≥ Complete response (CR) rates|Progression-free survival (PFS)|Best response on-study|Objective response rate (ORR) defined as the proportion of treated subjects who achieve a best response of CR, stringent complete response (sCR), very good partial response (VGPR), or partial response (PR)|Duration of response (DOR)|Overall survival (OS)|Minimal residual disease (MRD) detection","Emory University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00097882|NCI-2017-02052|Winship4101-17","January 25, 2019","January 30, 2021","November 30, 2021","November 28, 2018",,"December 5, 2019","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03756896"
723,"NCT03751709","Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL",,"Recruiting","No Results Available","B-Cell Acute Lymphoblastic Leukaemia|ALL, Adult|B-ALL","Drug: Blinatumomab|Other: Haplo-Mismatched Cell Therapy (HMCT)","Incidence of DLTs|Number of participants experiencing complete response (CR) from time of transplant to one day following the second treatment|Number of participants experiencing complete response with partial recovery of peripheral blood counts (CRh) from time of transplant to one day following the second treatment|Number of participants experiencing complete response with incomplete count recovery (CRi) from time of transplant to one day following the second treatment|Response blast-free hypoplastic or aplastic bone marrow from time of transplant to one day following the second treatment|Disease burden measured as the minimal residual disease (MRD) response from time of transplant to one day following the second treatment","Cedars-Sinai Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIT2017-05-MERIN-BLINHMCT","March 2020","July 2021","July 2022","November 23, 2018",,"January 7, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03751709"
724,"NCT03751072","Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)","FRENCH-CYTO","Recruiting","No Results Available","Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission",,"Overall Survival in R/R and MRD+ cohorts|Response rates|Adverse events|Disease free survival","Group for Research in Adult Acute Lymphoblastic Leukemia|Amgen","All","18 Years and older   (Adult, Older Adult)",,"92","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","FRENCH-CYTO","July 16, 2018","November 30, 2018","January 30, 2019","November 23, 2018",,"November 23, 2018","CABANNES-HAMY Aurélie, Paris, France",,"https://ClinicalTrials.gov/show/NCT03751072"
725,"NCT03714828","Study of TVEC in Patients With Cutaneous Squamous Cell Cancer",,"Recruiting","No Results Available","Squamous Cell Carcinoma|Skin Cancer|Keratoacanthoma|Cutaneous Tumor|Skin Cancer, Squamous Cell|Lesion Skin","Drug: Injection of TVEC into target lesions - week 1-2|Drug: Injection of TVEC into target lesions 3wks after 1st injection|Drug: Injection of TVEC into target lesions 2wks after 2nd injection|Drug: Injection of TVEC into target lesions 2wks after 3rd injection","Overall response rate|Number of participants with events requiring the discontinuation of study drug|Time of response.|Duration of overall response.|Assess durable response.|Time to progression.|Overall response rate by ultrasound.|Overall clinical response rate - targeted lesions.|Overall clinical response rate - non-injected lesion(s).|Number of safety adverse events (SAE) as assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0|Number of adverse effects to tumors according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) 4.0","University of Arizona|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1807738975|29088","August 24, 2018","March 30, 2020","September 1, 2020","October 22, 2018",,"November 20, 2019","University of Arizona Cancer Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03714828"
726,"NCT03706079","Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma","DESTINATION","Enrolling by invitation","No Results Available","Asthma","Biological: Tezepelumab|Other: Placebo","Exposure adjusted rates of AEs/SAEs|Annualized asthma exacerbation rate (AAER)","AstraZeneca|Amgen","All","13 Years to 81 Years   (Child, Adult, Older Adult)","Phase 3","966","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00018","January 7, 2019","August 4, 2022","August 4, 2022","October 15, 2018",,"November 12, 2019","Research Site, Dothan, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Desert, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Westminster, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Zachary, Louisiana, United States|Research Site, White Marsh, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Northfield, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Allen, Texas, United States|Research Site, Amarillo, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Manassas, Virginia, United States|Research Site, Cudahy, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Quilmes, Argentina|Research Site, San Fernando, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Kent Town, Australia|Research Site, Murdoch, Australia|Research Site, New Lambton, Australia|Research Site, Prahran, Australia|Research Site, Westmead, Australia|Research Site, Woolloongabba, Australia|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Blumenau, Brazil|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Salvador, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brest Cedex 2, France|Research Site, Grenoble cedex 9, France|Research Site, Le Kremlin-Bicêtre, France|Research Site, Lyon Cedex 4, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Strasbourg Cedex, France|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Koblenz, Germany|Research Site, Landsberg, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Rehovot, Israel|Research Site, Bucheon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Jeju-do, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Kraków, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Izhevsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Bellville, South Africa|Research Site, Boksburg, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lenasia Ext8, South Africa|Research Site, Middelburg, South Africa|Research Site, Mowbray, South Africa|Research Site, Parow, South Africa|Research Site, Umkomaas, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Dnipro, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03706079"
727,"NCT03691311","Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer","D-BIOMARK","Recruiting","No Results Available","Breast Neoplasm Female|Stage I Breast Cancer|Stage II Breast Cancer|Hormone Receptor Negative Neoplasm|Hormone Receptor Positive Tumor","Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]","Antiproliferative and/or pro-apoptotic activity of denosumab|Correlation between antiproliferative activity of denosumab and Rank/RankL expression|Differential antiproliferative activity of denosumab among the different phenotypes of breast cancers.|Differential antiproliferative activity of denosumab among pre and post menopausal patients|Safety of denosumab and biopsy procedures in terms of Frequency of adverse events (CTCAE V4.)","Institut Català d'Oncologia|Amgen","Female","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICO 13-001|2016-002678-11|20119112","July 5, 2018","July 5, 2020","February 5, 2021","October 1, 2018",,"August 7, 2019","Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03691311"
728,"NCT03689946","Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by CCTA and Microcalcification by F18-NaF PET",,"Recruiting","No Results Available","Cardiovascular Disease|Hyperlipidemia","Drug: Evolocumab|Diagnostic Test: 18F-NaF PET|Diagnostic Test: CCTA","Change in noncalcified coronary artery plaque volume (NCPV)|Change in plaque composition (fibrous, fibrofatty, fatty, and calcified)","Cedars-Sinai Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","54274","March 22, 2019","December 31, 2021","December 31, 2022","October 1, 2018",,"March 26, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03689946"
729,"NCT03688074","Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)","CASCADE","Active, not recruiting","No Results Available","Asthma|Bronchial Diseases|Respiratory Tract Diseases|Lung Diseases, Obstructive|Lung Diseases|Respiratory Hypersensitivity|Hypersensitivity, Immediate|Hypersensitivity|Immune System Diseases","Biological: Tezepelumab|Other: Placebo","The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.|The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies|The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies|The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies","AstraZeneca|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00013","November 2, 2018","September 16, 2020","September 16, 2020","September 28, 2018",,"January 18, 2020","Research Site, Denver, Colorado, United States|Research Site, Boston, Massachusetts, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Galveston, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Aarhus N, Denmark|Research Site, Hvidovre, Denmark|Research Site, København NV, Denmark|Research Site, Naestved, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Ålborg, Denmark|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Landsberg, Germany|Research Site, Cambridge, United Kingdom|Research Site, Headington, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03688074"
730,"NCT03636373","Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout",,"Recruiting","No Results Available","Gout Attack","Drug: Etanercept|Drug: Triamcinolone Acetonide","Joint pain intensity in the most affected joint|Joint pain on numeric pain scale|Patient's assessment of response to treatment|Physician's assessment of response to treatment|Rescue Medication|Safety and Tolerability of Etanercept","Rutgers, The State University of New Jersey|Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro2018000562","May 29, 2019","December 2020","December 2020","August 17, 2018",,"October 9, 2019","Rutgers, Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03636373"
731,"NCT03635021","Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","CR-SEQUENCE","Recruiting","No Results Available","Colorectal Cancer","Drug: FOLFOX regimen|Drug: Panitumumab|Drug: Bevacizumab|Drug: FOLFIRI regimen","Progression-free survival rate at 35 months|overall survival rate at 35 months|overall survival|progression-free from randomization to second progression or death|progression-free survival in first-line treatment and in second-line treatment|time to first-line treatment failure and to second-line treatment failure|objective response rate|proportion of patients with Early Tumour Shrinkage|Depth of Response|disease control rate|duration of disease control|duration of response|time to response|Incidence and severity of AEs CTCAE v4.03 criteria","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","370","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-18-01","October 15, 2018","September 15, 2021","September 15, 2024","August 17, 2018",,"November 26, 2018","Spanish Cooperative Group for the Treatment of Digestive Tumors, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03635021"
732,"NCT03620149","Reduced Dose-density of Denosumab for Unresectable GCTB","REDUCE","Recruiting","No Results Available","Bone Giant Cell Tumor","Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]","Progression free survival (PFS)|Osteonecrosis of the jaw (ONJ) incidence|Overall survival|Denosumab treatment duration|Occurrence of Adverse Events","European Organisation for Research and Treatment of Cancer - EORTC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC 1762-STBSG|2018-002096-17|20177203","September 26, 2019","September 2024","March 2025","August 8, 2018",,"December 26, 2019","IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), Barcelona, Spain|Vall d'Hebron Institut d'Oncologia, Barcelona, Spain|Hospital Universitario San Carlos, Madrid, Spain|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03620149"
733,"NCT03620019","Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma",,"Recruiting","No Results Available","Melanoma Stage Iii|Melanoma Stage Iv|Melanoma|Melanoma (Skin)|Cutaneous Melanoma","Drug: Denosumab|Drug: Pembrolizumab|Drug: Nivolumab","The antitumor effect of denosumab alone as represented by the change in recent thymic emigrant cells in peripheral blood|The antitumor effect of denosumab alone as represented by the change in density of tumor-infiltrating cluster of differentiation (CD8+) cells (TILs) in tumor tissue.|The antitumor effect of denosumab combined with anti-PD-1 inhibitor as represented by the change in recent thymic emigrant cells in peripheral blood|The antitumor effect of denosumab combined with anti-PD-1 inhibitor as represented by the change in density of tumor-infiltrating cluster of differentiation (CD8+) cells (TILs) in tumor tissue.|Safety of the denosumab- anti-PD-1 inhibitor combination in unresectable stage III or distant metastatic PD-1/PD-L1 inhibitor-naïve cutaneous melanoma|Overall response rate|Overall survival rate|Progression free survival rate","UNC Lineberger Comprehensive Cancer Center|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC1620","September 25, 2018","August 2020","August 2022","August 8, 2018",,"June 27, 2019","UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03620019"
734,"NCT03619993","Patient Preference for Pegfilgrastim (Neulasta®) Application Forms","CONVENIENCE","Completed","No Results Available","Non Hodgkin Lymphoma|Breast Cancer","Device: On-body injector|Device: Pre-filled syringe","Patient preference for type of pegfilgrastim application assessed via project specific survey answered after 4 applications.|Time point of pegfilgrastim application within a chemotherapy cycle|Patient preference for pegfilgrastim application assessed via project specific survey answered at time of enrollment|Impact of type of pegfilgrastim application on daily life of the patient assessed by direct questioning using project specific patient survey.|Percentage of nurses favoring pegfilgrastim application via On-body injector at study start and at end of study as stated via a project specific nurse survey|Preference of investigators for either type of pegfilgrastim application at study start und at end of study assessed via project specific investigator survey|Cost factors for the health care system for both types of application of pegfilgrastim","iOMEDICO AG|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","404","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IOM-040369","June 25, 2018","September 10, 2019","September 10, 2019","August 8, 2018",,"December 17, 2019","Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Celle, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Flensburg, Germany|Research Site, Frankfurt an der Oder, Germany|Research Site, Freiburg, Germany|Research Site, Georgsmarienhütte, Germany|Research Site, Goslar, Germany|Research Site, Göttingen, Germany|Research Site, Halberstadt, Germany|Research Site, Halle (Saale), Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildburghausen, Germany|Research Site, Hildesheim, Germany|Research Site, Kaiserslautern, Germany|Research Site, Kassel, Germany|Research Site, Krefeld, Germany|Research Site, Köthen, Germany|Research Site, Mannheim, Germany|Research Site, Mayen, Germany|Research Site, Moers, Germany|Research Site, Mühlhausen, Germany|Research Site, Mülheim an der Ruhr, Germany|Research Site, München, Germany|Research Site, Naunhof, Germany|Research Site, Neunkirchen, Germany|Research Site, Neustadt In Sachsen, Germany|Research Site, Nordhorn, Germany|Research Site, Offenbach am Main, Germany|Research Site, Oldenburg, Germany|Research Site, Ostfildern, Germany|Research Site, Passau, Germany|Research Site, Plauen, Germany|Research Site, Ratingen, Germany|Research Site, Rostock, Germany|Research Site, Singen, Germany|Research Site, Spremberg, Germany|Research Site, Stolberg, Germany|Research Site, Stralsund, Germany|Research Site, Sömmerda, Germany|Research Site, Würselen, Germany",,"https://ClinicalTrials.gov/show/NCT03619993"
735,"NCT03605199","Denosumab in Subjects With Giant Cell Rich Tumors of Bone",,"Recruiting","No Results Available","Aneurysmal Bone Cysts|Giant Cell Granuloma|Osteoblastoma|Chondroblastoma|Chondromyxoid Fibroma","Drug: Denosumab","Efficacy (proportion of subjects who do not require surgery during the study)|Efficacy (proportion of subjects undergoing the planned versus performed type of surgery during the study)|Efficacy (Radiological response)|Efficacy (disease progression based on clinical disease assessment)|Efficacy (combined pain scores)|Toxicity according to CTCAE v 4.03|Disease recurrence after denosumab followed by surgery.|Symptomatic improvement.|Time to surgery|Time to recurrence after surgery (for patients with salvageable disease)|Progression free survival|Overall survival.","Leiden University Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20159990","June 18, 2018","June 2021","June 2023","July 30, 2018",,"August 26, 2019","Centre Léon Bérard, Lyon, France|Istituto Ortopedico Rizzoli, Bologna, Italy|Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT03605199"
736,"NCT03584711","FOLFOX + Panitumumab According to a ""Stop and go"" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation","OPTIPRIME","Recruiting","No Results Available","Metastatic Colorectal Cancer","Combination Product: FOLFOX + panitumumab","Time to failure of the strategy","Federation Francophone de Cancerologie Digestive|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","118","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FFCD 1605","April 26, 2018","April 2020","December 2020","July 12, 2018",,"July 26, 2019","Clinique Trenel, Sainte Colombe, Lyon, France|Clinique Claude Bernard, Albi, France|Hopital Sud, Amiens, France|Clinique de L'Europe, Amiens, France|Chu D'Angers, Angers CEDEX 9, France|Hopital Prive D'Antony, Antony, France|Hopital Les Bonnettes, Arras CEDEX, France|Centre Marie Curie, Arras, France|Ch Cote Basque, Bayonne CEDEX, France|Ch de Beauvais, Beauvais, France|Polyclinique Saint Privat, Boujan-sur-Libron, France|Cmco Cote D'Opale, Boulogne-sur-Mer, France|Hopital Duchenne, Boulogne-sur-Mer, France|Hopital Morvan - Chu, Brest, France|Ch de Beziers Cedex, Béziers, France|Centre Francois Baclesse, Caen, France|Ch Cahors, Cahors, France|Ch de Cholet, Cholet, France|Centre Hospitalier General, Châlons-en-Champagne, France|Hopitaux Civils de Colmar, Colmar, France|Service de Medecine, Digne-les-Bains, France|CH, Dunkerque CEDEX 01, France|Hopital Jacques Monod, Flers CEDEX, France|Chi de Frejus Saint-Raphael, Fréjus, France|Polyclinique de Blois - 3Eme Etage, La Chaussee St Victor, France|Chd Vendee, La Roche-sur-Yon, France|Ch Du Mans, Le Mans CEDEX 9, France|Centre Hospitalier Schaffner, Lens, France|Chru Hopital Claude Huriez 4Eme Est, Lille, France|Ch St Joseph-St Luc, Lyon, France|Hopital Europeen Marseille, Marseille, France|Ch de Meaux, Meaux, France|Hopital Layne, Mont-de-Marsan, France|Polyclinique de Gentilly, Nancy, France|Hopital Prive Du Confluent Sas, Nantes, France|Ch de Niort - Sce D'Oncologie, Niort CEDEX, France|Groupe Hospitalier Pitie-Salpetriere, Paris CEDEX 13, France|Chu Cochin, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|Polyclinique de Courlancy, Reims, France|Centre Hospitalier, Saint-Quentin CEDEX, France|Clinique Ste Anne, Strasbourg, France|Centre Paul Strauss, Strasbourg, France|Polyclinique de L'Ormeau, Tarbes, France|Clinique Pasteur, Toulouse, France|Chu de Fort de France, Fort-de-France, Martinique",,"https://ClinicalTrials.gov/show/NCT03584711"
737,"NCT03571633","Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","BREASTIMMU02","Recruiting","No Results Available","HER2-positive Breast Cancer|Operable Breast Cancer","Drug: Trastuzumab + Paclitaxel|Drug: Pegfilgrastim","Pathological complete response rate (pCR)|Disease Free survival|Time to relapse|Overall survival|Adverse events reporting","Centre Leon Berard|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET17-057|2017-002069-22","August 6, 2018","November 2021","November 2021","June 27, 2018",,"July 10, 2019","Centre Leon Berard, Lyon, France|HCL - Centre Hospitalier Lyon Sud, Lyon, France|Hopital Prive Jean Mermoz, Lyon, France|Institut de Cancerologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France",,"https://ClinicalTrials.gov/show/NCT03571633"
738,"NCT03554044","Talimogene Laherparepvec With Paclitaxel or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer",,"Recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma","Drug: Anastrozole|Drug: Exemestane|Drug: Fulvestrant|Drug: Letrozole|Drug: Paclitaxel|Biological: Talimogene Laherparepvec|Drug: Tamoxifen","Distribution for the maximum observed grade for each adverse event of talimogene laherparepvec in both arms|Maximum tolerated volume defined as the highest volume (up to 4mL) that results in ≤ 1 dose limiting toxicity in 6 treated patients for each treatment cohort|Overall response rate (ORR)|Response duration","University of California, San Francisco|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17753|NCI-2018-00652","October 10, 2019","December 1, 2020","December 1, 2021","June 12, 2018",,"January 22, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03554044"
739,"NCT03532087","Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer","PERIDENO","Withdrawn","No Results Available","Breast Neoplasms","Drug: Denosumab 120 mg|Drug: Denosumab 60 mg","Change in intratumoral T-cell (CD4, CD8 and Treg) numbers and function between the baseline biopsy and the surgical specimen.|Change in myeloid cell (M1/M2 Macrophage, MDSC, DC) numbers and function between the baseline biopsy and the surgical specimen.|Shift in activated T effector cell levels.|Shift in regulatory T-cell levels.|Change in functional response of T-cells.|Change in mature and immature myeloid cells (M1/M2 macrophage, MDSC, DC).|Shift in myeloid cell function.|Change in stimulation capacity APCs.|Change in serum levels of RANKL and OPG.|Change in serum cytokine levels (TNF-alpha, interleukines, IFN gamma).|Correlation of tumor measurements with serum measurements.|Correlation of tumor measurements with PBMCs measurements.|Correlation of serum measurements and PBMCs measurements.|Toxicity according to NCI CTCAE v4.03.|Difference in descriptive event free survival (EFS) at 3 years based on immune response.","Borstkanker Onderzoek Groep|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BOOG-2017-02|2016-005210-22","February 2018","February 2021","June 2023","May 22, 2018",,"January 18, 2020","Ziekenhuisgroep Twente (Twenteborg ZH Almelo), Almelo, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Zuyderland Medisch Centrum (Heerlen), Heerlen, Netherlands|Spaarne Gasthuis (Hoofddorp), Hoofddorp, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Fransiscus (Vlietland), Schiedam, Netherlands|VieCuri Medisch Centrum (Venlo), Venlo, Netherlands|'t Lange Land Ziekenhuis, Zoetermeer, Netherlands",,"https://ClinicalTrials.gov/show/NCT03532087"
740,"NCT03520231","Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases",,"Recruiting","No Results Available","Urothelial Carcinoma|Kidney Cancer|Ureter Cancer|Bladder Cancer","Drug: Denosumab|Other: Denosumab Placebo|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin|Dietary Supplement: Calcium|Dietary Supplement: Vitamin D","Difference in mean percentage change in serum c-telopeptide (sCTX) between the two arms (investigational drug arm and placebo arm).|Number of patients with a change in sCTx|Mean percentage change in serum bone-specific alkaline phosphatase (bALP) in the investigational arm|Mean percentage change in urinary N-telopeptide (uNTx) levels in the investigational arm|Mean percentage change in sCTx levels in the investigational arm|Mean percentage change in bALP levels in the investigational arm|Mean percentage change in uNTx levels in the investigational arm|Mean percentage change in serum bone-specific alkaline phosphatase (bALP) in the placebo arm.|Mean percentage change in urinary N-telopeptide (uNTx) levels in the placebo arm.|Mean percentage change in sCTx levels in the levels in the placebo arm.|Mean percentage change in bALP levels in the levels in the placebo arm.|Mean percentage change in uNTx levels in the levels in the placebo arm.|Time to first on study symptomatic skeletal related events|Progression free survival rate|Overall survival rate|Number of participants with side effects in the investigational drug arm|Number of participants with side effects in the placebo arm","University Health Network, Toronto|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DENIM","September 4, 2018","December 1, 2019","June 1, 2020","May 9, 2018",,"February 4, 2019","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03520231"
741,"NCT03469661","Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)",,"Recruiting","No Results Available","Immune Thrombocytopenia|Myelodysplastic Syndromes",,"Morphological profile|Immunological profile|Immunophenotypic abnormalities|Morphological abnormalities","Fundacion CRIS de Investigación para Vencer el Cáncer|Amgen","All","18 Years and older   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","FCR-PTI-2017-01","April 25, 2018","April 2020","July 2020","March 19, 2018",,"August 28, 2019","Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital de Burgos, Burgos, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain",,"https://ClinicalTrials.gov/show/NCT03469661"
742,"NCT03430687","Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma",,"Withdrawn","No Results Available","Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7|Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7|Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7|Stage I Bladder Urothelial Carcinoma AJCC v6 and v7","Other: Laboratory Biomarker Analysis|Biological: Talimogene Laherparepvec","Incidence of treatment-related toxicities according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (Dose escalation)|Pathologic T0 rate (Dose expansion)|Relapse-free survival rate (Dose expansion)|Change in antigen presenting cell (APC) within bladder tumor tissue by immunohistochemical (IHC) assessment|Change in circulating immune cells following intravesical talimogene laherparepvec, by flow cytometric assessment|Change in T cell and other immune cell infiltration within bladder tumor tissue by IHC assessment|Herpes simplex virus (HSV) status assessed by rate of HSV seroconversion in patients who were previously HSV-seronegative and relationship between HSV status and immunologic infiltration within tumor|Viral replication as measured by viral titers","University of California, San Francisco|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15521|NCI-2018-00109|15-17558|P30CA082103","June 1, 2018","December 31, 2019","December 31, 2020","February 13, 2018",,"May 18, 2018","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03430687"
743,"NCT03406078","Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma","SOURCE","Active, not recruiting","No Results Available","Asthma","Biological: Tezepelumab|Other: Placebo","Categorized percent reduction from baseline in the daily OCS dose while not losing asthma control.|Annualised asthma exacerbation rate (AAER)|Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 48|Proportion of subjects with daily OCS dose ≤5 mg at Week 48|Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 48|Change from baseline in pre-BD forced expiratory volume in 1 second (FEV1)|Change from baseline in Weekly mean daily Asthma Symptom Score via the daily Asthma Symptom Diary|Change from baseline in weekly mean rescue medication use|Change from baseline in weekly mean home peak expiratory flow (PEF) (morning and evening)|Change from baseline in weekly mean number of night-time awakening due to asthma|Change from baseline in Asthma Control Questionnaire 6 (ACQ-6) score|Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) total score|Change from baseline in European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score|Number of asthma specific resource utilizations|Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questionnaire (WPAI+CIQ) score|Change from baseline in FENO|Change from baseline in peripheral blood eosinophils|Change from baseline from total IgE|PK: Serum trough concentrations|Immunogenicity: Incidence of anti-drug antibodies (ADA)","AstraZeneca|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00009","March 5, 2018","September 30, 2020","December 23, 2020","January 23, 2018",,"January 13, 2020","Research Site, Bakersfield, California, United States|Research Site, Newark, Delaware, United States|Research Site, Celebration, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Homestead, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aire, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Quilmes, Argentina|Research Site, San Fernando, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Aschaffenburg, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Koblenz, Germany|Research Site, Lübeck, Germany|Research Site, Mainz Am Rhein, Germany|Research Site, München, Germany|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kraków, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Manisa, Turkey|Research Site, Dnipro, Ukraine|Research Site, Kherson, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03406078"
744,"NCT03398954","a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia",,"Unknown status","No Results Available","Familial Hypercholesterolemia",,"The screening out rate of FH|The clinical characteristics of clinical diagnosed FH patients|The pharmaceutical therapy for clinical diagnosed FH patients|LDL-C concentrations over time|Use of lipid-modifying therapies over time|Proportion of patients within and at distance from 2016 China guideline's LDL-C target|Incidence of cardiovascular event","China Cardiovascular Association|Amgen","All","Child, Adult, Older Adult",,"1128","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20177276","January 18, 2018","December 30, 2019","December 30, 2019","January 16, 2018",,"March 12, 2018","Beijing Anzhen Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT03398954"
745,"NCT03396315","Bisphosphonates for Prevention of Post-Denosumab Bone Loss",,"Recruiting","No Results Available","IOP|Osteoporosis","Drug: Alendronate|Drug: Zoledronic Acid","Difference in BMD at the Lumbar spine (L1-4) within group","Columbia University|Amgen","Female","20 Years to 55 Years   (Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR5220","January 29, 2018","January 1, 2023","January 1, 2024","January 10, 2018",,"December 9, 2019","Creighton University, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03396315"
746,"NCT03387605","Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine",,"Recruiting","No Results Available","Heart Failure|Cardiogenic Shock|Tachycardia","Drug: Ivabradine|Drug: Placebo","Heart rate|cardiac index|plasma brain natriuretic peptide (BNP) level","Loyola University|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","209939","March 15, 2018","January 2020","June 2020","January 2, 2018",,"May 23, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03387605"
747,"NCT03347279","Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma","NAVIGATOR","Active, not recruiting","No Results Available","Asthma","Biological: Experimental: Tezepelumab|Other: Placebo","Annualized asthma exacerbation rate (AERR)|Change from baseline in pre-dose/pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)|Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(S)+12) total score|Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) Score|Change from baseline in weekly mean daily Asthma Symptom Diary score|Time to first asthma exacerbation|Change from baseline in fractional exhaled nitric oxide FENO (ppb)|Change from baseline in weekly mean rescue medication use|Work Productivity and Activity Impairment (WPAI+CIQ) Questionnaire and Classroom Impairment Questionnaire score|Serum trough concentrations|European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score|Patient Global Impression of Change/Severity (PGI-C, PGI-S) and Clinician Global Impression of Change (CGI-C)|Change from baseline in peripheral blood eosinophils|Change from baseline in total serum IgE|Asthma specific resource utilization (eg, unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications)|Change from baseline in weekly mean morning and evening peak expiratory flow (PEF)|Change from baseline in weekly mean number of night time awakenings|Immunogenicity anti-drug antibodies|Proportion of subjects with >=1 asthma exacerbation|Annualized rate of exacerbations associated with emergency room visit, urgent care visit, or hospitalization","AstraZeneca|Amgen","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","1038","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5180C00007","November 23, 2017","September 11, 2020","December 4, 2020","November 20, 2017",,"October 24, 2019","Research Site, Dothan, Alabama, United States|Research Site, Foley, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Encinitas, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Desert, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Westminster, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Celebration, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Fayetteville, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Michigan City, Indiana, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Zachary, Louisiana, United States|Research Site, White Marsh, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Northfield, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Mayfield Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Allen, Texas, United States|Research Site, Amarillo, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Lampasas, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Cudahy, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Quilmes, Argentina|Research Site, Campbelltown, Australia|Research Site, Kent Town, Australia|Research Site, Murdoch, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton, Australia|Research Site, Prahran, Australia|Research Site, Westmead, Australia|Research Site, Woolloongabba, Australia|Research Site, Klagenfurt, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Blumenau, Brazil|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Salvador, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Vitória, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brest Cedex, France|Research Site, GRENOBLE Cedex 9, France|Research Site, Le Kremlin Bicêtre, France|Research Site, Lille Cedex, France|Research Site, Lyon Cedex 04, France|Research Site, MARSEILLE Cedex 20, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes Cedex 1, France|Research Site, PARIS Cedex 12, France|Research Site, Paris Cedex 18, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse CEDEX 09, France|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Landsberg, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Rehovot, Israel|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Edogawa-ku, Japan|Research Site, Fujieda-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Habikino-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Himeji-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakyusyu, Japan|Research Site, Kodaira-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kokubunji-shi, Japan|Research Site, Matsusaka-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Minato-ku, Japan|Research Site, Mizunami-shi, Japan|Research Site, Nagaoka-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Ogaki-shi, Japan|Research Site, Ohota-ku, Japan|Research Site, Omuta-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Setagaya-ku, Japan|Research Site, Setagaya-ku, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsukubo-gun, Japan|Research Site, Ube, Japan|Research Site, Yokkaichi-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yoshida-gun, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Jeju-si, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Izhevsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Bellville, South Africa|Research Site, Boksburg North, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lenasia Ext8, South Africa|Research Site, Middelburg, South Africa|Research Site, Mowbray, South Africa|Research Site, Parow, South Africa|Research Site, Pretoria, South Africa|Research Site, Umkomaas, South Africa|Research Site, Witbank, South Africa|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Yilan, Taiwan|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, London, United Kingdom|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03347279"
748,"NCT03331666","Impact of LDL-cholesterol Lowering on Platelet Activation",,"Recruiting","No Results Available","Familial Hypercholesterolemia","Drug: Evolocumab","Change in P2Y12 Reaction Units|Change in platelet P-selectin level","Columbia University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","AAAR1041","November 16, 2018","July 1, 2021","November 1, 2021","November 6, 2017",,"July 2, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03331666"
749,"NCT03311750","Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","A-REPEAT","Recruiting","No Results Available","Advanced Colorectal Cancer","Drug: Panitumumab","Evaluation of overall response rate of the addition of panitumumab rechallenge to standard third-line therapy|Evaluation of overall response rate by RAS status|Evaluation of Progression Free Survival|Evaluation of Overall Survival|Evaluation of safety of the combination of standard 3rd-line irinotecan-based or oxaliplatin-based chemotherapy with panitumumab rechallenge.|Mutation status of KRAS gene|Mutation status of NRAS gene|Next generation sequencing performed on plasma cell-free DNA.|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in Codon 12 of KRAS gene mutations|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in Codon 61 of KRAS gene mutations|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 15 of BRAF gene mutations|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in Codon 12 of NRAS gene mutations|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in Codon 61 of NRAS gene mutations|Mutations analysis on platelet-resorbed tumour RNA (with Real-time PCR) in exon 20 of PIK3CA gene mutations","Hellenic Cooperative Oncology Group|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HE6B/16|2016-003644-37","March 26, 2018","February 2020","April 2020","October 17, 2017",,"May 2, 2019","Bank Of Cyprus Oncology Centre, Strovolos, Nicosia, Cyprus|""Attikon"" University Hospital, Chaïdári, Athens, Greece|University Hospital of Heraklion, Heraklion, Crete, Greece|Ioannina University Hospital, Ioánnina, Ioannina, Greece|Agii Anargiri Cancer Hospital, Athens, Kalyftaki, Nea Kifisia, Greece|Agii Anargiri Cancer Hospital, Athens, Kalyftaki, Nea Kifisia, Greece|Metropolitan Hospital, Athens, Neo Faliro, Greece|Metropolitan Hospital, Athens, Neo Faliro, Greece|University Hospital of Patra, Río, Patra, Greece|Euromedica General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT03311750"
750,"NCT03292146","Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study",,"Recruiting","No Results Available","Bone Density|Bone Loss|Anorexia Nervosa|Eating Disorder|Atypical Anorexia Nervosa","Drug: Denosumab 60 MG [Prolia]|Drug: Placebo Injection","Change in bone density","Massachusetts General Hospital|Amgen","Female","20 Years to 60 Years   (Adult)","Early Phase 1","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2017P000529","October 25, 2017","September 2020","September 2020","September 25, 2017",,"September 6, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03292146"
751,"NCT03182725","Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome","POTS","Recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome","Drug: Ivabradine|Drug: Placebo","Change in Heart Rate|Change in Quality of Life","University of California, San Diego|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","170694","February 6, 2018","February 2020","June 2020","June 9, 2017",,"August 19, 2019","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03182725"
752,"NCT03182699","Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients","EtECAR-HD","Recruiting","No Results Available","Secondary Hyperparathyroidism|Chronic Kidney Disease Requiring Chronic Dialysis|Left Ventricular Hypertrophy","Diagnostic Test: cardiac MRI|Diagnostic Test: echocardiography with strain|Diagnostic Test: Laboratory tests|Diagnostic Test: Body composition monitoring|Diagnostic Test: lung ultrasound","Left ventricular mass index|Cardiac structure|Laboratory parameters","Rainer Oberbauer|Amgen|Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 4","62","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Etecarhd","October 1, 2017","November 1, 2019","December 1, 2020","June 9, 2017",,"July 25, 2019","Medical University of Vienna, Vienna, Austria|Wiener Dialysezentrum, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03182699"
753,"NCT03137537","Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.",,"Recruiting","No Results Available","Lymphoma|Autonomic Imbalance|Cancer Survivorship","Drug: Ivabradine|Drug: Placebo Oral Tablet","To Investigate Whether Ivabradine Lowers Resting HR, Compared To Placebo, In Survivors Of Lymphoma|To Evaluate Whether Ivabradine Improves Exercise Duration, Compared To Placebo, In Survivors Of Lymphoma","Dana-Farber Cancer Institute|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17-022","February 27, 2018","April 30, 2021","April 30, 2023","May 2, 2017",,"December 18, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03137537"
754,"NCT03121534","Study of Blinatumomab in Richter Transformation",,"Recruiting","No Results Available","Hematopoietic/Lymphoid Cancer|Richter's Transformation","Drug: Blinatumomab|Drug: Dexamethasone","Overall Response Rate (ORR) in Richter's transformation (RT) After Initial Induction with Blinatumomab Treatment|Toxicity of Blinatumomab in Richter's Transformation (RT)","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0765","June 22, 2017","June 1, 2020","June 1, 2021","April 20, 2017",,"May 20, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03121534"
755,"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma|Pre B-Cell Acute Lymphoblastic Leukaemia","Drug: Blinatumomab|Drug: Dexamethasone","Overall survival at two years post first treatment cycle|Non-Relapse Mortality|Progression-free survival|Disease-free Survival|Overall Survival|Minimal Residual Disease","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1713|IRB00125679","September 5, 2017","May 2020","May 2020","April 14, 2017",,"June 13, 2019","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03114865"
756,"NCT03096288","Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity",,"Recruiting","No Results Available","Atherosclerotic Cardiovascular Disease","Drug: Evolocumab|Other: Placebo","HPR rate by VerifyNow|HPR rate by light transmittance aggregometry (LTA)","University of Florida|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIS AMG001","September 18, 2017","December 2019","February 2020","March 30, 2017",,"July 10, 2019","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03096288"
757,"NCT03086642","Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer",,"Recruiting","No Results Available","Pancreatic Cancer","Drug: Talimogene laherparepvec","Maximum Tolerated Dose (MTD)|Change in size of injected lesion(s)|Overall response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)","Yvonne Saenger|Amgen|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAQ9966","November 16, 2017","April 2021","April 2026","March 22, 2017",,"November 14, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03086642"
758,"NCT03072771","Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Blinatumomab|Procedure: Autologous stem cell transplant|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Procedure: Peripheral blood draws","Feasibility and tolerability of blinatumomab consolidation post auto-SCT as measured by percentage of patients who can finish a full course of blinatumomab post-auto-SCT|Progression-free survival (PFS)|Overall survival|Complete remission rate in patients with residual disease after auto-SCT","Washington University School of Medicine|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201704108","August 1, 2017","December 31, 2019","December 31, 2022","March 7, 2017",,"February 20, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03072771"
759,"NCT02990104","First Report, Five Years Experience of the Acute Leukemia Work Group","PR-GTLA","Unknown status","No Results Available","Acute Leukemia (Category)",,"Get the incidence of Acute Lymphoblastic Leukemia in Mexico City reference hospitals|Clinic characteristics, biological and survival in Acute Lymphoblastic Leukemia patients in Mexico City reference hospitals","Mexican Agrupation for Hematology Study|Amgen","All","18 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2016001/PR-GTLA","November 2016","January 2017","July 2017","December 13, 2016",,"December 13, 2016","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT02990104"
760,"NCT02976818","Lp(a) and Aortic Valve Calcification","FHLPA","Active, not recruiting","No Results Available","Heterozygous Familial Hypercholesterolemia",,"Association between Lp(a) concentrations and aortic valve calcification","Laval University|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ISS 20167474","April 30, 2017","October 31, 2019","February 19, 2020","November 29, 2016",,"February 27, 2019","Institute of Nutrition and Functional Foods (INAF), Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02976818"
761,"NCT02891811","Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Thalidomide|Drug: Lenalidomide|Drug: Dexamethasone","Response Rates|Feasibility of a carfilzomib monotherapy maintenance|Safety (adverse events) of a carfilzomib monotherapy maintenance|Overall response rate (efficacy) of a carfilzomib monotherapy maintenance|Response|Overall survival (OS)|Progression free survival (PFS)|Safety and tolerability (adverse events) of induction and maintenance treatment|Changes in quality of life (QoL)|Changes in quality of life (QoL) using multiple myeloma specific questionnaire|Changes of general health status","Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT_MM-2|2016-000475-24","March 10, 2017","September 2023","September 2023","September 8, 2016",,"October 1, 2019","Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie, Graz, Austria|Med. Universität Innsbruck, Univ.-Klinik f. Innere Medizin V, Hämatologie u. Onkologie, Innsbruck, Austria|Bezirkskrankenhaus Kufstein, Innere Medizin, Interne II u. onkologische Tagesklinik, Kufstein, Austria|LKH Hochsteiermark, Standort Leoben, Leoben, Austria|Ordensklinikum Linz - Barmherzige Schwestern Linz, Interne I, Linz, Austria|Ordensklinikum Linz - Elisabethinen, I. Interne Abt. Haemato-Onkologie, Linz, Austria|Kepler Univ.-Klinikum Linz, Klinik f. Interne 3, Linz, Austria|Univ.Klinikum Krems, Klin. Abt. f. Innere Medizin 2, Mitterweng, Austria|Landeskrankenhaus Rankweil, Interne E (Hämatologie u. Onkologie), Rankweil, Austria|PMU Salzburg, Salzburg, Austria|Univ.-Klinikum St. Pölten, Innere Medizin 1, St.Pölten, Austria|Landeskrankenhaus Steyr, Innere Medizin II Onkologie, Steyr, Austria|Medizinische Univ. Wien, Univ.Klinik f. Innere Medizin I, Onkologie, Vienna, Austria|Hanusch-Krankenhaus, Vienna, Austria|Sozialmedizinisches Zentrum Ost - Donauspital, 2. Medizinische Abteilung, Vienna, Austria|Medizinische Univ. Wien, Univ.Klinik f. Innere Medizin I, Hämatologie u. Hämostaseologie, Vienna, Austria|Wilhelminenspital, Vienna, Austria|Landesklinikum Wiener Neustadt, Abteilung Onkologie, Wiener Neustadt, Austria|Krankenhaus Zams, Innere Medizin, Internistische Onkologie u. Hämatologie, Zams, Austria|UK Leipzig Medizinische Klinik und Poliklinik I, Leipzig, Germany|UK Würzburg Medizinische Klinik und Poliklinik II, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT02891811"
762,"NCT02851732","Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular Prevention","BRIDGE-CV","Completed","No Results Available","Cardiovascular Diseases","Behavioral: Quality Improvement Intervention","Adherence to evidence based therapies|LDL < 100mg/dL in 12 months|LDL < 70mg/dL in 12 months|Adherence to Lipid Lowering Agents (Statins)|Adherence to Antiplatelets|Adherence to ACE inhibitors or ARBs|Composite Outcome of Major Cardiovascular Events|Adherence to Beta Blockers|Smoke Cessation Education|Blood Pressure < 140 x 90 mmHg|Blood Pressure < 120 mmHg","Hospital do Coracao|Amgen","All","40 Years and older   (Adult, Older Adult)","Not Applicable","1623","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","BRIDGE0003","August 26, 2016","August 31, 2018","September 2018","August 2, 2016",,"October 2, 2018",,,"https://ClinicalTrials.gov/show/NCT02851732"
763,"NCT02827500","Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)","PRIME-HF","Completed","Has Results","Heart Failure","Drug: ivabradine|Other: Usual Care","Number of Participants Taking Ivabradine at 180 Days|Change in Heart Rate|Heart Rate at 180 Days|Number of Patients With Heart Rate <70 Bpm at 180 Days|Changes in Symptoms and Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score|Changes in Symptoms and Quality of Life as Measured by Patient Global Assessment (PGA)","Duke University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","104","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00071309","July 2016","October 15, 2018","October 15, 2018","July 11, 2016","October 1, 2019","October 1, 2019","University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Athens Regional Medical Center, Athens, Georgia, United States|University Hospital, Augusta, Georgia, United States|Tanner Medical Center, Carrollton, Georgia, United States|Midwest Cardiovascular Research, Elkhart, Indiana, United States|Saint Vincent Medical Group, Inc., Indianapolis, Indiana, United States|Great Lakes Heart Center of Alpena, Alpena, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Ohio State University- Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|William Beaumont Army Medical Center, El Paso, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02827500/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02827500/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02827500"
764,"NCT02819843","A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",,"Recruiting","No Results Available","Melanoma|Merkel Cell Carcinoma|Other Solid Tumors","Drug: TALIMOGENE LAHERPAREPVEC (TVEC)|Radiation: Hypofractionated Radiotherapy","response","Memorial Sloan Kettering Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-224","June 2016","June 2020","June 2020","June 30, 2016",,"September 12, 2019","Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02819843"
765,"NCT02811679","A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma",,"Recruiting","No Results Available","Non-Hodgkin Lymphoma","Drug: Blinatumomab","Overall Response Rate|Overall Survival Rate|Progression Free Survival Rate|Time To Response Rate|Duration of Response|Rate Patients Are Discontinued From The Drug","Massachusetts General Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-118","August 2016","December 2022","December 2023","June 23, 2016",,"November 27, 2019","Massachusetts general Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02811679"
766,"NCT02807883","Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Blinatumomab|Procedure: Hematopoietic Cell Transplantation","Feasibility of Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia|Progression Free Survival (PFS)|Overall Survival (OS)","M.D. Anderson Cancer Center|Amgen","All","1 Year to 70 Years   (Child, Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0576|NCI-2016-01182","August 2016","August 2020","August 2021","June 21, 2016",,"June 18, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02807883"
767,"NCT02779855","Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma","Biological: Talimogene laherparepvec|Drug: Paclitaxel","Phase I: Maximum Tolerated Dose (MTD) / Recommended Phase II Dose (RP2D)|Phase II: Pathologic Complete Response Rate (pCR)","H. Lee Moffitt Cancer Center and Research Institute|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18621","March 22, 2017","August 31, 2021","August 31, 2022","May 20, 2016",,"September 9, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02779855"
768,"NCT02771860","RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints",,"Active, not recruiting","No Results Available","Hand Osteoarthritis","Drug: denosumab|Drug: Placebo|Dietary Supplement: Calcium/Vit D supplementation","Evaluate the change in the negative evolution in GUSS scores in the target IP joints from baseline to week 24","University Hospital, Ghent|Amgen","All","30 Years and older   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AGO/2015/008|2015-003223-53","March 2016","June 26, 2019","June 2020","May 13, 2016",,"October 3, 2019","UZ Ghent, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT02771860"
769,"NCT02613416","Denosumab and MRI Breast Imaging","Dmab","Recruiting","No Results Available","Breast Cancer","Drug: Denosumab","Breast Density|Blood markers","Stony Brook University|Amgen","Female","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","706513","November 2015","November 2020","November 2020","November 24, 2015",,"September 18, 2019","Stony Brook University Cancer Center, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT02613416"
770,"NCT02537535","Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada","GOAL","Enrolling by invitation","No Results Available","Dyslipidemia","Other: survey","Mean LDL-C level according to lipid lowering treatment received|Mean LDL-C level in patients with Familial Hypercholesterolemia|Mean LDL-C level in patients with statin intolerance|Mean LDL-C level in patients receiving combination dyslipidemia therapy|Mean LDL-C level according to statin efficacy|Mean LDL-C level according to their type of medication insurance coverage","Canadian Heart Research Centre|Amgen","All","18 Years and older   (Adult, Older Adult)",,"3000","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","CHRC2014-GOAL Canada Study","January 2016","September 1, 2019","December 1, 2019","September 1, 2015",,"July 17, 2018",,,"https://ClinicalTrials.gov/show/NCT02537535"
771,"NCT02525094","Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis","ALLEVIAD","Completed","Has Results","Atopic Dermatitis","Biological: MEDI9929|Biological: Placebo","Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12|Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12|Mean Change From Baseline in EASI Total Score at Week 12|Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline|Mean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12|Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50|Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75|Mean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12|Mean Change From Baseline in 5-D Pruritus Score at Week 12|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)|Mean Trough Serum Concentration of MEDI9929|Number of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies","MedImmune LLC|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5240C00001","August 15, 2015","May 9, 2016","July 15, 2016","August 17, 2015","February 15, 2018","February 15, 2018","Research Site, North Miami Beach, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Arlington Hts, Illinois, United States|Research Site, Carmel, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Berlin, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, ACT, Australia|Research Site, Liverpool, Australia|Research Site, Woolloongabba, Australia|Research Site, Surrey, British Columbia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Berlin, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Gera, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Debrecen, Hungary|Research Site, Kaposvár, Hungary|Research Site, Miskolc, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Szombathely, Hungary|Research Site, Tauranga, New Zealand|Research Site, Wellington, New Zealand",,"https://ClinicalTrials.gov/show/NCT02525094"
772,"NCT02517944","MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)","CHOLCOEUR","Unknown status","No Results Available","Familial Hypercholesterolemia - Heterozygous",,"Percentage of patients presenting with at least one micro infarction at RMI|LDL-Cholesterol burden (compared to standard values)|Anatomic and functional indexes of the aorta (maximal and minimal areas of aortic lumen, aortic flow)|Correlations between LDL-Cholesterol burden & presence of micro infarction, between LDL-Cholesterol burden & myocardial fibrosis, and between LDL-Cholesterol burden & aortic stiffness indexes","Institute of Cardiometabolism and Nutrition, France|Amgen","All","40 Years to 60 Years   (Adult)",,"110","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","14DRM_CHOLCOEUR","November 2014","September 2015","November 2015","August 7, 2015",,"August 7, 2015","Unité de prévention des maladies cardiovasculaires- Unité INSERM 939 Pôle Cardiologie/Métabolisme Groupe Hospitalier Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT02517944"
773,"NCT02512900","A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma",,"Completed","Has Results","Asthma","Drug: MEDI9929, 140 mg","Area Under the Concentration-time Curve From Zero to Infinity (AUC [0-infinity])|Area Under the Concentration-Time Curve From Zero to Last Observation (AUC [0-t])|Dose-normalized AUC (0-infinity) (AUC [0 Infinity]/D)|Maximum Observed Serum Concentration (Cmax)|Dose-normalized Cmax (Cmax/D)|Time to Reach Cmax (Tmax)|Terminal Phase Elimination Half Life (t1/2,z)|Apparent Clearance (CL/F)|Apparent Steady-state Volume of Distribution (Vss/F)|Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events|Treatment-emergent Adverse Events Related to Vital Sign Parameters and Physical Findings|Treatment-emergent Adverse Events Related to Laboratory Parameters|Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations|Number of Participants Positive for Anti-drug Antibodies and With Neutralizing Antibodies for MEDI9929 at Any Visit","MedImmune LLC|Amgen","All","12 Years to 17 Years   (Child)","Phase 1","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5180C00002|2014-005450-19","September 10, 2015","May 17, 2016","May 17, 2016","July 31, 2015","February 23, 2017","June 21, 2017","Research Site, Kielce, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland",,"https://ClinicalTrials.gov/show/NCT02512900"
774,"NCT02453191","TVEC and Preop Radiation for Sarcoma",,"Active, not recruiting","No Results Available","Soft Tissue Sarcoma","Drug: talimogene laherparepvec|Radiation: Radiotherapy","Phase 1b: To determine the safety and tolerability of neoadjuvant talimogene laherparepvec in combination with preoperative EBRT|Phase 2: To estimate the efficacy of neoadjuvant talimogene laherparepvec and radiotherapy|Overall response rate (ORR) as measured by RECIST 1.1 or a later tool for monitoring disease progression|Time to progression|Overall survival rate (OS) at 5 years|Patients will be monitored for adverse events to assess the safety of talimogene laherparepvec","Mohammed M Milhem|Amgen|University of Iowa","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201504731","July 13, 2015","January 22, 2019","October 16, 2023","May 25, 2015",,"March 19, 2019","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02453191/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02453191/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02453191"
775,"NCT02442648","B-Cell Targeted Carfilzomib Desensitization",,"Recruiting","No Results Available","Transplants and Implants","Drug: Carfilzomib|Drug: Rituximab","Safety of carfilzomib will be assessed by incidence of grade 3 and above non-hematologic toxicities, incidence of grade 4 hematologic toxicities and incidence of all grades of peripheral neuropathy|Efficacy of carfilzomib","E. Steve Woodle|Amgen|University of Cincinnati","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Carfilzomib","December 2014","June 2019","September 2019","May 13, 2015",,"August 8, 2018","The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02442648"
776,"NCT02435147","Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index",,"Completed","Has Results","Osteoporosis|Bone Fracture","Drug: denosumab","Proportion of Change in Mean Trabecular Bone Score|Proportion of Change in Mean Femur Strength Index Score","HealthEast Care System|Amgen","Female","40 Years to 90 Years   (Adult, Older Adult)",,"86","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HE 15 03 003","April 2015","June 2016","June 2016","May 6, 2015","October 29, 2018","October 29, 2018","HealthEast Care System, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02435147"
777,"NCT02420587","AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)",,"Withdrawn","No Results Available","Prostate Cancer","Drug: AMG 208|Behavioral: Questionnaire","Progression-Free Survival (PFS)","M.D. Anderson Cancer Center|Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-1049","October 2014","October 2019",,"April 20, 2015",,"April 20, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02420587"
778,"NCT02392039","Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: Pegfilgrastim|Drug: Loratadine|Other: Placebo|Behavioral: Questionnaires","Bone Pain Related Quality of Life (QOL) Measured by FACT-Bone Pain (FACT-BP) Questionnaire","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2014-0880|NCI-2015-00592","December 14, 2015","April 4, 2018","April 4, 2018","March 18, 2015",,"April 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02392039"
779,"NCT02334306","A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome",,"Completed","Has Results","Primary Sjögren's Syndrome","Biological: AMG 557/MEDI5872|Other: Placebo","Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99|Ratio to Baseline in Peripheral Blood Biomarkers at Day 99|Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99|Ratio to Baseline in Focus Score at Day 99|Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Patient Reported Index (ESSPRI) Score at Day 99|Percentage of ESSDAI Responders at Day 99|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants With Adverse Events of Special Interest (AESIs)","MedImmune LLC|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5181C00001","June 8, 2015","January 16, 2018","August 13, 2018","January 8, 2015","March 19, 2019","March 19, 2019","Research Site, San Francisco, California, United States|Research Site, Bethesda, Maryland, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Brest Cedex, France|Research Site, Le Kremlin-bicêtre, France|Research Site, Lille Cedex, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Strasbourg, France|Research Site, Stockholm, Sweden|Research Site, London, United Kingdom|Research Site, Newcastle-upon-Tyne, United Kingdom|Research Site, Swindon, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02334306/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02334306/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02334306"
780,"NCT02318784","Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers",,"Active, not recruiting","No Results Available","Neuroendocrine Cancer","Drug: Carfilzomib","Overall Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Number of treatment-emergent adverse events as a measure of safety and tolerability","SCRI Development Innovations, LLC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GI 195","July 15, 2015","February 1, 2020","February 1, 2020","December 17, 2014",,"April 12, 2019","Rocky Mountain Cancer Center, Denver, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Ingalls Cancer Research Center, Harvey, Illinois, United States|Research Medical Center, Kansas City, Missouri, United States|Oncology Hematology Care, INC., Cincinnati, Ohio, United States|Spartanburg Regional Medical Center/Gibbs Cancer Center, Spartanburg, South Carolina, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02318784"
781,"NCT02302495","Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma","IFM2012-03","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib","Dose Maximum Tolerate of Carfilzomib Weekly|number of patients who reach Very Good Partial Response and Complete","University Hospital, Lille|Amgen","All","65 Years and older   (Older Adult)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012_32|2012-004490-10","January 2014","July 2021","July 2021","November 27, 2014",,"June 25, 2019","Centre Hospitalier H. Duffaut, Avignon, France|Centre Hospitalier de la côte basque, Bayonne, France|Hôpital Jean Minjoz, Besançon, France|Institut Bergonie, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Hospitalier William Morey, Chalons-sur-Saone, France|Centre Hospitalier de Chambery, Chambery, France|Hôpital St Antoine Béclére, Clamart, France|CH Louis Pasteur, Colmar, France|CH Francilien, Corbeil - Essonnes, France|CHU Henri Mondor, Creteil, France|Hématologie Clinique, CHU, Hôpital d'Enfants, Dijon, France|Centre hospitalier départemental La Roche sur Yon, La Roche sur Yon, France|Centre Jean Bernard, Le Mans, France|Hôpital St Vincent de Paul - GH-ICL, Lille, France|Chru Lille, Lille, France|CHU de Limoges, Limoges, France|Hématologie, Institut Paoli Calmette, Marseille, France|CH Meaux, Meaux, France|Hôpital Notre Dame de Bon Secours, Metz, France|Hopital J Monod, Montivilliers, France|Hôpital E Muller, Mulhouse, France|CHRU, Hôtel Dieu, Nantes, France|Centre de NICE 2/ Hôpital Archet, Nice, France|CHU Nimes CAREMEAU, Nimes, France|Hôpital St Antoine, Paris, France|Groupe hospitalier Pitié Salpétrière, Paris, France|Hôpital Haut-Leveque, PESSAC cedex, France|Centre Hospitalier Lyon Sud -1, Pierre Benite, France|Unité de Recherche Clinique - CH Perigueux, Périgueux, France|Hématologie Clinique, Hôpital Robert Debré, CHU Reims, Reims, France|Hématologie, IUCT oncopole, Toulouse, France|CHRU, Hôpitaux de Brabois, Vandoeuvre, France",,"https://ClinicalTrials.gov/show/NCT02302495"
782,"NCT02301962","Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer",,"Recruiting","No Results Available","Cancer","Drug: Panitumumab","Number of subjects with adverse event.|Progression free survival.|Overall Response Rate.|Duration of response.","Dr. Reddy's Laboratories Limited|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRL-INDG02-PAN/2018","July 28, 2015","June 30, 2021","January 31, 2022","November 26, 2014",,"December 16, 2019","DRL Investigational Site, Vijayawada, Andhra Pradesh, India|DRL Investigational Site, Mumbai, Maharashtra, India|DRL Investigational Site, Nagpur, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Ludhiāna, Punjab, India|DRL Investigational Site, Jaipur, Rajasthan, India|DRL Investigational Site, Madurai, Tamilnadu, India|DRL Investigational Site, Hyderabad, Telangana, India|DRL Investigational Site, Kolkata, West Bengal, India|DRL Investigational Site, New Delhi, India|DRL Investigational Site, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02301962"
783,"NCT02294357","Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Prednisone|Drug: Methylprednisolone|Drug: Lenalidomide|Drug: Pomalidomide","Overall response rate (ORR)|Clinical Benefit Rate (CBR)|Number of patients undergoing adverse events|Time to Progression (TTP)|Progression-Free Survival (PFS)|Time to Response (TTR)|Duration of Response (DOR)|Overall Survival (OS)","Oncotherapeutics|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IST-CAR-2014-100701 (20159897)","December 2014","June 2020","July 2020","November 19, 2014",,"December 10, 2019","California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Wellness Oncology and Hematology, West Hills, California, United States|James R Berenson, MD, Inc., West Hollywood, California, United States|Cancer Specialists of North Florida, Fleming Island, Florida, United States|Hudson Valley Hem/Onc Associates, Poughkeepsie, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Blood & Cancer Center of East Texas, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02294357"
784,"NCT02293109","Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma",,"Recruiting","No Results Available","Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia","Drug: carfilzomib|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: dexamethasone|Drug: methotrexate|Drug: cytarabine|Drug: leucovorin calcium|Drug: methylprednisolone|Biological: rituximab|Other: laboratory biomarker analysis","Maximum tolerated dose of carfilzomib with hyper-CVAD, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4|Rate of remission|Rate of minimal residual disease (MRD) in bone marrow aspirate samples|Rate of MRD in bone marrow aspirate samples","University of California, Davis|Amgen","All","18 Years to 64 Years   (Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","660258|UCDCC#246|NCI-2014-02245","December 2015","December 2018","December 2018","November 18, 2014",,"March 2, 2018","University of California Davis, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT02293109"
785,"NCT02273570","Optimal Anemia Treatment in End Stage Renal Disease (ERSD)","OPTIMAL","Unknown status","No Results Available","Hyperparathyroidism, Secondary","Drug: standard care|Drug: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D","percent reduction in weekly ESA consumption to maintain Hb levels within the recommended range 10.0-11.5 g/dl|Change in iron status and storage.|Difference in prevalence of cardiac valvular calcification progression detected by echocardiography between groups.|Difference in pulse wave velocity assessed by applanation tonometry between groups.|CKD-MBD control","Azienda Ospedaliera Sant'Anna|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AOSantAnna","March 2015","December 2016","March 2017","October 24, 2014",,"September 15, 2015","Azienda Ospedaliera Sant'Anna, San Fermo della battaglia (CO), Italy",,"https://ClinicalTrials.gov/show/NCT02273570"
786,"NCT02257476","Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Neoplasms|Malignancies","Drug: Carfilzomib|Drug: Dexamethasone","Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of a weekly 4-hour carfilzomib infusion in patients with advanced solid malignancies|Pharmacokinetics (PK) of escalating doses of weekly intravenous carfilzomib|Changes in pharmacodynamic (PD) biomarkers before and during treatment with carfilzomib using peripheral blood mononuclear cells (PBMC) and paired tumor biopsies|Preliminary anti-tumor efficacy (objective response rate)|Preliminary anti-tumor efficacy (clinical benefit rate)|Preliminary anti-tumor efficacy (progression free survival)|Preliminary anti-tumor efficacy (overall survival)","Emory University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00071307|WINSHIP2598-13","August 2014","November 2016","November 2016","October 6, 2014",,"February 7, 2017","Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02257476"
787,"NCT02235740","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",,"Terminated","No Results Available","Cancer","Drug: Afuresertib|Drug: Carfilzomib","Part1: Number of participants with adverse events (AEs) as a measure of safety|Part1: Safety assessed by monitoring the changes in vital signs|Part1: Safety assessed by monitoring the changes in laboratory parameters|Part1: Safety assessed by monitoring the changes in electrocardiograms (ECG)|Part 2: Progression Free Survivial (PFS)|Part 1: Composite of PK parameters of afuresertib and carfilzomib alone or in combination with each other will be assessed following multiple afuresertib doses and following a single dose of carfilzomib|Part 1: Afuresertib concentrations|Part1: Overall response rate (ORR)|Part1: PFS|Part1: Overall survival (OS)|Part1: Duration of response (DOR)|Part 2: ORR|Part 2: OS|Part 2: DOR|Part 2: Number of participants with adverse events (AEs) as a measure of safety|Part 2: Safety assessed by monitoring the changes in vital signs|Part 2: Safety assessed by monitoring the changes in laboratory parameters|Part 2: Safety assessed by monitoring the changes in ECG|Part 2: Afuresertib concentrations","Novartis|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200623","November 2014","October 2015","October 2015","September 10, 2014",,"May 4, 2016","Novartis Investigative Site, Cary, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02235740"
788,"NCT02128230","UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: MEL-CFZ-TD-PACE","The remission rate for participants with high-risk myeloma","University of Arkansas|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","134668","August 2014","May 2025","May 2025","May 1, 2014",,"October 22, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02128230"
789,"NCT02054130","Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma",,"Completed","Has Results","Asthma","Drug: Placebo|Drug: MEDI9929 70 mg|Drug: MEDI9929 210 mg|Drug: MEDI9929 280 mg","Annualized Asthma Exacerbation Rate (AER) Through Week 52|Reduction in AER on Subpopulations at Week 52|Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52|Change From Baseline in FEV1 on Subpopulations at Week 52|Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52|Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52|Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52|Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52|Rate of Severe Asthma Exacerbation Through Week 52|Time to First Asthma Exacerbation Through Week 52|Time to First Severe Asthma Exacerbation Through Week 52|Number of Participants With at Least One Asthma Exacerbations Through Week 52|Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52|Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52|Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52|Total Amount of Study Drug Exposure|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With TEAEs Related to Vital Sign Parameters|Number of Participants With TEAEs Related to Clinical Laboratory Evaluation|Number of Participants With TEAEs Related to Electrocardiogram Evaluations|Mean Serum Concentrations of MEDI9929|Number of Participants With Positive Antibodies to MEDI9929","MedImmune LLC|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CD-RI-MEDI9929-1146|2013-003269-33","December 13, 2013","December 12, 2016","March 1, 2017","February 4, 2014","December 4, 2018","December 4, 2018","Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Miami, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Dublin, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Brandys nad Labem, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Mlada Boleslav, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha 8, Czechia|Research Site, Strakonice, Czechia|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csorna, Hungary|Research Site, Debrecen, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Gödöllő, Hungary|Research Site, Komarom, Hungary|Research Site, Mateszalka, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Szeged, Hungary|Research Site, Százhalombatta, Hungary|Research Site, Torokbalint, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petach Tikva, Israel|Research Site, Rehovot, Israel|Research Site, Tel Hashomer, Israel|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Kiyose-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Ora-gun, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saitama-Ken, Japan|Research Site, Sapporo-shi, Japan|Research Site, Taito-ku, Japan|Research Site, Toshima-ku, Japan|Research Site, Yokkaichi-shi, Japan|Research Site, Daugavpils, Latvia|Research Site, Rezekne, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Ilava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Poprad, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Sturovo, Slovakia|Research Site, Surany, Slovakia|Research Site, Topolcany, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Durban, South Africa|Research Site, Middelburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Mykolayiv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Suprunivka Vil., Poltava Regio, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT02054130"
790,"NCT02052882","Study of Romiplostim for Chemotherapy Induced Thrombocytopenia",,"Active, not recruiting","No Results Available","Isolated Chemotherapy-induced Thrombocytopenia","Biological: romiplostim","Achievement of platelet counts of ≥ 100,000/mcL|Assessment of potential toxicity","Memorial Sloan Kettering Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-132","January 30, 2014","January 2020","January 2020","February 3, 2014",,"March 8, 2019","Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02052882"
791,"NCT02047253","Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment",,"Completed","Has Results","Metastatic Castration-resistant Prostate Cancer","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Acyclovir","Progression-free Survival (PFS)|Overall Survival|Number of Participants With Prostate-Specific Antigen (PSA) Changes|Number of Participants With Circulating Tumor Cell (CTC) Decline Over Three Time Points (Before Study Initiation, Day 1 of Cycles 2 and 4|Assessment of Toxicities","University of Alabama at Birmingham|Amgen","Male","19 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F130725012 (UAB 1336)","April 2014","June 8, 2017","July 14, 2017","January 28, 2014","December 19, 2018","December 19, 2018","Birmingham VA Medical Center, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Cancer Life Center, Navicent Health, Macon, Georgia, United States|University of Tulane, New Orleans, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02047253/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02047253"
792,"NCT01989689","Etanercept and Vascular Function in Psoriasis","EVIP","Completed","Has Results","PSORIASIS","Drug: Etanercept|Drug: Placebo","Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD)|Vascular Function as Measured by Brachial Artery Flow Mediated Dilation (FMD)","Emory University|Amgen","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00039574","August 2010","September 2013","September 2013","November 21, 2013","December 19, 2014","December 19, 2014","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01989689"
793,"NCT01971346","The Immunological Basis for Treatment Resistance to Anti-TNF Treatments",,"Completed","Has Results","Psoriasis","Drug: etanercept","Change in Psoriasis Area and Severity Index (PASI) Score|Tumor Necrosis Factor (TNF)-Alpha Signal Strength|Interferon (IFN)-Alpha Signal Strength|Psoriasis Area and Severity Index (PASI) Response Profile","University of Michigan|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Derm 652","March 13, 2014","November 1, 2017","November 1, 2017","October 29, 2013","January 9, 2019","January 9, 2019","University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01971346/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01971346"
794,"NCT01952054","Denosumab for Breast Cancer With Bone Mets",,"Terminated","Has Results","Breast Cancer","Drug: Denosumab","The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) Among Breast Cancer Patients With Bone Metastases.|The Changes of Epithelial-mesenchymal Transition (EMT) in CTCs|The Changes in Urine N-telopeptide Level","M.D. Anderson Cancer Center|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0007|NCI-2014-01273","February 9, 2015","October 10, 2018","October 10, 2018","September 27, 2013","November 22, 2019","November 22, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01952054/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01952054"
795,"NCT01926665","Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",,"Completed","No Results Available","Lymphoma","Drug: Carfilzomib|Drug: Dexamethasone","Maximum Tolerated Dose (MTD) of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT)|Efficacy of Carfilzomib (CFZ) After Autologous Stem Cell Transplantation (ASCT)","M.D. Anderson Cancer Center|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-1070|NCI-2014-00994","June 17, 2014","September 17, 2017","September 17, 2017","August 21, 2013",,"September 19, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01926665"
796,"NCT01926158","Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women","ProliaHip","Completed","No Results Available","Hip Osteoarthritis","Drug: Denosumb|Drug: Placebo (for denosumab)","Periprosthetic bone mineral density (BMD)|Radiostereometric analysis (RSA) of prosthesis stem migration","Turku University Hospital|Amgen","Female","60 Years to 85 Years   (Adult, Older Adult)","Phase 4","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ISS 20109714|2011-000628-14","December 2013","February 4, 2017","December 31, 2017","August 20, 2013",,"April 30, 2018","Turku University Hospital, Turku, Finland",,"https://ClinicalTrials.gov/show/NCT01926158"
797,"NCT01920568","A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors",,"Completed","Has Results","Fractures, Bone","Biological: Denosumab 70 mg/mL|Drug: Zoledronic acid 4 mg|Drug: Placebo IV|Drug: Placebo SC|Dietary Supplement: Calcium supplement|Dietary Supplement: Vitamin D supplement","Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)|Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.|Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.|Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.|Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)|Number of Participants With Worst-case (WC) On-therapy Increase in the Indicated Clinical Chemistry Parameters From Baseline Grade to the Indicated Grade.|Number of Participants With Worst-case On-therapy Increase in the Indicated Hematology Parameters From Baseline Grade to the Indicated Grade.|Number of Participants With Confirmed Anti-denosumab Antibody Formation at Day 1, Week 25 and Week 53.|Serum Concentration of Denosumab on Day 1, at Week 2, Week 5, Week 9, Week 13, Week 17, Week 19, Week 21, Week 25 and Week 49","GlaxoSmithKline|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","487","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","114273","August 2013","February 2015","April 2016","August 12, 2013","August 25, 2016","January 16, 2017","GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Changchun, Jilin, China|GSK Investigational Site, Chengdu, Sichuan, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Fuzhou, China|GSK Investigational Site, Hangzhou, China|GSK Investigational Site, Harbin, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01920568"
798,"NCT01916109","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",,"Terminated","Has Results","Bladder Cancer","Drug: Gemcitabine|Drug: Carboplatin|Drug: Panitumumab|Procedure: radical cystectomy","Pathologic Complete Response Rate (<pT0)","Memorial Sloan Kettering Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-103","August 2013","July 2015",,"August 5, 2013","February 12, 2016","February 12, 2016","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT01916109"
799,"NCT01907308","Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma",,"Withdrawn","No Results Available","Urothelial Carcinoma","Drug: AMG 386|Drug: Docetaxel","Response rate|Overall survival","University of Colorado, Denver|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-1502.cc|NCI-2013-01348","February 2014","April 2014","April 2014","July 24, 2013",,"April 29, 2014",,,"https://ClinicalTrials.gov/show/NCT01907308"
800,"NCT01842776","Care Transitions in Renal Disease Patients","CT","Unknown status","No Results Available","Renal Disease",,"30-day readmission rate","Fresenius Medical Care North America|Amgen","All","18 Years and older   (Adult, Older Adult)",,"3300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20129159","March 2013","June 2014","December 2014","April 30, 2013",,"April 30, 2013","Fresenius, Franklin, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01842776"
801,"NCT01814501","Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab",,"Active, not recruiting","No Results Available","Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer","Biological: panitumumab|Drug: irinotecan hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium","Progression free survival(PFS)|Frequency and severity of toxicities of the regimens, graded according to the NCI CTCAE v4.0|Overall response rate, as described in RECIST v1.1 criteria|Overall survival","John Hays|Amgen|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-11131|NCI-2013-00432","February 1, 2013","December 31, 2019","December 31, 2019","March 20, 2013",,"March 27, 2019","Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01814501"
802,"NCT01792102","Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib and Dexamethasone","Establish maximum tolerated dose (MTD)|Establish efficacy as assessed by the overall response rate","Oncotherapeutics|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IST-CAR-585","April 2013","December 2018","December 2018","February 15, 2013",,"March 5, 2018","James R. Berenson M.D. Inc., West Hollywood, California, United States|John Theuer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01792102"
803,"NCT01789242","A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis",,"Completed","No Results Available","Amyloidosis|Systemic Light Chain Amyloidosis","Drug: Carfilzomib|Drug: Dexamethasone","Adverse Events as a Measure of Safety and Tolerability|Hematologic Response|Organ Response|Progression Free Survival|Time to next therapy","Criterium, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMyC 11MM02|IST-CAR-545","February 2013","December 2016","July 2017","February 12, 2013",,"October 18, 2017","City of Hope, Duarte, California, United States|Stanford Cancer Institute, Stanford, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Boston University Medical Center, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01789242"
804,"NCT01775553","Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib",,"Completed","Has Results","Relapse Multiple Myeloma|Refractory Multiple Myeloma","Drug: Carfilzomib","Safety and Efficacy of High Dose Carfilzomib|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Duration of Response to High Dose Carfilzomib|Markers of ER Stress","Ajai Chari|Amgen|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-1506|CAR IST 534","September 2013","May 2016","May 2016","January 25, 2013","June 21, 2017","June 21, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01775553"
805,"NCT01738594","Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma",,"Terminated","Has Results","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome","Drug: carfilzomib|Drug: romidepsin|Other: laboratory biomarker analysis","Number of Patients With Dose Limiting Toxicities (DLTs)|Overall Response Rate (ORR) of the Disease When Treated With Carfilzomib Alone and When Taken With Romidepsin|Duration of Response of the Disease When Treated With Carfilzomib Alone and When Taken With Romidepsin|Time to Progression (TTP) of the Disease When Treated With Carfilzomib Alone and When Taken With Romidepsin","Northwestern University|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 12H06|STU00071042|NCI-2012-01952","March 22, 2013","October 11, 2016","October 11, 2016","November 30, 2012","August 29, 2019","August 29, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01738594"
806,"NCT01710722","The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man",,"Completed","No Results Available","Obesity","Drug: caffeine and ephedrine|Drug: Leptin A|Drug: caffeine, ephedrine, and leptin A","Compare the percent loss of total body fat to the percent loss of visceral fat with leptin alone, caffeine and ephedrine and the combination of leptin,caffeine and ephedrine.|Compare the loss of fat and lean tissue with leptin alone.|To compare the loss of fat and lean tissue with caffeine with ephedrine alone.|compare the loss of fat and lean tissue with leptin, ephedrine and caffeine combination.|To compare weight loss with leptin alone.|To compare weight loss caffeine with ephedrine alone.|To compare weight loss with leptin, ephedrine and caffeine combination.|To compare the changes in insulin, with leptin alone.|To compare the changes in insulin, with caffeine with ephedrine alone|To compare the changes in insulin, with leptin , ephedrine and caffeine combination.|To compare the changes in triglycerides, with leptin alone.|To compare the changes in triglycerides, caffeine with ephedrine alone.|To compare the changes in triglycerides, with leptin , ephedrine and caffeine combination|To compare the changes in cholesterol, with leptin alone.|To compare the changes in cholesterol, caffeine with ephedrine alone.|To compare the changes in cholesterol with leptin , ephedrine and caffeine combination|To compare the changes in HDL cholesterol, with leptin alone.|To compare the changes in HDL cholesterol, caffeine with ephedrine alone.|To compare the changes in HDL cholesterol, with leptin , ephedrine and caffeine combination|To compare the changes in LDL cholesterol, with leptin alone.|To compare the changes in LDL cholesterol, caffeine with ephedrine alone.|To compare the changes in LDL cholesterol, with leptin , ephedrine and caffeine combination|To compare the changes in glucose, with leptin alone.|To compare the changes in glucose, caffeine with ephedrine alone.|To compare the changes in glucose, with leptin , ephedrine and caffeine combination|To compare the changes in uric acid, with leptin alone.|To compare the changes in uric acid, caffeine with ephedrine alone.|To compare the changes in uric acid, with leptin , ephedrine and caffeine combination|To compare the changes in Alanine Aminotransferase (ALT )with leptin alone.|To compare the changes in Alanine Aminotransferase (ALT ) caffeine with ephedrine alone.|To compare the changes in Alanine Aminotransferase (ALT ) with leptin , ephedrine and caffeine combination","Pennington Biomedical Research Center|Amgen","All","18 Years to 60 Years   (Adult)","Not Applicable","45","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PBRC 20034","February 2001","February 2002","February 2002","October 19, 2012",,"December 18, 2015","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01710722"
807,"NCT01692912","Psoriatic Arthritis Treat to Target vs. Usual Care","PRC-05-2011","Withdrawn","No Results Available","Psoriatic Arthritis (PsA)","Other: Intensive Care","Percentage of patients achieving low DAS|Time to achieving DAS28<2.6|Absolute change in DAS28|Percentage of Patients achieving ACR 20, 50, and 70|Percentage of patients achieving PsARC|Absolute change in HAQ-DI","Pope Research Corporation|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","PRC-05-2011","October 2012","November 2014","November 2014","September 25, 2012",,"April 7, 2017","Pope Research Corp., 68 Green Acres Drive, London, Ontario, Canada|The Arthritis Program Research Group, Newmarket, Ontario, Canada|Arthur Karasik, Toronto, Ontario, Canada|Institut de Rheumatologie de Montreal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01692912"
808,"NCT01690143","Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation",,"Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Melphalan","Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple Myeloma(MM) [Phase I Portion of Study]|Very Good Partial Response (VGPR) Rate.|Complete Response (CR) Rate.|Median Time for Neutrophil and Platelet Engraftment.|Frequency of Grades 3 and 4 Non-hematologic Adverse Events During the Transplant Component ( 135 Days)","University of Alabama at Birmingham|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTO 101669|Onyx IST-CAR-536","May 2012","November 1, 2017","November 1, 2017","September 21, 2012","July 10, 2018","August 7, 2018","UAB, Birmingham, Alabama, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01690143/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01690143/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01690143"
809,"NCT01671319","Dose Dense TC + Pegfilgrastim Support for Breast Cancer","ddTC","Completed","Has Results","Female Breast Cancer","Drug: docetaxel + cyclophosphamide + pegfilgrastim","Feasibility for Dose-dense TC Therapy: Number of Participants Receiving at Least 90% of Total Dose of Therapy|Incidence of Febrile Neutropenia|Incidence of Neuropathy","University of Wisconsin, Madison|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO10104|2011-0062|NCI-2011-03640|A535900|SMPH\ONCOLOGY\ONCOLOGY","June 2011","April 2013","April 2013","August 23, 2012","October 12, 2017","November 27, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01671319"
810,"NCT01660750","A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma","11-MM-01","Completed","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Adverse Events as a measure of safety and tolerability|Overall Response after induction therapy|Overall Response post ASCT|Time to Progression|Progression Free Survival|Time to Next Therapy","Criterium, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMyC 11-MM-01|CAR-IST-520","January 2013","August 2015","December 2015","August 9, 2012",,"October 18, 2017","Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States|Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|University of Massachusettes Memorial, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01660750"
811,"NCT01541072","Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation","PALM2","Terminated","No Results Available","Non Hodgkin Lymphoma","Drug: Pegfilgrastim|Drug: Filgrastim","3 months kinetics of lymphocyte reconstitution, in the two arms|6 months kinetics of lymphocyte reconstitution, in the two arms|6 months kinetics of lymphocyte subsets reconstitution by phenotyping, in the 2 arms|Average duration of neutropenia and thrombopenia, in the 2 arms|Number of days with temperature ≥38°, in the 2 arms|Number of bacterial and/or viral and/or fungal infection longer than 7 days, average duration of anti-viral, anti-fungal and antibiotic treatments, in the 2 arms|Number of red blood cell units and platelets concentrates transfused to patient, in the 2 arms|Evaluation of duration of Filgrastim treatment, in arm ""Filgrastim""|Overall survival|Progression free survival|Average duration of febrile neutropenia (with neutrophils<0.5 G/L and temperature ≥38°), in the 2 arms","Centre Leon Berard|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET2011-010|2011-A00662-39","February 2012","June 2014","September 2014","February 29, 2012",,"November 1, 2016","CHU Clermont-Ferrand, Hôpital d'Estaing, Clermont-Ferrand, France|Centre Leon Berard, Lyon, France",,"https://ClinicalTrials.gov/show/NCT01541072"
812,"NCT01525654","Patient Rheumatoid Arthritis Social Support Study","PARASS","Active, not recruiting","No Results Available","Rheumatoid Arthritis","Behavioral: Peer Support Program","change in functional status|change in medication adherence|change in self-efficacy|change in fatigue|change in pain","Brigham and Women's Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","65","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2006P000795","March 2009","January 2020","January 2020","February 3, 2012",,"February 26, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01525654"
813,"NCT01516619","Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia","ProRom","Unknown status","No Results Available","Non-Hodgkin Lymphoma","Drug: Romiplostim","safety|activity","Andres J. M. Ferreri|Amgen|IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ProRom","November 2011","November 2013","September 2014","January 25, 2012",,"January 25, 2012","Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01516619"
814,"NCT01502982","Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)","CRY-04","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R-CHOEP14x6+HD-AraC+HD-Mtx","Time to treatment failure|Number of participants with adverse events|Clinical response rate|Time to progression|Overall survival|Incidence of CNS relapse|Molecular factors important for clinical outcome","Nordic Lymphoma Group|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","160","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-04|2004-003075-37","November 2004","December 2013","May 2014","January 2, 2012",,"September 30, 2014","Odense University Hospital, Odense, Denmark|Helsinki University central Hospital, Helsinki, Finland|Oslo University Hospital, Oslo, Norway|Lund University Hospital, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT01502982"
815,"NCT01479179","Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab",,"Withdrawn","No Results Available","Breast Cancer","Drug: AMG 479|Drug: Trastuzumab","Maximum tolerated dose (MTD)|Clinical Benefit Rate (CBR)","M.D. Anderson Cancer Center|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0542","November 2012","November 2015",,"November 24, 2011",,"October 26, 2016",,,"https://ClinicalTrials.gov/show/NCT01479179"
816,"NCT01470196","Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia","CaRD","Completed","Has Results","Waldenstrom's Macroglobulinemia","Drug: Dexamethasone|Drug: Carfilzomib|Drug: Rituximab","Overall Response Rate|Neuropathy Incidence Rate|Time to Progression|Major Response Rate|Very Good Partial Response and Complete Response Rate","Dana-Farber Cancer Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-279","October 2011","September 2016","September 2016","November 11, 2011","March 21, 2017","November 20, 2018","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01470196"
817,"NCT01384994","Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients",,"Unknown status","No Results Available","Colorectal Cancer|KRAS Wildtype|After Resection of Liver Metastases","Drug: Folic Acid|Drug: 5-FU|Drug: Oxaliplatin|Drug: Panitumumab","Progression Free Survival|Tolerability and side effects|Overall Survival","PD Dr. med. Volker Heinemann|Amgen|Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PARLIM","August 2011","August 2013","August 2014","June 29, 2011",,"July 9, 2012","Ludwig-Maximilians - University of Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT01384994"
818,"NCT01365559","Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments",,"Completed","No Results Available","Multiple Myeloma","Drug: Group A: Carfilzomib & Non-IMiD Regimen|Drug: Group B: Carfilzomib & IMiD containing regimen.","Establish MTD, determine DLT and to determine the efficacy as assessed by the overall response rate.|To establish safety and efficacy following treatment.","Oncotherapeutics|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IST-CAR-516","May 2, 2011","June 13, 2014","March 1, 2016","June 3, 2011",,"March 5, 2018","Pacific Oncology and Hematology, Encinitas, California, United States|Pacific Cancer Care, Salinas, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|James R. Berenson, MD, Inc., West Hollywood, California, United States|Cancer Centers of America, Zion, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Family Cancer Center Foundation, Inc., Memphis, Tennessee, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01365559"
819,"NCT01351623","Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib","To Evaluate the Best Overall Response Rate (ORR)","Memorial Sloan Kettering Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-228","May 9, 2011","January 26, 2016","January 26, 2016","May 11, 2011","March 13, 2017","April 13, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01351623"
820,"NCT01351038","Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma",,"Terminated","No Results Available","KRAS Wild Type|Resectable Type II Gastric Adenocarcinoma","Drug: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab","Efficacy|Safety|Histopathological response|overall survival after one year|Progression free survival after one year|Proportion of patients completing 3 treatment cycles","Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGMT Gastric-4",,,,"May 10, 2011",,"June 4, 2013","LKH Feldkirch, Feldkirch, Austria|KH Elisabethinen Linz, Linz, Austria|AKh Linz, Linz, Austria|Universitätsklinik für Innere Medizin III, Salzburg, Austria|Klinikum Kreuzschwestern Wels GmbH, Wels, Austria|St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria",,"https://ClinicalTrials.gov/show/NCT01351038"
821,"NCT01313884","Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma",,"Terminated","Has Results","Bone Cancer|Ewing's Sarcoma","Drug: Irinotecan|Drug: Vincristine|Drug: Temozolomide|Drug: Doxorubicin|Drug: Cytoxan|Drug: Pegfilgrastim","Overall Response Rate (Partial and Complete Response)|Progression-free Survival (PFS)","Stanford University|Amgen","All","13 Years and older   (Child, Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-20323|SU-03082011-7559|SARCOMA0007","May 2011","July 2014","July 2014","March 14, 2011","February 2, 2017","November 24, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01313884"
822,"NCT01312857","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",,"Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: panitumumab|Drug: Randomization to No Panitumumab","to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases|to assess toxicity as per the NCI Common Toxicity Criteria|to determine survival|to analyze tumor tissue for predictive biomarkers","Memorial Sloan Kettering Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-137","March 2011","March 2020","March 2020","March 11, 2011",,"August 16, 2019","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT01312857"
823,"NCT01312493","Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab",,"Withdrawn","No Results Available","Head and Neck Cancer","Drug: Panitumumab|Radiation: Intensity Modulated Radiation Therapy","Recurrence Rate of Locally Advanced Head & Neck Cancer|Patterns of Failure|Time to Relapse|Morbidity of Treatment","UNC Lineberger Comprehensive Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1017","December 2011","December 2017","December 2018","March 10, 2011",,"August 28, 2015",,,"https://ClinicalTrials.gov/show/NCT01312493"
824,"NCT01308840","Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer","UGIH09067","Completed","Has Results","Biliary Tract Cancer|Gallbladder Cancer","Drug: Panitumumab|Drug: oxaliplatin|Drug: gemcitabine","The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response Evaluation Criteria In Solid Tumors (RECIST) Criteria.|Median Progression Free Survival|Median Overall Survival|The Number of Participants Who Experience an Adverse Event","University of Rochester|Amgen","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UGIH09067","December 2010","January 2013","January 2013","March 4, 2011","August 17, 2016","August 17, 2016","Dana-Farber / Harvard Cancer Center, Boston, Massachusetts, United States|University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01308840"
825,"NCT01305772","Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN","TOP0901","Terminated","Has Results","Squamous Cell Carcinoma of the Head and Neck","Drug: Panitumumab|Procedure: Surgery|Procedure: Radiation Therapy","Change in Tumor (Primary Tumor and Lymph Node) Response and Progression Between Pre- and Post- Panitumumab Therapy|Nine (9) Month Progression Free Survival (PFS)|Nine (9) Month Overall Survival (OS)","Neal Ready|Amgen|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00023859|20080645","January 2011","March 2012","May 2012","March 1, 2011","August 29, 2014","August 29, 2014","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01305772"
826,"NCT01296035","Panitumumab and Gemcitabine in Relapsed Ovarian Cancer","PanGem","Terminated","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Biological: Panitumumab","Overall Response Rate, Measured by RECIST Criteria|Adverse Events, Measured by Active Version of the NCI Common Toxicity Criteria","Women and Infants Hospital of Rhode Island|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WIH 20050782","February 2011","October 2013","November 2013","February 15, 2011","August 25, 2015","August 25, 2015","Women & Infants' Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01296035"
827,"NCT01290263","Amgen 386 for Recurrent Glioblastoma",,"Completed","Has Results","Glioblastoma Multiforme","Drug: Amgen 386|Drug: Bevacizumab","6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B]|AMG 386 Maximum Tolerated Dose (MTD) [Cohort B Phase I]|AMG 386 Dose Limiting Toxicity (DLT) [Cohort B Phase I]|Best Radiographic Response [Cohort A and Cohort B]|Overall Survival (OS) [Cohort A and Cohort B]|Progression-Free Survival (PFS) [Cohort A and Cohort B]","Dana-Farber Cancer Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-185","December 2010","July 2015","January 2017","February 4, 2011","May 25, 2017","July 2, 2017","University of California Los Angeles, Los Angeles, California, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Worcester, Massachusetts, United States|New York - Presbyterian/Columbia University Medical Center, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01290263"
828,"NCT01250405","Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients","ECIRA","Completed","No Results Available","Chronic Kidney Disease","Drug: Cinacalcet|Drug: Placebo","Arterial stiffness|Ventricular function","Laval University|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","CA2009-0008","May 2012","April 2014","April 2014","November 30, 2010",,"April 7, 2014","Karine Marquis, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01250405"
829,"NCT01233687","AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer",,"Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: AMG 102 and erlotinib","Percentage of Participants That Experienced a Dose Limiting Toxicity|Disease Control Rate (DCR)|Objective Response Rate (ORR/Clinical Response)|Progression-free Survival (PFS)|Overall Survival (OS)","Ahmad Tarhini|Amgen|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-058","August 2011","November 2014","November 2014","November 3, 2010","September 1, 2016","June 22, 2017","University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01233687"
830,"NCT01226719","FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only",,"Completed","Has Results","Colorectal Cancer","Drug: Panitumumab|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Leucovorin|Drug: 5-Fluorouracil","Overall Response Rate (ORR)|R0 Resection Rate|Progression-free Survival (PFS)|To Determine the Acute Toxicity Produced by This Regimen.|Overall Survival (OS)","SCRI Development Innovations, LLC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI GI 134","December 2010","March 2014","March 2014","October 22, 2010","May 27, 2015","May 27, 2015","NEA Baptist Clinic, Jonesboro, Arkansas, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists, St. Petersburg, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Hope Cancer Center, Terre Haute, Indiana, United States|Providence Medical Group, Terre Haute, Indiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Oncology Hematology Care, Inc, Cincinnati, Ohio, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01226719"
831,"NCT01212380","Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)",,"Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia|Hematopoietic/Lymphoid Cancer|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia","Drug: carfilzomib|Other: Cytokine Assessment|Other: Pharmacodynamic Studies|Other: Proteosome Inhibition Assessment|Other: Pharmacogenomic Studies","Determine safety of carfilzomib by evaluating the toxicity profile.|To evaluate the efficacy of Carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL)/prolymphocytic leukemia (PLL)","Ohio State University Comprehensive Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-09108|NCI-2010-01884","October 2010","July 2014","September 2015","September 30, 2010",,"May 9, 2016","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01212380"
832,"NCT01202409","CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater",,"Completed","No Results Available","Gastrointestinal Cancer","Drug: Panitumumab","Response Rate (RR) of Patients","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0458|NCI-2012-01894","November 2, 2010","July 3, 2018","July 3, 2018","September 15, 2010",,"July 26, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01202409"
833,"NCT01191385","GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start",,"Withdrawn","No Results Available","Carcinoma, Hepatocellular","Drug: Any treatment for unresectable HCC as chosen by the physician","Determination of 'real-life' practice patterns of physicians involved in the care of patients with HCC (collection of data on treatments prescribed as well as demographic data and data on the entire medical history)|Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)|Evaluation of natural course and outcomes of patients with HCC (collection of data of disease status during the course of the study and the outcome of treatment)|Evaluation of treatment modalities that are used for patients with HCC during the course of their disease (collection of data of all treatments prescribed during the course of the study)|Evaluation of safety and tolerability of treatments that are used for patients with HCC (collection of all adverse events)|Evaluation efficacy parameters including: overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR) and stable disease (SD) rate of the various interventions employed in the care of patients with HCC|To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14611|NX0901","November 2010","December 2013","December 2013","August 30, 2010",,"August 16, 2017","Multiple Locations, Arkansas, United States|Multiple Locations, California, United States|Multiple Locations, Colorado, United States|Multiple Locations, District of Columbia, United States|Multiple Locations, Florida, United States|Multiple Locations, Georgia, United States|Multiple Locations, Illinois, United States|Multiple Locations, Indiana, United States|Multiple Locations, Iowa, United States|Multiple Locations, Kentucky, United States|Multiple Locations, Louisiana, United States|Multiple Locations, Maryland, United States|Multiple Locations, Massachusetts, United States|Multiple Locations, Michigan, United States|Multiple Locations, Minnesota, United States|Multiple Locations, Missouri, United States|Multiple Locations, New Hampshire, United States|Multiple Locations, New Jersey, United States|Multiple Locations, New York, United States|Multiple Locations, Oregon, United States|Multiple Locations, Pennsylvania, United States|Multiple Locations, South Carolina, United States|Multiple Locations, Texas, United States|Multiple Locations, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01191385"
834,"NCT01182610","Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma",,"Terminated","Has Results","Gastroesophageal Adenocarcinoma|Adenocarcinoma of the Distal Esophagus|Adenocarcinomas of the Gastroesophageal Junction|Adenocarcinoma of the Proximal Stomach","Drug: Panitumumab|Drug: Paclitaxel|Drug: Carboplatin|Drug: 5FU","Response Rate|Pathologic Response Rate|Resection Rate of Surgery|Thirty-day Surgical Mortality|Survival","Accelerated Community Oncology Research Network|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACORN ARCHESO0611","April 2011","March 2012","March 2012","August 17, 2010","November 28, 2012","December 3, 2012","Clopton Clinic, Jonesboro, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT01182610"
835,"NCT01175733","Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer","Vectibix","Completed","No Results Available","Pancreatic Cancer","Drug: Panitumumab","Phase I: the recommended safe dosing for the combination of chemoradiation with gemcitabine plus panitumumab.|Phase II: the proportion of patients that is alive and progression-free at 7 months.|Phase II: safety and tolerability|Early signs of clinical activity of the combination of chemoradiation with gemcitabine plus panitumumab.|Clinical response rate of the combination of chemoradiation with gemcitabine plus panitumumab.|Time-to-progression (TTP) and overall survival","VU University Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080686","July 8, 2010","March 2016","May 2016","August 5, 2010",,"March 20, 2017","VU University Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01175733"
836,"NCT01172717","Study of Panitumumab in the Treatment of Carcinoid Syndrome",,"Withdrawn","No Results Available","Carcinoid Syndrome","Drug: Panitumumab","Radiographic measures|Tumor Marker Evaluations|Quality of LIfe","Boston Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-31701","July 2013","July 2013","July 2013","July 30, 2010",,"July 26, 2013","Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01172717"
837,"NCT01163669","A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients",,"Completed","No Results Available","Hyperparathyroidism",,"plasma parathyroid hormone(PTH)level|corrected total serum calcium and phosphorus concentration","The Cleveland Clinic|Amgen","All","18 Years and older   (Adult, Older Adult)",,"15","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20080093","July 2010","November 2012","November 2012","July 16, 2010",,"August 13, 2013","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01163669"
838,"NCT01161498","Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer",,"Terminated","Has Results","Squamous Cell Carcinoma|Head and Neck Cancer","Biological: Talimogene Laherparepvec|Radiation: Radiation|Drug: Cisplatin","2-year Event-free Survival|Clinical Objective Response (cOR)|Metabolic Complete Response (mCR)|Pathologic Complete Response (mCR)|Time to Locoregional Failure|Time to Distant Failure|Time to Any Failure|Overall Survival|Disease-specific Survival|Participants With N1-2 Disease at Baseline Requiring Neck Dissection","BioVex Limited|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","006/09|20110130","February 2011","October 2011","October 2011","July 13, 2010","December 17, 2015","February 8, 2016","Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States|Gabrail Cancer Center, Canton, Ohio, United States|Medical Univesity of South Carolina, Charleston, South Carolina, United States|VCU Massey Cancer Center, Richmond, Virginia, United States|The Royal Marsden Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01161498"
839,"NCT01156090","A Retrospective Cohort Study of Infusion Reactions Due to Vectibix",,"Completed","No Results Available","Infusion Reaction",,"Rate of Vectibix-related infusion reactions w/high rate of Erbitux-related infusion reactions","SCRI Development Innovations, LLC|Amgen","All","Child, Adult, Older Adult",,"141","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","SCRI Outcomes 04","June 2010","December 2012","January 2013","July 2, 2010",,"August 28, 2015","Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01156090"
840,"NCT01144195","A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy","ACTIVE","Unknown status","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab + FOLFIRI","Objective Response Rate|disease control rate|duration of response|time to response|progression-free survival|time to progression|time to treatment failure|duration of stable disease|Incidence of adverse events","Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACROSS-08-01|2009-010975-26","September 2009","December 2011",,"June 15, 2010",,"November 10, 2010","Associació Catalana per la Recerca Oncològica i les Seves Implicacions Sanitaries i Socials, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01144195"
841,"NCT01139918","Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis",,"Completed","No Results Available","Psoriatic Arthritis|Psoriasis",,"There is no primary outcome in this study. See objectives.","Innovaderm Research Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)",,"105","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Inno-6017","June 2010","July 2014","July 2014","June 9, 2010",,"July 24, 2014","Kirk Barber Research, Calgary, Alberta, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|Dermatrials Research, Hamilton, Ontario, Canada|Lynderm Research Inc., Markham, Ontario, Canada|Windsor Clinical Research Inc., Windsor, Ontario, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|Diex Research Sherbrooke east, Sherbrooke, Quebec, Canada|Clinique Médicale Dr Isabelle Delorme, St-Hyacinthe, Quebec, Canada|Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01139918"
842,"NCT01132235","An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use","ENBRECAP2009","Unknown status","No Results Available","Psoriasis","Biological: etanercept","The proportion of patients achieving a Physician's Global Assessment (PGA) score of minimal (1) or clear (0) at week 12.","Florida Academic Dermatology Centers|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENBRECAP2009","April 2010","December 2010","December 2010","May 27, 2010",,"May 28, 2010","Florida Academic Dermatology Center, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01132235"
843,"NCT01128387","Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer",,"Terminated","Has Results","Cancer","Drug: Panitumumab","MTD of Panitumumab in Combination With Cisplatin/Fluorouracil and Radiation for Locally Advanced Esophageal Cancer Determined by Number of Participants Experiencing DLT|Pathologic Response","University of Wisconsin, Madison|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-2009-0214|RO09211|NCI-2011-00735|A533300|SMPH\HUMAN ONCOLOGY\HUMAN ONCO","May 2010","October 2016","October 2016","May 21, 2010","January 23, 2018","December 9, 2019","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01128387"
844,"NCT01126112","Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer","FRAIL","Completed","No Results Available","Colorectal Cancer","Biological: Panitumumab","Progression-free survival rate at 6 months|Progression-free survival|Objective Response Rate|Disease control rate|Time to response|Time to progression|Time to treatment failure|Duration of response|Duration of stable disease|Overall survival|Changes in patient-reported outcomes|Adverse events|Evaluation of molecular predictive markers for response.","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","All","70 Years and older   (Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-09-03|2009-016661-28","May 2010","July 2014","July 2014","May 19, 2010",,"March 24, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01126112"
845,"NCT01122095","Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis",,"Unknown status","No Results Available","Psoriasis|Obesity|Cardiovascular Risk|Inflammation",,"Obesity risk assessment","University of California, San Diego|Amgen","All","up to 18 Years   (Child, Adult)",,"100","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","20080414","April 2010",,"April 2011","May 12, 2010",,"May 31, 2010","Rady Children's Hospital Dermatolgoy, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01122095"
846,"NCT01113398","AMG 102 and Avastin for Recurrent Malignant Glioma",,"Completed","Has Results","Glioblastoma Multiforme|Gliosarcoma","Drug: AMG 102|Drug: Avastin","Radiographic Response|Median Overall Survival (OS)|Six-month Progression-free Survival (PFS6)|Percentage of Participants Who Experience Treatment-related Grade 2 or Greater CNS Hemorrhage or Grade 4 or Greater Non-hematologic Toxicities","Katy Peters|Amgen|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00022491","August 2010","November 2014","September 2015","April 29, 2010","December 10, 2015","December 10, 2015","The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01113398"
847,"NCT01053819","Can We Miss Pigmented Lesions in Psoriasis Patients?",,"Completed","Has Results","Psoriasis|Melanoma|Non-melanoma Skin Cancer","Drug: etanercept","The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.|A Secondary Objective Will be to Evaluate the Identified Pigmented Lesions for Suspicious Criteria","University of Alabama at Birmingham|Amgen","All","19 Years and older   (Adult, Older Adult)","Phase 4","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F070629011","September 2007","April 2012","April 2012","January 21, 2010","August 22, 2012","February 23, 2018","UAB Dermatology, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01053819"
848,"NCT01042288","Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC",,"Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: Carboplatin|Drug: Pemetrexed|Drug: Panitumumab","Median Time to Progression (TTP)|Median Progression-free Survival (PFS)|Median Overall Survival (OS)|Objective Response Rate|Frequency of Adverse Events and Severity as a Measure of Toxicity","SCRI Development Innovations, LLC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LUN 183","June 2010","December 2014","July 2015","January 5, 2010","April 15, 2016","May 11, 2016","Florida Cancer Specialists, Ft. Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Baptist Hospital East, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Cancer Centers of Southwest Oklahoma, Lawton, Oklahoma, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01042288"
849,"NCT01017653","Panitumumab and Irinotecan for Malignant Gliomas",,"Terminated","Has Results","Malignant Glioma of Brain","Drug: Irinotecan|Drug: Panitumumab","6-month Progression-free Survival (PFS)|One-Year Overall Survival|Safety of Panitumumab in Combination With Irinotecan|Effect of Panitumumab in Combination With Irinotecan on Corticosteroid Dose|Relationship Between Epidermal Growth Factor Receptor (EGF-R) Mutational Analysis and Efficacy or Toxicity|Objective Response Rate|Median Overall Survival (OS)","Annick Desjardins|Amgen|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00015447","February 2010","October 2011","October 2011","November 20, 2009","September 4, 2013","September 4, 2013","The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01017653"
850,"NCT01009879","Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants",,"Withdrawn","No Results Available","Rheumatoid Arthritis","Drug: Etanercept","The primary objective of the study is to quantify early B cell bone marrow emigrants in the peripheral blood of adults with rheumatoid arthritis (RA) before and after etanercept therapy.|Secondary objectives will include granulocyte numbers, serum cytokine (CRP, IL-1β and TNFα) levels, rheumatoid arthritis disease activity and changes in anti-CCP and RF levels before and after etanercept therapy.","University of Pittsburgh|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AMGEN 2006_1112","November 2009","February 2012","February 2012","November 9, 2009",,"July 2, 2013","University of Pittsburgh - Oakland Falk Clinic, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01009879"
851,"NCT00997529","Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors","MiniSolid","Completed","No Results Available","Metastatic Solid Tumor","Drug: nonmyeloablative stem cell transplant","To determine the percent 100-day survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic stem cell transplantation (SCT).|To determine the incidence of treatment-related toxicity and acute and chronic graft versus host disease.|To determine the overall survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.|To evaluate the tumor response in patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.","Beth Israel Deaconess Medical Center|Amgen","All","18 Years to 60 Years   (Adult)","Not Applicable","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E-00-0154-FB/2001-P-000092/8","November 2000","November 2007","June 2010","October 19, 2009",,"July 18, 2016","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00997529"
852,"NCT00984282","Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer",,"Completed","Has Results","Thyroid Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation|Overall Survival (OS)|Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation|Disease Control Rate (DCR) Based on Central Assessment|Response Rate Based on Central Assessment|Duration of Response (DOR) Based on Central Assessment|Maximum Percent Reduction in Target Lesion Size Based on Central Assessment|AUC(0-12h),ss (Area Under the Concentration Time Curve From Time 0 to 12 Hours at Steady State)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","417","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14295|2009-012007-25","October 15, 2009","August 31, 2012","August 30, 2017","September 25, 2009","December 10, 2013","September 13, 2018","Los Angeles, California, United States|Stanford, California, United States|New Haven, Connecticut, United States|Atlanta, Georgia, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Seattle, Washington, United States|Wien, Austria|Bruxelles - Brussel, Belgium|Sofia, Bulgaria|Guangzhou, Guangdong, China|Beijing, China|Beijing, China|Chengdu, China|Hangzhou, China|Shanghai, China|Shanghai, China|Tianjin, China|Odense C, Denmark|Angers, France|Bordeaux, France|Caen, France|LILLE cedex, France|Lyon, France|MARSEILLE cedex, France|Paris, France|Villejuif, France|Erlangen, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Napoli, Campania, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Catania, Sicilia, Italy|Pisa, Toscana, Italy|Siena, Toscana, Italy|Perugia, Umbria, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Koto-ku, Tokyo, Japan|Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Groningen, Netherlands|Leiden, Netherlands|Gliwice, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Obninsk, Russian Federation|Riyadh, Saudi Arabia|Majadahonda, Madrid, Spain|Barcelona, Spain|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Aberdeen, Aberdeenshire, United Kingdom|Cardiff, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00984282"
853,"NCT00984217","Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies",,"Withdrawn","No Results Available","Adenoma, Pleomorphic|Mixed Salivary Gland Tumor|Salivary Gland Tumor, Mixed|Syringoma, Chondroid","Radiation: Radiation|Drug: Panitumumab","To evaluate the recurrence-free survival of advanced salivary gland cancer patients undergoing postoperative chemoradiotherapy with panitumumab compared to historical control data|To evaluate the overall survival, local recurrence-free survival, distant recurrence-free survival and toxicities.|To correlate efficacy parameters with a) EGFR and downstream pathway activation, b) FcyR polymorphisms, and c) serum cytokine profiles.|To collect tumor tissue from pretreatment biopsies for cytokine/chemokine and immune biomarker studies on tumor tissue.","University of Pittsburgh|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-112","August 2011","August 2011","August 2011","September 25, 2009",,"January 8, 2016","UPMC Cancer Center - Teramana Cancer Center - Steubenville, Steubenville, Ohio, United States|UPMC Cancer Center - Beaver, Beaver, Pennsylvania, United States|UPMC Cancer Center - Clairton, Clairton, Pennsylvania, United States|UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg, Greensburg, Pennsylvania, United States|UPMC Cancer Center - Oakbrook Commons - Greensburg, Greensburg, Pennsylvania, United States|UPMC Cancer Center - Oakbrook Commons, Greensburg, Pennsylvania, United States|UPMC Cancer Center -Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC Cancer Center - Indiana, Indiana, Pennsylvania, United States|UPMC Cancer Center - John P. Murtha Pavilion - Johnstown, Johnstown, Pennsylvania, United States|UPMC Cancer Center - McKeesport, McKeesport, Pennsylvania, United States|UPMC Cancer Center - Monroeville, Monroeville, Pennsylvania, United States|UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group, Moon Township, Pennsylvania, United States|UPMC Cancer Center -Mt. Pleasant, Mt. Pleasant, Pennsylvania, United States|UPMC Cancer Center - New Castle, New Castle, Pennsylvania, United States|UPMC Presbyterian -Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center - St. Margaret's, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center -Delafield Rd., Pittsburgh, Pennsylvania, United States|Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center -UPMC Shadyside, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center - Passavant, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center - Upper St. Clair, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center -Drake, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center -UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Cancer Center - Uniontown, Uniontown, Pennsylvania, United States|UPMC Cancer Center - Washington, Washington, Pennsylvania, United States|UPMC Cancer Center - North Hills, Wexford, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00984217"
854,"NCT00967538","Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments",,"Completed","No Results Available","Psoriasis","Drug: etanercept 50 mg","Proportion of patients who reach a Physician's Global Assessment (PGA) of clear or almost clear after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg every other week (EOW).|Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.|Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.|Mean Body Surface Area (BSA) after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.|Mean BSA after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.|Mean BSA after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.|Mean Psoriasis Area and Severity Index (PASI) score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.|Mean PASI score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.|Mean PASI score after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.|Safety of etanercept in patients who have shown an unsatisfactory response to adalimumab, who have lost their satisfactory response to adalimumab or who have lost their satisfactory response to infliximab.","Innovaderm Research Inc.|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","89","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inno-6011|CA-2009-0004","September 2009","July 2014","July 2014","August 28, 2009",,"July 24, 2014","Kirk Barber Research, Calgary, Alberta, Canada|PerCuro Clinical Research Ltd, Victoria, British Columbia, Canada|Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada|Nexus Clinical Research, St John's, Newfoundland and Labrador, Canada|New Lab Clinical Research, St John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Research Associates Ltd, Halifax, Nova Scotia, Canada|Dermatrials Research, Hamilton, Ontario, Canada|Mediprobe Research Inc., London, Ontario, Canada|Lynderm research Inc., Markham, Ontario, Canada|Dermatology Associates, North York, Ontario, Canada|Sudbury Skin Clinic, Sudbury, Ontario, Canada|Dr. Jay Brian Taradash, Toronto, Ontario, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|Siena Medical Research, Montreal, Quebec, Canada|Clinique Esthetique Dr Isabelle Delorme, St-Hyacinthe, Quebec, Canada|Centre de Recherches Dermatologiques du Quebec Metropolitain, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00967538"
855,"NCT00965666","Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia",,"Completed","No Results Available","Fanconi Anemia","Drug: Etanercept","To assess toxicity of Etanercept (Enbrel) in children with Fanconi Anemia (FA) and early marrow failure.|To assess efficacy of Etanercept (Enbrel) in improving hematopoiesis (i.e. peripheral counts) in patients with FA.|Correlation of biological studies to measure the impact of Etanercept (Enbrel) on Tumor Necrosis Factor - alpha (TNF-alpha) production.","Children's Hospital Medical Center, Cincinnati|Amgen","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","05-07-24","October 2005","October 2010","October 2010","August 25, 2009",,"March 8, 2012","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00965666"
856,"NCT00958386","Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)","SPECTRA","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab+irinotecan","Objective response rate|disease control rate|duration of response|time to progression|time to response|time to treatment failure|duration of stable disease|Progression free survival|Overall survival|Safety profile|Evaluation of molecular predictive markers","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-08-06","August 2009","July 2014","July 2014","August 13, 2009",,"March 24, 2015","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00958386"
857,"NCT00949546","Treatment of Hidradenitis Suppurativa Using Etanercept",,"Completed","No Results Available","Hidradenitis Suppurativa","Drug: etanercept","Physician global assessment of HS of clear or mild at week 12","Penn State University|Amgen","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20031168","April 2005","January 2008","January 2008","July 30, 2009",,"November 24, 2017","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00949546"
858,"NCT00941863","Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",,"Completed","Has Results","Carcinoma","Drug: Sorafenib 100 mg (50-mg tablet)|Drug: Sorafenib 200 mg (50-mg tablet)|Drug: Sorafenib 400 mg (50-mg tablet)|Drug: Sorafenib 400 mg (200-mg tablet)|Drug: Sorafenib 400 mg (Expansion)","Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin|Participants With Hematological and Biochemical Toxicities|Tumor Response|Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1|Maximum Concentration (CMAX) Start From Day 2 of Cycle 1|Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","158","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100375","July 2002","May 2005","April 2008","July 20, 2009","October 8, 2010","March 22, 2016","Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00941863"
859,"NCT00930592","Peds Metabolic Syndrome in Psoriasis",,"Completed","No Results Available","Psoriasis|Metabolic Syndrome",,"The primary objective of this study is to determine if children with psoriasis will have an increased prevalence of the metabolic syndrome.|Metabolic syndrome in children with psoriasis will be determined using body weight, BMI, waist circumference, blood pressure, fasting blood sugar, and blood lipid profile.|Surrogate endpoints indicating potential increased cardiovascular risks, including high sensitivity CRP, flow-mediated dilation (FMD) during reactive hyperemia, and hyperemia-induced, pulse wave amplitudes.|For psoriasis patients only: PASI, BSA, and PGA will be measured to establish extent of disease.|Safety Outcome Measures: All adverse events (AEs) will be recorded and monitored.","Tufts Medical Center|Amgen","All","10 Years to 17 Years   (Child)",,"42","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Peds Metabolic Syndrome","April 2009","July 2012","December 2012","June 30, 2009",,"April 16, 2019","Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00930592"
860,"NCT00926380","Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis","DATA","Completed","Has Results","Osteoporosis","Drug: denosumab|Drug: teriparatide","Change in Spine Bone Density From Baseline to 2 Years","Massachusetts General Hospital|Amgen","Female","45 Years and older   (Adult, Older Adult)","Phase 2","94","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080723|2009P000525","June 2009","December 2016","December 2016","June 23, 2009","May 8, 2018","June 29, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00926380"
861,"NCT00885885","Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases","PLANET","Completed","No Results Available","Colorectal Cancer","Drug: Panitumumab+FOLFOX-4|Drug: Panitumumab+FOLFIRI","Objective response rate|% of patients whose disease becomes resectable|Time to resection|Duration of response|Progression-free survival|Time to treatment failure|Time to disease relapse following surgery.|Adverse Events|Evaluation of molecular predictive markers for response.","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-08-04|EudraCT: 2008-006766-28","May 2009","March 2015","March 2015","April 22, 2009",,"August 1, 2017","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00885885"
862,"NCT00883415","Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease",,"Completed","No Results Available","Cardiomyopathy|Chronic Kidney Disease|Anemia","Drug: Darbepoetin alfa","Change to myocardial glucose uptake as measured by fluoro-deoxy-D-glucose (FDG) positron emission tomography (PET) scan from pre-treatment compared to 6 months after anemia therapy initiation.","University of Maryland, Baltimore|Amgen","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","HP-00041025|Amgen ISS#20061907","May 2008","November 2012","November 2012","April 17, 2009",,"November 4, 2019","Baltimore VA Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00883415"
863,"NCT00869284","Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas","073","Completed","No Results Available","Lymphoma","Drug: CEEP regimen|Procedure: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)","Complete response|overall survival disease free survival","French Innovative Leukemia Organisation|Amgen","All","15 Years to 60 Years   (Child, Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOELAMS 073|no other identification number","October 1994","July 1999","February 2009","March 25, 2009",,"March 25, 2009","Emmanuel Gyan, Tours, France",,"https://ClinicalTrials.gov/show/NCT00869284"
864,"NCT00865709","Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)","Progression-Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Overall Response|Duration of Response","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13162|2008-005025-11","March 2009","January 2011","February 2012","March 19, 2009","March 20, 2012","December 11, 2014","Wichita, Kansas, United States|Metairie, Louisiana, United States|Brockton, Massachusetts, United States|Burlington, Massachusetts, United States|Dallas, Texas, United States|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Liege, Belgium|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyor, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Castelfranco Veneto, Treviso, Italy|Genova, Italy|Macerata, Italy|Palermo, Italy|Pordenone, Italy|Torino, Italy|Udine, Italy|Verona, Italy|Bialystok, Poland|Elblag, Poland|Gdansk, Poland|Gdynia, Poland|Krakow, Poland|Krakow, Poland|Olsztyn, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Alba Iulia, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Craiova-Dolj, Romania|Iasi, Romania|Oradea, Romania|Suceava, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Astrakhan, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Khabarovsk, Russian Federation|Krasnodar, Russian Federation|Kursk, Russian Federation|Magnitogorsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Pjatygorsk, Russian Federation|Rostov-on-Don, Russian Federation|Samara, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tula, Russian Federation|Ulyanovsk, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Santander, Cantabria, Spain|Palma de Mallorca, Illes Baleares, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Krivoy Rog, Ukraine|Lugansk, Ukraine|Lviv, Ukraine|Mariupol, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Bristol, Avon, United Kingdom|Liverpool, Merseyside, United Kingdom|Northwood, Middlesex, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00865709"
865,"NCT00848354","Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Phase 1: Etanercept|Drug: Phase 1: Methotrexate|Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX|Drug: Phase 1: Conventiaonal DMARD","Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response at Week 24|Change From Baseline in HAQ Score at Week 24|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Score at Week 24|Change From Baseline in Van Der Heijde Modified Total Sharp Score (vdH mTSS), Annualized, at Week 24|Change From Baseline in Disease Activity Score Based on a 28-joint Count (DAS28) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in DAS28 at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Summary of Changes in Therapy at the Beginning of Phase 2|Percentage of Participants Achieving ACR50 Response at Week 2, Week 4, Week 8, Week 12, Week 16, and Week 20|Percentage of Participants Achieving ACR50 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving ACR20 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving ACR20 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving ACR70 Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving ACR70 Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Disease Activity Score (DAS) at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in DAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS<2.4 (Low Disease Activity) Response at Week 24|Percentage of Participants Achieving DAS<1.6 (Remission) Response at Week 24|Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving Moderate/Good DAS-Based European League Against Rheumatism (EULAR) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving Moderate/Good Disease DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving Good DAS-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving Moderate/Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving Good DAS28-Based EULAR Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS28<2.6 (Remission) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS28<3.2 (Low Disease Activity) Response at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS28 Improvement of ≥0.6 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Percentage of Participants Achieving DAS28 Improvement of ≥1.2 From Baseline at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Painful Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Painful Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Swollen Joint Counts at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Swollen Joint Counts at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Physician Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Physician Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Subject Global Assessment Score at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24|Change From Baseline in Subject Global Assessment Score at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Duration of Morning Stiffness at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Duration of Morning Stiffness at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in General Health VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in General Health VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Pain VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Pain VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Fatigue VAS at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Fatigue VAS at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in Joint Space Narrowing Score Using vdH mTSS at Week 24|Change From Baseline in Erosion Score Using vdH mTSS at Week 24|Change From Baseline in Westergren ESR at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in Westergren ESR at Week 37, Week 50, Week 63, Week 76, Week 89, Week 102, Week 115, and Week 128|Change From Baseline in CRP at Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24|Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Vitality Domain Score at Week 50, Week 76, Week 102, and Week 128|Change From Baseline in SF-36 Health Survey Mental Component Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Mental Component Score at Week 50, Week 76, Week 102, and Week 128|Change From Baseline in SF-36 Health Survey Physical Component Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Physical Component Score at Week 50, Week 76, Week 102, and Week 128|Change From Baseline in SF-36 Health Survey Bodily Pain Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Role Limitations Due to Emotional Problems Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey General Health Perceptions Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Mental Health Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Physical Functioning Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Role Limitations Due to Physical Health Domain Score at Week 8, Week 16, and Week 24|Change From Baseline in SF-36 Health Survey Social Functioning Domain Score at Week 8, Week 16, and Week 24","Pfizer|Amgen","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 4","429","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0881A1-4532|B1801004","June 2009","April 2013","April 2013","February 20, 2009","April 19, 2012","January 18, 2016","Consultorios Especializados en Investigaciones Medicas, Capital Federal, Buenos Aires, Argentina|CER San Juan, San Juan, Provinica de San Juan, Argentina|Instituto CAICI, Rosario, Santa Fe, Argentina|OMI, Buenos Aires, Argentina|Centro de Investigaciones en Enfermedades Reumaticas, Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Argentina|Atencion Integral en Reumatologia, Buenos Aires, Argentina|Investigaciones Reumatológicas y Osteológicas, Ciudad Autónoma de Buenos Aires, Argentina|Centro de Osteopatías Médicas, Ciudad Autónoma de Buenos Aires, Argentina|Sanatorio Mayo, Cordoba, Argentina|Hospital Escuela Gral. San Martin, Corrientes, Argentina|Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina|Centro de Investigaciones Reumatologicas, Tucuman, Argentina|Dr Miranda Private Practice, Santiago, Region Metropolitana, Chile|Hospital del Salvador, Santiago, Region Metropolitana, Chile|Reumalab, Medellin, Antioquia, Colombia|Centro de Reumatologia y Ortopedia, Barranquilla, Atlantico, Colombia|IPS Centro Integral de Rematología del Caribe S.A.S CIRCARIBE S.A.S Sede 1, Barranquilla, Atlantico, Colombia|IPS Centro Integral de Rematología del Caribe S.A.S CIRCARIBE S.A.S Sede 2, Barranquilla, Atlantico, Colombia|Centro Integral de Reumatologia e Inmunologia LTDA, Bogota, Cundinamarca, Colombia|Foqus Ips Ltda, Bogota, Cundinamarca, Colombia|Fundacion Instituto de Reumatologia Fernando Chalem, Bogota, Cundinamarca, Colombia|Riesgo de fractura S.A. Clinica de Artritis y Rehabilitacion, Bogota, Cundinamarca, Colombia|Preventive Care Ltda, Chia, Cundinamarca, Colombia|Centro Medico Carlos Ardila Lulle, Bucaramanga, Santander, Colombia|Servimed EU, Bucaramanga, Santander, Colombia|Hospital Angeles Chapalita, Guadajara, Jalisco, Mexico|Centro de Especialidades Medicas del Sureste SA de CV, Merida, Yucatan, Mexico|Centro de Investigación y Biomedicina de Chihuahua, Chihuahua, Mexico|Hospital Christus Mugerza, Chihuahua, Mexico|Hospital Christus Muguerza del Parque, Chihuahua, Mexico|Centro de Infusion Marbella, Panama, Panama|Centro de Investigacion Marbella, Panama, Panama",,"https://ClinicalTrials.gov/show/NCT00848354"
866,"NCT00841789","Etanercept in Kawasaki Disease",,"Active, not recruiting","No Results Available","Mucocutaneous Lymph Node Syndrome|Kawasaki Disease","Drug: Etanercept|Drug: Placebo","Determine if Etanercept at the dosing regimen of 0.8 mg/kg (50 mg max) SQ X3 doses given at weekly intervals, when used in conjunction with IVIG and aspirin will reduce the incidence of fever persistence or recrudescence.|Determine if the safety profile differs between the etanercept treated group and the placebo group.|Determine if Etanercept treatment alters the rate of coronary artery dilation and disease (CAD) at 2 and 6 weeks after treatment.|CRP Laboratory Measurements|Hemoglobin Laboratory Measurements","Michael Portman|Amgen|Seattle Children's Hospital","All","2 Months to 20 Years   (Child, Adult)","Phase 2","196","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SEA-12652|FD003526","March 2009","January 2018","August 2018","February 11, 2009",,"April 18, 2018","Montefiore Medical Center, Bronx, New York, United States|Feinstein Institute for Medical Rsearch, New Hyde Park, New York, United States|Columbia University Medical Center, New York, New York, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Sainte-Justine Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00841789"
867,"NCT00836277","Phase II Study of Irinotecan and Panitumumab",,"Completed","Has Results","Esophageal Cancer","Drug: Panitumumab|Drug: Irinotecan","Response Rate (RR)|Clinical Benefit Rate (CBR)|Progression-free Survival (PFS)|Overall Survival (OS)|1-year (Overall) Survival Rate","Weijing Sun, MD, FACP|Amgen|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-161","May 2009","August 2015","August 2015","February 4, 2009","November 15, 2016","November 15, 2016","University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00836277"
868,"NCT00833729","The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab",,"Completed","No Results Available","Plaque Psoriasis","Drug: etanercept","Mean change in PGA score|Mean change in body surface area covered in psoriasis|Mean change in DLQI|Treatment satisfaction|Proportion of patients achieving an improvement in PGA score|Safety","Dermatrials Research|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA-2008-0008","February 2009","February 2010","February 2010","February 2, 2009",,"June 28, 2010","Dermatrials Research, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00833729"
869,"NCT00802815","Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis",,"Completed","No Results Available","Inclusion Body Myositis","Drug: Etanercept","Change in Quantitative Muscle Testing on 12 proximal and 12 distal muscles","Washington University School of Medicine|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20031148","April 2005","May 2014","May 2014","December 5, 2008",,"May 29, 2014","Washington University Department of Neurology, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00802815"
870,"NCT00798655","Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer",,"Completed","Has Results","Cancer of Head|Cancer of Head and Neck|Cancer of Neck|Cancer of the Head|Cancer of the Head and Neck|Cancer of the Neck|Head and Neck Cancer|Head Cancer|Head Neoplasms|Head, Neck Neoplasms|Neck Cancer|Neck Neoplasms|Neoplasms, Head|Neoplasms, Head and Neck|Neoplasms, Neck|Neoplasms, Upper Aerodigestive Tract|UADT Neoplasms|Upper Aerodigestive Tract Neoplasms","Drug: Panitumumab|Drug: Cisplatin|Radiation: Radiation Therapy","Probability of Progression-free Survival (PFS) at 2 Years|Probability of 2-year Overall Survival","Robert Ferris|Amgen|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-120","November 2007","June 2015","November 9, 2016","November 26, 2008","August 9, 2016","October 3, 2017","University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00798655"
871,"NCT00794261","Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma","PALM","Completed","No Results Available","Lymphoma|Myeloma","Drug: Injection of Pegfilgrastim|Drug: Injection of Filgrastim","Efficacy of a single administration of Pegfilgrastim at D5 in shortening the duration of febrile neutropenia|Average duration of neutropenia, average duration of thrombocytopenia, number of days with temperature, number of red blood cell units and platelet concentrates transfused to the patient|Average duration of hospital stay since PSC transplantation|Number of bacterial and/or viral and/or fungal infections, average duration of antibiotic, antiviral and/or antifungal treatment|Treatment tolerance|Evaluation of treatment by Filgrastim|Evaluation of treatment costs in the two arms","Centre Leon Berard|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PALM|ET2007 - 113","September 2008","January 2010","June 2010","November 20, 2008",,"July 8, 2010","CHU Angers, Angers, France|CHU Brest, Brest, France|Centre Leon Berard, Lyon, France|Hopital Edouard Herriot, Lyon, France|Hôpital Lapeyronnie, Montpellier, France|CHU Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Centre Henri Becquerel, Rouen, France|CHU Toulouse - Hôpital Purpam, Toulouse, France|CHU Tours - Hôpital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00794261"
872,"NCT00769704","Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma",,"Completed","Has Results","Melanoma","Biological: Talimogene laherparepvec|Biological: GM-CSF","Durable Response Rate|Overall Survival|Objective Response Rate|Duration of Response|Response Onset|Time to Treatment Failure|Response Interval","BioVex Limited|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","437","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","005/05|20110263|2008-006140-20","April 2009","February 2013","September 2014","October 9, 2008","December 17, 2015","July 13, 2016","University of Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California San Diego, Moores Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|San Francisco Oncology Associates, San Francisco, California, United States|Northern California Melanoma Center, St. Mary's Medical Center, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Redwood Regional Medical Group Inc, North Bay Melanoma Program, Sebastopol, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Mount Sinai Medical Center CCOP, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Center at Lutheran General Hospital, Park Ridge, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Hubert H Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Cancer Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|St. Louis University Hospital, St. Louis, Missouri, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Mountainside Hospital, Morristown, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia Medical University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina At Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio, United States|Earle A Chiles Research Institute, Providence Cancer Center, Portland, Oregon, United States|St Luke's Hospital & Health Network, Bethlehem, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Institute for Translational Oncology Research, Greenville, South Carolina, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Texas Cancer Center, Abilene, Abilene, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University of Texas - MD Anderson, Houston, Texas, United States|Texas Oncology, Allison Cancer Center, Midland, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Aurora/St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|GVI Oncology, Port Elizabeth, Eastern Cape, South Africa|Dr. Fourie & Bonnet, Bloemfontein, Free State, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Wits Donald Gordon Clinical Trial Site, Parktown, Guateng, South Africa|University of Pretoria, Pretoria, Guateng, South Africa|Mary Potter Oncology Centre, Pretoria, Guateng, South Africa|Hopelands Cancer Centre, Pietermaritzburg, Kwa-Zulu Natal, South Africa|Wilgers Oncology Center, Hatfield, Pretoria, South Africa|GVI Onocology Clinical Trials Unit, Cape Town, Western Cape, South Africa|GVI Oncology Centre, Cape Town, Western Cape, South Africa|University of Birmingham, Birmingham, United Kingdom|Addenbrookes Hospital, Cambridge, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|St. James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Free Hospital, London, United Kingdom|St. George's University of London, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Clatterbridge Centre for Oncology, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00769704"
873,"NCT00751894","Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)","MEG-5","Unknown status","No Results Available","Solid Malignancies","Drug: Pegfilgrastim (Neulasta, Amgen)","percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed)|Side effects Number of apheresis required to achieved a graft of at least 5x10e6 CD34 cells","University Hospital, Clermont-Ferrand|Amgen","All","up to 18 Years   (Child, Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0041",,,,"September 12, 2008",,"January 19, 2011","CHU, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT00751894"
874,"NCT00730392","Etanercept in New Onset Type 1 Diabetes",,"Completed","No Results Available","Type 1 Diabetes","Drug: Etanercept|Drug: Placebo","The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC).|Secondary end points are insulin dose and number of insulin injection discontinued, if any","University at Buffalo|Amgen","All","3 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20020197","October 2002","October 2007","January 2008","August 8, 2008",,"August 8, 2008",,,"https://ClinicalTrials.gov/show/NCT00730392"
875,"NCT00724386","Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Vinorelbine|Drug: Filgrastim|Radiation: Radiation","feasibility of administering study therapy to limit skin toxicity|dose-limiting toxicity|response|time to progression|overall survival|Bcl-2 detection by immunohistochemistry","University of Chicago|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCIRB 9849","June 1999","October 2005","November 2012","July 29, 2008",,"March 7, 2014","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00724386"
876,"NCT00704652","Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus","EPOinDR","Terminated","No Results Available","Diabetic Retinopathy",,"Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients|Functional improvement in best corrected visual acuity (BCVA) and microperimetry following darbepoetin alpha therapy compared to control patients.|Changes in anterior chamber flare and cell count following darbepoetin alpha therapy compared to control patients.|Changes in the fundus image and fluorescein angiographic features following darbepoetin alpha therapy compared to control patients.|Changes in blood count, chemistry, Astrup and blood clotting following darbepoetin alpha therapy compared to control patients.","Medical University of Vienna|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)",,"5","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","394/2007","May 2008","September 2009","September 2009","June 25, 2008",,"April 7, 2015","Departmen of Ophthalmology, Medical Unversity of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00704652"
877,"NCT00695370","Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children",,"Terminated","No Results Available","Solid Malignancies","Drug: Pegfilgrastim (drug)","percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)|Side effects Number of apheresis required to achieved a graft of at least 5x10e6 CD34 cells","University Hospital, Clermont-Ferrand|Amgen","All","up to 18 Years   (Child, Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0035","January 2006","December 2007","January 2008","June 11, 2008",,"June 13, 2008",,,"https://ClinicalTrials.gov/show/NCT00695370"
878,"NCT00682383","Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Unresectable Locally Advanced NSCLC","Drug: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta","To determine the safety and efficacy of administering pegfilgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgramstim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.|To determine the frequency of dose reductions, dose delays, and dose omissions during chemoradiotherapy with filgrastim and consolidation therapy with pegfilgrastim.","Mt. Sinai Medical Center, Miami|Amgen","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LUN 07","September 2003","January 2010","January 2010","May 22, 2008",,"October 30, 2012","Mount Sinai Medical Center, Miami Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00682383"
879,"NCT00657644","Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: Levitra (Vardenafil, BAY38-9456)","Erectile Function (EF) domain score|Change from baseline of Erectile Function domain score|IIEF domain scores|Patient Diary Questions|Global Assessment Question (GAQ)|Premature termination, adverse events, laboratory abnormalities and concomitant medication usage|Measurements and changes from baseline in vital signs, ECG cardiac cycle measurements and ECG heart rate|Haematology, Clinical Chemistry, Urinalysis","Bayer|Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 3","130","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11182","August 2003","March 2004","March 2004","April 14, 2008",,"December 25, 2014","Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00657644"
880,"NCT00640393","Safety and Efficacy of Combining nbUVB to Etanercept in Patients",,"Completed","Has Results","Psoriasis Vulgaris","Drug: Etanercept|Device: nbUVB","Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI 90) - ITT|Number of Participants Attaining a 75 Percent Reduction in PASI From Baseline (PASI 75) - ITT|Number of Participants Attaining a 100% Reduction in PASI From Baseline (PASI 100) - ITT|Number of Participants Attaining a 50% Reduction From Baseline in PASI From Baseline (PASI-50) - ITT|Number of Participants Attaining a 75 % Reduction in PASI From Baseline (PASI-75) - ITT|Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI-90) - ITT|Number of Participants Attaining a 100 Percent Reduction in PASI From Baseline (PASI-100) - ITT|Number of Patients Attaining a PGA (Physician's Global Assessment) of 0 or 1 - ITT|Body Surface Area (BSA) Affected by Psoriasis - ITT|Dermatology Life Quality Index (DLQI) - ITT|Number of Adverse Drug Reactions - ITT|Number of Infectious Adverse Events - ITT|Number of Serious Adverse Events - ITT|Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI 90) - PP|Number of Participants Attaining a 75 Percent Reductionin PASI From Baseline (PASI-75) - PP|Number of Participants Attaining a 100 Percent Reduction in PASI From Baseline (PASI-100) - PP|Number of Patients Attaining a PGA (Physician's Global Assessment) of 0 or 1 - PP|Body Surface Area (BSA) Affected by Psoriasis - PP|Dermatology Life Quality Index (DLQI) - PP","Innovaderm Research Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","99","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Inno-6007","April 2008","February 2010","March 2010","March 21, 2008","December 14, 2010","September 9, 2011","Winnipeg Clinic, Winnipeg, Manitoba, Canada|Mediprobe Research inc., London, Ontario, Canada|The Guenther Dermatology Research Centre, London, Ontario, Canada|Lynderm Research Inc., Markham, Ontario, Canada|Bank on Beauty, Niagara Falls, Ontario, Canada|Sudbury Skin Clinic, Sudbury, Ontario, Canada|Innovaderm Research Laval Inc, Laval, Quebec, Canada|Clinique Dermatologique Fleury, Montreal, Quebec, Canada|Innovaderm Research Inc., Montreal, Quebec, Canada|Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00640393"
881,"NCT00636909","Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders","MINI HEME","Completed","No Results Available","AML|ALL|CML Chronic Phase, Accelerated Phase, or Blast Crisis|CLL|MDS|RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Drug: Cyclophosphamide|Drug: fludarabine|Drug: cyclosporine|Drug: methotrexate|Biological: G-CSF","durable engraftment|hematopoeitic reconstitution|evaluate the patterns of post-transplant chimerism among lymphoid and antigen presenting cells|disease free survival and overall survival|incidence of treatment related toxicity and acute and chronic graft versus host disease","Beth Israel Deaconess Medical Center|Amgen","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2001P002293|W-99-0234-FB","July 1999","March 2006",,"March 17, 2008",,"April 6, 2017",,,"https://ClinicalTrials.gov/show/NCT00636909"
882,"NCT00626639","A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy",,"Completed","Has Results","Mucositis|Head and Neck Cancer","Drug: Placebo|Drug: palifermin|Radiation: Radiotherapy|Drug: Cisplatin","Number of Participants With Adverse Events (AEs)|Ratio of Ki67-positive Cells Before and After Palifermin Treatment|Pharmacokinetics of Palifermin|Number of Participants With Severe Oral Mucositis (OM) (Adapted RTOG/EORTC Grade ≥3)|Patient-Reported Mouth and Throat Soreness Score|Number of Participants With Disease Progression by Week 12|Overall Survival","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20040124","July 2005","May 2007","July 2015","February 29, 2008","March 6, 2014","June 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00626639"
883,"NCT00615901","Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim","The Number of Patients Who Completed 8 Cycles.","Memorial Sloan Kettering Cancer Center|Amgen","Female","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-133","January 2008","June 2010","June 2010","February 14, 2008","March 3, 2017","March 3, 2017","Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center at Mercy, Rockville Centre, New York, United States|Memoral Sloan-Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States",,"https://ClinicalTrials.gov/show/NCT00615901"
884,"NCT00594620","Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy",,"Completed","No Results Available","Prostate Cancer","Dietary Supplement: Flav-ein capsules|Drug: Placebo","efficacy of using isoflavones as safer alternative to synthetic estrogens","University of Kansas|Amgen|University of Kansas Medical Center","Male","18 Years and older   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","9639","August 2004","April 2010","April 2010","January 15, 2008",,"May 11, 2011","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT00594620"
885,"NCT00585650","Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet",,"Completed","Has Results","Psoriasis","Biological: Etanercept|Other: Placebo injections","The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks","University of California, Irvine|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2006-5092|Amgen Protocol 20060514","May 2007","May 2008","May 2008","January 3, 2008","November 8, 2011","December 7, 2018","UC Irvine Dermatology Clinical Research Center, Irvine, California, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Dermatology Associates, PLLC, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00585650"
886,"NCT00578071","Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer","POXX","Completed","Has Results","Cancer of the Esophagus","Drug: Panitumumab|Drug: Capecitabine|Drug: Oxaliplatin|Radiation: Radiation Therapy (RT)","Panitumumab Maximum Tolerated Dose in Milligrams (mg)|Number of Participants With Dose-limiting Toxicities (DLTs)|Overall Survival Rates for the Patients Studied on This Protocol.|Pathological Complete Response Rates Associated With This Regimen.","Brian Czito|Amgen|Duke University","All","18 Years to 82 Years   (Adult, Older Adult)","Phase 1|Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00002207|SPS 151596","December 2007","July 2011","June 2012","December 20, 2007","August 7, 2012","July 2, 2015","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00578071"
887,"NCT00570999","Palifermin After Haploidentical PBSCT","KGF Haplo Allo","Withdrawn","No Results Available","Non-Hodgkin's Lymphoma or Hodgkin's Disease|Acute Leukaemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Osteomyelofibrosis","Drug: Palifermin|Other: Placebo","To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)|To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation|To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections|To assess drug related safety","European Group for Blood and Marrow Transplantation|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EudraCt: 2007-003241-32","February 2008",,"January 2013","December 11, 2007",,"May 10, 2012","Dr Ruth Seggewiss, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00570999"
888,"NCT00562523","Sorafenib/Docetaxel Dose Escalation Trial",,"Completed","No Results Available","Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)","To determine the safety, maximum tolerated dose and dose-limiting toxicities of oral sorafenib|To determine if there is a pharmacokinetic interaction between sorafenib and docetaxel when they are administered together","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12438","November 2007","March 2009","March 2009","November 22, 2007",,"May 23, 2013","Tampa, Florida, United States|Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00562523"
889,"NCT00540332","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy",,"Withdrawn","No Results Available","Head and Neck Cancer","Drug: Placebo|Drug: palifermin","Incidence of treatment-emergent proteinuria|Duration of treatment-emergent proteinuria|Incidence of chronic proteinuria|Time (days) to onset of treatment-emergent proteinuria|Maximum protein-to-creatinine ratio values during the treatment period|Pharmacokinetic profile to include Systemic clearance, volume of distribution at steady state, estimated initial concentration, area under the conc-time curve, terminal half-life and mean residual time|Time (days) to onset of severe Oral Mucositis WHO grade 3 or 4|Disease status at End of Treatment visit|Incidence of serum anti-palifermin antibody formation|Incidence of second primary tumors|Incidence of other malignancies|Progression-free survival|Overall survival|Incidence of adverse events and laboratory abnormalities|Incidence (%) and duration (days) of severe Oral Mucositis WHO grade 3 or 4","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20070201","October 2007","September 2008","September 2008","October 8, 2007",,"March 2, 2009",,,"https://ClinicalTrials.gov/show/NCT00540332"
890,"NCT00509600","Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia",,"Terminated","Has Results","Leukemia","Drug: Etanercept","Patient Response","M.D. Anderson Cancer Center|Amgen","All","6 Months to 18 Years   (Child, Adult)","Phase 2","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0215","September 2004","April 2009","April 2009","July 31, 2007","December 2, 2010","August 7, 2012","UT MD . Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00509600"
891,"NCT00501228","Tissue Repair in Stem Cell Transplant Recipients",,"Terminated","Has Results","Graft-Versus-Host Disease","Drug: Filgrastim","Number of Donor Derived Cells After G-CSF Therapy","M.D. Anderson Cancer Center|Amgen","All","Child, Adult, Older Adult","Not Applicable","2","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID02-300","February 2003","September 2008","September 2008","July 16, 2007","November 20, 2009","August 7, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00501228"
892,"NCT00499525","Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: paclitaxel|Drug: sorafenib tosylate|Other: placebo","Progression-free survival|Overall survival|Time to progression|Overall response rate|Duration of overall response|Treatment-emergent adverse events as assessed by NCI CTCAE v3.0","Northwestern University|Amgen","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NU 07B1|STU00000776","June 2007","December 2020","December 2022","July 11, 2007",,"May 3, 2019","Northwest Alabama Cancer Center, PC - Muscle Shoals, Muscle Shoals, Alabama, United States|Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States|Pacific Cancer Medical Center, Incorporated, Anaheim, California, United States|Pacific Coast Hematology/Oncology Medical Group, Incorporated, Fountain Valley, California, United States|Desert Hematology-Oncology Medical Group, Incorporated, Rancho Mirage, California, United States|Sutter Cancer Center, Sacramento, California, United States|Saint Helena, California, United States|Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital, Soquel, California, United States|Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Medical Oncology and Hematology, PC at Harold Leever Cancer Center, Waterbury, Connecticut, United States|George Washington University Cancer Institute, Washington, District of Columbia, United States|Pasco Hernando Oncology Associates, PA - Brooksville, Brooksville, Florida, United States|Pasco Hernando Oncology Associates, PA - New Port Richey, New Port Richey, Florida, United States|Northeast Georgia Cancer Care, LLC - Medical Oncology, Athens, Georgia, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Cancer Institute at Alexian Brothers, Elk Grove Village, Illinois, United States|Medical and Surgical Specialists, LLC, Galesburg, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Kellogg Cancer Care Center, Oak Park, Illinois, United States|Hematology/Oncology of the North Shore at Gross Point Medical Center, Skokie, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Family Medicine of Vincennes Clinical Trial Center, Vincennes, Indiana, United States|Kentuckiana Cancer Institute, PLLC, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, Columbia, Missouri, United States|Nebraska Hematology-Oncology, PC, Lincoln, Nebraska, United States|Essex Oncology of North Jersey, Belleville, New Jersey, United States|Sussex County Medical Associates - Sparta, Sparta, New Jersey, United States|Piedmont Hematology-Oncology Associates, Winston-Salem, North Carolina, United States|Tri-County Hematology/Oncology Associates, Incorporated, Canton, Ohio, United States|Hematology Oncology Consultants, Incorporated, Columbus, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Hematology and Oncology Associates of Rhode Island, Cranston, Rhode Island, United States|West Clinic - East Memphis, Memphis, Tennessee, United States|Patients' Comprehensive Cancer Center - Carrollton, Carrollton, Texas, United States|Oncology Consultants - Memorial City, Houston, Texas, United States|Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00499525"
893,"NCT00493636","1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy",,"Completed","Has Results","Breast Cancer","Drug: Gemcitabine|Drug: Sorafenib|Drug: Placebo|Drug: Capecitabine","Progression Free Survival|Overall Survival|Time to Progression|Overall Response Rate|Duration of Overall Response","Accelerated Community Oncology Research Network|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACORN AC01B07","June 2007","September 2010","November 2012","June 28, 2007","May 16, 2014","May 20, 2014","Providence Cancer Center / Katmai Oncology Group LLC, Anchorage, Alaska, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Compassionate Cancer Care-Corona, Corona, California, United States|Compassionate Cancer Care-Fountain Valley, Fountain Valley, California, United States|California Cancer Care, Greenbrae, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Compassionate Cancer Care-Riverside, Riverside, California, United States|Sutter Cancer Center, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Hematology Oncology PC / Bennett Cancer Center, Stamford, Connecticut, United States|Oncology Associates of Bridgeport, Trumbull, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Pasco Hernando Oncology Associates PA, Brooksville, Florida, United States|Pasco Hernando Oncology Associates PA, New Port Richey, Florida, United States|Augusta Oncology Associates, PC, Augusta, Georgia, United States|Cascade Cancer Center, Macon, Georgia, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|Northwestern University-Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Boston Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Columbia Comprehensive Cancer Care Clinic & Research Institute, Jefferson City, Missouri, United States|Oncology Hematology Specialists, PA, Denville, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hematology Oncology Associates of New York, East Syracuse, New York, United States|Queens Cancer Center, Jamaica, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Hematology Oncology of Northeast Pennsylvania, Dunmore, Pennsylvania, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Oncology Alliance, Glendale, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00493636"
894,"NCT00477191","Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis",,"Terminated","Has Results","Psoriasis|Metabolic Syndrome|Hyperlipidemia|Obesity|Hypertension","Drug: Etanercept","Change in CRP Levels From Baseline to 6 Months of Treatment in Subjects With Psoriasis and Metabolic Syndrome|Change in Plasma Glucose in Subjects With Psoriasis and Metabolic Syndrome|Change of Endothelial Function by Measurement of Flow-mediated Vasodilation Using the Reactive Hyperemia Index (RHI) in 6 Months|Change in the Safety and Tolerability of Etanercept in Patients With Psoriasis and Metabolic Syndrome Over a 6-month Period.","Massachusetts General Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2007-P-000494","May 2007","December 2013","December 2013","May 22, 2007","May 16, 2016","May 16, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00477191"
895,"NCT00475293","Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC",,"Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab and CPT-11","objective response rate|disease control rate, duration of response, time to response, progression-free survival, time to progression,time to treatment failure,duration of stable disease|adverse events","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTD-06-04","May 2007","March 2010","March 2010","May 21, 2007",,"September 13, 2013","Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00475293"
896,"NCT00413400","Study of TNF-Antagonism in the Metabolic Syndrome (II)",,"Completed","Has Results","Metabolic Syndrome","Drug: Etanercept|Drug: Placebo","C-reactive Protein (CRP)|Interleukin-6 (IL-6)|Adiponectin|Glucose Tolerance|Endothelial Function|White Blood Cell (WBC) Count|Cardiac Echo Ejection Fraction (EF)|Body Composition|Tumor Necrosis Factor (TNF) Receptor|Other Adipocytokines|Lipid Levels|Adipocyte Messenger Ribonucleic Acid (mRNA) Levels of Adipocytokines Including Tumor Necrosis Factor (TNF) -Alpha","Massachusetts General Hospital|Amgen","All","18 Years to 60 Years   (Adult)","Not Applicable","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2006-P-001060","December 2006","September 2009","September 2009","December 19, 2006","December 2, 2010","December 2, 2010","MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00413400"
897,"NCT00409318","Study of TNF-Antagonism in Metabolic Syndrome",,"Completed","No Results Available","Metabolic Syndrome","Drug: Etanercept|Drug: Placebo","CRP|Insulin resistance|Muscle adiposity|High molecular weight adiponectin|resistin|leptin|TNF-R1|TNF-R2|weight|WBC|Lipids|IL-6|Fibrinogen|adiponectin","Massachusetts General Hospital|Amgen","All","18 Years to 55 Years   (Adult)","Not Applicable","56","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-P-001699","April 2004","May 2005","May 2005","December 8, 2006",,"May 28, 2008","MGH, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00409318"
898,"NCT00400764","A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas",,"Terminated","Has Results","Non-Hodgkin's Lymphoma","Drug: Dulanermin|Drug: Rituximab","Phase Ib: Number of Participants With a Dose-limiting Toxicity|Number of Participants With Treatment-Emergent Adverse Events by Severity Grade|Phase II: Objective Response as Assessed by the Independent Review Facility (IRF)|Vital Signs: Change From Baseline in Diastolic and Systolic Blood Pressure at Treatment Termination Visit|Vital Signs: Change From Baseline in Heart Rate at Treatment Termination Visit|Vital Signs: Change From Baseline in Body Temperature at Treatment Termination Visit|Number of Participants With a Clinically Significant Laboratory Abnormality|Mean Serum Concentration of Dulanermin|Phase II: Progression Free Survival|Phase II: Overall Survival|Phase II: Objective Response as Assessed by the Investigator|Phase II: Duration of Response as Assessed by the Investigator","Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APO3585g","June 2006","May 2010",,"November 17, 2006","October 7, 2011","November 23, 2011",,,"https://ClinicalTrials.gov/show/NCT00400764"
899,"NCT00381836","Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer",,"Terminated","No Results Available","Prostatic Neoplasms|Anemia","Drug: Darbepoetin Alfa","The haematopoietic response at week 4, 8, 12, 16 and 20|Quality of Life (EQ-5D and QLQ-C30) at week 8 and 20|Number of blood transfusions at week 4, 8, 12, 16 and 20|Change in haemoglobin at week 4, 8, 12, 16 and 20|Number of days admitted to hospital during the 20 week study period","University of Aarhus|Amgen","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2005-005658-37|LM: 2612-3148|Ethical: 20060074|Data Protection: 2005-41-6015","October 2006","February 2007","February 2007","September 28, 2006",,"December 4, 2015","Department of Urology, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT00381836"
900,"NCT00375310","Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer",,"Completed","No Results Available","Pancreatic Cancer|Adenocarcinoma of the Pancreas","Drug: Gemcitabine, Sorafenib|Procedure: Radiotherapy","To evaluate the safety and tolerability of the combined treatment with Gemcitabine with Sorafenib and radiotherapy in patients with localized unresectable pancreatic cancer.|To evaluate the response rate (CR + PR), clinical benefit (CR + PR + SD) and tumor shrinkage (CR + PR + SD that shrinks) of Gemcitabine with Sorafenib and radiotherapy|To evaluate time to disease progression and overall survival.|To evaluate pharmacodynamic changes in tumor vascular parameters (e.g blood flow, blood volume, time to peak in ROC -receiver operator characteristics curve) by DCE-MRI and correlate with outcomes.|To evaluate biologic markers such as VEGF, eNOS and HIF1-alpha, VEGF-R2 genetic polymorphisms and serum proteomics, and correlate with outcomes.|To evaluate resectability rates of tumors after treatment.|To evaluate the maximum tolerated dose (MTD) for Sorafenib during Chemo-radiation.","Indiana University School of Medicine|Amgen|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0607-09; IUCRO-0155","September 2006","November 2010","November 2014","September 12, 2006",,"February 29, 2016","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00375310"
901,"NCT00353119","A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis",,"Completed","Has Results","Palmoplantaris Pustulosis","Drug: Placebo comparator|Drug: Etanercept","Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover|Number of Adverse Events|Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPPASI)|Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPPASI) After Crossover","Innovaderm Research Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2.3","April 2006","March 2007","March 2007","July 17, 2006","December 21, 2010","September 9, 2011","Innovaderm Research Incorporated, Laval, Quebec, Canada|Innovaderm Research Incorporated, Montreal, Quebec, Canada|Centre de Recherche Dermatologique du Québec métropolitain, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00353119"
902,"NCT00346099","Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum",,"Withdrawn","No Results Available","Rectal Cancer|Neoplasm Metastasis","Drug: Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|Drug: Panitumumab with capecitabine and radiation","Percentage of patients with clinical complete response rate in tumor in the pelvis at 4 to 6 weeks after completion of radiation therapy|Percentage of patients with pathologic complete response rate of the primary rectal tumor and resected regional lymph nodes(tissue removed at the time of surgery)|Percentage of patients whose surgical evaluation following therapy indicates candidacy for resection|Percentage of patients who have progressive disease in the pelvis from the time of study entry to 2 years|The toxicity of panitumumab in combination with chemotherapy and in combination with chemoradiotherapy","NSABP Foundation Inc|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSABP FR-1","June 2006",,"May 2007","June 29, 2006",,"January 7, 2008",,,"https://ClinicalTrials.gov/show/NCT00346099"
903,"NCT00333034","Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: Etanercept","The primary efficacy endpoint is the PASI 75 response at week 12. PASI 75 is defined as a 75% or greater improvement in PASI score from baseline.|The secondary efficacy endpoints will include but not limited to: PASI 50, PASI 75 (at visit other than week 12, PASI 90, PASI score PGA of 0 or 1 (clear or minimal, Patient global assessment of psoriasis, DLQI,|EQ5D, FACIT-F.","Wyeth is now a wholly owned subsidiary of Pfizer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0881A6-318","June 2006",,"May 2007","June 2, 2006",,"December 6, 2007","Innsbruck, Austria|Brussels, Belgium|Leuven, Belgium|Paris, France|Paris, France|Bonn, Germany|Hamburg, Germany|Muenster, Germany|Munchen, Germany|Regensburg, Germany|Miskolc, Hungary|Szolnok, Hungary|Messina, Italy|Novara, Italy|Drachten, Netherlands|Nijmegen, Netherlands|Lodz, Poland|Wroclaw, Poland|Bucharest, Romania|Cluj-Napoca, Romania|La Coruna, Spain|Madrid, Spain|Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT00333034"
904,"NCT00300001","Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes",,"Unknown status","No Results Available","Cancer|Solid Tumor|Hematologic Malignancy",,,"Community Cancer Care|Amgen","All","18 Years and older   (Adult, Older Adult)",,"300","Other|Industry","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","2005-0186","March 2006",,,"March 7, 2006",,"August 25, 2006","Quality Oncology Care, Inc., Indianapolis, Indiana, United States|Community Regional Cancer Center-Community Hospital North, Indianapolis, Indiana, United States|Morgan Hospital and Medical Center, Martinsville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00300001"
905,"NCT00299182","Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: AMG 531|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Placebo","Optimal biologic dose (OBD) of AMG 531 given to treat thrombocytopenia (low platelet counts) in participants who have received chemotherapy|Number of Participants with Adverse Events","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2005-0146","March 2006","April 2012","April 2012","March 6, 2006",,"September 5, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00299182"
906,"NCT00283621","Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide",,"Completed","No Results Available","Sarcoma","Drug: Aranesp (darbepoetin alfa)|Drug: Neulasta (pegfilgrastim)|Drug: Adriamycin|Drug: Ifosfamide","CBC diff/platelet counts|Iron Stores|Peripheral blood and bone marrows|Neurocognitive functions and Symptom burden assessment","M.D. Anderson Cancer Center|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","51","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ID02-326","June 2, 2003","April 12, 2006","April 12, 2006","January 30, 2006",,"November 7, 2018","UT MDAnderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00283621"
907,"NCT00245895","Study of Aranesp to Treat Anemia in Prostate Cancer Patients.",,"Completed","No Results Available","Prostate Cancer|Anemia","Drug: Aranesp","Hemoglobin greater than or equal to 12.5|The median time to achieving the primary endpoint.|The dose required to achieve the primary endpoint of more than 50% of patients.|A description of the qualitative and quantitative toxicities of the administration of Aranesp (darbepoetin alfa) in this patient population.|Changes in QOL from baseline compared to 3 and 6 month time point using the anemia subscale of FACT-P.","University of Washington|Amgen","Male","Child, Adult, Older Adult","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","03-6503-A","April 2003",,"February 2005","October 28, 2005",,"November 29, 2007","Oregon Health and Sciences University, Portland, Oregon, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00245895"
908,"NCT00230321","A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)",,"Completed","No Results Available","Blood Cancer|Myelodysplastic Syndromes|Myelodysplastic Syndromes (MDS)","Drug: Darbepoetin alfa","hemoglobin and/or red blood cell (RBC) transfusion-dependence.|To assess erythroid responses to DARBEPOETIN ALFA, as determined by changes in|To assess bone marrow progenitor BFU-E growth before and after treatment|DARBEPOETIN ALFA","Peter L Greenberg|Amgen|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HEMMDS0001|13536","February 2002","November 2007","January 2008","September 30, 2005",,"February 4, 2013","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00230321"
909,"NCT00204334","Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients",,"Completed","No Results Available","Kidney Transplantation|Anemia","Drug: darbopoeitin","Vessel wall stiffness|expression of endothelial cell markers","University Hospital Muenster|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Haus_Lang-Endothel-Mono-Hb|DE-2004-4077","June 2005","January 2010","January 2010","September 20, 2005",,"January 13, 2010","UKM, Münster, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT00204334"
910,"NCT00189488","Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation",,"Completed","Has Results","Graft Versus Host Disease|Hematologic Malignancies","Drug: Palifermin|Drug: Placebo|Other: Conditioning Regimen|Procedure: Allogeneic stem cell transplant|Drug: Methotrexate","Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)|Number of Participants With Grade 2 to 4 Acute Graft Versus Host Disease (GVHD)|Number of Participants With Day 11 Methotrexate Graft Versus Host Disease Prophylaxis Administration|Number of Participants With Severe (Grade 3 or 4) Oral Mucositis|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Duration of Hospitalization|Area Under the Curve (AUC) of Mouth and Throat Soreness Score","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040213","December 2005","November 2008","August 2013","September 19, 2005","September 15, 2014","September 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00189488"
911,"NCT00169143","Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma",,"Completed","No Results Available","Untreated CD20-positive Large B-cell Lymphoma","Drug: Rituximab + ACVBP regimen plus Pegfilgrastim|Procedure: Autologous stem cell transplant","To evaluate the optimal combined dose intensity of the drug regimen|Specific dose intensities, incidence of neutropenia and neutropenic fever, duration of severe neutropenia, complete response rate, event-free and overall survival","Lymphoma Study Association|Amgen","All","18 Years to 61 Years   (Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH 03-39B","May 2004","January 2007","January 2007","September 15, 2005",,"August 23, 2018","Hôpital Henri Mondor, Créteil, France|Service d'Hématologie Clinique - CHU Le Bocage, Dijon, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Henri Becquerel, Rouen, France|CHRU de Nancy Brabois, Vandoeuvre-les-Nancy, France",,"https://ClinicalTrials.gov/show/NCT00169143"
912,"NCT00169104","Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function",,"Terminated","Has Results","Metastatic Breast Cancer","Drug: G-CSF|Drug: trastuzumab|Drug: vinorelbine|Drug: saline placebo","Antibody Dependent Cell-mediated Cytotoxicity of Effector Cells Isolated From Subjects Receiving Trastuzumab With Either G-CSF or a Saline Placebo Against a Her-2 Overexpressing Target in Vitro|Antibody Dependent Cell-mediated Cytotoxicity of Effector Cells Isolated From Subjects Receiving Chemotherapy, Trastuzumab, and G-CSF Against a Her-2 Overexpressing Target in Vitro|Clinical Response Rate of the Combination of Trastuzumab, G-CSF, and Vinorelbine in Subjects With Her-2 Overexpressing Metastatic Breast Cancer|Safety of the Combination of Trastuzumab, G-CSF, and Vinorelbine in Subjects With Her-2 Overexpressing Metastatic Breast Cancer","Dartmouth-Hitchcock Medical Center|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D-0140","July 2002","March 2009","March 2009","September 15, 2005","July 20, 2018","July 20, 2018",,,"https://ClinicalTrials.gov/show/NCT00169104"
913,"NCT00153868","A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer",,"Active, not recruiting","No Results Available","Anemia|Cancer","Drug: darbepoetin alfa","A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).|A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).|A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13).","Dartmouth-Hitchcock Medical Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D-0341","October 2003","December 2025","December 2025","September 12, 2005",,"November 13, 2019","Norris Cotton Cancer Center, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT00153868"
914,"NCT00147225","AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin",,"Completed","Has Results","Solid Tumors|Advanced Cancer","Drug: AMG 531|Drug: Carboplatin|Drug: Adriamycin|Drug: Ifosfamide","Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy|Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2005-0099","August 2005","March 2013","March 2013","September 7, 2005","May 8, 2014","May 8, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00147225"
915,"NCT00144755","R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma",,"Completed","No Results Available","Diffuse Large Cell Lymphoma","Drug: Darbepoetin alfa","Efficacy of R-CHOP 14 vs R-CHOP 21 measured by event-free survival (EFS)|Efficacy of darbepoetin alfa in association with chemotherapy measured by the EFS.|Efficacy and toxicity of R-CHOP 14 vs R-CHOP 21|Efficacy and toxicity of Darbepoetin alfa in association with R-CHOP.","Lymphoma Study Association|Amgen","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 3","600","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-6B","December 2003","December 2012","December 2012","September 5, 2005",,"September 2, 2015","Université de Gent, Gent, Belgium|Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Polyclinique Bordeaux Nord, Bordeaux, France|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT00144755"
916,"NCT00140660","ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma",,"Terminated","No Results Available","Diffuse Large Cell Lymphoma","Drug: rituximab","Event-free survival (EFS)|Response rate at the end of the treatment|Disease-free survival for complete responders|Overall survival|additionnal toxicities with R-ACVBP","Lymphoma Study Association|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","223","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-1B","December 2003","July 2008","April 2012","September 1, 2005",,"March 13, 2017","Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium|Hôpital Henri Mondor, Créteil, France|Hématologie CHU de Lille, Lille, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Centre Pluridisciplinaire d'Oncologie, CHUV, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT00140660"
917,"NCT00140595","ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1",,"Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide","Event-free survival (EFS), events defined as death from any cause, relapse for complete responders (CR) and unconfirmed complete responders (CRu), progression during or after treatment, changes of therapy during allocated treatment.|Response rate at the end of the treatment, progression rate, relapse rate, disease-free survival for complete responders, overall survival, neuromeningeal relapse rate and additional toxicities with ACVBP+rituximab combination","Lymphoma Study Association|Amgen","All","18 Years to 59 Years   (Adult)","Phase 3","380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LNH03-2B","December 2003","January 2009","January 2009","September 1, 2005",,"March 4, 2011","Groupe d'étude des lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Centre Léon Bérard, Lyon, France|Hôpital Saint Louis, Paris, France|Hématologie Adultes - Hôpital Necker, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Hématologie CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT00140595"
918,"NCT00140205","Pharmacokinetics of Leptin Administration During Fasting",,"Completed","Has Results","Energy Deficiency Due to Short-term Fasting","Drug: r-metHuLeptin","Leptin Pharmacokinetic Parameters - TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetics Parameters - AUC 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetic Parameters TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.1 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 72-hour Fasting Day 3 Leptin Dose 0.1 mg/kg|Leptin Pharmacokinetics Parameters - AUC 72-hour Fasting Day 3 Leptin Dose 0.1 mg/kg|Leptin Pharmacokinetic Parameters - TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 72-hour Fasting Day 3 Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetics Parameters - AUC 72-hour Fasting Day 3 Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetic Parameters - TIME(T1/2) / TMAX 24-hour Fed Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 24-hour Fed Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetics Parameters - AUC 24-hour Fed Leptin Dose 0.3 mg/kg|Leptin Pharmacokinetic Parameters - TIME(T1/2) / TMAX 24-hour Fed Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 24-hour Fed Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetics Parameters - AUC 24-hour Fed Leptin Dose 0.01 mg/kg|Leptin Pharmacokinetic Parameters - TIME(T1/2) / TMAX 24-hour Fed Leptin Dose 0.1 mg/kg|Leptin Pharmacokinetics Parameters - c(MAX) / L0 (ENDOGENOUS LEPTIN LEVEL) 24-hour Fed Leptin Dose 0.1 mg/kg|Leptin Pharmacokinetics Parameters - AUC 24-hour Fed Leptin Dose 0.1 mg/kg|Cytokine Levels 24h Fed or 72h Fasting for All Different Leptin Doses (0,01-0,1-0,3 mg/kg)|Neuroendocrine Hormone Levels 24h Fed or 72h Fasting for All Different Leptin Doses (0,01-0,1-0,3 mg/kg)|Adipokine Hormone Levels 24h Fed or 72h Fasting for All Different Leptin Doses (0,01-0,1-0,3 mg/kg)","Beth Israel Deaconess Medical Center|Amgen","All","18 Years to 30 Years   (Adult)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2001P000260","February 2001","June 2004","December 2016","September 1, 2005","November 2, 2018","November 2, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00140205"
919,"NCT00122720","The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery",,"Completed","No Results Available","Colorectal Cancer","Drug: Darbepoetin Alfa","The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life|Muscular strength|Weight|Body composition|Blood transfusion|Postoperative complications","Herning Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","2612-2277","June 2003",,"January 2006","July 22, 2005",,"July 7, 2006","Surgical Department, Middelfart Hospital, Middelfart, Fyn, Denmark|Surgical Department, Odense University Hospital, Odense, Fyn, Denmark|Surgical Department, Svendborg Hospital, Svendborg, Fyn, Denmark|Surgical Department, Herning Hospital, Herning, Ringkobing, Denmark|Surgical Department, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT00122720"
920,"NCT00121433","Leptin and Endothelial Function",,"Completed","No Results Available","Healthy","Drug: leptin","flow-mediated dilatation (FMD) of the brachial artery (conduit artery shear stress-mediated endothelial-dependent vasodilatation)|basal brachial arterial diameter (BAD) (resting conduit artery tone)|basal brachial arterial blood flow (BABF) (resting resistance artery tone)","University of Michigan|Amgen","All","18 Years to 50 Years   (Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","GCRC 1955|IRB 2003-0383","September 2004",,"December 2004","July 21, 2005",,"June 27, 2006",,,"https://ClinicalTrials.gov/show/NCT00121433"
921,"NCT00116181","Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: Etanercept","Proportion of subjects achieving a responder status on the Physician's Global Assessment (PGA) at week 24|Subject incidence rates of serious adverse events, serious infections, non-melanoma skin cancer, and all malignancies","Rockefeller University|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JKR 542","October 2004","January 2007",,"June 28, 2005",,"March 18, 2011","Rockefeller University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00116181"
922,"NCT00112385","A Pilot Study of Etanercept in Dermatomyositis",,"Completed","Has Results","Dermatomyositis","Drug: Etanercept|Drug: Placebo","Occurrence of at Least One Adverse Event|Tolerability|Average Change in Oral Temperature From Baseline to Week 52|Average Change in Respiration Rate From Baseline to Week 52|Average Change in Systolic Blood Pressure From Baseline to Week 52|Average Change in Diastolic Blood Pressure Comparing Baseline to Week 52.|Average Change in Pulse Comparing Baseline to Week 52|Average Change in Body Weight in Kilograms (kg) Comparing Baseline to Week 52.|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Creatine Kinase (CK) Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Alanine Aminotransferase (ALT) Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Gamma-glutamyl Transpeptidase (GGT) Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Aldolase Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Glucose Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Potassium Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal White Blood Cell Count (WBC) Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Hemoglobin Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Hematocrit Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Platelet Counts From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Urine Leukocyte Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Urine Protein Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Urine Glucose Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Urine Ketone Laboratory Values From Baseline to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Serum 25-hydroxyvitamin D (25-OH VitD) Laboratory Values From the Screening Visit to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Antinuclear Antibody Test (ANA) Values From the Screening Visit to Week 52|Frequency of Subjects With Treatment Emergent, Clinically Significant, Abnormal Monoclonal Protein Detection by Serum Protein Electrophoresis (SPEP) From the Screening Visit to Week 52|Average Cumulative Dosage of Prednisone Over the One Year Study Period|Average Prednisone Dosage After Week 24|Average Daily Dose of Prednisone From Baseline to Week 52","Brigham and Women's Hospital|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1R01NS049639-01A2","March 2006","June 2010","June 2010","June 3, 2005","June 21, 2011","June 21, 2011","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00112385"
923,"NCT00111007","A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma",,"Completed","Has Results","Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Carboplatin/Paclitaxel|Drug: Placebo","Progression Free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Duration of Response (DOR)|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to the Visit When the Best Tumor Response Was Noted","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11718|2005-000941-12","May 2005","September 2006","January 2009","May 17, 2005","February 23, 2011","October 31, 2014","Birmingham, Alabama, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Aurora, Colorado, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Louisville, Kentucky, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Montclair, New Jersey, United States|Buffalo, New York, United States|New York, New York, United States|Columbus, Ohio, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|Warartah, New South Wales, Australia|Westmead, New South Wales, Australia|Brisbane, Queensland, Australia|East Melbourne, Victoria, Australia|Heidelberg, Victoria, Australia|Malvern, Victoria, Australia|Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bordeaux, France|Boulogne-billancourt, France|Brest, France|Lyon Cedex, France|Montpellier Cedex, France|Paris, France|Paris, France|Villejuif, France|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Essen, Nordrhein-Westfalen, Germany|Trier, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Kiel, Schleswig-Holstein, Germany|Berlin, Germany|Amsterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Southampton, Hampshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Bebington, Merseyside, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, West Yorkshire, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00111007"
924,"NCT00110994","Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma",,"Completed","Has Results","Cancer|Melanoma","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Dacarbazine","Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants in Tumor Response Categories|Time to Progression (TTP)|Duration of Response (DOR)|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to the Visit When the Best Tumor Response Was Noted|Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the Visit at Which Best Response Was First Noted|Change of European Quality of Life 5-dimensional (EQ-5D) Questionnaire Index Score From Baseline to the End of Treatment|Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the Visit at Which Best Response Was First Noted|Change of European Quality of Life Visual Analogue Scale (EQ-VAS) Score From Baseline to the End of Treatment","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11715","April 2005","October 2006","March 2008","May 17, 2005","June 1, 2011","June 8, 2015","Tucson, Arizona, United States|Aurora, Colorado, United States|Lakeland, Florida, United States|Park Ridge, Illinois, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Charlotte, North Carolina, United States|Pittsburgh, Pennsylvania, United States|Hilton Head Island, South Carolina, United States|Nashville, Tennessee, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00110994"
925,"NCT00109031","Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)",,"Completed","Has Results","Cancer|Lymphoma|Leukemia","Drug: palifermin|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Placebo","Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4)|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Area Under the Curve (AUC) of Mouth and Throat Soreness Score|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Number of Participants With WHO Grades 2, 3 or 4 Oral Mucositis|Duration of WHO Grade 2, 3 or 4 Oral Mucositis|Number of Participants With WHO Grade 4 Oral Mucositis","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20040212","January 2005","February 2006","December 2010","April 25, 2005","September 15, 2014","September 15, 2014",,,"https://ClinicalTrials.gov/show/NCT00109031"
926,"NCT00101582","Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer",,"Completed","Has Results","Mucositis|Solid Tumors|Stomatitis|Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Placebo|Drug: palifermin|Drug: cisplatin chemotherapy|Radiation: Radiotherapy","Number of Participants With Severe (Grade 3 or 4) Oral Mucositis|Duration of Severe (WHO Grade 3 or 4) Oral Mucositis|Time to Onset of Severe (WHO Grade 3 or 4) Oral Mucositis|Number of Participants With Xerostomia at Month 4 (Grade 2 or Higher)|Patient-Reported Mouth and Throat Soreness Score|Total Dose of Opioid Analgesics Used for Mucositis Within 15 Weeks|Number of Participants With Unplanned Breaks in Cisplatin Chemotherapy Treatment|Number of Participants With Unplanned Breaks in Radiotherapy","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20020402","August 2005","September 2007","August 2016","January 13, 2005","September 15, 2014","September 27, 2016",,,"https://ClinicalTrials.gov/show/NCT00101582"
927,"NCT00101413","BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)",,"Completed","Has Results","Cancer|Carcinoma, Non-Small Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)","Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)|Duration of Stable Disease|Overall Survival|Percentage of Subjects With Stable Disease (SD)|Change From Baseline of Health-Related Quality of Life (HRQOL) Score Assessed at Cycle 2, Cycle 4, and End of Treatment (EOT)","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100557","April 2004","June 2005","April 2008","January 11, 2005","April 8, 2010","October 30, 2013","Houston, Texas, United States|Großhansdorf, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT00101413"
928,"NCT00094861","Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Dysphagia|Non-Small Cell Lung Cancer|Lung Cancer","Drug: Palifermin|Drug: Placebo|Radiation: Radiotherapy|Drug: Paclitaxel|Drug: Carboplatin","Number of Participants With Grade 2 or Higher Dysphagia|Duration of Grade 2 or Higher Dysphagia|Maximal Dysphagia Grade|Number of Participants With Severe (Grade 3 or Higher) Dysphagia|Number of Participants With Unplanned Breaks in Radiotherapy|Maximal Eastern Cooperative Oncology Group (ECOG) Performance Status Increase|Number of Participants Hospitalized|Maximal Body Weight Loss","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20030185","January 2005","December 2007","January 2014","October 27, 2004","March 6, 2014","March 14, 2017",,,"https://ClinicalTrials.gov/show/NCT00094861"
929,"NCT00079612","Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Number of progressions post randomization to placebo or sorafenib|Time to progression|Duration of objective tumor response|Overall survival time","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","100391","September 2002",,"January 2007","March 11, 2004",,"December 19, 2014","Chicago, Illinois, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|London, Greater London, United Kingdom|Glasgow, Strathclyde, United Kingdom|Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00079612"
930,"NCT00073307","Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population|Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population|Final Progression-Free Survival (PFS) - Independent Radiological Review|Best Overall Response - Independent Radiological Review|Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment|Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment","Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","903","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11213","November 2003","September 2006","April 2010","November 21, 2003","December 14, 2011","February 6, 2014","Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Hamden, Connecticut, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Lafayette, Louisiana, United States|Frederick, Maryland, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Bronx, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Laredo, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Rosario, Santa Fe, Argentina|Santa Fé, Santa Fe, Argentina|Capital Federal-Buenos Aires, Argentina|Mendoza, Argentina|Garran, Australian Capital Territory, Australia|Camperdown, New South Wales, Australia|Liverpool, New South Wales, Australia|Westmead, New South Wales, Australia|Heidelberg, Victoria, Australia|Wodonga, Victoria, Australia|Bruxelles - Brussel, Belgium|Bruxelles - Brussel, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Edmonton, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Santiago de Chile, Chile|Bordeaux, France|Caen Cedex 5, France|Lille Cedex, France|Lyon Cedex, France|Marseille, France|Nantes, France|Paris Cedex 15, France|Strasbourg, France|Toulouse, France|Villejuif, France|Mannheim, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Zalaegerszeg, Hungary|Haifa, Israel|Tel Aviv, Israel|Milano, Italy|Modena, Italy|Pavia, Italy|Perugia, Italy|Reggio Emilia, Italy|Roma, Italy|Nijmegen, Netherlands|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Barnaul, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Bloemfontein, Freestate, South Africa|Pretoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cruces/Barakaldo, Bilbao, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Donetsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Northwood, Middlesex, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Sutton, Surrey, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Birmingham, West Midlands, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00073307"
931,"NCT00070616","Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support",,"Completed","No Results Available","Leukemia|Lymphoma|Myeloma","Drug: Palifermin 6 x 60 μg/kg/day|Drug: Palifermin 2 x 180 μg/kg/day|Radiation: radiotherapy|Drug: Chemotherapy","To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation|To assess the safety and tolerability of rHuKGF in subjects with hematologic malignancies undergoing TBI and high-dose chemotherapy followed by PBPC transplantation.|To assess oral mucositis in subjects receiving rHuKGF.","Swedish Orphan Biovitrum|Amgen","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010182","December 2001","March 2005","March 2005","October 8, 2003",,"October 24, 2014",,,"https://ClinicalTrials.gov/show/NCT00070616"
932,"NCT00067639","Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Pegfilgrastim (Neulasta)|Procedure: Apheresis","Efficacy of pegfilgrastim in mobilizing progenitor cells","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ID03-0164","December 2003","April 2007","April 2007","August 26, 2003",,"August 1, 2012","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00067639"
933,"NCT00050674","Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma",,"Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Filgrastim-SD/01",,"Schwartzberg, Lee, M.D.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SD01-20010120","November 2001","February 2007","February 2007","December 18, 2002",,"December 27, 2012","The West Clinic, PC, Southaven, Mississippi, United States|The West Clinic, PC, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00050674"
934,"NCT00038792","Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD",,"Terminated","No Results Available","Acute Graft Versus Host Disease","Drug: Recombinant Human Keratinocyte Growth Factor","Number of Participants with resolution of diarrhea","M.D. Anderson Cancer Center|Amgen","All","Child, Adult, Older Adult","Phase 1|Phase 2","7","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID00-036","October 2000","January 2003","January 2003","June 7, 2002",,"August 2, 2012","MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00038792"
935,"NCT00000626","Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease",,"Completed","No Results Available","HIV Infections|Hodgkin's Disease","Drug: Vinblastine sulfate|Drug: Dacarbazine|Drug: Filgrastim|Drug: Bleomycin sulfate|Drug: Doxorubicin hydrochloride",,"National Institute of Allergy and Infectious Diseases (NIAID)|Amgen","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","27","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 149|11124",,,"February 1999","August 31, 2001",,"May 23, 2012","Alabama Therapeutics CRS, Birmingham, Alabama, United States|USC CRS, Los Angeles, California, United States|Northwestern University CRS, Chicago, Illinois, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States|Washington U CRS, St. Louis, Missouri, United States|SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States|The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00000626"
936,"NCT02315716","Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma","Cardamon","Active, not recruiting","No Results Available","Multiple Myeloma","Procedure: Autologous Stem Cell Transplant (ASCT)|Drug: Consolidation with 4 cycles of CarCyDex","Response rate|PFS|Toxicity|Disease response rate|Overall survival|MRD conversion following treatment|MRD conversion following maintenance","University College, London|Amgen (Europe) GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","281","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/12/0500","June 16, 2015","November 2019","November 2029","December 12, 2014",,"July 22, 2019","Queen's Hospital, Romford, Essex, United Kingdom|Royal United Hospital, Bath, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|NHS Lanarkshire, Bothwell, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Kent and Canterbury Hospital, Canterbury, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Medway NHS Foundation Trust, Gillingham, United Kingdom|St James' Hospital, Leeds, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Barnet Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|University College London Hospital, London, United Kingdom|Maidstone and Tunbridge Wells, Maidstone, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Royal Stoke University Hospital, Stoke, United Kingdom|City Hospital Sunderland, Sunderland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02315716"
937,"NCT04176718","Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM",,"Not yet recruiting","No Results Available","Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse|Relapse","Drug: Daratumumab|Drug: Carfilzomib|Drug: Pomalidomide|Drug: Dexamethasone","Objective response rate of the daratumumab, carfilzomib, pomalidomide, and dexamethasone combination|Number of dose limiting toxicity grade 4 or higher treatment related|Progression-free survival (PFS)|Rate of Minimal residual disease (MRD) negative status","Andrew Yee, MD|Amgen|Janssen Research & Development, LLC|Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-379","November 2019","November 2023","November 2024","November 25, 2019",,"November 25, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04176718"
938,"NCT04034173","Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation",,"Not yet recruiting","No Results Available","Treatment Related Cancer","Drug: Panitumumab|Drug: Irinotecan|Drug: Folinic acid|Drug: 5-FU","Overall Response Rate|Progression free survival (PFS)|Overall Survival (OS)|Investigation of Early Tumor shrinkage (ETS) as an alternative early-on-treatment predictor of treatment efficacy|Investigation of Depth of Response (DpR) to define the nadir of tumour response","Ludwig-Maximilians - University of Munich|Amgen|ClinAssess GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIRE-5","August 1, 2019","August 1, 2024","August 1, 2026","July 26, 2019",,"July 26, 2019","Ludwigs Maximialians University, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT04034173"
939,"NCT03802604","Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","PROMETEO","Recruiting","No Results Available","Breast Cancer","Biological: Talimogene laherparepvec|Drug: Atezolizumab","Changes in the expression of a gene signature tracking activated CD8 T-cells.|Rate of pCRB (ypT0/Tis) and pCRBL (ypT0/TisypN0)|Tumor ORR|Rate of residual cancer burden (RCB)|Safety of T-VEC in combination with atezolizumab","SOLTI Breast Cancer Research Group|Amgen|Roche Pharma AG","Female","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SOLTI-1503","December 10, 2018","November 2020","November 2023","January 14, 2019",,"November 5, 2019","Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico universitario de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03802604"
940,"NCT03792763","Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients","DEFENCE","Recruiting","No Results Available","Multiple Myeloma","Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Drug: Placebo 1.7 ml Subcutaneous Solution","Time to progression|Percentage of patients transforming in 3 years|Overall survival|Time to first skeletal-related event|Incidence of bone lesions as MM defining events|Time to first anti-myeloma treatment","Arbeitsgemeinschaft medikamentoese Tumortherapie|Amgen|Assign Data Management and Biostatistics GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","164","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AGMT_MM-3","September 30, 2019","July 2024","July 2024","January 3, 2019",,"October 2, 2019","Landeskrankenhaus Steyr, Innere Medizin, Hämatologie, Onkologie, Steyr, Oberösterreich, Austria|Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie, Graz, Austria|Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie, Innsbruck, Austria|LKH Hochsteiermark, Standort Leoben, Leoben, Austria|BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie, Linz, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria|Medizinische Univ. Wien, Univ.Klinik f. Innere Medizin I, Hämatologie u. Hämostaseologie, Vienna, Austria|Wilhelminenspital, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT03792763"
941,"NCT03751176","Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal","BEYOND","Recruiting","No Results Available","Colorectal Cancer Metastatic","Drug: Panitumumab|Drug: Irinotecan|Drug: Folinic acid|Drug: 5-FU","Progression-free survival at 6 months|Progression-free survival (PFS)|Overall response rate (ORR)|Overall survival (OS)|Safety and tolerability. ( assessment will consist of monitoring adverse events (AEs), including serious adverse events (SAEs) and laboratory safety parameters)|Biomarkers analysis by liquid biopsies.","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|Pivotal S.L.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","85","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMCAD-17-01|2017-004519-38","November 8, 2018","May 2019","December 2021","November 23, 2018",,"November 23, 2018","ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain|Hospital de Granollers, Granollers, Barcelona, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Hospital General Universitario de Elche, Alicante, Elche, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|H. Universitari Sant Joan de Reus, Reus, Tarragona, Spain|Hospital de La Ribera de Alzira, Alzira, Valencia, Spain|Hospital Universitario Vall d`Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universtiario la Paz, Madrid, Spain|CIOCC Sanchinarro, Madrid, Spain|Complejo Hospitalario de Navarra, Navarro, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03751176"
942,"NCT03448731","Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)","DERMIA","Recruiting","No Results Available","Skin Toxicity","Drug: Doxycycline 50Mg Tablet","Efficacy in the prevention of skin toxicity|Quality of life of patients during the treatment|Incidence of Treatment-Emergent Adverse Events","Fundacion CRIS de Investigación para Vencer el Cáncer|Amgen|Apices Soluciones S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DERMIA|2017-004413-98","May 10, 2018","April 2020","April 2020","February 28, 2018",,"August 28, 2019","Hospital Punta Europa, Algeciras, Spain|Hospital Puerta del Mar, Cadiz, Spain|Hospital Puerto Real, Cadiz, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Clinico San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital de Jerez, Jerez De La Frontera, Spain|Hospital Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT03448731"
943,"NCT03446157","Palbociclib and Cetuximab in Metastatic Colorectal Cancer",,"Recruiting","No Results Available","Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer|Neoplasms, Colonic","Drug: Cetuximab|Drug: Palbociclib","Disease Control Rate|Overall Response rate|Length of Overall Survival|Length of progression free survival|Toxicity of Treatment","UNC Lineberger Comprehensive Cancer Center|Amgen|Pfizer","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","57","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC1717","March 13, 2018","July 13, 2020","July 13, 2023","February 26, 2018",,"January 10, 2020","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03446157"
944,"NCT03442569","PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC",,"Recruiting","No Results Available","Colon Cancer","Drug: Panitumumab|Drug: Nivolumab|Drug: Ipilimumab","Overall Response Rate|Overall Response Rate per irRECIST|Length of Progression Free Survival|Length of Overall Survival|Duration of Response|Toxicity of Treatment","UNC Lineberger Comprehensive Cancer Center|Amgen|Bristol-Myers Squibb","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC1632","March 9, 2018","December 14, 2020","December 14, 2023","February 22, 2018",,"May 23, 2019","Moffitt Cancer Center, Tampa, Florida, United States|Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03442569"
945,"NCT03287609","EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)","EVOPACS","Completed","No Results Available","Acute Coronary Syndrome","Drug: Evolocumab 140 mg/mL|Drug: Placebo","Percent change in calculated LDL-C in the intent to treat (ITT) population|Number of patients with adverse events and serious adverse events","University Hospital Inselspital, Berne|Amgen|University of Bern","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2017-01753","January 23, 2018","May 20, 2019","August 7, 2019","September 19, 2017",,"August 14, 2019","Basel University Hospital, Basel, BS, Switzerland|HFR Kantonsspital, Fribourg, FR, Switzerland|Hopitaux Universitaires Geneve, Geneva, GE, Switzerland|Cardiocentro Ticino, Lugano, TI, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, VD, Switzerland|University Hospital, Zurich, ZH, Switzerland|Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03287609"
946,"NCT03224507","Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma","MASTER","Recruiting","No Results Available","Multiple Myeloma","Drug: KRdD followed by auto-HCT|Drug: KRdD only","Percentage of patients with MRD(-) remissions at the completion of consolidation therapy|Serious adverse events (SAEs) from the KRdD treatment|Percentage of patients with MRD(-) status at the completion of induction therapy|Percentage of patients with auto-HCT that convert from positive to negative MRD|Percentage of patients achieving complete remission following complete therapy|Percentage of patients that convert from MRD(-) to MRD(+) following treatment discontinuation|Progression-free survival|Overall survival","University of Alabama at Birmingham|Amgen|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F170525008 (UAB 1735)","March 14, 2018","April 1, 2021","April 1, 2023","July 21, 2017",,"March 26, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Oregon Health and Science University, Portland, Oregon, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|University of Wisconsin, school of medicine and public health, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03224507"
947,"NCT03168529","Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit","OBSERVE-IVA","Recruiting","No Results Available","Heart Failure","Drug: Ivabradine|Drug: Placebo","Change in Heart Rate|Change in Heart Rate in self-identified African Americans","Phillip Levy|Amgen|iRhythm Technologies, Inc.|Wayne State University","All","19 Years to 89 Years   (Adult, Older Adult)","Phase 4","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1701000235","July 1, 2018","December 31, 2019","June 30, 2020","May 30, 2017",,"October 4, 2018","Wayne State University, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03168529"
948,"NCT03142516","FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status","OPALO","Active, not recruiting","No Results Available","Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Cancer Metastatic|Neoplasm Metastasis","Drug: Panitumumab|Drug: Irinotecan|Drug: Folinic acid|Drug: 5-FU","Progression-free survival at one year|Progression-free survival (PFS)|Objective response rate|Disease control rate|Duration of response|Time to response|Overall survival (OS)|Time to treatment failure|Proportion of patients with early tumour shrinkage (ETS)|Depth of response (DpR)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Combined analysis of prognostic factors in metastatic disease","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|Pivotal S.L.","All","70 Years and older   (Older Adult)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMCAD-16-03|2017-001639-38","October 31, 2017","January 31, 2021","January 31, 2021","May 5, 2017",,"February 8, 2019","ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan Despí-Moises Broggi, Sant Joan Despí, Barcelona, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Clínic, Barcelona, Spain|Hospital General Universitario de Elda, Elda, Spain|Hospital Universitario Arnau de Vilanova, Lleida, Spain|Hospital Universitario la Paz, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Son Espases, Palma, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT03142516"
949,"NCT03131453","A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","Generation S2","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: CNP520 50mg|Drug: CNP520 15mg|Other: Placebo to CNP520","Time to event|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in cerebral amyloid angiopathy (CAA)|Change on volume of brain regions|Change in amyloid deposition as measured by standardized uptake ratio (SUVR) of positron emission tomography (PET) scan with amyloid radiotracer|Change in CSF levels of Aβ40, Aβ42|Change in CSF levels of total tau and phosphorylated tau|Number of participants with adverse events as a measure of safety|Change in neurofibrillary tangle burden as measured by standardized uptake ratio (SUVR) of PET scans with tau radiotracer (where available)","Novartis Pharmaceuticals|Amgen|Banner Alzheimer's Institute|Novartis","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1145","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCNP520A2202J|2016-002976-28","August 3, 2017","July 30, 2024","March 31, 2025","April 27, 2017",,"October 7, 2019","Banner Alzheimer's Institute, 901 East Willetta Street, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B, Sun City, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|ATP Clinical Research Inc, 3151 Airway Avenue T 3, Costa Mesa, California, United States|Novartis Investigative Site, Garden Grove, California, United States|Irvine Center for Clinical Res, 2515 McCabe Way, Irvine, California, United States|Torrance Clinical Research Institute, 25043 Narbonne Avenue, Lomita, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|Mountain Neurological Research, 350 Market Street, Suite 316, Basalt, Colorado, United States|Colorado Springs Neurological, 2312 North Nevada Avenue, Suite 100, Colorado Springs, Colorado, United States|Denver Neurological Clinic, 950 E Harvard Ave, Denver, Colorado, United States|Yale University, One Church Street, Suite 600, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlantis, Florida, United States|Quantum Laboratories, Deerfield Beach, Florida, United States|Brain Matters Research, Inc., 800 NW 17th Avenue, Delray Beach, Florida, United States|Infinity Clinical Research LLC, 4925 Sheridan Street, Suite 200, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, 5065 State Road 7, Suite 102, Lake Worth, Florida, United States|Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States|Novartis Investigative Site, Melbourne, Florida, United States|Novartis Investigative Site, Merritt Island, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|New Horizon Research Center, 11880 SW 40 St., Suite 405, Miami, Florida, United States|Miami-Dade Medical Research, 8955 SW 87 CT, Suite 112, Miami, Florida, United States|Compass Research, LLC,100 West Gore Street, Suite 202, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Palm Beach Gardens, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Roskamp Institute, Inc., 2040 Whitfield Avenue, Sarasota, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Hawaii Pacific Neuroscience, 2230 Liliha st 104, Honolulu, Hawaii, United States|Advanced Clinical Research, 2950 E Magic View Dr, Suite 182, Meridian, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Alexian Brothers Neuroscience, 800 Biesterfield Rd, Neuroscience Institute Brock, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Fairway, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|QUEST Research Institute, 28595 Orchard Lake Road, Suite 301, Farmington Hills, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Hattiesburg Clinic, 415 South 28th Avenue, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, West Long Branch, New Jersey, United States|Albuquerque Neuroscience, 101 Hospital Loop ne, 209 209, Albuquerque, New Mexico, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Latham, New York, United States|NYU Langone Medical Center, 145 East 32nd Street, 2nd Floor, Room 226, New York, New York, United States|Novartis Investigative Site, Orangeburg, New York, United States|Novartis Investigative Site, Rochester, New York, United States|ANI Neurology, PLLC dba Alzhe, 7809 Sardis Road, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Tulsa Clinical Research LLC, 1705 E 19th ST., STE 406/408, Tulsa, Oklahoma, United States|Summit Research Network, 2701 NW Vaughn St, Suite 350, Portland, Oregon, United States|OHSU Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|Novartis Investigative Site, Jenkintown, Pennsylvania, United States|Abington Neurological Associate Ltd., 2325 Maryland Road, Suite 100, Willow Grove, Pennsylvania, United States|Rhode Island Hospital and Memory Research Institute, 1018 Waterman Ave, East Providence, Rhode Island, United States|Butler Hospital, 345 Blackstone Blvd., Providence, Rhode Island, United States|Roper Hospital, 316 Calhoun Street 5th Floor, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Bennington, Vermont, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Cordoba, ARG, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Mar del Plata, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg West, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, 1 Valleybrook Drive Suite 400, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Guang Zhou, China|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Strasbourg, Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, PARIS Cedex 13, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villeurbanne, France|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Tōon, Ehime, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Kodaira, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Suwon, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Hertogenbosch, Netherlands|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Torres Vedras, Portugal|Novartis Investigative Site, Guaynabo, Puerto Rico|Inspira Clinical Research, Ave Hostos 405, San Juan, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Rosebank, Johannesburg, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, ZAF, South Africa|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, New Taipei City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03131453"
950,"NCT03070002","Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",,"Terminated","Has Results","Breast Carcinoma Metastatic in the Bone|Circulating Tumor Cell Count|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Stage IV Breast Cancer","Biological: Denosumab|Other: Laboratory Biomarker Analysis","Fraction of Patients With Reduction in CTCs|Percent Change in CTCs|Median Progression Free Survival","Northwestern University|Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16B09|STU00203216|P30CA060553|NCI-2017-00015","October 19, 2017","March 6, 2018","April 24, 2018","March 3, 2017","November 20, 2018","November 20, 2018","Northwestern University, Chicago, Illinois, United States|Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03070002/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03070002"
951,"NCT03069378","A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma",,"Recruiting","No Results Available","Sarcoma","Drug: Talimogene Laherparepvec (T-VEC)|Drug: Pembrolizumab","best objective response rate","Memorial Sloan Kettering Cancer Center|Amgen|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1534","March 3, 2017","March 2020","March 2020","March 3, 2017",,"August 14, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03069378"
952,"NCT02682693","Denosumab as an add-on Neoadjuvant Treatment (GeparX)","GeparX","Active, not recruiting","No Results Available","Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III","Drug: Denosumab|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab","pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.|pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks|To test for interaction of denosumab treatment with RANK expression.|To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.","German Breast Group|Amgen|Celgene Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","780","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 88","February 13, 2017","October 2019","December 2019","February 15, 2016",,"April 1, 2019","Charité Campus Mitte, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02682693"
953,"NCT02597062","High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Overall response rate after 4 cycles|Number and severity of adverse events|Response rates assessed by current International Myeloma Working Group (IMWG) criteria.|Progression-free survival assessed by biochemistry, radiology and immunology tests|Overall survival","Canadian Cancer Trials Group|Amgen|Myeloma Canada Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYX1|MCRN003","March 29, 2016","June 19, 2019","December 2022","November 4, 2015",,"September 12, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada|Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada|CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02597062"
954,"NCT02512926","Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children","POE14-01","Recruiting","No Results Available","Relapsed Solid Tumors|Refractory Solid Tumors|Leukemias","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Etoposide","To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors|Collect information on all adverse events that occur with this regimen|Determine patient response rate (CR, PR, SD, PD) with this regimen|Circulating plasma proteasome (cProt) levels post treatment|Levels of proteasome activity|Inhibition of proteasome activity by carfilzomib|Proteasome inhibition in patient PBMCs before and during treatment by determination of the level of protein ubiquitination.|In vitro sensitivity of patient leukemias and solid tumors to carfilzomib alone and in combination with study chemotherapeutic agents|Alterations of proteasome activity in tumor samples|Expression of actionable mutations","Phoenix Children's Hospital|Amgen|Pediatric Oncology Experimental Therapeutics Investigators' Consortium","All","6 Months to 29 Years   (Child, Adult)","Phase 1","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POE14-01","July 2015","December 2019","December 2019","July 31, 2015",,"March 25, 2019","Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02512926"
955,"NCT03974360","Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache",,"Recruiting","No Results Available","Post-Traumatic Headache|Mild Traumatic Brain Injury|Post-Concussion Syndrome","Drug: AMG 334","Effect of Erenumab on Headache Days with Moderate or Severe Intensity|Erenumab on number of Headache Days|Proportion of Patient reaching at least 75% reduction in monthly average number of headache days|Proportion of Patient reaching at least 50% reduction in monthly average number of headache days|Proportion of Patient reaching at least 25% reduction in monthly average number of headache days|Headache Impact Test (HIT-6)|Tolerability of Erenumab will be assessed by recording number and type of adverse events","Danish Headache Center|Novartis|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-003943-46","April 5, 2019","December 31, 2019","December 31, 2019","June 4, 2019",,"June 4, 2019","Danish Headache Center, Glostrup, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03974360"
956,"NCT03811418","A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer","ATTILA","Withdrawn","No Results Available","Advanced Breast Cancer|HER2-positive Breast Cancer","Drug: Trastuzumab|Drug: Pertuzumab|Drug: Vinorelbine|Drug: Docetaxel","Patient-reported health-related quality of life (QoL): FACT-B|Progression-free survival (PFS) assessed by the investigator|Overall survival (OS)|Overall response rate (ORR)|Clinical benefit rate (CBR)|Time to treatment failure (TTF)|Incidence of (Serious) Adverse events ((S)AEs)|Blood count: Hemoglobin|Blood count: Platelet Count|Blood count: Leukocytes|Blood count: Absolute Neutrophil Count|Safety monitoring (coagulation): Coagulation (INR)|Clinical chemistry: Alkaline Phosphatase|Clinical chemistry: Alanine transaminase (ALT)|Clinical chemistry: Aspartate transaminase (AST)|Clinical chemistry: Bilirubin total|Clinical chemistry: Creatinine (Serum)|Left Ventricular Ejection Fraction (LVEF) monitoring|Patient-reported health-related quality of life (QoL): Trial Outcome Index-Physical/Functional/Breast (TOI-PFB)|Patient-reported health-related quality of life (QoL): FACT-B TOI-PFB|Patient-reported health-related quality of life (QoL): FACT-B total score|Patient-reported health-related quality of life (QoL): FACT-B subscale physical well-being (PWB)|Patient-reported health-related quality of life (QoL): FACT-B subscale social/family well-being (SWB)|Patient-reported health-related quality of life (QoL): FACT-B subscale emotional well-being (EWB)|Patient-reported health-related quality of life (QoL): FACT-B subscale functional well-being (FWB)|Patient-reported health-related quality of life (QoL): FACT-B breast cancer subscale (BCS)|Patient-reported health-related quality of life (QoL): FACT-B breast cancer subscale (BCS) score decline|Patient-reported health-related quality of life (QoL): FACT/GOG-Ntx4 subscale|Exploratory endpoint: Treatment costs|Exploratory endpoints: Duration of hospitalizations|Exploratory endpoints: Number of hospitalizations|Exploratory endpoints: Reasons for hospitalizations|Exploratory endpoints: Febrile infections|Exploratory endpoints: Employment status","iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","iOM-110383|2017-004749-25","January 2019","April 2019","April 2019","January 22, 2019",,"November 26, 2019","iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany",,"https://ClinicalTrials.gov/show/NCT03811418"
957,"NCT03797261","A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies",,"Suspended","No Results Available","Acute Myeloid Leukemia|Non-Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma","Drug: Venetoclax|Drug: AMG 176","Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD) for Venetoclax + AMG 176|Number of Participants With Adverse Events|Composite Complete Remission Rate (CRc) for Participants with AML|Objective Response Rate (ORR) for Participants with AML|ORR for Participants with NHL|Maximum Plasma Concentration (Cmax) of Venetoclax|Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax|AUC of Venetoclax|Maximum Plasma Concentration (Cmax) of AMG 176|Half-life (t1/2) of AMG 176|AUC of AMG 176|Clearance (CL) of AMG 176","AbbVie|Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-785|2018-003314-41","March 15, 2019","September 2, 2022","September 2, 2022","January 9, 2019",,"October 1, 2019","City of Hope /ID# 207393, Duarte, California, United States|USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States|Miami Cancer Institute - Baptist Health South Florida /ID# 209825, Miami, Florida, United States|University of Iowa Hospitals and Clinics /ID# 207459, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 207480, Kansas City, Kansas, United States|Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 206995, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 207390, New York, New York, United States|Unc /Id# 207388, Chapel Hill, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh, Pennsylvania, United States|Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia|Royal Adelaide Hospital /ID# 210602, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210601, Fitzroy, Victoria, Australia|Alfred Hospital /ID# 210350, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 210599, Melbourne, Victoria, Australia|Universitaetsklinikum Leipzig /ID# 209824, Leipzig, Sachsen, Germany|Charite Universitatsmedizin B- /ID# 207987, Berlin, Germany|Universitaetklinikum Dresden /ID# 207803, Dresden, Germany|Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt, Germany|Univ Klinik Eppendorf Hamburg /ID# 207788, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03797261"
958,"NCT03597009","A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion",,"Recruiting","No Results Available","Malignant Pleural Effusion|Stage IV Metastatic Cancer|Lung Cancer","Drug: Talimogene laherparepvec (TVEC)|Drug: Nivolumab","Phase I Number of participants with treatment-related adverse events|Phase II Resolution of MPE|Median Progression free survival|Overall Survival|Response Rate|Phase II Number of participants with treatment-related adverse events|Average Dyspnea Score","UNC Lineberger Comprehensive Cancer Center|CareFusion|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 1626","March 6, 2019","December 30, 2020","December 30, 2028","July 24, 2018",,"May 20, 2019","Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03597009"
959,"NCT03500445","Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma",,"Recruiting","No Results Available","Myeloma|Multiple Myeloma","Drug: Daratumumab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Rate of stringent complete response (sCR)|Rate of minimal residual disease (MRD)-negative disease as assessed by Next Generation Sequencing|Long term rate of MRD-negative disease|Duration of response|Rate of progression free survival|Time to progression|Overall survival rate|Overall response rate|Number of grade 2 or higher side effects as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria","University of Chicago|Janssen Scientific Affairs, LLC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB17-1097","February 13, 2019","June 2021","January 2023","April 18, 2018",,"October 8, 2019","The University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03500445"
960,"NCT03300609","5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab",,"Recruiting","No Results Available","Colorectal Adenocarcinoma|RAS Wild Type|Stage III Colorectal Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7","Biological: Panitumumab|Drug: Oxaliplatin|Drug: Leucovorin Calcium|Drug: Fluorouracil|Drug: Capecitabine|Other: Quality-of-Life Assessment|Other: Laboratory Biomarker Analysis","Progression free survival 1|Treatment Response","University of Southern California|National Cancer Institute (NCI)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","450","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3C-16-6|NCI-2017-01414|P30CA014089","February 27, 2018","February 27, 2022","February 27, 2023","October 3, 2017",,"May 20, 2019","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03300609"
961,"NCT03280667","Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma","KEYPAD","Recruiting","No Results Available","Renal Cell Carcinoma, Clear Cell|Metastatic Kidney Cancer","Drug: Pembrolizumab plus denosumab","Objective tumour response|Progression-free survival (PFS)|Disease control rate (DCR)|Time to objective tumour response (OTR)|Time to first skeletal related event (SRE)|Frequency and severity of adverse events|Frequency of treatment delays and discontinuation due to toxicity","Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Merck Sharp & Dohme Corp.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANZUP1601|20149171|53963","December 12, 2017","April 4, 2021","October 4, 2021","September 12, 2017",,"June 21, 2019","Northern Cancer Institute, Frenchs Forest, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|St George, Sydney, New South Wales, Australia|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Icon Cancer Care, Brisbane, Queensland, Australia|Royal Brisbane and Womens hospital, Herston, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Box Hill, Box Hill, Victoria, Australia|Monash Health, Melbourne, Victoria, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Ballarat Oncology & Haematology Services, Wendouree, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03280667"
962,"NCT03239145","Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",,"Recruiting","No Results Available","Advanced Solid Tumor","Drug: Pembrolizumab|Drug: Trebananib","Dose Limiting Toxicity|Objective Response Rate|Progression Free Survival|Overall Survival","Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-217","August 31, 2017","August 31, 2020","August 31, 2024","August 3, 2017",,"February 7, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03239145"
963,"NCT03160079","Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts",,"Recruiting","No Results Available","B-Cell Acute Lymphoblastic Leukemia, Adult","Drug: blinatumomab|Drug: pembrolizumab","Overall Response Rate (ORR)|Complete Response Rate (CR)|Minimal residual disease (MRD) negativity rate in subjects achieving a CR or CRh|2 year relapse-free survival|2-year overall survival|Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.0","Matthew Wieduwilt, M.D., Ph.D.|Merck Sharp & Dohme Corp.|Amgen|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","161287/UCHMC1504","August 4, 2017","August 2020","August 2023","May 19, 2017",,"September 9, 2019","UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03160079"
964,"NCT03088176","Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",,"Recruiting","No Results Available","Melanoma|BRAF Gene Mutation","Drug: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Drug: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Drug: Dabrafenib|Drug: Trametinib","Rate of Dose Limiting Toxicities (DLT)|Progression Free Survival|Objective Response Rate|Change in tumor burden|Time to Response|Duration of Response","West Cancer Center|University of Tennessee Health Science Center|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WCC20149189","June 25, 2017","June 30, 2020","June 30, 2021","March 23, 2017",,"October 1, 2019","West Cancer Center, Germantown, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03088176"
965,"NCT03087851","Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis","ZOLARMAB","Active, not recruiting","No Results Available","Osteoporosis","Drug: Zoledronic Acid","BMD lumbar spine|BMD total hip, femoral neck and spine|BMD total hip and femoral neck|BMD total hip, femoral neck and lumbar spine|Bone microarchitecture: Trabecular bone volume fraction and cortical porosity|Bone turnover markers: S-carboxy-terminal collagen crosslinks (CTX) and s-procollagen type I N-terminal propeptide (PINP)|Morphometric vertebral fractures","Aarhus University Hospital|University of Aarhus|Amgen","All","50 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-005529-37","March 13, 2017","September 1, 2020","December 1, 2020","March 23, 2017",,"April 3, 2019","Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT03087851"
966,"NCT03000374","Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery","PIER","Recruiting","No Results Available","Rectal Cancer","Drug: Panitumumab|Drug: 5Fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin","Pathologic complete response (pCR)|Rates of R0 resection and free mesorectal fascia (or circumferential margin)|Tumor regression grade (TRG)|Rate of tumor downstaging (mrT versus ypT)|Quality of surgery|Adverse events and changes in laboratory results|Surgical complications|Rate of local recurrence|Distant metastasis rate|Disease free survival|Overall survival","Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMCAD-1601|2016-002333-29","May 30, 2017","January 31, 2022","April 30, 2022","December 22, 2016",,"June 3, 2019","Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital de Sabadell, Sabadell, Barcelona, Spain|Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Hospital Politécnico Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03000374"
967,"NCT02983097","Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","R²-DHAP","Terminated","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III°)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)","Drug: Rituximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Lenalidomide|Drug: PegFilgrastim|Procedure: peripheral stem cell collection","Overall Response Rate (ORR)|Maximum tolerated dose (MTD)|Rate of complete remission|Rate of primary progression|Rate of treatment related deaths|Relapse Rate|Overall Survival|Progression free survival|tumour control|feasibility of stem cell mobilization|incidence of non-hematological toxicities > grade 2 CTC|incidence and duration of neutropenia and thrombopenia grade 4","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Celgene|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSHNHL 2008 R6|2009-010824-25","November 2010","January 2014","April 28, 2015","December 6, 2016",,"January 19, 2018","Diakonie Krankenhaus Bremen, Bremen, Germany|Klinikum Chemnitz, Chemnitz, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany|Universitätsklinikum Göttingen, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Westpfalz Klinikum, Kaiserslautern, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|LMU Klinikum München-Großhadern, München, Germany",,"https://ClinicalTrials.gov/show/NCT02983097"
968,"NCT01508000","Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases","BOS2","Terminated","No Results Available","Colorectal Cancer Metastatic|Liver Metastases|KRAS Wild Type Colorectal Cancer","Drug: FOLFOX6|Biological: Bevacizumab|Biological: Panitumumab|Procedure: Surgery","Progression free survival|Pathological response rate|Resection rate|Overall survival|Safety","European Organisation for Research and Treatment of Cancer - EORTC|Amgen|Roche Pharma AG","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-40091|2010-019238-29","June 2013","September 2016","September 2016","January 11, 2012",,"October 12, 2016","Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria|Hopital Universitaire Brugmann, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge Kortrijk - Campus Kennedylaan, Kortrijk, Belgium|AZ Turnhout - Campus Sint Elisabeth, Turnhout, Belgium|Centre Hospitalier Peltzer-La Tourelle, Verviers, Belgium|Institut Sainte Catherine, Avignon, France|Institut Bergonie, Bordeaux, France|CHU Ambroise Pare, Boulogne Billancourt, France|Assistance Publique - Hôpitaux de Paris - Hopital De Bicetre AP-HP, Le Kremlin Bicetre, France|Centre Hospitalier Saint Joseph Saint Luc, Lyon, France|Centre Leon Berard, Lyon, France|Hopital Prive Jean Mermoz, Lyon, France|Centre Antoine Lacassagne, Nice, France|Hopital Europeen Georges Pompidou, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon - Site Reuilly, Paris, France|CHU de Lyon - Centre Hospitalier Lyon Sud, Pierre-Benite (lyon), France|CHU de Reims - Hôpital Robert Debré, Reims, France|Hopital Charles Nicolle, Rouen, France|CHU Saint-Etienne - CHU de Saint-Etienne - Hopital Nord, Saint Priest en Jarez, France|Centre Hospitalier Privé Saint-Grégoire, Saint-Gregoire, France|CHU d'Amiens - CHU Amiens - Hopital Sud, Salouel, France|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Hospital General Vall D'Hebron, Barcelona, Spain|Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie, Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT01508000"
969,"NCT01464034","A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Pomalidomide|Drug: Dexamethasone","Adverse Events as a Measure of Safety and Tolerability|Overall Response in Phase II|Overall Response in Phase I|Time to Progression|Progression Free Survival|Time to next therapy","Criterium, Inc.|Amgen|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","117","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMyC 10-MM-01|IST-CAR-521|PO-MM-PI-0034","November 2011","December 2017","June 2018","November 3, 2011",,"October 18, 2017","Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01464034"
970,"NCT02802163","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: Panobinostat|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Phase I: Maximum Tolerated Dose (MTD)|Stringent Complete Remission (sCR) Rate after 4 and 8 Cycles of Treatment|Phase II: Overall Response Rate (ORR)","H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-18665","June 2017","September 2020","December 2020","June 16, 2016",,"April 25, 2017",,,"https://ClinicalTrials.gov/show/NCT02802163"
971,"NCT01379807","Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","SPIGA","Unknown status","No Results Available","Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Drug: panitumumab + docetaxel + cisplatino","Objective response rate|Disease control rate|Duration of response|Time to response|Time to progression|Time to treatment failure|Duration of stable disease|Progression free survival|Overall survival|Safety profile|Exploratory Objectives","Grupo Gallego de Investigaciones Oncologicas|Amgen|Trial Form Support S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GGIO-2010-01","December 2010","December 2014","December 2015","June 23, 2011",,"March 11, 2015","Hospital Arquitecto Mercide, Ferrol, La Coruña, Spain|Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, La Coruña, Spain|Complejo Hospitalario Universitario de Vigo (Xeral Cies), Vigo, Pontevedra, Spain|Policlínica de Vigo S.A., Vigo, Pontevedra, Spain|Complejo Hospitalario Universitario de A Coruña, La Coruña, Spain|Centro Oncológico de Galícia, La Coruña, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Complejo Hospitalario Ourense, Ourense, Spain|Hospital de Pontevedra, Pontevedra, Spain",,"https://ClinicalTrials.gov/show/NCT01379807"
972,"NCT01358669","Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty",,"Active, not recruiting","No Results Available","Revision Surgery of Total Hip Arthroplasty","Drug: Denosumab|Other: Placebo","Osteoclast number|Change in serum or urine levels of βCTXI, NTXI/Cr, TRAcP5b, CTXMMP, PINP, OPG, RANKL|Difference between the denosumab and placebo groups in mean eroded, quiescent, and osteoblast surfaces at the membrane bone interface|Difference between the denosumab and placebo groups in ratio of viable to apoptotic osteoclast, macrophage fibroblast, and osteoblasts by TUNEL staining and relative number of cells staining positive for apoptosis markers","Sheffield Teaching Hospitals NHS Foundation Trust|Amgen|University of Sheffield","All","30 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STH15714","December 14, 2011","January 2, 2019","July 31, 2020","May 24, 2011",,"November 7, 2019","Academic Unit of Bone Metabolism, Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01358669"
973,"NCT01328171","FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","VOLFI","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: FOLFOXIRI + Panitumumab|Drug: FOLFOXIRI","overall response rate|overall response rate in each cohort|secondary resection rate with curative intent for patients cohort I|pathological response in liver surgery specimen|disease control rate|progression free survival|duration of response|time to response|overall survival|time to recurrence (cohort II in case of secondary resection)|toxicity and feasibility|liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment|QL (QLQ C30)|translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes","AIO-Studien-gGmbH|Amgen|ClinAssess GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","93","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO KRK 0109|2009-017731-17","April 2011","June 2017","January 2022","April 4, 2011",,"August 7, 2018","Klinikum Esslingen, Esslingen, Baden-Württemberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Baden-Württemberg, Germany|Ortenau Klinikum, Lahr, Baden-Württemberg, Germany|Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany|Universitätsklinikum Mannheim, Mannheim, Baden-Württemberg, Germany|Klinikum Schwäbisch Gmünd, Mutlangen, Baden-Württemberg, Germany|Kreiskliniken Esslingen gGmbH Klinik Nürtingen, Nürtingen, Baden-Württemberg, Germany|Schwerpunktpraxis und Tagesklinik Onkologie Hämatologie Gastroenterologie Palliativmedizin Drs. Höring, Respondek, Schwinger, Thunert, Stuttgart, Baden-Württemberg, Germany|Universitätsklinikum Ulm Zentrum für Innere Medizin, Ulm, Baden-Württemberg, Germany|Klinikum Augsburg, Augsburg, Bayern, Germany|Leopoldina-Krankenhaus der Stadt Schweinfurth gGmbH, Schweinfurt, Bayern, Germany|Klinikum der J.W. Goethe-Universität Frankfurt, Frankfurt, Hessen, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Hessen, Germany|Franziskus Hospital Niels-Stensen-Kliniken Klinik für Internistische Onkologie und Hämatologie, Georgsmarienhütte, Niedersachsen, Germany|Marienhospital Osnabrück Niels-Stensen-Kliniken Klinik für Innere Medizin, Osnabrück, Niedersachsen, Germany|St. Vincenz-Krankenhaus, Paderborn, Nordrhein-Westfalen, Germany|Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier, Rheinland-Pfalz, Germany|Universitätsklinikum Halle, Halle, Sachsen-Anhalt, Germany|Universitätsklinikum Jena, Jena, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT01328171"
974,"NCT01288339","Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer","PULSE","Completed","No Results Available","Metastatic Colorectal Cancer","Drug: Panitumumab + FOLFOX (DP)|Drug: Panitumumab + FOLFOX (no-DP)","Progression-free survival time according to the MMP7 status (PFS)|Duration of response (DOR)|Time to response (TTR)|Time to treatment failure (TtTF)|Objective response rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS)|Time To Progression (TTP)|Duration of Stable Disease (DoSD)|Incidence and severity of AEs|Molecular predictive markers for response.","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|TFS Trial Form Support","All","18 Years and older   (Adult, Older Adult)","Phase 2","78","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMCAD-0903|2009-017331-18","November 8, 2010","February 13, 2015","February 13, 2015","February 2, 2011",,"May 16, 2018","Hospital General Universitario de Elche, Elche, Alicante, Spain|Hosptial General de l'Hospitalet de Barcelona, Hospitalet de Llobregat, Barcelona, Spain|Corporació Sanitaria Parc Taulí de Barcelona, Sabadell, Barcelona, Spain|Hospital de l'Esperit Sant, Santa Coloma De Gramenet, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellon, Castellón De La Plana, Castellon, Spain|Hospital Son Espases de Mallorca, Palma De Mallorca, Illes Balears, Spain|Hosptial Son Llatzer de Mallorca, Palma De Mallorca, Illes Balears, Spain|Hosptial de Logroño, Logroño, La Rioja, Spain|Hospital Universitario La Paz de Madrid, Madrid, Madrdi, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Xeral Cies de Vigo, Vigo, Pontevedra, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau de Barcelona, Barcelona, Spain|Complejo Asitencia de Burgos. Hospital General Yague, Burgos, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Institut Català d'Oncologia (ICO) de Girona, Girona, Spain|Centro Oncológico de Galícia, La Coruña, Spain|Hosptial Dr. Negrin de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hospital Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Infanta Sofía de Madrid, Madrid, Spain|Hospital Universitario Puerta de Hierro de Madrid, Madrid, Spain|Hospital de Fuenlabrada de Madrid, Madrid, Spain|Hospital Morales Meseguer, Murcia, Spain|Hosptial de Sant Pau i Santa Tecla de Tarragona, Tarragona, Spain|Hospital La Fe de Valencia, Valencia, Spain|Instituto Valenciano de Oncología de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Dr. Peset de Valencia, Valencia, Spain|Hospital Miguel Servet de Zaragoza, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01288339"
975,"NCT01285778","Vectibix for the Treatment of Anal Cancer","VITAL","Completed","No Results Available","Anal Squamous Cell Carcinoma","Drug: panitumumab, mytomicin C, 5-FU, radiation","Three-year disease-free survival rate|Disease free survival rate|Three-year free local-regional failure rate|Overall survival|Colostomy-free survival rate|Complete response rate|Safety profile|Predictive potential of different biomarkers","Grupo Espanol Multidisciplinario del Cancer Digestivo|Amgen|Trial Form Support S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","58","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMCAD-0902","October 2010","March 24, 2017","March 24, 2017","January 28, 2011",,"May 16, 2018","Hospital Universitario Germans Trias i Pujol. Institut Català Oncologia, Badalona, Barcelona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Hospital Infanta Sofía, San Sebastian de los Reyes, Madrid, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall Hebron, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Virgen Blanca, León, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01285778"
976,"NCT01264328","Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer","VECTITAX","Completed","No Results Available","Head and Neck Cancer","Drug: Panitumumab + paclitaxel","objective response rate|Time to response, duration of response, progression free-survival, overall survival.","Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|Amgen|Trial Form Support S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTCC-2009-03","March 9, 2011","October 2011","September 29, 2014","December 21, 2010",,"April 16, 2019","Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital General de Yagüe, Burgos, Spain|H. Virgen de las Nieves, Granada, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General Universitario, Valencia, Spain|Hospital Universitario la Fe de Valencia, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01264328"
977,"NCT01234324","ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction","NEOPECX","Completed","No Results Available","Stomach Neoplasms|Gastroesophageal Junction Neoplasms","Drug: Epirubicin, Cisplatin, Capecitabine, Panitumumab|Drug: Epirubicin, Cisplatin, Capecitabine","Frequency of pT3/T4 categories after surgery|Frequencies of pN2/N3 categories after surgery","AIO-Studien-gGmbH|Amgen|WiSP Wissenschaftlicher Service Pharma GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","171","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO/CAO-STO-0801|2008-007798-18","October 2010","August 2016","August 2017","November 4, 2010",,"January 23, 2018","AIO-Studien gGmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01234324"
978,"NCT01207934","Recombinant Human Leptin Therapy Effects on Insulin Action","Leptin","Completed","Has Results","Type Two Diabetes Mellitus","Dietary Supplement: placebo|Drug: low-dose leptin|Drug: high-dose leptin","Baseline Glucose Disposal - a Measure of the Body's Ability to Process Sugars.|Post-treatment Glucose Disposal. I.e. Glucose Disposal After Treatment With Leptin or Placebo.|Baseline Plasma Leptin Concentrations|Post-treatment Plasma Leptin Levels","Washington University School of Medicine|Amgen|National Institutes of Health (NIH)","All","25 Years to 75 Years   (Adult, Older Adult)","Not Applicable","18","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","98-0643","August 1998","July 2000","July 2000","September 23, 2010","August 10, 2011","July 9, 2015","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01207934"
979,"NCT01194869","Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer",,"Terminated","Has Results","Breast Cancer","Drug: Sorafenib|Drug: Cisplatin|Drug: Paclitaxel","Pathologic Complete Response (pCR) at the Time of Surgery After Preoperative Treatment|Clinical Response Rate During Follow-up (Disease Recurrence)|Clinical Response Rate (Complete Pathologic Response Rate After Surgery)","Emory University|Amgen|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00019781|WCI1590-08","June 2010","June 2015","June 2015","September 3, 2010","July 28, 2016","October 18, 2016","Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01194869"
980,"NCT02415413","Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma",,"Active, not recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Melphalan","Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT|Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance|Efficacy- Months to progression free survival|Efficacy -Months to overall survival","PETHEMA Foundation|Celgene Corporation|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","90","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM-CESAR","May 2015","July 31, 2017","May 2020","April 14, 2015",,"October 4, 2018","Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital de Son Llàtzer, Plama De Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Reina Sofía, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02415413"
981,"NCT01139138","Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer","PIE","Completed","No Results Available","Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal","Drug: Panitumumab|Drug: Irinotecan|Drug: Everolimus","Dose limiting toxicities|Safety & toxicity|Response rate|Progression free survival|Overall Survival","The Queen Elizabeth Hospital|Amgen|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AU-2009-0003/CRAD001CAU06T","June 2010","August 2015","June 2017","June 8, 2010",,"November 6, 2017","The Queen Elizabeth Hospital, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT01139138"
982,"NCT01122199","Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors",,"Completed","No Results Available","Neoplasm Metastases","Drug: RAD001 + AMG479","To determine the maximum tolerated (MTD) and recommended Phase II doses for AMG479 and RAD001 in patients with refractory solid tumors|To evaluate the grade and severity of adverse events as a measure of safety and toxicity|To determine preliminary antitumor efficacy of AMG479 and RAD001 in solid tumors","Shadia Jalal|Amgen|Novartis|Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1002-16; IUCRO-0287","May 14, 2010","January 19, 2015","January 19, 2015","May 13, 2010",,"May 10, 2017","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01122199"
983,"NCT02269085","Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma",,"Terminated","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Carfilzomib|Behavioral: Phone Calls","Maximum Tolerated Dose (MTD) of Carfilzomib When Given With Ibrutinib|Response Rate of Carfilzomib When Given With Ibrutinib","M.D. Anderson Cancer Center|Pharmacyclics LLC.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0677|NCI-2014-02495","April 20, 2015","May 29, 2018","May 29, 2018","October 20, 2014",,"February 28, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02269085"
984,"NCT01020175","Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome","Procedure: Bone marrow transplantation|Procedure: Peripheral blood stem cell transplantation","The primary end point of the study was the maximum grade of acute graft versus host (GVH) disease observed in the recipient.|Incidence of acute GVH disease grade II or above|Time to acute GVH disease|Time to an unsupported platelet count of 20 _ 109/L and 50 _ 109/L|Time to absolute neutrophil count (ANC) of 0.5 x 10e9/L and 1 x 10e9/L|Incidence and severity of chronic GVH disease|Leukemia-free survival|Overall survival","European Group for Blood and Marrow Transplantation|Amgen|Hoffmann-La Roche","All","18 Years to 55 Years   (Adult)","Phase 3","350","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCSF-940136","January 1995","December 1999","December 2002","November 25, 2009",,"November 25, 2009","Dr. Norbert Schmitz, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01020175"
985,"NCT01013181","Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the "" Real-life "" : Result of the French Experience in 72 Adults","ATU-r","Completed","No Results Available","Thrombopenia",,"Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP)","Henri Mondor University Hospital|Amgen|Paris 12 Val de Marne University","All","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ATU Romiplostim registry","January 2008","July 2008","August 2009","November 13, 2009",,"November 17, 2009",,,"https://ClinicalTrials.gov/show/NCT01013181"
986,"NCT02129699","Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","SPLENDOUR","Active, not recruiting","No Results Available","Lung Cancer Non-small Cell Stage IV","Drug: Denosumab|Other: None, standard chemotherapy only","Overall survival|Progression-free survival (PFS) based on RECIST 1.1|Response based on RECIST 1.1|Toxicity profile of denosumab|Evaluation of potential predictive biomarkers for denosumab activity","European Thoracic Oncology Platform|European Organisation for Research and Treatment of Cancer - EORTC|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","514","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETOP 5-12 / EORTC 08111|2013-003156-21|20080166|SNCTP000000954","January 6, 2015","January 2020","September 2020","May 2, 2014",,"November 29, 2019","Univ. Klinik für Innere Medizin V, Innsbruck, Austria|KH der Elisabethinen Linz, Linz, Austria|AKH Wien, Wien, Austria|Otto-Wagner-Spital Department 1, Wien, Austria|Otto-Wagner-Spital Department 2, Wien, Austria|Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium|University Hosptial Ghent, Ghent, Belgium|Centre Hospitalier Regional De La Citadelle, Liege, Belgium|Clinique et Maternite Sainte Elisabeth, Namur, Belgium|Centre hospitalier universitaire d`Angers, Angers, France|Centre Hospitalier Annecy, Annecy, France|Centre Hospitalier De Beauvais, Beauvais Cedex, France|Hôpitale de la Cavale Blanche - CHRU de BREST, Brest, France|GHPSO (Sie de Creil), Creil, France|Centre Hospitalier Intercommunal Creteil, Creteil, France|Hospital Center Le Mans, Le Mans, France|Hôpital du Cluzeau, Limoges, France|CHBS Lorient, Lorient, France|Hôpital Louis Pradel, Lyon, France|Assistance Publique-Hôitaux de Marseille, Marseille, France|Institut Paoli-Calmettes, Marseille, France|Centre Hospitalier de Meaux, Meaux, France|Centre Hospitalier Universitaire Rennes, Rennes, France|Clinique Mutualiste de l`Estuaire, Saint-Nazaire, France|CHICAS, Sisteron, France|Hôpital de Villefranche-sur-Saône, Villefranche-sur-saône, France|ASKLEPIOS - Fachkliniken München - Gauting, München, Germany|Pius Hospital, Oldenburg, Germany|Cork University Hospital, Cork, Ireland|Beaumont Hospital, Dublin, Ireland|Mater Miscordia University Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|The Adelaide and Meath Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|University Hospital Limerick, Limerick, Ireland|Hospital Waterford, Waterford, Ireland|S.G Moscati Hospital, Aversa, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|San Paolo Hospital, Milan, Italy|Ospedale San Gerardo, Monza, Italy|Maria Sklodowska-Curie Memorial Car, Gliwice, Poland|University Clinic Golnik, Golnik, Slovenia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital General de Alicante, Alicante, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Català d'Oncologia - L'Hospitalet, Barcelona, Spain|Hospital General Castellón, Castelló, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|H. U. Insular Gran Canaria, Las Palmas, Spain|Regional Universitario Carlos Haya, Malaga, Spain|H Morales Meseguer, Murcia, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Hospital Arnau Vilanova Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Graubünden, Chur, Switzerland|HFR Fribourg, Fribourg, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Onkologiezentrum Berner Oberland, Thun, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Oxford University Hospitals Trust, Oxford, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02129699"
987,"NCT00894504","Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer",,"Completed","Has Results","Metastatic Breast Cancer","Drug: Panitumumab|Drug: Carboplatin|Drug: Gemcitabine","Progression-free Survival (PFS)|Objective Response Rate and Clinical Benefit Rate|Number of Treatment-related Toxicities Occurring in ≥10% of Patients as a Measure of Tolerability and Toxicity|Correlation of Biomarker Expressions of EGFR, K-ras, p53, PTEN Expression, and PI3K in Triple-negative Breast Cancer With Response to Treatment With the Combination of Gemcitabine, Carboplatin, and Panitumumab","SCRI Development Innovations, LLC|Amgen|Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI BRE 126","February 2010","September 2014","September 2014","May 7, 2009","December 15, 2014","May 15, 2015","Los Robles, Thousand Oaks, California, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Providence Medical Group, Terre Haute, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|National Capital Clinical Research Consortium, Bethesda, Maryland, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Research Medical Center, Kansas, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Atlantic Health System, Morristown, New Jersey, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Health Physician Group, Dallas, Texas, United States|Peninsula Cancer Institute, Newport News, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00894504"
988,"NCT00879385","KRAS Wild-type Metastatic Colorectal Cancer Trial",,"Completed","No Results Available","Colorectal Cancer","Drug: Dacogen™ (decitabine)|Drug: Vectibix® (panitumumab)","Evaluate safety & feasibility of sequential use of a DNA methyltransferase (DNMT) inhibitor (decitabine) with targeted biological agent against EGFR (panitumumab) for KRAS wild type tumors in second or third line treatment of colorectal cancer.|To examine re-expression or a reduction in promoter methylation in genes involved in tumor suppressor pathways known to be important in colorectal cancer (CRC) or involved in EGFR signaling pathway.|Evaluate overall response (OR = CR +PR) according to RECIST criteria at 2, 4, and 6 cycles. Progression free survival, measured as the first evidence of tumor growth from the start of treatment will also be assessed.|Measure CEA levels at the beginning of each cycle to examine if they correlate with treatment response or disease progression.","University of Utah|Amgen|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCI31116","December 2009","January 2013","January 2013","April 10, 2009",,"October 31, 2014","Huntsman Cancer Institute, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00879385"
989,"NCT01991873","Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer","PanaMa","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Maintenance Chemotherapy|Drug: Panitumumab (Within maintenance phase)|Drug: mFOLFOX6 (Within re-induction phase)|Drug: Panitumumab (Within re-induction phase)","Progression-free survival|failure of treatment strategy|Progression-free survival of re-induction|Objective response after 12 weeks of induction chemotherapy|Objective best response during maintenance and re-induction|Overall survival|Safety|Health and skin related Quality of life","AIO-Studien-gGmbH|ClinAssess GmbH|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIO-KRK-0212|2012-005422-30|PanaMa_DE-2009-0003","April 2014","December 2019","June 2020","November 25, 2013",,"March 6, 2019","St.-Antonius-Hospital Eschweiler, Eschweiler, Germany|Zentrum für Tumorbiologie und Integrative Medizin, Klinikum Wilhelmshaven, Wilhelmshaven, Germany",,"https://ClinicalTrials.gov/show/NCT01991873"
990,"NCT01959698","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma",,"Active, not recruiting","No Results Available","CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Drug: Carboplatin|Drug: Carfilzomib|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Best overall response rate (PR + CR) (Phase Ib)|MTD defined as the dose of carfilzomib added to standard R-ICE chemotherapy which, if exceeded, would put the patient at an undesirable risk of medically unacceptable dose-limiting toxicities (Phase I)|Complete response rate according to the International Working Group Response criteria as reported by the revised Cheson criteria|Overall survival|Pharmacokinetics (PK)/pharmacodynamics (PD) of carfilzomib and standard R-ICE combination therapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma|Progression-free survival|Toxicity of the addition of carfilzomib to R-ICE at the MTD, assessed by the CTEP version 4.0 of the NCI CTCAE","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","27","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 240813|NCI-2013-01784|P30CA016056|R01CA136907","April 17, 2014","July 15, 2023","July 15, 2023","October 10, 2013",,"January 6, 2020","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT01959698"
991,"NCT00617370","Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility",,"Completed","No Results Available","Breast Cancer|Adenocarcinoma of the Breast","Drug: epirubicin, cyclophosphamide, Paclitaxel,","To evaluate the feasibility and safety of this dose-dense regimen.","Memorial Sloan Kettering Cancer Center|Amgen|Pfizer","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-065","November 2004","July 2005","June 2008","February 18, 2008",,"December 23, 2015","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00617370"
992,"NCT01690702","Study of Nab-Paclitaxel in High Risk Early Breast Cancer","GAIN-2","Active, not recruiting","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: nab-Paclitaxel|Drug: Cyclophosphamide|Drug: Docetaxel","invasive disease-free survival (IDFS)|locoregional relapse-free survival (LRRFS)|overall survival (OS)|distant disease-free survival (DDFS)|local relapse-free survival (LRFS)|regional relapse-free survival (RRFS)|brain metastasis free survival (in the subgroup of TNBC and HER2+)|compliance|safety|side effects of taxane|treatment effects by intrinsic subtypes|Ovarian substudy|Pharmacogenetic substudy|biology of lymph node metastases","German Breast Group|Celgene|Amgen","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2886","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 68","September 2012","January 2020","December 2020","September 24, 2012",,"July 13, 2017","Klinikum Frankfurt Höchst, Frankfurt, Hessen, Germany",,"https://ClinicalTrials.gov/show/NCT01690702"
993,"NCT00591851","Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility",,"Completed","Has Results","Breast Cancer","Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)","Cardiac Saftey","Memorial Sloan Kettering Cancer Center|Amgen|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-126","December 2004","June 2008","June 2008","January 11, 2008","December 1, 2014","December 1, 2014","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00591851"
994,"NCT01555268","Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia",,"Completed","No Results Available","Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia","Biological: trebananib|Drug: cytarabine|Other: laboratory biomarker analysis|Other: pharmacological study","Safety of trebananib when administered alone and in combination with low-dose cytarabine measured by number of participants with toxicities according to CTCAE|PK/PD profile of trebananib when administered alone|PK/PD profile of trebananib when administered in combination with low-dose cytarabine|Clinical response in AML patients following trebananib therapy alone or given in combination with low-dose cytarabine therapy|Alterations in Ang1, Ang2, Tie2, VEGF, and VEGFR expression|Changes in bone marrow vascularization and hypoxia|Changes in gene and/or microRNA expression|Characterization of time course of trebananib concentrations in relation to target inhibition and clinical response using PK/PD modeling","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 186010|NCI-2011-02979|P30CA016056","October 31, 2011","September 24, 2013","August 3, 2016","March 15, 2012",,"February 15, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01555268"
995,"NCT01545648","Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer",,"Terminated","Has Results","Early Stage Breast Cancer","Drug: Denosumab","Percentage of Change in Reduction of Disseminated Tumor Cells (DTC)/Mililitre (ml)|Disseminated Tumor Cell Counts|Correlation of Local Recurrence With DTC","Hope Rugo, MD|University of California, San Francisco|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117527|NCI-2012-02802","November 1, 2012","June 9, 2015","June 9, 2016","March 7, 2012","January 2, 2020","January 2, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01545648"
996,"NCT00398372","Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",,"Completed","No Results Available","Lymphoma, Non-Hodgkin|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Cutaneous Lymphoma|Lymphomas: Non-Hodgkin Diffuse Large B-Cell|Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell|Lymphomas: Non-Hodgkin Mantle Cell|Lymphomas: Non-Hodgkin Marginal Zone|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia","Drug: Rituximab|Drug: Epratuzumab","To characterize the molecular and cell biology of the tumor cells in lymphoma.","Stanford University|Amgen|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","LYMNHL0031|200114861|77550|CA09287|CA111827","November 2000","June 2007","September 2009","November 10, 2006",,"June 2, 2011","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00398372"
997,"NCT01349088","Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer",,"Withdrawn","No Results Available","Breast Cancer|Metastatic Breast Cancer|Stage IV Breast Cancer","Drug: Ixabepilone|Drug: Capecitabine|Drug: Motesanib","Progression-Free Survival|Maximum Tolerated Dose of Motesanib|Overall Response Rate|Toxicity|Correlation of Tumor Levels|Pharmacokinetics of Study Regimen","Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Amgen|Thomas Jefferson University","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10G.30|2009-34","December 2013","September 2015","September 2018","May 6, 2011",,"October 21, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01349088"
998,"NCT01336920","Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma",,"Completed","No Results Available","Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma","Drug: carfilzomib","MTD of carfilzomib, determined by incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","University of Nebraska|National Cancer Institute (NCI)|Amgen","All","19 Years and older   (Adult, Older Adult)","Phase 1","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","518-10|NCI-2010-02257|P50CA136411|P30CA036727","June 2011","April 2015","March 2018","April 18, 2011",,"July 27, 2018","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01336920"
999,"NCT01325194","CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","CHIC","Unknown status","No Results Available","Primary Disease","Drug: liposomal cytarabine","Time to treatment failure|Maximal hematological, gastrointestinal, neuronal and other toxicities|Clinical response rate|Incidence of central nervous system(CNS) relapse in cerebrospinal fluid (CSF )cytology neg/flow cytometry positive cases|Incidence of CNS relapse in a subgroup of patients with more than one extranodal site and elevated lactate dehydrogenase (LDH)|Progression free survival|Overall survival|Molecular predictors|CNS relapse rate","Nordic Lymphoma Group|Mundipharma Pte Ltd.|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","143","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NLG-LBC-05","March 2011","December 2014","December 2017","March 29, 2011",,"September 7, 2017","Department of Hematology, Århus University Hospital, Århus, Denmark|Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland|Department of Oncology, Oslo University Hospital, Oslo, Norway|Department of Oncology, Lund University Hospital, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT01325194"
1000,"NCT00355407","Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation",,"Completed","No Results Available","Hematologic Malignancies","Drug: Darbepoetin alfa","Evaluate the percentage of patients achieving a target hemoglobin of 11 g/dL or greater by day 100 following allogeneic stem cell transplantation.|Evaluate the percentage of patients achieving a greater than 1 g/dL hemoglobin increase between days 30 and 100 after allogeneic stem cell transplantation|record transfusion requirements between days 30 and 100 in patients undergoing darbepoetin alfa administration following allogeneic stem cell transplantation.","Dana-Farber Cancer Institute|Amgen|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-420","June 2006","August 2007","August 2007","July 21, 2006",,"March 13, 2009","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00355407"
1001,"NCT00293202","Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients",,"Terminated","No Results Available","End Stage Renal Disease","Drug: Etanercept|Drug: Saline","increased serum albumin concentration|reduced C-reactive protein concentration|effect of treatment on prealbumin concentration","Kaysen, George A., M.D., Ph.D.|Amgen|Dialysis Clinic, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","200311904","March 2005","March 2008","June 2010","February 17, 2006",,"April 5, 2012","University of California, Davis, Medical Center, Sacramento, California, United States",,"https://ClinicalTrials.gov/show/NCT00293202"
1002,"NCT01196715","Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","REGIME","Unknown status","No Results Available","Myelodysplastic Syndrome","Drug: Darbepoetin alpha|Drug: Filgrastim|Procedure: Blood Red Cell Transfusion","Quality of Life|Haemoglobine response|Utility of prognostic factor and predictive factor assessment","Barts & The London NHS Trust|Cancer Research UK|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","360","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","MDS201001|2009-017462-23|CRUK/08/009","November 2010","November 2013","November 2015","September 8, 2010",,"March 15, 2012","Birmingham Cancer Research UK Clinical Trial Unit, Birmingham, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|CECM Institute of Cancer, London, United Kingdom|King's College Hospital Haematoloy Laboratory, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01196715"
1003,"NCT00194753","Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12",,"Completed","No Results Available","Breast Neoplasm","Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: G-CSF","Delivered dose intensity|Toxicity|Time to treatment failure|Overall survival","University of Washington|Amgen|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18229-A|00-5889-A 07","December 2001","March 2011","March 2011","September 19, 2005",,"September 13, 2012","University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00194753"
1004,"NCT01049425","Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","planB","Completed","No Results Available","Primary Breast Cancer|Her2 Non-overexpressing","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel","disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatment","West German Study Group|Sanofi|Amgen","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","3198","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WSG AM04","February 5, 2009","March 1, 2017","May 15, 2018","January 14, 2010",,"August 14, 2019","Bethesda Krankenhaus, Moenchengladbach, Germany",,"https://ClinicalTrials.gov/show/NCT01049425"
1005,"NCT01036087","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",,"Active, not recruiting","No Results Available","Breast Cancer","Drug: Panitumumab|Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","Pathologic Complete Response (CR) Rate","M.D. Anderson Cancer Center|Celgene Corporation|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0372|NCI-2012-00935","November 2010","November 2021","November 2022","December 21, 2009",,"May 16, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01036087"
1006,"NCT00997022","Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients",,"Completed","No Results Available","Hepatocellular Cancer","Drug: Sorafenib","Maximum tolerated dose of daily sorafenib|Duration of disease free survival|Duration of progression free survival","Columbia University|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAD3519","May 2009","May 2015","May 2015","October 16, 2009",,"August 10, 2015","University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00997022"
1007,"NCT00953446","Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma",,"Suspended","No Results Available","Renal Cell Carcinoma","Procedure: Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging","To explore the association of baseline blood flow in renal cell carcinoma(RCC) measured by ASL MRI and tumor response to treatment with the combination of sunitinib and AMG386|To explore the association of changes in tumor blood flow that occur early in the course of therapy compared to baseline and response of RCC to treatment with the combination of sunitinib and AMG386|To evaluate the association between changes in tumor blood flow on ASL over the course of therapy and at the time of disease progression and resistance to therapy.|To compare above results to those observed in a comparable patient population receiving sunitinib alone.","Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-105","August 2009","August 2011",,"August 6, 2009",,"November 19, 2010","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00953446"
1008,"NCT00915252","Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","AML-AZA","Completed","No Results Available","Acute Myeloid Leukemia","Drug: azacitidine|Drug: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine","Median Event Free Survival (EFS) of all AML patients|Median event free survival of AML patients with different cytogenetic and molecular risk groups|Median overall survival of all AML patients|Median overall survival of AML patients with different cytogenetic and molecular risk groups|Relapse free survival","University Hospital Muenster|Celgene Corporation|Amgen","All","61 Years and older   (Adult, Older Adult)","Phase 2","214","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101010","July 2009","December 2012","December 2012","June 5, 2009",,"December 17, 2012","RWTH Aachen, Medizinische Klinik IV, Aachen, Germany|Sozialstiftung Bamberg, Klinikum am Bruderwald, Med. Klinik V, Bamberg, Germany|Klinikum Bayreuth, Medizinische Klinik IV, Bayreuth, Germany|Charite Campus Benjamin Franklin, Universitätsmedizin Berlin, Medizinische Klinik III, Berlin, Germany|Städt. Kliniken Bielefeld gem. GmbH, Klinikum Mitte, Klinik für Hämatologie, Onkologie, Palliativmedizin, Bielefeld, Germany|Klinikum Chemnitz, Krankenhaus Küchenwald, Klinik für Innere Medizin III, Chemnitz, Germany|Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany|Katholische Krankenhaus Duisburg, Duisburg, Germany|Universitätsklinikum Erlangen, Medizinische Klinik 5, Erlangen, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany|Klinikum der Johann Wolfgang Goethe-Universität Frakfurt am Main, Frankfurt am Main, Germany|Asklepios Klinik St. Georg, Hämatologische Abteilung, Hamburg, Germany|St. Bernward Krankenhaus Hildesheim, Medizinische Klinik II, Hildesheim, Germany|Westpfalz-Klinikum GmbH, Med. Klinik I, Kaiserslautern, Germany|Stiftungsklinikum Mittelrhein, Hämatologie/ Onkologie, Koblenz, Germany|Johannes Gutenberg-Universität Mainz Klinikum, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Phillips Universität Marburg, Fachbereich 20, ZIM, Marburg, Germany|Klinikum rechts der Isar, III. Medizinische Klinik, Muenchen, Germany|Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A, Münster, Germany|Klinikum Nürnberg, Medizinische Klinik 5, Nurnberg, Germany|Klinikum Osnabrück, Klinik für Onkologie, Hämatologie, Immunologie, Osnabruck, Germany|Klinikum der Universität Regensburg, Klinik und Poliklinik für Innere Medizin I, Regensburg, Germany|Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin, Stuttgart, Germany|Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I, Trier, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany|Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Wurzburg, Germany",,"https://ClinicalTrials.gov/show/NCT00915252"
1009,"NCT00757172","Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction",,"Completed","Has Results","Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer","Biological: panitumumab|Drug: cisplatin|Drug: docetaxel|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Number of Participants With Pathologic Complete Response Following Surgery|Number of Participants With Near-complete Response Rate (≤ 10% Residual Cancer in Primary Tumor Viable)|Percentage of Participants With 3-year Overall Survival|Percentage of Participants With 2-year Disease-free Survival|Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACOSOG-Z4051|CDR0000596674|NCI-2009-00346|U10CA076001","January 2009","November 2011","December 2014","September 23, 2008","August 19, 2014","March 11, 2016","Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|Simmons Cooper Cancer Institute, Springfield, Illinois, United States|Central Baptist Hospital, Lexington, Kentucky, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Good Samaritan Hospital, Dayton, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center and Children's Hospital, Portland, Oregon, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00757172"
1010,"NCT00639717","Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant",,"Completed","Has Results","Graft Versus Host Disease","Procedure: stem cell transplant|Drug: tacrolimus (standard GVHD prophylaxis)|Drug: mycophenolate (standard GVHD prophylaxis)|Drug: etanercept|Drug: methoxsalen","Percentage of Patients Alive at 6 Months|Percentage of Patients Who Experienced Relapse by 6 Months|The Percentage of Patients That Experienced Graft Versus Host Disease|Measured Level of Circulating Plasma Markers After Transplant|Regulatory T Cell Numbers Post-transplant","University of Michigan Rogel Cancer Center|Mallinckrodt|Amgen","All","Child, Adult, Older Adult","Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","umcc 2008.003","March 2009","January 2012","April 2016","March 20, 2008","September 25, 2014","August 1, 2017","University of Michigan Cancer Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00639717"
1011,"NCT00513383","Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck",,"Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Panitumumab|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Intensity Modulated Radiation Therapy|Drug: 5-Fluorouracil|Drug: Docetaxel|Drug: Cisplatin","To identify the maximally tolerated dose of paclitaxel given with panitumumab plus carboplatin chemoradiotherapy.|To identify the maximally tolerated dose or biologically acceptable dose of TPF, varying the 5-FU dose, given with a fixed dose of panitumumab, prior to concurrent carboplatin, paclitaxel, panitumumab chemoradiotherapy.|To evaluate the safety and tolerability of the combination of Pan-CRT and Pan-TPF.|To estimate the overall response rate to Pan-TPF.|To estimate the overall response rate of sequential therapy.|To estimate the rate of pathologic complete response of primary tumor biopsy, to estimate 2-year disease free survival and overall survival.|To evaluate functional outcome at 2 years with respect to speech, swallowing and overall quality of life.","Massachusetts General Hospital|Brigham and Women's Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-401","April 2006","October 2010","October 2012","August 8, 2007",,"March 1, 2017","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00513383"
1012,"NCT00456716","Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma",,"Completed","No Results Available","Lung Cancer","Drug: sorafenib","Response rate|One-year survival|Median survival|Median progression-free survival|Toxicities","Swedish Medical Center|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRC 0639","March 2007","December 2008","December 2008","April 5, 2007",,"March 4, 2010","Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00456716"
1013,"NCT00445042","Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer",,"Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sorafenib","Tumor progression rate by RECIST criteria|Overall response rate|Time to progression and overall survival","The Methodist Hospital System|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","71","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAC IRB#03-0194-05|Sorafenib-RCC-01","November 2005","September 2008","October 2008","March 8, 2007",,"March 17, 2016","Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00445042"
1014,"NCT00443430","Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis",,"Completed","Has Results","Juvenile Chronic Polyarthritis|Juvenile Idiopathic Arthritis|Juvenile Rheumatoid Arthritis","Drug: methotrexate|Drug: methotrexate - etanercept - prednisolone arm","Proportion of Participants Who Attain Inactive Disease by 6 Months|Safety Profiles, Including the Number of Treatment-emergent, Serious, or Unexpected Adverse Events and Other Important Medical Events|Clinical Remission on Medication","Seattle Children's Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Amgen","All","2 Years to 17 Years   (Child)","Phase 4","85","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","R01AR049762|5R01AR049762-02","May 2007","October 2010","October 2010","March 6, 2007","May 31, 2013","May 31, 2013","Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Texas Scottish Rite Hospital, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00443430"
1015,"NCT00418743","Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)",,"Unknown status","No Results Available","Small Cell Lung Cancer",,,"Groupe Francais De Pneumo-Cancerologie|Baxter Healthcare Corporation|Amgen","All","18 Years and older   (Adult, Older Adult)",,"138","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GFPC 05-01","December 2005",,"May 2010","January 5, 2007",,"March 9, 2010","Centre Hospitalier Universitaire, Angers, France|Site 05, Bastia, France|Site 22, Beauvais, France|Centre Hospitalier du Morvan, Brest, France|Centre François Baclesse, Caen, France|Site 43, Caen, France|Centre Hospitalier René Dubos, Cergy-pontoise, France|Site 33, Creteil, France|Site 07, Draguignan, France|Site 32, Elbeuf, France|Site 04, GAP, France|Centre Hospitalier Les Oudairies, La Roche Sur Yon, France|Hospital du Cluzeau, Limoges, France|Centre Hospitalier Régional, Longjumeau, France|Centre Hospitalier Lyon Sud, Lyon, France|Site 25, Mantes La Jolie, France|Site 06, Marseille, France|Site 27, Martigues, France|Site 01, Meaux, France|Hospital Saint Antoine, Paris, France|Site 17, Rouen, France|Hôpital Yves Le Foll, Saint Brieuc, France|Site 14, Toulon, France|Site 11, Villefranche Sur Saone, France",,"https://ClinicalTrials.gov/show/NCT00418743"
1016,"NCT00314977","Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.","INTENS","Completed","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel","The pathologic complete response rate to neoadjuvant chemotherapy.|The delivered chemotherapy dose and dose-intensity of both chemotherapy regimens|The tolerability (grade 3/4 CTC toxicities) of both chemotherapy regimens.|The clinical responses of neoadjuvant chemotherapy correlated to pathological responses after neoadjuvant chemotherapy.|The value of breast MRI in evaluating response to neoadjuvant chemotherapy as compared to clinical palpation, ultrasound techniques and histo-pathological outcome.|The false-negative rate of the sentinel node biopsy after neoadjuvant chemotherapy.|The disease-free and overall survival after 3 and 5 years follow-up.|The relation between pCR and DFS/OS.|The feasibility of the criteria for reporting pathological tumour response in surgical breast and axillary node resection specimens.|The prognostic and predictive value of tumour- and molecular markers, including ER, PgR, c-erbB2, microarray and other tumour characteristic analyses.","Radboud University|Sanofi|Amgen","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IKO 2005-01 / BOOG 2007-02","February 2006","April 2009",,"April 17, 2006",,"March 18, 2010","Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|HAGA Ziekenhuis, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Slingeland Hospital, Doetinchem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|St. Anna Hospital, Geldrop, Netherlands|St. Jansdal Ziekenhuis, Harderwijk, Netherlands|Atrium Medisch Centrum, Heerlen, Netherlands|Elkerliek Ziekenhuis, Helmond, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Academical Hospital Maastricht (AZM), Maastricht, Netherlands|St. Antonius Hospital, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Centre, Nijmegen, Netherlands|Waterland Hospital, Purmerend, Netherlands|Maasland Hospital, Sittard, Netherlands|St. Elisabeth Ziekenhuis, Tilburg, Netherlands|Mesos Medisch Centrum, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|Maxima Medisch Centrum, Veldhoven, Netherlands|Zaans Medical Centre, Zaandam, Netherlands",,"https://ClinicalTrials.gov/show/NCT00314977"
1017,"NCT00280787","Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: CPT-11|Drug: Pegfilgrastim|Radiation: Conformal radiotherapy","Number of subjects experiencing toxicity|Efficacy of 2 cycles of induction paclitaxel/carboplatin/irinotecan|Progression Free Survival","UNC Lineberger Comprehensive Cancer Center|AstraZeneca|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0215","November 2003","January 2006","October 2010","January 23, 2006",,"February 5, 2013","University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00280787"
1018,"NCT00240097","Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Intervention A: Irinotecan; Oxaliplatin; Neulasta|Drug: Intervention B: Etoposide; Carboplatin; Neulasta","Objective Response Rate (Part I)|Response Rate After Relapse|Progression Free Survival (Part I)|Overall Survival (Part I)","University of Alabama at Birmingham|Sanofi-Synthelabo|Amgen","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F041222002|UAB 0421","June 2005","June 2010","June 2010","October 17, 2005","November 27, 2014","November 27, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00240097"
1019,"NCT00193479","Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab","Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment","SCRI Development Innovations, LLC|Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI LYM 28","April 2003","July 2008","February 2010","September 19, 2005","February 21, 2014","February 21, 2014","Florida Cancer Specialists, Fort Myers, Florida, United States|Tennessee Oncology, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00193479"
1020,"NCT00189670","Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer",,"Completed","No Results Available","Node Positive Breast Cancer","Procedure: 6 TEC q 3 weeks|Procedure: 4 EC q 2 weeks followed by 4 TXT q 2 weeks|Procedure: 4 TXT q 2 weeks followed by 4 EC q 2 weeks",,"Association Européenne de Recherche en Oncologie|Aventis Pharmaceuticals|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2",,"Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AERO-B03",,,,"September 19, 2005",,"September 19, 2005",,,"https://ClinicalTrials.gov/show/NCT00189670"
1021,"NCT00140244","Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome",,"Completed","Has Results","HAART-induced Lipodystrophy and Metabolic Syndrome","Drug: r-metHuLeptin|Drug: Placebo","Serum Lipid Levels|Insulin Resistance (as Assessed by HOMA-IR)|Glycemia (as Assessed by Fasting Glucose)|Low Density Lipoprotein (LDL) Cholesterol Levels|Free Fatty Acid (FFA) Levels|Blood Pressure|Fibrinogen|Insulin Levels|Lean Body Mass|Viral Load|CD4+ Lymphocytes|Interleukin-6 (IL-6) Levels|Hepatic Fat Content","Beth Israel Deaconess Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2001P000484|R01DK058785","December 2001","June 2011","June 2011","September 1, 2005","April 6, 2017","May 11, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00140244"
1022,"NCT00001059","Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS",,"Completed","No Results Available","Sarcoma, Kaposi|HIV Infections","Drug: Doxorubicin hydrochloride (liposomal)|Drug: Filgrastim|Drug: Bleomycin sulfate|Drug: Vincristine sulfate",,"National Institute of Allergy and Infectious Diseases (NIAID)|Sequus Pharmaceuticals|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 286|11262",,,"August 1998","August 31, 2001",,"April 17, 2012","Alabama Therapeutics CRS, Birmingham, Alabama, United States|USC CRS, Los Angeles, California, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Ucsf Aids Crs, San Francisco, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Univ. of Miami AIDS CRS, Miami, Florida, United States|Queens Med. Ctr., Honolulu, Hawaii, United States|Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Bmc Actg Crs, Boston, Massachusetts, United States|Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States|Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States|Washington U CRS, St. Louis, Missouri, United States|SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00001059"
1023,"NCT02937571","High Dose Carfilzomib for Newly Diagnosed Myeloma",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Number of patients with dose limiting toxicity","Memorial Sloan Kettering Cancer Center|Onyx/Amgen|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-326","October 2016","October 2020","October 2020","October 18, 2016",,"December 18, 2019","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02937571"
1024,"NCT04113018","Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab","Complete Response|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Next Treatment (TTNT)|Duration of Response (DoR)|Time to Disease Progression (TTP)|Overall Response (OR)","Saad Z. Usmani, MD|Amgen|Celgene|Janssen, LP|Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-HEM-MYE-KRDD-001|00037709","November 12, 2019","October 2026","October 2026","October 2, 2019",,"December 18, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04113018"
1025,"NCT03851263","Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion","MARKOV","Withdrawn","No Results Available","Coronary Artery Disease","Biological: Evolocumab","Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography(CCTA) (FFRCT) at 18 months from baseline|Mean change in normalized area under the curve of fractional flow reserve derived from coronary computed tomography (FFRCT) at 36 months from baseline.|Percent change of total atheroma burden (TAB) and changes in plaque composition at 18 and 36 months measured by Hounsfield unit of plaque with positive remodeling (>1.10) assessed by coronary computed tomography.|Change and percent change after 18 and 36 months from baseline of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), lipoprotein (a), triglycerides, apolipoprotein A1 and B.|Number of treatment emergent adverse events (TEAEs) and adverse events (AEs) of special interest (i.e. acute kidney injury, pregnancy and lactation)|Incidence of all-cause death and the composite of Cardiovascular death, myocardial infarction, stroke, or coronary revascularization. The composite of Cardiovascular death, Myocardial infarction, or stroke","ECRI bv|Amgen|GE Healthcare|HeartFlow, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECRI-11","August 30, 2019","August 27, 2021","February 24, 2023","February 22, 2019",,"December 6, 2019",,,"https://ClinicalTrials.gov/show/NCT03851263"
1026,"NCT03829046","The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease",,"Recruiting","No Results Available","Atherosclerotic Vascular Disease|Type2 Diabetes|Microvascular Dysfunction","Drug: Placebo|Drug: Evolocumab","Number of Adverse Events|Seattle Angina Questionnaire|MDA Level|MPO Level|IL-6 Level|IL-18 Level|TNF-α Level|PECAM Level|ICAM Level|VCAM Level|Alpha5/Beta3 Activation Levels","Robert Rosenson|Amgen|University of Toronto|University of Michigan|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","GCO 18-1412|20167719","June 3, 2019","October 2020","October 2020","February 4, 2019",,"October 8, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States|St. Michael's - University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03829046"
1027,"NCT03155100","Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines","KEd","Active, not recruiting","No Results Available","Multiple Myeloma in Relapse","Drug: Carfilzomib for Inj 60 milligram (MG)|Drug: Elotuzumab 400 MG|Drug: Dexamethasone","Overall response rate|Severe adverse events","Raija Silvennoinen|Amgen|Bristol-Myers Squibb|Hospital District of Helsinki and Uusimaa|Helsinki University Central Hospital","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NMSG#24/15|2016-001178-13","August 7, 2017","June 21, 2020","June 30, 2023","May 16, 2017",,"December 18, 2019","Helsinki University Central Hospital, Helsinki, Finland|Central Finland Central Hospital, Jyväskylä, Finland|Kymenlaakso Central Hospital, Kotka, Finland|Kuopio University Hospital, Kuopio, Finland|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03155100"
1028,"NCT03988036","A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)","Keyriched-1","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Drug: Trastuzumab Biosimilar ABP 980|Drug: Pertuzumab","Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-HER2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with HER2-enriched early breast cancer assessed by PAM50 testing|Number and percentage of fatal adverse events as assessed by CTCAE 5.0|Number and percentage of serious treatment-emergent adverse events as assessed by CTCAE 5.0|Number and percentage of treatment-related adverse events as assessed by CTCAE 5.0|Number and percentage of treatment-emergent adverse events of interest as assessed by CTCAE 5.0|Number and percentage of adverse events leading to investigational product discontinuation|Number and percentage of severity of adverse events as assessed by CTCAE 5.0|Number and percentage of causality of adverse events as assessed by investigator and sponsor|Number and percentage of outcome of adverse events as per investigator assessment|Number and percentage of seriousness of adverse events as assessed by CTCAE 5.0","West German Study Group|Merck Sharp & Dohme Corp.|Amgen|NanoString Technologies, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WSG-AM09|2018-003996-37","November 2019","July 2021","July 2021","June 17, 2019",,"October 1, 2019",,,"https://ClinicalTrials.gov/show/NCT03988036"
1029,"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",,"Recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9;22)","Biological: Blinatumomab|Drug: Cytarabine|Drug: Methotrexate|Drug: Ponatinib","Complete molecular response (CMR) rate in newly diagnosed Ph-positive and/or BCR-ABL-positive acute lymphoblastic leukemia (ALL)|Overall response rate (ORR) in relapsed/refractory ALL|Relapse-free survival|Event-free survival|Overall survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Amgen|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0792|NCI-2018-01078|P30CA016672","November 29, 2017","November 30, 2023","November 30, 2023","August 28, 2017",,"August 22, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03263572"
1030,"NCT03161756","Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma","CHARLI","Recruiting","No Results Available","Melanoma Stage Iv|Melanoma Stage Iii|Melanoma","Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab","Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity","Melanoma and Skin Cancer Trials Limited|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01.15","December 7, 2017","June 2021","June 2023","May 22, 2017",,"January 6, 2020","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Bendigo Health, Bendigo, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03161756"
1031,"NCT03117751","Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma","Drug: Prednisone|Drug: Vincristine|Drug: Daunorubicin|Drug: Pegaspargase|Drug: Erwinase®|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Mercaptopurine|Drug: Dasatinib|Drug: Methotrexate|Drug: Blinatumomab|Drug: Ruxolitinib|Drug: Bortezomib|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Clofarabine|Drug: Vorinostat|Drug: Idarubicin|Drug: Nelarabine|Drug: Thioguanine","Event-free survival of ALL patients (EFS)|Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during Continuation|Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotype|5-year overall survival (OS) of ALL patients compared to historical controls|EFS of LLy patients|5-year OS of LLy patients|Comparison of MRD measurements between flow cytometry and sequencing|Log hazard ratio of the association of low level of MRD and treatment outcome|Comparison of bone marrow and peripheral blood MRD|Isolated CNS relapse in CNS1b patients|Level of clonal diversity and rise of leukemic clones during treatment|Number and type of germline or somatic genomic variants associated with drug resistance|Comparison of drug sensitivity of ALL cells between diagnosis and relapse in vitro and in vivo|Magnitude change in spatial span backward standard score (SSB)|Change in bone mineral density (BMD) in the tibia|Change in markers of bone turnover","St. Jude Children's Research Hospital|Incyte Corporation|Amgen|Servier","All","1 Year to 18 Years   (Child, Adult)","Phase 2|Phase 3","1000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TOT17|NCI-2017-00582","March 29, 2017","September 30, 2026","March 31, 2028","April 18, 2017",,"December 19, 2019","Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|St. Jude Affiliate-Charlotte, Charlotte, North Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03117751"
1032,"NCT01627379","Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer","POWER","Terminated","No Results Available","Esophageal Squamous Cell Cancer","Drug: Cisplatin, 5-FU|Drug: Panitumumab","Overall Survival|Progression-free survival|1-year survival|Response rate|Overall incidence of patients with adverse events|Quality of life","AIO-Studien-gGmbH|Amgen|Assign Data Management and Biostatistics GmbH|Assign Clinical Research GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POWER / AIO-STO-0309|2010-020606-15","May 2012","May 2015","May 2017","June 25, 2012",,"March 2, 2018","Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Rheinland-Pfalz, Germany",,"https://ClinicalTrials.gov/show/NCT01627379"
1033,"NCT02969837","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Elotuzumab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Rate of sCR|Rate of negative MRD|Number of participants with adverse events of elotuzumab in combination with KRd|Rate of MRD|Duration of response|Progression free survival|Time to progression|Overall survival","University of Chicago|Bristol-Myers Squibb|Amgen|Multiple Myeloma Research Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB16-1138","July 10, 2017","December 2020","December 2022","November 21, 2016",,"October 9, 2019","University of Chicago, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02969837"
1034,"NCT02208869","Russian Familial Hypercholesterolemia Registry","RuFH","Recruiting","No Results Available","Familial Hypercholesterolemia",,"Prevalence of FH patients in the Russian Federation|Number of patients with heterozygous and homozygous forms of FH in Russia|Distribution of lipoprotein(a) in individuals diagnosed with definite and probable FH.|Severity of carotid atherosclerosis, aortic valve stenosis and coronary heart disease in Russian patients with FH|Mutations in following genes: low-density lipoprotein receptor (LDLR), proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein B (apoB)|Russian Registry of individuals with FH|Prognosis of individuals with FH","Russian Cardiology Research and Production Center|Pfizer|Amgen|AstraZeneca","All","7 Years to 80 Years   (Child, Adult, Older Adult)",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","SSCRES0179","January 2014","December 31, 2017","December 31, 2026","August 5, 2014",,"September 19, 2018","Chelyabinsk State Medical Academy, Chelyabinsk, Russian Federation|Russian Research and Production Center, Moscow, Russian Federation|Novosibirsk Research Institute of Internal Medicine, Institute of Internal Medicine Siberian Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russian Federation|Saint-Petersburg State University and North-West State Medical University n.a. I.I.Mechnikov, Saint Petersburg, Russian Federation|Samara State Medical University, Samara, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02208869"
1035,"NCT03773107","LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Ruxolitinib|Drug: Dexamethasone","Progression Free Survival","Saad Z. Usmani, MD|Incyte Corporation|Multiple Myeloma Research Consortium|Amgen|Atrium Health","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCI-HEM-MYE-CRD-004|00031040","January 3, 2019","December 31, 2020","December 31, 2025","December 12, 2018",,"December 16, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03773107"
1036,"NCT03141203","Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients","RomiCar","Recruiting","No Results Available","Peripheral T Cell Lymphoma","Drug: Romidepsin|Drug: Carfilzomib","Maximum Tolerated Dose of the combination of romidepsin and carfilzomib|Best overall response rate (PR + CR) at the MTD|Toxicity of the combination of romidepsin and carfilzomib|Best overall response at the MTD|Maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the Revised Response Criteria for Malignant Lymphoma|Duration of response from time of first documented response until relapse or progression|Progression free survival|Overall survival","University of Birmingham|Bloodwise|Celgene|Amgen","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","58","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG_13-107|2013-001879-20","July 13, 2015","August 2019","February 2021","May 5, 2017",,"June 12, 2018","Queen Elizabeth Hospital, Birmingham, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Guy's Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03141203"
1037,"NCT03139630","COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients","COPANA","Completed","No Results Available","HIV Seropositivity|Dyslipidemias|PCSK9",,"PCSK9 plasma level change after initiation of ART including protease inhibitor boosted with ritonavir (PI/r)|PCSK9 correlation with lipid parameters|PCSK9 correlation with inflammatory makers/adipocytokines|PCSK9 comparison between HIV-infected and uninfected patients","Franck Boccara|National Agency for Research on AIDS and Viral Hepatitis (ANRS)|Institut National de la Santé Et de la Recherche Médicale, France|Amgen|Saint Antoine University Hospital","All","18 Years and older   (Adult, Older Adult)",,"193","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COPANA - A09 PCSK 9 substudy","March 2016","September 2016","September 2016","May 4, 2017",,"May 4, 2017","Cardiology Department, Saint Antoine University Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03139630"
1038,"NCT00557817","Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)",,"Completed","No Results Available","Hematological Malignancies","Drug: Darbepoetin alpha (Aranesp)|Drug: Iron saccharate (Venofer)","Median time to achieve hemoglobin (Hb) level > 13 g/dL in each arm.|Proportion of complete correctors (i.e. patients reaching Hb > 13 g/dL) before day 126 in each arm.|Median time to increase Hb level by > 2 g/dL in each arm.|Proportion of responders (i.e. patients increasing Hb by > 2 g/dL) before day 126 in each arm.|Proportion of correctors (i.e. patients reaching Hb > 12 g/dL) before day 126 in each arm.|Proportion of patients requiring red blood cell transfusions between day 28 and day 126 in each arm.|Total number of red blood cell transfusions between day 28 and day 126 in each arm.|Area under the curve of mean Hb level between day 28 and day 126 after the transplant in each arm.|Mean Hb values on days 42, 56, 70, 84, 98, 112, and 126 in each arm.|Mean change in Quality Of Life (QOL) measurements between day 28 and day 126 in each arm.","University of Liege|Amgen|KU Leuven|Vrije Universiteit Brussel","All","16 Years to 69 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","125","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJE0301","March 2004","August 2008","August 2008","November 14, 2007",,"January 11, 2010","Vrije Universiteit Brussel, Brussels, Belgium|Katholieke Universiteit Leuven, Leuven, Belgium|CHR la citadelle, Liege, Belgium|CHU Sart Tilman, Liege, Belgium",,"https://ClinicalTrials.gov/show/NCT00557817"
1039,"NCT00259610","Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)","TEAR","Completed","Has Results","Rheumatoid Arthritis","Drug: methotrexate|Drug: sulfasalazine|Drug: hydroxychloroquine|Drug: etanercept","Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR)|Radiographic Disease Progression Between Baseline and Week 102 as Assessed by Van Der Heijde Modified Sharp Scores.","University of Alabama at Birmingham|Amgen|Barr Laboratories|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","755","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","X031030004|20040391","May 2004","June 2009","June 2009","November 29, 2005","July 17, 2014","July 17, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT00259610"
1040,"NCT02126449","DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer","DIRECT","Completed","No Results Available","Fasting Mimicking Diet|Breast Cancer|Neoadjuvant Chemotherapy|Pathological Complete Response","Other: Fasting mimicking diet","The percentage of patients with grade III/IV toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI CTCAE) v4.03.|The percentage of pCR.|Clinical response measured by MRI (RECIST1.1) after 4 cycles chemotherapy.|Grade I/II side effects of chemotherapy according to NCI CTCAE v4.03.|Metabolic (Glucose, insulin, insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein 3 (IGF-BP3), free thyroxin (FT4), triiodothyronine (T3) and thyroid-stimulating hormone (TSH)) and inflammatory response (CRP) to chemotherapy.|DNA damage, apoptosis, immunology and nutrient sensing system activity in the tumor.|Patient's quality of life (using EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires), burden of therapy noted by a visual analogue scale (VAS) (Distress Thermometer) and differences of Illness Perceptions (B-IPQ).|Long term efficacy of treatment (DFS, OS).|Hormone receptor percentage, Ki67 and immunologic tumor profile and tumor/stroma ratio as predictive biomarker|SNPs used as biomarker to predict treatment outcome.","Leiden University Medical Center|Borstkanker Onderzoek Groep|Pink Ribbon Inc.|Amgen","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","131","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL44684.058.13|BOOG2013-04|p13.135","February 2014","November 2018","November 2018","April 30, 2014",,"October 24, 2019","Leids Universitair Medisch Centrum, Leiden, Zuid-holland, Netherlands|Medisch Centrum Alkmaar, Alkmaar, Netherlands|OLVG, Amsterdam, Netherlands|Alexander Monro hospital, Bilthoven, Netherlands|Amphia Hospital, Breda, Netherlands|Deventer Hospital, Deventer, Netherlands|Ziekenhuis Gelderse Valei, Ede, Netherlands|, Catharina ziekenhuis Hospital, Eindhoven, Netherlands|Kennemer gasthuis, Haarlem, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Bronovo Hospital, The Hague, Netherlands|Haga Hospital, The Hague, Netherlands|VieCurie Hospital, Venlo, Netherlands|Lange Land Hospital, Zoetermeer, Netherlands|Isala, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT02126449"
1041,"NCT00007813","Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors",,"Completed","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation",,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Amgen|Baxter Healthcare Corporation|Nexell Therapeutics Inc","All","up to 35 Years   (Child, Adult)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JHOC-9512|CDR0000064263|NCI-V95-0688|94-12-23-02","May 31, 1997","February 1, 2005","February 1, 2005","April 2, 2004",,"March 15, 2019","Johns Hopkins Oncology Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00007813"
1042,"NCT00785421","Chemotherapy With or Without Enoxaparin in Pancreatic Cancer","PROSPECT","Completed","No Results Available","Pancreatic Cancer","Drug: enoxaparin|Drug: chemotherapy with LMWH - enoxaparin|Drug: only chemotherapy","DVT/TVE event rate|TTP, OS, side effects","CONKO-Studiengruppe|Sanofi|Amgen|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","312","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONKO 004|CCT-NAPN-16752","April 2004","January 2009","June 2009","November 5, 2008",,"January 8, 2015","Universitätsmedizin - Berlin - Charite, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00785421"
1043,"NCT00544232","Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)",,"Completed","No Results Available","Breast Cancer","Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","Relapse-free survival time and overall survival","German Breast Group|Pharmacia|Amgen|Bristol-Myers Squibb","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","720","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 49","August 2002","September 2006","September 2006","October 16, 2007",,"February 15, 2016",,,"https://ClinicalTrials.gov/show/NCT00544232"
1044,"NCT01558115","Denosumab in Primary Hyperparathyroidism",,"Completed","No Results Available","Primary Hyperparathyroidism","Drug: Denosumab|Other: Placebo","Change in Bone Mineral Density (BMD) at the lumbar spine|Change in Bone Mineral Density (BMD) at the distal 1/3 radius|Change in Bone Mineral Density (BMD) at the hip","John P. Bilezikian|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen|Columbia University","Female","40 Years and older   (Adult, Older Adult)","Phase 4","8","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AAAF2568|R01DK032333|20090741","January 2012","October 2014","October 2014","March 20, 2012",,"April 9, 2015","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01558115"
1045,"NCT01554852","Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","Myeloma XI","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)","Overall survival|Progression-free survival|Response|Toxicity","University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","4420","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT number: 2009-010956-93","May 2010","December 2021","December 2022","March 15, 2012",,"June 11, 2018","112 sites UK wide, United Kingdom, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01554852"
1046,"NCT00041470","Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial",,"Terminated","Has Results","Breast Cancer","Drug: Paclitaxel|Drug: Vinorelbine|Drug: Herceptin|Drug: Filgrastim","To Measure Response Rates, Time to Progression and Survival in Patients so Treated.|To Measure the Qualitative and Quantitative Toxicity of This Regimen.","University of Washington|Amgen|Bristol-Myers Squibb|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18245","March 2001","August 2008","August 2008","July 10, 2002","June 6, 2017","July 17, 2017","Seattle Cancer Care Alliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00041470"
1047,"NCT00417248","Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer",,"Terminated","Has Results","Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Procedure: Radiotherapy|Drug: Sorafenib","Time to Disease Progression (TTP)|Overall Survival","Nasser Hanna, M.D.|Bayer|Amgen|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOG LUN06-107","June 2007","April 2008","April 2008","December 29, 2006","July 25, 2016","July 25, 2016","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Oncology Partners Network, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00417248"
1048,"NCT00231582","High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II",,"Completed","No Results Available","Testicular Neoplasms","Drug: epirubicin|Procedure: high-dose and autologous stem cell transplantation|Drug: paclitaxel|Drug: etoposide|Drug: ifosfamide|Drug: carboplatin","Complete response rate|Survival (overall and progression-free), toxicity, toxic-death rate.","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France|Amgen|Baxter Healthcare Corporation","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P031101","September 2004","January 2010","January 2010","October 4, 2005",,"February 25, 2011","Hôpital TENON, Service d'Oncologie Médicale, Paris, France",,"https://ClinicalTrials.gov/show/NCT00231582"
1049,"NCT01002703","Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma",,"Unknown status","No Results Available","Multiple Myeloma","Drug: Lenalidomide, Bendamustine, Prednisone","To determine the maximum tolerable dose (MTD) of lenalidomide in combination with bendamustine and prednisone (RBP) in refractory and relapsed MM stage I/III|To determine the safety of lenalidomide, bendamustine and prednisone at MTD","University of Leipzig|Celgene Corporation|Mundipharma Pte Ltd.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RBP-01/08|OSHO77","September 2009","October 2012","October 2014","October 27, 2009",,"August 12, 2011","University of Leipzig, Leipzig, Germany",,"https://ClinicalTrials.gov/show/NCT01002703"
1050,"NCT00940316","Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer","Biological: panitumumab|Drug: erlotinib hydrochloride|Drug: irinotecan hydrochloride","Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD)|Time to Disease Progression|Time to Treatment Failure|Toxicity of the Combination of Study Drugs|Effect on Downstream Targets of Epidermal Growth Factor Receptor (EGFR) in Skin Rash Associated With Pharmacologic EGFR Inhibition","Northwestern University|Genentech, Inc.|OSI Pharmaceuticals|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 07I4|STU00004101|OSI 4263s","January 18, 2010","January 2015","January 2015","July 16, 2009","May 7, 2019","May 7, 2019","Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights, Illinois, United States|Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Hematology/Oncology Associates, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Hope Cancer Center, Terre Haute, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Virtua Memorial (Regional Cancer Care Associates of Mount Holly), Mount Holly, New Jersey, United States|Mercy Clinic Oncology and Hematology, Oklahoma City, Oklahoma, United States|The Jones Clinic, Germantown, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00940316"
1051,"NCT00842257","Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer","Drug: panitumumab","Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab.|Median Progression Free Survival (PFS)|Median Overall Survival|Disease Control Rate as Defined by RECIST Criteria","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-287|20070602","May 2009","December 2011","December 2011","February 12, 2009","May 16, 2017","May 16, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00842257"
1052,"NCT00808639","Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma",,"Completed","Has Results","Bladder Cancer|Muscle-invasive Bladder Cancer","Drug: Methotrexate|Drug: Doxorubicin|Drug: vinblastine|Drug: cisplatin|Drug: Pegfilgrastim","Number of Patients Achieving Pathologic Response|Number of Patients Experiencing Febrile Neutropenia|Number of Patients Experiencing Surgery-related Toxicity","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-208","December 2008","December 2013","September 2016","December 16, 2008","May 15, 2014","October 24, 2016","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00808639"
1053,"NCT00786058","A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003",,"Approved for marketing","No Results Available","Pancreatic Cancer","Drug: OFF in experimental arm",,"CONKO-Studiengruppe|Sanofi|medac GmbH|Amgen","All","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"CONKO 003|CCT-NAPN-16751",,,,"November 5, 2008",,"June 15, 2009",,,"https://ClinicalTrials.gov/show/NCT00786058"
1054,"NCT00632541","A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer",,"Terminated","Has Results","Metastatic Breast Cancer","Drug: Sorafenib|Drug: Bevacizumab|Other: Imaging","Progression-Free Survival|Assess the Clinical Benefit Response: the Proportion of Patients With Clinical Benefit (CR+PR+SD > 6 Months Duration) Will be Assessed at the Completion of the Study.|Assess the Overall Response Rate.|Determine the Adverse Event Profile of Sorafenib Combined With Bevacizumab in This Patient Population.","Hoosier Cancer Research Network|Genentech, Inc.|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRE06-109","October 2007","March 2009","March 2009","March 10, 2008","January 7, 2016","February 14, 2018","Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States|Arnett Cancer Care, Lafayette, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Ireland Cancer Center - University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00632541"
1055,"NCT00586443","BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)","BEP","Completed","No Results Available","Solid Tumors","Drug: bevacizumab, everolimus, panitumumab","To determine the MTD/recommended phase II regimen and evaluate safety of panitumumab added to RAD001 plus bevacizumab in adult patients with advanced solid tumors.|To preliminarily describe any clinical activity (PR, CR or duration of SD) associated with this regimen","Herbert Hurwitz, MD|Novartis|Genentech, Inc.|Amgen|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","Pro00001082","November 2007","September 2014","September 2014","January 4, 2008",,"November 19, 2014","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00586443"
1056,"NCT00040651","Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients",,"Terminated","No Results Available","Scleroderma|Systemic Sclerosis","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Thymoglobulin|Procedure: Leukapheresis|Procedure: Self bone marrow transplant","Non-hematologic toxicity experienced|Clinical and laboratory responses to chemotherapy and self bone marrow transplant","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|University of Pittsburgh|Amgen|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","NIH|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N01 AR92239|NIAMS-047","July 2002","March 2007","March 2007","July 10, 2002",,"December 28, 2007","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00040651"
1057,"NCT00405366","Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer","NRR","Completed","No Results Available","Kidney Cancer","Drug: sorafenib tosylate","Number of subjects experiencing adverse events while taking sorafenib prior to nephrectomy|Feasibility of neoadjuvant systemic therapy prior to nephrectomy|Response in primary renal tumors|Effects of sorafenib tosylate therapy on gene expression, protein expression, and metabolic profile","UNC Lineberger Comprehensive Cancer Center|Doris Duke Charitable Foundation|Bayer|Amgen","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0603|CDR0000550127","November 2006","June 2009","July 2015","November 30, 2006",,"April 18, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00405366"
1058,"NCT00140231","Role of Leptin in the Neuroendocrine and Immune Response to Fasting",,"Completed","Has Results","Fasting","Drug: r-metHuLeptin|Other: placebo","Cortisol|ACTH Mean Level|Immune Function CD3 Count|%Fat Mass|(RMR)|Autonomic Function","Beth Israel Deaconess Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Amgen","All","18 Years to 30 Years   (Adult)","Phase 1|Phase 2","13","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2002P000049|2M01RR001032-30|5R01DK058785-07","October 2002","March 2011","December 2016","September 1, 2005","June 7, 2017","June 7, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00140231"
1059,"NCT00130117","Study of Leptin for the Treatment of Hypothalamic Amenorrhea",,"Completed","Has Results","Amenorrhea","Drug: r-metHuLeptin|Drug: Oral Contraceptive Pills (OCPs)|Other: Placebo","the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks|Bone Markers - Ctx and Sclerostin|Body Composition BMI|Total Body BMD|Body Fat|Lumbar BMD|Radial BMD|Hip BMD","Beth Israel Deaconess Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Amgen","Female","18 Years to 35 Years   (Adult)","Phase 2","20","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2004P000123|1R34HD048526-01|5M01RR001032-32","April 2010","August 2011","December 2016","August 15, 2005","May 17, 2017","May 17, 2017","Beth Israel Deaconess Medical Center General Clinical Research Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00130117"
1060,"NCT00100477","Use of Topotecan in Patients With Refractory Acute Leukemia",,"Completed","No Results Available","Non-Hodgkin's Lymphoma|Leukemia","Drug: Topotecan|Drug: Mitozantrone|Drug: Etoposide",,"US Department of Veterans Affairs|Immunex Corporation|SmithKline Beecham|Amgen|VA Office of Research and Development","All","18 Years to 60 Years   (Adult)","Phase 2","10","U.S. Fed|Industry","Interventional",,"CADE-RCD1","August 1998","January 2001","June 2001","December 31, 2004",,"September 25, 2013","North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00100477"
1061,"NCT00072319","Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer",,"Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy",,"Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pharmacia|Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2",,"Other|NIH|Industry","Interventional","Primary Purpose: Treatment","03-092|P30CA008748|MSKCC-03092","August 2003","November 2006","November 2006","November 6, 2003",,"March 4, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00072319"
1062,"NCT03815279","A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)","iStopMM","Enrolling by invitation","No Results Available","Multiple Myeloma|Smoldering Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Rate of MRD negativity|Progression free survival|Overall survival","Landspitali University Hospital|Amgen|Celgene|University of Iceland|Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSH-17-001","June 24, 2019","January 2024","January 2028","January 24, 2019",,"August 16, 2019","Landspitali University Hospital, Reykjavík, Iceland",,"https://ClinicalTrials.gov/show/NCT03815279"
1063,"NCT03289299","Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant","ASCENT","Recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: Carfilzomib|Drug: Lenalidomide|Drug: Daratumumab|Drug: Dexamethasone","Stringent complete response rate|MRD negativity after each treatment phase|MRD negativity at 1 year post treatment|Overall Survival|Progression-free survival|Adverse events","International Myeloma Foundation|Amgen|Janssen Scientific Affairs, LLC|Celgene|Trevie, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BS001|20159417|54767414MMY2009|RV-CL-MM-IMF-008479","May 25, 2018","June 1, 2022","June 1, 2026","September 20, 2017",,"December 4, 2018","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medicine, New York, New York, United States|Swedish Cancer Institute, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03289299"
1064,"NCT02833610","A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Denosumab Q4W","Percent Change Of sCTX Levels|Percent Change In Bone Mineral Density|Percent Change In uNTX Levels|Subject Incidence Of Hypocalcemia|Subject Incidence Of Occurrence Of Documented SRE At 12 Months|Subject Incidence Of Adverse Events|Percent Change In Bone Turnover Markers","Massachusetts General Hospital|Amgen|Emory University|University of Rochester|University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-571","August 2016","October 2020","October 2022","July 14, 2016",,"November 26, 2019","Emory University Hospital, Atlanta, Georgia, United States|Massachusetts general Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States|Newton Wellesley Hospital, Newton, Massachusetts, United States|University of Rochester Medical Center, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02833610"
1065,"NCT02125344","A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)",,"Completed","No Results Available","Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer","Drug: non-pegylated liposomal doxorubicin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Ferric carboxymaltose","pathological complete response (pCR= ypT0/is ypN0)|Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2|pcR rates per arm|Clinical and imaging response|Rates of ypT0 ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0; and the residual cancer burden (RCB) score.|Toxicity and Compliance including incidence of febrile neutropenia|Breast conservation rate|loco-regional invasive recurrence free survival (LRRFS) in both arms and according to stratified subpopulations|distant-disease-free survival (DDFS) in both arms and according to stratified subpopulations.|invasive disease-free survival (IDFS) in both arms and according to stratified subpopulations.|overall survival (OS) in both arms and according to stratified subpopulations.|regional recurrence free survival (RRFS) in patients with initial node-positive axilla|pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy|Correlation of response|Examination and comparison of molecular markers|Examination of PIK3CA mutation|Only for those patients randomized for the supportive anemia treatment: Quality of life|Only for those patients randomized for the supportive anemia treatment: median time to achieve a hemoglobin level ≥11g/dl|Only for those patients randomized for the supportive anemia treatment: frequency of patients with a hemoglobin level ≥11g/dl|Pharmacogenetic substudy|GeparPET substudy|Ovarian function","German Breast Group|Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma","Female","18 Years and older   (Adult, Older Adult)","Phase 3","961","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 84","December 2014","November 2016","January 30, 2017","April 29, 2014",,"July 13, 2017","NTC, Heidelberg, Baden-Württemberg, Germany",,"https://ClinicalTrials.gov/show/NCT02125344"
1066,"NCT04128475","Observational Study of Cardiovascular Disease.","FOURIER LEGACY","Not yet recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Morbidity|Coronary Heart Disease|Low-density-lipoprotein-type","Other: N/A - observational study.","To evaluate the potential long-term effect of evolocumab treatment on a composite of CV death, MI, stroke or coronary revascularisation in participants completing participation in the FOURIER OUTCOMES trial.|To evaluate the potential long-term effect of evolocumab treatment on a composite of CV death, MI, stroke or coronary revascularization in patients completing participation in the FOURIER OUTCOMES trial.|To evaluate the long-term effect of evolocumab treatment on CV death.|To evaluate the long-term effects of evolocumab treatment on CHD death.|To evaluate the long-term effect of evolocumab treatment on the individual components of the primary endpoint and any other CV hospitalizations.|To evaluate the long-term effect of evolocumab treatment on amputations and peripheral revascularization.|To evaluate the long-term effect of evolocumab treatment in terms of all-cause death (and non-CV, including cancer, death).|To assess the effect modification of use or prescription lipid-lowering treatment classes (statins, cholesterol absorption inhibitors, PCSK9i) administered at FOURIER OUTCOMES trial entry on the outcomes above.|To assess the effect modification by baseline characteristics on defined study outcomes above.","University of Sydney|The Thrombolysis in Myocardial Infarction Study Group, Harvard University|Imperial College London|University of Oslo|Amgen","All","Child, Adult, Older Adult",,"10000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CTC0173","November 1, 2019","January 1, 2022","January 1, 2023","October 16, 2019",,"October 18, 2019",,,"https://ClinicalTrials.gov/show/NCT04128475"
1067,"NCT00309556","Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: Docetaxel|Drug: Capecitabine|Drug: Trastuzumab","Rate of pathological complete remissions|Rates of axillary lymph node involvement and breast-conserving procedures","Austrian Breast & Colorectal Cancer Study Group|Amgen|Ebewe Pharma GmbH|Hoffmann-La Roche|Sanofi","Female","19 Years to 80 Years   (Adult, Older Adult)","Phase 3","536","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABCSG-24|Ro 09-1978","February 2005","November 2009","November 2011","April 3, 2006",,"December 30, 2011","Hospital Guessing, Guessing, Burgenland, Austria|Hospital Oberpullendorf, Oberpullendorf, Burgenland, Austria|Hospital Oberwart, Oberwart, Burgenland, Austria|State Hospital Klagenfurt, Klagenfurt, Carinthia, Austria|Ordination Dr. Wette, St. Veit a. d. Glan, Carinthia, Austria|Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria|State Hospital Villach, Villach, Carinthia, Austria|State Hospital Wolfsberg, Wolfsberg, Carinthia, Austria|Hospital Baden, Baden bei Wien, Lower Austria, Austria|Hospital Krems, Krems, Lower Austria, Austria|Hospital of Wiener Neustadt, Wiener Neustadt, Lower Austria, Austria|Gynaegological Medical University Graz, Graz, Styria, Austria|Medical University of Graz, Oncology, Graz, Styria, Austria|State Hospital Leoben, Leoben, Styria, Austria|Medical University of Innsbruck, Innsbruck, Tyrol, Austria|District Hospital Kufstein, Kufstein, Tyrol, Austria|State Hospital Kirchdorf, Kirchdorf, Upper Austria, Austria|Hospital BHS Linz, Linz, Upper Austria, Austria|General Hospital Linz, Linz, Upper Austria, Austria|State Hospital Steyr, Steyr, Upper Austria, Austria|Klinikum Wels-Grieskirchen, Wels, Upper Austria, Austria|State Hospital Feldkirch/Rankweil, Rankweil, Vorarlberg, Austria|Paracelsus Medical University Salzburg - Oncology, Salzburg, Austria|Medical University Vienna, General Hospital, Vienna, Austria|State Hospital Vienna-Hietzing, Vienna, Austria|Hanusch Hospital, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT00309556"
1068,"NCT01099436","Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients","NEO-ZOTAC","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: zoledronic acid|Procedure: neoadjuvant therapy","Pathologic complete response after neoadjuvant chemotherapy with or without zoledronic|Correlation of clinical response with pathological responses of both treatment arms|Disease-free survival|Overall survival|Safety and tolerability|Heterogeneity of the ER/PR and HER2 measurement in core biopsy and the surgical specimen","Borstkanker Onderzoek Groep|Dutch Cancer Society|Amgen|Sanofi|Novartis","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BOOG-2010-01|CDR0000669246|BOOG-NEO-ZOTAC|2009-016932-11","April 2010","April 2012","September 2013","April 7, 2010",,"January 21, 2020","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01099436"
1069,"NCT02565511","A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","Generation S1","Recruiting","No Results Available","Alzheimer's Disease","Biological: CAD106 Immunotherapy|Other: Placebo to CAD106|Drug: CNP520|Other: Placebo to CNP520","Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease|Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score|Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score|Number of participants with Adverse Events as a measure of Safety and Tolerability|Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)|Change in the Everyday Cognition scale (ECog) total scores|Change in Alzheimer's Disease related biomarkers|Change in APCC Test Score|Change in CDR-SOB|Aβ-specific immune response","Novartis Pharmaceuticals|Banner Alzheimer's Institute|National Institute on Aging (NIA)|Alzheimer's Association|Amgen|Novartis","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","481","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAPI015A2201J|2015-002715-15|1UF1AG046150-01","November 30, 2015","December 31, 2024","March 31, 2025","October 1, 2015",,"October 28, 2019","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Scottsdale, Arizona, United States|Banner Sun City Research Institute, Sun City, Arizona, United States|ATP Clinical Research, Inc., Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|University of Southern California Keck School of Medicine Alzheimer Disease Research Center, Los Angeles, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Novartis Investigative Site, Sebastopol, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|Novartis Investigative Site, Temecula, California, United States|Novartis Investigative Site, Basalt, Colorado, United States|Yale University Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|JEM Research Institute, Atlantis, Florida, United States|Florida Atlantic University, Clinical Translational Research Unit, Boca Raton, Florida, United States|Brain Matters Research, Delray Beach, Florida, United States|Meridien Research, Maitland, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Mount Sinai Medical Center - The Wien Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Compass Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Medical Research & Health Education Foundation, Inc., Columbus, Georgia, United States|NeuroStudies, Decatur, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Alzheimer's Disease Center, Fairway, Kansas, United States|Via Christi Research, Wichita, Kansas, United States|Sanders Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Memory Disorders Program, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Memory Enhancement Center, Eatontown, New Jersey, United States|The Memory Center of Northeastern New York, Latham, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Nathan S. Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Duke University Medical center, Durham, North Carolina, United States|Triad Clinical Trials, LLC, Greensboro, North Carolina, United States|University Hospitals Cleveland Medical Center / Case Western Reserve University, Beachwood, Ohio, United States|Novartis Investigative Site, Centerville, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Memory Health Center at Summit Research Network, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis - CBRI, Charleston, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|CNS Healthcare, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|Kerwin Research Center & Memory Care, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center, Houston, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|Novartis Investigative Site, Spokane, Washington, United States|Universal Research Group, Tacoma, Washington, United States|The Medical College of WI, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Heidelberg Heights, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Okanagan Clinical Trials, Kelowna, British Columbia, Canada|Novartis Investigative Site, Kentville, Nova Scota, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Toronto Memory Program, Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Gatineau, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Boblingen, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Münster, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wenzenbach, Germany|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Terrassa, Barcelona, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Donostia-San Sebastian, Spain|Novartis Investigative Site, Basel, CH, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Westbruy On Trym, Bristol, United Kingdom|Novartis Investigative Site, Exeter, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Avon, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02565511"
1070,"NCT00925821","Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Procedure: allogeneic stem cell transplant versus second autologous transplantation|Drug: RAD","Response rate to RAD induction and transplant (stringent CR, CR, very good PR)|Progression-free survival (PFS)|Incidence and relationship of severe adverse events","Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation|Amgen|medac GmbH","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSMM XII","June 2009",,,"June 22, 2009",,"June 28, 2012","Charité University Hospital - Virchow Klinikum, Berlin, Germany|Dresden University Hospital, Dresden, Germany|Erlangen University Hospital, Erlangen, Germany|Freiburg University Hospital, Freiburg, Germany|Jena University Hospital, Jena, Germany|Kiel University Hospital, Kiel, Germany|Munich Grosshadern University Hospital, Munich, Germany|University Hospital of Munich Technical University, Munich, Germany|Klinikum Nuremberg, Nuremberg, Germany|Regensburg University Hospital, Regensburg, Germany|Rostock University Hospital, Rostock, Germany|Ulm University Hospital, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT00925821"
1071,"NCT00863460","Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients","PRECIS","Active, not recruiting","No Results Available","Primary Central Nervous System Lymphoma","Radiation: cranial radiotherapy|Drug: intensive chemotherapy and hematopoietic stem cell rescue|Drug: MTX based chemotherapy","2-years progression-free survival in each arm|Overall response rate at the end of the procedure|Overall survival|Event-free survival|Neurotoxicity","Institut Curie|Ministry of Health, France|Hoffmann-La Roche|Amgen|Pierre Fabre Laboratories","All","18 Years to 60 Years   (Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRH 07/422/H|EudraCT N° 2007-005378-30","October 3, 2008","May 17, 2016","May 2026","March 18, 2009",,"February 5, 2019","Cancérologie Hôpital Sud, Amiens, France|Chu D'Angers, Angers, France|CHR Argenteuil, Argenteuil, France|CHU de Besancon, Besançon, France|Institut Bergonié, Bordeaux, France|CHU Hôtel Dieu, Clermont-Ferrand, France|CHU Michalon, Grenoble, France|Centre Hospitalier Lens, Lens, France|CHU de Limoges, Limoges, France|CHU de la Timone, Marseille, France|Hôtel Dieu Nantes, Nantes, France|Centre Antoine Lacassagne, Nice, France|CHU de Nimes, Nîmes, France|GH Pitié-Salpétrière, Paris, France|CHG Saint Jean, Perpignan, France|CHU Hôpital Bernard, Poitiers, France|Chu Reims, Reims, France|Hôpital Pontchaillou, Rennes, France|Centre René Huguenin, Saint Cloud, France|Institut de Cancérologie, Saint-Priest en Jarez, France|CH de Saint-Quentin, Saint-Quentin, France|Hôpital Bretonneau, Tours, France|CHU Nancy - Hôpital Neurologique, Vandoeuvre les Nancy, France",,"https://ClinicalTrials.gov/show/NCT00863460"
1072,"NCT01701076","Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma","BRd","Completed","No Results Available","Multiple Myeloma","Drug: Bendamustine","Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen|Objective response rates (sCR, CR, VGPR, PR, MR)|Best response (sCR, CR, VGPR, PR, MR)|Time to progression (TTP)|Overall survival (OS)|Safety and tolerability","Cantonal Hospital of St. Gallen|Celgene Corporation|Mundipharma Research GmbH & Co KG|Mundipharma Medical Company|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTU10.041/BRd|2010-022253-42","March 2012","February 2016","February 2016","October 4, 2012",,"August 24, 2016","Kantonsspital St. Gallen, St. Gallen, Switzerland",,"https://ClinicalTrials.gov/show/NCT01701076"
1073,"NCT00544765","Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","GeparTrio","Completed","No Results Available","Breast Cancer","Drug: TAC|Drug: NX","Determination of pCR rates|To determine the toxicity and compliance to each arm|To determine the breast conservation rate in each arm|To determine the disease-free and overall survival in each arm|To determine the specificity and sensitivity of a presurgical core biopsy to predict the degree of pathologic tumor regression","German Breast Group|Roche Pharma AG|Sanofi|Amgen|University Hospital, Frankfurt","Female","18 Years and older   (Adult, Older Adult)","Phase 3","2014","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GBG 24","September 2002","February 2008","February 2008","October 16, 2007",,"February 10, 2016",,,"https://ClinicalTrials.gov/show/NCT00544765"
1074,"NCT01024387","AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors",,"Completed","Has Results","Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor","Drug: AMG 479","Objective Response Rate|Duration of Response|Grade 3-4 Toxicity Rate|Progression Free Survival|1-Year Overall Survival","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|H. Lee Moffitt Cancer Center and Research Institute|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-240","March 2010","January 2016","January 2017","December 2, 2009","December 27, 2017","March 8, 2018","H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01024387"
1075,"NCT00129896","Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients",,"Completed","No Results Available","Breast Cancer","Drug: Myocet|Drug: Taxotere|Drug: Herceptin","Tolerability (Phase I): Recommended Doses of the combination treatment|Efficacy (Phase II): Percentage (%) pathological Complete Response achieved according to Miller and Payne Criteria|Clinical response rates|Surgery type (conservative surgery versus mastectomy)|Potential cardiac toxicity|Safety: Adverse Events evaluated according to NCI CTC v2.0|Post-surgery node status|Molecular changes in blood and tissue exams","Spanish Breast Cancer Research Group|Cephalon|Sanofi|Hoffmann-La Roche|Amgen","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","73","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEICAM 2003-03","January 2004","December 2008","February 2010","August 12, 2005",,"July 26, 2018","Hospital Universitario Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Althaia-Xarxa Assistencial de Manresa, Manresa, Barcelona, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Onkologikoa, Donostia-San Sebastian, Guipúzcoa, Spain|Hospital de la Ribera, Alzira, Valencia, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT00129896"
1076,"NCT02009345","Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada","FHCanada","Recruiting","No Results Available","Familial Hypercholesterolemia|Lipid Disorder",,"Number of Patients with FH|Prevalence rates of FH in Canada","McGill University Health Centre/Research Institute of the McGill University Health Centre|Amgen|Sanofi|Pfizer|Merck Sharp & Dohme Corp.|Aegerion Pharmaceuticals, Inc.","All","Child, Adult, Older Adult",,"6000","Other|Industry","Observational",,"FH Canada","November 2013","November 2016","November 2020","December 12, 2013",,"June 23, 2014","Research Institute of the McGill University Health Centre: Royal Victoria Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02009345"
1077,"NCT03315468","French Clinical Datbase of Melanoma Patients (RIC-Mel)","RIC-Mel","Recruiting","No Results Available","Melanoma (Skin)",,"Overall survival of melanoma patients included in the RIC-Mel database|Percentage of melanoma patients included in the RIC-Mel database categorized by genders|Percentage of melanoma patients included in the RIC-Mel database categorized by histological subtypes|Percentage of melanoma patients included in the RIC-Mel database categorized by breslow thickness|Percentage of melanoma patients included in the RIC-Mel database categorized by ulceration|Percentage of melanoma patients included in the RIC-Mel database categorized by Melanoma stage|Percentage of Participants With Mutation Status|Percentage of treatment types among melanoma stage|Progression-free survival of melanoma patients included in the RIC-Mel database","Nantes University Hospital|CENGEPS|Bristol-Myers Squibb|Hoffmann-La Roche|GlaxoSmithKline|Amgen","All","Child, Adult, Older Adult",,"16000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Prog 09/37-11","March 1, 2012","March 1, 2020","March 1, 2020","October 20, 2017",,"November 23, 2018","Nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT03315468"
1078,"NCT00943943","Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations",,"Completed","No Results Available","Acute Myelogenous Leukemia|Leukemia","Drug: G-CSF|Drug: Plerixafor|Drug: Sorafenib","Maximum Tolerated Dose (MTD) of Sorafenib","M.D. Anderson Cancer Center|Bayer|Genzyme, a Sanofi Company|Amgen|National Cancer Institute (NCI)|Georgia Institute of Technology","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0501|R01FD003733|R21CA143805|NCI-2009-01512","October 29, 2010","March 23, 2017","March 23, 2017","July 22, 2009",,"March 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00943943"
1079,"NCT00210249","Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment","ONCOGERIATRIE","Completed","No Results Available","Lymphoma|Digestive System Diseases|Ovarian Diseases|Pulmonary Disease|Prostatic Disease|Bladder Disease",,,"Institut Bergonié|Sanofi-Synthelabo|Aventis Pharmaceuticals|Amgen|Chugai Pharmaceutical|Bristol-Myers Squibb","All","70 Years and older   (Older Adult)",,"360","Other|Industry","Observational",,"IB2002-26|ONCOGERIATRIE","September 2002",,"June 2006","September 21, 2005",,"July 26, 2013","Centre de radiothérapie d'Agen, Agen, France|Centre Hospitalier Universitaire d'Agen, Agen, France|Clinique Esquirol Saint Hilaire, Agen, France|Centre Hospitalier Universitaire de Bayonne, Bayonne, France|Centre Hospitalier de la Côte Basque, Bayonne, France|Clinique Saint Etienne du Pays Basque, Bayonne, France|Clinique Tivoli, Bordeaux, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest, Bordeaux, France|Centre Hospitalier Universitaire de Dax, Dax, France|Hopital Sub-Urbain du Bouscat, Le Bouscat, France|Hôpital Robert Boulin, Libourne, France|Centre Hospitalier Universitaire de Mont de Marsan, Mont de Marsan, France|Centre Hospitalier Universitaire de Pau, Pau, France|Centre Hospitalier Universitaire de Perigueux, Perigueux, France|Clinique Francheville, Perigueux, France|Maison de Santé Protestante Bagatelle, Talence, France|Centre Hospitalier Universitaire de Villeneuve sur Lot, Villeneuve sur Lot, France",,"https://ClinicalTrials.gov/show/NCT00210249"
1080,"NCT00186602","Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?",,"Completed","No Results Available","Breast Cancer","Behavioral: Peer counseling",,"Stanford University|California Breast Cancer Research Program|Genentech, Inc.|Amgen|Johnson & Johnson|Google Inc.","Female","20 Years to 85 Years   (Adult, Older Adult)",,,"Other|Industry","Observational",,"7BB-2400|12382","July 1, 2000","November 30, 2006","November 30, 2006","September 16, 2005",,"November 22, 2019","WomenCARE, Santa Cruz, California, United States",,"https://ClinicalTrials.gov/show/NCT00186602"
1081,"NCT02925234","The Drug Rediscovery Protocol (DRUP Trial)","DRUP","Unknown status","No Results Available","Cancer|Tumors|Neoplasm|Neoplasia","Drug: Panitumumab|Drug: Olaparib|Drug: Dabrafenib|Drug: Nilotinib|Drug: Trametinib|Drug: Erlotinib|Drug: Trastuzumab and Pertuzumab (combination treatment)|Drug: Vemurafenib and Cobimetinib (combination treatment)|Drug: Vismodegib|Drug: Regorafenib|Drug: Nivolumab","Percentage of patients that are treated based on their molecular tumor profile|Objective tumor response|Stable disease|Treatment-related grade≥3 and serious adverse events|Progression-free survival|Overall survival|Duration of treatment on study (time on drug)","The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15DRU","August 2016","August 2019","December 2019","October 5, 2016",,"October 5, 2016","Meander Medical Center, Amersfoort, Utrecht, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|AZVU, Amsterdam, Netherlands|Amphia Hospital, Breda, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Orbis Concern, Geleen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud umc, NIjmegen, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|St. Elisabeth, Tilburg, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02925234"
1082,"NCT04098250","Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH",,"Not yet recruiting","No Results Available","Post-Traumatic Headache","Drug: Erenumab|Other: Placebo","Moderate-to-severe headache day frequency|Responder rate|Chronic headache|Headache Impact Test (HIT-6)|Treatment day frequency","Mayo Clinic|University of Arizona|Translational Genomics Research Institute|Arizona State University|Phoenix VA Health Care System|United States Department of Defense|Amgen","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","112","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","19-003200","February 1, 2020","October 31, 2022","August 31, 2023","September 23, 2019",,"January 13, 2020","Phoenix VA Health Care System, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04098250"
1083,"NCT01549431","Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Drug: Panobinostat|Drug: Carfilzomib|Drug: Dexamethasone","Maximum tolerated dose (MTD) of the combination of panobinostat and carfilzomib","Emory University|Multiple Myeloma Research Consortium|Novartis|Onyx Therapeutics, Inc.|Amgen|University of California, San Francisco|University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00049368|WCI2011-11/MMRC036","January 2012","February 2016","April 2017","March 9, 2012",,"January 16, 2019","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01549431"
1084,"NCT00679419","Coronary Artery Disease and Renal Failure Registry","CAD-REF","Unknown status","No Results Available","Coronary Artery Disease|Renal Failure",,"all cause mortality|manner of death","Institut für Klinisch-Kardiovaskuläre Forschung GmbH|BMBf (Federal Ministry of Education and Research)|KfH Kuratorium für Dialyse und Nierentransplantation e.V.|Amgen|AstraZeneca|Boehringer Ingelheim|Sanofi-Aventis Deutschland GmbH","All","18 Years and older   (Adult, Older Adult)",,"3352","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1-071812","December 2007","May 2011","May 2013","May 16, 2008",,"November 2, 2012","Universitätsklinikum Aachen, Aachen, Germany|Zentralklinik Bad Berka, Bad Berka, Germany|Herz- und Gefäßklinik Bad Neustadt, Bad Neustadt, Germany|Schüchtermann-Klinik, Bad Rothenfelde, Germany|Herzzentrum Brandenburg, Brandenburg, Germany|St.-Vincenz-Hospital, Coesfeld, Germany|Klinikum Lippe-Detmold, Detmold, Germany|Herzzentrum Duisburg, Duisburg, Germany|Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany|Alfried Krupp Krankenhaus Essen, Essen, Germany|Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany|Universitätsklinikum Halle/Saale, Halle/Saale, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Evangelisches Krankenhaus Hamm, Hamm, Germany|St. Marienhospital Hamm, Hamm, Germany|Medizinische Hochschule Hannover, Hannover, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Privatklinik Dr. Schindlbeck, Herrsching, Germany|Herzzentrum Lahr, Lahr, Germany|Kardiologische Praxis Dr. Schön, Mühldorf, Germany|Klinik Augustium München, München, Germany|Klinikum Neuperlach, München, Germany|Raphaelsklinik Münster, Münster, Germany|St. Franziskus-Hospital, Münster, Germany|Universitätsklinikum Münster, Münster, Germany|Lukaskrankenhaus Neuss, Neuss, Germany|Euregioclinic Nordhorn, Nordhorn, Germany|St. Vincenz-Krankenhaus, Paderborn, Germany|Klinikum Pirna, Pirna, Germany|Christliches Krankenhaus Quakenbrück e.V., Quakenbrück, Germany|Zentralklinikum Suhl, Suhl, Germany|Josephs-Hospital Warendorf, Warendorf, Germany",,"https://ClinicalTrials.gov/show/NCT00679419"
1085,"NCT01745068","Partnership for Applied Research in Fracture Prevention Programs for the Elderly","OPTI-FRAC","Active, not recruiting","No Results Available","Osteoporosis With Current Fragility Fracture","Other: Integrated program","Incidence of secondary fragility fracture|Initiation of osteoporosis treatment by the primary care physician|Compliance with osteoporosis treatment.|Time to first fall event|Incidence of secondary fragility fractures.|Number of clinically significant fall events.|Fall-related hospitalizations|Fragility fracture-related death|Participants' quality of life|Practice of physical activities|Fragility fracture-related costs|Admission to a long-term care facility|Participants' perceptions of care integration|Intervention participant's satisfaction with the fragility fracture prevention program","Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Ministere de la Sante et des Services Sociaux|Merck Sharp & Dohme Corp.|Novartis|Amgen|CSSS-IUGS Estrie","All","50 Years and older   (Adult, Older Adult)","Not Applicable","631","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CIHR grant # 267395","January 2013","November 2016","June 2019","December 7, 2012",,"October 29, 2018","Centre hospitalier Hôtel-Dieu d'Amos, Amos, Quebec, Canada|CSSS du Roché Percé (Centre hospitalier de Chandler), Chandler, Quebec, Canada|Hôpital de Hull, Gatineau, Quebec, Canada|Hôpital Charles Lemoyne, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Hôpital Jean-Talon, Montreal, Quebec, Canada|Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada|Centre hospitalier régional de Lanaudière, Saint-Charles-Borromée, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|CSSS de St-Jérôme (Hôpital régional de St-Jérôme), St-Jérôme, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01745068"
1086,"NCT00359047","Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme",,"Active, not recruiting","No Results Available","Osteoporosis","Behavioral: Documentation|Behavioral: Video","The present diagnostic and treatment rates of osteoporosis 6 months after a fragility fracture|The osteoporosis diagnostic rate and on the osteoporosis pharmacological treatment rate 12 months after the educational interventions|The average 5-year, 10-year, 15-year, and 20-year probabilities of a fragility fracture by age, site of previous fragility fracture, and type of ROCQ intervention.|Changes of modifiable risk factors for osteoporosis 12 months after the intervention|Proportion of fragility versus traumatic fractures.|Health care resource utilization associated with specific types of fragility fracture and recurrent fractures.|Assess health utility index (EQ-5D) after a fragility fracture.|Satisfaction with the process of care before and after implementing ROCQ's interventions.|One-year mortality rate following a fragility fracture.|Persistence to pharmacological treatment 12 months after the intervention|Incidence of recurrent fracture and health care resources utilization between women who previously had a fragility fracture and those who had a traumatic fracture.","CHU de Quebec-Universite Laval|Merck Frosst Canada Ltd.|Sanofi|Procter and Gamble|Amgen|Eli Lilly and Company|Novartis","Female","50 Years and older   (Adult, Older Adult)","Not Applicable","2830","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CHUL 61.05.05","June 2003","October 2007","December 2025","August 1, 2006",,"November 21, 2017","CHUdeQuebec, CHUL, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00359047"
1087,"NCT03993847","CLassification of Axial SpondyloarthritiS Inception Cohort","CLASSIC","Recruiting","No Results Available","Spondyloarthritis",,"Physician diagnosis of axial spondyloarthritis at the final diagnostic evaluation.","Spondyloarthritis Research and Treatment Network|AbbVie|Amgen|Janssen Scientific Affairs, LLC|Eli Lilly and Company|Novartis Pharmaceuticals|Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CLASSIC","December 4, 2019","January 2023","January 2024","June 21, 2019",,"December 20, 2019","UCSF Medical Center - Rheumatology Clinic, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03993847"
1088,"NCT02921191","Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated",,"Unknown status","No Results Available","Breast Cancer|Lung Cancer","Drug: filgrastim, TBO-filgrastim or pegfilgrastim","Hospitalizations for severe neutropenia|Incidence severe neutropenia","Biologics & Biosimilars Collective Intelligence Consortium|Henry Ford Health System|Aetna, Inc.|Amgen|College of Pharmacy, University of Nebraska College|College of Pharmacy, University of New England|HealthPartners Institute|Momenta Pharmaceuticals, Inc.|Harvard Pilgrim Health Care","All","18 Years and older   (Adult, Older Adult)",,"100000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BBCIC -GCFs","January 2008","September 2015","February 2017","October 3, 2016",,"October 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02921191"
1089,"NCT01015625","Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer","POSYTIVE","Active, not recruiting","No Results Available","Synchronous Metastasized Breast Cancer|Circulating Tumor Cells","Procedure: Surgery|Procedure: Surgery on Demand","to evaluate the median survival of patients with synchronous metastasized breast cancer and the primary tumor in place comparing arm A with local therapy to the primary tumor versus arm B without local therapy|time to distant progression (TTPd)|time to local progression (TTPl)","Austrian Breast & Colorectal Cancer Study Group|Bayer|Amgen|Hoffmann-La Roche|AstraZeneca|Sanofi Aventis GmbH, Austria|Wyeth Lederle Pharma GmbH, Austria|GlaxoSmithKline|Merck Sharp & Dohme GmbH, Austria|Fond of the Viennese Mayor","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","254","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ABCSG 28 / POSYTIVE|ABCSG 28","October 2010","June 2021","June 2021","November 18, 2009",,"December 19, 2018","Hospital Guessing, Guessing, Burgenland, Austria|Hospital Oberpullendorf, Oberpullendorf, Burgenland, Austria|Ordination Dr. Wette, St. Veit a. d. Glan, Carinthia, Austria|Gynaegological Medical University Graz, Graz, Styria, Austria|Medical University Graz, Oncology, Graz, Styria, Austria|Medical University of Innsbruck, Innsbruck, Tyrol, Austria|Hospital BHS Linz, Coop. Study Group, Linz, Upper Austria, Austria|Hospital Elisabethinen Linz, Linz, Upper Austria, Austria|General Hospital Linz, Linz, Upper Austria, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Upper Austria, Austria|State Hospital Feldkirch, Feldkirch, Vorarlberg, Austria|Paracelsus Medical University Salzburg-Oncology, Coop. Group, Salzburg, Austria|Medical University of Vienna-General Hospital Vienna, Vienna, Austria|Medical University of Vienna, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01015625"
1090,"NCT01277419","German Spondyloarthritis Inception Cohort","GESPIC","Recruiting","No Results Available","Ankylosing Spondylitis|Non-radiographic Axial Spondyloarthritis",,,"Charite University, Berlin, Germany|German Federal Ministry of Education and Research (BMBF): 2000-2007 and 2010-2019|2010-2019: AbbVie (Abbott)|Amgen|Centocor, Inc.|Schering-Plough|Wyeth is now a wholly owned subsidiary of Pfizer|Berlin Institute of Health|2019-current: Novartis","All","Child, Adult, Older Adult",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GESPIC","July 2000","July 2030","July 2030","January 17, 2011",,"September 11, 2019","Charité - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01277419"
1091,"NCT02922192","Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis",,"Unknown status","No Results Available","Rheumatoid Arthritis|Inflammatory Bowel Disease|Psoriasis|Psoriatic Arthritis|Ankylosing Spondylitis","Drug: TNF-α antagonists, non-TNFs, DMARD non-biologics","Incidence of hospitalization for serious infections","Biologics & Biosimilars Collective Intelligence Consortium|HealthCore, Inc.|Aetna, Inc.|University of Alabama; Rheumatologist and Healthcare Research|AbbVie|Amgen|Boehringer Ingelheim|Kaiser Permanente|Harvard Pilgrim Health Care|Merck Sharp & Dohme Corp.|Momenta Pharmaceuticals, Inc.|Pfizer|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)",,"100000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BBCIC-Anti-inflammatory","January 2006","September 2015","January 2017","October 4, 2016",,"October 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02922192"
1092,"NCT02922179","Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics",,"Unknown status","No Results Available","Diabetes","Drug: Long- and intermediate- acting insulins","serious hypoglycemic events|Serious cardiac events","Biologics & Biosimilars Collective Intelligence Consortium|HealthCore, Inc.|Aetna, Inc.|University of Alabama; Rheumatologist and Healthcare Research|AbbVie|Amgen|Boehringer Ingelheim|Kaiser Permanente|Harvard Pilgrim Health Care|Merck Sharp & Dohme Corp.|Momenta Pharmaceuticals, Inc.|Pfizer|University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)",,"100000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BBCIC Insulins","January 2011","September 2015","January 2017","October 4, 2016",,"October 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02922179"
1093,"NCT01936376","A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers",,"Unknown status","No Results Available","Head and Neck Cancer",,"biomarker change from baseline","Foundation for the National Institutes of Health|University of Southern California|University of Minnesota|M.D. Anderson Cancer Center|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen|AstraZeneca|Eli Lilly and Company|Johnson & Johnson|Merck Sharp & Dohme Corp.|Pfizer|Critical Path Institute - Predictive Safety Testing Consortium","All","18 Years and older   (Adult, Older Adult)",,"150","Other|NIH|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Kidney Safety - Cisplatin","September 2012","June 2015","June 2015","September 6, 2013",,"January 27, 2015","Harvard Medical School - Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas MD Anderson, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01936376"
1094,"NCT02215200","ATG-GCSF in New Onset Type 1 Diabetes","ATG-GCSF","Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Anti-Thymocyte Globulin (ATG)|Drug: Granulocyte colony stimulating factor (GCSF)|Drug: Placebo (for ATG)|Drug: Placebo (for GCSF)","Measure of area under the stimulated C-peptide curve over the first 2 hours of a mixed meal glucose tolerance test conducted at the one-year visit.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association|Sanofi|The Leona M. and Harry B. Helmsley Charitable Trust|Amgen","All","12 Years to 45 Years   (Child, Adult)","Phase 2","84","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ATG-GCSF (IND)|Type 1 Diabetes TrialNet|TN19|UC4DK106993|UC4DK117009","December 2014","August 2017","October 2018","August 13, 2014",,"December 26, 2017","University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Benaroya Research Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02215200"
1095,"NCT01543620","Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis",,"Unknown status","No Results Available","Cystic Fibrosis",,,"Foundation for the National Institutes of Health|University of Southern California|University of Minnesota|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen|AstraZeneca|Eli Lilly and Company|Johnson & Johnson|Merck Sharp & Dohme Corp.|Pfizer|Critical Path Institute|Predictive Safety Testing Consortium","All","18 Years and older   (Adult, Older Adult)",,"150","Other|NIH|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Kidney Safety - Aminoglycoside","February 2012","June 2015","June 2015","March 5, 2012",,"December 9, 2014","University of Southern California, Los Angeles, California, United States|University of Minnesota - Cystic Fibrosis Center, Minneapolis, Minnesota, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01543620"
1096,"NCT00512499","Strategies to Treat Osteoporosis Following a Fragility Fracture","OPTIMUS","Completed","No Results Available","Osteoporosis|Fractures","Behavioral: Control group|Behavioral: Minimal Intervention|Behavioral: Intensive Intervention","Percentage of patients pursuing an effective osteoporosis treatment|Rate of recurrent fragility fractures according to the site of the inclusion fracture","Université de Sherbrooke|Merck Sharp & Dohme Corp.|Procter and Gamble|Sanofi|Novartis|Amgen|Eli Lilly and Company|Servier|Warner Chilcott","All","50 Years to 95 Years   (Adult, Older Adult)","Not Applicable","1410","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research","06-091","February 2007","July 2013","July 2016","August 7, 2007",,"January 9, 2018","Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00512499"
1097,"NCT01016795","Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma","SCF980266","Terminated","No Results Available","Malignant Lymphoma","Drug: r-metHuSCF and Filgrastim|Drug: Chemotherapy plus Filgrastim","Safety and Toxicity was assessed by morbidity, including unexpected adverse events associated with the priming and the transplantation phases during study, and measured and graded by CTC criteria.|To compare the time dependent level of blood circulating and harvested haematopoietic stem cells and progenitors (PBSC) in patients treated with either a combination of r-metHuSCF and Filgrastim, or conventional chemotherapy plus Filgrastim.","Aalborg University Hospital|Herlev Hospital|Rigshospitalet, Denmark|Helsinki University Central Hospital|Turku University Hospital|University Hospital, Linkoeping|Umeå University|Oslo University Hospital|Nordic Lymphoma Group|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCF 980266|H-KA-99040-GMS","January 1999","November 2000","November 2009","November 20, 2009",,"June 25, 2015","Aalborg Hospital, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev University Hospital, Copenhagen, Denmark|University Hospital Helsinki, Helsinki, Finland|University Hospital Turku, Turku, Finland|Radiumhospitalet, Oslo, Norway|University Hospital Linköping, Linköping, Sweden|University Hospital Umeå, Umeå, Sweden",,"https://ClinicalTrials.gov/show/NCT01016795"
1098,"NCT00231803","The Canadian Prevention of Renal and Cardiovascular Endpoints Trial",,"Unknown status","No Results Available","Chronic Kidney Disease","Procedure: Combined CKD and CVD Prevention|Procedure: Cardiovascular Disease prevention|Procedure: Treatment of Chronic Kidney Disease complications","Time to major cardiovascular event(myocardial infarction, stroke, coronary or peripheral revascularization, hospitalization for heart failure or unstable angina, or death due to cardiovascular cause)|- Time to first major clinical event (ESRD, non-fatal cardiovascular events as in secondary (a) or all cause death)|• # patients screened via lab|• # patients seen meeting eligibility criteria|• # patients enrolled over documented period|• OR similar assessment of the success of recruitment if non-laboratory based|• Description of baseline characteristics including care in place at study entry to compare to existing databases on clinic patients and community data|• Description of how the intervention is applied (by chart review, interviews and activity records)|• Assessment of the workload and study staff requirements|• The % of patients having a cardiovascular or kidney related clinical outcome event by one and two years of study|• The % of patients lost to follow-up each year from the experimental and control groups|• The % of patients in the experimental and control groups achieving targets for blood pressure, lipids, diabetes control, anemia, and mineral metabolism at six months, one and two years.|• The % of patients in the experimental and control groups smoking at six months, one and two years.|• The quality of life of those in the experimental and control groups at baseline, six, twelve and 24 months.|• The satisfaction with care received in the experimental and control groups","Memorial University of Newfoundland|Canadian Institutes of Health Research (CIHR)|Canadian Diabetes Association|The Kidney Foundation of Canada|Heart and Stroke Foundation of Canada|Merck Frosst Canada Ltd.|Amgen|Janssen-Ortho Inc., Canada","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 4","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HIC#04.154|CIHR Grant# NET-54003","April 2005",,"December 2007","October 4, 2005",,"October 10, 2005","St. Paul's Hospital, Vancouver, British Columbia, Canada|Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada|Capitol District Health Authority, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Charles LeMoyne Hospital, Greenfield Park, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00231803"
